<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003366.pub3" GROUP_ID="BREASTCA" ID="248901080815401279" MERGED_FROM="" MODIFIED="2015-06-11 02:10:08 +0100" MODIFIED_BY="Ava Grace Tan-Koay" REVIEW_NO="36" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2015-06-11 02:10:08 +0100" MODIFIED_BY="Ava Grace Tan-Koay">
<TITLE MODIFIED="2014-07-23 15:22:51 +1000" MODIFIED_BY="Melina Willson">Taxane-containing regimens for metastatic breast cancer</TITLE>
<CONTACT>
<PERSON ID="4646" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Davina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ghersi</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Principal Research Scientist</POSITION>
<EMAIL_1>davina.ghersi@nhmrc.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+61 467 808 141</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Research Translation Group</DEPARTMENT>
<ORGANISATION>National Health and Medical Research Council</ORGANISATION>
<ADDRESS_1>16 Marcus Clarke Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Canberra</CITY>
<ZIP>2601</ZIP>
<REGION>ACT</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 6217 9522</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 6217 9035</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-06-09 17:21:42 +1000" MODIFIED_BY="Ava Grace Tan-Koay">
<PERSON ID="4646" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Davina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ghersi</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Principal Research Scientist</POSITION>
<EMAIL_1>davina.ghersi@nhmrc.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+61 467 808 141</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Research Translation Group</DEPARTMENT>
<ORGANISATION>National Health and Medical Research Council</ORGANISATION>
<ADDRESS_1>16 Marcus Clarke Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Canberra</CITY>
<ZIP>2601</ZIP>
<REGION>ACT</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 6217 9522</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 6217 9035</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="21112985843031412251100205080801" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Melina</FIRST_NAME>
<MIDDLE_INITIALS>L</MIDDLE_INITIALS>
<LAST_NAME>Willson</LAST_NAME>
<SUFFIX/>
<POSITION>Managing editor, Cochrane Breast Cancer Group</POSITION>
<EMAIL_1>melina.willson@ctc.usyd.edu.au</EMAIL_1>
<EMAIL_2>melina.willson@ctc.usyd.edu.au</EMAIL_2>
<URL>http://breastcancer.cochrane.org/</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Systematic Reviews and Health Technology Assessments</DEPARTMENT>
<ORGANISATION>NHMRC Clinical Trials Centre, The University of Sydney</ORGANISATION>
<ADDRESS_1>Locked Bag 77</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP>1450</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 9562 5081</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 9565 1863</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="26EFB0D882E26AA200DE99847B111CF7" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Matthew Ming Ki</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chan</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Oncology Advanced Trainee Registrar</POSITION>
<EMAIL_1>mmk_chan@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medical Oncology</DEPARTMENT>
<ORGANISATION>The Crown Princess Mary Cancer Centre Westmead, Westmead Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>New South Wales</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4982" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>John</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Simes</LAST_NAME>
<SUFFIX>MD,SM,FRACP</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>john@ctc.usyd.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>NHMRC Clinical Trials Centre</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1>Locked Bag 77</ADDRESS_1>
<ADDRESS_2/>
<CITY>Camperdown</CITY>
<ZIP>1450</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 02 95625000 ext: 5001</PHONE_1>
<PHONE_2/>
<FAX_1>+61 02 95651863</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12749" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Emma</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Donoghue</LAST_NAME>
<SUFFIX/>
<POSITION>Research Officer</POSITION>
<EMAIL_1>edonoghuermt@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Melbourne Conservatorium of Music</DEPARTMENT>
<ORGANISATION>The University of Melbourne</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Melbourne</CITY>
<ZIP>3004</ZIP>
<REGION>Victoria</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61 3 8866 0411</PHONE_1>
<PHONE_2/>
<FAX_1>61 3 8866 0499</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5088" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Nicholas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wilcken</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Staff Specialist</POSITION>
<EMAIL_1>nicholas.wilcken@sydney.edu.au</EMAIL_1>
<EMAIL_2>nicholas_wilcken@wmi.usyd.edu.au</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medical Oncology</DEPARTMENT>
<ORGANISATION>Westmead and Nepean Hospitals</ORGANISATION>
<ADDRESS_1>Department of Medical Oncology and Palliative Care</ADDRESS_1>
<ADDRESS_2>Westmead Hospital</ADDRESS_2>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61 02 9845 6954</PHONE_1>
<PHONE_2/>
<FAX_1>61 02 9845 6391</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-06-11 02:10:08 +0100" MODIFIED_BY="Ava Grace Tan-Koay">
<UP_TO_DATE>
<DATE DAY="14" MONTH="2" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="2" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-06-09 17:30:09 +1000" MODIFIED_BY="Ava Grace Tan-Koay">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2015-06-09 17:30:09 +1000" MODIFIED_BY="Ava Grace Tan-Koay">
<DATE DAY="14" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>Breast cancer management has evolved considerably since the first version of this Cochrane Review. There is now an emphasis on the different biological subtypes of breast cancer and there is a rapidly developing array of targeted therapies to be used in place of or as adjuncts to cytotoxic chemotherapy. Therefore, the results of this review confined to trials of chemotherapy alone are unlikely to change and further updates of this review are not planned</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-06-09 17:27:53 +1000" MODIFIED_BY="Ava Grace Tan-Koay">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-06-09 17:27:53 +1000" MODIFIED_BY="Ava Grace Tan-Koay">
<DATE DAY="14" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>Ten new studies were included, adding 3228 participants. A further two studies 'awaiting classification' and 11 'ongoing studies' have been identified<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-06-09 17:27:53 +1000" MODIFIED_BY="Ava Grace Tan-Koay">
<DATE DAY="14" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>Performed search for new studies on 14 February 2013</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-03-21 15:27:42 +1100" MODIFIED_BY="Melina Willson">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="3" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-05-27 09:47:11 +1000" MODIFIED_BY="Melina L Willson">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NHMRC Clinical Trials Centre</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-05-27 09:47:11 +1000" MODIFIED_BY="Melina L Willson">
<SOURCE>
<NAME>U.S. Army Medical Research Acquisition Activity</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2015-05-27 09:47:11 +1000" MODIFIED_BY="Melina L Willson">
<NAME>National Breast Cancer Foundation (Australia)</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>Provided financial support to update this priority review topic</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-06-04 08:55:37 +1000" MODIFIED_BY="Melina L Willson">
<SUMMARY MODIFIED="2015-06-02 10:17:01 +1000" MODIFIED_BY="Melina L Willson">
<TITLE MODIFIED="2015-04-17 13:59:20 +1000" MODIFIED_BY="Melina L Willson">Taxane-containing regimens for metastatic breast cancer</TITLE>
<SUMMARY_BODY MODIFIED="2015-06-02 10:17:01 +1000" MODIFIED_BY="Melina L Willson">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence about the effect of taxane-containing chemotherapy regimens in women with metastatic breast cancer. This is an update of a Cochrane review first published in 2003.</P>
<P>
<B>Background</B>
</P>
<P>Treatment for women with metastatic breast cancer (that is, cancer that has spread beyond the breast) usually involves chemotherapy to try to shrink or slow the growth of the cancer. Chemotherapy can involve a single drug or a combination of drugs. Paclitaxel and docetaxel are chemotherapy drugs known as taxanes. Taxanes can inhibit cancer cells from dividing and reproducing, and their adverse effects can include nausea, vomiting, and hair loss, as well as allergic reactions, which can be reduced by premedication. We wanted to examine whether or not taxane-containing chemotherapy improves survival and extends time to disease progression in women with metastatic breast cancer.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The evidence is current to February 2013. We included 28 studies that randomised 6871 women. Women were assigned to receive either a taxane-containing chemotherapy regimen (single taxane or in combination with other chemotherapy drugs) or a non-taxane chemotherapy regimen. There were variations in the taxane-containing chemotherapy regimen and the non-taxane treatments. Approximately half of the studies used paclitaxel and the other half used docetaxel, and in the majority of cases, taxanes were administered every three weeks. Of the 28 studies, 20 studies included women who received taxanes as their first treatment after their diagnosis of metastatic breast cancer, and 21 studies involved women who had not been previously treated with anthracyclines in the metastatic setting. From those studies reporting median follow-up, this ranged from 9 months to 69 months.</P>
<P>
<B>Key results</B>
</P>
<P>This review showed that chemotherapy regimens including taxanes improved survival and decreased the progression of metastatic breast cancer. If the analyses were restricted to those studies where women received taxanes as their first treatment after their diagnosis of metastatic breast cancer, the survival benefit persisted. Taxanes also appeared to cause tumours to shrink more than chemotherapy regimens without taxanes. However, there were differences in side effects. The risk of experiencing neurotoxicity (tingling of hands and feet) with taxanes increased compared to non-taxane chemotherapy. Hair loss also seemed to be more likely with taxane than with non-taxane-containing regimens. However, less nausea/vomiting was observed with taxanes. There was no difference in the rates of leukopaenia (low white blood cells) or treatment-related deaths between taxane and non-taxane chemotherapy. Of the studies that reported quality of life measures, there did not appear to be any differences (overall or on subscales) in quality of life between the two groups.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We considered 19 out of the 28 studies to be at low risk of bias overall. However, some studies failed to report details on concealing drug treatments and methods of outcome assessment for those outcomes more likely to be at risk of bias (for example tumour response rate). The degree of variability seen across the included studies probably reflects the varying efficacy of the non-taxane chemotherapy regimens used in these studies and indicates that taxane-containing chemotherapies are more effective than some, but not all, non-taxane-containing regimens.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-05-26 13:18:39 +1000" MODIFIED_BY="Melina L Willson">
<ABS_BACKGROUND MODIFIED="2014-11-04 16:46:07 +1100" MODIFIED_BY="Melina L Willson">
<P>It is generally accepted that taxanes are among the most active chemotherapy agents in the management of metastatic breast cancer. This is an update of a Cochrane review first published in 2003.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-05-25 15:05:16 +1000" MODIFIED_BY="Melina L Willson">
<P>The objective of this review was to compare taxane-containing chemotherapy regimens with regimens not containing a taxane in the management of women with metastatic breast cancer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-05-22 08:46:15 +1000" MODIFIED_BY="Melina L Willson">
<P>In this review update, we searched the Cochrane Breast Cancer Group Specialised Register, MEDLINE, EMBASE, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP), and ClinicalTrials.gov on 14 February 2013 using keywords such as 'advanced breast cancer' and 'chemotherapy'. We searched reference lists of articles, contacted study authors, and did not apply any language restrictions.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-05-21 01:20:05 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials comparing taxane-containing chemotherapy regimens to regimens without taxanes in women with metastatic breast cancer. We included published and unpublished studies.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-05-26 13:18:39 +1000" MODIFIED_BY="Melina L Willson">
<P>Two review authors independently assessed trial quality and extracted data. We derived hazard ratios (HRs) for overall survival, time to progression, and time to treatment failure where possible, and used a fixed-effect model for meta-analysis. We represented objective tumour response rates and toxicity as risk ratios (RRs). We extracted quality of life data where present.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-05-26 13:17:47 +1000" MODIFIED_BY="Melina L Willson">
<P>This review included 28 studies. The updated analysis included 6871 randomised women, while the original review had 3643 women. Of the 28 included studies, we considered 19 studies to be at low risk of bias overall; however, some studies failed to report details on allocation concealment and methods of outcome assessment for those outcomes that are more likely to be influenced by a lack of blinding (for example tumour response rate). Studies varied in the taxane-containing chemotherapy backbone, and the comparator arms and were categorised into three groups: Regimen A plus taxane versus Regimen A (2 studies); Regimen A plus taxane versus Regimen B (14 studies); and single-agent taxane versus Regimen C (13 studies). Thirteen studies used paclitaxel, 14 studies used docetaxel, and 1 study allowed the investigator to decide on the type of taxane; the majority of studies delivered a taxane every 3 weeks. Twenty studies administered taxanes as first-line treatment, and 21 studies involved anthracycline naïve women in the metastatic setting. The combined HR for overall survival and time to progression favoured the taxane-containing regimens (HR 0.93, 95% confidence interval (CI) 0.88 to 0.99, P = 0.002, deaths = 4477; and HR 0.92, 95% CI 0.87 to 0.97, P = 0.002, estimated 5122 events, respectively) with moderate to substantial heterogeneity across trials. If the analyses were restricted to studies of first-line chemotherapy, this effect persisted for overall survival (HR 0.93, 95% CI 0.87 to 0.99, P = 0.03) but not for time to progression (HR 0.96, 95% CI 0.90 to 1.02, P = 0.22). Tumour response rates appeared to be better with taxane-containing chemotherapy in assessable women (RR 1.20, 95% CI 1.14 to 1.27, P &lt; 0.00001) with substantial heterogeneity across studies. Taxanes were associated with an increased risk of neurotoxicity (RR 4.84, 95% CI 3.18 to 7.35, P &lt; 0.00001, 24 studies) and hair loss (RR 2.37, 95% CI 1.45 to 3.87, P = 0.0006, 11 studies) but less nausea/vomiting compared to non-taxane-containing regimens (RR 0.62, 95% CI 0.46 to 0.83, P = 0.001, 26 studies). Leukopaenia and treatment-related death did not differ between the two groups (RR 1.07, 95% CI 0.97 to 1.17, P = 0.16, 28 studies; and RR 1.00, 95% CI 0.63 to 1.57, P = 0.99, 23 studies, respectively). For quality of life measures, none of the individual studies reported a difference in overall or any of quality of life subscales between taxane-containing and non-taxane chemotherapy regimens.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-05-21 01:20:05 +1000" MODIFIED_BY="[Empty name]">
<P>Taxane-containing regimens appear to improve overall survival, time to progression, and tumour response rate in women with metastatic breast cancer. Taxanes are also associated with an increased risk of neurotoxicity but less nausea and vomiting compared to non-taxane-containing regimens. The considerable heterogeneity encountered across studies probably reflects the varying efficacy of the comparator regimens used in these studies and indicates that taxane-containing regimens are more effective than some, but not all, non-taxane-containing regimens.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-06-04 08:55:37 +1000" MODIFIED_BY="Melina L Willson">
<BACKGROUND MODIFIED="2015-06-02 10:18:14 +1000" MODIFIED_BY="Melina L Willson">
<CONDITION MODIFIED="2015-05-25 15:04:06 +1000" MODIFIED_BY="Melina L Willson">
<P>Breast cancer is the most common type of cancer in women, with more cases being diagnosed in less developed compared to more developed regions (<LINK REF="REF-Ferlay-2015" TYPE="REFERENCE">Ferlay 2015</LINK>). It is the most common cause of cancer death among women in less developed regions and the second most frequent cause of cancer death in more developed regions (<LINK REF="REF-Ferlay-2015" TYPE="REFERENCE">Ferlay 2015</LINK>). In 2012 there were an estimated 1.67 million new cases and approximately 522,000 deaths from breast cancer worldwide; an age standardised death rate of 12.9 (per 100,000) (<LINK REF="REF-Ferlay-2015" TYPE="REFERENCE">Ferlay 2015</LINK>).</P>
<P>The stage of breast cancer at the time of diagnosis is an important indicator of prognosis. Once breast cancer becomes metastatic it is rarely curable, with reported median survival of 18 to 24 months from the time of recurrence, although some women do experience long-term survival (<LINK REF="REF-Hayes-1995" TYPE="REFERENCE">Hayes 1995</LINK>; <LINK REF="REF-NCI-2003" TYPE="REFERENCE">NCI 2003</LINK>). Although there is no randomised evidence comparing chemotherapy with observation in women with metastatic breast cancer, it is widely accepted that women with metastatic disease should receive some form of systemic therapy at some time during the course of their disease.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>Chemotherapy is considered by many to be the appropriate first treatment option for women with multiple sites of recurrence or where visceral disease is not easily treated by local modalities (<LINK REF="REF-Beslija-2009" TYPE="REFERENCE">Beslija 2009</LINK>; <LINK REF="REF-Hayes-1995" TYPE="REFERENCE">Hayes 1995</LINK>; <LINK REF="REF-NCI-2003" TYPE="REFERENCE">NCI 2003</LINK>). Chemotherapy is also considered to be useful in women whose cancer is hormone refractory, or expected to be hormone resistant (<LINK REF="REF-Hortobagyi-1996" TYPE="REFERENCE">Hortobagyi 1996</LINK>).</P>
<P>It is generally accepted that taxanes are among the most active chemotherapy agents in the management of metastatic breast cancer. The term 'taxanes' describes a group of drugs used in the treatment of cancer, specifically paclitaxel (Taxol® Bristol-Myers Squibb) and docetaxel (Taxotere® Rhone-Poulenc Rorer). The first taxane, paclitaxel, was identified in 1971 as part of a National Cancer Institute program that screened medicinal plants for potential anti-cancer activity. It was originally isolated from the bark of the Pacific yew tree (<I>Taxus brevifolia</I>, native to western North America), but now a semisynthetic form is derived from the needles and twigs of the more common Himalayan or European yew (<I>Taxus bacatta</I>). Paclitaxel was first used in clinical trials in 1983 (<LINK REF="REF-BMS-1996" TYPE="REFERENCE">BMS 1996</LINK>). Docetaxel was first synthesised in 1986 and is similar, although not identical, to paclitaxel in its mechanism of action.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-05-25 15:17:27 +1000" MODIFIED_BY="Melina L Willson">
<P>Taxanes are unique as they affect cell structures known as microtubules (or spindle fibres). In normal cell growth, microtubules are formed when a cell starts dividing and when the cell stops dividing, the microtubules are broken down or destroyed. Taxanes work by blocking the microtubules from breaking down. Cancer cells then become blocked with microtubules and stop dividing hence potentially slowing the growth of the cancer or killing the cells. The known side effects of paclitaxel include hypersensitivity reactions (such as shortness of breath or skin rash), myelosuppression (neutropaenia), peripheral neuropathy, cardiac rhythm disturbances, joint or muscle pain, diarrhoea, nausea and vomiting, or hair loss. Patients often receive premedication before receiving taxanes to prevent possible allergic reactions. The side-effect profile of docetaxel is similar to that of paclitaxel, although docetaxel causes less neuropathy and more myelotoxicity (<LINK REF="REF-Vasey-2001" TYPE="REFERENCE">Vasey 2001</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-06-02 10:18:14 +1000" MODIFIED_BY="Melina L Willson">
<P>In the previous version of this review, the primary aim was to assess taxane use in the first-line setting, but the follow-up data were insufficient for this to be adequately assessed. In this review update, data on an additional 3000 participants were available, with time-to-event data for 87% of the participants randomised, compared to 57% in the original review. Only one other systematic review and meta-analysis appears to have been published, in 2008, but the focus was on taxanes alone or in combination with anthracyclines (refer to <LINK REF="REF-Piccart_x002d_Gebhart-2008" TYPE="REFERENCE">Piccart-Gebhart 2008</LINK>). The <LINK REF="REF-Piccart_x002d_Gebhart-2008" TYPE="REFERENCE">Piccart-Gebhart 2008</LINK> review included first-line therapy using individual participant data but did not conduct assessments of trial conduct and reporting or drug side effects. An update of the efficacy and safety of taxanes overall and in the first-line setting in the form of an updated Cochrane review seemed warranted given the availability of mature follow-up data and new trial data.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>The original review was conducted as part of a series of reviews comparing more intense (or more active) chemotherapy with less intense (or less active) chemotherapy in women with advanced (metastatic) breast cancer.</P>
<P>The objective of this review and review update was to compare taxane-containing chemotherapy regimens with regimens not containing a taxane in the management of women with metastatic breast cancer. Subquestions within the review were:</P>
<UL>
<LI>subquestion A: regimen A plus taxane versus regimen A (e.g. doxorubicin plus docetaxel versus doxorubicin alone)</LI>
<LI>subquestion B: regimen A plus taxane versus regimen B (e.g. doxorubicin plus docetaxel versus doxorubicin plus cyclophosphamide)</LI>
<LI>subquestion C: single-agent taxane versus regimen C (e.g. docetaxel versus doxorubicin plus cyclophosphamide)</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson">
<SELECTION_CRITERIA MODIFIED="2015-05-25 15:22:41 +1000" MODIFIED_BY="Melina L Willson">
<CRIT_STUDIES MODIFIED="2014-11-03 10:29:07 +1100" MODIFIED_BY="Melina L Willson">
<P>Randomised controlled trials (RCTs).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>Women with advanced (metastatic) breast cancer, either newly diagnosed or recurrent. Trials that included both women with metastatic disease and women with locoregionally recurrent disease were only eligible for inclusion if it was possible to distinguish between the two groups (that is the data were reported separately) or if women with isolated locoregional recurrence were less than 20% of the total group. We applied no age restrictions.</P>
<P>In the protocol for this review we proposed to include trials in which the women randomised to receive chemotherapy were receiving first-line treatment (that is no previous chemotherapy given except as adjuvant therapy). In the original review, as very few completed trials involved first-line treatment, all trials meeting the remaining eligibility criteria were included in the review. Results were presented separately for all trials (that is all lines) and first-line only. In the 2013 review update, the number of first-line trials increased, but for completeness, we still reported all lines and analysed as per the original review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Intervention group: Any chemotherapy regimen containing a taxane.</LI>
<LI>Comparator: Any chemotherapy regimen not containing a taxane.</LI>
</UL>
<P>Participants may also have received endocrine therapy if the study planned to give it to both treatment groups.</P>
<P>Trials may or may not have specified recommended treatment upon disease progression/initial treatment failure. This treatment may have included cross-over to the alternative treatment arm of the trial. We did not include trials where the primary intention was to investigate sequencing of treatment regimens, including, for example:</P>
<UL>
<LI>trials where participants received a given number of cycles of one regimen, followed by a given number of cycles of another regimen (randomisation being to which regimen commenced first);</LI>
<LI>trials where regimens were alternated (e.g. one cycle of regimen A followed by one cycle of regimen B followed by a second cycle of regimen A, etc.).</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-05-25 15:22:41 +1000" MODIFIED_BY="Melina L Willson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-05-18 13:31:55 +1000" MODIFIED_BY="[Empty name]">
<P>1. Overall survival<BR/>2. Time to progression</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-05-25 15:22:41 +1000" MODIFIED_BY="Melina L Willson">
<P>3. Time to treatment failure<BR/>4. Objective tumour response rate<BR/>5. Toxicity<BR/>6. Health related quality of life</P>
<P>For the purpose of this review, the following outcome definitions apply:<BR/>1. Overall survival: time from date randomised to date of death (any cause).<BR/>2. Time to progression: time from date randomised to date of progression or death (any cause). May also be referred to as progression-free survival.<BR/>3. Time to treatment failure: time from date randomised to date of progression, death (any cause), withdrawal due to adverse event, participant refusal, or further anticancer therapy for documented progression.<BR/>4. Objective tumour response rate: the proportion of participants with a complete or partial response.</P>
<P>This review also attempted to investigate treatment-related death which, for the purpose of this review, was defined as death due to the toxicity of the drug and not to disease progression. If an individual trial did not include the definition used by that trial but used the terms "toxic death" or "lethal toxicity", then we included the information in the review.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-05-25 15:19:54 +1000" MODIFIED_BY="Melina L Willson">
<ELECTRONIC_SEARCHES MODIFIED="2015-05-25 15:19:54 +1000" MODIFIED_BY="Melina L Willson">
<P>For the review update, we searched the following databases or registries.</P>
<OL>
<LI>Cochrane Breast Cancer Group (CBCG) Specialised Register on 14 February 2013. Details of the search strategy applied by the Group to create the register, and the procedure used to code references, are described in the Group's module on the Cochrane Library. The register includes both published and unpublished (including ongoing) trials. The CBCG codes 'advanced' and 'chemotherapy' were applied to the specialised register and combined with the keywords (imported with the references from MEDLINE) 'Taxol', 'docetaxel', or 'paclitaxel', and a search of all non-indexed fields for the following text words: taxane, taxanes, taxol, taxotere, paclitaxel, paxene, nsc-125973, docetaxel, or anzatax.</LI>
<LI>MEDLINE (via OvidSP) from 2008 to February 2013, see <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1407240838242533645461326943493&amp;format=REVMAN#APP-01">Appendix 1</A>
</LI>
<LI>EMBASE (via Embase.com) from 2008 to 14 February 2013, see <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1407240838242533645461326943493&amp;format=REVMAN#APP-02">Appendix 2</A>
</LI>
<LI>World Health Organization International Clinical Trials Registry Platform search portal (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>) for all prospectively registered and ongoing trials on 14 February 2013, see <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1407240838242533645461326943493&amp;format=REVMAN#APP-03">Appendix 3</A>
</LI>
<LI>ClinicalTrials.gov register (<A HREF="http://clinicaltrials.gov/ct2/search">http://clinicaltrials.gov/ct2/search</A>) on 14 February 2013 for additional unpublished and ongoing studies, see <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1407240838242533645461326943493&amp;format=REVMAN#APP-04">Appendix 4</A>
</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>We also searched the reference lists of other related literature reviews. In the original Cochrane Review, the systematic reviews searched included <LINK REF="REF-Fossati-1998" TYPE="REFERENCE">Fossati 1998</LINK> and <LINK REF="REF-Stockler-2000" TYPE="REFERENCE">Stockler 2000</LINK> as well as review articles identified by the search strategy. In the 2013 review update, we screened the references in the systematic review by <LINK REF="REF-Piccart_x002d_Gebhart-2008" TYPE="REFERENCE">Piccart-Gebhart 2008</LINK>.</P>
<P>We obtained a copy of the full article for each reference reporting a potentially eligible trial. In the 2013 review update, the review authors contacted the trial authors to provide additional information if data were available in abstract form only.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson">
<STUDY_SELECTION MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>In the original review and 2013 review update, two review authors (original review: DG, ED; 2013 review update: MC, MW) applied the selection criteria to each reference identified by the search strategy. A third review author (NW) resolved any discrepancies regarding eligibility. We recorded studies deemed ineligible in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table. Articles in languages other than English were translated where required. Only one study required translation, from Hungarian into English (<LINK REF="STD-Szanto-2001" TYPE="STUDY">Szanto 2001</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>In the original review and 2013 review update, two review authors (original review: DG, ED; 2013 review update: MC, MW) independently extracted the data and resolved queries through discussion with a third review author (NW), National Health and Medical Research Council Clinical Trial Centre statisticians, and the CBCG's Statistical Editor. We extracted data on study accrual, randomisation methods, participants' baseline characteristics (that is age, first-line/second-line, prior anthracyclines/anthracycline naïve), chemotherapy regimens (number of cycles and duration), outcome definitions, follow-up, and analyses conducted. We collected multiple publications on the same study and assigned the most complete report (that is the one with the outcomes most relevant to the review or the most recent outcomes) as the primary reference.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>We used The Cochrane Collaboration's 'Risk of bias' assessment tool to assess potential sources of bias in the included studies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). In the 2013 review update, two review authors (MC, MW) independently assessed the potential risk of bias for each study; any differences in judgement were resolved through discussion. The domains assessed were random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. We assigned ratings of 'high', 'low', or 'unclear' risk of bias to each domain for each included study following the criteria outlined in the<I> Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). For phase III oncology studies, open-label studies are common owing to difficulty in concealing different chemotherapy schedules, toxicities, etc. The blinding of outcome assessment domain was therefore lumped into those outcome measures most unlikely or most likely to be influenced by a lack of blinding. The outcomes were segregated into (a) overall survival (b) progression-free survival, time to treatment failure, response rates, and toxicity and (c) quality of life.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>We analysed overall survival, progression-free survival, and time to treatment failure as time-to-event outcomes for which the hazard ratio (HR) is the most appropriate statistic. When possible, the HR and associated variances were extracted directly from the trial publication(s). If it was not reported, we obtained it indirectly employing the methods described by Tierney et al using either other available summary statistics (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>), or from data extracted from published Kaplan-Meier curves (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>; <LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>). In studies that did not report the relevant effect estimates and required curve extraction, we adjusted the numbers at risk based on estimated minimum and maximum follow-up times. If these were not reported in any of the available reports, we estimated minimum follow-up using the estimated time taken to complete treatment, and estimated maximum follow-up using the last event reported in the relevant time-to-event curve (as per methods in <LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>). We have recorded these follow-up estimates in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table under 'Notes'. A HR less than 1.0 favoured regimens containing taxanes.</P>
<P>We analysed response rates as dichotomous variables (complete or partial versus stable disease or no response) and derived a pooled risk ratio (RR) with 95% confidence interval (CI). As trialists usually report RRs for both randomised and assessable participants, the same was done in the original and updated review. A RR larger than 1.0 favoured regimens containing taxanes.</P>
<P>We analysed toxicity data as dichotomous outcomes and added up the total number of grade 3 and 4 events and number at risk across trials. In the original review, a single odds ratio (with 95% CIs) was calculated in assessable and randomised participants. In the 2013 review update, we calculated the total number of grade 3 and 4 events and the number of assessable participants in each treatment arm and derived a pooled RR with 95% CI. The denominator was the number of assessable (not randomised) participants to ensure that toxicity outcomes were only measured in those participants who actually received the treatment. In those studies where the number assessable was not provided, we used the number of participants randomised to each treatment group. We have outlined any deviations from assessable number of participants as the denominator in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' 'Notes' section. We extracted the total number of toxic events for treatment-related death, leukopaenia, nausea or vomiting, neurotoxicity, and alopecia. If grade 3/4 nausea and vomiting were reported separately, we used data for vomiting.</P>
<P>We collected quality of life data using a variety of instruments across trials. These data were not statistically synthesised but were summarised and evaluated qualitatively.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>Three studies were three-arm trials (ECOG E1193: split into <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>). The three treatment regimens in the ECOG E1193 study were eligible for both subquestions A (<LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>) and C (<LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>). This was taken into account when the overall effect of taxanes was calculated by halving the control group each time the trial was used (which was twice). In <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>, data from two arms were used. We excluded the alternating treatment regimen of doxorubicin plus cyclophosphamide versus alternating doxorubicin plus cyclophosphamide and docetaxel. We included the treatment comparison doxorubicin plus cyclophosphamide versus docetaxel. In <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>, there was one experimental arm (that is taxane-containing regimen) and two control arms (ixabepilone plus bevacizumab, with different schedules for both drugs). In this case, the treatment arm where participants were randomised to receive bevacizumab 10 mg/kg every 14 days was the most appropriate control comparator arm for the taxane-containing arm. We did not include the third control arm in this analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>In the original review, no attempt had been made to contact most trial investigators for additional information. Many trials were in active follow-up and others were still recruiting participants. The UK Medical Research Council had been contacted in relation to the <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01 </LINK>trial, but additional information on this trial was not yet available at that time. Aventis was also contacted regarding the <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK> trial, but further details were not yet available.</P>
<P>In the 2013 review update, we contacted a number of trialists to obtain time-to-event data and clarification on whether or not analyses had been adjusted in the trial publication. The following trial reports provided additional information, or, in some cases, unpublished manuscripts: <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>, <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>, <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>, <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>, <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>, and <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>. We have provided further details of the data obtained in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table 'Notes' section.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>We used the Chi<SUP>2</SUP> test and the I<SUP>2</SUP> statistic to test for heterogeneity over all trials, as well as visual inspection of forest plots (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). For the Chi<SUP>2</SUP> test, a P value of 0.10 indicated evidence of heterogeneity. We used the I<SUP>2</SUP> statistic as a rough guide to assess heterogeneity: 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; and 75% to 100% considerable heterogeneity. We evaluated the value of the I<SUP>2</SUP> statistic alongside the magnitude and direction of effects, and the P value for the Chi<SUP>2 </SUP>test (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>When appropriate, we used a fixed-effect model for the primary analysis. We considered and discussed heterogeneity between results in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section of the review and tested where appropriate (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK> and <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK> sections).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-05-21 01:20:06 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed reporting bias using Cochrane's 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We used trial registers (WHO ICTRP and ClinicalTrials.gov) and published protocols (where available) to cross-check the reporting of outcomes in the trial publications.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-05-26 13:33:25 +1000" MODIFIED_BY="Melina L Willson">
<P>For time-to-event outcome data, we obtained a pooled HR from the derived observed (O) - expected (E) number of events and the variance for each trial using the fixed-effect model (<LINK REF="REF-Yusuf-1985" TYPE="REFERENCE">Yusuf 1985</LINK>). The pooled HR represents the overall risk of an event on taxane-containing chemotherapy versus non-taxane-containing chemotherapy.</P>
<P>For objective tumour response rates and treatment-related death, we obtained a pooled RR using the fixed-effect model (Mantel-Haenszel analysis).</P>
<P>For leukopaenia, nausea/vomiting, neurotoxicity, and alopecia, we obtained a pooled RR using the random-effects model (Mantel-Haenszel analysis).</P>
<P>We have narratively described and presented quality of life results in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>We performed all analyses using Review Manager software (<LINK REF="REF-RevMan" TYPE="REFERENCE">RevMan</LINK>) in accordance with the <I>Cochrane Handbook for Systematic Reviews of Interventions.</I>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson">
<P>Several subgroup analyses had been pre-specified (refer to <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). In the original review and the 2013 review update, the following subgroup analyses were possible:</P>
<UL>
<LI>type of taxane (docetaxel/paclitaxel)</LI>
<LI>prior exposure to anthracyclines</LI>
<LI>single-agent taxane versus single-agent anthracycline, and single-agent taxane versus non-anthracycline combination</LI>
</UL>
<P>We applied Chi<SUP>2</SUP> tests for interaction to these subgroup analyses.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-05-25 15:28:44 +1000" MODIFIED_BY="Melina L Willson">
<P>In this review update, we conducted a sensitivity analysis to assess the impact of high or unclear risk of bias on the primary outcomes overall survival and time to progression. Each study was categorised overall as having low, unclear or high risk of bias based on assessing each risk of bias domain. If the majority of the eight or nine domains (that is, those studies reporting quality of life measures) were considered at unclear or high risk of bias, the study was assessed as being at risk of bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson">
<STUDY_DESCRIPTION MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson">
<SEARCH_RESULTS MODIFIED="2015-05-25 15:32:25 +1000" MODIFIED_BY="Melina L Willson">
<P>In the review update, searching the Cochrane Breast Cancer Group Specialised Register, MEDLINE, and EMBASE on the 14 February 2013 yielded 1077 records. Searching the WHO ICTRP and ClinicalTrials.gov on 14 February 2013 retrieved eight potential ongoing studies. After removing duplicates, we screened the titles and abstracts of the remaining 903 records for review inclusion. Of these, we discarded 855 records and further assessed 48 records relating to full-text articles or ongoing trial records. After full-text review, we excluded nine records, with reasons provided in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
<P>Of the remaining 39 records, 18 records related to 12 new studies (<LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>; <LINK REF="STD-TIPP" TYPE="STUDY">TIPP</LINK>; <LINK REF="STD-Xu" TYPE="STUDY">Xu</LINK>), 6 records related to updated data for 6 previously included studies (<LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>), 4 records were supplementary records of 3 previously included studies (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>), and 11 records were classified as 'ongoing' studies (<LINK REF="STD-EUCTR2012_x002d_003530_x002d_16_x002d_ES" TYPE="STUDY">EUCTR2012-003530-16-ES</LINK>; <LINK REF="STD-EUCTR2012_x002d_003743_x002d_30_x002d_SE" TYPE="STUDY">EUCTR2012-003743-30-SE</LINK>; <LINK REF="STD-ISRCTN97330959" TYPE="STUDY">ISRCTN97330959</LINK>; <LINK REF="STD-JPRN_x002d_C000000416" TYPE="STUDY">JPRN-C000000416</LINK>; <LINK REF="STD-NCT00321633" TYPE="STUDY">NCT00321633</LINK>; <LINK REF="STD-NCT00490646" TYPE="STUDY">NCT00490646</LINK>; <LINK REF="STD-NCT00600340" TYPE="STUDY">NCT00600340</LINK>; <LINK REF="STD-NCT01126138" TYPE="STUDY">NCT01126138</LINK>; <LINK REF="STD-NCT01303679" TYPE="STUDY">NCT01303679</LINK>; <LINK REF="STD-NTR1349" TYPE="STUDY">NTR1349</LINK>; <LINK REF="STD-Pegram" TYPE="STUDY">Pegram</LINK>).</P>
<P>The original Cochrane review identified 21 eligible studies: 18 included studies and 3 ongoing studies (refer to <LINK REF="REF-Ghersi-2003" TYPE="REFERENCE">Ghersi 2003</LINK>). When we combined studies from the original review and the review update, there were 41 eligible studies involving 28 included studies (referring to 29 treatment comparisons), 2 studies awaiting classification, and 11 ongoing studies (refer to the PRISMA flowchart, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The PRISMA flowchart for the original review can be found in the previously published version of this review (<LINK REF="REF-Ghersi-2003" TYPE="REFERENCE">Ghersi 2003</LINK>).</P>
<P>Since the publication of the original review, two studies categorised as ongoing studies have become included studies (<LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>), while one previously eligible study that was withdrawn by outcome in the original review, due to being written in Hungarian, has now been transferred to the excluded studies list (<LINK REF="STD-Szanto-2001" TYPE="STUDY">Szanto 2001</LINK>). The Szanto article was translated in 2012 and reported results from one trial site from the international study referred to as the <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group </LINK>in this review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson">
<SUBSECTION>
<HEADING LEVEL="4">Question A: regimen A plus taxane versus regimen A</HEADING>
<P>Two included studies, <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>, and two ongoing studies, <LINK REF="STD-NTR1349" TYPE="STUDY">NTR1349</LINK> and <LINK REF="STD-SAKK" TYPE="STUDY">SAKK</LINK>, addressed question A. The taxane used in <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> was paclitaxel, while <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK> used docetaxel. Both <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK> recruited anthracycline naïve women receiving first-line chemotherapy for metastatic breast cancer.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Question B: regimen A plus taxane versus regimen B</HEADING>
<P>Fourteen included studies (<LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>), one study awaiting classification (<LINK REF="STD-Xu" TYPE="STUDY">Xu</LINK>), and five potential ongoing studies (<LINK REF="STD-NCT00490646" TYPE="STUDY">NCT00490646</LINK>; <LINK REF="STD-NCT00600340" TYPE="STUDY">NCT00600340</LINK>; <LINK REF="STD-NCT01126138" TYPE="STUDY">NCT01126138</LINK>; <LINK REF="STD-NCT01303679" TYPE="STUDY">NCT01303679</LINK>; <LINK REF="STD-Xu" TYPE="STUDY">Xu</LINK>) addressed question B. All 14 studies recruited women who were receiving first-line chemotherapy for metastatic breast cancer, and the majority of participants in all of these trials were anthracycline naïve in the metastatic setting. Paclitaxel was the taxane used in seven studies (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>), and docetaxel was the taxane used in six studies (<LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>). In the TRAVIOTA study, women were randomised to receive taxane therapy, which could be paclitaxel or docetaxel, at the investigator's choice. We categorised the <LINK REF="STD-Xu" TYPE="STUDY">Xu</LINK> study as awaiting classification while we sought further details on the data presented in the trial publication from the trialists.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Question C: single-agent taxane versus regimen C</HEADING>
<P>Thirteen included studies (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>), one study awaiting classification (<LINK REF="STD-TIPP" TYPE="STUDY">TIPP</LINK>), and six potential ongoing studies (<LINK REF="STD-EUCTR2012_x002d_003530_x002d_16_x002d_ES" TYPE="STUDY">EUCTR2012-003530-16-ES</LINK>; <LINK REF="STD-EUCTR2012_x002d_003743_x002d_30_x002d_SE" TYPE="STUDY">EUCTR2012-003743-30-SE</LINK>; <LINK REF="STD-ISRCTN97330959" TYPE="STUDY">ISRCTN97330959</LINK>; <LINK REF="STD-JPRN_x002d_C000000416" TYPE="STUDY">JPRN-C000000416</LINK>; <LINK REF="STD-NCT00321633" TYPE="STUDY">NCT00321633</LINK>; <LINK REF="STD-Pegram" TYPE="STUDY">Pegram</LINK>) addressed question C. Paclitaxel was used in six studies (<LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>), and docetaxel was used in seven studies (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). The majority of participants in 5 of the 13 included studies received first-line chemotherapy (<LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>), and 6 of the 13 studies were anthracycline naïve (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). We categorised the <LINK REF="STD-TIPP" TYPE="STUDY">TIPP</LINK> study as awaiting classification because we could not use the data in its present abstract form.</P>
<P>In this review update, there were 28 included studies containing 29 treatment comparisons: 2 for question A, 14 for question B, and 13 for question C. Of the 28 included studies, 26 were fully published in peer-reviewed journals (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; ECOG: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>), 2 had been reported only in abstract form (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>); and 1 study was provided as an unpublished manuscript from the trialists (<LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>).</P>
<P>Thirteen studies reported time to progression (or similar definition) as the primary outcome (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>). In the 2013 review update, we combined studies using slight variations on the 'time to progression' definition in the same analysis (refer to <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Time to progression data from the <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK> study has therefore been added in this review update where it had been previously excluded in the original review. Seven studies reported objective tumour response rate as the primary outcome (<LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). Two studies had two primary outcomes: <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>: time to progression and overall survival; and <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>: time to progression and objective response rate. Eight studies did not make a distinction between primary and secondary outcomes (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; ECOG E1193: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>).</P>
<P>Overall, paclitaxel was used in 13 studies, docetaxel was used in 14 studies, and the investigator could decide which taxane was used in 1 study. Twenty studies included first-line taxane treatment, and 21 studies administered taxanes in anthracycline naïve women in the metastatic setting. Median follow-up ranged from 36 weeks to 69 months in studies that reported this information.</P>
<P>Not all of the included studies collected data on all of the outcomes investigated in this review, or reported information on all of the outcomes that would have been expected (owing to immature follow-up or incomplete presentation of the data in the trial publication). The number of studies with reported and useable information by outcome are as follows.</P>
<UL>
<LI>Overall survival: 22 included studies involving 23 treatment comparisons</LI>
<LI>Time to progression: 21 included studies involving 22 treatment comparisons</LI>
<LI>Time to treatment failure: 5 included studies</LI>
<LI>Response rate: 28 included studies involving 29 treatment comparisons</LI>
<LI>Toxicity: treatment-related toxicity: 22 studies; grade 3/4 leukopaenia: 27 studies with 28 treatment comparisons; grade 3/4 nausea/vomiting: 25 studies with 26 treatment comparisons; grade 3/4 neurotoxicity: 23 studies with 24 treatment comparisons; grade 3/4 alopecia: 11 studies</LI>
<LI>Quality of life: 12 studies with 13 treatment comparisons</LI>
</UL>
<P>We have provided details on trials withdrawn only for certain outcomes in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>. The study ECOG E1193, that is <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>, contributed data towards question A and question C.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded six records from the review update (<LINK REF="STD-Brufsky-2012" TYPE="STUDY">Brufsky 2012</LINK>; <LINK REF="STD-Gennari-2001" TYPE="STUDY">Gennari 2001</LINK>; <LINK REF="STD-Ghosn-2011" TYPE="STUDY">Ghosn 2011</LINK>; <LINK REF="STD-Hamberg-2011" TYPE="STUDY">Hamberg 2011</LINK>; <LINK REF="STD-Huang-2011" TYPE="STUDY">Huang 2011</LINK>; <LINK REF="STD-Sakurai-2007" TYPE="STUDY">Sakurai 2007</LINK>; <LINK REF="STD-Schmid-2005" TYPE="STUDY">Schmid 2005</LINK>); reasons are provided in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-05-25 15:33:29 +1000" MODIFIED_BY="Melina L Willson">
<P>Refer to <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for a summary of the 'Risk of bias' judgements for each 'Risk of bias' domain of the included studies.</P>
<ALLOCATION MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>The 28 studies, relating to 29 treatment comparisons, were described as randomised. The method of random sequence generation was described adequately (that is with low risk of bias) in 17 studies (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>). It was not possible to accurately assess the method of random sequence generation in 11 studies owing to the lack of information presented in the published trial report or abstract. We classified these 11 studies as having an unclear risk of bias: <LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>, ECOG E1193 (<LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>), <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>, <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>, <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>, <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>, <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>, <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>, <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>, <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>, <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>.</P>
<P>Seventeen of the 28 studies were at low risk of bias for allocation concealment. These studies described central randomisation systems (computer or telephone) as their method for randomisation of treatment assignment (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>). The remaining 11 studies did not describe methods of concealment either in the trial publication (ECOG E1193: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>) or available abstract (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>); we judged these studies as having unclear risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>Eleven studies were described as "non-blinded" or "open-label" (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>). We could not rule out performance bias owing to the lack of blinding of participants and personnel; we judged these 11 studies as at high risk on this domain. We judged the remaining 17 studies as at unclear risk of bias as the information needed to make a firm conclusion about whether or not they were 'open-label' studies was not presented in the trial publication (<LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; ECOG E1193: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>), abstract (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>), or unpublished manuscript (<LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>).</P>
<P>We assessed detection bias by grouping outcomes with similar risks of bias: (a) overall survival (b) time to progression, time to treatment failure, objective tumour response rate, and toxicity, and (c) quality of life. For overall survival, we perceived a lack of blinding as being unlikely to have an impact on this outcome assessment, therefore we assessed all studies as at low risk of bias. For outcome measures that were more likely to be influenced by a lack of blinding, that is time to progression, objective tumour response rate, and toxicity, we assessed whether outcome assessments were confirmed through imaging and biochemical tests and reviewed by independent panels/adjudication committees (especially for tumour response rates) in each study. We assessed 11 studies to be at low risk of bias due to these outcomes being measured through formal assessments including scans, blood tests, and an independent clinical or radiological review group, or both (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>). Seventeen studies provided partial or minimal information on outcome assessments and were therefore classified as having an unclear risk of bias on this domain (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; ECOG E1193: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). Quality of life measures were likely to be affected by a lack of blinding. Twelve out of the 28 studies collected data on quality of life completed by participants and in some cases questionnaires completed by physicians (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; ECOG E1193: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>); we therefore considered these studies to be at high risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>Twenty-five of the 28 studies outlined that data analyses were conducted according to intention-to-treat or provided information, or both for participant exclusions (if these occurred) in their analyses. We judged the following 25 studies as at low risk of bias: <LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; ECOG E1193: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). We judged three studies as having unclear risk of bias due to no reporting of attrition or exclusions in the abstract (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>) or an analysis plan (<LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-05-25 15:33:29 +1000" MODIFIED_BY="Melina L Willson">
<P>One study, <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>, did not report outcome results (that is quality of life data) in the trial publication, yet the clinical trials registration record listed quality of life as a secondary outcome. In two studies, <LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK> and <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>, results were available only in abstract form, and it was difficult to assess whether selective reporting had occurred; as their most recent abstract publications were in 2000 and 2002, respectively, we ranked these studies as at unclear risk of bias. All other studies had either (i) outcomes listed in the methods section of the trial publication reported in the results section of the same publication (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; ECOG E1193: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>), or (ii) had a trial registration record with the listed outcomes found in the methods and results section of the trial publication (<LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>We considered differences in baseline characteristics and trials prematurely stopped due to poor accrual (for example) under this domain. Six studies were prematurely stopped owing to either recruitment issues (<LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>), the chance of finding a difference in an outcome so low that the data monitoring committee recommended early trial closure (<LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>), or results reported from another trial meant the discontinuation of the trial (<LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>). Five studies reported some baseline imbalances or did not provide sufficient information to discount that baseline differences may have influenced results (<LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>). We therefore classified 11 studies as at unclear risk of bias. We judged the remaining 17 studies as at low risk of bias, as we identified no other biases.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-05-26 13:33:25 +1000" MODIFIED_BY="Melina L Willson">
<P>It should be noted that 6871 women were randomised to the 28 included studies (involving 29 treatment comparisons), and that time-to-event data (that is overall survival and time to progression) were available for 87% of the participants randomised.</P>
<P>All trials included for questions A and B were of first-line chemotherapy for metastatic breast cancer: a total of 3984 randomised women. Three studies did not report time-to-event data (question B: <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>). All five trials of first-line chemotherapy eligible for question C reported time-to-event data.</P>
<P>Readers can refer to <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> when interpreting the plots, particularly given the variety of regimens used in the control group.</P>
<P>One study was a three-armed trial eligible for both questions A and C (<LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>). This was taken into account when the overall effect of taxanes was calculated (by halving the control group each time the trial was used (which was twice)). We labelled the plots for the overall effect of taxane-containing regimens versus non-taxane-containing regimens 'Overall effect of taxanes' for overall survival, time to progression, objective tumour response rate and toxicity.</P>
<SUBSECTION>
<HEADING LEVEL="4">Overall survival</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Overall effect</HEADING>
<P>Data from 22 studies (23 treatment comparisons) of the 26 studies reporting on overall survival were available to enable a hazard ratio (HR) calculation for overall survival for taxane-containing versus non-taxane containing regimens. There were an estimated 4477 deaths in 6008 women randomised. There was a statistically significant improvement in overall survival in favour of taxane-containing regimens with a HR of 0.93 (95% confidence interval (CI) 0.88 to 0.99; P = 0.002; participants = 6008; treatment comparisons = 23; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). There was moderate heterogeneity across trials (I<SUP>2 </SUP>= 52%; P = 0.002).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">First-line trials only (overall)</HEADING>
<P>If we limited the analysis to the 15 studies (16 treatment comparisons; involving an estimated 3352 deaths in 4439 women) using first-line chemotherapy for metastatic breast cancer, the difference remained statistically significant (HR 0.93; 95% CI 0.87 to 0.99; P = 0.03; participants = 4439; treatment comparisons = 16; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). There was moderate heterogeneity across the trials (I<SUP>2</SUP> = 55%; P = 0 .004).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subquestions: types of regimens</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Question A: regimen A plus taxane versus regimen A</HEADING>
<P>Two included studies provided information on survival (<LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>). There were 493 deaths in 630 women randomised. The HR was 1.00 (95% CI 0.84 to 1.18; P = 0.97; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), and there was no significant heterogeneity (I<SUP>2 </SUP>= 0%; P = 0.91).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question B: regimen A plus taxane versus regimen B</HEADING>
<P>Nine studies provided adequate information on survival (<LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>). There were 1946 deaths in 2645 women randomised. The HR was 0.92 (95% CI 0.84 to 1.00; P = 0.05; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), and there was substantial heterogeneity (I<SUP>2 </SUP>= 70%; P = 0.0009).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question C: single-agent taxane versus regimen C</HEADING>
<P>Twelve studies provided sufficient information on survival (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). There were 2210 deaths in 2957 women randomised. The HR was 0.95 (95% CI 0.87 to 1.03; P = 0.19; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), and there was moderate heterogeneity (I<SUP>2 </SUP>= 42%; P = 0.06). Variability in the efficacy of the comparator is of potential concern in this subquestion. If we excluded the three trials with potentially suboptimal comparators (mitomycin, vinblastine, and fluorouracil with vinorelbine: <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group;</LINK> <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>), there remains no benefit for taxane-containing regimens (HR 0.97; 95% CI 0.89 to 1.07; P = 0.55) and moderate heterogeneity (I<SUP>2</SUP> = 34%; P = 0.14).</P>
<UL>
<LI>Single taxane versus single anthracycline:</LI>
</UL>
<P>Four studies comparing single-agent taxane with single-agent anthracycline (involving an estimated 900 deaths in 1212 women randomised) were available to enable us to calculate a HR for overall survival (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). There was no difference in favour of either regimen with a HR of 1.02 (95% CI 0.90 to 1.16; P = 0.72; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). There was no significant heterogeneity (I<SUP>2 </SUP>= 0%; P = 0.52).</P>
<UL>
<LI>Single taxane versus non-anthracycline combination:</LI>
</UL>
<P>Sufficient data from all eight studies comparing single-agent taxane with a non-anthracycline-containing regimen (involving an estimated 1208 deaths in 1736 women randomised) were available to enable us to calculate a HR for overall survival (<LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>). There was no detectable difference in overall survival with a HR of 0.94 (95% CI 0.84 to 1.06; P = 0.31; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), and there was significant heterogeneity across these trials (I<SUP>2 </SUP>= 52%; P = 0.04).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Type of taxane</HEADING>
<P>We conducted post-hoc subgroup analyses to investigate the treatment effect within the types of taxane (paclitaxel or docetaxel). Nine studies (10 treatment comparisons) used paclitaxel, and there were 2232 deaths in 2834 women (<LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>). There was no detectable difference between the paclitaxel-containing versus non-taxane-containing regimens for overall survival with a HR of 1.01 (95% CI 0.93 to 1.10; P = 0.84; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). There was significant heterogeneity (I<SUP>2</SUP> = 67%; P = 0.001) for this outcome across studies.</P>
<P>Thirteen studies used docetaxel in the taxane-containing arm, and there were 2245 deaths in 3174 women randomised (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). There was a statistically significant difference in favour of docetaxel-containing regimens compared to non-taxane-containing regimens for overall survival. The HR was 0.87 (95% CI 0.80 to 0.94; P = 0.0008; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>), and there was minimal heterogeneity across studies (I<SUP>2</SUP> = 2%; P = 0.43).</P>
<P>Although the test for differences between type of taxane subgroups was statistically significant (P = 0.01), this was considered weak evidence given the variability in the comparator arms and taxane schedules (weekly versus three weekly) in these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Prior anthracyclines</HEADING>
<P>We conducted post-hoc subgroup analyses to investigate the treatment effect in women who had or had not received previous anthracyclines for advanced disease. Six studies included women who had received prior anthracyclines, and there were 918 deaths in 1243 women (<LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>). There was no detectable difference between taxane-containing and non-taxane-containing regimens for overall survival (HR 0.97; 95% CI 0.85 to 1.11; P = 0.66; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), and there was significant heterogeneity for this outcome across trials (I<SUP>2</SUP> = 58%; P = 0.04).</P>
<P>Sixteen studies (17 treatment comparisons) included women with no prior anthracyclines in the advanced setting, and there were 3359 deaths in 4765 women (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). There was a significance in favour of taxane-containing regimens for overall survival (HR 0.93; 95% CI 0.87 to 0.99; P = 0.02; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), but there was significant heterogeneity (I<SUP>2</SUP> = 52%; P = 0.007).</P>
<P>A test of differences between prior and no prior exposure to anthracyclines revealed no significant interaction (P = 0.51).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time to progression</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Overall effect</HEADING>
<P>Data from 21 studies (22 treatment comparisons) reporting on time to progression (involving an estimated 5122 events in 5960 women) were available to enable us to calculate a HR for taxane-containing versus non-taxane-containing regimens. Six studies did not provide adequate information to calculate HRs (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>).</P>
<P>There was a statistically significant difference in favour of taxane-containing regimens with a HR of 0.92 (95% CI 0.87 to 0.97; P = 0.002; participants = 5960; treatment comparisons = 22; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>), but there was significant heterogeneity across trials (I<SUP>2 </SUP>= 73%; P &lt; 0.00001). We did a sensitivity analysis by removing <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK> (that is the study where only individual participant data were available for time to progression from a published meta-analysis by <LINK REF="REF-Piccart_x002d_Gebhart-2008" TYPE="REFERENCE">Piccart-Gebhart 2008</LINK>), which showed that the benefit in favour of taxane-containing regimens persisted (HR 0.92; 95% CI 0.87 to 0.97; P = 0.002).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">First-line trials only (overall)</HEADING>
<P>If the analysis was limited to the 15 studies (16 treatment comparisons) in women receiving first-line chemotherapy for metastatic breast cancer, the difference was no longer statistically significant (HR 0.96; 95% CI 0.90 to 1.02; P = 0.22; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), and there was substantial heterogeneity (I<SUP>2</SUP> = 62%; P = 0.0005).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subquestions: type of regimens</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Question A: regimen A plus taxane versus regimen A</HEADING>
<P>One study provided adequate information on time to progression (<LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>). Three hundred and forty women progressed out of 454 randomised, and there was no detectable difference between the use of chemotherapy with or without the addition of a taxane (HR 0.99; 95% CI 0.81 to 1.21; P = 0.94; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question B: regimen A plus taxane versus regimen B</HEADING>
<P>Ten studies provided adequate information on time to progression (<LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>) and 2422 women progressed out of 2891 randomised. Data suggested a benefit in terms of time to progression in favour of taxanes with a HR of 0.90 (95% CI 0.83 to 0.98; P = 0.01; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). There was moderate heterogeneity (I<SUP>2 </SUP>= 45%; P = 0.06). We did a sensitivity analysis by removing <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK> (that is the study where only individual participant data were available for time to progression from a published meta-analysis by <LINK REF="REF-Piccart_x002d_Gebhart-2008" TYPE="REFERENCE">Piccart-Gebhart 2008</LINK>), which did not affect the benefit in favour of taxanes for time to progression (HR 0.90; 95% CI 0.83 to 0.98; P = 0.01). Similarly, by omitting <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK> (that is the one study where the chemotherapy backbone in the taxane arm was not the same in the comparator arm), the benefit in favour of the taxane-containing regimen persisted (HR 0.91; 95% CI 0.83 to 0.98; P = 0.02).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question C: Single-agent taxane versus regimen C</HEADING>
<P>Ten studies involving 11 treatment comparisons provided adequate information on time to progression (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>) and 2431 women progressed out of 2839 randomised. The HR was 0.93 (95% CI 0.86 to 1.00; P = 0.05; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) with substantial heterogeneity (I<SUP>2 </SUP>= 84%; P &lt; 0.00001) across trials. If we excluded the three trials with potentially suboptimal comparators (mitomycin, vinblastine, and fluorouracil with vinorelbine: <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group;</LINK> <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>), the HR was 1.00 (95% CI 0.91 to 1.09) with substantial heterogeneity persisting (I<SUP>2 </SUP>= 85%; P &lt; 0.00001). If the analysis was limited to the five trials in women receiving first-line chemotherapy for metastatic breast cancer (<LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>), there was no detectable difference between taxane-containing and non-taxane-containing regimens (HR 1.03; 95% CI 0.93 to 1.14; P = 0.59; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) with substantial heterogeneity (I<SUP>2 </SUP>= 80%; P = 0.0004).</P>
<UL>
<LI>Single taxane versus single anthracycline:</LI>
</UL>
<P>Four studies comparing single-agent taxane with single-agent anthracycline (involving an estimated 1000 women who had progressed out of 1212 randomised) were available to enable us to calculate a HR for progression-free survival (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). There was no difference in time to progression between the two arms (HR 1.08; 95% CI 0.96 to 1.22; P = 0.20; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>) with substantial heterogeneity (I<SUP>2 </SUP>= 80%; P = 0.002).</P>
<UL>
<LI>Single taxane versus non-anthracycline combination:</LI>
</UL>
<P>Seven studies comparing single taxane versus non-anthracycline regimen, involving an estimated 1333 women who had progressed out of 1618 randomised, were available (<LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>). There was a statistically significant difference in favour of taxane-containing regimens with a HR of 0.85 (95% CI 0.76 to 0.94; P = 0.002; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>) with substantial heterogeneity (I<SUP>2</SUP> = 84%; P &lt; 0.00001).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Type of taxane</HEADING>
<P>Ten studies involving 11 treatment comparisons used paclitaxel, and 2679 women progressed out of 3080 randomised (<LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>). There was no significant difference between paclitaxel-containing versus non-taxane-containing regimens (HR 1.04; CI 0.96 to 1.12; P = 0.32; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>) with substantial heterogeneity (I<SUP>2</SUP> = 73%; P &lt; 0.0001).</P>
<P>Eleven studies used docetaxel in the taxane-containing regimen, and 2348 women progressed out of 2880 randomised (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). There was a significant difference in favour of docetaxel-containing regimens (HR 0.80; 95% CI 0.74 to 0.86; P &lt; 0.00001; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>) with moderate heterogeneity across studies (I<SUP>2</SUP>= 48%; P = 0.04).</P>
<P>There was a significant interaction between subgroups for time to progression, suggesting that the effect of taxanes is greater in studies randomising women to docetaxel than to paclitaxel (P &lt; 0.00001) for this outcome. However, there was significant and substantial heterogeneity (I<SUP>2 </SUP>= 95.5%; P &lt; 0.00001) in both docetaxel and paclitaxel studies, and variability may relate to the differences in the comparator arms and taxane schedule (that is weekly versus three weekly) in these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Prior anthracyclines</HEADING>
<P>Five studies included women who had had prior anthracyclines in the advanced setting, and 940 women progressed out of 1125 randomised (<LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>). There was a detectable difference between taxane-containing and non-taxane-containing regimens for time to progression (HR 0.76; 95% CI 0.67 to 0.86; P &lt; 0.0001; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>) with moderate heterogeneity (I<SUP>2</SUP> = 85%; P &lt; 0.0001).</P>
<P>Sixteen studies (17 treatment comparisons) included anthracycline-naive women, and there were 4087 progression-free survival events out of 4835 randomised (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; ECOG: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). There was no detectable difference for time to progression (HR 0.96; 95% CI 0.90 to 1.02; P = 0.16; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>) and moderate heterogeneity (I<SUP>2</SUP> = 60%; P = 0.0009).</P>
<P>There was significant heterogeneity between subgroups for time to progression, suggesting the effect of taxanes is greater in studies randomising women who had prior anthracyclines (P = 0.001).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time to treatment failure</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Overall effect</HEADING>
<P>Five studies reported on time to treatment failure, two addressing subquestion B, that is <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK> and <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>, and three addressing subquestion C (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>). Although ECOG E1193 (<LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>) reported this outcome, the definition of failure used in the study was more aligned with progression-free survival (as defined by this review). Data suggested a benefit in favour of taxanes with a HR of 0.90 (95% CI 0.82 to 0.98; P = 0.02; participants = 1724; studies = 5; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). There was substantial heterogeneity (I<SUP>2 </SUP>= 91%; P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">First-line trials only (overall)</HEADING>
<P>When we restricted analysis to the three first-line studies (that is <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>), this difference was no longer statistically different (HR 1.01; 95% CI 0.89 to 1.13; P = 0.92).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Objective tumour response rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Overall effect</HEADING>
<P>Data from all 28 included studies involving 29 treatment comparisons were available to enable us to calculate a risk ratio (RR) for response rate. It is recognised that there are some differences in the definition of response across (but not within) trials. There was a significant difference in favour of taxane-containing regimens with an RR of 1.20 (95% CI 1.14 to 1.27; P &lt; 0.00001; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>: assessable participants; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). There was substantial heterogeneity across trials (I<SUP>2 </SUP>= 69%; P &lt; 0.00001). We observed the same result based on randomised women (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">First-line trials only (overall)</HEADING>
<P>If we limited the analysis to the 20 studies (21 treatment comparisons) of first-line treatment involving a total of 5512 assessable women, the difference persisted in favour of taxane-containing regimens (RR 1.16; 95% CI 1.10 to 1.23; P &lt; 0.00001; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>). However, there was substantial heterogeneity (I<SUP>2</SUP> = 63%; P &lt; 0.0001). This result was reproduced for women randomised (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subquestions: type of regimens</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Question A: regimen A plus taxane versus regimen A</HEADING>
<P>Two studies, <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>, reported on 627 assessable participants and suggested a difference in favour of taxanes (RR 1.47; 95% CI 1.21 to 1.79; P = 0.0001; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>). There was substantial heterogeneity (I<SUP>2</SUP> = 77%; P = 0.04). We observed a similar result using women randomised (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question B: regimen A plus taxane versus regimen B</HEADING>
<P>Fourteen studies involving 3740 assessable participants provided data on response rate (<LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>). There was a statistically significant difference in favour of taxane-containing regimens with an RR of 1.19 (95% CI 1.12 to 1.26; P &lt; 0.00001; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>). However, there was a moderate level of heterogeneity (I<SUP>2 </SUP>= 49%; P = 0.02). This result was reproduced for women randomised (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>). A sensitivity analysis done by omitting <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK> (that is the one study where the chemotherapy backbone in the taxane arm was not the same in the comparator arm) did not affect the benefit of taxanes for objective tumour response rate (RR 1.19; 95% CI 1.12 to 1.27; P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question C: single-agent taxane versus regimen C</HEADING>
<P>Twelve studies, 13 treatment comparisons, involving 2856 assessable participants, provided data on response rate (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). There was a statistically significant difference in favour of taxanes with an RR of 1.14 (95% CI 1.03 to 1.27; P = 0.01; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>). There was substantial heterogeneity across trials (I<SUP>2 </SUP>= 78%; P &lt; 0.00001). We observed a similar result using women randomised (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>).</P>
<P>When we restricted the analysis to first-line chemotherapy (that is five studies: <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>), the difference was no longer present with a RR of 0.90 (95% CI 0.77 to 1.05; P = 0.18; <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>) with substantial heterogeneity (I<SUP>2 </SUP>= 62%; P = 0.03). We observed a similar result using women randomised (<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Type of taxane</HEADING>
<P>Thirteen studies involving 14 treatment comparisons used a paclitaxel-containing regimen (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; ECOG E1193: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>). There was no detectable difference between the paclitaxel-containing and non-taxane-containing regimens (RR 1.06; 95% CI 0.99 to 1.14; P = 0.12; <LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>) with moderate heterogeneity (I<SUP>2</SUP> = 57%; P = 0.004).</P>
<P>Fourteen studies used a docetaxel-containing regimen (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). There was a significant difference in favour of docetaxel-containing regimens (RR 1.40; 95% CI 1.29 to 1.51; P &lt; 0.00001; <LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>) with substantial heterogeneity (I<SUP>2</SUP> = 63%; P = 0.0008).</P>
<P>There was a significant interaction between subgroups for response rate, suggesting that the effect of taxanes is greater in studies randomising women to docetaxel than to paclitaxel (P &lt; 0.00001). However, caution is required in considering this result owing to the variability in the control arms and taxane schedules (that is weekly versus three weekly) in these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Prior anthracyclines</HEADING>
<P>Seven studies included women who had prior anthracyclines in the advanced setting (<LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>). There was a detectable difference between taxane-containing and non-taxane containing regimens for response rate (RR 1.43; 95% CI 1.20 to 1.72; P &lt; 0.0001; <LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>) with substantial heterogeneity (I<SUP>2</SUP> = 79%; P &lt; 0.0001).</P>
<P>Twenty-one studies (22 treatment comparisons) included anthracycline-naive women (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). Taxane-containing regimens were associated with a higher objective tumour response rate compared to non-taxane-containing regimens with a RR of 1.17 (95% CI 1.11 to 1.24; P &lt; 0.00001; <LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>), but there was substantial heterogeneity (I<SUP>2</SUP> = 64%; P &lt; 0.0001).</P>
<P>A test for interaction between subgroups (that is prior use versus naive) for objective tumour response rate was significant (P = 0.04).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Toxicity</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Treatment-related death</HEADING>
<P>Twenty-two studies reported on treatment-related deaths (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>; <LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>; <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>). Sixty-six treatment-related deaths were reported: 33 on taxane-containing regimens and 33 on non-taxane-containing regimens in an estimated 5517 women (assessable). There was no statistically significant difference between taxane-containing and non-taxane-containing regimens (RR 1.00; 95% CI 0.63 to 1.57; P = 0.99; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). No heterogeneity was present (I<SUP>2 </SUP>= 0%; P = 0.75).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Grade 3/4 leukopaenia</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Overall effect</HEADING>
<P>Data from 27 studies (involving 28 treatment comparisons) were available for this outcome. Only one study, <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>, did not collect such data. Overall, there was no difference in the risk of leukopaenia (RR 1.07; 95% CI 0.97 to 1.17; P = 0.16; participants = 6564; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>) with significant heterogeneity across the studies (I<SUP>2</SUP> = 90%; P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subquestions: type of regimens</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Question A: regimen A plus taxane versus regimen A</HEADING>
<P>Two studies provided data on leukopaenia. The taxane-containing regimen was associated with an increased risk of leukopaenia (RR 1.76; 95% CI 1.11 to 2.80; P = 0.02; participants = 624), and there was substantial heterogeneity (I<SUP>2</SUP> = 89%; P = 0.003).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question B: regimen A plus taxane versus regimen B</HEADING>
<P>Thirteen out of the 14 studies collected data on leukopaenia. The taxane-containing regimen was associated with an increased risk of leukopaenia (RR 1.11; 95% CI 1.02 to 1.20; P = 0.01; participants = 3209) but substantial heterogeneity (I<SUP>2</SUP> = 74%; P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question C: single-agent taxane versus regimen C</HEADING>
<P>All 13 studies provided data on leukopaenia. There was no difference in the risk for leukopaenia (RR 1.07; 95% CI 0.86 to 1.34; P = 0.55; participants = 2955) and substantial heterogeneity (I<SUP>2</SUP> = 95%; P &lt; 0.00001).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Grade 3/4 nausea or vomiting</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Overall effect</HEADING>
<P>Data from 25 studies (involving 26 treatment comparisons) were available for this outcome. Only two studies for subquestion B, <LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK> and <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>, and one study for subquestion C, <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>, did not collect such data. When we combined all studies, the taxane-containing regimen appeared to be associated with significantly less nausea or vomiting (RR 0.62; 95% CI 0.46 to 0.83; P = 0.001; participants = 6245) with moderate heterogeneity across the studies (I<SUP>2</SUP> = 46%; P = 0.005).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subquestions: type of regimens</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Question A: regimen A plus taxane versus regimen A</HEADING>
<P>Two studies provided data on nausea or vomiting, and there was no statistically significant difference between the taxane-containing and non-taxane-containing regimens (RR 1.13; 95% CI 0.55 to 2.34; P = 0.74; participants = 624) with no heterogeneity (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question B: regimen A plus taxane versus regimen B</HEADING>
<P>Twelve studies reported on nausea and vomiting, and there was no significant difference between the taxane-containing and non-taxane-containing regimens for this outcome (RR 0.79; 95% CI 0.57 to 1.11; P = 0.17; participants = 2990) with moderate heterogeneity (I<SUP>2</SUP> = 38%; P = 0.09).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question C: single-agent taxane versus regimen C</HEADING>
<P>Twelve studies reported on nausea and vomiting. The taxane-containing regimens appeared to be associated with significantly less nausea or vomiting (RR 0.46; 95% CI 0.27 to 0.78; P = 0.004; participants = 2855) with moderate heterogeneity (I<SUP>2</SUP> = 47%; P = 0.04).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Grade 3/4 neurotoxicity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Overall effect</HEADING>
<P>Data from 23 studies (involving 24 treatment comparisons) were available for this outcome. One study for subquestion A (<LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>) and two studies for subquestion B (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>) and subquestion C (<LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>) did not collect data on this outcome. The taxane-containing regimens were associated with an increased risk of neurotoxicity (RR 4.84; 95% CI 3.18 to 7.35; P &lt; 0.00001; participants = 5783) with minimal heterogeneity (I<SUP>2</SUP> = 8%; P = 0.36).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subquestions: type of regimens</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Question A: regimen A plus taxane versus regimen A</HEADING>
<P>Only <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> provided data on neurotoxicity with an increased risk in the taxane-containing arm (RR 12.17; 95% CI 2.92 to 50.79; P = 0.0006; participants = 454).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question B: regimen A plus taxane versus regimen B</HEADING>
<P>Twelve studies reported on neurotoxicity, and the taxane-containing regimens were associated with greater neurotoxicity (RR 4.89; 95% CI 2.55 to 9.38; P &lt; 0.00001; participants = 2991) and minimal heterogeneity (I<SUP>2</SUP> = 28%; P = 0.19).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question C: single-agent taxane versus regimen C</HEADING>
<P>Eleven studies provided data, and the taxane-containing regimens appeared to be associated with significantly greater neurotoxicity (RR 5.99; 95% CI 2.91 to 12.31; P &lt; 0.00001; participants = 2562) with no heterogeneity (I<SUP>2</SUP> = 0%; P = 0.60).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Grade 3/4 alopecia</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Overall effect</HEADING>
<P>Data from 11 studies were available for this outcome. The two studies for subquestion A (<LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>; <LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>) and eight studies aligned to subquestions B (<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>; <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>) and C (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>; <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>; <LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>; <LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>) did not collect data on this outcome. Overall, the taxane-containing regimens appeared to be associated with greater hair loss (RR 2.37; 95% CI 1.45 to 3.87; P = 0.0006; participants = 2437). There was substantial heterogeneity (I<SUP>2</SUP> = 94%; P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subquestions: type of regimens</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Question A: regimen A plus taxane versus regimen A</HEADING>
<P>Neither study provided data on grade 3/4 alopecia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question B: regimen A plus taxane versus regimen B</HEADING>
<P>Based on data from six studies, the taxane-containing regimens were associated with greater hair loss (RR 1.17; 95% CI 1.02 to 1.34; P = 0.02; participants = 1634). There was no significant heterogeneity (I<SUP>2</SUP> = 28%; P = 0.24).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Question C: single-agent taxane versus regimen C</HEADING>
<P>Based on data from five studies, the taxane-containing regimens were associated with greater hair loss (RR 4.12; 95% CI 2.94 to 5.77; P &lt; 0.00001; participants = 803). There was no significant heterogeneity (I<SUP>2</SUP> = 30%; P = 0.23).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>We have summarised details of quality of life data reported in 12 studies in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Compliance with completion of baseline and follow-up quality of life instruments varied across studies, ranging from 61% to 99% for baseline and approximately 30% to 87% for follow-up. Some studies reported problems with participants in poorer health not completing questionnaires (for example <LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>). None of the individual studies reported a statistically significant difference in overall quality of life or in any of the subscales between taxane-containing and non-taxane-containing chemotherapy regimens.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Low versus high or unclear risk of bias</HEADING>
<P>We conducted post-hoc subgroup analyses to investigate the treatment effect in studies with low risk of bias compared to unclear/high risk of bias. Of the 28 studies, we considered 19 studies to be at low risk of bias overall. Nine studies, involving 10 treatment comparisons, were grouped as having unclear or high risk of bias overall: <LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>; <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>; <LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>; <LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Overall survival</HEADING>
<P>Eighteen of the 19 low risk of bias studies had data available for this outcome. For these studies, there was a statistically significant difference in favour of taxane-containing regimens with a HR of 0.91 (95% CI 0.85 to 0.97; P = 0.004; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>) with moderate heterogeneity (I<SUP>2 </SUP>= 48%; P = 0.01).</P>
<P>Data for five of the nine studies (10 treatment comparisons) with an unclear/high risk of bias were available. When combining these studies, there was no difference in overall survival with a HR of 1.05 (95% CI 0.92 to 1.20; P = 0.50; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>) with moderate heterogeneity (I<SUP>2 </SUP>= 59%; P = 0.04).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Time to progression</HEADING>
<P>Seventeen of the 19 low risk of bias studies had data available for time to progression. In these studies with a low risk of bias, there was an improvement in women who received the taxane-containing regimens however it did not reach the threshold for statistical significance (HR 0.95, 95% CI 0.89 to 1.00; P = 0.07; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>). There was substantial heterogeneity (I<SUP>2</SUP> = 74%; P &lt; 0.00001).</P>
<P>Data for five of the nine studies (10 treatment comparisons) with an unclear/high risk of bias were available. For these studies, there was statistically significant improvement in women who received the taxane-containing regimens with a HR of 0.80 (95% CI 0.70 to 0.90; P = 0.0005; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>). There was moderate heterogeneity (I<SUP>2</SUP> = 65%; P = 0.02).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-06-02 10:56:48 +1000" MODIFIED_BY="Melina L Willson">
<SUMMARY_OF_RESULTS MODIFIED="2015-06-02 10:56:48 +1000" MODIFIED_BY="Melina L Willson">
<P>This is a comprehensive review of the available evidence with overall survival data available from 22 of the 26 studies, contributing information on over 6000 women. This review update shows a statistically significant survival advantage of taxane-containing regimens, a finding that is consistent with the findings of the previous version of this review. It is reassuring that this benefit has remained since the publication of results from an additional 10 studies. This review update also confirmed the improvements in objective tumour response rate and time to progression associated with the use of taxane-containing regimens. Results for overall survival limited to the available first-line treatment studies showed a benefit in favour of taxane-containing regimens that was statistically significant. This was not statistically significant in the previous version of the review due to the limited number of completed first-line studies. This is consistent with the observed significant benefit in objective tumour response rate among the first-line trials. Taxane-containing regimens were associated with a greater degree of leukopaenia and neurotoxicity, but less nausea and vomiting than the comparator group, and the overall impact on quality of life did not appear to differ in any of the trials.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-05-25 15:24:23 +1000" MODIFIED_BY="Melina L Willson">
<P>A limitation when interpreting the results of this review relates to the statistical and clinical heterogeneity of the studies. A certain amount of heterogeneity is to be expected given the different drugs, dosages, and schedules being used across the included studies, and the different patient groups and treatment settings. However, there was substantial statistical evidence of heterogeneity among the trials when examining the effect of treatment on time to progression and objective tumour response rate (P less than 0.00001). One explanation for this is the varying efficacy of the comparator regimens. In particular, the regimens of mitomycin, vinblastine, and fluorouracil with vinorelbine could be regarded as suboptimal chemotherapy for breast cancer. If these regimens are excluded, the advantages for single-agent taxane when compared to a non-taxane-containing regimen are no longer statistically significant. Consequently it is reasonable to conclude that taxanes are more effective than some, but not all, regimens to which they have been compared, and are at least as effective as the other regimens.</P>
<P>The two subgroup analyses of most relevance to clinical practice are the relative merits of the different taxanes and the context in which they are used (that is, in anthracycline-naïve patients or not). The available data suggested that docetaxel may be more active than paclitaxel, at least when given in three-weekly schedules. It is important to note that this is based on an indirect comparison of these two drugs and, as already discussed, the various comparator regimens used also need to be considered when interpreting these results. Furthermore, paclitaxel has since been shown to be more effective in the adjuvant and metastatic settings when given as a weekly schedule (<LINK REF="REF-Mauri-2010" TYPE="REFERENCE">Mauri 2010</LINK>).</P>
<P>The benefit of taxanes also appears to be less apparent in participants who have not had previous anthracyclines. While subset analyses may be useful for informing clinical practice, caution is warranted when interpreting such analyses given the smaller number of participants available to address each subgroup, and the potential effect of confounding. When interpreting the indirect comparison of paclitaxel and docetaxel, for example, we did not consider the relative efficacy of the comparators used in the included trials. We also did not state our intention to investigate some of these subgroups a priori. Such analyses should therefore primarily be considered as hypothesis generating. Interestingly, the Piccart individual patient meta-analysis found that taxanes did worse than anthracyclines for progression-free survival; however, overall survival and response were similar (<LINK REF="REF-Piccart_x002d_Gebhart-2008" TYPE="REFERENCE">Piccart-Gebhart 2008</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-05-25 15:24:38 +1000" MODIFIED_BY="Melina L Willson">
<P>This review included studies that were generally well-conducted, multicentre phase 3 trials. Overall, we considered 19 out of the 28 included studies to be at low risk of bias. However, as some studies (that is 11 out of 28 studies) failed to report details on the methods related to random sequence generation or allocation concealment, it was not possible to adequately judge whether or not these aspects of trial conduct had been done. We categorised such studies as at unclear risk of bias based on the information presented in the trial publication, unpublished manuscript, or conference proceeding abstract, and this may be perceived as a hard judgement. In addition, for outcomes assessments more likely to be influenced by a lack of blinding (that is time to progression, objective tumour response rate, and toxicity), only 11 of the 28 studies involved formal outcome assessments through scans, blood tests, and independent clinical and/or radiological adjudication committees. Future studies might consider using independent committees for those outcomes more prone to detection bias. We only encountered selective reporting of outcomes in one instance, and this was for a secondary outcome (that is quality of life). Six studies were closed prematurely owing to recruitment issues, data monitoring committee recommendation, or results being published by another trial group.</P>
<P>Only two studies were designed with overall survival being the primary outcome. In 13 out of the 28 included studies, time to progression (or similar definition) was the primary outcome, while in 7 studies objective tumour response rate was the primary outcome. The remaining studies made no distinction between primary or secondary outcomes.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>The concern about reporting bias raised in the previous version of this review is lessened now that an additional 10 trials have reported time-to-event data for the outcome overall survival, with only 4 studies yet to report data on this outcome. We did not undertake extensive grey literature searching, so there may still be unpublished trials not included in this review. It is therefore possible that the size of the treatment effects reported may be overestimated.</P>
<P>The definition of time to progression varied slightly across those studies that reported data on this outcome. Of those included studies that contributed time-to-progression data, three studies gave no definition for this outcome and seven studies reported progression-free survival, which in this review update we deemed to be relatively synonymous with time to progression. The medical literature has previously noted slight differences in the definition of time to progression and progression-free survival (<LINK REF="REF-Mauri-2010" TYPE="REFERENCE">Mauri 2010</LINK>; <LINK REF="REF-Saad-2009" TYPE="REFERENCE">Saad 2009</LINK>). As we combined data for this outcome irrespective of such differences, time-to-progression findings should be viewed with a degree of caution.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>We identified one other systematic review using individual participant data investigating taxanes (anthracycline-taxane versus anthracycline-based regimen or single-agent taxane versus single-agent anthracycline) for women with metastatic breast cancer (<LINK REF="REF-Piccart_x002d_Gebhart-2008" TYPE="REFERENCE">Piccart-Gebhart 2008</LINK>). The chemotherapy regimens assessed in the Piccart et al review did not entirely overlap (only a subset) with those included in this Cochrane review. The <LINK REF="REF-Piccart_x002d_Gebhart-2008" TYPE="REFERENCE">Piccart-Gebhart 2008</LINK> review examined first-line treatment only, and overall their results generally confirmed an observed benefit of taxanes in shrinking tumours. It was difficult to compare such outcomes as overall survival and time to progression across the two reviews; the Cochrane review included data from new studies published in the last few years (<LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>; <LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>; <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>), and we did not have access to some data in abstract form. More recent systematic reviews are examining the efficacy of weekly versus three-weekly taxane regimens (<LINK REF="REF-Belfiglio-2012" TYPE="REFERENCE">Belfiglio 2012</LINK>; <LINK REF="REF-Mauri-2010" TYPE="REFERENCE">Mauri 2010</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-06-04 08:55:37 +1000" MODIFIED_BY="Melina L Willson">
<IMPLICATIONS_PRACTICE MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>When we consider all trials, we have sufficient evidence to determine the effects of taxane-containing chemotherapy regimens in women with metastatic breast cancer. Taxane-containing regimens appear to improve overall survival, time to progression, and overall response in women with metastatic breast cancer. The degree of heterogeneity encountered indicates that taxane-containing regimens are more effective than some, but not all, non-taxane-containing regimens.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-06-04 08:55:37 +1000" MODIFIED_BY="Melina L Willson">
<P>Breast cancer management has evolved considerably since the first version of this review. Specifically, there is an increasing emphasis on the different biological subtypes of breast cancer and a rapidly developing array of targeted therapies to be used in place of or as adjuncts to cytotoxic chemotherapy. Thus the results of this review, which was confined to trials of chemotherapy alone, are unlikely to change, and further updates are not planned. However, if future trials examine either the role of taxanes in specific subtypes of breast cancer, or the role of taxanes together with or versus targeted therapies, then a new review would be warranted.</P>
<P>A meta-analysis examining docetaxel versus paclitaxel trials suggests that it is unlikely that there is a clinically significant difference in efficacy between the two agents (<LINK REF="REF-Qi-2013" TYPE="REFERENCE">Qi 2013</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-05-27 09:50:02 +1000" MODIFIED_BY="Melina L Willson">
<P>We would like to thank Libby Weir and Fergus Tai for their work in searching for studies across multiple databases. We also acknowledge the contribution made to the original concept for this review by I. Craig Henderson, Kathleen Pritchard, Martin Tattersall, Martin Stockler, Christine Brunswick, Roldano Fossati, and Alessandro Liberati.</P>
<P>We gratefully acknowledge the statistical and methodological advice provided by Kristy Mann, Mark Donoghue, and Val Gebski (NHMRC Clinical Trial Centre statisticians) and Dianne O'Connell (Cancer Council NSW) during the data extraction phase.</P>
<P>We thank John Kis-Rugo, Cochrane Consumers and Communication Review Group, for translating Szanto's paper.</P>
<P>We acknowledge the financial support provided by the National Breast Cancer Foundation (Australia) that allowed the completion of this review update.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-05-22 15:24:32 +1000" MODIFIED_BY="Melina L Willson">
<P>DG: none known<BR/>MW: none known<BR/>MC: no relevant conflict of interest<BR/>JS: no relevant conflict of interest<BR/>ED: none known<BR/>NW: has received honoraria from Aventis<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-05-25 15:51:30 +1000" MODIFIED_BY="Melina L Willson">
<P>DG designed the review; developed the protocol; identified, selected, and critically appraised the studies; applied eligibility criteria; extracted and entered data; analysed the data; and wrote the first draft of the 2003 review. DG reviewed and approved the final version of the review update.<BR/>MW identified, selected, and critically appraised the studies; applied eligibility criteria; extracted and entered data; assessed risk of bias; analysed the data; and drafted the manuscript for the review update.<BR/>MC identified, selected, and critically appraised the studies; applied eligibility criteria; extracted and entered data; assessed risk of bias; analysed the data; and drafted the manuscript for the review update.<BR/>JS commented on the design of the review and the protocol and contributed to and approved the 2003 review.<BR/>ED critically appraised the studies to be included in the review; applied eligibility criteria; extracted data; and reviewed the draft and final versions of the 2003 review.<BR/>NW collaborated in the design of the review and the development of the protocol and reviewed the draft and final versions of the 2003 review. NW screened studies for the review update, reviewed the drafts and approved the final version of the review update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson">
<P>Differences between original review and review update:</P>
<UL>
<LI>'Risk of bias' assessments: In the original review, risk of bias was assessed on three domains (quality of randomisation, comparability between groups (treatment arms) at the baseline, and inclusion of all randomised participants in the analysis). In the review update, we assessed risk of bias for all the domains of the Cochrane risk of bias tool for previously included studies and new studies.</LI>
<LI>The forest plot labels for objective tumour response rates: In the original review, a pooled risk ratio was derived for tumour response rates, but the default mode in Review Manager labelled the summary statistic as odds ratio in the forest plots. In the review update, we have changed the forest plot labels to reflect the appropriate summary statistic (i.e. risk ratios for response rates).</LI>
<LI>The forest plot labels for time-to-event outcomes: In the original review, overall survival, time to progression, and time to treatment failure were analysed as time-to-event outcomes with the effect measure being the hazard ratio, however the forest plots were labelled as odds ratio plots as part of Review Manager's default mode. In the review update, we have changed the labels to reflect the appropriate summary statistic, that is hazard ratios.</LI>
<LI>We added data from the <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK> study for the outcome time to progression into the review update. In the original review, the definition of time to progression did not exactly match the pre-specified definition in the review and was therefore withdrawn by outcome.</LI>
<LI>Effect measure for toxicity: In the original review, toxicity data was narratively presented as odds ratio. In the review update, we have presented such data as risk ratios and pooled.</LI>
<LI>Subgroup analysis: A number of subgroups were specified in the original review and updated in 2013 (refer to <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). In the review update, some of these subgroups were possible, e.g. single taxane versus single anthracycline regimens, however subgroups related to subquestion B (e.g. substitution fluorouracil and cyclophosphamide) were still not possible because very few studies were available.</LI>
<LI>Sensitivity analysis: To test the robustness of the results for the outcomes overall survival and time to progression, we conducted a sensitivity analysis by separating high/unclear risk of bias studies from low risk of bias studies</LI>
<LI>We have removed Table 1 and Figure 3 in the original review from the review update; they can be viewed in <LINK REF="REF-Ghersi-2003" TYPE="REFERENCE">Ghersi 2003</LINK>.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2015-05-22 15:28:24 +1000" MODIFIED_BY="Melina L Willson">
<P>18 February 2005<BR/>Error corrected: There was a data entry error for the value of O-E for the <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK> trial for the outcomes overall survival and time to progression, which resulted in the direction of the treatment effect being in the wrong direction for those outcomes for that trial. Although the correction does change the pooled estimate and confidence interval, it does not change the conclusions of the review.<BR/>
<BR/>16 May 2005<BR/>Error corrected: In Table 4 the denominator for alopecia for single-agent taxane versus regimen C was incorrect due to a misinterpretation of the data in the primary paper. The numerator remains the same. The odds ratio changes but does not change direction, and the interpretation remains the same.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-06-02 10:47:10 +1000" MODIFIED_BY="Melina L Willson">
<STUDIES MODIFIED="2015-05-26 13:31:19 +1000" MODIFIED_BY="Melina L Willson">
<INCLUDED_STUDIES MODIFIED="2015-05-26 13:27:44 +1000" MODIFIED_BY="Melina L Willson">
<STUDY DATA_SOURCE="PUB" ID="STD-_x0033_03-Study-Group" MODIFIED="2015-05-25 13:37:38 +1000" MODIFIED_BY="Melina L Willson" NAME="303 Study Group" YEAR="1994">
<REFERENCE MODIFIED="2015-05-22 11:11:15 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;3611&lt;/p&gt;" NOTES_MODIFIED="2015-05-22 11:11:15 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aapro M</AU>
<TI>Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group</TI>
<SO>Seminars in Oncology</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>5 Supplement 12</NO>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 12:14:03 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Ref ID 2009&lt;br&gt;Slides from talk associated with this abstract printed from web site&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 12:14:03 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chan S, Friedrichs K, Noel D, Duarte R, Vorobiof D, Pinter T, et al</AU>
<TI>Docetaxel (Taxotere) vs doxorubicin in patients with metastatic breast cancer (MBC) who have failed alkylating chemotherapy. Randomized multicenter phase III trial</TI>
<SO>Proceedings of American Society of Clinical Oncology; 1997</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>Abstract 540</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 11:46:49 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Ref ID 4776&lt;/p&gt;" NOTES_MODIFIED="2015-05-22 11:46:49 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al</AU>
<TI>A phase III study of taxotere vs doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen</TI>
<SO>Breast Cancer Research and Treatment; San Antonio Breast Cancer Symposium; 1997; San Antonio</SO>
<YR>1997</YR>
<VL>46</VL>
<PG>Abstract 1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4776"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-22 13:45:12 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;4451&lt;/p&gt;" NOTES_MODIFIED="2014-07-22 13:45:12 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al</AU>
<TI>Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. John Crown for the 303 Study Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>8</NO>
<PG>2341-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:37:27 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;2417&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:37:27 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan S</AU>
<TI>Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy</TI>
<SO>Oncology (Huntington)</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>8 Supplement 8</NO>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:37:38 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;3616&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:37:38 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nabholtz JM, Crown J</AU>
<TI>Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results</TI>
<SO>Seminars in Oncology</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>6 Supplement 13</NO>
<PG>4-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x0033_04-Study-Group" MODIFIED="2015-05-26 13:27:44 +1000" MODIFIED_BY="Melina L Willson" NAME="304 Study Group" YEAR="1994">
<REFERENCE MODIFIED="2015-05-25 13:37:50 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;3616&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:37:50 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nabholtz JM, Crown J</AU>
<TI>Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results</TI>
<SO>Seminars in Oncology</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>6 Supplement 13</NO>
<PG>4-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 11:44:40 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;3961&lt;/p&gt;" NOTES_MODIFIED="2015-05-22 11:44:40 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, et al</AU>
<TI>Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>5</NO>
<PG>1413-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 12:17:24 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;5960&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 12:17:24 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nabholtz JM, Thuerlimann B, Beswoda WR, Melnychuk D, Deschenes L, Douma J, et al</AU>
<TI>Taxotere (T) improves survival over mitomycin C vinblastine (mv) in patients (pts) with metastatic breast cancer (mbc) who have failed an anthracycline (ant) containing regimen: final results of a phase III randomized trial</TI>
<SO>Proceedings of American Society of Clinical Oncology; 1998</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>Abstract 390</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 13:07:18 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;4812&lt;/p&gt;" NOTES_MODIFIED="2015-05-22 13:07:18 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nabholtz JM, Thuerlimann B, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, et al</AU>
<TI>Taxotere vs mitomycin c-vinblastine in patients with metastatic breast cancer who have failed an anthracycline containing regimen</TI>
<SO>Breast Cancer Research and Treatment; San Antonio Breast Cancer Symposium; 1997; San Antonio</SO>
<YR>1997</YR>
<VL>46</VL>
<PG>Abstract 401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 11:57:13 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;2160&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 11:57:13 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nabholtz JM, Thuerlimann B, Bezwoda WR, Melnychuk D, Deschenes L, Douma, J, et al</AU>
<TI>Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer</TI>
<SO>Oncology (Huntington)</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>8 Supplement 8</NO>
<PG>32-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-26 13:27:44 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;2008&lt;/p&gt;" NOTES_MODIFIED="2015-05-26 13:27:44 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nabholtz JM</AU>
<TI>Docetaxel (Taxotere) vs mitomycin C + vinblastine in patients with metastatic breast cancer (MBC) who have failed an anthracycline-containing regimen. Preliminary evaluation of a randomized phase III study</TI>
<SO>Proceedings of American Society of Clinical Oncology; 1997</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>Abstract 148a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x0033_06-Study-Group" MODIFIED="2015-05-25 12:17:47 +1000" MODIFIED_BY="Melina L Willson" NAME="306 Study Group" YEAR="1996">
<REFERENCE MODIFIED="2015-05-22 13:09:56 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al</AU>
<TI>Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>6</NO>
<PG>968-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 12:17:47 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nabholtz JM, Falkson G, Campos D, Szanto J, Martin M, Chan S, et al</AU>
<TI>A Phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as firstline chemotherapy for MBC</TI>
<SO>Proceedings of American Society of Clinical Oncology; 1999</SO>
<YR>1999</YR>
<VL>18</VL>
<PG>Abstract 485</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AGO" MODIFIED="2015-05-25 12:18:25 +1000" MODIFIED_BY="Melina L Willson" NAME="AGO" YEAR="1996">
<REFERENCE MODIFIED="2015-05-25 12:18:10 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Konecny G, Kuhn W, Sattler D, Thomssen C, Bauknecht T, Eidtmann H, et al</AU>
<TI>Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC) as first line chemotherapy (CRx) in metastatic breast cancer (MBC): toxicity data and overall response rates of a randomized multicenter trial</TI>
<SO>Breast Cancer Research and Treatment; San Antonio Breast Cancer Symposium; 1998; San Antonio</SO>
<YR>1998</YR>
<VL>50</VL>
<PG>Abstract 222</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 13:20:03 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Konecny G, Thomssen C, Pegram M, Luck H, Untch M, Pauletti G, et al</AU>
<TI>HER-2/neu Gene amplification and response to paclitaxel in patients with metastatic breast cancer</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>Abstract 88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 12:18:25 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Luck HJ, Thomssen C, Untch M, Kuhn W, Eidtmann H, du Bois A, et al</AU>
<TI>Multicentric Phase III Study in firstline treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the Ago Breast Cancer Group</TI>
<SO>Proceedings of American Society of Clinical Oncology; 2000</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>Abstract 280</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 13:31:00 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Müller V, Bauknecht T, du Bois A, Eidtmann H, Jackisch C, Köhler G, et al</AU>
<TI>A randomized multicenter phase III trial comparing epirubicin and paclitaxel as first line chemotherapy in patients with metastatic breast cancer</TI>
<SO>Breast Cancer Research and Treatment; San Antonio Breast Cancer Symposium; 1999; San Antonio</SO>
<YR>1999</YR>
<VL>57</VL>
<PG>Abstract 331</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 14:06:16 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schroeder W, Luck HJ, Thomssen C, Mobus V, Kuhn W, von Minckwitz G</AU>
<TI>Phase III multicenter trial of epirubicin-paclitaxel vs epirubicin-cyclophosphamide first-line therapy of metastatic breast cancer. An AGO Study protocol</TI>
<SO>European Society for Medical Oncology Congress Proceedings; 1998</SO>
<YR>1998</YR>
<VL>9 (Supplement 4)</VL>
<PG>Abstract 560</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 14:08:30 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Minckwitz G, Kuhn W, Thomssen C, Untch M, Bauknecht T, Eidtmann D, et al</AU>
<TI>Phase III trial comparing epirubicin/paclitaxel vs epirubicin/cyclophosphamide as first line treatment in metastatic breast cancer: preliminary results of a German AGO trial</TI>
<SO>European Journal of Cancer</SO>
<YR>1998</YR>
<VL>34 (Supplement 5)</VL>
<PG>S90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ANZ-TITG" MODIFIED="2015-05-25 13:38:59 +1000" MODIFIED_BY="Melina L Willson" NAME="ANZ TITG" YEAR="1993">
<REFERENCE MODIFIED="2015-05-25 12:04:05 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;5430&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 12:04:05 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>Bishop JF, Australia and New Zealand Taxol Investigators Trials Group</AU>
<TI>Taxol versus CMFP combination therapy in advanced untreated patients with breast cancer (protocol)</TI>
<SO>Trial protocol</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 12:06:49 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;3930&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 12:06:49 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bishop JF, Dewar J, Tattersall MH, Smith J, Olver I, Ackland S, et al</AU>
<TI>A randomized phase III study of Taxol (paclitaxel) vs CMFP in untreated patients with metastatic breast cancer</TI>
<SO>Proceedings of American Society of Clinical Oncology; 1996; Chicago</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>Abstract 107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:38:47 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;2153&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:38:47 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, et al</AU>
<TI>A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand</TI>
<SO>Seminars in Oncology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>5 Supplement 17</NO>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 12:10:27 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;4450&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 12:10:27 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, et al</AU>
<TI>Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>8</NO>
<PG>2355-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4450"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:38:59 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;2507&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:38:59 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackland S, et al</AU>
<TI>Paclitaxel as first-line treatment for metastatic breast cancer</TI>
<SO>Oncology (Huntington)</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>4 Supplement 3</NO>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blohmer" MODIFIED="2015-05-25 12:19:58 +1000" MODIFIED_BY="Melina L Willson" NAME="Blohmer" YEAR="2010">
<REFERENCE MODIFIED="2015-05-25 12:19:58 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Blohmer JU, Hauschild M, Hilfich J, Kleine-Tebbe A, Kuemmel S, Lichtenegger W</AU>
<TO>Safety and efficacy of first-line epirubicin-docetaxel versus epirubicin-cyclophosphamide; updated results of multicentre randomised phase III trial in metastatic breast cancer</TO>
<SO>Proceedings of American Society of Clinical Oncology; 2004</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>Abstract 14S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-20 19:42:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blohmer JU, Schmid P, Hilfich J, Friese K, Kleine-Tebbe A, Koelbl H, et al</AU>
<TI>Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial</TI>
<SO>Annals of Oncology</SO>
<YR>2010</YR>
<VL>21</VL>
<PG>1430-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonneterre" MODIFIED="2015-05-25 12:20:41 +1000" MODIFIED_BY="Melina L Willson" NAME="Bonneterre" YEAR="1998">
<REFERENCE MODIFIED="2015-05-25 12:20:41 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;6016&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 12:20:41 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre M, Delozier T, et al</AU>
<TI>6 cycles of epirubicin / docetaxel (ET) versus 6 cycles of 5FU epirubicin / cyclophosphamide (FEC) as first line metastatic breast cancer (MBC) treatment</TI>
<SO>Proceedings of American Society of Clinical Oncology; 2001</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>Abstract 42a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 14:12:18 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre ME, Delozier T, et al</AU>
<TI>Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>2004</YR>
<VL>91</VL>
<NO>8</NO>
<PG>1466-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 14:30:08 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;5732&lt;/p&gt;" NOTES_MODIFIED="2015-05-22 14:30:08 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre M-E, Mayer F, Delozier T, et al</AU>
<TI>6 cycles of epirubicin/taxotere (ET) versus 6 cycles of 5FU/epirubicin/cyclophosphamide (FEC) as first line metastatic breast cancer (MBC) treatment: preliminary results of a randomised phase II trial</TI>
<SO>Breast Cancer Research and Treatment; San Antonio Breast Cancer Symposium; 2000; San Antonio</SO>
<YR>2001</YR>
<VL>64</VL>
<PG>Abstract 314</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bontenbal" MODIFIED="2015-05-22 14:35:13 +1000" MODIFIED_BY="Melina L Willson" NAME="Bontenbal" YEAR="1997">
<REFERENCE MODIFIED="2015-05-22 14:35:13 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bontenbal M, Braun JJ, Creemers GJ, de Boer AC, Janssen JTP, Leys MBL, et al</AU>
<TI>Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC)</TI>
<SO>European Journal of Cancer Supplements</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>5</NO>
<PG>S201-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-03 10:50:39 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, et al</AU>
<TI>Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch community setting trial for the clinical trial group of the comprehensive cancer centre</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>28</NO>
<PG>7081-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CECOG-BM1" MODIFIED="2015-05-25 12:22:06 +1000" MODIFIED_BY="Melina L Willson" NAME="CECOG BM1" YEAR="1999">
<REFERENCE MODIFIED="2015-05-25 12:22:06 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zielinski C, Beslija S, Cervek J, Mrsic-Krmpotic Z, Tchernozemsky I, Wiltschke C, et al</AU>
<TI>Gemcitabine/Epirubicin/Paclitaxel (GET) vs. 5-fluorouracil/Epirubicin/Cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase III trial of the Central European Cooperative Oncology Group (CECOG)</TI>
<SO>Proceedings of American Society of Clinical Oncology; 2001</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>Abstract 1958</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-20 19:50:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, et al</AU>
<TI>Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>7</NO>
<PG>1401-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dieras" MODIFIED="2015-05-22 14:37:12 +1000" MODIFIED_BY="Melina L Willson" NAME="Dieras" YEAR="1995">
<REFERENCE MODIFIED="2015-05-22 14:37:12 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;148&lt;/p&gt;" NOTES_MODIFIED="2015-05-22 14:37:12 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dieras V, Marty M, Tubiana N, Corette L, Morvan F, Serin D, et al</AU>
<TI>Phase II randomised study of paclitaxel versus mitomycin in advanced breast cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>4</NO>
<PG>33-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ECOG-E1193-_x0028_A_x0029_" MODIFIED="2015-05-25 13:27:35 +1000" MODIFIED_BY="Melina L Willson" NAME="ECOG E1193 (A)" YEAR="1993">
<REFERENCE MODIFIED="2015-05-25 13:25:22 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;5965&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:25:22 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sledge GW, Jr., Neuberg D, Ingle J, Martino S, Wood W</AU>
<TI>Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial</TI>
<SO>Proceedings of American Society of Clinical Oncology; 1997</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-20 19:52:49 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al</AU>
<TI>Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>4</NO>
<PG>588-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:27:35 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;2554&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:27:35 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sledge GW</AU>
<TI>Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience</TI>
<SO>Seminars in Oncology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>5 Supplement 12</NO>
<PG>123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-22 13:48:11 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;3366&lt;/p&gt;" NOTES_MODIFIED="2014-07-22 13:48:11 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sledge GWJ, Robert N, Sparano JA, Cogleigh M, Goldstein LJ, Neuberg D, et al</AU>
<TI>Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>105-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ECOG-E1193-_x0028_B_x0029_" MODIFIED="2015-05-20 19:54:23 +1000" MODIFIED_BY="[Empty name]" NAME="ECOG E1193 (B)" YEAR="1993">
<REFERENCE MODIFIED="2015-05-20 19:54:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al</AU>
<TI>Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>4</NO>
<PG>588-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EORTC-10923" MODIFIED="2015-05-25 13:37:06 +1000" MODIFIED_BY="Melina L Willson" NAME="EORTC 10923" YEAR="1993">
<REFERENCE MODIFIED="2015-05-25 13:33:12 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;4777&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:33:12 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Awada A, Paridaens R, Bruning P, Klijn J, Gamucci T, Houston S, et al</AU>
<TI>Doxorubicin or taxol as first-line chemotherapy for metastatic breast cancer: Results of an EORTC-IDBBC/ECSG randomised trial with crossover (EORTC 10923)</TI>
<SO>Breast Cancer Research and Treatment; San Antonio Conference Proceedings; 1997; San Antonio</SO>
<YR>1997</YR>
<VL>46</VL>
<PG>Abstract 2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:35:23 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruning P, Piccart MJ, Klijn J, Gamucci T, Kusenda Z, Roy JA, et al</AU>
<TI>Paclitaxel (P) versus doxorubicin (D) as first line chemotherapy (CT) in advanced breast cancer (ABC): a randomized trial with crossover of the EORTC-IDBBC in collaboration with EORTC-ECSG</TI>
<SO>European Journal of Cancer (Supplement)</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>2</NO>
<PG>50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-22 13:49:04 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;5340&lt;/p&gt;" NOTES_MODIFIED="2014-07-22 13:49:04 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, et al</AU>
<TI>Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>12</NO>
<PG>1498-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-22 13:49:09 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;5359&lt;/p&gt;" NOTES_MODIFIED="2014-07-22 13:49:09 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramer JA, Curran D, Piccart M, de Haes JC, Bruning PF, Klijn JG, et al</AU>
<TI>Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist</TI>
<SO>European Journal of Cancer</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>12</NO>
<PG>1488-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-22 13:49:18 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;4696&lt;/p&gt;" NOTES_MODIFIED="2014-07-22 13:49:18 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, et al</AU>
<TI>Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>4</NO>
<PG>724-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:36:25 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paridaens R, Bruning P, Calabresi F, Awada A, Roy JA, Kusenda Z, et al</AU>
<TI>Taxol or doxorubicin as first line chemotherapy in advanced breast cancer (ABC). A prospective randomized phase II study with crossover</TI>
<SO>European Journal of Cancer (Supplement)</SO>
<YR>1995</YR>
<VL>31A</VL>
<NO>5</NO>
<PG>S75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:36:43 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;3612&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:36:43 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paridaens R</AU>
<TI>Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey</TI>
<SO>Seminars in Oncology</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>5 Supplement 12</NO>
<PG>3-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:37:06 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;1967&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:37:06 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piccart-Gebhart MJ, Bruning P, Gamucci T, Klijn J, Roy JA, Awada A, et al</AU>
<TI>An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>5 Supplement 11</NO>
<PG>11-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EORTC-10961" MODIFIED="2015-05-25 13:41:21 +1000" MODIFIED_BY="Melina L Willson" NAME="EORTC 10961" YEAR="1996">
<REFERENCE MODIFIED="2011-05-10 16:24:16 +1000" MODIFIED_BY="Melina Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, et al</AU>
<TI>Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: EORTC 10961</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>14</NO>
<PG>3114-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-03 10:51:17 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biganzoli L, Cufer T, Bruning P, Coleman RE, Duchateau L, Rapoport B, et al</AU>
<TI>Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer Multicenter Trial</TI>
<SO>Cancer</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>1</NO>
<PG>40-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-20 19:57:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, et al</AU>
<TI>Randomized, controlled trial investigating short-term health-related quality of life with doxorubicini and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>13</NO>
<PG>2576-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:41:21 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;3715&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 13:41:21 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>Piccart-Gebhart MJ</AU>
<TI>Phase III randomised study of first-line chemotherapy with doxorubicin/paclitaxel vs doxorubicin/cyclophosphamide in metastatic breast cancer</TI>
<SO>Physician Data Query (NCI website)</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-EU_x002d_93011" MODIFIED="2015-05-25 13:47:59 +1000" MODIFIED_BY="Melina L Willson" NAME="EU-93011" YEAR="1994">
<REFERENCE MODIFIED="2015-05-25 13:43:30 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Heidemann E, Hollander N, von Minckwitz G, Souchon R, Clemens MR, Mahike M, et al</AU>
<TI>Mitoxantrone (M) versus mitoxantrone plus docetaxel (MDoc) as first-line therapy for patients with high-risk metastatic breast cancer: results of a multicentre randomized trial. Unpublished manuscript (as supplied March 2011)</TI>
<SO>Data on file</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:45:49 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Heidemann E, Minckwitz GV, Hollander N, Souchon R, Clemens M, Mahike M, et al</AU>
<TI>Mitoxantrone plus docetaxel vs single agent mitoxantrone in metastatic breast cancer (MBC): results of a multicenter randomized trial</TI>
<SO>Proceedings of American Society of Clinical Oncology; 2004</SO>
<YR>2004</YR>
<VL>22, No 14S</VL>
<PG>637</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:47:59 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00002544</AU>
<TI>Mitoxantrone with or without docetaxel in treating women with metastatic breast cancer</TI>
<SO>http://clinicaltrials.gov/show/NCT00002544</SO>
<YR>(accessed 12 January 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HERNATA" MODIFIED="2014-07-22 14:33:20 +1000" MODIFIED_BY="[Empty name]" NAME="HERNATA" YEAR="2011">
<REFERENCE MODIFIED="2014-07-22 14:33:20 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21149659&lt;br&gt;IN - Department of Oncology 5073, Rigshospitalet, 9 Blegdamsvej, 2100 Copenhagen, Denmark. michael.andersson@rh.regionh.dk&lt;br&gt;CM - Comment in: J Clin Oncol. 2011 Jan 20;29(3):251-3; PMID: 21149664&lt;br&gt;PT - Clinical Trial, Phase III&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;DC - 20110119&lt;/p&gt;" NOTES_MODIFIED="2014-07-22 14:33:20 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, et al</AU>
<TI>Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>3</NO>
<PG>264-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-07-18 15:16:27 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jassem" MODIFIED="2015-05-25 13:54:27 +1000" MODIFIED_BY="Melina L Willson" NAME="Jassem" YEAR="1996">
<REFERENCE MODIFIED="2014-07-22 14:48:17 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19745590&lt;br&gt;IN - Dept. of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland. jjassem@amg.gda.pl&lt;br&gt;AS - Onkologie. 32(8-9):468-72, 2009 Sep&lt;br&gt;JC - 7808556, ohr&lt;br&gt;SB - IM&lt;br&gt;CP - Switzerland&lt;br&gt;PT - Clinical Trial, Phase III&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2014-07-22 14:48:17 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Berzins J, et al</AU>
<TI>Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial</TI>
<SO>Onkologie</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>8-9</NO>
<PG>468-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-22 14:48:21 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;5645&lt;/p&gt;" NOTES_MODIFIED="2014-07-22 14:48:21 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, et al</AU>
<TI>Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>6</NO>
<PG>1707-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:53:59 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pluzanska A, Jassem J, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, et al</AU>
<TI>Randomized open-label phase III multicenter trial comparing TAXOL/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>Supplement 4</NO>
<PG>S314</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:54:27 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pluzanska A, Pienkowski T, Jelic S, Mrsic-Krmpotic Z, Gorbunova V, Garin A, et al</AU>
<TI>Phase III multicenter trial comparing Taxol®/Doxorubicin (AT) vs 5-fluorouracil/Doxorubicin and Cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer</TI>
<SO>Breast Cancer Research and Treatment; San Antonio Breast Cancer Symposium; 1999; San Antonio</SO>
<YR>1999</YR>
<VL>57</VL>
<PG>Abstract 21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JCOG9802" MODIFIED="2015-05-25 13:58:08 +1000" MODIFIED_BY="Melina L Willson" NAME="JCOG9802" YEAR="">
<REFERENCE MODIFIED="2015-05-25 13:57:15 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Katsumata N, Minami H, Aogi K, Tabei T, Sano M, Masuda N, et al</AU>
<TI>Phase III trial of doxorubicin (A)/cyclophosphamide (C) (AC), docetaxel (D), and alternating AC and D (AC-D) as front-line chemotherapy for metastatic breast cancer (MBC): Japan Clinical Oncology Group trial (JCOG9802)</TI>
<SO>Journal of Clinical Oncology; Proceedings of American Society of Clinical Oncology; 2005</SO>
<YR>2005</YR>
<VL>23, No 16S</VL>
<PG>Abstract 521</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 13:58:08 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M, et al</AU>
<TI>Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)</TI>
<SO>Annals of Oncology</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>7</NO>
<PG>1210-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyman" MODIFIED="2015-05-22 15:33:51 +1000" MODIFIED_BY="Melina L Willson" NAME="Lyman" YEAR="">
<REFERENCE MODIFIED="2015-05-22 15:33:51 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lyman GH, Green SK, Ravdin PM, Geyer Jn CE, Russell CA, Balcerzak SP, et al</AU>
<TI>A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer</TI>
<SO>Breast Cancer Research and Treatment</SO>
<YR>2004</YR>
<VL>85</VL>
<NO>2</NO>
<PG>143-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meier" MODIFIED="2015-05-22 15:33:04 +1000" MODIFIED_BY="Melina L Willson" NAME="Meier" YEAR="">
<REFERENCE MODIFIED="2015-05-22 15:33:04 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meier CR, Illiger HJ, Steder M, Janssen J, Deertz H, Braun M, et al</AU>
<TI>Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment</TI>
<SO>Onkologie</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>8-9</NO>
<PG>447-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nabholtz" MODIFIED="2015-05-25 14:00:49 +1000" MODIFIED_BY="Melina L Willson" NAME="Nabholtz" YEAR="1998">
<REFERENCE MODIFIED="2015-05-25 14:00:49 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mackey JR, Paterson A, Dirix LY, Dewar J, Chap L, Martin M, et al</AU>
<TO>Final results of the phase III randomized trial comparing doectaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)</TO>
<SO>Proceedings of American Society of Clinical Oncology; 2002</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>Abstract 137</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 14:00:37 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;5973&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 14:00:37 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Nabholtz JA, Paterson A, Dirix L, Dewar J, Chap L, Martin M, et al</AU>
<TI>A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients (Pts) with metastatic breast cancer (MBC)</TI>
<SO>Proceeding of American Society of Clinical Oncology; 2001</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>Abstract 83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rugo" MODIFIED="2015-05-25 14:06:47 +1000" MODIFIED_BY="Melina L Willson" NAME="Rugo" YEAR="">
<REFERENCE MODIFIED="2014-07-22 15:03:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, et al</AU>
<TI>A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer</TI>
<SO>Breast Cancer Research and Treatment</SO>
<YR>2013</YR>
<VL>139</VL>
<NO>2</NO>
<PG>411-9</PG>
<IDENTIFIERS MODIFIED="2014-07-18 17:45:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="23649189"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 14:05:31 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rugo HS, Campone M, Amadori D, Wardley A, Villa E, Conte PF, et al</AU>
<TI>Randomized phase II study of weekly versus every-3-week ixabepilone plus bevaziumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC)</TI>
<SO>Proceedings of American Society of Clinical Oncology; 2009</SO>
<YR>2009</YR>
<VL>27 No 15S</VL>
<PG>Abstract 1029</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 14:06:47 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rugo HS, Campone M, Amadori D, Wardley AM, Aldrighetti D, Conte PF, et al</AU>
<TI>Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results</TI>
<SO>Journal of Clinical Oncology; American Society of Clinical Oncology Annual Meeting Proceedings; 2010</SO>
<YR>2010</YR>
<VL>28 Supplement 15</VL>
<PG>Abstract 1040</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sjostrom" MODIFIED="2015-05-25 14:36:30 +1000" MODIFIED_BY="Melina L Willson" NAME="Sjostrom" YEAR="1994">
<REFERENCE MODIFIED="2015-05-20 20:21:58 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;4827&lt;/p&gt;" NOTES_MODIFIED="2015-05-20 20:21:58 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakamies-Blomqvist L, Luoma M, Sjostrom J, Pluzanska A, Sjodin M, Mouridsen H, et al</AU>
<TI>Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group</TI>
<SO>European Journal of Cancer</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>11</NO>
<PG>1411-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-22 15:06:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luoma ML, Hakamies-Blomqvist L, Sjostrom J, Pluzanska A, Ottoson S, Mouridsen H, et al</AU>
<TI>Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>2003</YR>
<VL>39</VL>
<NO>10</NO>
<PG>1370-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12826039 12826039"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-22 15:06:19 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;4457&lt;/p&gt;" NOTES_MODIFIED="2014-07-22 15:06:19 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, et al</AU>
<TI>Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1194-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 14:36:30 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;5959&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 14:36:30 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sjostrom J, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson N-O, Ostenstad B, et al</AU>
<TI>Taxotere (T) versus methotrexate-5-fluorouracil (MF) in patients with advanced anthracycline-resistant breast cancer: preliminary results of a randomized phase III study by Scandanavian Breast Group</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>Abstract 427</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talbot" MODIFIED="2015-05-22 15:07:07 +1000" MODIFIED_BY="Melina L Willson" NAME="Talbot" YEAR="1996">
<REFERENCE MODIFIED="2015-05-22 15:07:07 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Albo Conejo E, Ackland S, et al</AU>
<TI>Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines</TI>
<SO>British Journal of Cancer</SO>
<YR>2002</YR>
<VL>86</VL>
<NO>9</NO>
<PG>1367-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TOG" MODIFIED="2015-05-25 14:52:23 +1000" MODIFIED_BY="Melina L Willson" NAME="TOG" YEAR="1997">
<REFERENCE MODIFIED="2015-05-25 14:51:30 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Ref ID 6661&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 14:51:30 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Icli F, Akbulut H, Uner A, Bulent Y, Altinbas M, Baltali E, et al</AU>
<TI>Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<PG>Abstract 47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 14:52:23 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Ref ID (not on BCRG SG yet)&lt;br&gt;Slides from talk available online.&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 14:52:23 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Icli F, Akbulut H, Uner A, Yalcin B, Altinbas M, Baltali E, et al</AU>
<TI>Paclitaxel (T) vs cisplatin + VP-16 (EP) in advanced breast cancer patients pre-treated with anthracyclines: A phase III randomized study, Turkish Oncology Group</TI>
<SO>Annals of Oncology; Proceedings of the 27th ESMO Congress; 2002; Nice</SO>
<YR>2002</YR>
<VL>13 Supplement 15</VL>
<PG>Abstract 167O</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-03 10:53:23 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, et al</AU>
<TI>Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group</TI>
<SO>British Journal of Cancer</SO>
<YR>2005</YR>
<VL>92</VL>
<PG>639-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TRAVIOTA" MODIFIED="2015-05-25 14:02:48 +1000" MODIFIED_BY="Melina L Willson" NAME="TRAVIOTA" YEAR="2007">
<REFERENCE MODIFIED="2015-05-25 14:02:48 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Burstein HJ, Keshaviah A, Baron A, Hart R, Lambert-Falls R, Marcom PK, et al</AU>
<TI>Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: the TRAVIOTA study</TI>
<SO>Americal Society of Clinical Oncology Annual Meeting Proceedings; 2006; Chicago</SO>
<YR>2006</YR>
<VL>24, No 18S</VL>
<PG>Abstract 650</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-22 14:35:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, et al</AU>
<TI>Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study</TI>
<SO>Cancer</SO>
<YR>2007</YR>
<VL>110</VL>
<NO>5</NO>
<PG>965-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TXT" MODIFIED="2015-05-25 14:02:02 +1000" MODIFIED_BY="Melina L Willson" NAME="TXT" YEAR="1995">
<REFERENCE MODIFIED="2015-05-25 14:02:02 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Ref ID 5525&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 14:02:02 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bonneterre J, Roche H, Monnier A, Fargeot P, Namer M, Guastella JP, et al</AU>
<TI>Docetaxel (D) versus 5 fluorouracil-vinorelbine (FUN) in patients (PTS) with metastatic breast cancer (MBC) as second line chemotherapy: a phase III study</TI>
<SO>Breast Cancer Research and Treatment; San Antonio Breast Cancer Symposium; 1998; San Antonio</SO>
<YR>1998</YR>
<VL>50</VL>
<PG>Abstract 223</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-22 15:25:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, et al</AU>
<TI>Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure</TI>
<SO>British Journal of Cancer</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>11</NO>
<PG>1210-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="22325575"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 14:46:58 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;5814&lt;/p&gt;" NOTES_MODIFIED="2015-05-22 14:46:58 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Monnier A, Bonneterre J, Roche H, Fargeot P, Namer M, Guastalla JP</AU>
<TI>Phase III study: Taxotere (TXT) versus 5-fluorouracil + navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy (CT) (preliminary results)</TI>
<SO>Annals of Oncology. Congress of the European Society for Medical Oncology; 1998; Athens</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>Abstract 580</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UKCCCR-AB01" MODIFIED="2015-05-25 14:01:34 +1000" MODIFIED_BY="Melina L Willson" NAME="UKCCCR AB01" YEAR="1996">
<REFERENCE MODIFIED="2015-05-22 15:04:15 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;Ref ID 2010&lt;br&gt;Protocol published on PDQ&lt;/p&gt;" NOTES_MODIFIED="2015-05-22 15:04:15 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>Carmichael J, Jones A</AU>
<TI>A randomised trial of epirubicin &amp; cyclophosphamide vs epirubicin &amp; paclitaxel in metastatic breast cancer</TI>
<SO>http://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cdrid=65426&amp;version=healthprofessional</SO>
<YR>(accessed 1997)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 14:01:34 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;5974&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 14:01:34 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Carmichael J</AU>
<TI>UKCCCR trial of epirubicin and cyclophosphamide (EC) vs epirubicin and taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC)</TI>
<SO>Proceedings of American Society of Clinical Oncology; 2001</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>Abstract 84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 14:51:22 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Langley RE, Carmichael J, Jones AL, Cameron DA, Qian W, Uscinska B, et al</AU>
<TI>Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>33</NO>
<PG>8322-30</PG>
<IDENTIFIERS MODIFIED="2015-05-22 14:51:22 +1000" MODIFIED_BY="Melina L Willson"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yardley" MODIFIED="2014-11-03 10:53:41 +1100" MODIFIED_BY="Melina L Willson" NAME="Yardley" YEAR="">
<REFERENCE MODIFIED="2014-11-03 10:53:41 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yardley DA, Burris HA, Spigel DR, Clark BL, Vazquez E, Shipley D, et al</AU>
<TI>A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer</TI>
<SO>Clinical Breast Cancer</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>4</NO>
<PG>247-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-05-25 14:56:41 +1000" MODIFIED_BY="Melina L Willson">
<STUDY DATA_SOURCE="PUB" ID="STD-Brufsky-2012" MODIFIED="2014-11-03 10:53:49 +1100" MODIFIED_BY="Melina L Willson" NAME="Brufsky 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-11-03 10:53:49 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, et al</AU>
<TI>Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial</TI>
<SO>Breast Cancer Research and Treatment</SO>
<YR>2012</YR>
<VL>133</VL>
<PG>1067-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gebbia-2003" MODIFIED="2015-05-20 20:36:41 +1000" MODIFIED_BY="[Empty name]" NAME="Gebbia 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-05-20 20:36:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gebbia V, Blasi L, Borsellino N, Caruso M, Leonardi V, Agostara B, et al</AU>
<TI>Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomised phase II study</TI>
<SO>Anticancer Research</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>1B</NO>
<PG>765-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12680181"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gennari-2001" MODIFIED="2015-05-25 14:54:46 +1000" MODIFIED_BY="Melina L Willson" NAME="Gennari 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-04-17 15:45:09 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, Lorusso V, et al</AU>
<TI>Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>24</NO>
<PG>3912-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 14:54:46 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;5734&lt;/p&gt;" NOTES_MODIFIED="2015-05-25 14:54:46 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gennari A, Manzione L, Del Mastro L, Amadori D, De Lena M, Moretti G, et al</AU>
<TI>Paclitaxel (P) maintenance treatment following first line chemotherapy with anthracyclines plus paclitaxel in metastatic breast cancer (MBC): preliminary results from the Italian MANTA 1 study</TI>
<SO>Breast Cancer Research and Treatment</SO>
<YR>2001</YR>
<VL>64</VL>
<PG>Abstract 325</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghosn-2011" MODIFIED="2014-11-03 10:53:57 +1100" MODIFIED_BY="Melina L Willson" NAME="Ghosn 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-11-03 10:53:57 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghosn M, Aftimos P, Farhat FS, Kattan JG, Hanna C, Haddad N, et al</AU>
<TI>A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer</TI>
<SO>Medical Oncology</SO>
<YR>2011</YR>
<VL>28</VL>
<PG>S142-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamberg-2011" MODIFIED="2014-11-03 10:54:04 +1100" MODIFIED_BY="Melina L Willson" NAME="Hamberg 2011" YEAR="">
<REFERENCE MODIFIED="2014-11-03 10:54:04 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamberg P, Bos MMEM, Braun HJJ, Southard JML, van Deijk GA, Erdkamp FLG, et al</AU>
<TI>Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial</TI>
<SO>Clinical Breast Cancer</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>2</NO>
<PG>103-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2011" MODIFIED="2014-11-03 10:54:12 +1100" MODIFIED_BY="Melina L Willson" NAME="Huang 2011" YEAR="">
<REFERENCE MODIFIED="2014-11-03 10:54:12 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang HY, Jiang ZF, Wang T, Zhang SH, Bian L, Cao Y, et al</AU>
<TI>Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer</TI>
<SO>Chinese Journal of Oncology [Zhonghua Zhong Liu Za Zhi]</SO>
<YR>2011</YR>
<VL>33</VL>
<NO>11</NO>
<PG>850-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakurai-2007" MODIFIED="2015-05-20 20:39:26 +1000" MODIFIED_BY="[Empty name]" NAME="Sakurai 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-20 20:39:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakurai K, Enomoto K, Kitajima A, Tani M, Amano S</AU>
<TI>Efficacy of trastuzumab alone therapy was compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancers [article in Japanese]</TI>
<SO>Gan To Kagaku Ryoho</SO>
<YR>2007</YR>
<VL>34</VL>
<NO>12</NO>
<PG>1911-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmid-2005" MODIFIED="2014-11-03 10:54:28 +1100" MODIFIED_BY="Melina L Willson" NAME="Schmid 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-11-03 10:54:28 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, et al</AU>
<TI>Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>3</NO>
<PG>432-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-07-22 15:42:02 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szanto-2001" MODIFIED="2015-05-25 14:56:41 +1000" MODIFIED_BY="Melina L Willson" NAME="Szanto 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-05-25 14:56:41 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szanto J, Pinter T, Szanto J</AU>
<TI>Effectiveness of doxorubicin + docetaxel (DD) or doxorubicin + cyclophosphamide (DC) combination in advanced breast cancer with distant metastases</TI>
<SO>Orvosi Hetilap</SO>
<YR>2001</YR>
<VL>142</VL>
<NO>14</NO>
<PG>723-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-05-26 13:30:18 +1000" MODIFIED_BY="Melina L Willson">
<STUDY DATA_SOURCE="PUB" ID="STD-TIPP" MODIFIED="2015-05-26 13:30:18 +1000" MODIFIED_BY="Melina L Willson" NAME="TIPP" YEAR="">
<REFERENCE MODIFIED="2015-05-25 14:58:47 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Friedrich M, Wasemann C, Hollander M, Ertan K, Schmidt W</AU>
<TI>Randomized phase II study of docetaxel vs. epirubicin/cyclophosphamide to optimize first-line therapy of metastatic breast cancer (MBC): preliminary results of the TIPP study</TI>
<SO>Proceedings of American Society of Clinical Oncology; 2002</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>Abstract 2028</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-26 13:30:18 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Wasemann C, Ertan AK, Schmidt W, Diedrich K, Friedrich M</AU>
<TI>Randomized phase II study of docetaxel vs epirubicin/cyclophoshamide to optimize first-line therapy of metastatic breast cancer: end results of TIPP study</TI>
<SO>International Journal of Gynecological Cancer; 2005</SO>
<YR>2005</YR>
<VL>15, Supplement 2</VL>
<PG>Abstract 000408</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu" MODIFIED="2014-09-22 10:37:51 +1000" MODIFIED_BY="Melina L Willson" NAME="Xu" YEAR="2013">
<REFERENCE MODIFIED="2014-09-22 10:37:51 +1000" MODIFIED_BY="Melina L Willson" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21465229&lt;br&gt;IN - Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan, Chaoyang District, Beijing, 100021, China. bhxu@hotmail.com&lt;br&gt;AS - Breast Cancer. 18(3):203-12, 2011 Jul&lt;br&gt;JC - 100888201, due&lt;br&gt;SB - IM&lt;br&gt;CP - Japan&lt;br&gt;PT - Clinical Trial, Phase II&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;br&gt;DC - 20110722&lt;/p&gt;" NOTES_MODIFIED="2014-09-22 10:37:51 +1000" NOTES_MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Xu B, Jiang Z, Kim SB, Yu S, Feng J, Malzyner A, et al</AU>
<TI>Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial</TI>
<SO>Breast Cancer</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>3</NO>
<PG>203-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2015-05-26 13:31:19 +1000" MODIFIED_BY="Melina L Willson">
<STUDY DATA_SOURCE="UNPUB" ID="STD-EUCTR2012_x002d_003530_x002d_16_x002d_ES" MODIFIED="2014-07-22 16:41:08 +1000" MODIFIED_BY="[Empty name]" NAME="EUCTR2012-003530-16-ES" YEAR="">
<REFERENCE MODIFIED="2014-07-22 16:41:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>EUCTR2012-003530-16-ES</AU>
<TI>Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer</TI>
<SO>http://apps.who.int/trialsearch/trial.aspx?trialid=EUCTR2012-003530-16-ES (accessed 22 July 2014)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-EUCTR2012_x002d_003743_x002d_30_x002d_SE" MODIFIED="2014-11-03 10:54:55 +1100" MODIFIED_BY="Melina L Willson" NAME="EUCTR2012-003743-30-SE" YEAR="">
<REFERENCE MODIFIED="2014-11-03 10:54:55 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>EUCTR2012-003743-30-SE</AU>
<TI>A prospective randomized Phase II study to identify predictive biomarkers and mechanisms of therapy resistance in patients with HER2-negative metastatic breast cancer (MBC) treated with the combination of bevacizumab and paclitaxel</TI>
<SO>http://apps.who.int/trialsearch/trial.aspx?trialid=EUCTR2012-003743-30-SE (accessed 22 July 2014)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ISRCTN97330959" MODIFIED="2015-05-26 13:30:43 +1000" MODIFIED_BY="Melina L Willson" NAME="ISRCTN97330959" YEAR="2007">
<REFERENCE MODIFIED="2015-05-26 13:30:43 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN97330959</AU>
<TI>Triple negative trial: a randomised phase III trial of carboplatin compared to docetaxel for patients with advanced oestrogen receptor-progesterone receptor-human epidermal growth factor receptor two-breast cancer TNT</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=ISRCTN97330959</SO>
<YR>(accessed 23 July 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-22 13:21:24 +1100" MODIFIED_BY="Melina Willson">
<IDENTIFIER MODIFIED="2011-03-22 13:21:24 +1100" MODIFIED_BY="Melina Willson" TYPE="OTHER" VALUE="EudraCT No: 200+-004470-26"/>
<IDENTIFIER MODIFIED="2011-03-22 12:58:02 +1100" MODIFIED_BY="Melina Willson" TYPE="OTHER" VALUE="ICR-CTSU/2006/10003"/>
<IDENTIFIER MODIFIED="2011-03-22 12:57:49 +1100" MODIFIED_BY="Melina Willson" TYPE="OTHER" VALUE="NCT00532727"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-JPRN_x002d_C000000416" MODIFIED="2014-11-03 10:55:03 +1100" MODIFIED_BY="Melina L Willson" NAME="JPRN-C000000416" YEAR="2000">
<REFERENCE MODIFIED="2011-03-22 16:35:39 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>JPRN-C000000416</AU>
<TI>Randomised study of taxane vs TS-1 in metastatic or recurrent breast cancer patients</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN-C000000416</SO>
<YR>(accessed 23 July 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-03 10:55:03 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mukai H, Takashima T, Hozumi Y, Watanabe T, Murakami S, Masuda N, et al</AU>
<TI>Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC) [trial protocol]</TI>
<SO>Japanese Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>40</VL>
<NO>8</NO>
<PG>811-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00321633" MODIFIED="2011-03-22 16:27:36 +1100" MODIFIED_BY="Melina L Willson" NAME="NCT00321633" YEAR="2004">
<REFERENCE MODIFIED="2011-03-22 16:27:36 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00321633</AU>
<TI>Carboplatin or docetaxel in treating women with metastatic genetic breast cancer</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT00321633</SO>
<YR>(accessed 23 July 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-22 14:53:23 +1100" MODIFIED_BY="Melina Willson">
<IDENTIFIER MODIFIED="2011-03-22 14:52:58 +1100" MODIFIED_BY="Melina Willson" TYPE="ISRCTN" VALUE="43372330"/>
<IDENTIFIER MODIFIED="2011-03-22 14:53:23 +1100" MODIFIED_BY="Melina Willson" TYPE="OTHER" VALUE="Eudract-2004-001496-20"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00490646" MODIFIED="2015-05-20 20:44:06 +1000" MODIFIED_BY="[Empty name]" NAME="NCT00490646" YEAR="2007">
<REFERENCE MODIFIED="2015-05-20 20:44:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00490646</AU>
<TI>A phase II combination of trastuzumab and ixabepilone versus trastuzumab and docetaxel in patients with advanced and/or metastatic breast cancer</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT00490646</SO>
<YR>(accessed 23 July 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-22 12:20:41 +1100" MODIFIED_BY="Melina Willson">
<IDENTIFIER MODIFIED="2011-03-22 12:20:20 +1100" MODIFIED_BY="Melina Willson" TYPE="OTHER" VALUE="CA163-140"/>
<IDENTIFIER MODIFIED="2011-03-22 12:20:41 +1100" MODIFIED_BY="Melina Willson" TYPE="OTHER" VALUE="Eudract No: 2007-000721-21"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00600340" MODIFIED="2011-03-22 16:43:26 +1100" MODIFIED_BY="Melina L Willson" NAME="NCT00600340" YEAR="2008">
<REFERENCE MODIFIED="2011-03-22 16:43:25 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00600340</AU>
<TI>2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT00600340</SO>
<YR>(accessed 23 July 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-22 12:00:58 +1100" MODIFIED_BY="Melina Willson">
<IDENTIFIER MODIFIED="2011-03-22 12:00:58 +1100" MODIFIED_BY="Melina Willson" TYPE="OTHER" VALUE="CECOG/BC1.3.005"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01126138" MODIFIED="2015-05-20 20:45:04 +1000" MODIFIED_BY="[Empty name]" NAME="NCT01126138" YEAR="2010">
<REFERENCE MODIFIED="2015-05-20 20:45:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01126138</AU>
<TI>A randomised phase III study to investigate the efficacy and safety of docetaxel plus capecitabine vs vinorelbine plus capecitabine followed by capecitabine alone as first line therapy on locally advanced and metastatic breast cancer patients</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01126138</SO>
<YR>(accessed 23 July 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-22 10:15:29 +1100" MODIFIED_BY="Melina Willson">
<IDENTIFIER MODIFIED="2011-03-22 10:15:29 +1100" MODIFIED_BY="Melina Willson" TYPE="OTHER" VALUE="ML25241"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01303679" MODIFIED="2015-05-26 13:31:19 +1000" MODIFIED_BY="Melina L Willson" NAME="NCT01303679" YEAR="3679">
<REFERENCE MODIFIED="2015-05-26 13:31:19 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01303679</AU>
<TI>Phase III randomised multicenter trial comparing continued maintenance therapy with the bevacizumab + taxane versus bevacizumab + substituting exemestane in patients with metastatic breast cancer or locally advanced with estrogen receptor positive and having at least a stable disease after 16 to 18 weeks of treatment with bevacizumab + taxane</TI>
<SO>http://clinicaltrials.gov/show/NCT01303679</SO>
<YR>(accessed 23 July 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NTR1349" MODIFIED="2011-03-22 16:53:46 +1100" MODIFIED_BY="Melina L Willson" NAME="NTR1349" YEAR="2008">
<REFERENCE MODIFIED="2011-03-22 16:53:45 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NTR1349</AU>
<TI>A randomised phase II study of concomitant trastuzumab, bevacizumab with paclitaxel versus trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab and paclitaxel at progression as first-line treatment of patients with metastatic breast cancer with HER2-neu overexpression</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=NTR1349</SO>
<YR>(accessed 23 July 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-22 11:15:43 +1100" MODIFIED_BY="Melina Willson">
<IDENTIFIER MODIFIED="2011-03-22 11:15:43 +1100" MODIFIED_BY="Melina Willson" TYPE="OTHER" VALUE="M08HAT"/>
<IDENTIFIER MODIFIED="2011-03-22 11:15:36 +1100" MODIFIED_BY="Melina Willson" TYPE="OTHER" VALUE="PTC09.0140"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Pegram" MODIFIED="2014-11-03 10:55:18 +1100" MODIFIED_BY="Melina L Willson" NAME="Pegram" YEAR="">
<REFERENCE MODIFIED="2014-11-03 10:55:18 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00081796/EUDRACT-2004-000618-38</AU>
<TI>Phase III randomized study of XRP9881 versus capecitabine in patients with locally recurrent inoperable or metastatic breast cancer that progressed after prior taxane- and anthracycline-based therapy</TI>
<SO>National Cancer Institute - Clinical Trials (PDQ)</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SAKK" NAME="SAKK" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Copied to CCN Sept 2000&lt;br&gt;4068&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Goldhirsch A</AU>
<TI>Phase III randomised study of trastuzumab (Herceptin) alone followed by paclitaxel plus trastuzumab versus upfront combination of trastuzumab and paclitaxel in women with HER2 overexpressing metastatic breast cancer</TI>
<SO>CancerNet (http://ctnetdb.nci.nih.gov)</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-06-02 10:47:10 +1000" MODIFIED_BY="Melina L Willson">
<ADDITIONAL_REFERENCES MODIFIED="2015-06-02 10:47:10 +1000" MODIFIED_BY="Melina L Willson">
<REFERENCE ID="REF-Belfiglio-2012" MODIFIED="2014-11-03 10:55:28 +1100" MODIFIED_BY="Melina L Willson" NAME="Belfiglio 2012" TYPE="JOURNAL_ARTICLE">
<AU>Belfiglio M, Fanizza C, Tinari N, Ficorella C, Iacobelli S, Natoli C, et al</AU>
<TI>Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer</TI>
<SO>Journal of Cancer Research and Clinical Oncology</SO>
<YR>2012</YR>
<VL>138</VL>
<NO>2</NO>
<PG>221-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beslija-2009" MODIFIED="2014-11-03 10:55:33 +1100" MODIFIED_BY="Melina L Willson" NAME="Beslija 2009" TYPE="JOURNAL_ARTICLE">
<AU>Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, et al</AU>
<TI>Third consensus on medical treatment of metastatic breast cancer</TI>
<SO>Annals of Oncology</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>11</NO>
<PG>1771-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BMS-1996" MODIFIED="2015-05-25 14:58:05 +1000" MODIFIED_BY="Melina L Willson" NAME="BMS 1996" TYPE="BOOK">
<AU>Bristol-Myers Squibb (BMS) Oncology</AU>
<SO>Breast Cancer: Taxane Clinical Perspectives</SO>
<YR>1996</YR>
<PB>Bristol-Myers Squibb</PB>
<CY>Princeton, New Jersey, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferlay-2015" MODIFIED="2015-05-22 10:35:46 +1000" MODIFIED_BY="Melina L Willson" NAME="Ferlay 2015" TYPE="JOURNAL_ARTICLE">
<AU>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al</AU>
<TI>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</TI>
<SO>International Journal of Cancer</SO>
<YR>2015</YR>
<VL>136</VL>
<NO>5</NO>
<PG>E359-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fossati-1998" MODIFIED="2015-05-20 20:53:02 +1000" MODIFIED_BY="[Empty name]" NAME="Fossati 1998" TYPE="JOURNAL_ARTICLE">
<AU>Fossati R, Confalonierir C, Torri V, Ghislandi E, Penna A, Pistotti V, et al</AU>
<TI>Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>10</NO>
<PG>3439-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghersi-2003" MODIFIED="2015-05-22 10:44:58 +1000" MODIFIED_BY="Melina L Willson" NAME="Ghersi 2003" TYPE="COCHRANE_REVIEW">
<AU>Ghersi D, Wilcken N, Simes J, Donoghue E</AU>
<TI>Taxane containing regimens for metastatic breast cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-05-22 10:44:58 +1000" MODIFIED_BY="Melina L Willson">
<IDENTIFIER MODIFIED="2015-05-22 10:44:52 +1000" MODIFIED_BY="Melina L Willson" TYPE="DOI" VALUE="10.1002/14651858.CD003366"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hakamies_x002d_Blomqvist-2000" MODIFIED="2015-05-25 16:17:01 +1000" MODIFIED_BY="Melina L Willson" NAME="Hakamies-Blomqvist 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hakamies-Blomqvist L, Luoma M, Sjostrom J, Pluzanska A, Sjodin M, Mouridsen H, et al</AU>
<TI>Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group</TI>
<SO>European Journal of Cancer</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>11</NO>
<PG>1411-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayes-1995" MODIFIED="2015-05-20 20:54:01 +1000" MODIFIED_BY="[Empty name]" NAME="Hayes 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hayes DF, Henderson IC, Shapiro CL</AU>
<TI>Treatment of metastatic breast cancer: present and future prospects</TI>
<SO>Seminars in Oncology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>2</NO>
<PG>5-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-11-03 10:58:50 +1100" MODIFIED_BY="Melina L Willson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hortobagyi-1996" MODIFIED="2015-05-26 13:32:04 +1000" MODIFIED_BY="Melina L Willson" NAME="Hortobagyi 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hortobagyi GN, Piccart-Gebhart MJ</AU>
<TI>Current management of advanced breast cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>Supplement 11</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mauri-2010" MODIFIED="2014-11-03 10:58:57 +1100" MODIFIED_BY="Melina L Willson" NAME="Mauri 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, et al</AU>
<TI>Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>2010</YR>
<VL>36</VL>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCI-2003" MODIFIED="2015-05-22 10:47:21 +1000" MODIFIED_BY="Melina L Willson" NAME="NCI 2003" TYPE="OTHER">
<AU>National Cancer Institute</AU>
<TI>Breast cancer (PDQ): treatment summary</TI>
<SO>http://www.cancer.gov/cancerinfo/pdq/treatment/breast/healthprofessional/</SO>
<YR>(accessed 01 February 2003)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2011-05-11 14:08:04 +1000" MODIFIED_BY="Melina Willson" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Piccart_x002d_Gebhart-2008" MODIFIED="2015-05-20 20:57:29 +1000" MODIFIED_BY="[Empty name]" NAME="Piccart-Gebhart 2008" TYPE="JOURNAL_ARTICLE">
<AU>Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Luck HJ, et al</AU>
<TI>Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>12</NO>
<PG>1980-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Qi-2013" MODIFIED="2015-06-02 10:47:05 +1000" MODIFIED_BY="Melina L Willson" NAME="Qi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al</AU>
<TI>Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>2013</YR>
<VL>29</VL>
<NO>2</NO>
<PG>117-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan" MODIFIED="2014-11-03 10:59:09 +1100" MODIFIED_BY="Melina L Willson" NAME="RevMan" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saad-2009" MODIFIED="2014-11-03 10:59:15 +1100" MODIFIED_BY="Melina L Willson" NAME="Saad 2009" TYPE="JOURNAL_ARTICLE">
<AU>Saad ED, Katz A</AU>
<TI>Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined</TI>
<SO>Annals of Oncology</SO>
<YR>2009</YR>
<VL>20</VL>
<PG>460-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stockler-2000" MODIFIED="2015-05-22 10:50:21 +1000" MODIFIED_BY="Melina L Willson" NAME="Stockler 2000" TYPE="JOURNAL_ARTICLE">
<AU>Stockler M, Wilcken NR, Ghersi D, Simes RJ</AU>
<TI>Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>3</NO>
<PG>151-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tierney-2007" MODIFIED="2015-05-20 21:02:09 +1000" MODIFIED_BY="[Empty name]" NAME="Tierney 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR</AU>
<TI>Practical methods for incorporating summary time-to-event data into meta-analysis</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vasey-2001" MODIFIED="2015-05-22 11:09:40 +1000" MODIFIED_BY="Melina L Willson" NAME="Vasey 2001" TYPE="CONFERENCE_PROC">
<AU>Vasey P on behalf of the Scottish Gynaecologic Cancer Trials Group</AU>
<TI>Preliminary results of the SCOTROC trial: A phase III comparison of paclitaxel-carboplatin and docetaxel-carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian cancer</TI>
<SO>Proceedings of the American Society of Clinical Oncology; 2001; Chicago</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>Abstract 804</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-1985" MODIFIED="2014-11-03 10:59:29 +1100" MODIFIED_BY="Melina L Willson" NAME="Yusuf 1985" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Peto R, Lewis J, Colins R, Sleight P</AU>
<TI>Beta blockade during and after myocardial infarction. An overview of randomized trials</TI>
<SO>Progress in Cardiovascular Disease</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>5</NO>
<PG>335-71</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2015-05-20 21:01:12 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bonneterre-2002" MODIFIED="2015-05-20 21:00:49 +1000" MODIFIED_BY="[Empty name]" NAME="Bonneterre 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, et al</AU>
<TI>Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure</TI>
<SO>British Journal of Cancer</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>11</NO>
<PG>1210-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12439707"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Icli-2005" MODIFIED="2015-05-20 21:01:12 +1000" MODIFIED_BY="[Empty name]" NAME="Icli 2005" TYPE="JOURNAL_ARTICLE">
<AU>Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, et al</AU>
<TI>Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group</TI>
<SO>British Journal of Cancer</SO>
<YR>2005</YR>
<VL>92</VL>
<NO>4</NO>
<PG>639-44</PG>
<IDENTIFIERS MODIFIED="2014-07-18 17:41:18 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15726120"/>
</IDENTIFIERS>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-06-02 09:39:56 +1000" MODIFIED_BY="Melina L Willson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x0033_03-Study-Group">
<CHAR_METHODS MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 04/1994 to 01/1997<BR/>Multicentre, international<BR/>Centralised randomisation, method not specified<BR/>Slight imbalance in some baseline characteristics (see 'Risk of bias' table)<BR/>Median follow-up: 23 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>Female<BR/>Age range 25 to 74 years, median age 52.0 years in both arms<BR/>100% metastatic breast cancer<BR/>100% &gt; first-line<BR/>All participants anthracycline naïve</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 23:50:37 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: docetaxel 100 mg/m<SUP>2</SUP>
</P>
<P>Arm 2: doxorubicin 75 mg/m<SUP>2</SUP>
</P>
<P>Both arms q21 days for maximum 7 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 05:50:22 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Time to progression, defined as from date randomised to date of progression or death</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival, defined as date of randomisation until the date of death for any reason</LI>
<LI>Time to treatment failure, defined as date of randomisation to the date of progression, death for any reason, withdrawal due to an adverse event, participant refusal, or further anticancer therapy before documentation of progression</LI>
<LI>Response</LI>
<LI>Toxicity</LI>
<LI>Quality of life</LI>
<LI>Toxic deaths</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 05:51:41 +1000" MODIFIED_BY="[Empty name]">
<P>Follow-up details not reported</P>
<UL>
<LI>estimated minimum 5.5 months</LI>
<LI>estimated maximum 34 months (OS), 20 months (PFS), 19.5 months (TTF)</LI>
</UL>
<P>All randomised participants included in time-to-event analyses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 23:55:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x0033_04-Study-Group">
<CHAR_METHODS MODIFIED="2015-05-20 06:01:31 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 07/1994 to 02/1997<BR/>Multicentre, international<BR/>Randomisation "centralised ... with a block design by institution"<BR/>Baseline comparability: no significant imbalance apparent or reported except for number of organs involved<BR/>Median follow-up: 19 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 06:02:26 +1000" MODIFIED_BY="[Empty name]">
<P>Female<BR/>Age range 30 to 78 years, median age 51.0 (docetaxel) and 52.0 (mitomycin)<BR/>100% metastatic breast cancer<BR/>19% first-line, 81% &gt; first-line<BR/>All women had failed previous anthracycline-containing regimens</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 23:51:56 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: docetaxel 100 mg/m<SUP>2</SUP> q21 days<BR/>Arm 2: mitomycin 12 mg/m<SUP>2</SUP> q6 weeks + vinblastine 6 mg/m<SUP>2</SUP> q21 days<BR/>Both arms for a maximum of 10 3-week cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 06:11:19 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Time to progression, defined as from date randomised to date of progression or death</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival, defined as date of randomisation until the date of death for any reason</LI>
<LI>Time to treatment failure, defined as date of randomisation to the date of progression, death for any reason, withdrawal due to an adverse event, participant refusal, or further anticancer therapy before documentation of progression</LI>
<LI>Response</LI>
<LI>Toxicity</LI>
<LI>Quality of life</LI>
<LI>Toxic deaths</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 06:12:42 +1000" MODIFIED_BY="[Empty name]">
<P>Follow-up details not reported:</P>
<UL>
<LI>estimated minimum 4.5 months</LI>
<LI>estimated maximum 33 months (OS), 19 months (PFS)</LI>
</UL>
<P>All randomised participants included in time-to-event analyses<BR/>Estimate for time-to-event outcomes obtained using exact P value and total events</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 06:27:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x0033_06-Study-Group">
<CHAR_METHODS MODIFIED="2014-07-23 09:37:44 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 06/1996 to 03/1998<BR/>Multicentre, international<BR/>Randomisation centralised (block design)<BR/>Baseline comparability: well balanced<BR/>Median follow-up: 49 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 06:24:08 +1000" MODIFIED_BY="[Empty name]">
<P>Median age 52.5 in doxorubicin + docetaxel group and 54 years in doxorubicin + cyclophosphamide group<BR/>100% metastatic breast cancer<BR/>100% first-line<BR/>Anthracycline naïve</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 06:26:55 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: doxorubicin + docetaxel (50/75 mg/m<SUP>2</SUP>)<BR/>Arm 2: doxorubicin + cyclophosphamide (60/600 mg/m<SUP>2</SUP>)<BR/>Both arms q21 days, maximum 8 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 06:25:38 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Time to progression (defined as from date randomised to date of first progression)</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Time to treatment failure</LI>
<LI>Response</LI>
<LI>Toxicity</LI>
<LI>Toxic death</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 06:27:19 +1000" MODIFIED_BY="[Empty name]">
<P>Follow-up details not reported<BR/>Report numbers at risk on survival curve<BR/>All randomised participants included in time-to-event analyses<BR/>Estimate for time to progression obtained from reported hazard ratio and 95% confidence intervals. Estimate for overall survival obtained from P value and total events. Estimate for time to treatment failure obtained from time-to-event curve</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 17:10:27 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-AGO">
<CHAR_METHODS MODIFIED="2014-07-23 09:38:31 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 10/1996 to 05/1999<BR/>Multicentre, national (Germany)<BR/>Randomisation method not specified<BR/>Baseline comparability: no significant imbalance reported<BR/>Median follow-up: 36 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 07:30:09 +1000" MODIFIED_BY="[Empty name]">
<P>Median age 56 years in both arms<BR/>26% had "locally metastatic disease"<BR/>In the remainder the main site of metastases were liver or lung (although proportions do not add up)<BR/>100% first-line<BR/>Anthracycline naïve (except for 3% of participants in epirubicin + paclitaxel group)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 07:30:23 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: epirubicin 60 mg/m<SUP>2</SUP> + paclitaxel 175 mg/m<SUP>2</SUP>)<BR/>Arm 2: epirubicin 60 mg/m<SUP>2</SUP> + cyclophosphamide 600 mg/m<SUP>2</SUP>)<BR/>
</P>
<P>Both arms q21 days for at least 6 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-25 17:10:27 +1000" MODIFIED_BY="Melina L Willson">
<P>Outcomes were not separated into primary and secondary:</P>
<UL>
<LI>Response</LI>
<LI>Toxicity</LI>
<LI>Progression-free survival (no definition provided in the abstract)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-23 09:38:19 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only available. Full article has not yet been published</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 17:10:22 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-ANZ-TITG">
<CHAR_METHODS MODIFIED="2015-05-20 06:55:15 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 30 September 1993 to 30 September 1995<BR/>Multi-centre, international<BR/>Centralised, computer-generated randomisation<BR/>Baseline comparability: no significant imbalance reported<BR/>Median follow-up: 26 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 06:52:04 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 32 to 80 years, median age 54 years in both arms<BR/>Approximately 90% metastatic breast cancer<BR/>100% first-line<BR/>Did not exclude prior anthracycline use, however only 1% of participants on CMFP and 0 participants on paclitaxel had received anthracyclines</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-25 16:07:16 +1000" MODIFIED_BY="Melina L Willson">
<P>Arm 1: paclitaxel 200 mg/m<SUP>2</SUP>
<BR/>Arm 2: cyclophosphamide 100 mg/m<SUP>2</SUP>+ methotrexate 40 mg/m<SUP>2</SUP>+ fluorouracil 600 mg/m<SUP>2</SUP>+ prednisone 40 mg/m<SUP>2</SUP> (CMFP)<BR/>Both arms q21 days for 8 courses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-25 17:10:22 +1000" MODIFIED_BY="Melina L Willson">
<P>Outcomes were not separated into primary or secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Progression-free survival, defined as from date randomised to date of progression or death without progression</LI>
<LI>Response</LI>
<LI>Toxicity</LI>
<LI>Quality of life</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 06:54:37 +1000" MODIFIED_BY="[Empty name]">
<P>Follow-up details reported</P>
<UL>
<LI>minimum 17 months</LI>
<LI>maximum 40 months</LI>
</UL>
<P>All randomised participants included in time-to-event analyses<BR/>Estimate for time-to-event outcomes obtained using exact P value and total events</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 16:03:34 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-Blohmer">
<CHAR_METHODS MODIFIED="2015-05-20 07:04:57 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 02/2000 to 11/2003<BR/>Multicentre, open-label, randomised phase III trial at 49 centres in Germany<BR/>Randomisation &#8220;centralised with a block design by study centre&#8221;<BR/>Imbalance in the number of participants randomised to each arm (that is epirubicin + docetaxel group, n = 125; epirubicin + cyclophosphamide group, n = 111)<BR/>Median follow-up: 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 07:05:23 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 31 to 73 years, median age 57 years (epirubicin + docetaxel group) and 56 years (epirubicin + cyclophosphamide group)<BR/>100% metastatic breast cancer<BR/>First-line<BR/>No previous chemotherapy/anthracyclines allowed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 07:07:23 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: epirubicin 75 mg/m<SUP>2</SUP> (IV bolus or infusion for 10 min) + docetaxel 75 mg/m<SUP>2 </SUP>(IV infusion over 1 hour)</P>
<P>Arm 2: epirubicin 90 mg/m<SUP>2</SUP> (IV) + cyclophosphamide 600 mg/m<SUP>2 </SUP>(IV over 30 min)<BR/>Treatment (both arms) q21 days, 6 cycles and in some cases 8 cycles if &#8220;maximum benefit had not been reached&#8221;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 07:08:52 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Time to progression, defined as the time from registration until disease progression</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival, defined as date of registration to the date of death for any reason</LI>
<LI>Objective response rates </LI>
<LI>Adverse events and toxic effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:03:34 +1000" MODIFIED_BY="Melina L Willson">
<P>Trial prematurely stopped due to inadequate accrual and unlikelihood of reaching primary end point.</P>
<P>We contacted the trialists (Peter Schmid) who provided the number of events in each treatment arm for the outcomes OS and PFS.<BR/>Method 4 (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>) was then used to estimate O-E, and V.</P>
<P>For toxicity, the number of randomised women was used as the denominator.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 16:06:58 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-Bonneterre">
<CHAR_METHODS MODIFIED="2015-05-20 07:18:05 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 09/1998 to 11/2000<BR/>Multicentre, national (France)<BR/>Randomisation centralised and stratified according to centre<BR/>Baseline comparability: no significant imbalance reported, although ET arm had a higher proportion of participants with an original diagnosis of stage IV disease and more advanced disease than FEC arm<BR/>Median follow-up: 23.8 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 07:18:58 +1000" MODIFIED_BY="[Empty name]">
<P>Female<BR/>Age range 23 to 73 years, median age 54 years for both arms<BR/>100% metastatic breast cancer<BR/>100% first-line<BR/>Slightly higher number of participants had ER or PR positive tumours in FEC group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-25 16:06:58 +1000" MODIFIED_BY="Melina L Willson">
<P>Arm1:<BR/>ET: epirubicin 75 mg/m<SUP>2</SUP> over 10 min + docetaxel 75 mg/m<SUP>2</SUP>
</P>
<P>Arm 2:<BR/>FEC: fluorouracil 500 mg/m<SUP>2</SUP> over 1 hour + epirubicin 75 mg/m<SUP>2</SUP> over 10 min + cyclophosphamide 500 mg/m<SUP>2</SUP>
<BR/>All agents given once q21 days for up to 8 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-21 01:20:07 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Objective response rate, taken as the best response obtained from the start of treatment until disease progression</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival, defined as the time from beginning treatment to the time of death from any cause or the date of first contact if death was not recorded before the cutoff date</LI>
<LI>Time to progression, not defined</LI>
<LI>Duration of response, defined as the time from complete or partial response to the time that recurrent or progressive disease or death was first noted</LI>
<LI>Toxicity, graded using the NCI-CTC criteria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 07:38:07 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract was only available in the previous version of this Cochrane review.</P>
<P>The full article was published in 2004.</P>
<P>For overall survival, hazard ratios were estimated using methods outlined by <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>; for TTP, individualised participant data from <LINK REF="REF-Piccart_x002d_Gebhart-2008" TYPE="REFERENCE">Piccart-Gebhart 2008</LINK> was used and sensitivity analysis conducted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 16:03:44 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-Bontenbal">
<CHAR_METHODS MODIFIED="2015-05-20 07:44:33 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 03/1997 to 04/2002<BR/>Multicentre, national (Netherlands)<BR/>Randomisation (by central telephone number) stratified for centre, previous chemotherapy, WHO performance status, and presence of bone metastases<BR/>Baseline comparability: no significant imbalance reported<BR/>Median follow-up: 8.7 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-23 09:41:29 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 30 to 70 years, median age 53 years in AT group and 54 years in FAC group<BR/>100% metastatic breast cancer<BR/>100% first-line<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 07:46:55 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1:<BR/>AT: doxorubicin + docetaxel 50/75 mg/m<SUP>2</SUP>
<BR/>Arm 2:<BR/>FAC: fluorouracil, doxorubicin + cyclophosphamide 500/50/500 mg/m<SUP>2</SUP>
</P>
<P>Both arms q21 days for a maximum of 6 cycles<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 07:48:14 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Objective response rate</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Time to progression, defined as the date of random assignment to the date of progression, death, or withdrawal</LI>
<LI>Duration of response</LI>
<LI>Toxicity, assessed before each new cycle and graded according to the NCI-CTC</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:03:44 +1000" MODIFIED_BY="Melina L Willson">
<P>Phase III trial prematurely closed due to an unplanned interim analysis that indicated that the chance of finding a statistical difference in TTP between treatment arms had become too low.</P>
<P>For TTP, method 3 was used to estimate O-E and V (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>).</P>
<P>For toxicity, the number of randomised women was used as the denominator.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 08:03:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CECOG-BM1">
<CHAR_METHODS MODIFIED="2015-05-20 07:58:24 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 10/1999 to 11/2002<BR/>Multicentre phase III study, 29 centres in 12 countries<BR/>Centralised randomisation based on a minimising algorithm and stratified by prior adjuvant chemotherapy and centre<BR/>Baseline characteristics balanced between treatment arms except for menopausal status; FEC arm had a higher percentage of pre-menopausal participants compared to GET arm (P = 0.024)<BR/>Median follow-up: 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-23 09:43:00 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 29 to 74 years, median 53 years (GET) and 54 years (FEC)<BR/>100% metastatic breast cancer<BR/>100% first-line</P>
<P>All participants anthracycline naïve</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 08:02:06 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: <BR/>GET: gemcitabine (1000 mg/m<SUP>2</SUP> day 1 and 4), epirubicin (90 mg/m<SUP>2</SUP> day 1), and paclitaxel (175 mg/m<SUP>2</SUP> day 1)</P>
<P>Arm 2:<BR/>FEC: fluorouracil (500 mg/m<SUP>2</SUP> day 1), epirubicin (90 mg/m<SUP>2</SUP> day 1), and cyclophosphamide (500 mg/m<SUP>2</SUP> day 1)<BR/>
</P>
<P>Both arms: q21 days for a maximum of 8 cycles</P>
<P>No other anticancer drugs were allowed during the study including hormonal agents or immunotherapy or both</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 08:02:30 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes were not separated into primary or secondary:</P>
<UL>
<LI>Time to progressive disease, defined as from dates of randomisation until disease progression or death, whichever occurred first</LI>
<LI>Time to response, defined as interval between the dates of randomisation and first documented complete response or partial response</LI>
<LI>Overall survival, defined as dates of randomisation until death from any cause</LI>
<LI>Toxicity</LI>
<LI>Objective response rate</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 08:03:09 +1000" MODIFIED_BY="[Empty name]">
<P>Data were not mature for overall survival. However, curve extraction using method 10 was undertaken to estimate TTP (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 11:49:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dieras">
<CHAR_METHODS MODIFIED="2015-05-20 08:07:46 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual dates cannot be determined<BR/>Multicentre, national, phase II<BR/>Randomisation centralised "performed by computerized log, without direct access of the investigator"<BR/>Baseline comparability: no significant imbalance reported<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 08:08:39 +1000" MODIFIED_BY="[Empty name]">
<P>Female<BR/>Pre-, peri-, and post-menopausal<BR/>Age range 29 to 69 years, median 52 years (arm 1) and 52.5 years (arm 2)<BR/>100% metastatic breast cancer<BR/>100% &gt; first-line<BR/>98% had prior anthracycline treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 08:09:58 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: paclitaxel 175 mg/m<SUP>2</SUP> by 3-hour infusion q21 days<BR/>Arm 2: mitomycin 12 mg/m<SUP>2</SUP> in slow bolus q6 weeks<BR/>Both arms given for a minimum of 2 cycles (total cumulative dose of mitomycin limited to 60 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 08:11:09 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes were not separated into primary or secondary in trial report:</P>
<UL>
<LI>Overall survival</LI>
<LI>Time to progression (not defined)</LI>
<LI>Response</LI>
<LI>Toxicity</LI>
<LI>Quality of life</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 11:49:41 +1000" MODIFIED_BY="[Empty name]">
<P>Cross-over to alternate regimen on progression. Many more cycles of paclitaxel were received than mitomycin.</P>
<P>Follow-up details not reported</P>
<UL>
<LI>estimated minimum 1.5 months</LI>
<LI>estimated maximum 23 months (OS), 12 months (PFS)</LI>
</UL>
<P>Efficacy data available for 72/81 randomised participants. (4 participants did not receive allocated treatment and 5 received hormonal treatment while on study)<BR/>Estimate for time-to-event outcomes obtained from time-to-event curves</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 17:10:53 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_">
<CHAR_METHODS MODIFIED="2015-05-20 08:15:57 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 2/1993 to 9/1995<BR/>Multicentre<BR/>Cross-over (on progression)<BR/>Randomisation method not described<BR/>Baseline comparability: no significant imbalance reported<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 08:17:39 +1000" MODIFIED_BY="[Empty name]">
<P>Female<BR/>Age range 25 to 79 years, median age 58 years (arm 1), 56 years (arm 2), and 56 years (arm 3)<BR/>Progressing regional disease (13% to 19% of participants) or metastatic disease<BR/>100% first-line<BR/>All participants anthracycline naïve</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-25 16:07:52 +1000" MODIFIED_BY="Melina L Willson">
<P>Arm 1: doxorubicin 60 mg/m<SUP>2</SUP>
<BR/>Arm 2: paclitaxel 175 mg/m<SUP>2</SUP>/24 hour<BR/>Arm 3: doxorubicin 50 mg/m<SUP>2</SUP> + paclitaxel 150 mg/m<SUP>2</SUP>/24 hour + granulocyte-colony stimulating factor q21 days. Doxorubicin for a maximum 8 cycles; paclitaxel until disease progression</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-25 17:10:53 +1000" MODIFIED_BY="Melina L Willson">
<P>Outcomes were not separated into primary and secondary:</P>
<UL>
<LI>Overall response rate</LI>
<LI>Overall survival</LI>
<LI>Time to treatment failure, defined as from date randomised to date of progression, toxic death, or death attributed to breast cancer within 6 weeks of date participant last known alive with stable disease</LI>
<LI>Toxicity</LI>
<LI>Quality of life</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:05:49 +1000" MODIFIED_BY="Melina L Willson">
<P>Single agents cross-over to alternate single agent on progression.</P>
<P>Did not report as ITT 739 randomised (8 cancelled). Of 731 remaining, 33 excluded as ineligible (reasons explained). Data on 683 participants included in time-to-event analyses (reasons for exclusion of additional 15 participants not explained).</P>
<P>Follow-up details not reported, therefore</P>
<UL>
<LI>estimated minimum months </LI>
<LI>estimated maximum months (OS), months (PFS)</LI>
</UL>
<P>The definition of TTF used in this trial was date of study entry to date progressive disease, toxic death, or death due to breast cancer within 6 weeks of date participant last known alive with stable disease. This meets the definition of PFS as used in this review.<BR/>The number of participants who received treatment cannot be determined<BR/>Estimate for time-to-event outcomes obtained from time-to-event curves</P>
<P>ECOG E1193(A) compared arms 1 &amp; 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 08:40:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_">
<CHAR_METHODS>
<P>See E1193 (A)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>See E1193 (A)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>See E1193 (A)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>See E1193 (A)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 08:40:22 +1000" MODIFIED_BY="[Empty name]">
<P>See E1193 (A)<BR/>ECOG E1193(B) compared arms 1 &amp; 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 11:50:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EORTC-10923">
<CHAR_METHODS MODIFIED="2015-05-20 08:43:32 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 8/1993 to 5/1996<BR/>Multicentre, international<BR/>Cross-over<BR/>Randomisation "performed centrally...by telephone, fax or computer"<BR/>Baseline comparability: no significant imbalance apparent or reported<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-23 09:47:15 +1000" MODIFIED_BY="[Empty name]">
<P>Female<BR/>Age range 26 to 75 years, median age 54 years (paclitaxel group) and 55 years (doxorubicin group)<BR/>100% metastatic breast cancer in overt progression (73% had 2 or more metastatic sites)<BR/>100% first-line<BR/>All participants anthracycline naïve</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 08:44:24 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: paclitaxel 200 mg/m<SUP>2</SUP>
<BR/>Arm 2: doxorubicin 75 mg/m<SUP>2</SUP>
<BR/>Both arms q21 days for 7 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 08:45:25 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Progression-free survival, defined as from date randomised to date of progression or death if it occurred before documentation of progressive disease</LI>
<LI>Response rate</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Toxicity</LI>
<LI>Quality of life</LI>
<LI>Toxic death</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 11:50:09 +1000" MODIFIED_BY="[Empty name]">
<P>Cross-over to alternate regimen on progression</P>
<P>Follow-up details not reported</P>
<UL>
<LI>estimated minimum 5 months</LI>
<LI>estimated maximum 46 months (OS), 46 months (PFS)</LI>
</UL>
<P>All randomised participants included in time-to-event analyses<BR/>Estimate for time-to-event outcomes obtained using exact P value and total events</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 11:50:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EORTC-10961">
<CHAR_METHODS MODIFIED="2014-07-23 09:48:03 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 11/1996 to 02/1999<BR/>Multicentre, international<BR/>Centrally randomised at EORTC data centre<BR/>Baseline comparability: no significant imbalance reported<BR/>Median follow-up: 29.2 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 08:53:10 +1000" MODIFIED_BY="[Empty name]">
<P>Pre- and post-menopausal women aged 18 to 70 years<BR/>100% metastatic breast cancer<BR/>100% first-line<BR/>All participants anthracycline and taxane naive</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 08:53:39 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: doxorubicin 60 mg/m<SUP>2</SUP> + paclitaxel 175 mg/m<SUP>2</SUP>
<BR/>Arm 2: doxorubicin 60 mg/m<SUP>2</SUP> + cyclophosphamide 600 mg/m<SUP>2</SUP>
<BR/>Both arms q21 days to a maximum of 6 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 08:58:49 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Progression-free survival, defined as from randomisation to date of progression or death or whichever occurred first</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Response rate</LI>
<LI>Toxicity</LI>
<LI>Quality of life (EORTC QLQ-C30 and QLQ-BR23 (Breast cancer module))</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 11:50:19 +1000" MODIFIED_BY="[Empty name]">
<P>Follow-up details not reported</P>
<UL>
<LI>estimated minimum 5.5 months</LI>
<LI>estimated maximum 36 months (OS), 24 months (PFS)</LI>
</UL>
<P>All randomised participants included in time-to-event analyses<BR/>Estimate for time-to-event outcomes obtained from reported hazard ratio and 95% confidence intervals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 16:09:28 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-EU_x002d_93011">
<CHAR_METHODS MODIFIED="2015-05-20 09:05:47 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 06/1997 to 12/2001. Observed until the end of 2003<BR/>Multicentre study (Germany)<BR/>Randomisation carried out centrally using block sizes of various lengths<BR/>Participants stratified by age, treatment centre, disease-free interval (&gt; or &lt; 18 months), hormone receptor status, prior adjuvant therapy with anthracyclines, presence of liver metastases and lung metastases<BR/>No baseline characteristics reported<BR/>Median follow-up: 43.6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 09:07:51 +1000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 80 years, no further details provided<BR/>100% metastatic breast cancer<BR/>First-line<BR/>Anthracycline naïve</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 09:11:01 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: mitoxantrone (12 mg/m<SUP>2</SUP> q21 days). Administered until complete response (plus 2 cycles) or cumulative dose 160 mg/m<SUP>2</SUP>
<BR/>Arm 2: mitoxantrone (12 mg/m<SUP>2</SUP> q21 days) for up to 6 cycles plus docetaxel (80 mg/m<SUP>2 </SUP>q21 days) until progressive disease for up to 6 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-25 16:09:28 +1000" MODIFIED_BY="Melina L Willson">
<P>Primary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Time to progression (i.e. progression-free survival, defined as the duration from randomisation until progressive disease, death, or last contact)</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Best overall response</LI>
<LI>Gain from treatment as measured by Modified Brunner's Score (MBS)</LI>
<LI>Toxicity</LI>
<LI>Quality of life</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 09:15:36 +1000" MODIFIED_BY="[Empty name]">
<P>We contacted the trialists, and Martin Schumacher forwarded data from an unpublished manuscript for inclusion into this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 16:12:48 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-HERNATA">
<CHAR_METHODS MODIFIED="2015-05-20 11:32:35 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 05/2004 to 08/2008</P>
<P>Multicentre, phase III trial, conducted in Denmark, Sweden, and Norway</P>
<P>Randomisation occurred centrally<BR/>Baseline characteristics were balanced<BR/>Median follow-up: 34 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-23 15:15:03 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 29 to 72 years, median age 56 years (docetaxel + trastuzumab arm) and 57 years (vinorelbine + trastuzumab) 96.1% metastatic breast cancer; 3.9% locally advanced breast cancer<BR/>HER2 status: IHC 3+ = &gt; 81%, FISH + = 35.2%, unknown 1.4%</P>
<P>First-line for metastatic breast cancer or locally advanced disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 11:40:10 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: docetaxel 100 mg/m<SUP>2</SUP> IV over 60 minutes q21 days</P>
<P>Arm 2: vinorelbine 30 mg/m<SUP>2</SUP> or 35 mg/m<SUP>2</SUP> IV as bolus injections days 1 and 8 q21 days</P>
<P>Both arms q21 days for a median of 8 cycles (0 to 26 for docetaxel + trastuzumab) and 10.5 cycles (2 to 42 for vinorelbine + trastuzumab)</P>
<P>Trastuzumab given before chemotherapy as IV infusion over 90 minutes with 8 mg/kg in the first cycle and subsequent cycles over 30 minutes with 6 mg/kg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 11:51:10 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Time to progression, defined as from date of randomisation to date of documented progression with censoring for participants alive at last visit/date of death</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival (date of randomisation to date of death with censoring for participants still alive at last visit date)</LI>
<LI>Time to treatment failure (time from randomisation to date of the last study chemotherapy administration, with censoring for participants still on treatment)</LI>
<LI>Rate of response, assessed by investigators according the RECIST version 3.0</LI>
<LI>Toxicity (using NCI-CTC version 3.0)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:12:48 +1000" MODIFIED_BY="Melina L Willson">
<P>All randomised participants included in ITT analysis</P>
<P>For OS and TTP, method 3 used to estimate O-E and V (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 17:11:12 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-Jassem">
<CHAR_METHODS MODIFIED="2014-07-23 09:49:39 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 11/1996 to 4/1998<BR/>Multicentre, international<BR/>"central randomisation"<BR/>Baseline comparability: no significant imbalance reported<BR/>Median follow-up: 69 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-23 09:50:02 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 24 to 72 years, median age 50 years (in both groups)<BR/>100% metastatic breast cancer<BR/>100% first-line<BR/>All participants anthracycline naïve</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-25 17:11:12 +1000" MODIFIED_BY="Melina L Willson">
<P>Arm 1: doxorubicin 50 mg/m<SUP>2</SUP> followed 24 hour later by paclitaxel 220 mg/m<SUP>2</SUP>
</P>
<P>Arm 2: fluorouracil 500 mg/m<SUP>2</SUP> + doxorubicin 50 mg/m<SUP>2 </SUP>IV + cyclophosphamide 500 mg/m<SUP>2</SUP>
<BR/>Both arms q21 days for up to 8 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 12:04:06 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Time to progression (not defined)</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Response rate</LI>
<LI>Toxicity</LI>
<LI>Quality of life</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:14:43 +1000" MODIFIED_BY="Melina L Willson">
<P>For OS and TTP, method 3 was used to estimate O-E and V (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 16:15:14 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-JCOG9802">
<CHAR_METHODS MODIFIED="2015-05-20 12:18:23 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 01/1999 to 05/2003</P>
<P>Randomised, multicentre, non-blinded phase III study that took place at 29 institutions (Japan)</P>
<P>Participants were randomly assigned to 1 of 3 treatment groups by the minimisation method, balancing the arms according to disease status (stage IV versus recurrent disease), prior anthracyclines, liver metastasis, and institution</P>
<P>All prognostic factors well balanced between the 3 treatment groups<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 12:17:52 +1000" MODIFIED_BY="[Empty name]">
<P>Participant age range 26 to 75 years, median age 54 years (AC), 54 years (D), and 56 years (AC+D)</P>
<P>100% metastatic breast cancer</P>
<P>No previous anthracyclines or taxanes were allowed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 12:20:13 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: AC: doxorubicin 40 mg/m<SUP>2</SUP> + cyclophosphamide 500 mg/m<SUP>2</SUP> q21 days for 6 cycles</P>
<P>Arm 2: D: docetaxel 60 mg/m<SUP>2</SUP>
</P>
<P>Arm 3 (not used in review): AC+D: 3 cycles of AC and 3 cycles of D</P>
<P>Treatment was administered q21 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 12:22:04 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Time to treatment failure, from date of randomisation to the date of first documentation of discontinuation of first-line chemotherapy, disease progression, or death from any cause</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival, defined as the date of randomisation to the date of death from any cause</LI>
<LI>Progression-free survival, defined as the date of randomisation to the date of the first documentation of disease progression or death from any cause</LI>
<LI>Response rate (based on the number of assessable participants)</LI>
<LI>Adverse events (based on the number of assessable participants)</LI>
</UL>
<P>Pilot study: quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:15:14 +1000" MODIFIED_BY="Melina L Willson">
<P>Only 2 arms of this 3-arm trial were used. The sequential treatment comparison (i.e. AC vs AC+D) was excluded from analysis as it was not the focus of this review.</P>
<P>This review compared AC vs D only (arm 1 vs arm 2)<BR/>
</P>
<P>We contacted the trialists, and Noriyuki Katsumata provided the number of events in each group, the hazard ratio, confidence intervals, and P values for OS, TTP, and TTF. Method 3 was used to estimate O-E and V (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 17:11:25 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-Lyman">
<CHAR_METHODS MODIFIED="2014-07-23 09:51:51 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 02/1996 to 01/1997<BR/>Multi-institutional cooperative group trial<BR/>Randomised phase II study<BR/>Baseline characteristics were balanced between treatment arms except that performance status was &#8220;somewhat better on the doxorubicin/paclitaxel arm&#8221; (p.146)<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 12:31:02 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 30 to 79 years, median age 53.7 years (doxorubicin and paclitaxel) and 55.9 years (doxorubicin and cyclophosphamide)</P>
<P>Metastatic breast cancer or locally advanced breast cancer (number of participants with locally advanced breast cancer not provided)</P>
<P>No prior therapy with anthracyclines, anthracenediones, paclitaxel, or docetaxel permitted</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-25 17:11:25 +1000" MODIFIED_BY="Melina L Willson">
<P>Arm 1: AT: doxorubicin 60 mg/m<SUP>2</SUP> IV over 30 min followed by paclitaxel 200 mg/m<SUP>2</SUP> IV over 3 hour q21 days. Combined treatment was stopped after 6 cycles</P>
<P>Arm 2: AC: doxorubicin 60 mg/m<SUP>2</SUP> IV over 30 min followed by cyclophosphamide 600 mg/m<SUP>2</SUP> IV.</P>
<P>After 6 cycles, participants could be treated with any appropriate regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 12:33:27 +1000" MODIFIED_BY="[Empty name]">
<P>No distinction between primary and secondary outcomes provided:</P>
<UL>
<LI>Complete response, defined as complete disappearance of all measurable and evaluable disease and no evidence of non-evaluable disease</LI>
<LI>Overall survival, not defined</LI>
<LI>Toxicity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:15:42 +1000" MODIFIED_BY="Melina L Willson">
<P>We contacted the trialists, and William Barlow provided the unadjusted hazard ratio, confidence interval, and P value for OS. Method 3 used to estimate O-E and V</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 12:44:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meier">
<CHAR_METHODS MODIFIED="2015-05-20 12:41:18 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 11/1998 to 01/2004<BR/>Central randomisation<BR/>Baseline characteristics appear to be balanced; no mention of any significant differences<BR/>Cross-over (on disease progression or intolerable toxicity)<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-23 09:52:19 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 31 to 78 years, median age 60 years in both treatment arms<BR/>100% metastatic breast cancer<BR/>Pre-treated with anthracyclines</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 12:43:18 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: vinorelbine 30 mg/m<SUP>2</SUP> weekly x6 q8 weeks<BR/>Arm 2: docetaxel 35 mg/m<SUP>2</SUP> weekly x6 q8 weeks</P>
<P>For both arms: up to 4 consecutive cycles</P>
<P>From cycle 2, participants had the option to cross-over to the alternate treatment arm</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 12:43:57 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Time to progression, not defined</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Response</LI>
<LI>Toxicity</LI>
<LI>Quality of life (i.e. EORTC QLQ-C30 patient questionnaire)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 12:44:40 +1000" MODIFIED_BY="[Empty name]">
<P>For OS, hazard ratios were estimated using methods outlined by <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 12:48:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nabholtz">
<CHAR_METHODS MODIFIED="2014-07-23 09:52:43 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 1/1998 to 12/1999<BR/>Multicentre, international<BR/>Randomisation method not specified<BR/>Baseline comparability: no significant imbalance reported<BR/>Median follow-up: 30 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 12:46:43 +1000" MODIFIED_BY="[Empty name]">
<P>Median age: 54 years (no further details provided in abstract)<BR/>100% metastatic breast cancer<BR/>100% first-line</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 12:47:21 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: docetaxel 75 mg/m<SUP>2</SUP> + doxorubicin 50 mg/m<SUP>2</SUP> + cyclophosphamide 500 mg/m<SUP>2</SUP>
<BR/>Arm 2: fluorouracil 500 mg/m<SUP>2</SUP> + doxorubicin 50 mg/m<SUP>2</SUP> + cyclophosphamide 500 mg/m<SUP>2</SUP>
<BR/>Both arms q21 days for maximum of 8 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 12:48:07 +1000" MODIFIED_BY="[Empty name]">
<P>No distinction made between primary or secondary outcomes:</P>
<UL>
<LI>Response</LI>
<LI>Overall survival</LI>
<LI>Time to progression, no definition provided</LI>
<LI>Toxicity</LI>
<LI>Discontinuation due to toxicity</LI>
<LI>Toxic deaths</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 12:48:36 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only available<BR/>Reported response and toxicity as percentages; assumed to be percentage of participants receiving treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 17:12:31 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-Rugo">
<CHAR_METHODS MODIFIED="2015-05-20 12:54:14 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual dates not provided<BR/>Participants randomised in a 3:3:2 ratio to treatment arms 1, 2, and 3 respectively<BR/>Baseline characteristics were balanced between treatment arms except for site of metastasis; fewer participants had liver or lung metastasis or both in arm 3 than in arms 1 and 2<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 12:52:30 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 27 to 83 years, median age 60 years (arm 1), 59 years (arm 2), and 59 years (arm 3)<BR/>Locally advanced or metastatic breast cancer<BR/>First-line<BR/>No prior chemotherapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-25 17:12:31 +1000" MODIFIED_BY="Melina L Willson">
<P>Participants randomised in a 3:3:2 ratio to arms 1, 2, 3<BR/>Arm 1: ixabepilone 16 mg/m<SUP>2</SUP> IV on days 1, 8, and 15 q28 days + bevacizumab 10 mg/kg IV q14 days</P>
<P>Arm 2: ixabepilone 40 mg/m<SUP>2</SUP> IV q21 days + bevacizumab 15 mg/kg IV q21 days</P>
<P>Arm 3: paclitaxel 90 mg/m<SUP>2</SUP> IV + bevacizumab 10 mg/kg IV q14 days<BR/>Treatment continued until disease progression or unacceptable toxicity</P>
<P>Median of 6 cycles in arm 1, 7 cycles in arm 2, and 6.5 cycles in arm 3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 13:00:58 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Overall response rates</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Progression-free survival, defined as time from randomisation to disease progression or death</LI>
<LI>Safety</LI>
<LI>Week 24 PFS rate</LI>
<LI>Time to response</LI>
<LI>Overall survival</LI>
<LI>Duration of response</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:15:58 +1000" MODIFIED_BY="Melina L Willson">
<P>Only data from arms 1 and 3 were included in this review. Arm 1 was chosen as the most appropriate control comparator (i.e. bevacizumab 10 mg/kg q14 days) to the paclitaxel arm (with the same bevacizumab dose)</P>
<P>ClinicalTrials.gov record: <A HREF="http://www.clinicaltrials.gov/ct2/show/NCT00370552">http://www.clinicaltrials.gov/ct2/show/NCT00370552</A>
</P>
<P>For OS, data immature at the time of trial publication. For TTP, method 6 was used to estimate O-E and V (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 13:14:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sjostrom">
<CHAR_METHODS MODIFIED="2014-07-23 10:50:59 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 12/1994 to 10/1997<BR/>Multicentre, international<BR/>Cross-over allowed after relapse<BR/>Randomisation method not specified<BR/>Baseline comparability: no significant imbalance apparent or reported<BR/>Median follow-up: 11 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 13:10:15 +1000" MODIFIED_BY="[Empty name]">
<P>Pre- and post-menopausal<BR/>Age range 26 to 69 years, median age 50 years (arm 1) and 51 years (arm 2)<BR/>100% metastatic breast cancer<BR/>15% first-line<BR/>85% &gt; first-line<BR/>All participants had failed prior anthracycline therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 13:12:03 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: docetaxel 100 mg/m<SUP>2</SUP>
<BR/>Arm 2: sequential methotrexate 200 mg/m<SUP>2</SUP> --&gt; fluorouracil 600 mg/m<SUP>2</SUP>
<BR/>Both arms q21 days for at least 6 cycles (responding and stable participants only)</P>
<P>Median number of cycles: 6</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 13:12:32 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes were not reported as primary or secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Time to progression, defined as from date randomised to date of progression or death or last follow-up visit</LI>
<LI>Response</LI>
<LI>Toxicity</LI>
<LI>Quality of life</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 13:14:58 +1000" MODIFIED_BY="[Empty name]">
<P>1 participant in the methotrexate-fluorouracil arm did not have breast cancer recurrence and was not included by the trialists or in the current meta-analysis</P>
<P>Follow-up details reported</P>
<UL>
<LI>minimum 4 months</LI>
<LI>maximum 36 months</LI>
</UL>
<P>Time-to-event analyses based on 282/283 randomised<BR/>Estimate for time-to-event outcomes obtained from time-to-event curves</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-20 13:26:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Talbot">
<CHAR_METHODS MODIFIED="2015-05-20 13:20:52 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 05/1996 to 03/1997<BR/>Multicentre, international<BR/>Randomisation method not specified<BR/>Baseline comparability: reported that well-balanced<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 13:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 27 to 73 years, median age 52 years in both groups </P>
<P>95% metastatic breast cancer<BR/>Majority (% unclear) &gt; first-line for metastatic breast cancer<BR/>All participants were either anthracycline resistant or failing</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 13:25:05 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: paclitaxel 175 mg/m<SUP>2</SUP> q21 days</P>
<P>Arm 2: intermittent oral capecitabine (1255 mg/m<SUP>2</SUP> twice daily, 2 weeks plus 1 week's rest, minimum 2 cycles)</P>
<P>OR</P>
<P>Arm 3: arm closed (recruited only 2 participants). Continuous oral capecitabine (666 mg/m<SUP>2</SUP> twice daily)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 13:25:57 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Overall response rate</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Time to progression, defined as the interval between first day of treatment and first recording of disease progression or death</LI>
<LI>Time to response</LI>
<LI>Duration of response</LI>
<LI>Toxicity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 13:26:59 +1000" MODIFIED_BY="[Empty name]">
<P>No Kaplan-Meier curves were provided for OS and TTP. Hazard ratio and confidence intervals could not be calculated as limited information provided in trial report</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 16:17:59 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-TOG">
<CHAR_METHODS MODIFIED="2015-05-20 13:31:16 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 12/1997 to 08/2002<BR/>Multicentre, national, non-blinded<BR/>Cross-over allowed at progression or if no response at end of 2 cycles<BR/>Randomisation performed centrally by the data centre of TOG (Turkish Oncology Group)<BR/>Baseline comparability: no significant imbalance apparent or reported except for receptor status (paclitaxel/cisplatin + etoposide: ER/PR positive 30/26, ER/PR negative 13/25, unknown 53/46)<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 13:36:01 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 24 to 70 years, median age 49 years (paclitaxel) and 47 years (cisplatin + etoposide)<BR/>100% metastatic breast cancer<BR/>Approximately 20% first-line, 80% &gt; first-line<BR/>All participants had been previously treated with anthracyclines</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-25 16:17:52 +1000" MODIFIED_BY="Melina L Willson">
<P>Arm 1: paclitaxel 175 mg/m<SUP>2</SUP> IV on day 1<BR/>Arm 2: cisplatin 70 mg/m<SUP>2</SUP> IV on day 1 + etoposide 50 mg PO twice daily for 7 days</P>
<P>Both arms q21 days for up to 6 cycles</P>
<P>At least 2 cycles of study treatment were planned unless there was clear evidence of progression following the first cycle</P>
<P>Median number of treatment cycles was 4 (range 1 to 8) for both arms</P>
<P>Cross-over was allowed at the discretion of the physician</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 13:44:32 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Time to progression, defined as the duration between the first day of study treatment and date of progression</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival, defined as the time interval between the first day of study treatment and date of death. Overall survival was calculated on ITT basis</LI>
<LI>Tumour response rate, assessed according to WHO criteria</LI>
<LI>Duration of response, defined as the date of response to date of progression</LI>
<LI>Toxicity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:17:59 +1000" MODIFIED_BY="Melina L Willson">
<P>We contacted the trialists, and Fikri Icli provided the number of events in each group, the hazard ratio, confidence intervals, and P values for OS and TTP. Method 3 was used to estimate O-E and V (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 16:22:07 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-TRAVIOTA">
<CHAR_METHODS MODIFIED="2015-05-20 13:55:00 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 09/2001 to 12/2003<BR/>Multicentre (34), national (USA)<BR/>Randomisation: method not specified<BR/>Baseline comparability: not uniform, differences in hormone receptor-positive tumours, performance status of 0, liver metastases, prior adjuvant chemotherapy, and likelihood of having had metastatic disease &gt; 2 years<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 13:55:30 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 36 to 83 years, median age 55 years (arm 1) and 50 years (arm 2)<BR/>100% metastatic breast cancer<BR/>100% first-line</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-25 16:22:07 +1000" MODIFIED_BY="Melina L Willson">
<P>Arm 1: trastuzumab (2 mg/kg q7 days, after 1 loading dose of 4 mg/kg) + vinorelbine (25 mg/m<SUP>2 </SUP>q7 days)<BR/>Arm 2: trastuzumab (2 mg/kg q7 days, after 1 loading dose of 4 mg/kg) + taxane (paclitaxel 80 mg/m<SUP>2</SUP> or docetaxel 35 mg/m<SUP>2</SUP> q7 days or paclitaxel 175 mg/m<SUP>2 </SUP>+ carboplatin AUC6 q21 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 14:04:02 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Response rate, using RECIST criteria and modified RECIST criteria (i.e. confirmation that responses lasted for over 4 weeks were not required)</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Time to progression, defined according to RECIST criteria</LI>
<LI>Time to treatment failure, defined as the time until TTP or until participants were taken off study for treatment-related toxicity</LI>
<LI>Toxicity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 14:06:16 +1000" MODIFIED_BY="[Empty name]">
<P>The study was closed early because of poor accrual</P>
<P>Data values for TTP or TTF could not be calculated because length of follow-up was unclear in paper; when follow-up was estimated it did not contribute to censoring on the Kaplan-Meier curve. Curve extraction of data points only (no censoring) leads to "erroneously precise values" and therefore was not conducted (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-TXT">
<CHAR_METHODS MODIFIED="2014-07-23 10:54:24 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 06/1995 to 07/1997<BR/>Multicentre<BR/>Randomisation method not specified ("patients were randomly assigned on a one-to-one basis to 1 of 2 groups, stratified by accruing centre")<BR/>Baseline comparability: no significant imbalance apparent or reported<BR/>Median follow-up: 30.3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 14:12:16 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 27 to 79 years, median age 54.9 years (docetaxel) and 54.55 years (FUN)<BR/>32% first-line<BR/>68% &gt; first-line<BR/>All participants had been pre-treated with anthracyclines regimen</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 14:17:05 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: docetaxel 100 mg/m<SUP>2</SUP>
<BR/>Arm 2: fluorouracil 750 mg/m<SUP>2</SUP> + vinorelbine 25 mg/m<SUP>2</SUP> (FUN)</P>
<P>Both arms q21 days for a median of 6 (range 1 to 12) cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 14:18:03 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Time to progression (defined as from time of first treatment infusion to first objective evidence of tumour progression)</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Response</LI>
<LI>Toxicity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson">
<P>Follow-up details reported</P>
<UL>
<LI>minimum 10.4 months</LI>
<LI>maximum 45 months</LI>
</UL>
<P>Time-to-event analyses based on 176/178 randomised (2 in docetaxel arm excluded).<BR/>Estimate for time-to-event outcomes obtained from time-to-event curve for OS.</P>
<P>TTP data were added to this review update (unlike the original review). Variations in TTP definitions were accepted in the 2013 review update (see <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 16:25:29 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-UKCCCR-AB01">
<CHAR_METHODS MODIFIED="2015-05-20 14:36:10 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 1996 to 1999<BR/>Multicentre, UK and Republic of Ireland<BR/>Random assignment was performed using a minimisation process stratified by centre, previous anthracyclines, site of disease, measurable/assessable disease, and WHO performance status<BR/>Baseline comparability: no significant imbalance apparent and reported as well balanced<BR/>Median follow-up: not provided</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 14:37:34 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 32 to 83 years, median 55 years (epirubicin and paclitaxel) and 54 years (epirubicin and cyclophosphamide)<BR/>100% metastatic breast cancer<BR/>100% first-line<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 14:39:44 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: EP: epirubicin 75 mg/m<SUP>2</SUP> (bolus or short infusion) followed by paclitaxel 200 mg/m<SUP>2</SUP> as a 3-hour infusion<BR/>Arm 2: EC: epirubicin 75 mg/m<SUP>2</SUP> followed by cyclophosphamide 600 mg/m<SUP>2</SUP> (both as bolus or short infusion)<BR/>Both arms q21 days for 6 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 14:40:23 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Progression-free survival, defined as time from random assignment to first appearance of progressive disease or death from any cause</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Objective response rate</LI>
<LI>Toxicity</LI>
<LI>Quality of life reported</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:25:29 +1000" MODIFIED_BY="Melina L Willson">
<P>Data updated with 2005 published results</P>
<P>Method 3 was used to estimate O-E and V (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-25 16:25:35 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-Yardley">
<CHAR_METHODS MODIFIED="2015-05-20 14:52:19 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 03/2001 to 07/2007<BR/>Randomised phase II, multicentre, national, cross-over trial<BR/>Baseline characteristics of treatment arms similar with no statistical differences<BR/>Cross-over at progression<BR/>Median follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-23 10:55:13 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 31 to 87 years, median 62 years (doxorubicin) and 63 years (docetaxel)<BR/>100% metastatic breast cancer<BR/>First-line</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 14:54:45 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: liposomal doxorubicin 40 mg/m<SUP>2</SUP> by 1-hour IV infusion repeated q28 days</P>
<P>Arm 2: docetaxel 36 mg/m<SUP>2</SUP> by 30-minute IV infusion on days 1, 8, and 15. Cycles were repeated q28 days</P>
<P>Participants eligible at time of tumour progression to cross-over to the other treatment arm</P>
<P>Median treatment duration of 4 cycles in both groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 14:56:02 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Response rates</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Overall survival, defined as the interval between the date of first study treatment and the date of death</LI>
<LI>Progression-free survival, defined as the interval from first study treatment until the date that the first progression of breast cancer was documented</LI>
<LI>Toxicity, graded according to the NCI-CTC version 3</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-25 16:25:35 +1000" MODIFIED_BY="Melina L Willson">
<P>Trial prematurely stopped at 102 participants instead of the planned 120 participants due to slow accrual</P>
<P>For OS, we contacted the trialists, and John Hainsworth kindly provided the number of events, hazard ratio, confidence interval, and P value for OS. Method 3 was used to estimate O-E and V (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>).</P>
<P>For PFS, data were extracted from the Kaplan-Meier curve (Method 10, <LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>) by 2 authors. For each time point, an average was taken.</P>
<P>Estimated minimum follow-up: 2 months</P>
<P>Estimated maximum follow-up: 48.75 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CR: complete response<BR/>ER/PR: oestrogen receptor/progesterone receptor<BR/>FACT-B: Functional Assessment of Cancer Therapy - Breast<BR/>HER2: human epidermal growth factor receptor 2<BR/>ITT: intention to treat<BR/>LVEF: left ventricular ejection fraction<BR/>MBS: Modified Brunner's score<BR/>NCI-CTC: National Cancer Institute Common Terminology Criteria<BR/>OS: overall survival<BR/>O-E: observed and expected events<BR/>PFS: progression-free survival<BR/>PO: oral administration<BR/>PR: partial response<BR/>q: every/each<BR/>QoL: quality of life<BR/>RECIST: Response Evaluation Criteria in Solid Tumors<BR/>TTF: time to treatment failure<BR/>TTP: time to progression<BR/>V: variance<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-05-25 16:30:08 +1000" MODIFIED_BY="Melina L Willson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-11-03 10:46:55 +1100" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-Brufsky-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-03 10:46:55 +1100" MODIFIED_BY="Melina L Willson">
<P>Taxane may not be in the treatment arm as investigator could choose chemotherapy regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-20 15:09:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gebbia-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-20 15:09:13 +1000" MODIFIED_BY="[Empty name]">
<P>This 3-armed trial compared epidoxorubicin/cyclophosphamide (arm A), doxorubicin/paclitaxel (arm B) and epidoxorubicin/paclitaxel (arm C) as first-line chemotherapy for metastatic breast cancer. The authors describe the trial as "centrally registered and randomised in a 1:2 fashion to arm A or arm B with stratification for previous exposure to anthracycline drugs", however all participants who had previously received anthracyclines received a taxane-containing regimen. The authors also describe the trial as "not comparative", but it is not clear what this means. As there were clearly questions regarding the effectiveness of the randomisation process used in this trial, we decided not to include it in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-20 15:09:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gennari-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-20 15:09:59 +1000" MODIFIED_BY="[Empty name]">
<P>All participants received paclitaxel as part of first-line treatment for metastatic breast cancer and were then randomised to additional paclitaxel vs no further treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-20 15:11:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghosn-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-20 15:11:39 +1000" MODIFIED_BY="[Empty name]">
<P>All participants received vinorelbine and capecitabine (Navcap); participants with no disease progression were then randomised to Navcap or docetaxel.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-03 10:47:12 +1100" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-Hamberg-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-03 10:47:12 +1100" MODIFIED_BY="Melina L Willson">
<P>Docetaxel in both arms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-20 15:12:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-20 15:12:06 +1000" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-20 15:15:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sakurai-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-20 15:15:08 +1000" MODIFIED_BY="[Empty name]">
<P>The trial included trastuzumab alone (group A) vs trastuzumab plus taxanes (group B); after 6 months, group A received taxane therapy. The primary question was the action of trastuzumab plus taxane rather than taxane versus other chemotherapeutic regimens.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-20 15:16:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmid-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-20 15:16:24 +1000" MODIFIED_BY="[Empty name]">
<P>An atypical chemotherapy regimen (i.e. high-dose chemotherapy) was used in only one arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-25 16:30:08 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-Szanto-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-25 16:30:08 +1000" MODIFIED_BY="Melina L Willson">
<P>Study reported in Hungarian and translated in 2012. The paper reported the results from a single country (i.e. Hungary) of the multicentre, multinational <LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-05-25 17:12:59 +1000" MODIFIED_BY="Melina L Willson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-05-25 17:12:59 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-TIPP">
<CHAR_METHODS MODIFIED="2015-05-20 15:20:12 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual period not specified<BR/>2-centre, randomised phase II study<BR/>No information provided concerning baseline characteristics of treatment arms<BR/>Median follow-up: not provided</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-23 10:56:58 +1000" MODIFIED_BY="[Empty name]">
<P>Age range unknown<BR/>100% metastatic breast cancer<BR/>No prior chemotherapy for metastatic disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 15:21:22 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: docetaxel 100 mg/m<SUP>2</SUP> with standard oral dexamethasone premedication</P>
<P>Arm 2: epirubicin 90 mg/m<SUP>2</SUP> as IV bolus + cyclophosphamide 600 mg/m<SUP>2</SUP> IV infusion<BR/>For both arms, cycles repeated q21 days for a maximum of 6 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-25 17:12:59 +1000" MODIFIED_BY="Melina L Willson">
<P>Outcomes were not reported as primary or secondary:</P>
<UL>
<LI>Overall survival</LI>
<LI>Time to progression, no definition provided</LI>
<LI>Time to response (median)</LI>
<LI>Response rate</LI>
<LI>Toxicity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 15:29:53 +1000" MODIFIED_BY="Melina L Willson">
<P>Only abstracts from conference proceedings were available</P>
<P>Wrote to author on 10 January 2014 to ask for further details about the number of participants in each group and end results; no reply </P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-05-20 15:39:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu">
<CHAR_METHODS MODIFIED="2015-05-20 15:27:01 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual: 03/2005 to 12/2007, follow-up completed 11/2009<BR/>Randomised phase II, open-label, multicentre trial<BR/>Conducted at 21 sites in China, Brazil, India, Mexico, South Korea, and Turkey<BR/>3-arm trial<BR/>Baseline characteristics of treatment arms were generally similar, except that gemcitabine/cisplatin arm had a longer disease-free interval of &gt; 24 months compared to the other 2 treatment arms<BR/>Follow-up continued until death or 24 months postrandomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 15:30:15 +1000" MODIFIED_BY="[Empty name]">
<P>Median age 49 years (paclitaxel/gemcitabine), 45 years (gemcitabine/carboplatin), and 48 years (gemcitabine/cisplatin)<BR/>100% metastatic breast cancer<BR/>First-line</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 15:36:20 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: paclitaxel 150 mg/m<SUP>2 </SUP>3-hour infusion followed by 2500 mg/m<SUP>2 </SUP>gemcitabine on day 1 repeated q14 days</P>
<P>Arm 2: gemcitabine 2500 mg/m<SUP>2 </SUP>30-60 min IV infusion followed by carboplatin 30-60 min IV (AUC 2.5 mg/mL x min) repeated q14 days</P>
<P>Arm 3: gemcitabine 2500 mg/m<SUP>2 </SUP>30-60 min IV infusion followed by cisplatin 50 mg/m<SUP>2</SUP> 60 min IV q14 days</P>
<P>Maximum of 8 cycles</P>
<P>Median number of cycles received were:</P>
<P>Arm 1: 8 (range 1 to 12)</P>
<P>Arm 2: 8 (range 3 to 8)</P>
<P>Arm 3: 7 (range 1 to 8)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 15:38:03 +1000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<UL>
<LI>Objective tumour response</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Duration of tumour response, defined as the time from the first objective response (complete or partial) to disease progression</LI>
<LI>Time to treatment failure</LI>
<LI>Overall survival</LI>
<LI>Progression-free survival</LI>
<LI>Time to overall disease progression</LI>
<LI>Drug exposure measures</LI>
<LI>Frequency and nature of adverse events, graded according to the NCI-CTC version 2</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 15:39:41 +1000" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov record: <A HREF="http://clinicaltrials.gov/show/NCT00191854">http://clinicaltrials.gov/show/NCT00191854</A>
</P>
<P>We contacted the trialists on 28 May 2014 regarding the number of events in each arm for progression-free survival, overall survival, time to treatment failure, and clarification on adjusted hazard ratios. No reply received as yet</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>NCI-CTC: National Cancer Institute Common Terminology Criteria</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-06-02 09:39:56 +1000" MODIFIED_BY="Melina L Willson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-05-22 15:30:10 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-EUCTR2012_x002d_003530_x002d_16_x002d_ES">
<CHAR_STUDY_NAME MODIFIED="2015-05-20 15:49:41 +1000" MODIFIED_BY="[Empty name]">
<P>Study evaluating weekly oral vinorelbine versus weekly paclitaxel in a population of people with advanced breast cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-11-03 10:47:37 +1100" MODIFIED_BY="Melina L Willson">
<P>Randomised study, open label</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 15:41:44 +1000" MODIFIED_BY="[Empty name]">
<P>Locally recurrent or metastatic breast cancer<BR/>First-line</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 15:42:15 +1000" MODIFIED_BY="[Empty name]">
<P>Weekly vinorelbine 20 mg vs vinorelbine 30 mg vs weekly paclitaxel</P>
<P>No indication of dose of paclitaxel provided in trial record</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 15:43:16 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Disease control rate</LI>
<LI>Response rate</LI>
<LI>Duration of response</LI>
<LI>Duration of stable disease</LI>
<LI>Progression-free survival</LI>
<LI>Time-to-treatment failure</LI>
<LI>Overall survival</LI>
<LI>Safety profile</LI>
<LI>Quality of life</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-22 15:30:10 +1000" MODIFIED_BY="Melina L Willson">
<P>Date of registration: 12 November 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-03 10:47:38 +1100" MODIFIED_BY="Melina L Willson">
<P>Gustavo Villanova, Pierre Fabre Medicament, email: <A HREF="mailto:Gustavo.villanova@pierre-fabre.com">Gustavo.villanova@pierre-fabre.com</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-03 10:47:38 +1100" MODIFIED_BY="Melina L Willson">
<P>Source of support: Pierre Fabre Medicament</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-20 15:45:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR2012_x002d_003743_x002d_30_x002d_SE">
<CHAR_STUDY_NAME MODIFIED="2015-05-20 15:44:18 +1000" MODIFIED_BY="[Empty name]">
<P>A randomised trial to identify markers for personalised treatment in participants treated with bevacizumab and paclitaxel for advanced breast cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-11-03 10:47:43 +1100" MODIFIED_BY="Melina L Willson">
<P>Randomised study, open label</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-03 10:47:43 +1100" MODIFIED_BY="Melina L Willson">
<P>Age 18-70 years<BR/>Stage IV or recurrent HER-2 negative breast cancer<BR/>First-line treatment<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 15:45:16 +1000" MODIFIED_BY="[Empty name]">
<P>Bevacizumab vs paclitaxel<BR/>No indication of dose and frequency provided in trial record</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 15:45:26 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Molecular biomarkers or gene expression signatures</LI>
<LI>Frequency and grade of complications</LI>
<LI>Response rate</LI>
<LI>Progression-free survival</LI>
<LI>Overall survival</LI>
<LI>Safety of performing metastatic tumour biopsies</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-20 15:45:44 +1000" MODIFIED_BY="[Empty name]">
<P>Date of registration: 30 September 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-03 10:47:46 +1100" MODIFIED_BY="Melina L Willson">
<P>Clinical Trials Unit, Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden; email: <A HREF="mailto:pia.schonbeck@karolinska.se">pia.schonbeck@karolinska.se</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-03 10:47:46 +1100" MODIFIED_BY="Melina L Willson">
<P>Sponsor: Roche AB</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-25 16:31:27 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-ISRCTN97330959">
<CHAR_STUDY_NAME MODIFIED="2015-05-25 16:31:27 +1000" MODIFIED_BY="Melina L Willson">
<P>Triple-negative trial: a randomised phase III trial of carboplatin compared to docetaxel for people with advanced oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2 breast cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-11-03 10:47:53 +1100" MODIFIED_BY="Melina L Willson">
<P>Phase III<BR/>Multicentre, randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 16:22:39 +1000" MODIFIED_BY="[Empty name]">
<P>Women aged 18 years or older<BR/>Histologically confirmed ER, PR, and HER2 negative breast cancer<BR/>Measurable confirmed metastatic or recurrent locally advanced disease<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 16:04:33 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: carboplatin AUC 6 q21 days for 6 cycles (18 weeks)<BR/>Arm 2: docetaxel 100 mg/m<SUP>2</SUP> q21 days for 6 cycles (18 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 16:05:17 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Response</LI>
<LI>Time to progression (start of treatment until the confirmation of progression)</LI>
<LI>Progression-free survival (start of treatment until the confirmation of progression or death)</LI>
<LI>Time to treatment failure (time from randomisation to discontinuation of protocol treatment)</LI>
<LI>Overall survival (time from randomisation until death from any cause in the ITT population)</LI>
<LI>Toxicity (throughout treatment period using NCI-CTCAE v3.0)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-22 15:30:21 +1000" MODIFIED_BY="Melina L Willson">
<P>16 January 2008<BR/>Estimated completion date: January 2014<BR/>Accrual target: 370 to 450 participants</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-03 10:47:53 +1100" MODIFIED_BY="Melina L Willson">
<P>Andrew Tutt (Principal Investigator), King's College London, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, SE1 9RT</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-11 12:54:09 +1100" MODIFIED_BY="Melina L Willson">
<P>Sponsor(s): Institute of Cancer Research, United Kingdom; King's College London; Cancer Research UK; Breakthrough Breast Cancer</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-25 16:31:44 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-JPRN_x002d_C000000416">
<CHAR_STUDY_NAME MODIFIED="2015-05-20 16:08:35 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study of taxane vs TS-1 in people with metastatic or recurrent breast cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-11-03 10:47:59 +1100" MODIFIED_BY="Melina L Willson">
<P>Randomised method</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 16:10:08 +1000" MODIFIED_BY="[Empty name]">
<P>Women aged 20 to 75 years old<BR/>Histologically confirmed breast cancer, distant metastasis (stage IV) in first diagnosis<BR/>At least 1 assessable lesion<BR/>No prior taxane administration or at least 6 months ago<BR/>No prior fluorouracil administration or last administration over 6 months ago<BR/>No hormonal therapy over the last 7 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-25 16:31:44 +1000" MODIFIED_BY="Melina L Willson">
<P>Arm 1: taxane<BR/>(a) docetaxel 60 to 75 mg/m<SUP>2 </SUP>(1 cycle: 3 or 4 week interval)<BR/>(b) paclitaxel 175 mg/m<SUP>2</SUP> (1 cycle: 3 or 4 week interval)<BR/>(c) paclitaxel 175 mg/m<SUP>2</SUP> (1 cycle: every 3 weeks continuously followed by 1-week rest period)</P>
<P>Arm 2: TS-1 40 to 60 mg/m<SUP>2</SUP>, twice a day (AM and PM) for 28 days continuously followed by 14 days rest. Total 6 weeks as 1 cycle and 4 cycles repeated or unless cancer progresses<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 16:14:59 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Overall survival</LI>
<LI>Progression-free survival</LI>
<LI>Time to treatment failure</LI>
<LI>Adverse events</LI>
<LI>Health-related quality of life</LI>
<LI>Efficacy of medical economy</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-20 16:15:19 +1000" MODIFIED_BY="[Empty name]">
<P>1 January 2006<BR/>Estimated completion date: unknown<BR/>Accrual target: 600 participants</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-03 10:47:59 +1100" MODIFIED_BY="Melina L Willson">
<P>Yasuo Ohashi, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan<BR/>ohashi@epistat.m.u-tokyo.ac.jp</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-03 10:47:59 +1100" MODIFIED_BY="Melina L Willson">
<P>Sponsor: Public Health Research Foundation</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-22 15:30:27 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-NCT00321633">
<CHAR_STUDY_NAME MODIFIED="2014-11-03 10:48:06 +1100" MODIFIED_BY="Melina L Willson">
<P>Carboplatin or docetaxel in treating women with metastatic genetic breast cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-05-20 16:17:11 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study<BR/>Multicentre, pilot study<BR/>Participants stratified according to gene mutation (BRCA1, BRCA2), prior adjuvant taxane chemotherapy (yes vs no), liver or lung metastasis (yes vs no), Jewish ancestry (yes vs no), first-line vs second-line treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 16:18:10 +1000" MODIFIED_BY="[Empty name]">
<P>Women with histologically confirmed BRCA1 or BRAC2 mutation carrier<BR/>Measurable disease defined as &gt; 1 unidimensionally measurable lesion<BR/>Patients with bone metastasis or brain metastasis are eligible<BR/>Patients who have not received anthracycline chemotherapy in adjuvant setting may receive a non-taxane, anthracycline regimen as first-line metastatic treatment<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 16:18:54 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: carboplatin IV over 1 hour on day 1<BR/>Arm 2: docetaxel IV over 1 hour on day 1</P>
<P>For both arms, repeat treatment q21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. If disease progresses, treatment cross-over can occur</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 16:19:02 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Response and toxicity</LI>
<LI>Time to progression</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-22 15:30:27 +1000" MODIFIED_BY="Melina L Willson">
<P>January/September 2005<BR/>Estimated completion date: September 2009<BR/>Accrual target: 148 participants</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-11 12:54:22 +1100" MODIFIED_BY="Melina L Willson">
<P>James Mackay, North East Thames Clinical Genetics Service, Great Ormond Street Hospital &amp; the Institute of Child Health, 30 Guilford Street WC1 1EH, London, United Kingdom</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-05-20 16:20:31 +1000" MODIFIED_BY="[Empty name]">
<P>Sponsor(s): University College London (UK), Breakthrough Breast Cancer, Cancer Research UK (via Clinical Trials Awards and Advisory Committee)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-25 16:33:03 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-NCT00490646">
<CHAR_STUDY_NAME MODIFIED="2015-05-20 16:22:05 +1000" MODIFIED_BY="[Empty name]">
<P>A phase II combination of trastuzumab and ixabepilone vs trastuzumab and docetaxel in people with advanced or metastatic breast cancer, or both</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-11-03 10:48:11 +1100" MODIFIED_BY="Melina L Willson">
<P>Phase II, randomised study<BR/>Multicentre, international<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-03 10:48:11 +1100" MODIFIED_BY="Melina L Willson">
<P>Women aged 18 years or older<BR/>Locally advanced or metastatic HER2+ breast cancer<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-25 16:32:45 +1000" MODIFIED_BY="Melina L Willson">
<P>Arm 1: ixabepilone 40 mg/m<SUP>2 </SUP>+ trastuzumab 2 mg/kg (loading dose 4 mg/kg) q21 days, duration of combination approximately 10 cycles<BR/>Arm 2: docetaxel 100 mg/m<SUP>2 </SUP>+ trastuzumab 2 mg/kg (loading dose 4 mg/kg) q21 days, duration of combination approximately 10 cycles</P>
<P>Trastuzumab can continue up to 38 months in both arms.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 16:26:36 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Objective response rate</LI>
<LI>Progression-free survival</LI>
<LI>Duration of response</LI>
<LI>Time to response</LI>
<LI>Safety</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-25 16:33:03 +1000" MODIFIED_BY="Melina L Willson">
<P>February 2008<BR/>Estimated completion date: November 2011<BR/>Accrual target: 80 participants</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-11 12:54:38 +1100" MODIFIED_BY="Melina L Willson">
<P>Bristol-Myers Squibb noted as study director</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-03 10:48:11 +1100" MODIFIED_BY="Melina L Willson">
<P>Primary sponsor: Bristol-Myers Squibb</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-22 15:30:34 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-NCT00600340">
<CHAR_STUDY_NAME MODIFIED="2014-11-03 10:48:15 +1100" MODIFIED_BY="Melina L Willson">
<P>A randomised phase III 2-arm trial of paclitaxel plus bevacizumab vs capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-11-03 10:48:15 +1100" MODIFIED_BY="Melina L Willson">
<P>Randomised (non-inferiority) method<BR/>Multicentre, international<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-03 10:48:15 +1100" MODIFIED_BY="Melina L Willson">
<P>Women and men aged &gt; 18 years<BR/>Histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast with locally recurrent or metastatic breast cancer<BR/>Permitted prior (neo)adjuvant chemotherapy, last dose more than 6 months prior to randomisation<BR/>Permitted prior adjuvant radiotherapy, last fraction at least 6 months prior to randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 16:32:48 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: bevacizumab 10 mg/kg IV days 1 and 15 q28 days + paclitaxel 90 mg/m<SUP>2</SUP> days 1, 8, and 15 q28 days<BR/>Arm 2: bevacizumab 15 mg/kg IV day 1 q21 days + capecitabine 1000 mg/m<SUP>2</SUP> BD day 1 to 14 q21 days<BR/>Treatment given until first disease progression, unacceptable toxicity, or withdrawal of patient consent</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-03 10:48:16 +1100" MODIFIED_BY="Melina L Willson">
<P>Overall survival (assessed from date of randomisation until date of death)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-22 15:30:34 +1000" MODIFIED_BY="Melina L Willson">
<P>April 2008<BR/>Estimated study completion date November 2013<BR/>Accrual target: 560 participants</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-03 10:48:16 +1100" MODIFIED_BY="Melina L Willson">
<P>Christoph C Zielinski (Principal Investigator), Department of Internal Medicin I, Oncology, Medical University of Vienna, Austria</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-03 10:48:16 +1100" MODIFIED_BY="Melina L Willson">
<P>Sponsors/collaborators: Central European Cooperative Oncology Group</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-22 15:31:11 +1000" MODIFIED_BY="Melina L Willson" STUDY_ID="STD-NCT01126138">
<CHAR_STUDY_NAME MODIFIED="2015-05-20 16:36:40 +1000" MODIFIED_BY="[Empty name]">
<P>NX vs TX as 1-line chemotherapy on metastatic breast cancer (MBC)<BR/>A randomised phase III study to investigate the efficacy and safety of vinorelbine plus capecitabine (NX) and docetaxel plus capecitabine (TX) as first-line treatment followed by capecitabine alone as first-line therapy on people with locally advanced and metastatic breast cancer (BOOG 2008-03)<BR/>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-05-22 15:31:11 +1000" MODIFIED_BY="Melina L Willson">
<P>Participant recruitment underway<BR/>Randomisation (non-inferiority) method<BR/>Recruiting centre in China<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 16:38:15 +1000" MODIFIED_BY="[Empty name]">
<P>Pathologically confirmed and documented metastatic or locally advanced breast cancer (at least 1 lesion measured by radiological method)<BR/>Women aged 18 years and older<BR/>Permitted adjuvant or neoadjuvant chemotherapy (including anthracyclines)<BR/>Permitted hormone therapy if HER2 positive<BR/>Prior radiation therapy concluded 14 days before enrolment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 16:45:14 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: vinorelbine plus capecitabine for 6 cycles followed by capecitabine. Capecitabine 1000 mg/m<SUP>2</SUP> PO BD (day 1 to 14); vinorelbine 25 mg/m<SUP>2</SUP> IV over 3 hours on day 1 and 8, q21 days as 1 cycle and 6 cycles are required<BR/>Arm 2: docetaxel plus capecitabine for 6 cycles, followed by capecitabine. Capecitabine 1000 mg/m<SUP>2</SUP> PO BD (day 1 to 14); docetaxel 75 mg/m<SUP>2</SUP> IV over 3 hours on day 1, q21 days as 1 cycle and 6 cycles are required. Followed by capecitabine 1000 mg/m<SUP>2</SUP> PO BD (day 1 to 14), 21 days as 1 cycle until progression or unacceptable toxicity<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 16:46:37 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Progression-free survival (up to 2 years until disease progression or death)</LI>
<LI>Adverse events (occurring up to 28 days after last intake of study medication)</LI>
<LI>Overall survival (up to 3 years after last intake of study medication)</LI>
<LI>Response rate (up to 2 years until disease progression, unacceptable toxicity, or death). Tumour response rate assessed using RECIST</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-20 16:47:54 +1000" MODIFIED_BY="[Empty name]">
<P>May 2010 (as stated on ClinicalTrials.gov)<BR/>Target accrual: 200 participants</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-03 10:48:20 +1100" MODIFIED_BY="Melina L Willson">
<P>Binghe Xu (Principal Investigator), Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China, 100021</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-03 10:48:20 +1100" MODIFIED_BY="Melina L Willson"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-20 16:53:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01303679">
<CHAR_STUDY_NAME MODIFIED="2015-05-20 16:48:13 +1000" MODIFIED_BY="[Empty name]">
<P>First-line treatment of bevacizumab-taxane vs bevacizumab-exemestane in metastatic breast cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-11-03 10:48:25 +1100" MODIFIED_BY="Melina L Willson">
<P>Randomised controlled trial</P>
<P>Open label</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 16:49:14 +1000" MODIFIED_BY="[Empty name]">
<P>Metastatic or locally advanced breast cancer<BR/>ER-positive; HER2-negative</P>
<P>Patients receiving paclitaxel-bevacizumab first-line chemotherapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 16:51:04 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: paclitaxel 80 mg/m<SUP>2</SUP> d1, d8, d15 + bevacizumab 10 mg/kg at d1, d15<BR/>Arm 2: exemestane 25 mg daily + bevacizumab 15 mg/kg q21 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-03 10:48:25 +1100" MODIFIED_BY="Melina L Willson">
<P>Primary free survival (time frame: 24 months for recruitment and 18 months for follow-up)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-20 16:52:43 +1000" MODIFIED_BY="[Empty name]">
<P>June 2010<BR/>Estimated completion date: May 2018<BR/>Estimated primary completion date: June 2014 (final data collection date for primary outcome measures)</P>
<P>Target accrual: 117 participants</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-03 10:48:25 +1100" MODIFIED_BY="Melina L Willson">
<P>Thomas Bachelot (Principal Investigator), ARCAGY/GINECO Group, France</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-05-20 16:53:28 +1000" MODIFIED_BY="[Empty name]">
<P>The ClinicalTrials.gov record stated that the study has been terminated; and did not reveal any significant difference between the 2 arms</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-20 17:03:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NTR1349">
<CHAR_STUDY_NAME MODIFIED="2015-05-20 16:56:58 +1000" MODIFIED_BY="[Empty name]">
<P>A randomised phase II study of concomitant trastuzumab, bevacizumab with paclitaxel vs trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab, and paclitaxel at progression as first-line treatment of people with metastatic breast cancer with HER2/neu overexpression</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-11-03 10:48:30 +1100" MODIFIED_BY="Melina L Willson">
<P>Randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 16:58:22 +1000" MODIFIED_BY="[Empty name]">
<P>People 18 years or older<BR/>Histologically confirmed breast cancer, locally recurrent or metastatic lesions in pre- or post-menopausal women<BR/>Measurable lesions have at least 1 dimension as &gt; 1 cm<BR/>HER2 protein overexpression<BR/>Permitted trastuzumab in the adjuvant setting as long as they received at least 10 months of therapy with trastuzumab and &gt; 6 months have elapsed since last adjuvant administration<BR/>Permitted anthracyclines in adjuvant or neoadjuvant setting if their last dose was &gt; 6 months prior to randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 17:02:23 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: trastuzumab 8 mg/kg loading dose 90 minutes IV then 6 mg/kg 30 minutes IV q21 days until progression + bevacizumab 15 mg/kg in 90 minutes on day 1 q21 days until progression + paclitaxel 90 mg/m<SUP>2</SUP>; day 1, 8, 15 q28 days for 6 cycles<BR/>Arm 2: trastuzumab 8 mg/kg loading dose 90 minutes IV then 6 mg/kg 30 minutes IV q21 days until progression + bevacizumab 15 mg/kg IV in 90 minutes on day 1 q21 days until progression. At progression followed by trastuzumab 6 mg/kg and bevacizumab 15 mg/kg q21 days until further progression + paclitaxel 90 mg/m<SUP>2</SUP> at days 1, 8, and 15 of a 4-week cycle for 6 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 17:02:44 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Progression-free survival at 1 year</LI>
<LI>Median progression-free survival</LI>
<LI>Median overall survival</LI>
<LI>Best overall response</LI>
<LI>Duration of response</LI>
<LI>Safety and tolerability of both regimens. Response evaluated every 12 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-20 17:03:37 +1000" MODIFIED_BY="[Empty name]">
<P>1 April 2009<BR/>Expected closing date: 1 September 2011<BR/>Target accrual: 84 participants</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-03 10:48:30 +1100" MODIFIED_BY="Melina L Willson">
<P>Dr S Sleijfer, Erasmus Medical Center - Daniel den Hoed, Department of Medical Oncology, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-03 10:48:30 +1100" MODIFIED_BY="Melina L Willson">
<P>Primary sponsor(s): Breast Cancer Study Group (BOOG) and Roche Nederland BV</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-20 17:10:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pegram">
<CHAR_STUDY_NAME MODIFIED="2015-05-20 17:05:01 +1000" MODIFIED_BY="[Empty name]">
<P>Phase III randomised study of XRP9881 vs capecitabine in people with locally recurrent inoperable or metastatic breast cancer that progressed after prior taxane- and anthracycline-based therapy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-11-03 10:48:34 +1100" MODIFIED_BY="Melina L Willson">
<P>Randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-20 17:05:47 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmed metastatic breast cancer or locally recurrent disease and inoperable with curative intent<BR/>HER2/neu positive disease allowed<BR/>Received prior anthracycline- or taxane-based treatment in the adjuvant or metastatic setting</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 17:09:33 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: XRP9881 IV over 1 hour on day 1</P>
<P>Arm 2: capecitabine twice daily on days 1-14</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 17:09:49 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Time to progression</LI>
<LI>Overall survival</LI>
<LI>Duration of response, response rate, single-time progression rate, time to treatment failure</LI>
<LI>Safety and tolerability</LI>
<LI>QoL</LI>
<LI>Clinical benefit measures</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-11-03 10:48:34 +1100" MODIFIED_BY="Melina L Willson">
<P>Registered/published in March 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-05-20 17:10:25 +1000" MODIFIED_BY="[Empty name]">
<P>Mark Pegram, Protocol Chair, Jonsson Comprehensive Cancer Centre, UCLA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-05-20 17:10:50 +1000" MODIFIED_BY="[Empty name]">
<P>Projected accrual: 800 participants</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-05-21 00:25:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SAKK">
<CHAR_STUDY_NAME MODIFIED="2015-05-20 17:11:32 +1000" MODIFIED_BY="[Empty name]">
<P>SWS-SAKK-22/99<BR/>Phase III randomised study of first-line trastuzumab (Herceptin) alone followed by combination trastuzumab and paclitaxel vs first-line combination trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-05-21 00:25:32 +1000" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS>
<P>Women aged 18-70 with HER2-overexpressing metastatic breast cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-20 17:12:08 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: trastuzumab (followed by trastuzumab and paclitaxel at progression)<BR/>Arm 2: trastuzumab and paclitaxel</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 17:12:58 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Efficacy</LI>
<LI>Toxicity, quality of life</LI>
<LI>QoL</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-07-22 17:03:15 +1000" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Aron Goldhirsch, Chair, Swiss Institute for Applied Cancer Research</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-05-20 17:13:09 +1000" MODIFIED_BY="[Empty name]">
<P>Projected accrual: 170-250 women</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>AUC: area under the curve<BR/>BD: twice a day<BR/>BRCA1/2: Breast Cancer (mutation) gene 1 or 2<BR/>d: day<BR/>ER: oestrogen receptor<BR/>HER2: human epidermal growth factor receptor 2<BR/>ITT: intention to treat<BR/>NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events<BR/>PR: progesterone receptor<BR/>PO: oral administration<BR/>q: every/each<BR/>QoL: quality of life<BR/>RECIST: Response Evaluation Criteria in Solid Tumors<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-05-25 17:10:01 +1000" MODIFIED_BY="Melina L Willson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-05-25 16:17:33 +1000" MODIFIED_BY="Melina L Willson" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:22:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_03-Study-Group">
<DESCRIPTION>
<P>Quote: "Patients were assigned randomly" and they used stratified randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 06:13:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_04-Study-Group">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned" and block randomisation by institution was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:52:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_06-Study-Group">
<DESCRIPTION>
<P>Quote from abstract: "Patients were randomly assigned to receive doxorubicin". Randomisation was centralised with block design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:54:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AGO">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned to receive either ...". No additional details were provided in the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-11 12:50:37 +1100" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-ANZ-TITG">
<DESCRIPTION>
<P>Quote: "Patients were stratified by institution and randomized to receive either...". Statistical methods section states "randomization was based on an adaptive biased coin procedure with a bias of 3n at each allocation in favor of the arm with n fewer patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:01:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blohmer">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomly assigned to receive either...&#8221;. Randomisation was centralised with a block design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:03:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonneterre">
<DESCRIPTION>
<P>Quote: &#8220;centralised predefined schedule with randomisation stratified according to centre..&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:06:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bontenbal">
<DESCRIPTION>
<P>Quote from abstract: &#8220;patients were randomly assigned to either...&#8221; and involved stratification randomisation based on centre, prior chemotherapy, WHO performance status, and presence of bone metastases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:03:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CECOG-BM1">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomly assigned to GET or FEC...based on a minimizing algorithm"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:12:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieras">
<DESCRIPTION>
<P>Quote: &#8220;Central randomization was performed by computerized log, without direct access of the investigator". Comment: random assignments were probably generated by computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:41:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomized to receive either...&#8221;. No additional details were provided on how random assignment was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:40:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomized to receive either...&#8221;. No additional details were provided on how random assignment was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:24:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EORTC-10923">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomly assigned to receive...&#8221;. No details on the random component were described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:28:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10961">
<DESCRIPTION>
<P>Quote: &#8220;...random assignment was undertaken using a minimization technique..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:30:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EU_x002d_93011">
<DESCRIPTION>
<P>Quote: "patients were randomly assigned using blocks of various lengths"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-25 16:13:37 +1000" MODIFIED_BY="Melina L Willson" RESULT="UNKNOWN" STUDY_ID="STD-HERNATA">
<DESCRIPTION>
<P>Quote: "patients were randomly assigned". No further details provided in the trial report or retrieved case report form</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-25 16:15:30 +1000" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-JCOG9802">
<DESCRIPTION>
<P>Quote: "...patients were then randomly assigned to one of the three treatment groups by the minimization method..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 12:04:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jassem">
<DESCRIPTION>
<P>Quote: &#8220;...patients were randomized in a 1:1 ratio to receive therapy with either...&#8221;. Involved stratified randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 14:04:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyman">
<DESCRIPTION>
<P>Quote: &#8220;Patients randomized between the two treatment arms in this study&#8221;. No additional details were provided on how random assignment was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 12:45:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meier">
<DESCRIPTION>
<P>Quote (abstract): &#8220;patients were randomized to receive...&#8221;. No additional details were provided on how random assignment was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 12:49:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nabholtz">
<DESCRIPTION>
<P>Quote: &#8220;A phase III randomized trial...&#8221;. No additional details were provided in the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:22:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rugo">
<DESCRIPTION>
<P>Quote: &#8220;Women...randomized in a 3:3:2 ratio...&#8221; and "randomisation was stratified"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-25 16:17:33 +1000" MODIFIED_BY="Melina L Willson" RESULT="UNKNOWN" STUDY_ID="STD-Sjostrom">
<DESCRIPTION>
<P>Quote (from <LINK REF="REF-Hakamies_x002d_Blomqvist-2000" TYPE="REFERENCE">Hakamies-Blomqvist 2000</LINK>): &#8220;...were randomised into this study...". No additional details were provided on how random assignment was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:29:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TOG">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomised, 100 to EoP and 101 to paclitaxel arms&#8221;. No additional details were provided on how random assignment was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 14:06:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TRAVIOTA">
<DESCRIPTION>
<P>Quote: "Patients were randomised 1:1 to receive...". No further details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:45:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TXT">
<DESCRIPTION>
<P>Quote: &#8220;Patients were randomly assigned on a one-to-one basis to 1 of 2 groups, stratified by accruing centre.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:27:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Talbot">
<DESCRIPTION>
<P>Quote: &#8220;Patients were randomised to three treatment arms in a 1:1:1 ratio&#8221; and "patients were stratified"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 14:41:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UKCCCR-AB01">
<DESCRIPTION>
<P>Quote: &#8220;Patients were randomly assigned to receive either EP or EC intravenously...&#8221; &#8220;Random assignment was performed using a minimization procedure stratified by centre...&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:50:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yardley">
<DESCRIPTION>
<P>Quote: &#8220;Patients underwent a 1:1 randomization to receive either...&#8221;. No additional details were provided on how random assignment was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-05-20 11:53:54 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:23:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_03-Study-Group">
<DESCRIPTION>
<P>Central allocation. Quote: "The randomization was centralized and stratified for treatment arm by institution"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:44:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_04-Study-Group">
<DESCRIPTION>
<P>Central allocation. Quote: "The randomization was centralized at Rhone-Pulene Rorer, Antony, France"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:52:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_06-Study-Group">
<DESCRIPTION>
<P>Quote: "The randomization was centralized..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:54:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AGO">
<DESCRIPTION>
<P>Method of concealment was not described in the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:56:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ANZ-TITG">
<DESCRIPTION>
<P>Quote: "Computer-generated randomization charts were prepared for each center and held at the Statistical Centre at Peter MacCallum Cancer Institute, Melbourne, Australia"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:01:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blohmer">
<DESCRIPTION>
<P>Quote: &#8220;The randomisation was centralized with a block design by study centre&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:03:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonneterre">
<DESCRIPTION>
<P>Quote: &#8220;...centralised predefined schedule with randomisation stratified according to centre to one of two treatment arms&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:06:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bontenbal">
<DESCRIPTION>
<P>Quote: &#8220;randomisation performed by calling a central telephone number who stratified for center.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:03:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CECOG-BM1">
<DESCRIPTION>
<P>Quote: &#8220;...via a centralised randomisation system based on a minimising algorithm&#8221;; stratified by centre and prior adjuvant chemotherapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:12:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieras">
<DESCRIPTION>
<P>Quote: &#8220;centralized randomization was performed by computerised log, without direct access of the investigator&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:21:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_">
<DESCRIPTION>
<P>Method of concealment was not described in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:21:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_">
<DESCRIPTION>
<P>Method of concealment was not described in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:25:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10923">
<DESCRIPTION>
<P>Central allocation. Quote: &#8220;randomization was performed centrally at the EORTC Data Center located in Brussels (Belgium) by telephone, fax or computer&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:28:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10961">
<DESCRIPTION>
<P>Quote: &#8220;patients were centrally randomized at the EORTC Data Center in Brussels&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:30:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EU_x002d_93011">
<DESCRIPTION>
<P>Quote: "randomization was carried out centrally by fax or telephone in blocks of variable length"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 11:53:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERNATA">
<DESCRIPTION>
<P>Central allocation. Quote: "...patients were, unstratified, randomly assigned centrally by the Danish Breast Cancer Cooperative Group Secretariat"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 14:02:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-JCOG9802">
<DESCRIPTION>
<P>Quote: &#8220;The randomisation of treatment assignments was centralized. After confirming that candidate subjects met all the inclusion and exclusion criteria, the Japan Clinical Oncology Group (JCOG) Data Center was informed by telephone or fax&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 14:01:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jassem">
<DESCRIPTION>
<P>Quote: &#8220;Before central randomization, patients were stratified according to...&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 14:05:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyman">
<DESCRIPTION>
<P>Method of concealment was not described in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:10:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meier">
<DESCRIPTION>
<P>Quote: &#8220;Eligible and consenting patients were centrally randomized&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:13:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nabholtz">
<DESCRIPTION>
<P>Method of concealment was not described in the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:22:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rugo">
<DESCRIPTION>
<P>Method of concealment was not described in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:25:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sjostrom">
<DESCRIPTION>
<P>Method of concealment was not described in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:29:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TOG">
<DESCRIPTION>
<P>Quote: &#8220;Randomisation was carried out centrally by the data centre of TOG&#8221; (Turkish Oncology Group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:43:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TRAVIOTA">
<DESCRIPTION>
<P>Method of concealment was not described in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:45:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TXT">
<DESCRIPTION>
<P>Method of concealment was not described in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:27:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Talbot">
<DESCRIPTION>
<P>Method of concealment was not described in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:47:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-UKCCCR-AB01">
<DESCRIPTION>
<P>Method of concealment was not described in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:50:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yardley">
<DESCRIPTION>
<P>Method of concealment was not described in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-08-01 15:39:33 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-11-03 10:45:37 +1100" MODIFIED_BY="Melina L Willson" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 12:23:51 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x0033_03-Study-Group">
<DESCRIPTION>
<P>Non-blinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 12:44:23 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x0033_04-Study-Group">
<DESCRIPTION>
<P>Non-blinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 12:52:40 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x0033_06-Study-Group">
<DESCRIPTION>
<P>Non-blinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 12:55:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AGO">
<DESCRIPTION>
<P>No information provided in the abstracts available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 12:57:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ANZ-TITG">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 13:01:30 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blohmer">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 13:03:32 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bonneterre">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 13:07:08 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bontenbal">
<DESCRIPTION>
<P>Non-blinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-09-23 10:57:55 +1000" MODIFIED_BY="Melina L Willson" RESULT="UNKNOWN" STUDY_ID="STD-CECOG-BM1">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 13:12:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dieras">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 13:22:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 13:22:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 13:25:12 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EORTC-10923">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 13:29:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EORTC-10961">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 13:30:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EU_x002d_93011">
<DESCRIPTION>
<P>No information in unpublished manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 13:56:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HERNATA">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 14:03:00 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-JCOG9802">
<DESCRIPTION>
<P>Non-blinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 14:01:25 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jassem">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 14:08:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyman">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 21:11:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meier">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-03 10:45:37 +1100" MODIFIED_BY="Melina L Willson" RESULT="UNKNOWN" STUDY_ID="STD-Nabholtz">
<DESCRIPTION>
<P>No information in the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 21:22:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rugo">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 21:25:25 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sjostrom">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 21:30:38 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-TOG">
<DESCRIPTION>
<P>Non-blinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 21:43:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TRAVIOTA">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 21:45:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TXT">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 21:27:32 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Talbot">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 21:48:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-UKCCCR-AB01">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-30 21:51:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yardley">
<DESCRIPTION>
<P>No information in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-05-25 16:25:15 +1000" MODIFIED_BY="Melina L Willson" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.03" NO="3">
<NAME>QoL</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Overall survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>TTP, TTF, Response rate &amp; Toxicity</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 12:24:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_03-Study-Group">
<DESCRIPTION>
<P>A non-blinded study. Unlikely that assessment of overall survival would be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 23:56:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_03-Study-Group">
<DESCRIPTION>
<P>Imaging and tumour evaluation at the end of cycles 2, 4, and 7 or at least every 3 months. CR had to be confirmed by a second evaluation more than 28 days later. Tumour assessments were reviewed by an independent panel of 2 radiologists and an oncologist.</P>
<P>Blood tests and scans (MUGA) or echocardiography conducted. Data "analysed directly from reported laboratory parameters"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-05-20 05:57:55 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x0033_03-Study-Group">
<DESCRIPTION>
<P>EORTC QLQ-C30 questionnaire completed by participants and Karnofsky Performance Status completed by physicians</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 12:44:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_04-Study-Group">
<DESCRIPTION>
<P>A non-blinded study. Unlikely that assessment of overall survival would be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 23:56:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_04-Study-Group">
<DESCRIPTION>
<P>Imaging and tumour evaluation at the end of cycles 3, 6, 8, and 10 or at discontinuation or at least every 3 months. CR had to be confirmed by a second evaluation more than 28 days later. Tumour assessments were reviewed by an independent panel of 2 radiologists and an oncologist in 10% of participants</P>
<P>Blood tests and scans. "Drug safety was analysed directly from reported laboratory parameters"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-05-20 06:16:34 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x0033_04-Study-Group">
<DESCRIPTION>
<P>EORTC QLQ-C30 questionnaire completed by participants and Karnofsky Performance Status used to assess participant's condition from physician's perspective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 12:52:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_06-Study-Group">
<DESCRIPTION>
<P>A non-blinded study. Unlikely that assessment of overall survival would be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 06:33:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_06-Study-Group">
<DESCRIPTION>
<P>Imaging and tumour evaluation after cycles 3, 6, 8 or study treatment discontinuation and then every 2 months until disease progression or death. "All tumour assessments from patients with radiologically assessable disease were reviewed by an independent expert panel" (3 radiologists and 1 medical oncologist)</P>
<P>Weekly blood counts performed. Measurement of LVEF performed after cycles 3, 6, 8 and as clinically indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-05-20 06:40:02 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x0033_06-Study-Group">
<DESCRIPTION>
<P>EORTC C30 and QLQ-BR23 completed by participants and Karnofsky Performance Status completed by physicians</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 12:54:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AGO">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 07:34:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AGO">
<DESCRIPTION>
<P>No information provided in the abstracts available.</P>
<P>NCI-CTC used.</P>
<P>Comment: blood tests were assumed to be conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-05-22 08:50:39 +1000" MODIFIED_BY="Melina L Willson" RESULT="UNKNOWN" STUDY_ID="STD-AGO">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 12:58:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ANZ-TITG">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-25 15:58:45 +1000" MODIFIED_BY="Melina L Willson" RESULT="UNKNOWN" STUDY_ID="STD-ANZ-TITG">
<DESCRIPTION>
<P>Weekly blood tests. Scans to evaluate disease repeated after 12 weeks and 24 weeks on therapy. Tests also repeated at time of suspected relapse or progression and at intervals no less than 4 weeks apart from PR or CR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-11-03 10:35:06 +1100" MODIFIED_BY="Melina L Willson" RESULT="NO" STUDY_ID="STD-ANZ-TITG">
<DESCRIPTION>
<P>QoL linear analog scales completed by participants and Spitzer QoL index completed by physicians (p. 2356)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:01:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blohmer">
<DESCRIPTION>
<P>Open-label study. Unlikely that assessment of overall survival would be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-08-01 15:49:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blohmer">
<DESCRIPTION>
<P>Tumour lesions were assessed at end of treatment cycles 2, 4, 6, 8 or at study discontinuation and then every 2 months. No description of how evaluations were done</P>
<P>Adverse events and toxicity were assessed weekly and recorded for every cycle. Scans were used to assess cardiac function at baseline and after cycles 3 and 6, and at the end of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:00:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blohmer">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:03:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonneterre">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-11-11 12:51:06 +1100" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-Bonneterre">
<DESCRIPTION>
<P>Physical examinations and blood tests run at the beginning of each treatment cycle. Target lesions assessed every 2 cycles. Responses reviewed by an independent committee of radiologists</P>
<P>Scans were performed every 4 cycles and then every 2 cycles once maximum cumulative dose reached (anthracyclines)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:00:43 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bonneterre">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:07:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bontenbal">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 07:53:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bontenbal">
<DESCRIPTION>
<P>X-ray, ultrasonography, and MRI, etc. used to assess tumour status. Up to a max of 8 representable lesions were evaluated after cycles 2, 4, 6 then every 2 months for the first year, etc.</P>
<P>Physical examination and biochemical tests and scans were performed weekly before each cycle</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:00:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bontenbal">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:10:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CECOG-BM1">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 08:05:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CECOG-BM1">
<DESCRIPTION>
<P>Tumour imaging and response assessment carried out every cycle<BR/>
</P>
<P>Blood tests weekly, so too ECG, echocardiogram (before cycles 5 &amp; 7) and toxicity (after each cycle)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:00:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CECOG-BM1">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:12:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieras">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-08-01 15:51:24 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dieras">
<DESCRIPTION>
<P>No information provided in the trial publication about tumour evaluations</P>
<P>Blood tests conducted prior to new course</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:00:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dieras">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:22:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 12:50:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_">
<DESCRIPTION>
<P>No information provided in the trial publication about tumour evaluations.<BR/>NCI toxicity criteria used. Comment: standard blood tests probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-05-20 08:39:11 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_">
<DESCRIPTION>
<P>FACT-B completed by participants at baseline and at week 16</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:22:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 12:50:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_">
<DESCRIPTION>
<P>No information provided in the trial publication about tumour evaluations.</P>
<P>NCI toxicity criteria used. Comment: standard blood tests probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-05-20 08:42:00 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_">
<DESCRIPTION>
<P>FACT-B completed by participants at baseline and at week 16</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:25:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10923">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 08:48:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10923">
<DESCRIPTION>
<P>Tumour response assessed per Union for International Cancer Control criteria. Serial evidence was documented by radiology or photography and assessed by external review. "All case report forms were reviewed by local investigators and to two independent radiologists who were blinded to treatment arm"</P>
<P>Weekly blood tests and toxicity assessed using NCI-CTC. MUGA or echocardiography for evaluating LVEF conducted at study entry and at completion of 5th and 7th course</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-05-20 08:50:15 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-EORTC-10923">
<DESCRIPTION>
<P>EORTC QLQ-C30 and Rotterdam Symptom Checklist completed by participants at baseline and at completion of cycles 3, 5, 7 and during follow-up (every 2 months) until disease progression</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:29:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10961">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 09:02:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EORTC-10961">
<DESCRIPTION>
<P>Tumour measurement performed every 6 weeks until tumour progression and assessed using WHO criteria. Comment: scans would have been done to use WHO criteria</P>
<P>Physical exam and blood tests repeated before each cycle, hematological monitoring weekly, and MUGA scan or echocardiography at study entry, before cycles 3, 5, 6 and 3 months after last chemotherapy. NCI-CTC used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-05-20 09:03:30 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-EORTC-10961">
<DESCRIPTION>
<P>EORTC QLQ-C30 &amp; BR23 completed by participants at baseline and before cycles 2, 4, and 6 and at first follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:30:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EU_x002d_93011">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-25 16:12:29 +1000" MODIFIED_BY="Melina L Willson" RESULT="UNKNOWN" STUDY_ID="STD-EU_x002d_93011">
<DESCRIPTION>
<P>Assessed MBS that was composed of time to progression, PS/WHO (WHO performance status during chemotherapy as compared to that before the start of treatment), SUJ (Patient's rating of the treatment benefit) and TOX (toxicity component based on alopecia and nausea/vomiting during therapy). Comment: scans to assess tumour response probably done<BR/>Toxicity graded per WHO criteria. Comment: standard blood tests probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:01:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EU_x002d_93011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 13:56:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERNATA">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-08-01 15:54:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HERNATA">
<DESCRIPTION>
<P>Imaging and tumour evaluation every 3 months</P>
<P>Lab tests (blood counts) repeated at each cycle</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:01:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HERNATA">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 14:03:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-JCOG9802">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-08-01 15:55:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-JCOG9802">
<DESCRIPTION>
<P>Objective responses were assessed by central review at regular meetings. Response was classified using criteria similar to WHO criteria. Comment: scans would have been done to use WHO-like criteria</P>
<P>Blood tests conducted. Toxicity assessed using criteria similar to NCI-CTC</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-11-03 10:45:17 +1100" MODIFIED_BY="Melina L Willson" RESULT="NO" STUDY_ID="STD-JCOG9802">
<DESCRIPTION>
<P>FACT-B questionnaire completed by first 50 participants in each treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 14:01:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jassem">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-08-01 15:54:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jassem">
<DESCRIPTION>
<P>All efficacy data was subjected to a blinded clinical and radiological independent review. Physical examination every cycle and imaging studies every other cycle</P>
<P>Blood tests repeated before each cycle; LVEF assessed before cycles 5 and 7 and at end of study; toxicity assessed using WHO criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-05-20 12:12:15 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jassem">
<DESCRIPTION>
<P>EORTC QLQ-C30 and EORTC QLQ-BR23 completed by participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 14:08:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lyman">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 13:17:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyman">
<DESCRIPTION>
<P>Responses assessed according to SWOG criteria, using markers and other lab values</P>
<P>LVEF assessed on study and after 6 cycles. Comment: scans/tests probably done to grade toxicity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:01:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyman">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 21:11:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meier">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-08-01 15:55:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meier">
<DESCRIPTION>
<P>No information provided regarding criteria or tests used to evaluate response or progression</P>
<P>NCI-CTC v2 was used. Comment: blood tests and scans were probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-11-03 10:45:31 +1100" MODIFIED_BY="Melina L Willson" RESULT="NO" STUDY_ID="STD-Meier">
<DESCRIPTION>
<P>EORTC QLQ-C30 completed by participants at the start of each treatment cycle</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-09-23 11:07:25 +1000" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-Nabholtz">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-08-01 15:55:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nabholtz">
<DESCRIPTION>
<P>No information provided regarding criteria or tests used to evaluate response or progression</P>
<P>NCI criteria used. Comment: blood tests and scans were probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:01:40 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nabholtz">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 21:22:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rugo">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-08-01 15:56:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rugo">
<DESCRIPTION>
<P>RECIST used. Comment: scans and tests probably done</P>
<P>NCI-CTC used, and blood tests completed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:01:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rugo">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 21:25:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sjostrom">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 13:17:50 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sjostrom">
<DESCRIPTION>
<P>Lesions assessed every third course of treatment and according to WHO criteria</P>
<P>Blood tests conducted during every course of treatment; assessment based on WHO criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-05-20 13:18:11 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sjostrom">
<DESCRIPTION>
<P>EORTC QLQ-C30 completed by participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 21:30:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TOG">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 13:47:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TOG">
<DESCRIPTION>
<P>Blood tests repeated during each cycle, X-rays every 6 weeks. WHO criteria used to assess responses. Responses reviewed by 2 independent experts.</P>
<P>Grade III and IV toxicity reported. Comment: blood tests and scans probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:01:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TOG">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 21:43:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TRAVIOTA">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 14:12:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TRAVIOTA">
<DESCRIPTION>
<P>Participants underwent re-assessment (blood tests and scans): tests every 8 weeks for the first 6 months and then every 12 weeks. An independent data and safety board reviewed accrual, toxicity, and efficacy data</P>
<P>Blood tests conducted every week. An independent data and safety board reviewed accrual, toxicity, and efficacy data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:02:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TRAVIOTA">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 21:45:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TXT">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-25 16:25:15 +1000" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-TXT">
<DESCRIPTION>
<P>Before each cycle, biochemical and blood tests and physical examination were conducted. "Tumour response and time-related parameters assessed according to WHO criteria. Before each cycle, biochemical and blood tests conducted"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:02:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TXT">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 21:27:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Talbot">
<DESCRIPTION>
<P>Unlikely that overall survival assessment was influenced by unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-08-01 15:56:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Talbot">
<DESCRIPTION>
<P>Tumour response assessed using WHO criteria. Comment: scans were probably done for this assessment</P>
<P>Assessed using the NCI-CTC. Blood tests undertaken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:01:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Talbot">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 21:48:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UKCCCR-AB01">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 14:45:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-UKCCCR-AB01">
<DESCRIPTION>
<P>Blood counts monitored during and before each cycle. Radiological assessments of known disease were performed after the 3rd and 6th chemotherapy cycle and 3 months thereafter</P>
<P>Blood counts and toxicity assessed during treatment and before each cycle</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-11-03 10:46:39 +1100" MODIFIED_BY="Melina L Willson" RESULT="NO" STUDY_ID="STD-UKCCCR-AB01">
<DESCRIPTION>
<P>FACT-B used; a QoL result briefly mentioned in the 2001 abstract but not in the full trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-30 21:51:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yardley">
<DESCRIPTION>
<P>Assessment of overall survival is unlikely to be influenced by no or incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2014-11-11 12:53:36 +1100" MODIFIED_BY="Melina L Willson" RESULT="UNKNOWN" STUDY_ID="STD-Yardley">
<DESCRIPTION>
<P>RECIST used. Comment: scans and tests probably done</P>
<P>Monitoring either by scan or echocardiogram for LVEF. Toxicity graded in line with NCI-CTC</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2014-08-01 16:02:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yardley">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-05-25 17:10:01 +1000" MODIFIED_BY="Melina L Willson" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 05:58:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_03-Study-Group">
<DESCRIPTION>
<P>Study reported 159/161 participants in the docetaxel group and 163/165 participants in the doxorubicin group received treatment. All participants were included in the efficacy (survival) and safety analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-25 17:10:01 +1000" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-_x0033_04-Study-Group">
<DESCRIPTION>
<P>Paper reported that 200/203 participants in docetaxel group and 187/189 participants in mitomycin group received treatment, and efficacy analyses used ITT principle. Safety analyses were conducted on all treated participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 23:52:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_06-Study-Group">
<DESCRIPTION>
<P>213/214 participants on AT and 210/215 participants on AC received treatment. Efficacy analyses performed on assessable and ITT populations. Safety analyses on all treated participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-30 12:55:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AGO">
<DESCRIPTION>
<P>No reporting of attrition or exclusions in the available abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 06:58:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ANZ-TITG">
<DESCRIPTION>
<P>105/107 participants received paclitaxel and 99/102 participants received CMFP. "All major endpoints were compared using ITT analysis that included all randomised patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 07:11:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blohmer">
<DESCRIPTION>
<P>240 participants enrolled; 4 participants (1.7%) did not receive study medication and were excluded from ITT and safety analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 07:40:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonneterre">
<DESCRIPTION>
<P>65/70 participants received ET and 67/72 participants FEC. ITT analysis undertaken on all (142) participants. For response rates, analyses used ITT population and assessable population</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-30 13:08:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bontenbal">
<DESCRIPTION>
<P>108/109 received AT treatment and 107/107 received FAC treatment. ITT analysis, and a separate per-protocol analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 08:06:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CECOG-BM1">
<DESCRIPTION>
<P>259 randomised participants; 124/124 on GET and 132/135 on FEC received study treatment. ITT was not used, instead assessable participants, for response and toxicity analyses. Survival data not yet mature</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 08:14:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieras">
<DESCRIPTION>
<P>No missing outcome data; all randomised participants included in analyses of baseline characteristics and efficacy, objective response rates also were analysed for evaluable participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 08:39:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_">
<DESCRIPTION>
<P>33/731 randomised participants were excluded from analysis with ineligibility reasons provided. 70% of eligible participants completed the follow-up assessment for QoL at week 16. Method of analyses not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 08:42:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_">
<DESCRIPTION>
<P>33/731 randomised participants were excluded from analysis with ineligibility reasons provided. 70% of eligible participants completed the follow-up assessment for QoL at week 16. Method of analyses not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 08:51:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10923">
<DESCRIPTION>
<P>164/166 randomised participants received paclitaxel; 163/165 randomised participants received doxorubicin. All randomly assigned participants were evaluated according to ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 09:03:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10961">
<DESCRIPTION>
<P>217/273 randomised participants received study treatment. Quote: &#8220;all randomized patients were evaluated for Response Rate, PFS and OS according to intention-to-treat principle&#8221;. Sensitivity analyses were performed to investigate missing data for QoL.<BR/>
<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 09:17:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EU_x002d_93011">
<DESCRIPTION>
<P>176/179 randomised participants and included in ITT analysis for primary outcomes. 3 participants excluded (1.7%) due to cerebral metastases and insufficient data (reasons provided in PRISMA flowchart)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 11:55:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERNATA">
<DESCRIPTION>
<P>At time of analysis, 128/139 in the docetaxel group and 120/138 in the vinorelbine group discontinued therapy, including 11 and 15 participants, respectively, due to "other reasons" including lost to follow-up. ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 12:28:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-JCOG9802">
<DESCRIPTION>
<P>TTF, PFS, and OS were analysed using ITT population; response and safety used assessable participants. 68% of participants in the AC arm, 76% in the D arm, and 77% in alternating AC+D arm completed 6 cycles mainly due to disease progression</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 12:13:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jassem">
<DESCRIPTION>
<P>267 participants were enrolled and randomised, with 264 receiving treatment and 259 assessable for response. TTP and OS analyses based on ITT population. 264/267 (98.9%) of participants available for toxicity analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 12:39:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lyman">
<DESCRIPTION>
<P>All participants accounted for in overall survival and objective complete response</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 12:45:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meier">
<DESCRIPTION>
<P>All participants accounted for, including cross-overs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-30 21:14:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nabholtz">
<DESCRIPTION>
<P>No reporting of attrition or exclusions in the available abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-25 16:16:06 +1000" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-Rugo">
<DESCRIPTION>
<P>PFS and OS analysed using randomised participants, while response rate and toxicity on evaluable-assessable participants. 95% of participants discontinued treatment at time of analysis with reasons and number of participants provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 13:18:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sjostrom">
<DESCRIPTION>
<P>Efficacy analyses done on ITT population. 19/283 (6.7%) participants were excluded from TTP analysis with reasons provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 13:50:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TOG">
<DESCRIPTION>
<P>91/100 participants and 95/101 participants randomised to cisplatin + etoposide and paclitaxel, respectively, reasons for exclusions provided. Survival data analysed on ITT principle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-25 16:22:20 +1000" MODIFIED_BY="Melina L Willson" RESULT="UNKNOWN" STUDY_ID="STD-TRAVIOTA">
<DESCRIPTION>
<P>85 participants were randomised; 4 participants (4.7%) did not contribute baseline or follow-up data, did not start treatment on trial, or went off study within 2 days of randomisation. Reasons for participant exclusions in response rate were provided. No description of analyses method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 14:29:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TXT">
<DESCRIPTION>
<P>Analyses performed on 176 out of 178 randomised participants. Number of participants censored provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 13:28:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Talbot">
<DESCRIPTION>
<P>ITT population consisted of 41/44 participants; reasons for non-inclusion were provided<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 14:49:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UKCCCR-AB01">
<DESCRIPTION>
<P>Analyses used ITT population for efficacy but not for toxicity or response. 71% of participants in both arms received 6 cycles of treatment; progressive disease was the main reason for participants not receiving treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 15:01:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yardley">
<DESCRIPTION>
<P>No missing outcome data. 48/50 participants on doxorubicin and 44/52 participants on docetaxel were evaluable for response to treatment; numbers and reasons for attrition were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-05-25 16:28:51 +1000" MODIFIED_BY="Melina L Willson" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:26:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_03-Study-Group">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods are reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 06:19:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_04-Study-Group">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:53:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_06-Study-Group">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods are reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:55:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AGO">
<DESCRIPTION>
<P>Unable to assess from the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:58:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ANZ-TITG">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods are reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 07:12:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blohmer">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 07:41:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonneterre">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 07:55:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bontenbal">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:07:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CECOG-BM1">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:15:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieras">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:39:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:42:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:51:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10923">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:29:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10961">
<DESCRIPTION>
<P>Expected outcomes were reported in 2 separate publications</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 09:18:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EU_x002d_93011">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the unpublished manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 11:57:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERNATA">
<DESCRIPTION>
<P>Pre-specified outcomes in ClinicalTrials.gov record (http://clinicaltrials.gov/ct2/show/NCT00430001?term=HERNATA&amp;rank=1) and the methods section of the trial publication are the same. All outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-25 16:27:42 +1000" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-JCOG9802">
<DESCRIPTION>
<P>Pre-specified outcomes in ClinicalTrials.gov record (<A HREF="https://clinicaltrials.gov/show/NCT00193037">https://clinicaltrials.gov/show/NCT00193037</A>) and the methods section of the trial publication are similar; the trial publication adds QoL. All outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 12:13:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jassem">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 12:39:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lyman">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 12:46:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meier">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:15:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nabholtz">
<DESCRIPTION>
<P>Unable to assess from the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-25 16:28:09 +1000" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-Rugo">
<DESCRIPTION>
<P>Pre-specified outcomes in ClinicalTrials.gov record (<A HREF="http://clinicaltrials.gov/show/NCT00370552">http://clinicaltrials.gov/show/NCT00370552</A>) and the methods section of the trial publication are the same. All outcomes were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 13:18:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sjostrom">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-25 16:28:30 +1000" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-TOG">
<DESCRIPTION>
<P>Pre-specified outcomes in ClinicalTrials.gov record (<A HREF="http://clinicaltrials.gov/show/NCT00370552">http://clinicaltrials.gov/show/NCT00370552</A>) and the methods section of the trial publication are the same. All outcomes were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-25 16:24:27 +1000" MODIFIED_BY="Melina L Willson" RESULT="NO" STUDY_ID="STD-TRAVIOTA">
<DESCRIPTION>
<P>Trial registration details stated QoL as a secondary outcome (<A HREF="https://clinicaltrials.gov/ct2/show/NCT00146549">https://clinicaltrials.gov/ct2/show/NCT00146549</A>), but no QoL data presented in trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 14:29:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TXT">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 13:28:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Talbot">
<DESCRIPTION>
<P>All pre-specified outcomes in the methods were reported in the results section of the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-25 16:28:51 +1000" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-UKCCCR-AB01">
<DESCRIPTION>
<P>Trial registration details outline outcomes as "activity and toxicity" (see <A HREF="http://clinicaltrials.gov/show/NCT00002953">http://clinicaltrials.gov/show/NCT00002953</A>). Toxicity and other time-to-event outcomes reported in methods and results sections of trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-25 16:26:18 +1000" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-Yardley">
<DESCRIPTION>
<P>Trial registration details outline overall response rate as primary endpoint and PFS as the secondary endpoint (see: <A HREF="https://clinicaltrials.gov/show/NCT00193037">https://clinicaltrials.gov/show/NCT00193037</A>). Both endpoints were reported in the methods and results sections of the trial publication, as well as additional endpoints OS and toxicity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-05-20 13:29:04 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 06:00:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_03-Study-Group">
<DESCRIPTION>
<P>Similar baseline characteristics in groups except for a slight imbalance in participants with bone metastases (docetaxel 55%, doxorubicin 63%; P = 0.012)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 06:22:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_04-Study-Group">
<DESCRIPTION>
<P>Baseline characteristics of both groups were comparable except for the number of organs involved (i.e. &#8805; 3 organs affected), however it was not mentioned if the difference was significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:53:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_06-Study-Group">
<DESCRIPTION>
<P>Quote: "Baseline characteristics were well balanced and major negative prognostic factors were similar in both groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 12:56:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AGO">
<DESCRIPTION>
<P>Quote: "Prognostic factors were balanced between treatment arms"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 06:59:50 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ANZ-TITG">
<DESCRIPTION>
<P>Baseline characteristics (e.g. ECOG performance status) provided by treatment arm but no indication whether there were any significant differences between groups. 3 of 7 potential prognostic factors in this study (includes ECOG performance status) "were shown to have a significant influence on survival"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:02:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blohmer">
<DESCRIPTION>
<P>Trial prematurely terminated due to inadequate accrual and results from the interim analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 07:42:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bonneterre">
<DESCRIPTION>
<P>Baseline characteristics generally comparable; however ET group had greater metastatic involvement of lung, liver, skin, bone or &gt; 3 organs; FEC group had a higher proportion of participants with oestrogen or progesterone receptor positive tumours</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:08:34 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bontenbal">
<DESCRIPTION>
<P>Early study closure date: &#8220;An independent Data Monitoring Committee determined that the chance of finding a statistical difference in TTP between the treatment arms had become so low that they recommended study closure&#8221;. No differences in baseline characteristics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:11:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CECOG-BM1">
<DESCRIPTION>
<P>Baseline characteristics mainly balanced between groups except for menopausal status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:13:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieras">
<DESCRIPTION>
<P>No baseline differences noted between treatment arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:40:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_">
<DESCRIPTION>
<P>Baseline characteristics well-matched across the 3 arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 08:42:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_">
<DESCRIPTION>
<P>Baseline characteristics well-matched across the 3 arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:26:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10923">
<DESCRIPTION>
<P>Baseline characteristics similar between the two groups; &#8220;no significant imbalance in classical prognostic factors&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 09:05:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-10961">
<DESCRIPTION>
<P>Participant characteristics between the 2 groups at baseline were balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:31:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EU_x002d_93011">
<DESCRIPTION>
<P>Recruitment stopped early because of poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 13:58:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERNATA">
<DESCRIPTION>
<P>Quote: "baseline demographics and other variables were well balanced between the treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 12:29:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-JCOG9802">
<DESCRIPTION>
<P>All prognostic factors well balanced between the 3 treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 14:02:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jassem">
<DESCRIPTION>
<P>Quote: &#8220;patient characteristics were well-balanced between two treatment arms&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 12:40:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyman">
<DESCRIPTION>
<P>Baseline characteristics for performance status differed between treatment groups with doxorubicin/paclitaxel arm somewhat better, but no statistics provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:12:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meier">
<DESCRIPTION>
<P>Baseline characteristics seemed to be comparable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:15:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nabholtz">
<DESCRIPTION>
<P>Baseline characteristics comparable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:24:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rugo">
<DESCRIPTION>
<P>Differences reported in baseline characteristics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:26:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sjostrom">
<DESCRIPTION>
<P>Baseline characteristics were similar between treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:32:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TOG">
<DESCRIPTION>
<P>Baseline characteristics were similar between treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:44:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TRAVIOTA">
<DESCRIPTION>
<P>Early closure of study due to poor accrual. Baseline characteristics between groups were not uniform</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:46:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TXT">
<DESCRIPTION>
<P>Baseline characteristics were similar between treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 13:29:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Talbot">
<DESCRIPTION>
<P>Quote: &#8220;baseline demographic and tumour characteristics, which were well balanced between treatment arms&#8221;. Premature discontinuation of the trial due to results from other trial data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:49:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UKCCCR-AB01">
<DESCRIPTION>
<P>Baseline characteristics were similar between treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-30 21:52:12 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yardley">
<DESCRIPTION>
<P>Trial prematurely stopped</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-05-26 13:33:25 +1000" MODIFIED_BY="Melina L Willson" NO="1">
<TITLE MODIFIED="2014-11-03 10:48:58 +1100" MODIFIED_BY="Melina L Willson">Quality of life (QoL)</TITLE>
<TABLE COLS="3" ROWS="13">
<TR>
<TH VALIGN="BOTTOM">
<P>Trial ID</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Instruments used</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Summary of findings</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed EORTC QLQ-C30 and physicians completed KPS</P>
</TD>
<TD VALIGN="TOP">
<P>80% of assessable participants completed QoL assessments in both groups for the first 4 cycles, but was higher in the docetaxel group from cycle 6. There was no statistically significant difference between the 2 groups in mean decreases in global health and physical functioning scores from baseline</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed EORTC QLQ-C30</P>
</TD>
<TD VALIGN="TOP">
<P>72% of questionnaires returned for docetaxel and 68% for MV for baseline and cycle 2, but deteriorated to 59% for docetaxel and 61% for MV by cycle 8. Attrition higher in MV compared to docetaxel, and did not occur at random. Significantly higher proportion of participants in MV discontinued treatment due to deterioration in condition; trial authors concluded that participants in the poorest health did not complete QoL questionnaires, hence QoL may be underestimated in both groups. Groups similar at baseline for global health, physical functioning, and symptoms except for role functioning and diarrhoea (imbalance in favour of docetaxel). Results: No significant difference in global health status. Significant difference in favour of docetaxel for nausea/vomiting and loss of appetite, and in favour of MV for role and social functioning</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed EORTC QLQ-C30 and QLQ-BR23 (Breast cancer module) 3 days before first infusion then before every alternate cycle and at each visit during follow-up until progression; and physicians completed KPS</P>
</TD>
<TD VALIGN="TOP">
<P>Overall compliance was high through to cycle 6 (&gt; 70%), then decreased during follow-up (&lt; 30%), although rates in both groups comparable. At cycle 8, more data were missing in AC group than in AT group. Baseline scores were comparable and remained constant during the study. There was no significant difference between groups in global health status/QoL score</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed linear analog scales, and physicians completed Spitzer Quality of Life Index</P>
</TD>
<TD VALIGN="TOP">
<P>Most QoL measures (physical well-being, mood, nausea and vomiting, appetite, overall quality of life, and physician-rated quality of life) were slightly better in the taxane arm. The exception is pain which was slightly better in the non-taxane arm. Differences were not statistically significant</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ECOG E1193: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed FACT-B</P>
</TD>
<TD VALIGN="TOP">
<P>93% (687/738) of randomised participants and 94% (640/683) of eligible participants completed the baseline survey. 70% (451/683) of eligible participants completed the survey at week 16. There was no statistically significant difference in overall QoL score or in any of the subscales between any of the treatment groups</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed EORTC QLQ-C30 and Rotterdam Symptom Checklist</P>
</TD>
<TD VALIGN="TOP">
<P>64% of randomised participants completed baseline EORTC QLQ-C30 and 61% completed baseline Rotterdam Symptom Checklist. QoL comparisons were only performed for the first 3 cycles. There was no difference in global health status/QoL between the 2 groups. Doxorubicin was associated with significantly more nausea/vomiting, loss of appetite, and burden of disease and treatment, but less bone pain and rash than paclitaxel</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed EORTC QLQ-C30 and QLQ-BR23 (Breast cancer module)</P>
</TD>
<TD VALIGN="TOP">
<P>79% of participants completed the baseline questionnaire. Overall compliance (over 4 assessments) was 66%. There was no significant difference in health-related QoL between the 2 treatment groups</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed EORTC QLQ-C30 and QLQ-BR23 (Breast cancer module)</P>
</TD>
<TD VALIGN="TOP">
<P>81% of questionnaires returned for AT patients and 77% for FAC patients (throughout study and follow-up), although compliance deteriorated over time. Information on non-compliers not reported. No statistically significant differences in changes from baseline in functional scales for role, emotional, cognitive, social, global health status, body image, sexual enjoyment, or future perspective. Significant difference in favour of FAC for physical and sexual functioning scales, pain, fatigue, insomnia, and diarrhoea. Significant difference in favour of AT for nausea and vomiting. There was no significant difference in other symptoms.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed FACT-B</P>
</TD>
<TD VALIGN="TOP">
<P>99% of the first 150 participants (i.e. 148/150) returned completed questionnaires at baseline, 89% at 6 weeks, and 87% at 18 weeks. There was no statistically significant difference between the 2 treatment arms of interest (for this review) at baseline, 6 weeks, or 18 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed EORTC QLQ-C30</P>
</TD>
<TD VALIGN="TOP">
<P>102/120 participants completed QoL questionnaires. There was no significant difference between treatment groups at baseline. Compliance declined (54% at cycle 4), thereby making QoL comparisons difficult. A non-significant trend for better scores in participants continuing on original docetaxel treatment was noted</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed EORTC QLQ-C30</P>
</TD>
<TD VALIGN="TOP">
<P>82% of questionnaires were returned over the entire study (overall compliance). Physical deterioration was greater in the methotrexate + fluorouracil group, hence possible bias in its favour. No statistically significant difference at baseline or by cycle 4 in any functional or symptom scale. No significant difference in median values of mean changes in QoL scores from baseline to cycle 6.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Participants completed FACT-B</P>
</TD>
<TD VALIGN="TOP">
<P>Abstract available in 2001 reported that QoL was "similar for both arms during treatment". No other results were available in the 2001 abstract or full trial publication in 2005</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>FAC: 5-fluorouracil, doxorubicin, cyclophosphamide<BR/>FACT-B: Functional Assessment of Cancer Therapy - Breast<BR/>KPS: Karnofsky Performance Status<BR/>MV: mitomycin C/vinblastine<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson" NO="2">
<TITLE MODIFIED="2014-10-23 16:40:14 +1100" MODIFIED_BY="Melina L Willson">Possible subgroups</TITLE>
<TABLE COLS="2" ROWS="3">
<TR>
<TH VALIGN="BOTTOM">
<P>Question</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Subgroups</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Subgroups within Question B:</P>
</TD>
<TD VALIGN="TOP">
<UL>
<LI>substitution of cyclophosphamide with taxane (<LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>, <LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>, <LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>, <LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>, <LINK REF="STD-Lyman" TYPE="STUDY">Lyman</LINK>, <LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>)</LI>
<LI>substitution of fluorouracil + cyclophosphamide with taxane (<LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>, <LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>, <LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>)</LI>
<LI>substitution of fluorouracil with taxane (<LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>)</LI>
<LI>substitution of anthracycline with taxane (no studies identified)</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Subgroups within Question C:</P>
</TD>
<TD VALIGN="TOP">
<UL>
<LI>single-agent taxane vs single-agent anthracycline (<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>, <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK>, <LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>)</LI>
<LI>single-agent taxane vs non-anthracycline single agent (<LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>, <LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>)</LI>
<LI>single-agent taxane vs anthracycline-containing combination (no studies identified)</LI>
<LI>single-agent taxane vs non-anthracycline-containing combination (<LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>; <LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>; <LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>; <LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>; <LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>; <LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>; <LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>)</LI>
</UL>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson" NO="3">
<TITLE MODIFIED="2014-09-22 17:02:54 +1000" MODIFIED_BY="Melina L Willson">Definitions of time to progression</TITLE>
<TABLE COLS="2" ROWS="28">
<TR>
<TD VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
<P>
<B>Variation in definitions and reporting of 'time to progression' used in 2013 Cochrane review update</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: date randomised to date of progression or death</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: date randomised to date of progression or death</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-_x0033_06-Study-Group" TYPE="STUDY">306 Study Group</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: date randomised to date of first progression</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>PFS: no definition provided in the abstract.<BR/>Data for this outcome were not included in the review due to an inadequate amount of information presented in the abstract</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ANZ-TITG" TYPE="STUDY">ANZ TITG</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>PFS: date randomised to date of progression or death without progression</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Blohmer" TYPE="STUDY">Blohmer</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: time from registration until disease progression</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: not defined in the trial publication</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bontenbal" TYPE="STUDY">Bontenbal</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: date of random assignment to the date of progression, death, or withdrawal</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: dates of randomisation until disease progression or death, whichever occurred first</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dieras" TYPE="STUDY">Dieras</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: not defined in trial publication</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ECOG E1193: <LINK REF="STD-ECOG-E1193-_x0028_A_x0029_" TYPE="STUDY">ECOG E1193 (A)</LINK> and <LINK REF="STD-ECOG-E1193-_x0028_B_x0029_" TYPE="STUDY">ECOG E1193 (B)</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTF: date randomised to date of progression, toxic death, death attributed to breast cancer within 6 weeks of date last known alive with stable disease</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EORTC-10923" TYPE="STUDY">EORTC 10923</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>PFS: date randomised to date of progression or death if it occurred before documentation of progressive disease</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EORTC-10961" TYPE="STUDY">EORTC 10961</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>PFS: randomisation to date of progression or death or whichever occurred first</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: i.e. progression-free survival, the duration from randomisation until progressive disease, death, or last contact.</P>
<P>Data presented for this outcome was incomplete (i.e. the number of events was not provided in the manuscript)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HERNATA" TYPE="STUDY">HERNATA</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: date of randomisation to date of documented progression with censoring for participants alive at last visit/date of death</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jassem" TYPE="STUDY">Jassem</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: not defined in trial publication</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-JCOG9802" TYPE="STUDY">JCOG9802</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>PFS: date of randomisation to the date of the first documentation of disease progression or death from any cause</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Meier" TYPE="STUDY">Meier</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: not defined in trial publication.</P>
<P>Inadequate information presented in the trial publication to allow accurate data extraction. Trial authors were contacted for additional information</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: no definition provided in the abstract.<BR/>Data for this outcome were not included in the review due to an inadequate amount of information presented in the abstract</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>PFS: time from randomisation to disease progression or death</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sjostrom" TYPE="STUDY">Sjostrom</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: date randomised to date of progression or death or last follow-up visit</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: interval between first day of treatment and first recording of disease progression or death.</P>
<P>Data for this outcome were not included in the review as limited information in the trial publication owing to premature discontinuation of the trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-TOG" TYPE="STUDY">TOG</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: duration between the first day of study treatment and date of progression</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: defined according to the RECIST criteria.</P>
<P>Data for this outcome were not included in the review as we were unable to accurately estimate the length of follow-up</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-TXT" TYPE="STUDY">TXT</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>TTP: time of first treatment infusion to first objective evidence of tumour progression</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-UKCCCR-AB01" TYPE="STUDY">UKCCCR AB01</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>PFS: time from random assignment to first appearance of progressive disease or death from any cause</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yardley" TYPE="STUDY">Yardley</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>PFS: interval from first study treatment until the date that the first progression of breast cancer was documented</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>PFS: progression-free survival<BR/>RECIST: Response Evaluation Criteria in Solid Tumors<BR/>TTF: time to treatment failure<BR/>TTP: time to progression<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2015-05-26 13:34:02 +1000" MODIFIED_BY="Melina L Willson" NO="4">
<TITLE MODIFIED="2014-11-03 11:02:41 +1100" MODIFIED_BY="Melina L Willson">Included RCTs, withdrawn by outcome, with reasons</TITLE>
<TABLE COLS="3" ROWS="11">
<TR>
<TH VALIGN="BOTTOM">
<P>Trial ID</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Outcome</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Reason not included</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-_x0033_03-Study-Group" TYPE="STUDY">303 Study Group</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Toxicity: alopecia</P>
</TD>
<TD VALIGN="TOP">
<P>Data reported but not as grade 3 or 4 toxicity, therefore it was not possible to calculate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-_x0033_04-Study-Group" TYPE="STUDY">304 Study Group</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Toxicity: alopecia</P>
</TD>
<TD VALIGN="TOP">
<P>Reported but no numerical data provided</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-AGO" TYPE="STUDY">AGO</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Time to progression</P>
</TD>
<TD VALIGN="TOP">
<P>Inadequate amount of information presented in abstract form; we contacted trialists but received no reply</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bonneterre" TYPE="STUDY">Bonneterre</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Time to progression (sensitivity analysis undertaken)</P>
</TD>
<TD VALIGN="TOP">
<P>The number of events in each group for time to progression were not provided in the trial publication; individual participant data from the <LINK REF="REF-Piccart_x002d_Gebhart-2008" TYPE="REFERENCE">Piccart-Gebhart 2008</LINK> systematic review were used instead</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-CECOG-BM1" TYPE="STUDY">CECOG BM1</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>The trial publication stated that the data for this outcome are not yet mature</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nabholtz" TYPE="STUDY">Nabholtz</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Overall survival, time to progression</P>
</TD>
<TD VALIGN="TOP">
<P>Inadequate amount of information presented in abstract form; we contacted trialists but received no reply</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rugo" TYPE="STUDY">Rugo</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>Data for arms A and C (comparable control arm) were immature at the time of analysis</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Talbot" TYPE="STUDY">Talbot</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Overall survival, time to progression</P>
</TD>
<TD VALIGN="TOP">
<P>Data for outcome were not provided in the trial publication owing to premature discontinuation of the trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-TRAVIOTA" TYPE="STUDY">TRAVIOTA</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Time to progression, time to treatment failure</P>
</TD>
<TD VALIGN="TOP">
<P>Duration of follow-up not provided in the trial publication, therefore it was not possible to estimate the number of events in the taxane-containing or non-taxane-containing arms, or hazard ratio</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EU_x002d_93011" TYPE="STUDY">EU-93011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Time to progression, toxicity: alopecia</P>
</TD>
<TD VALIGN="TOP">
<P>Time to progression: unpublished manuscript did not provide the number of events in each treatment arm. Alopecia: reported but no numerical data provided</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-05-26 13:24:39 +1000" MODIFIED_BY="Melina L Willson">
<COMPARISON ID="CMP-001" MODIFIED="2015-04-17 12:18:27 +1000" MODIFIED_BY="Melina L Willson" NO="1">
<NAME>Overall Survival</NAME>
<IPD_OUTCOME CHI2="45.79248793190622" CI_END="0.9911193812882022" CI_START="0.8818906160479131" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_SIZE="0.93491116248619" ESTIMABLE="YES" EVENTS_1="2314" EVENTS_2="2163" I2="51.957185570012776" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.003874031173559493" LOG_CI_START="-0.05458527857880814" LOG_EFFECT_SIZE="-0.029229654876183807" MODIFIED="2014-10-07 17:41:01 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="0.0021027045772009645" P_Q="0.7784258706580437" P_Z="0.023857105963129042" Q="0.5009630512924269" SCALE="2.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3139" TOTAL_2="2869" WEIGHT="100.0" Z="2.2594226633804464">
<NAME>Overall effect: Taxane-containing regimens vs. not</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.603267584891823E-4" CI_END="1.1967243627184356" CI_START="0.8066883003490297" DF="1" EFFECT_SIZE="0.9825393336389188" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="157" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.07799413241538068" LOG_CI_START="-0.09329424171911944" LOG_EFFECT_SIZE="-0.007650054651869392" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9848552456146866" P_Z="0.8610236787704966" STUDIES="2" TAU2="0.0" TOTAL_1="319" TOTAL_2="199" WEIGHT="8.765018012742019" Z="0.17507121161245362">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<IPD_DATA CI_END="1.2553793807837803" CI_START="0.771132304878123" EFFECT_SIZE="0.9839022285777522" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="86" LOG_CI_END="0.09877499122136313" LOG_CI_START="-0.11287110268962938" LOG_EFFECT_SIZE="-0.007048055734133123" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88007" O_E="-1.05" SE="0.1243219632283784" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="64.7" WEIGHT="5.741006938898649"/>
<IPD_DATA CI_END="1.3709306552239469" CI_START="0.7004846843394492" EFFECT_SIZE="0.9799571048141957" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" LOG_CI_END="0.13701548774702912" LOG_CI_START="-0.15460135585226642" LOG_EFFECT_SIZE="-0.00879293405261867" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="298" O_E="-0.69" SE="0.17129717745688292" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="89" TOTAL_2="87" VAR="34.08" WEIGHT="3.0240110738433685"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="26.412801280553193" CI_END="1.0012140985719027" CI_START="0.8373380553393037" DF="8" EFFECT_SIZE="0.9156170958847869" ESTIMABLE="YES" EVENTS_1="962" EVENTS_2="984" I2="69.71165642362169" ID="CMP-001.01.02" LOG_CI_END="5.269564863952724E-4" LOG_CI_START="-0.0770991705278868" LOG_EFFECT_SIZE="-0.03828610702074574" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="8.923630905594004E-4" P_Z="0.053192606097118664" STUDIES="9" TAU2="0.0" TOTAL_1="1331" TOTAL_2="1314" WEIGHT="42.67688867593036" Z="1.933353981581526">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<IPD_DATA CI_END="1.094482737649094" CI_START="0.7158603766291184" EFFECT_SIZE="0.8851535600038837" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="176" LOG_CI_END="0.03920891619827272" LOG_CI_START="-0.14517167541924206" LOG_EFFECT_SIZE="-0.05298137961048469" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88008" O_E="-10.4" SE="0.10830607221477646" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="85.25" WEIGHT="7.564464320573568"/>
<IPD_DATA CI_END="0.9470766982483457" CI_START="0.46425324017403724" EFFECT_SIZE="0.6630862883932402" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="62" LOG_CI_END="-0.02361484858150474" LOG_CI_START="-0.3332450564954644" LOG_EFFECT_SIZE="-0.1784299525384846" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="289" O_E="-12.42" SE="0.181878316822908" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="30.23" WEIGHT="2.682390104527143"/>
<IPD_DATA CI_END="1.2990436194752013" CI_START="0.5221833933701784" EFFECT_SIZE="0.8236133834229744" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="41" LOG_CI_END="0.11362373412101308" LOG_CI_START="-0.28217694385427516" LOG_EFFECT_SIZE="-0.08427660486663102" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="290" O_E="-3.59" SE="0.23249527748763857" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="18.5" WEIGHT="1.6415553071039413"/>
<IPD_DATA CI_END="0.9411828890058769" CI_START="0.5195714670653201" EFFECT_SIZE="0.6992937683245575" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="93" LOG_CI_END="-0.026325977031373307" LOG_CI_START="-0.2843547067836339" LOG_EFFECT_SIZE="-0.15534034190750357" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="291" O_E="-15.57" SE="0.15156735311928954" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="43.53" WEIGHT="3.862535271255923"/>
<IPD_DATA CI_END="1.4930454940731153" CI_START="0.8267377539045406" EFFECT_SIZE="1.1110162367163237" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="74" LOG_CI_END="0.17407304116366792" LOG_CI_START="-0.0826322293759436" LOG_EFFECT_SIZE="0.04572040589386211" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88009" O_E="4.63" SE="0.15078994662655074" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="43.98" WEIGHT="3.9024649949422345"/>
<IPD_DATA CI_END="1.4284508487654215" CI_START="0.7142101539442994" EFFECT_SIZE="1.0100564838654404" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="65" LOG_CI_END="0.1548653014375587" LOG_CI_START="-0.14617397972342236" LOG_EFFECT_SIZE="0.004345660857068142" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.32" SE="0.17683196392243516" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="31.98" WEIGHT="2.8376723633072456"/>
<IPD_DATA CI_END="0.8883608577417056" CI_START="0.5209462145046005" EFFECT_SIZE="0.6802854003685522" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="120" LOG_CI_END="-0.05141058524432588" LOG_CI_START="-0.28320711345606614" LOG_EFFECT_SIZE="-0.16730884935019605" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88010" O_E="-20.78" SE="0.1361584280828961" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="53.94" WEIGHT="4.786242879199276"/>
<IPD_DATA CI_END="3.3335070603080483" CI_START="1.2853844047239367" EFFECT_SIZE="2.069985021288101" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="33" LOG_CI_END="0.5229013792904649" LOG_CI_START="0.10903302641036595" LOG_EFFECT_SIZE="0.3159672028504154" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="294" O_E="12.31" SE="0.2431083191631576" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="16.92" WEIGHT="1.5013576106053346"/>
<IPD_DATA CI_END="1.1929135387911767" CI_START="0.8721316127970808" EFFECT_SIZE="1.019989023722031" ESTIMABLE="YES" EVENTS_1="321" EVENTS_2="320" LOG_CI_END="0.07660896757089686" LOG_CI_START="-0.059417971032557006" LOG_EFFECT_SIZE="0.008595498269169935" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="3.1" SE="0.07990289707987444" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="156.63" WEIGHT="13.898205824415694"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="18.87836327330212" CI_END="1.0261750072931228" CI_START="0.8678564519974044" DF="11" EFFECT_SIZE="0.9437015423097602" ESTIMABLE="YES" EVENTS_1="1102" EVENTS_2="1022" I2="41.73223684303047" ID="CMP-001.01.03" LOG_CI_END="0.011221433115252154" LOG_CI_START="-0.061552103465197794" LOG_EFFECT_SIZE="-0.02516533517497281" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0633122198120325" P_Z="0.175250554498511" STUDIES="12" TAU2="0.0" TOTAL_1="1489" TOTAL_2="1356" WEIGHT="48.55809331132762" Z="1.3555243545790785">
<NAME>Single agent taxane v Regimen C</NAME>
<IPD_DATA CI_END="1.1651388929210809" CI_START="0.6756586038191097" EFFECT_SIZE="0.8872632741449409" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.06637769946825568" LOG_CI_START="-0.17027268856897562" LOG_EFFECT_SIZE="-0.05194749455036" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88011" O_E="-6.19" SE="0.13900960937138318" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="51.75" WEIGHT="4.59191822392589"/>
<IPD_DATA CI_END="0.9273038448186192" CI_START="0.5779689705180647" EFFECT_SIZE="0.7320880060124333" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="138" LOG_CI_END="-0.03277793952680448" LOG_CI_START="-0.23809547696790737" LOG_EFFECT_SIZE="-0.13543670824735593" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88012" O_E="-21.44" SE="0.12060453783110545" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="68.75" WEIGHT="6.1003744520754575"/>
<IPD_DATA CI_END="1.0218698332411622" CI_START="0.5465909835724658" EFFECT_SIZE="0.7473585733998898" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="82" LOG_CI_END="0.00939557847442258" LOG_CI_START="-0.262337536596928" LOG_EFFECT_SIZE="-0.12647097906125274" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88013" O_E="-11.43" SE="0.15961737689352443" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="39.25" WEIGHT="3.482759232639443"/>
<IPD_DATA CI_END="3.4568880967894726" CI_START="0.7340935615929518" EFFECT_SIZE="1.593009508760216" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.5386853211873501" LOG_CI_START="-0.13424858491494696" LOG_EFFECT_SIZE="0.2022183681362016" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88014" O_E="2.98" SE="0.39528470752104744" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="6.4" WEIGHT="0.5678894035386608"/>
<IPD_DATA CI_END="1.1842933690356112" CI_START="0.7208776733635518" EFFECT_SIZE="0.9239754587922093" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="86" LOG_CI_END="0.07345929763303452" LOG_CI_START="-0.14213842500378135" LOG_EFFECT_SIZE="-0.0343395636853734" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88015" O_E="-4.93" SE="0.1266431695028047" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="62.35" WEIGHT="5.532485048536797"/>
<IPD_DATA CI_END="1.4272106364991446" CI_START="0.8726729889114566" EFFECT_SIZE="1.1160144138674604" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="124" LOG_CI_END="0.1544880736882081" LOG_CI_START="-0.059148466164880106" LOG_EFFECT_SIZE="0.047669803761664034" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88016" O_E="6.97" SE="0.12549116102763172" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="63.5" WEIGHT="5.63452767573515"/>
<IPD_DATA CI_END="1.045016871455751" CI_START="0.6720002152530321" EFFECT_SIZE="0.8380045122559394" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="125" LOG_CI_END="0.019123302046103026" LOG_CI_START="-0.17263058783428623" LOG_EFFECT_SIZE="-0.0767536428940916" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="293" O_E="-13.93" SE="0.11263718411280402" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="78.82" WEIGHT="6.9939129354558185"/>
<IPD_DATA CI_END="1.4768182261764857" CI_START="0.6818850378674761" EFFECT_SIZE="1.0035039870771474" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="53" LOG_CI_END="0.16932704356741982" LOG_CI_START="-0.16628883887474255" LOG_EFFECT_SIZE="0.0015191023463385711" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.09" SE="0.1971424306719378" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="25.73" WEIGHT="2.2830928676640223"/>
<IPD_DATA CI_END="1.2936595494582188" CI_START="0.7500290738179914" EFFECT_SIZE="0.9850290725232165" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.11181999870868686" LOG_CI_START="-0.12492190146964363" LOG_EFFECT_SIZE="-0.0065509513804783565" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88017" O_E="-0.78" SE="0.1390633640560572" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="51.71" WEIGHT="4.588368915153773"/>
<IPD_DATA CI_END="1.8703500986063712" CI_START="1.0088337927458086" EFFECT_SIZE="1.3736347344689426" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="77" LOG_CI_END="0.27192290689037213" LOG_CI_START="0.003819621302168777" LOG_EFFECT_SIZE="0.1378712640962704" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88018" O_E="12.8" SE="0.157485197087178" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.32" WEIGHT="3.577703242293563"/>
<IPD_DATA CI_END="1.3734359661262925" CI_START="0.7173879199803462" EFFECT_SIZE="0.9926159231875833" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" LOG_CI_END="0.137808416063621" LOG_CI_START="-0.14424594063753687" LOG_EFFECT_SIZE="-0.0032187622869579344" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88019" O_E="-0.27" SE="0.1656801253178433" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="36.43" WEIGHT="3.2325329642052205"/>
<IPD_DATA CI_END="1.8487852758950991" CI_START="0.8050362294154025" EFFECT_SIZE="1.2199750520011896" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.2668864736745507" LOG_CI_START="-0.0941845744381699" LOG_EFFECT_SIZE="0.0863509496181904" MODIFIED="2014-09-30 14:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="302" O_E="4.42" SE="0.21209492099192592" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="22.23" WEIGHT="1.972528350103817"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="33.3077138760771" CI_END="0.9928896734871705" CI_START="0.8676955388498194" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_SIZE="0.928184216766732" ESTIMABLE="YES" EVENTS_1="1752" EVENTS_2="1600" I2="54.965387129815646" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.003099006144761686" LOG_CI_START="-0.06163263541426139" LOG_EFFECT_SIZE="-0.032365820779511514" MODIFIED="2014-11-03 11:03:08 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.004254701854184861" P_Q="0.8135947963278123" P_Z="0.030196691560644043" Q="0.4125858808272181" SCALE="2.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2351" TOTAL_2="2088" WEIGHT="100.00000000000003" Z="2.167500763222806">
<NAME>First-line trials only: overall</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.603267584891823E-4" CI_END="1.1967243627184356" CI_START="0.8066883003490297" DF="1" EFFECT_SIZE="0.9825393336389188" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="157" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.07799413241538068" LOG_CI_START="-0.09329424171911944" LOG_EFFECT_SIZE="-0.007650054651869392" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9848552456146866" P_Z="0.8610236787704966" STUDIES="2" TAU2="0.0" TOTAL_1="319" TOTAL_2="199" WEIGHT="11.677641300878365" Z="0.17507121161245362">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<IPD_DATA CI_END="1.2553793807837803" CI_START="0.771132304878123" EFFECT_SIZE="0.9839022285777522" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="86" LOG_CI_END="0.09877499122136313" LOG_CI_START="-0.11287110268962938" LOG_EFFECT_SIZE="-0.007048055734133123" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88065" O_E="-1.05" SE="0.1243219632283784" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="64.7" WEIGHT="7.648748655262505"/>
<IPD_DATA CI_END="1.3709306552239469" CI_START="0.7004846843394492" EFFECT_SIZE="0.9799571048141957" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" LOG_CI_END="0.13701548774702912" LOG_CI_START="-0.15460135585226642" LOG_EFFECT_SIZE="-0.00879293405261867" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="298" O_E="-0.69" SE="0.17129717745688292" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="89" TOTAL_2="87" VAR="34.08" WEIGHT="4.02889264561586"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="26.412801280553182" CI_END="1.0012140985719027" CI_START="0.8373380553393037" DF="8" EFFECT_SIZE="0.9156170958847869" ESTIMABLE="YES" EVENTS_1="962" EVENTS_2="984" I2="69.71165642362169" ID="CMP-001.02.02" LOG_CI_END="5.269564863952724E-4" LOG_CI_START="-0.0770991705278868" LOG_EFFECT_SIZE="-0.03828610702074574" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="8.923630905597335E-4" P_Z="0.05319260609711862" STUDIES="9" TAU2="0.0" TOTAL_1="1331" TOTAL_2="1314" WEIGHT="56.85845677333934" Z="1.9333539815815264">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<IPD_DATA CI_END="1.094482737649094" CI_START="0.7158603766291184" EFFECT_SIZE="0.8851535600038837" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="176" LOG_CI_END="0.03920891619827272" LOG_CI_START="-0.14517167541924206" LOG_EFFECT_SIZE="-0.05298137961048469" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88066" O_E="-10.4" SE="0.10830607221477646" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="85.25" WEIGHT="10.078142548085449"/>
<IPD_DATA CI_END="0.9470766982483457" CI_START="0.46425324017403724" EFFECT_SIZE="0.6630862883932402" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="62" LOG_CI_END="-0.02361484858150474" LOG_CI_START="-0.3332450564954644" LOG_EFFECT_SIZE="-0.1784299525384846" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="289" O_E="-12.42" SE="0.181878316822908" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="30.23" WEIGHT="3.573750724089421"/>
<IPD_DATA CI_END="1.2990436194752013" CI_START="0.5221833933701784" EFFECT_SIZE="0.8236133834229744" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="41" LOG_CI_END="0.11362373412101308" LOG_CI_START="-0.28217694385427516" LOG_EFFECT_SIZE="-0.08427660486663102" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="290" O_E="-3.59" SE="0.23249527748763857" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="18.5" WEIGHT="2.187045596945229"/>
<IPD_DATA CI_END="0.9411828890058769" CI_START="0.5195714670653201" EFFECT_SIZE="0.6992937683245575" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="93" LOG_CI_END="-0.026325977031373307" LOG_CI_START="-0.2843547067836339" LOG_EFFECT_SIZE="-0.15534034190750357" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="291" O_E="-15.57" SE="0.15156735311928954" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="43.53" WEIGHT="5.146059180271667"/>
<IPD_DATA CI_END="1.4930454940731153" CI_START="0.8267377539045406" EFFECT_SIZE="1.1110162367163237" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="74" LOG_CI_END="0.17407304116366792" LOG_CI_START="-0.0826322293759436" LOG_EFFECT_SIZE="0.04572040589386211" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88067" O_E="4.63" SE="0.15078994662655074" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="43.98" WEIGHT="5.1992575866838475"/>
<IPD_DATA CI_END="1.4284508487654215" CI_START="0.7142101539442994" EFFECT_SIZE="1.0100564838654404" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="65" LOG_CI_END="0.1548653014375587" LOG_CI_START="-0.14617397972342236" LOG_EFFECT_SIZE="0.004345660857068142" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.32" SE="0.17683196392243516" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="31.98" WEIGHT="3.780633415692348"/>
<IPD_DATA CI_END="0.8883608577417056" CI_START="0.5209462145046005" EFFECT_SIZE="0.6802854003685522" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="120" LOG_CI_END="-0.05141058524432588" LOG_CI_START="-0.28320711345606614" LOG_EFFECT_SIZE="-0.16730884935019605" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88010" O_E="-20.78" SE="0.1361584280828961" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="53.94" WEIGHT="6.376715648606793"/>
<IPD_DATA CI_END="3.3335070603080483" CI_START="1.2853844047239367" EFFECT_SIZE="2.069985021288101" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="33" LOG_CI_END="0.5229013792904649" LOG_CI_START="0.10903302641036595" LOG_EFFECT_SIZE="0.3159672028504154" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="294" O_E="12.31" SE="0.2431083191631576" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="16.92" WEIGHT="2.0002600810980153"/>
<IPD_DATA CI_END="1.1929135387911767" CI_START="0.8721316127970808" EFFECT_SIZE="1.019989023722031" ESTIMABLE="YES" EVENTS_1="321" EVENTS_2="320" LOG_CI_END="0.07660896757089686" LOG_CI_START="-0.059417971032557006" LOG_EFFECT_SIZE="0.008595498269169935" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="3.1" SE="0.07990289707987444" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="156.63" WEIGHT="18.516591991866555"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="6.481966387938211" CI_END="1.0503533657185982" CI_START="0.8260071741338852" DF="4" EFFECT_SIZE="0.9314501679957091" ESTIMABLE="YES" EVENTS_1="540" EVENTS_2="459" I2="38.29033104146776" ID="CMP-001.02.03" LOG_CI_END="0.0213354314166505" LOG_CI_START="-0.08301618067813062" LOG_EFFECT_SIZE="-0.030840374630740016" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.16593026340546646" P_Z="0.2466573181603352" STUDIES="5" TAU2="0.0" TOTAL_1="701" TOTAL_2="575" WEIGHT="31.463901925782313" Z="1.1585067510230882">
<NAME>Single agent taxane v Regimen C</NAME>
<IPD_DATA CI_END="1.0218698332411622" CI_START="0.5465909835724658" EFFECT_SIZE="0.7473585733998898" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="82" LOG_CI_END="0.00939557847442258" LOG_CI_START="-0.262337536596928" LOG_EFFECT_SIZE="-0.12647097906125274" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88069" O_E="-11.43" SE="0.15961737689352443" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="39.25" WEIGHT="4.640083225951365"/>
<IPD_DATA CI_END="1.1842933690356112" CI_START="0.7208776733635518" EFFECT_SIZE="0.9239754587922093" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="86" LOG_CI_END="0.07345929763303452" LOG_CI_START="-0.14213842500378135" LOG_EFFECT_SIZE="-0.0343395636853734" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88070" O_E="-4.93" SE="0.1266431695028047" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="62.35" WEIGHT="7.370934755110003"/>
<IPD_DATA CI_END="1.4272106364991446" CI_START="0.8726729889114566" EFFECT_SIZE="1.1160144138674604" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="124" LOG_CI_END="0.1544880736882081" LOG_CI_START="-0.059148466164880106" LOG_EFFECT_SIZE="0.047669803761664034" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88071" O_E="6.97" SE="0.12549116102763172" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="63.5" WEIGHT="7.5068862381633545"/>
<IPD_DATA CI_END="1.045016871455751" CI_START="0.6720002152530321" EFFECT_SIZE="0.8380045122559394" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="125" LOG_CI_END="0.019123302046103026" LOG_CI_START="-0.17263058783428623" LOG_EFFECT_SIZE="-0.0767536428940916" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="293" O_E="-13.93" SE="0.11263718411280402" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="78.82" WEIGHT="9.317996429795835"/>
<IPD_DATA CI_END="1.8487852758950991" CI_START="0.8050362294154025" EFFECT_SIZE="1.2199750520011896" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.2668864736745507" LOG_CI_START="-0.0941845744381699" LOG_EFFECT_SIZE="0.0863509496181904" MODIFIED="2014-09-30 14:42:29 +1000" MODIFIED_BY="[Empty name]" ORDER="302" O_E="4.42" SE="0.21209492099192592" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="22.23" WEIGHT="2.628001276761754"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="46.08551817545987" CI_END="0.9942538088779397" CI_START="0.8875068627634009" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_SIZE="0.9393652530873293" ESTIMABLE="YES" EVENTS_1="2314" EVENTS_2="2335" I2="52.26266108967218" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.002502736603985603" LOG_CI_START="-0.05182828002075318" LOG_EFFECT_SIZE="-0.027165508312369375" MODIFIED="2014-10-07 17:41:14 +1100" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="0.0019280304820710192" P_Q="0.6662988123741194" P_Z="0.03086119800764887" Q="0.8120348438155482" SCALE="2.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3139" TOTAL_2="3093" WEIGHT="300.0" Z="2.158857834128517">
<NAME>Subquestions A, B &amp; C</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.013023877835692465" CI_END="1.182015593354483" CI_START="0.8402612751649299" DF="1" EFFECT_SIZE="0.9965951684294225" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="243" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.07262320587107132" LOG_CI_START="-0.07558565117736905" LOG_EFFECT_SIZE="-0.001481222653148859" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9091409215181313" P_Z="0.9687497673367775" STUDIES="2" TAU2="0.0" TOTAL_1="319" TOTAL_2="311" WEIGHT="100.0" Z="0.03917637732416776">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<IPD_DATA CI_END="1.2221117612500652" CI_START="0.8222791459674186" EFFECT_SIZE="1.0024554929359415" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="172" LOG_CI_END="0.0871109236436678" LOG_CI_START="-0.08498072385505585" LOG_EFFECT_SIZE="0.0010650998943059964" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="88089" O_E="0.24" SE="0.10108748560814411" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="224" VAR="97.86" WEIGHT="74.17007730786722"/>
<IPD_DATA CI_END="1.3709306552239469" CI_START="0.7004846843394492" EFFECT_SIZE="0.9799571048141957" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" LOG_CI_END="0.13701548774702912" LOG_CI_START="-0.15460135585226642" LOG_EFFECT_SIZE="-0.00879293405261867" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="298" O_E="-0.69" SE="0.17129717745688292" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="89" TOTAL_2="87" VAR="34.08" WEIGHT="25.829922692132786"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="26.412801280553186" CI_END="1.0012140985719027" CI_START="0.8373380553393037" DF="8" EFFECT_SIZE="0.9156170958847869" ESTIMABLE="YES" EVENTS_1="962" EVENTS_2="984" I2="69.71165642362169" ID="CMP-001.03.02" LOG_CI_END="5.269564863952724E-4" LOG_CI_START="-0.0770991705278868" LOG_EFFECT_SIZE="-0.03828610702074574" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="8.923630905599556E-4" P_Z="0.053192606097118664" STUDIES="9" TAU2="0.0" TOTAL_1="1331" TOTAL_2="1314" WEIGHT="99.99999999999999" Z="1.933353981581526">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<IPD_DATA CI_END="1.094482737649094" CI_START="0.7158603766291184" EFFECT_SIZE="0.8851535600038837" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="176" LOG_CI_END="0.03920891619827272" LOG_CI_START="-0.14517167541924206" LOG_EFFECT_SIZE="-0.05298137961048469" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="88090" O_E="-10.4" SE="0.10830607221477646" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="85.25" WEIGHT="17.724966733200265"/>
<IPD_DATA CI_END="0.9470766982483457" CI_START="0.46425324017403724" EFFECT_SIZE="0.6630862883932402" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="62" LOG_CI_END="-0.02361484858150474" LOG_CI_START="-0.3332450564954644" LOG_EFFECT_SIZE="-0.1784299525384846" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="289" O_E="-12.42" SE="0.181878316822908" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="30.23" WEIGHT="6.285345974717232"/>
<IPD_DATA CI_END="1.2990436194752013" CI_START="0.5221833933701784" EFFECT_SIZE="0.8236133834229744" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="41" LOG_CI_END="0.11362373412101308" LOG_CI_START="-0.28217694385427516" LOG_EFFECT_SIZE="-0.08427660486663102" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="290" O_E="-3.59" SE="0.23249527748763857" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="18.5" WEIGHT="3.84647371922821"/>
<IPD_DATA CI_END="0.9411828890058769" CI_START="0.5195714670653201" EFFECT_SIZE="0.6992937683245575" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="93" LOG_CI_END="-0.026325977031373307" LOG_CI_START="-0.2843547067836339" LOG_EFFECT_SIZE="-0.15534034190750357" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="291" O_E="-15.57" SE="0.15156735311928954" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="43.53" WEIGHT="9.05064870259481"/>
<IPD_DATA CI_END="1.4930454940731153" CI_START="0.8267377539045406" EFFECT_SIZE="1.1110162367163237" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="74" LOG_CI_END="0.17407304116366792" LOG_CI_START="-0.0826322293759436" LOG_EFFECT_SIZE="0.04572040589386211" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="88091" O_E="4.63" SE="0.15078994662655074" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="43.98" WEIGHT="9.144211576846306"/>
<IPD_DATA CI_END="1.4284508487654215" CI_START="0.7142101539442994" EFFECT_SIZE="1.0100564838654404" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="65" LOG_CI_END="0.1548653014375587" LOG_CI_START="-0.14617397972342236" LOG_EFFECT_SIZE="0.004345660857068142" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.32" SE="0.17683196392243516" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="31.98" WEIGHT="6.649201596806386"/>
<IPD_DATA CI_END="0.8883608577417056" CI_START="0.5209462145046005" EFFECT_SIZE="0.6802854003685522" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="120" LOG_CI_END="-0.05141058524432588" LOG_CI_START="-0.28320711345606614" LOG_EFFECT_SIZE="-0.16730884935019605" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="88092" O_E="-20.78" SE="0.1361584280828961" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="53.94" WEIGHT="11.215069860279439"/>
<IPD_DATA CI_END="3.3335070603080483" CI_START="1.2853844047239367" EFFECT_SIZE="2.069985021288101" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="33" LOG_CI_END="0.5229013792904649" LOG_CI_START="0.10903302641036595" LOG_EFFECT_SIZE="0.3159672028504154" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="294" O_E="12.31" SE="0.2431083191631576" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="16.92" WEIGHT="3.5179640718562872"/>
<IPD_DATA CI_END="1.1929135387911767" CI_START="0.8721316127970808" EFFECT_SIZE="1.019989023722031" ESTIMABLE="YES" EVENTS_1="321" EVENTS_2="320" LOG_CI_END="0.07660896757089686" LOG_CI_START="-0.059417971032557006" LOG_EFFECT_SIZE="0.008595498269169935" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="3.1" SE="0.07990289707987444" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="156.63" WEIGHT="32.56611776447105"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="18.84765817325544" CI_END="1.0271168398929276" CI_START="0.8726236388013304" DF="11" EFFECT_SIZE="0.9467240539362513" ESTIMABLE="YES" EVENTS_1="1102" EVENTS_2="1108" I2="41.63731165493629" ID="CMP-001.03.03" LOG_CI_END="0.011619849667890987" LOG_CI_START="-0.05917302643752891" LOG_EFFECT_SIZE="-0.02377658838481896" MODIFIED="2014-10-07 11:35:53 +1100" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="0.0638835503671068" P_Z="0.18798878423339002" STUDIES="12" TAU2="0.0" TOTAL_1="1489" TOTAL_2="1468" WEIGHT="100.0" Z="1.3165521581601833">
<NAME>Single agent taxane v Regimen C</NAME>
<IPD_DATA CI_END="1.1651388929210809" CI_START="0.6756586038191097" EFFECT_SIZE="0.8872632741449409" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.06637769946825568" LOG_CI_START="-0.17027268856897562" LOG_EFFECT_SIZE="-0.05194749455036" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="88093" O_E="-6.19" SE="0.13900960937138318" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="51.75" WEIGHT="8.948797316225424"/>
<IPD_DATA CI_END="0.9273038448186192" CI_START="0.5779689705180647" EFFECT_SIZE="0.7320880060124333" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="138" LOG_CI_END="-0.03277793952680448" LOG_CI_START="-0.23809547696790737" LOG_EFFECT_SIZE="-0.13543670824735593" MODIFIED="2014-10-07 11:35:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="88094" O_E="-21.44" SE="0.12060453783110545" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="68.75" WEIGHT="11.88849885005793"/>
<IPD_DATA CI_END="1.0218698332411622" CI_START="0.5465909835724658" EFFECT_SIZE="0.7473585733998898" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="82" LOG_CI_END="0.00939557847442258" LOG_CI_START="-0.262337536596928" LOG_EFFECT_SIZE="-0.12647097906125274" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="88095" O_E="-11.43" SE="0.15961737689352443" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="39.25" WEIGHT="6.787252070760346"/>
<IPD_DATA CI_END="3.4568880967894726" CI_START="0.7340935615929518" EFFECT_SIZE="1.593009508760216" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.5386853211873501" LOG_CI_START="-0.13424858491494696" LOG_EFFECT_SIZE="0.2022183681362016" MODIFIED="2014-10-07 11:35:52 +1100" MODIFIED_BY="Melina L Willson" ORDER="88096" O_E="2.98" SE="0.39528470752104744" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="6.4" WEIGHT="1.1067111656781201"/>
<IPD_DATA CI_END="1.1624789324926126" CI_START="0.7748765723960231" EFFECT_SIZE="0.9490930885284454" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="172" LOG_CI_END="0.06538509095114152" LOG_CI_START="-0.11076746935987533" LOG_EFFECT_SIZE="-0.022691189204366923" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="88097" O_E="-4.88" SE="0.10347288589592779" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="224" VAR="93.4" WEIGHT="16.151066074115064"/>
<IPD_DATA CI_END="1.4272106364991446" CI_START="0.8726729889114566" EFFECT_SIZE="1.1160144138674604" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="124" LOG_CI_END="0.1544880736882081" LOG_CI_START="-0.059148466164880106" LOG_EFFECT_SIZE="0.047669803761664034" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="88098" O_E="6.97" SE="0.12549116102763172" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="63.5" WEIGHT="10.980649846962597"/>
<IPD_DATA CI_END="1.045016871455751" CI_START="0.6720002152530321" EFFECT_SIZE="0.8380045122559394" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="125" LOG_CI_END="0.019123302046103026" LOG_CI_START="-0.17263058783428623" LOG_EFFECT_SIZE="-0.0767536428940916" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="293" O_E="-13.93" SE="0.11263718411280402" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="78.82" WEIGHT="13.629839699804597"/>
<IPD_DATA CI_END="1.4768182261764857" CI_START="0.6818850378674761" EFFECT_SIZE="1.0035039870771474" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="53" LOG_CI_END="0.16932704356741982" LOG_CI_START="-0.16628883887474255" LOG_EFFECT_SIZE="0.0015191023463385711" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.09" SE="0.1971424306719378" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="25.73" WEIGHT="4.449324733265317"/>
<IPD_DATA CI_END="1.2936595494582188" CI_START="0.7500290738179914" EFFECT_SIZE="0.9850290725232165" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.11181999870868686" LOG_CI_START="-0.12492190146964363" LOG_EFFECT_SIZE="-0.0065509513804783565" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="88099" O_E="-0.78" SE="0.1390633640560572" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="51.71" WEIGHT="8.941880371439936"/>
<IPD_DATA CI_END="1.8703500986063712" CI_START="1.0088337927458086" EFFECT_SIZE="1.3736347344689426" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="77" LOG_CI_END="0.27192290689037213" LOG_CI_START="0.003819621302168777" LOG_EFFECT_SIZE="0.1378712640962704" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="88018" O_E="12.8" SE="0.157485197087178" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.32" WEIGHT="6.972280343772156"/>
<IPD_DATA CI_END="1.3734359661262925" CI_START="0.7173879199803462" EFFECT_SIZE="0.9926159231875833" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" LOG_CI_END="0.137808416063621" LOG_CI_START="-0.14424594063753687" LOG_EFFECT_SIZE="-0.0032187622869579344" MODIFIED="2014-10-07 11:35:52 +1100" MODIFIED_BY="Melina L Willson" ORDER="88101" O_E="-0.27" SE="0.1656801253178433" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="36.43" WEIGHT="6.299607463383424"/>
<IPD_DATA CI_END="1.8487852758950991" CI_START="0.8050362294154025" EFFECT_SIZE="1.2199750520011896" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.2668864736745507" LOG_CI_START="-0.0941845744381699" LOG_EFFECT_SIZE="0.0863509496181904" MODIFIED="2014-09-30 14:41:51 +1000" MODIFIED_BY="[Empty name]" ORDER="302" O_E="4.42" SE="0.21209492099192592" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="22.23" WEIGHT="3.8440920645350953"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="17.586066284078207" CI_END="1.0636769253837692" CI_START="0.8979888622691458" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_SIZE="0.9773280063762186" ESTIMABLE="YES" EVENTS_1="1060" EVENTS_2="1048" I2="37.45048027051391" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.026809738081880783" LOG_CI_START="-0.04672904984165746" LOG_EFFECT_SIZE="-0.009959655879888323" MODIFIED="2014-10-08 11:37:37 +1100" MODIFIED_BY="Melina L Willson" NO="4" P_CHI2="0.09169584238602291" P_Q="0.3455429705228096" P_Z="0.5954938177227238" Q="0.8897581340041953" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1485" TOTAL_2="1463" WEIGHT="200.0" Z="0.5308917205241455">
<NAME>Chemotherapy regimens</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="2.2591319990002354" CI_END="1.1628536828923557" CI_START="0.9006432303036662" DF="3" EFFECT_SIZE="1.023384725961203" ESTIMABLE="YES" EVENTS_1="457" EVENTS_2="443" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.06552507267335338" LOG_CI_START="-0.0454472110131708" LOG_EFFECT_SIZE="0.010038930830091334" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5203954165582729" P_Z="0.7228817556857414" STUDIES="4" TAU2="0.0" TOTAL_1="608" TOTAL_2="604" WEIGHT="100.0" Z="0.3546100380496558">
<NAME>Single agent taxane vs single agent anthracycline</NAME>
<IPD_DATA CI_END="1.1651388929210809" CI_START="0.6756586038191097" EFFECT_SIZE="0.8872632741449409" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.06637769946825568" LOG_CI_START="-0.17027268856897562" LOG_EFFECT_SIZE="-0.05194749455036" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="88203" O_E="-6.19" SE="0.13900960937138318" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="51.75" WEIGHT="21.989462054899292"/>
<IPD_DATA CI_END="1.2221117612500652" CI_START="0.8222791459674186" EFFECT_SIZE="1.0024554929359415" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="172" LOG_CI_END="0.0871109236436678" LOG_CI_START="-0.08498072385505585" LOG_EFFECT_SIZE="0.0010650998943059964" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="88204" O_E="0.24" SE="0.10108748560814411" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="224" VAR="97.86" WEIGHT="41.58239143367043"/>
<IPD_DATA CI_END="1.4272106364991446" CI_START="0.8726729889114566" EFFECT_SIZE="1.1160144138674604" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="124" LOG_CI_END="0.1544880736882081" LOG_CI_START="-0.059148466164880106" LOG_EFFECT_SIZE="0.047669803761664034" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="88205" O_E="6.97" SE="0.12549116102763172" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="63.5" WEIGHT="26.982238463499616"/>
<IPD_DATA CI_END="1.8487852758950991" CI_START="0.8050362294154025" EFFECT_SIZE="1.2199750520011896" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.2668864736745507" LOG_CI_START="-0.0941845744381699" LOG_EFFECT_SIZE="0.0863509496181904" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="302" O_E="4.42" SE="0.21209492099192592" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="22.23" WEIGHT="9.445908047930653"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="14.437176151073777" CI_END="1.0555514193612723" CI_START="0.8419462114610727" DF="7" EFFECT_SIZE="0.9427181543460279" ESTIMABLE="YES" EVENTS_1="603" EVENTS_2="605" I2="51.51406392253953" ID="CMP-001.04.02" LOG_CI_END="0.02347939406332764" LOG_CI_START="-0.07471565293244067" LOG_EFFECT_SIZE="-0.0256181294345565" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04393018058769049" P_Z="0.30646346484386433" STUDIES="8" TAU2="0.0" TOTAL_1="877" TOTAL_2="859" WEIGHT="100.0" Z="1.0226709509122203">
<NAME>Single agent taxane vs non-anthracycline combination</NAME>
<IPD_DATA CI_END="0.9273038448186192" CI_START="0.5779689705180647" EFFECT_SIZE="0.7320880060124333" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="138" LOG_CI_END="-0.03277793952680448" LOG_CI_START="-0.23809547696790737" LOG_EFFECT_SIZE="-0.13543670824735593" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="88206" O_E="-21.44" SE="0.12060453783110545" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="68.75" WEIGHT="22.873207572279338"/>
<IPD_DATA CI_END="1.0218698332411622" CI_START="0.5465909835724658" EFFECT_SIZE="0.7473585733998898" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="82" LOG_CI_END="0.00939557847442258" LOG_CI_START="-0.262337536596928" LOG_EFFECT_SIZE="-0.12647097906125274" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="88207" O_E="-11.43" SE="0.15961737689352443" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="39.25" WEIGHT="13.05852214126493"/>
<IPD_DATA CI_END="3.4568880967894726" CI_START="0.7340935615929518" EFFECT_SIZE="1.593009508760216" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.5386853211873501" LOG_CI_START="-0.13424858491494696" LOG_EFFECT_SIZE="0.2022183681362016" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="88208" O_E="2.98" SE="0.39528470752104744" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="6.4" WEIGHT="2.1292876867285493"/>
<IPD_DATA CI_END="1.4284508487654215" CI_START="0.7142101539442994" EFFECT_SIZE="1.0100564838654404" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="65" LOG_CI_END="0.1548653014375587" LOG_CI_START="-0.14617397972342236" LOG_EFFECT_SIZE="0.004345660857068142" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.32" SE="0.17683196392243516" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="31.98" WEIGHT="10.63978440962172"/>
<IPD_DATA CI_END="1.4768182261764857" CI_START="0.6818850378674761" EFFECT_SIZE="1.0035039870771474" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="53" LOG_CI_END="0.16932704356741982" LOG_CI_START="-0.16628883887474255" LOG_EFFECT_SIZE="0.0015191023463385711" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.09" SE="0.1971424306719378" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="25.73" WEIGHT="8.56040190305087"/>
<IPD_DATA CI_END="1.2936595494582188" CI_START="0.7500290738179914" EFFECT_SIZE="0.9850290725232165" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.11181999870868686" LOG_CI_START="-0.12492190146964363" LOG_EFFECT_SIZE="-0.0065509513804783565" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="88209" O_E="-0.78" SE="0.1390633640560572" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="51.71" WEIGHT="17.203979106364574"/>
<IPD_DATA CI_END="1.8703500986063712" CI_START="1.0088337927458086" EFFECT_SIZE="1.3736347344689426" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="77" LOG_CI_END="0.27192290689037213" LOG_CI_START="0.003819621302168777" LOG_EFFECT_SIZE="0.1378712640962704" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="88210" O_E="12.8" SE="0.157485197087178" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.32" WEIGHT="13.41451242638986"/>
<IPD_DATA CI_END="1.3734359661262925" CI_START="0.7173879199803462" EFFECT_SIZE="0.9926159231875833" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" LOG_CI_END="0.137808416063621" LOG_CI_START="-0.14424594063753687" LOG_EFFECT_SIZE="-0.0032187622869579344" MODIFIED="2014-09-30 14:47:38 +1000" MODIFIED_BY="[Empty name]" ORDER="88211" O_E="-0.27" SE="0.1656801253178433" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="36.43" WEIGHT="12.120304754300165"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="45.79248793190622" CI_END="0.9911193812882022" CI_START="0.881890616047913" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_SIZE="0.93491116248619" ESTIMABLE="YES" EVENTS_1="2314" EVENTS_2="2163" I2="51.957185570012776" I2_Q="83.6389008448801" ID="CMP-001.05" LOG_CI_END="-0.003874031173559493" LOG_CI_START="-0.0545852785788082" LOG_EFFECT_SIZE="-0.029229654876183807" MODIFIED="2015-04-17 12:18:27 +1000" MODIFIED_BY="Melina L Willson" NO="5" P_CHI2="0.0021027045772009645" P_Q="0.013426331597727659" P_Z="0.023857105963129004" Q="6.112058795799599" SCALE="2.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3139" TOTAL_2="2869" WEIGHT="99.99999999999999" Z="2.259422663380447">
<NAME>Type of taxane</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="27.423040461150496" CI_END="1.0964970402987888" CI_START="0.9274355617496884" DF="9" EFFECT_SIZE="1.0084296448073995" ESTIMABLE="YES" EVENTS_1="1214" EVENTS_2="1018" I2="67.18088202965654" ID="CMP-001.05.01" LOG_CI_END="0.04000746375304113" LOG_CI_START="-0.03271625545816367" LOG_EFFECT_SIZE="0.003645604147438714" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0011901962770500818" P_Z="0.844215659843393" STUDIES="10" TAU2="0.0" TOTAL_1="1539" TOTAL_2="1295" WEIGHT="48.624642850804804" Z="0.19650405420323694">
<NAME>Paclitaxel containing</NAME>
<IPD_DATA CI_END="1.0218698332411622" CI_START="0.5465909835724658" EFFECT_SIZE="0.7473585733998898" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="82" LOG_CI_END="0.00939557847442258" LOG_CI_START="-0.262337536596928" LOG_EFFECT_SIZE="-0.12647097906125274" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88220" O_E="-11.43" SE="0.15961737689352443" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="39.25" WEIGHT="3.482759232639443"/>
<IPD_DATA CI_END="3.4568880967894726" CI_START="0.7340935615929518" EFFECT_SIZE="1.593009508760216" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.5386853211873501" LOG_CI_START="-0.13424858491494696" LOG_EFFECT_SIZE="0.2022183681362016" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88221" O_E="2.98" SE="0.39528470752104744" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="6.4" WEIGHT="0.5678894035386608"/>
<IPD_DATA CI_END="1.2553793807837803" CI_START="0.771132304878123" EFFECT_SIZE="0.9839022285777522" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="86" LOG_CI_END="0.09877499122136313" LOG_CI_START="-0.11287110268962938" LOG_EFFECT_SIZE="-0.007048055734133123" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88222" O_E="-1.05" SE="0.1243219632283784" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="64.7" WEIGHT="5.741006938898649"/>
<IPD_DATA CI_END="1.1842933690356112" CI_START="0.7208776733635518" EFFECT_SIZE="0.9239754587922093" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="86" LOG_CI_END="0.07345929763303452" LOG_CI_START="-0.14213842500378135" LOG_EFFECT_SIZE="-0.0343395636853734" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88223" O_E="-4.93" SE="0.1266431695028047" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="62.35" WEIGHT="5.532485048536797"/>
<IPD_DATA CI_END="1.4272106364991446" CI_START="0.8726729889114566" EFFECT_SIZE="1.1160144138674604" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="124" LOG_CI_END="0.1544880736882081" LOG_CI_START="-0.059148466164880106" LOG_EFFECT_SIZE="0.047669803761664034" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88224" O_E="6.97" SE="0.12549116102763172" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="63.5" WEIGHT="5.63452767573515"/>
<IPD_DATA CI_END="1.4930454940731153" CI_START="0.8267377539045406" EFFECT_SIZE="1.1110162367163237" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="74" LOG_CI_END="0.17407304116366792" LOG_CI_START="-0.0826322293759436" LOG_EFFECT_SIZE="0.04572040589386211" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88225" O_E="4.63" SE="0.15078994662655074" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="43.98" WEIGHT="3.9024649949422345"/>
<IPD_DATA CI_END="0.8883608577417056" CI_START="0.5209462145046005" EFFECT_SIZE="0.6802854003685522" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="120" LOG_CI_END="-0.05141058524432588" LOG_CI_START="-0.28320711345606614" LOG_EFFECT_SIZE="-0.16730884935019605" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88226" O_E="-20.78" SE="0.1361584280828961" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="53.94" WEIGHT="4.786242879199276"/>
<IPD_DATA CI_END="3.3335070603080483" CI_START="1.2853844047239367" EFFECT_SIZE="2.069985021288101" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="33" LOG_CI_END="0.5229013792904649" LOG_CI_START="0.10903302641036595" LOG_EFFECT_SIZE="0.3159672028504154" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="294" O_E="12.31" SE="0.2431083191631576" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="16.92" WEIGHT="1.5013576106053346"/>
<IPD_DATA CI_END="1.8703500986063712" CI_START="1.0088337927458086" EFFECT_SIZE="1.3736347344689426" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="77" LOG_CI_END="0.27192290689037213" LOG_CI_START="0.003819621302168777" LOG_EFFECT_SIZE="0.1378712640962704" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88227" O_E="12.8" SE="0.157485197087178" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.32" WEIGHT="3.577703242293563"/>
<IPD_DATA CI_END="1.1929135387911767" CI_START="0.8721316127970808" EFFECT_SIZE="1.019989023722031" ESTIMABLE="YES" EVENTS_1="321" EVENTS_2="320" LOG_CI_END="0.07660896757089686" LOG_CI_START="-0.059417971032557006" LOG_EFFECT_SIZE="0.008595498269169935" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="3.1" SE="0.07990289707987444" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="156.63" WEIGHT="13.898205824415694"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="12.257388674956129" CI_END="0.9441267692965349" CI_START="0.80219553941867" DF="12" EFFECT_SIZE="0.8702725337360935" ESTIMABLE="YES" EVENTS_1="1100" EVENTS_2="1145" I2="2.0998654915954207" ID="CMP-001.05.02" LOG_CI_END="-0.02496968842478854" LOG_CI_START="-0.09571975722752532" LOG_EFFECT_SIZE="-0.060344722826156945" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.42523632448620186" P_Z="8.27535123639694E-4" STUDIES="13" TAU2="0.0" TOTAL_1="1600" TOTAL_2="1574" WEIGHT="51.37535714919518" Z="3.343416773942262">
<NAME>Docetaxel containing</NAME>
<IPD_DATA CI_END="1.1651388929210809" CI_START="0.6756586038191097" EFFECT_SIZE="0.8872632741449409" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.06637769946825568" LOG_CI_START="-0.17027268856897562" LOG_EFFECT_SIZE="-0.05194749455036" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88228" O_E="-6.19" SE="0.13900960937138318" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="51.75" WEIGHT="4.59191822392589"/>
<IPD_DATA CI_END="0.9273038448186192" CI_START="0.5779689705180647" EFFECT_SIZE="0.7320880060124333" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="138" LOG_CI_END="-0.03277793952680448" LOG_CI_START="-0.23809547696790737" LOG_EFFECT_SIZE="-0.13543670824735593" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88229" O_E="-21.44" SE="0.12060453783110545" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="68.75" WEIGHT="6.1003744520754575"/>
<IPD_DATA CI_END="1.094482737649094" CI_START="0.7158603766291184" EFFECT_SIZE="0.8851535600038837" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="176" LOG_CI_END="0.03920891619827272" LOG_CI_START="-0.14517167541924206" LOG_EFFECT_SIZE="-0.05298137961048469" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88230" O_E="-10.4" SE="0.10830607221477646" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="85.25" WEIGHT="7.564464320573568"/>
<IPD_DATA CI_END="0.9470766982483457" CI_START="0.46425324017403724" EFFECT_SIZE="0.6630862883932402" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="62" LOG_CI_END="-0.02361484858150474" LOG_CI_START="-0.3332450564954644" LOG_EFFECT_SIZE="-0.1784299525384846" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="289" O_E="-12.42" SE="0.181878316822908" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="30.23" WEIGHT="2.682390104527143"/>
<IPD_DATA CI_END="1.2990436194752013" CI_START="0.5221833933701784" EFFECT_SIZE="0.8236133834229744" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="41" LOG_CI_END="0.11362373412101308" LOG_CI_START="-0.28217694385427516" LOG_EFFECT_SIZE="-0.08427660486663102" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="290" O_E="-3.59" SE="0.23249527748763857" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="18.5" WEIGHT="1.6415553071039413"/>
<IPD_DATA CI_END="0.9411828890058769" CI_START="0.5195714670653201" EFFECT_SIZE="0.6992937683245575" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="93" LOG_CI_END="-0.026325977031373307" LOG_CI_START="-0.2843547067836339" LOG_EFFECT_SIZE="-0.15534034190750357" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="291" O_E="-15.57" SE="0.15156735311928954" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="43.53" WEIGHT="3.862535271255923"/>
<IPD_DATA CI_END="1.3709306552239469" CI_START="0.7004846843394492" EFFECT_SIZE="0.9799571048141957" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" LOG_CI_END="0.13701548774702912" LOG_CI_START="-0.15460135585226642" LOG_EFFECT_SIZE="-0.00879293405261867" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="298" O_E="-0.69" SE="0.17129717745688292" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="89" TOTAL_2="87" VAR="34.08" WEIGHT="3.0240110738433685"/>
<IPD_DATA CI_END="1.4284508487654215" CI_START="0.7142101539442994" EFFECT_SIZE="1.0100564838654404" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="65" LOG_CI_END="0.1548653014375587" LOG_CI_START="-0.14617397972342236" LOG_EFFECT_SIZE="0.004345660857068142" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.32" SE="0.17683196392243516" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="31.98" WEIGHT="2.8376723633072456"/>
<IPD_DATA CI_END="1.045016871455751" CI_START="0.6720002152530321" EFFECT_SIZE="0.8380045122559394" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="125" LOG_CI_END="0.019123302046103026" LOG_CI_START="-0.17263058783428623" LOG_EFFECT_SIZE="-0.0767536428940916" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="293" O_E="-13.93" SE="0.11263718411280402" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="78.82" WEIGHT="6.9939129354558185"/>
<IPD_DATA CI_END="1.4768182261764857" CI_START="0.6818850378674761" EFFECT_SIZE="1.0035039870771474" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="53" LOG_CI_END="0.16932704356741982" LOG_CI_START="-0.16628883887474255" LOG_EFFECT_SIZE="0.0015191023463385711" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.09" SE="0.1971424306719378" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="25.73" WEIGHT="2.2830928676640223"/>
<IPD_DATA CI_END="1.2936595494582188" CI_START="0.7500290738179914" EFFECT_SIZE="0.9850290725232165" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.11181999870868686" LOG_CI_START="-0.12492190146964363" LOG_EFFECT_SIZE="-0.0065509513804783565" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88231" O_E="-0.78" SE="0.1390633640560572" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="51.71" WEIGHT="4.588368915153773"/>
<IPD_DATA CI_END="1.3734359661262925" CI_START="0.7173879199803462" EFFECT_SIZE="0.9926159231875833" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" LOG_CI_END="0.137808416063621" LOG_CI_START="-0.14424594063753687" LOG_EFFECT_SIZE="-0.0032187622869579344" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88232" O_E="-0.27" SE="0.1656801253178433" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="36.43" WEIGHT="3.2325329642052205"/>
<IPD_DATA CI_END="1.8487852758950991" CI_START="0.8050362294154025" EFFECT_SIZE="1.2199750520011896" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.2668864736745507" LOG_CI_START="-0.0941845744381699" LOG_EFFECT_SIZE="0.0863509496181904" MODIFIED="2014-09-30 14:48:57 +1000" MODIFIED_BY="[Empty name]" ORDER="302" O_E="4.42" SE="0.21209492099192592" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="22.23" WEIGHT="1.972528350103817"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="45.79248793190622" CI_END="0.9911193812882022" CI_START="0.881890616047913" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_SIZE="0.93491116248619" ESTIMABLE="YES" EVENTS_1="2314" EVENTS_2="2163" I2="51.957185570012776" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.003874031173559493" LOG_CI_START="-0.0545852785788082" LOG_EFFECT_SIZE="-0.029229654876183807" MODIFIED="2014-10-07 17:41:32 +1100" MODIFIED_BY="Melina L Willson" NO="6" P_CHI2="0.0021027045772009645" P_Q="0.5142425377219229" P_Z="0.023857105963129004" Q="0.4254247853627479" SCALE="2.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3139" TOTAL_2="2869" WEIGHT="200.0" Z="2.259422663380447">
<NAME>Prior anthracyclines</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="11.960208327063375" CI_END="1.1057862096445774" CI_START="0.8536043663162753" DF="5" EFFECT_SIZE="0.9715471871015506" ESTIMABLE="YES" EVENTS_1="460" EVENTS_2="458" I2="58.194708124890454" ID="CMP-001.06.01" LOG_CI_END="0.04367116951245836" LOG_CI_START="-0.0687433720955186" LOG_EFFECT_SIZE="-0.01253610129153014" MODIFIED="2014-10-07 14:52:44 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="0.03533715244107283" P_Z="0.6620116186671796" STUDIES="6" TAU2="0.0" TOTAL_1="627" TOTAL_2="616" WEIGHT="99.99999999999999" Z="0.4371375212938048">
<NAME>Prior anthracyclines</NAME>
<IPD_DATA CI_END="0.9273038448186192" CI_START="0.5779689705180647" EFFECT_SIZE="0.7320880060124333" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="138" LOG_CI_END="-0.03277793952680448" LOG_CI_START="-0.23809547696790737" LOG_EFFECT_SIZE="-0.13543670824735593" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88261" O_E="-21.44" SE="0.12060453783110545" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="68.75" WEIGHT="29.977326240516263"/>
<IPD_DATA CI_END="3.4568880967894726" CI_START="0.7340935615929518" EFFECT_SIZE="1.593009508760216" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.5386853211873501" LOG_CI_START="-0.13424858491494696" LOG_EFFECT_SIZE="0.2022183681362016" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88262" O_E="2.98" SE="0.39528470752104744" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="6.4" WEIGHT="2.790616551844423"/>
<IPD_DATA CI_END="1.4768182261764857" CI_START="0.6818850378674761" EFFECT_SIZE="1.0035039870771474" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="53" LOG_CI_END="0.16932704356741982" LOG_CI_START="-0.16628883887474255" LOG_EFFECT_SIZE="0.0015191023463385711" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.09" SE="0.1971424306719378" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="25.73" WEIGHT="11.219150606087032"/>
<IPD_DATA CI_END="1.2936595494582188" CI_START="0.7500290738179914" EFFECT_SIZE="0.9850290725232165" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.11181999870868686" LOG_CI_START="-0.12492190146964363" LOG_EFFECT_SIZE="-0.0065509513804783565" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88263" O_E="-0.78" SE="0.1390633640560572" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="51.71" WEIGHT="22.547309671230487"/>
<IPD_DATA CI_END="1.8703500986063712" CI_START="1.0088337927458086" EFFECT_SIZE="1.3736347344689426" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="77" LOG_CI_END="0.27192290689037213" LOG_CI_START="0.003819621302168777" LOG_EFFECT_SIZE="0.1378712640962704" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88264" O_E="12.8" SE="0.157485197087178" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.32" WEIGHT="17.580884276619866"/>
<IPD_DATA CI_END="1.3734359661262925" CI_START="0.7173879199803462" EFFECT_SIZE="0.9926159231875833" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" LOG_CI_END="0.137808416063621" LOG_CI_START="-0.14424594063753687" LOG_EFFECT_SIZE="-0.0032187622869579344" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88265" O_E="-0.27" SE="0.1656801253178433" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="36.43" WEIGHT="15.884712653701927"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="33.406854819480095" CI_END="0.9883617541134124" CI_START="0.8671507698204746" DF="16" EFFECT_SIZE="0.9257746248091704" ESTIMABLE="YES" EVENTS_1="1854" EVENTS_2="1705" I2="52.105637940300404" ID="CMP-001.06.02" LOG_CI_END="-0.005084068509606329" LOG_CI_START="-0.061905386020410465" LOG_EFFECT_SIZE="-0.03349472726500839" MODIFIED="2014-10-07 14:52:53 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.00652473679662724" P_Z="0.02084952867045886" STUDIES="17" TAU2="0.0" TOTAL_1="2512" TOTAL_2="2253" WEIGHT="100.0" Z="2.3106982374678546">
<NAME>Anthracyclines naive</NAME>
<IPD_DATA CI_END="1.1651388929210809" CI_START="0.6756586038191097" EFFECT_SIZE="0.8872632741449409" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.06637769946825568" LOG_CI_START="-0.17027268856897562" LOG_EFFECT_SIZE="-0.05194749455036" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88266" O_E="-6.19" SE="0.13900960937138318" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="51.75" WEIGHT="5.765117419009848"/>
<IPD_DATA CI_END="1.094482737649094" CI_START="0.7158603766291184" EFFECT_SIZE="0.8851535600038837" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="176" LOG_CI_END="0.03920891619827272" LOG_CI_START="-0.14517167541924206" LOG_EFFECT_SIZE="-0.05298137961048469" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88267" O_E="-10.4" SE="0.10830607221477646" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="85.25" WEIGHT="9.497125796533131"/>
<IPD_DATA CI_END="1.0218698332411622" CI_START="0.5465909835724658" EFFECT_SIZE="0.7473585733998898" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="82" LOG_CI_END="0.00939557847442258" LOG_CI_START="-0.262337536596928" LOG_EFFECT_SIZE="-0.12647097906125274" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88268" O_E="-11.43" SE="0.15961737689352443" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="39.25" WEIGHT="4.372576979635489"/>
<IPD_DATA CI_END="0.9470766982483457" CI_START="0.46425324017403724" EFFECT_SIZE="0.6630862883932402" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="62" LOG_CI_END="-0.02361484858150474" LOG_CI_START="-0.3332450564954644" LOG_EFFECT_SIZE="-0.1784299525384846" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="289" O_E="-12.42" SE="0.181878316822908" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="30.23" WEIGHT="3.367719798582951"/>
<IPD_DATA CI_END="1.2990436194752013" CI_START="0.5221833933701784" EFFECT_SIZE="0.8236133834229744" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="41" LOG_CI_END="0.11362373412101308" LOG_CI_START="-0.28217694385427516" LOG_EFFECT_SIZE="-0.08427660486663102" MODIFIED="2014-10-07 13:01:06 +1100" MODIFIED_BY="Melina L Willson" ORDER="718" O_E="-3.59" SE="0.23249527748763857" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="18.5" WEIGHT="2.060959850274052"/>
<IPD_DATA CI_END="0.9411828890058769" CI_START="0.5195714670653201" EFFECT_SIZE="0.6992937683245575" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="93" LOG_CI_END="-0.026325977031373307" LOG_CI_START="-0.2843547067836339" LOG_EFFECT_SIZE="-0.15534034190750357" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="291" O_E="-15.57" SE="0.15156735311928954" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="43.53" WEIGHT="4.849382826077269"/>
<IPD_DATA CI_END="1.2553793807837803" CI_START="0.771132304878123" EFFECT_SIZE="0.9839022285777522" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="86" LOG_CI_END="0.09877499122136313" LOG_CI_START="-0.11287110268962938" LOG_EFFECT_SIZE="-0.007048055734133123" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88269" O_E="-1.05" SE="0.1243219632283784" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="64.7" WEIGHT="7.207789314201684"/>
<IPD_DATA CI_END="1.1842933690356112" CI_START="0.7208776733635518" EFFECT_SIZE="0.9239754587922093" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="86" LOG_CI_END="0.07345929763303452" LOG_CI_START="-0.14213842500378135" LOG_EFFECT_SIZE="-0.0343395636853734" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88270" O_E="-4.93" SE="0.1266431695028047" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="62.35" WEIGHT="6.945991711599305"/>
<IPD_DATA CI_END="1.4272106364991446" CI_START="0.8726729889114566" EFFECT_SIZE="1.1160144138674604" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="124" LOG_CI_END="0.1544880736882081" LOG_CI_START="-0.059148466164880106" LOG_EFFECT_SIZE="0.047669803761664034" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88271" O_E="6.97" SE="0.12549116102763172" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="63.5" WEIGHT="7.074105432021746"/>
<IPD_DATA CI_END="1.4930454940731153" CI_START="0.8267377539045406" EFFECT_SIZE="1.1110162367163237" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="74" LOG_CI_END="0.17407304116366792" LOG_CI_START="-0.0826322293759436" LOG_EFFECT_SIZE="0.04572040589386211" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88272" O_E="4.63" SE="0.15078994662655074" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="43.98" WEIGHT="4.899514281894746"/>
<IPD_DATA CI_END="1.3709306552239469" CI_START="0.7004846843394492" EFFECT_SIZE="0.9799571048141957" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" LOG_CI_END="0.13701548774702912" LOG_CI_START="-0.15460135585226642" LOG_EFFECT_SIZE="-0.00879293405261867" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="298" O_E="-0.69" SE="0.17129717745688292" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="89" TOTAL_2="87" VAR="34.08" WEIGHT="3.7966222539102534"/>
<IPD_DATA CI_END="1.4284508487654215" CI_START="0.7142101539442994" EFFECT_SIZE="1.0100564838654404" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="65" LOG_CI_END="0.1548653014375587" LOG_CI_START="-0.14617397972342236" LOG_EFFECT_SIZE="0.004345660857068142" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.32" SE="0.17683196392243516" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="31.98" WEIGHT="3.562675460095361"/>
<IPD_DATA CI_END="0.8883608577417056" CI_START="0.5209462145046005" EFFECT_SIZE="0.6802854003685522" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="120" LOG_CI_END="-0.05141058524432588" LOG_CI_START="-0.28320711345606614" LOG_EFFECT_SIZE="-0.16730884935019605" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="88010" O_E="-20.78" SE="0.1361584280828961" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="53.94" WEIGHT="6.009090503988236"/>
<IPD_DATA CI_END="1.045016871455751" CI_START="0.6720002152530321" EFFECT_SIZE="0.8380045122559394" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="125" LOG_CI_END="0.019123302046103026" LOG_CI_START="-0.17263058783428623" LOG_EFFECT_SIZE="-0.0767536428940916" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="293" O_E="-13.93" SE="0.11263718411280402" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="78.82" WEIGHT="8.78080299451896"/>
<IPD_DATA CI_END="3.3335070603080483" CI_START="1.2853844047239367" EFFECT_SIZE="2.069985021288101" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="33" LOG_CI_END="0.5229013792904649" LOG_CI_START="0.10903302641036595" LOG_EFFECT_SIZE="0.3159672028504154" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="294" O_E="12.31" SE="0.2431083191631576" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="16.92" WEIGHT="1.8849427387371331"/>
<IPD_DATA CI_END="1.1929135387911767" CI_START="0.8721316127970808" EFFECT_SIZE="1.019989023722031" ESTIMABLE="YES" EVENTS_1="321" EVENTS_2="320" LOG_CI_END="0.07660896757089686" LOG_CI_START="-0.059417971032557006" LOG_EFFECT_SIZE="0.008595498269169935" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="3.1" SE="0.07990289707987444" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="156.63" WEIGHT="17.449088721536473"/>
<IPD_DATA CI_END="1.8487852758950991" CI_START="0.8050362294154025" EFFECT_SIZE="1.2199750520011896" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.2668864736745507" LOG_CI_START="-0.0941845744381699" LOG_EFFECT_SIZE="0.0863509496181904" MODIFIED="2014-09-30 14:49:06 +1000" MODIFIED_BY="[Empty name]" ORDER="302" O_E="4.42" SE="0.21209492099192592" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="22.23" WEIGHT="2.476493917383361"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-05-22 10:48:29 +1000" MODIFIED_BY="Melina L Willson" NO="2">
<NAME>Time to Progression</NAME>
<IPD_OUTCOME CHI2="77.98212684649558" CI_END="0.9679295800001945" CI_START="0.867503253095707" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_SIZE="0.91634167176754" ESTIMABLE="YES" EVENTS_1="2641" EVENTS_2="2481" I2="73.0707524285179" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.014156237867030696" LOG_CI_START="-0.0617288879505" LOG_EFFECT_SIZE="-0.03794256290876536" MODIFIED="2015-04-17 13:45:42 +1000" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="1.750459954763528E-8" P_Q="0.8198878036867665" P_Z="0.0017694827496076019" Q="0.39717572104919235" SCALE="5.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3105" TOTAL_2="2855" WEIGHT="100.00000000000001" Z="3.1264206072962235">
<NAME>Overall effect: Taxane-containing regimens vs not</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.2481431775239" CI_START="0.7611578256089859" DF="0" EFFECT_SIZE="0.974696848795964" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="83" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.09626440717488878" LOG_CI_START="-0.11852528319730952" LOG_EFFECT_SIZE="-0.01113043801121038" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.839032385253414" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="112" WEIGHT="4.905551347425797" Z="0.203131329034698">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<IPD_DATA CI_END="1.2481431775239" CI_START="0.7611578256089859" EFFECT_SIZE="0.974696848795964" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="83" LOG_CI_END="0.09626440717488878" LOG_CI_START="-0.11852528319730952" LOG_EFFECT_SIZE="-0.01113043801121038" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88020" O_E="-1.61" SE="0.1261685273507441" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="62.82" WEIGHT="4.905551347425797"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="16.31923608077669" CI_END="0.9784287667023691" CI_START="0.8341605816946515" DF="9" EFFECT_SIZE="0.9034194536200937" ESTIMABLE="YES" EVENTS_1="1244" EVENTS_2="1273" I2="44.850359689314224" ID="CMP-002.01.02" LOG_CI_END="-0.009470787128308565" LOG_CI_START="-0.07875033661554794" LOG_EFFECT_SIZE="-0.04411056187192826" MODIFIED="2015-04-17 13:45:42 +1000" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.06050713517131767" P_Z="0.012566154494585266" STUDIES="10" TAU2="0.0" TOTAL_1="1442" TOTAL_2="1449" WEIGHT="47.15248440172109" Z="2.4958335683960917">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<IPD_DATA CI_END="0.9480785668560276" CI_START="0.6053951307104737" EFFECT_SIZE="0.7576028959194938" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="209" LOG_CI_END="-0.02315567137692133" LOG_CI_START="-0.2179610764651355" LOG_EFFECT_SIZE="-0.12055837392102842" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88021" O_E="-21.2" SE="0.11442965925112424" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="76.37" WEIGHT="5.963657376677939"/>
<IPD_DATA CI_END="1.3236716880191266" CI_START="0.725510274191262" EFFECT_SIZE="0.9799680654562001" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="79" LOG_CI_END="0.12178027984474586" LOG_CI_START="-0.1393564329947128" LOG_EFFECT_SIZE="-0.008788076574983443" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="361" O_E="-0.86" SE="0.1533929977694741" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="42.5" WEIGHT="3.318782748576828"/>
<IPD_DATA CI_END="1.3092933958457849" CI_START="0.6166154300557208" EFFECT_SIZE="0.8985157262666935" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="56" LOG_CI_END="0.11703697727585574" LOG_CI_START="-0.2099856117791347" LOG_EFFECT_SIZE="-0.046474317251639495" MODIFIED="2014-10-07 14:28:56 +1100" MODIFIED_BY="Melina L Willson" ORDER="362" O_E="-2.9" SE="0.19209468759882464" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="27.1" WEIGHT="2.1162120585042836"/>
<IPD_DATA CI_END="0.8816359665874274" CI_START="0.5031422888900299" EFFECT_SIZE="0.6660242774828647" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="105" LOG_CI_END="-0.05471070096525379" LOG_CI_START="-0.29830917887829855" LOG_EFFECT_SIZE="-0.17650993992177622" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="363" O_E="-19.85" SE="0.1430909517580356" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="48.84" WEIGHT="3.8138670456586428"/>
<IPD_DATA CI_END="1.153991159066027" CI_START="0.6796321910775032" EFFECT_SIZE="0.8856012307580152" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="107" LOG_CI_END="0.06220248162426451" LOG_CI_START="-0.16772605876675473" LOG_EFFECT_SIZE="-0.05276178857124513" MODIFIED="2015-04-17 13:45:42 +1000" MODIFIED_BY="Melina L Willson" ORDER="364" O_E="-6.66" SE="0.13506116279031571" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="54.82" WEIGHT="4.280839300634864"/>
<IPD_DATA CI_END="1.2032284459026727" CI_START="0.7397644396507601" EFFECT_SIZE="0.943454088472272" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="125" LOG_CI_END="0.08034809066157232" LOG_CI_START="-0.13090654897984424" LOG_EFFECT_SIZE="-0.02527922915913598" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88023" O_E="-3.78" SE="0.1240920210526996" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="64.94" WEIGHT="5.071100039825393"/>
<IPD_DATA CI_END="1.4111895869133404" CI_START="0.8018057285579703" EFFECT_SIZE="1.0637198385235052" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="95" LOG_CI_END="0.1495853631656067" LOG_CI_START="-0.0959308452266442" LOG_EFFECT_SIZE="0.026827258969481224" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="365" O_E="2.97" SE="0.14421743613444024" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="48.08" WEIGHT="3.7545194012135035"/>
<IPD_DATA CI_END="0.9776017720116648" CI_START="0.5698564347541257" EFFECT_SIZE="0.7463864015427149" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="115" LOG_CI_END="-0.009838019893879411" LOG_CI_START="-0.24423454335795655" LOG_EFFECT_SIZE="-0.12703628162591804" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="366" O_E="-15.43" SE="0.13768567816430285" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="52.75" WEIGHT="4.11919505852771"/>
<IPD_DATA CI_END="1.1725782106316176" CI_START="0.43968483355502375" EFFECT_SIZE="0.7180284502523632" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="40" LOG_CI_END="0.06914181967107516" LOG_CI_START="-0.35685851463265333" LOG_EFFECT_SIZE="-0.1438583474807891" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="368" O_E="-5.29" SE="0.2502347051056742" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="15.97" WEIGHT="1.247081423406399"/>
<IPD_DATA CI_END="1.242237609675948" CI_START="0.9216603130561425" EFFECT_SIZE="1.0700098617414928" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="342" LOG_CI_END="0.09420467369996081" LOG_CI_START="-0.03542911294603589" LOG_EFFECT_SIZE="0.0293877803769625" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="370" O_E="11.67" SE="0.07614752797345155" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="172.46" WEIGHT="13.467229948695525"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="61.265715044669705" CI_END="0.9993871319153581" CI_START="0.8531531505058735" DF="10" EFFECT_SIZE="0.9233798136025158" ESTIMABLE="YES" EVENTS_1="1223" EVENTS_2="1125" I2="83.67765724645692" ID="CMP-002.01.03" LOG_CI_END="-2.662468227209728E-4" LOG_CI_START="-0.06897300113097202" LOG_EFFECT_SIZE="-0.0346196239768465" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="2.0862834793078378E-9" P_Z="0.048250654984699375" STUDIES="11" TAU2="0.0" TOTAL_1="1433" TOTAL_2="1294" WEIGHT="47.94196425085313" Z="1.9751541703896192">
<NAME>Single agent taxane v Regimen C</NAME>
<IPD_DATA CI_END="1.1593563745095063" CI_START="0.7168939139296295" EFFECT_SIZE="0.9116663473888819" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="134" LOG_CI_END="0.06421695424912825" LOG_CI_START="-0.1445451065410079" LOG_EFFECT_SIZE="-0.04016407614593982" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88025" O_E="-6.15" SE="0.12262786789699316" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="66.5" WEIGHT="5.192918888949626"/>
<IPD_DATA CI_END="0.8606019036744375" CI_START="0.5529144933305723" EFFECT_SIZE="0.6898110361029879" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="153" LOG_CI_END="-0.0651976975813867" LOG_CI_START="-0.2573420259212832" LOG_EFFECT_SIZE="-0.1612698617513349" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88026" O_E="-29.15" SE="0.11286652959662007" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="78.5" WEIGHT="6.1299869591360245"/>
<IPD_DATA CI_END="1.5489655912672018" CI_START="0.8922374420026595" EFFECT_SIZE="1.1756041412407432" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" LOG_CI_END="0.19004177044561008" LOG_CI_START="-0.04951955590503314" LOG_EFFECT_SIZE="0.07026110727028849" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88027" O_E="8.17" SE="0.14071950894605836" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="50.5" WEIGHT="3.943494795367761"/>
<IPD_DATA CI_END="0.9552546863030363" CI_START="0.3717309154505096" EFFECT_SIZE="0.5959007459533988" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="-0.019880823065822117" LOG_CI_START="-0.4297713187771968" LOG_EFFECT_SIZE="-0.22482607092150944" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88028" O_E="-8.93" SE="0.2407717061715384" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="17.25" WEIGHT="1.347035350892948"/>
<IPD_DATA CI_END="1.188372704901193" CI_START="0.7187967787097458" EFFECT_SIZE="0.9242285822184708" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="83" LOG_CI_END="0.0749526681678691" LOG_CI_START="-0.143393877850928" LOG_EFFECT_SIZE="-0.034220604841529494" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88029" O_E="-4.79" SE="0.12825784196427567" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="60.79" WEIGHT="4.747030665552598"/>
<IPD_DATA CI_END="1.9313798497361756" CI_START="1.2426029621310652" EFFECT_SIZE="1.5491734319573207" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" LOG_CI_END="0.28586769605857143" LOG_CI_START="0.09433238455445257" LOG_EFFECT_SIZE="0.19010004030651198" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88030" O_E="34.58" SE="0.1125087900926024" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="79.0" WEIGHT="6.169031462060458"/>
<IPD_DATA CI_END="1.091154611787768" CI_START="0.7291510882488825" EFFECT_SIZE="0.8919734147567617" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="145" LOG_CI_END="0.03788629255792961" LOG_CI_START="-0.1371824716902087" LOG_EFFECT_SIZE="-0.04964808956613951" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="371" O_E="-10.81" SE="0.10283625872371589" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="94.56" WEIGHT="7.3840963930688215"/>
<IPD_DATA CI_END="0.7330919635853363" CI_START="0.45974830958841484" EFFECT_SIZE="0.5805495594961814" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="132" LOG_CI_END="-0.13484154135828819" LOG_CI_START="-0.3374798589094025" LOG_EFFECT_SIZE="-0.2361607001338453" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88031" O_E="-38.38" SE="0.1190307508053739" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="70.58" WEIGHT="5.511522032813001"/>
<IPD_DATA CI_END="2.1088845598547143" CI_START="1.1394046157741393" EFFECT_SIZE="1.5501202539265384" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="83" LOG_CI_END="0.3240528071504604" LOG_CI_START="0.05667797446871984" LOG_EFFECT_SIZE="0.19036539080959014" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="17.77" SE="0.15705730024402176" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.54" WEIGHT="3.16572829711305"/>
<IPD_DATA CI_END="1.0946881874122818" CI_START="0.5629872265202923" EFFECT_SIZE="0.7850448818607547" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="68" LOG_CI_END="0.0392904317142165" LOG_CI_START="-0.2495014586383228" LOG_EFFECT_SIZE="-0.10510551346205321" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="375" O_E="-8.41" SE="0.16963778593599418" STUDY_ID="STD-TXT" TOTAL_1="88" TOTAL_2="90" VAR="34.75" WEIGHT="2.7135929532481127"/>
<IPD_DATA CI_END="1.3398711650835016" CI_START="0.5692494150059186" EFFECT_SIZE="0.8733389244199996" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.12706304091461088" LOG_CI_START="-0.24469740701906822" LOG_EFFECT_SIZE="-0.0588171830522287" MODIFIED="2014-09-30 14:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="376" O_E="-2.84" SE="0.21837392736013947" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="20.97" WEIGHT="1.6375264526507314"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="39.511177501181685" CI_END="1.0233965948851143" CI_START="0.9025111168459226" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_SIZE="0.9610550472403122" ESTIMABLE="YES" EVENTS_1="2035" EVENTS_2="1881" I2="62.03605929094017" I2_Q="70.00760190804641" ID="CMP-002.02" LOG_CI_END="0.010043967624309012" LOG_CI_START="-0.04454743988756162" LOG_EFFECT_SIZE="-0.01725173613162628" MODIFIED="2014-11-03 11:03:32 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="5.372589320300492E-4" P_Q="0.03564396157406735" P_Z="0.21543501886164917" Q="6.668356407741079" SCALE="5.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2373" TOTAL_2="2136" WEIGHT="100.0" Z="1.238758369856042">
<NAME>First-line trials only: overall</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.2481431775239" CI_START="0.7611578256089859" DF="0" EFFECT_SIZE="0.974696848795964" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="83" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.09626440717488878" LOG_CI_START="-0.11852528319730952" LOG_EFFECT_SIZE="-0.01113043801121038" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.839032385253414" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="112" WEIGHT="6.459839378078501" Z="0.203131329034698">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<IPD_DATA CI_END="1.2481431775239" CI_START="0.7611578256089859" EFFECT_SIZE="0.974696848795964" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="83" LOG_CI_END="0.09626440717488878" LOG_CI_START="-0.11852528319730952" LOG_EFFECT_SIZE="-0.01113043801121038" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="88072" O_E="-1.61" SE="0.1261685273507441" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="62.82" WEIGHT="6.459839378078501"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="16.319236080776694" CI_END="0.9784287667023691" CI_START="0.8341605816946515" DF="9" EFFECT_SIZE="0.9034194536200937" ESTIMABLE="YES" EVENTS_1="1244" EVENTS_2="1273" I2="44.85035968931423" ID="CMP-002.02.02" LOG_CI_END="-0.009470787128308565" LOG_CI_START="-0.07875033661554794" LOG_EFFECT_SIZE="-0.04411056187192826" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06050713517131756" P_Z="0.012566154494585266" STUDIES="10" TAU2="0.0" TOTAL_1="1442" TOTAL_2="1449" WEIGHT="62.09240387878289" Z="2.4958335683960917">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<IPD_DATA CI_END="0.9480785668560276" CI_START="0.6053951307104737" EFFECT_SIZE="0.7576028959194938" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="209" LOG_CI_END="-0.02315567137692133" LOG_CI_START="-0.2179610764651355" LOG_EFFECT_SIZE="-0.12055837392102842" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="88073" O_E="-21.2" SE="0.11442965925112424" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="76.37" WEIGHT="7.8531985562536635"/>
<IPD_DATA CI_END="1.3236716880191266" CI_START="0.725510274191262" EFFECT_SIZE="0.9799680654562001" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="79" LOG_CI_END="0.12178027984474586" LOG_CI_START="-0.1393564329947128" LOG_EFFECT_SIZE="-0.008788076574983443" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="361" O_E="-0.86" SE="0.1533929977694741" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="42.5" WEIGHT="4.370314765494051"/>
<IPD_DATA CI_END="1.3092933958457849" CI_START="0.6166154300557208" EFFECT_SIZE="0.8985157262666935" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="56" LOG_CI_END="0.11703697727585574" LOG_CI_START="-0.2099856117791347" LOG_EFFECT_SIZE="-0.046474317251639495" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="362" O_E="-2.9" SE="0.19209468759882464" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="27.1" WEIGHT="2.7867183563503244"/>
<IPD_DATA CI_END="0.8816359665874274" CI_START="0.5031422888900299" EFFECT_SIZE="0.6660242774828647" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="105" LOG_CI_END="-0.05471070096525379" LOG_CI_START="-0.29830917887829855" LOG_EFFECT_SIZE="-0.17650993992177622" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="363" O_E="-19.85" SE="0.1430909517580356" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="48.84" WEIGHT="5.022262897570105"/>
<IPD_DATA CI_END="1.153991159066027" CI_START="0.6796321910775032" EFFECT_SIZE="0.8856012307580152" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="107" LOG_CI_END="0.06220248162426451" LOG_CI_START="-0.16772605876675473" LOG_EFFECT_SIZE="-0.05276178857124513" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="364" O_E="-6.66" SE="0.13506116279031571" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="54.82" WEIGHT="5.6371918928090325"/>
<IPD_DATA CI_END="1.2032284459026727" CI_START="0.7397644396507601" EFFECT_SIZE="0.943454088472272" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="125" LOG_CI_END="0.08034809066157232" LOG_CI_START="-0.13090654897984424" LOG_EFFECT_SIZE="-0.02527922915913598" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="88075" O_E="-3.78" SE="0.1240920210526996" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="64.94" WEIGHT="6.677840961674909"/>
<IPD_DATA CI_END="1.4111895869133404" CI_START="0.8018057285579703" EFFECT_SIZE="1.0637198385235052" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="95" LOG_CI_END="0.1495853631656067" LOG_CI_START="-0.0959308452266442" LOG_EFFECT_SIZE="0.026827258969481224" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="365" O_E="2.97" SE="0.14421743613444024" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="48.08" WEIGHT="4.944111386469505"/>
<IPD_DATA CI_END="0.9776017720116648" CI_START="0.5698564347541257" EFFECT_SIZE="0.7463864015427149" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="115" LOG_CI_END="-0.009838019893879411" LOG_CI_START="-0.24423454335795655" LOG_EFFECT_SIZE="-0.12703628162591804" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="366" O_E="-15.43" SE="0.13768567816430285" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="52.75" WEIGHT="5.424331855995558"/>
<IPD_DATA CI_END="1.1725782106316176" CI_START="0.43968483355502375" EFFECT_SIZE="0.7180284502523632" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="40" LOG_CI_END="0.06914181967107516" LOG_CI_START="-0.35685851463265333" LOG_EFFECT_SIZE="-0.1438583474807891" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="368" O_E="-5.29" SE="0.2502347051056742" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="15.97" WEIGHT="1.6422100424691763"/>
<IPD_DATA CI_END="1.242237609675948" CI_START="0.9216603130561425" EFFECT_SIZE="1.0700098617414928" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="342" LOG_CI_END="0.09420467369996081" LOG_CI_START="-0.03542911294603589" LOG_EFFECT_SIZE="0.0293877803769625" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="370" O_E="11.67" SE="0.07614752797345155" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="172.46" WEIGHT="17.734223163696566"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="16.523585012663904" CI_END="1.2111470139104457" CI_START="0.9679397377631935" DF="4" EFFECT_SIZE="1.0827360357156086" ESTIMABLE="YES" EVENTS_1="617" EVENTS_2="525" I2="75.79217828979398" ID="CMP-002.02.03" LOG_CI_END="0.08319686275898083" LOG_CI_START="-0.014151680265566036" LOG_EFFECT_SIZE="0.0345225912467074" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0023913598420621796" P_Z="0.16449270808938468" STUDIES="5" TAU2="0.0" TOTAL_1="701" TOTAL_2="575" WEIGHT="31.4477567431386" Z="1.390119120313545">
<NAME>Single agent taxane v Regimen C</NAME>
<IPD_DATA CI_END="1.5489655912672018" CI_START="0.8922374420026595" EFFECT_SIZE="1.1756041412407432" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" LOG_CI_END="0.19004177044561008" LOG_CI_START="-0.04951955590503314" LOG_EFFECT_SIZE="0.07026110727028849" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="88077" O_E="8.17" SE="0.14071950894605836" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="50.5" WEIGHT="5.192962250763519"/>
<IPD_DATA CI_END="1.188372704901193" CI_START="0.7187967787097458" EFFECT_SIZE="0.9242285822184708" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="83" LOG_CI_END="0.0749526681678691" LOG_CI_START="-0.143393877850928" LOG_EFFECT_SIZE="-0.034220604841529494" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="88078" O_E="-4.79" SE="0.12825784196427567" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="60.79" WEIGHT="6.251092578691373"/>
<IPD_DATA CI_END="1.9313798497361756" CI_START="1.2426029621310652" EFFECT_SIZE="1.5491734319573207" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" LOG_CI_END="0.28586769605857143" LOG_CI_START="0.09433238455445257" LOG_EFFECT_SIZE="0.19010004030651198" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="88079" O_E="34.58" SE="0.1125087900926024" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="79.0" WEIGHT="8.123643917036"/>
<IPD_DATA CI_END="1.091154611787768" CI_START="0.7291510882488825" EFFECT_SIZE="0.8919734147567617" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="145" LOG_CI_END="0.03788629255792961" LOG_CI_START="-0.1371824716902087" LOG_EFFECT_SIZE="-0.04964808956613951" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="371" O_E="-10.81" SE="0.10283625872371589" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="94.56" WEIGHT="9.723693275885116"/>
<IPD_DATA CI_END="1.3398711650835016" CI_START="0.5692494150059186" EFFECT_SIZE="0.8733389244199996" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.12706304091461088" LOG_CI_START="-0.24469740701906822" LOG_EFFECT_SIZE="-0.0588171830522287" MODIFIED="2014-09-30 14:46:02 +1000" MODIFIED_BY="[Empty name]" ORDER="376" O_E="-2.84" SE="0.21837392736013947" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="20.97" WEIGHT="2.156364720762594"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="78.4232504686704" CI_END="0.971245176965746" CI_START="0.872719270538928" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_SIZE="0.9206651847202639" ESTIMABLE="YES" EVENTS_1="2590" EVENTS_2="2603" I2="73.22222698689419" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.012671124816371199" LOG_CI_START="-0.059125434258647934" LOG_EFFECT_SIZE="-0.03589827953750959" MODIFIED="2015-05-22 10:48:29 +1000" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="1.4788078095406831E-8" P_Q="0.6763061265725373" P_Z="0.0024521495088036336" Q="0.7822194948643234" SCALE="5.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3105" TOTAL_2="3079" WEIGHT="300.0" Z="3.0291844113148305">
<NAME>Subquestions A, B &amp; C</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.2138512457544872" CI_START="0.8117625437937871" DF="0" EFFECT_SIZE="0.9926524946026781" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="166" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.08416546836502438" LOG_CI_START="-0.09057099169693075" LOG_EFFECT_SIZE="-0.0032027616659531894" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9427222816254939" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="224" WEIGHT="100.0" Z="0.07184874311987374">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<IPD_DATA CI_END="1.2138512457544872" CI_START="0.8117625437937871" EFFECT_SIZE="0.9926524946026781" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="166" LOG_CI_END="0.08416546836502438" LOG_CI_START="-0.09057099169693075" LOG_EFFECT_SIZE="-0.0032027616659531894" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88102" O_E="-0.7" SE="0.10264106159981964" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="224" VAR="94.92" WEIGHT="100.0"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="16.31923608077669" CI_END="0.9784287667023691" CI_START="0.8341605816946515" DF="9" EFFECT_SIZE="0.9034194536200937" ESTIMABLE="YES" EVENTS_1="1193" EVENTS_2="1229" I2="44.850359689314224" ID="CMP-002.03.02" LOG_CI_END="-0.009470787128308565" LOG_CI_START="-0.07875033661554794" LOG_EFFECT_SIZE="-0.04411056187192826" MODIFIED="2015-05-22 10:48:29 +1000" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.06050713517131767" P_Z="0.012566154494585266" STUDIES="10" TAU2="0.0" TOTAL_1="1442" TOTAL_2="1449" WEIGHT="99.99999999999999" Z="2.4958335683960917">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<IPD_DATA CI_END="0.9480785668560276" CI_START="0.6053951307104737" EFFECT_SIZE="0.7576028959194938" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="165" LOG_CI_END="-0.02315567137692133" LOG_CI_START="-0.2179610764651355" LOG_EFFECT_SIZE="-0.12055837392102842" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88103" O_E="-21.2" SE="0.11442965925112424" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="76.37" WEIGHT="12.64759948992266"/>
<IPD_DATA CI_END="1.3236716880191266" CI_START="0.725510274191262" EFFECT_SIZE="0.9799680654562001" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="79" LOG_CI_END="0.12178027984474586" LOG_CI_START="-0.1393564329947128" LOG_EFFECT_SIZE="-0.008788076574983443" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="361" O_E="-0.86" SE="0.1533929977694741" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="42.5" WEIGHT="7.038404849046916"/>
<IPD_DATA CI_END="1.3092933958457849" CI_START="0.6166154300557208" EFFECT_SIZE="0.8985157262666935" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="56" LOG_CI_END="0.11703697727585574" LOG_CI_START="-0.2099856117791347" LOG_EFFECT_SIZE="-0.046474317251639495" MODIFIED="2014-10-07 14:38:02 +1100" MODIFIED_BY="Melina L Willson" ORDER="362" O_E="-2.9" SE="0.19209468759882464" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="27.1" WEIGHT="4.4880181508040335"/>
<IPD_DATA CI_END="0.8816359665874274" CI_START="0.5031422888900299" EFFECT_SIZE="0.6660242774828647" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="105" LOG_CI_END="-0.05471070096525379" LOG_CI_START="-0.29830917887829855" LOG_EFFECT_SIZE="-0.17650993992177622" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="363" O_E="-19.85" SE="0.1430909517580356" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="48.84" WEIGHT="8.088369242998857"/>
<IPD_DATA CI_END="1.153991159066027" CI_START="0.6796321910775032" EFFECT_SIZE="0.8856012307580152" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="107" LOG_CI_END="0.06220248162426451" LOG_CI_START="-0.16772605876675473" LOG_EFFECT_SIZE="-0.05276178857124513" MODIFIED="2015-05-22 10:48:29 +1000" MODIFIED_BY="Melina L Willson" ORDER="364" O_E="-6.66" SE="0.13506116279031571" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="54.82" WEIGHT="9.078714207641223"/>
<IPD_DATA CI_END="1.2032284459026727" CI_START="0.7397644396507601" EFFECT_SIZE="0.943454088472272" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="125" LOG_CI_END="0.08034809066157232" LOG_CI_START="-0.13090654897984424" LOG_EFFECT_SIZE="-0.02527922915913598" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88105" O_E="-3.78" SE="0.1240920210526996" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="64.94" WEIGHT="10.754682609343687"/>
<IPD_DATA CI_END="1.4111895869133404" CI_START="0.8018057285579703" EFFECT_SIZE="1.0637198385235052" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="95" LOG_CI_END="0.1495853631656067" LOG_CI_START="-0.0959308452266442" LOG_EFFECT_SIZE="0.026827258969481224" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="365" O_E="2.97" SE="0.14421743613444024" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="48.08" WEIGHT="7.962506003345311"/>
<IPD_DATA CI_END="0.9776017720116648" CI_START="0.5698564347541257" EFFECT_SIZE="0.7463864015427149" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="115" LOG_CI_END="-0.009838019893879411" LOG_CI_START="-0.24423454335795655" LOG_EFFECT_SIZE="-0.12703628162591804" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="366" O_E="-15.43" SE="0.13768567816430285" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="52.75" WEIGHT="8.735902489111172"/>
<IPD_DATA CI_END="1.1725782106316176" CI_START="0.43968483355502375" EFFECT_SIZE="0.7180284502523632" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="40" LOG_CI_END="0.06914181967107516" LOG_CI_START="-0.35685851463265333" LOG_EFFECT_SIZE="-0.1438583474807891" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="368" O_E="-5.29" SE="0.2502347051056742" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="15.97" WEIGHT="2.6447841279830415"/>
<IPD_DATA CI_END="1.242237609675948" CI_START="0.9216603130561425" EFFECT_SIZE="1.0700098617414928" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="342" LOG_CI_END="0.09420467369996081" LOG_CI_START="-0.03542911294603589" LOG_EFFECT_SIZE="0.0293877803769625" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="370" O_E="11.67" SE="0.07614752797345155" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="172.46" WEIGHT="28.56101882980309"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="61.32179489302939" CI_END="1.0011921559952657" CI_START="0.8579181496920983" DF="10" EFFECT_SIZE="0.9267906570297851" ESTIMABLE="YES" EVENTS_1="1223" EVENTS_2="1208" I2="83.69258431289538" ID="CMP-002.03.03" LOG_CI_END="5.174383979146357E-4" LOG_CI_START="-0.06655414435725043" LOG_EFFECT_SIZE="-0.033018352979667945" MODIFIED="2014-10-07 14:42:23 +1100" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="2.03577721347159E-9" P_Z="0.05364118807689492" STUDIES="11" TAU2="0.0" TOTAL_1="1433" TOTAL_2="1406" WEIGHT="100.0" Z="1.929722842689183">
<NAME>Single agent taxane v Regimen C</NAME>
<IPD_DATA CI_END="1.1593563745095063" CI_START="0.7168939139296295" EFFECT_SIZE="0.9116663473888819" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="134" LOG_CI_END="0.06421695424912825" LOG_CI_START="-0.1445451065410079" LOG_EFFECT_SIZE="-0.04016407614593982" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88107" O_E="-6.15" SE="0.12262786789699316" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="66.5" WEIGHT="10.322240158946977"/>
<IPD_DATA CI_END="0.8606019036744375" CI_START="0.5529144933305723" EFFECT_SIZE="0.6898110361029879" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="153" LOG_CI_END="-0.0651976975813867" LOG_CI_START="-0.2573420259212832" LOG_EFFECT_SIZE="-0.1612698617513349" MODIFIED="2014-10-07 14:42:21 +1100" MODIFIED_BY="Melina L Willson" ORDER="88108" O_E="-29.15" SE="0.11286652959662007" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="78.5" WEIGHT="12.184900037253199"/>
<IPD_DATA CI_END="1.5489655912672018" CI_START="0.8922374420026595" EFFECT_SIZE="1.1756041412407432" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" LOG_CI_END="0.19004177044561008" LOG_CI_START="-0.04951955590503314" LOG_EFFECT_SIZE="0.07026110727028849" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88109" O_E="8.17" SE="0.14071950894605836" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="50.5" WEIGHT="7.838693654538682"/>
<IPD_DATA CI_END="0.9552546863030363" CI_START="0.3717309154505096" EFFECT_SIZE="0.5959007459533988" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="-0.019880823065822117" LOG_CI_START="-0.4297713187771968" LOG_EFFECT_SIZE="-0.22482607092150944" MODIFIED="2014-10-07 14:42:22 +1100" MODIFIED_BY="Melina L Willson" ORDER="88110" O_E="-8.93" SE="0.2407717061715384" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="17.25" WEIGHT="2.6775735750651934"/>
<IPD_DATA CI_END="1.1645491838166122" CI_START="0.7722993786051251" EFFECT_SIZE="0.9483567952077294" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="166" LOG_CI_END="0.06615783534307426" LOG_CI_START="-0.11221431459639969" LOG_EFFECT_SIZE="-0.02302823962666271" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88111" O_E="-4.83" SE="0.10477668383082935" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="224" VAR="91.09" WEIGHT="14.139140692909477"/>
<IPD_DATA CI_END="1.9313798497361756" CI_START="1.2426029621310652" EFFECT_SIZE="1.5491734319573207" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" LOG_CI_END="0.28586769605857143" LOG_CI_START="0.09433238455445257" LOG_EFFECT_SIZE="0.19010004030651198" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88112" O_E="34.58" SE="0.1125087900926024" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="79.0" WEIGHT="12.262510865515956"/>
<IPD_DATA CI_END="1.091154611787768" CI_START="0.7291510882488825" EFFECT_SIZE="0.8919734147567617" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="145" LOG_CI_END="0.03788629255792961" LOG_CI_START="-0.1371824716902087" LOG_EFFECT_SIZE="-0.04964808956613951" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="371" O_E="-10.81" SE="0.10283625872371589" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="94.56" WEIGHT="14.677759841053025"/>
<IPD_DATA CI_END="0.7330919635853363" CI_START="0.45974830958841484" EFFECT_SIZE="0.5805495594961814" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="132" LOG_CI_END="-0.13484154135828819" LOG_CI_START="-0.3374798589094025" LOG_EFFECT_SIZE="-0.2361607001338453" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88113" O_E="-38.38" SE="0.1190307508053739" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="70.58" WEIGHT="10.955544517571091"/>
<IPD_DATA CI_END="2.1088845598547143" CI_START="1.1394046157741393" EFFECT_SIZE="1.5501202539265384" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="83" LOG_CI_END="0.3240528071504604" LOG_CI_START="0.05667797446871984" LOG_EFFECT_SIZE="0.19036539080959014" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="17.77" SE="0.15705730024402176" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.54" WEIGHT="6.292685955544518"/>
<IPD_DATA CI_END="1.0946881874122818" CI_START="0.5629872265202923" EFFECT_SIZE="0.7850448818607547" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="68" LOG_CI_END="0.0392904317142165" LOG_CI_START="-0.2495014586383228" LOG_EFFECT_SIZE="-0.10510551346205321" MODIFIED="2014-10-07 14:42:23 +1100" MODIFIED_BY="Melina L Willson" ORDER="375" O_E="-8.41" SE="0.16963778593599418" STUDY_ID="STD-TXT" TOTAL_1="88" TOTAL_2="90" VAR="34.75" WEIGHT="5.393952564261766"/>
<IPD_DATA CI_END="1.3398711650835016" CI_START="0.5692494150059186" EFFECT_SIZE="0.8733389244199996" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.12706304091461088" LOG_CI_START="-0.24469740701906822" LOG_EFFECT_SIZE="-0.0588171830522287" MODIFIED="2014-09-30 14:45:23 +1000" MODIFIED_BY="[Empty name]" ORDER="376" O_E="-2.84" SE="0.21837392736013947" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="20.97" WEIGHT="3.2549981373401216"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="40.778555131674004" CI_END="1.011819241289237" CI_START="0.8979371320497719" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_SIZE="0.953178927419209" ESTIMABLE="YES" EVENTS_1="2033" EVENTS_2="2050" I2="63.215960076160165" I2_Q="50.480524372170066" ID="CMP-002.04" LOG_CI_END="0.005102933924382055" LOG_CI_START="-0.04675406885569145" LOG_EFFECT_SIZE="-0.02082556746565471" MODIFIED="2014-10-07 14:51:34 +1100" MODIFIED_BY="Melina L Willson" NO="4" P_CHI2="3.4561484170436696E-4" P_Q="0.13273431894416554" P_Z="0.115434843641413" Q="4.0388149806578335" SCALE="5.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="2373" TOTAL_2="2360" WEIGHT="300.0" Z="1.5742275874831997">
<NAME>Subquestions A, B &amp; C: first-line only</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.2138512457544872" CI_START="0.8117625437937871" DF="0" EFFECT_SIZE="0.9926524946026781" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="166" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.08416546836502438" LOG_CI_START="-0.09057099169693075" LOG_EFFECT_SIZE="-0.0032027616659531894" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="1.0" P_Z="0.9427222816254939" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="224" WEIGHT="100.0" Z="0.07184874311987374">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<IPD_DATA CI_END="1.2138512457544872" CI_START="0.8117625437937871" EFFECT_SIZE="0.9926524946026781" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="166" LOG_CI_END="0.08416546836502438" LOG_CI_START="-0.09057099169693075" LOG_EFFECT_SIZE="-0.0032027616659531894" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="88171" O_E="-0.7" SE="0.10264106159981964" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="224" VAR="94.92" WEIGHT="100.0"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="16.31923608077669" CI_END="0.9784287667023691" CI_START="0.8341605816946515" DF="9" EFFECT_SIZE="0.9034194536200937" ESTIMABLE="YES" EVENTS_1="1193" EVENTS_2="1229" I2="44.850359689314224" ID="CMP-002.04.02" LOG_CI_END="-0.009470787128308565" LOG_CI_START="-0.07875033661554794" LOG_EFFECT_SIZE="-0.04411056187192826" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.06050713517131767" P_Z="0.012566154494585266" STUDIES="10" TAU2="0.0" TOTAL_1="1442" TOTAL_2="1449" WEIGHT="100.0" Z="2.4958335683960917">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<IPD_DATA CI_END="0.9480785668560276" CI_START="0.6053951307104737" EFFECT_SIZE="0.7576028959194938" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="165" LOG_CI_END="-0.02315567137692133" LOG_CI_START="-0.2179610764651355" LOG_EFFECT_SIZE="-0.12055837392102842" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="88172" O_E="-21.2" SE="0.11442965925112424" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="76.37" WEIGHT="12.64759948992266"/>
<IPD_DATA CI_END="1.3236716880191266" CI_START="0.725510274191262" EFFECT_SIZE="0.9799680654562001" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="79" LOG_CI_END="0.12178027984474586" LOG_CI_START="-0.1393564329947128" LOG_EFFECT_SIZE="-0.008788076574983443" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="361" O_E="-0.86" SE="0.1533929977694741" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="42.5" WEIGHT="7.038404849046916"/>
<IPD_DATA CI_END="1.3092933958457849" CI_START="0.6166154300557208" EFFECT_SIZE="0.8985157262666935" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="56" LOG_CI_END="0.11703697727585574" LOG_CI_START="-0.2099856117791347" LOG_EFFECT_SIZE="-0.046474317251639495" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="362" O_E="-2.9" SE="0.19209468759882464" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="27.1" WEIGHT="4.4880181508040335"/>
<IPD_DATA CI_END="0.8816359665874274" CI_START="0.5031422888900299" EFFECT_SIZE="0.6660242774828647" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="105" LOG_CI_END="-0.05471070096525379" LOG_CI_START="-0.29830917887829855" LOG_EFFECT_SIZE="-0.17650993992177622" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="363" O_E="-19.85" SE="0.1430909517580356" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="48.84" WEIGHT="8.088369242998857"/>
<IPD_DATA CI_END="1.153991159066027" CI_START="0.6796321910775032" EFFECT_SIZE="0.8856012307580152" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="107" LOG_CI_END="0.06220248162426451" LOG_CI_START="-0.16772605876675473" LOG_EFFECT_SIZE="-0.05276178857124513" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="364" O_E="-6.66" SE="0.13506116279031571" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="54.82" WEIGHT="9.078714207641223"/>
<IPD_DATA CI_END="1.2032284459026727" CI_START="0.7397644396507601" EFFECT_SIZE="0.943454088472272" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="125" LOG_CI_END="0.08034809066157232" LOG_CI_START="-0.13090654897984424" LOG_EFFECT_SIZE="-0.02527922915913598" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="88174" O_E="-3.78" SE="0.1240920210526996" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="64.94" WEIGHT="10.754682609343687"/>
<IPD_DATA CI_END="1.4111895869133404" CI_START="0.8018057285579703" EFFECT_SIZE="1.0637198385235052" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="95" LOG_CI_END="0.1495853631656067" LOG_CI_START="-0.0959308452266442" LOG_EFFECT_SIZE="0.026827258969481224" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="365" O_E="2.97" SE="0.14421743613444024" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="48.08" WEIGHT="7.962506003345311"/>
<IPD_DATA CI_END="0.9776017720116648" CI_START="0.5698564347541257" EFFECT_SIZE="0.7463864015427149" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="115" LOG_CI_END="-0.009838019893879411" LOG_CI_START="-0.24423454335795655" LOG_EFFECT_SIZE="-0.12703628162591804" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="366" O_E="-15.43" SE="0.13768567816430285" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="52.75" WEIGHT="8.735902489111172"/>
<IPD_DATA CI_END="1.1725782106316176" CI_START="0.43968483355502375" EFFECT_SIZE="0.7180284502523632" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="40" LOG_CI_END="0.06914181967107516" LOG_CI_START="-0.35685851463265333" LOG_EFFECT_SIZE="-0.1438583474807891" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="368" O_E="-5.29" SE="0.2502347051056742" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="15.97" WEIGHT="2.6447841279830415"/>
<IPD_DATA CI_END="1.242237609675948" CI_START="0.9216603130561425" EFFECT_SIZE="1.0700098617414928" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="342" LOG_CI_END="0.09420467369996081" LOG_CI_START="-0.03542911294603589" LOG_EFFECT_SIZE="0.0293877803769625" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="370" O_E="11.67" SE="0.07614752797345155" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="172.46" WEIGHT="28.56101882980309"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="20.420504070239485" CI_END="1.1365409464137215" CI_START="0.9292577817655951" DF="4" EFFECT_SIZE="1.0276864885509516" ESTIMABLE="YES" EVENTS_1="666" EVENTS_2="655" I2="80.41184494642552" ID="CMP-002.04.03" LOG_CI_END="0.055585086766837974" LOG_CI_START="-0.031863793359805166" LOG_EFFECT_SIZE="0.011860646703516433" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="4.124395827180827E-4" P_Z="0.5949630147845317" STUDIES="5" TAU2="0.0" TOTAL_1="701" TOTAL_2="687" WEIGHT="100.0" Z="0.5316578174261466">
<NAME>Single agent taxane v Regimen C</NAME>
<IPD_DATA CI_END="1.5489655912672018" CI_START="0.8922374420026595" EFFECT_SIZE="1.1756041412407432" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" LOG_CI_END="0.19004177044561008" LOG_CI_START="-0.04951955590503314" LOG_EFFECT_SIZE="0.07026110727028849" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="88176" O_E="8.17" SE="0.14071950894605836" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="50.5" WEIGHT="13.325241437542878"/>
<IPD_DATA CI_END="1.0298046190955557" CI_START="0.7339427129126441" EFFECT_SIZE="0.8693777061260337" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="213" LOG_CI_END="0.012754835484236107" LOG_CI_START="-0.13433783713688222" LOG_EFFECT_SIZE="-0.06079150082632305" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="88177" O_E="-18.75" SE="0.0864029640181174" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="224" VAR="133.95" WEIGHT="35.34487308037363"/>
<IPD_DATA CI_END="1.9313798497361756" CI_START="1.2426029621310652" EFFECT_SIZE="1.5491734319573207" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" LOG_CI_END="0.28586769605857143" LOG_CI_START="0.09433238455445257" LOG_EFFECT_SIZE="0.19010004030651198" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="88178" O_E="34.58" SE="0.1125087900926024" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="79.0" WEIGHT="20.845427199324504"/>
<IPD_DATA CI_END="1.091154611787768" CI_START="0.7291510882488825" EFFECT_SIZE="0.8919734147567617" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="145" LOG_CI_END="0.03788629255792961" LOG_CI_START="-0.1371824716902087" LOG_EFFECT_SIZE="-0.04964808956613951" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="371" O_E="-10.81" SE="0.10283625872371589" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="94.56" WEIGHT="24.95118475909019"/>
<IPD_DATA CI_END="1.3398711650835016" CI_START="0.5692494150059186" EFFECT_SIZE="0.8733389244199996" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.12706304091461088" LOG_CI_START="-0.24469740701906822" LOG_EFFECT_SIZE="-0.0588171830522287" MODIFIED="2014-10-07 14:50:07 +1100" MODIFIED_BY="Melina L Willson" ORDER="376" O_E="-2.84" SE="0.21837392736013947" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="20.97" WEIGHT="5.533273523668795"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="61.92049512224884" CI_END="1.0215064670441443" CI_START="0.8701832255242067" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="0.9428137633627918" ESTIMABLE="YES" EVENTS_1="1175" EVENTS_2="1158" I2="83.85025833489037" I2_Q="88.64339357660488" ID="CMP-002.05" LOG_CI_END="0.009241120447365657" LOG_CI_START="-0.06038929283425828" LOG_EFFECT_SIZE="-0.025574086193446283" MODIFIED="2014-10-07 17:40:11 +1100" MODIFIED_BY="Melina L Willson" NO="5" P_CHI2="1.5668225605836028E-9" P_Q="0.003003346725545253" P_Z="0.14994550608952842" Q="8.805447355646272" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1429" TOTAL_2="1401" WEIGHT="200.0" Z="1.4397239802081145">
<NAME>Chemotherapy Regimens</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="14.672593905258573" CI_END="1.2247402600844528" CI_START="0.9593266634501013" DF="3" EFFECT_SIZE="1.0839400293834651" ESTIMABLE="YES" EVENTS_1="502" EVENTS_2="498" I2="79.55371749963844" ID="CMP-002.05.01" LOG_CI_END="0.08804399435543814" LOG_CI_START="-0.018033484615482365" LOG_EFFECT_SIZE="0.03500525486997785" MODIFIED="2014-10-07 14:52:11 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="0.002118943115407168" P_Z="0.1958158372978773" STUDIES="4" TAU2="0.0" TOTAL_1="608" TOTAL_2="604" WEIGHT="100.0" Z="1.2935646563321908">
<NAME>Single agent taxane vs single agent anthracycline</NAME>
<IPD_DATA CI_END="1.1593563745095063" CI_START="0.7168939139296295" EFFECT_SIZE="0.9116663473888819" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="134" LOG_CI_END="0.06421695424912825" LOG_CI_START="-0.1445451065410079" LOG_EFFECT_SIZE="-0.04016407614593982" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88212" O_E="-6.15" SE="0.12262786789699316" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="66.5" WEIGHT="25.8192265879795"/>
<IPD_DATA CI_END="1.1645491838166122" CI_START="0.7722993786051251" EFFECT_SIZE="0.9483567952077294" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="166" LOG_CI_END="0.06615783534307426" LOG_CI_START="-0.11221431459639969" LOG_EFFECT_SIZE="-0.02302823962666271" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88213" O_E="-4.83" SE="0.10477668383082935" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="224" VAR="91.09" WEIGHT="35.36651653983538"/>
<IPD_DATA CI_END="1.9313798497361756" CI_START="1.2426029621310652" EFFECT_SIZE="1.5491734319573207" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" LOG_CI_END="0.28586769605857143" LOG_CI_START="0.09433238455445257" LOG_EFFECT_SIZE="0.19010004030651198" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88214" O_E="34.58" SE="0.1125087900926024" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="79.0" WEIGHT="30.672464668426777"/>
<IPD_DATA CI_END="1.3398711650835016" CI_START="0.5692494150059186" EFFECT_SIZE="0.8733389244199996" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.12706304091461088" LOG_CI_START="-0.24469740701906822" LOG_EFFECT_SIZE="-0.0588171830522287" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="376" O_E="-2.84" SE="0.21837392736013947" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="20.97" WEIGHT="8.141792203758348"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="38.442453861343985" CI_END="0.9434341087728398" CI_START="0.7628039724299197" DF="6" EFFECT_SIZE="0.8483249883728541" ESTIMABLE="YES" EVENTS_1="673" EVENTS_2="660" I2="84.39225544331515" ID="CMP-002.05.02" LOG_CI_END="-0.025288426390033335" LOG_CI_START="-0.11758705395862018" LOG_EFFECT_SIZE="-0.07143774017432682" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="9.203998126983137E-7" P_Z="0.0024136251515775426" STUDIES="7" TAU2="0.0" TOTAL_1="821" TOTAL_2="797" WEIGHT="100.0" Z="3.033964893455551">
<NAME>Single agent taxane vs non-anthracycline combination</NAME>
<IPD_DATA CI_END="0.8606019036744375" CI_START="0.5529144933305723" EFFECT_SIZE="0.6898110361029879" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="153" LOG_CI_END="-0.0651976975813867" LOG_CI_START="-0.2573420259212832" LOG_EFFECT_SIZE="-0.1612698617513349" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88215" O_E="-29.15" SE="0.11286652959662007" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="78.5" WEIGHT="23.074661963550852"/>
<IPD_DATA CI_END="1.5489655912672018" CI_START="0.8922374420026595" EFFECT_SIZE="1.1756041412407432" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" LOG_CI_END="0.19004177044561008" LOG_CI_START="-0.04951955590503314" LOG_EFFECT_SIZE="0.07026110727028849" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88216" O_E="8.17" SE="0.14071950894605836" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="50.5" WEIGHT="14.844209288653733"/>
<IPD_DATA CI_END="0.9552546863030363" CI_START="0.3717309154505096" EFFECT_SIZE="0.5959007459533988" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="-0.019880823065822117" LOG_CI_START="-0.4297713187771968" LOG_EFFECT_SIZE="-0.22482607092150944" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88217" O_E="-8.93" SE="0.2407717061715384" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="17.25" WEIGHT="5.070546737213404"/>
<IPD_DATA CI_END="1.4111895869133404" CI_START="0.8018057285579703" EFFECT_SIZE="1.0637198385235052" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="95" LOG_CI_END="0.1495853631656067" LOG_CI_START="-0.0959308452266442" LOG_EFFECT_SIZE="0.026827258969481224" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="365" O_E="2.97" SE="0.14421743613444024" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="48.08" WEIGHT="14.132863021751911"/>
<IPD_DATA CI_END="0.7330919635853363" CI_START="0.45974830958841484" EFFECT_SIZE="0.5805495594961814" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="132" LOG_CI_END="-0.13484154135828819" LOG_CI_START="-0.3374798589094025" LOG_EFFECT_SIZE="-0.2361607001338453" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="88218" O_E="-38.38" SE="0.1190307508053739" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="70.58" WEIGHT="20.746619635508523"/>
<IPD_DATA CI_END="2.1088845598547143" CI_START="1.1394046157741393" EFFECT_SIZE="1.5501202539265384" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="83" LOG_CI_END="0.3240528071504604" LOG_CI_START="0.05667797446871984" LOG_EFFECT_SIZE="0.19036539080959014" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="17.77" SE="0.15705730024402176" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.54" WEIGHT="11.916519694297472"/>
<IPD_DATA CI_END="1.0946881874122818" CI_START="0.5629872265202923" EFFECT_SIZE="0.7850448818607547" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="68" LOG_CI_END="0.0392904317142165" LOG_CI_START="-0.2495014586383228" LOG_EFFECT_SIZE="-0.10510551346205321" MODIFIED="2014-09-30 14:54:29 +1000" MODIFIED_BY="[Empty name]" ORDER="375" O_E="-8.41" SE="0.16963778593599418" STUDY_ID="STD-TXT" TOTAL_1="88" TOTAL_2="90" VAR="34.75" WEIGHT="10.214579659024103"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="77.98212684649558" CI_END="0.9679295800001945" CI_START="0.867503253095707" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_SIZE="0.91634167176754" ESTIMABLE="YES" EVENTS_1="2590" EVENTS_2="2437" I2="73.0707524285179" I2_Q="95.51614652761644" ID="CMP-002.06" LOG_CI_END="-0.014156237867030696" LOG_CI_START="-0.0617288879505" LOG_EFFECT_SIZE="-0.03794256290876536" MODIFIED="2015-04-17 12:18:42 +1000" MODIFIED_BY="Melina L Willson" NO="6" P_CHI2="1.750459954763528E-8" P_Q="2.3293768397492087E-6" P_Z="0.0017694827496076019" Q="22.302245293230143" SCALE="2.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3105" TOTAL_2="2855" WEIGHT="199.99999999999994" Z="3.1264206072962235">
<NAME>Type of taxane</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="36.390392084169534" CI_END="1.1206057755761147" CI_START="0.9633262889177387" DF="10" EFFECT_SIZE="1.038994226704616" ESTIMABLE="YES" EVENTS_1="1416" EVENTS_2="1263" I2="72.52021913676995" ID="CMP-002.06.01" LOG_CI_END="0.04945285648098074" LOG_CI_START="-0.01622658777142617" LOG_EFFECT_SIZE="0.016613134354777254" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="7.211301363907463E-5" P_Z="0.3214331752584618" STUDIES="11" TAU2="0.0" TOTAL_1="1650" TOTAL_2="1430" WEIGHT="99.99999999999997" Z="0.9915170682795568">
<NAME>Paclitaxel containing</NAME>
<IPD_DATA CI_END="1.5489655912672018" CI_START="0.8922374420026595" EFFECT_SIZE="1.1756041412407432" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" LOG_CI_END="0.19004177044561008" LOG_CI_START="-0.04951955590503314" LOG_EFFECT_SIZE="0.07026110727028849" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="88233" O_E="8.17" SE="0.14071950894605836" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="50.5" WEIGHT="7.5166706358656805"/>
<IPD_DATA CI_END="1.153991159066027" CI_START="0.6796321910775032" EFFECT_SIZE="0.8856012307580152" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="107" LOG_CI_END="0.06220248162426451" LOG_CI_START="-0.16772605876675473" LOG_EFFECT_SIZE="-0.05276178857124513" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="364" O_E="-6.66" SE="0.13506116279031571" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="54.82" WEIGHT="8.159680876399142"/>
<IPD_DATA CI_END="0.9552546863030363" CI_START="0.3717309154505096" EFFECT_SIZE="0.5959007459533988" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="-0.019880823065822117" LOG_CI_START="-0.4297713187771968" LOG_EFFECT_SIZE="-0.22482607092150944" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="88235" O_E="-8.93" SE="0.2407717061715384" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="17.25" WEIGHT="2.5675756132412473"/>
<IPD_DATA CI_END="1.2481431775239" CI_START="0.7611578256089859" EFFECT_SIZE="0.974696848795964" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="83" LOG_CI_END="0.09626440717488878" LOG_CI_START="-0.11852528319730952" LOG_EFFECT_SIZE="-0.01113043801121038" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="88236" O_E="-1.61" SE="0.1261685273507441" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="62.82" WEIGHT="9.350440581090734"/>
<IPD_DATA CI_END="1.188372704901193" CI_START="0.7187967787097458" EFFECT_SIZE="0.9242285822184708" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="83" LOG_CI_END="0.0749526681678691" LOG_CI_START="-0.143393877850928" LOG_EFFECT_SIZE="-0.034220604841529494" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="88237" O_E="-4.79" SE="0.12825784196427567" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="60.79" WEIGHT="9.048285306025242"/>
<IPD_DATA CI_END="1.9313798497361756" CI_START="1.2426029621310652" EFFECT_SIZE="1.5491734319573207" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" LOG_CI_END="0.28586769605857143" LOG_CI_START="0.09433238455445257" LOG_EFFECT_SIZE="0.19010004030651198" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="88238" O_E="34.58" SE="0.1125087900926024" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="79.0" WEIGHT="11.758752083829481"/>
<IPD_DATA CI_END="1.2032284459026727" CI_START="0.7397644396507601" EFFECT_SIZE="0.943454088472272" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="125" LOG_CI_END="0.08034809066157232" LOG_CI_START="-0.13090654897984424" LOG_EFFECT_SIZE="-0.02527922915913598" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="88239" O_E="-3.78" SE="0.1240920210526996" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="64.94" WEIGHT="9.665991902834005"/>
<IPD_DATA CI_END="0.9776017720116648" CI_START="0.5698564347541257" EFFECT_SIZE="0.7463864015427149" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="115" LOG_CI_END="-0.009838019893879411" LOG_CI_START="-0.24423454335795655" LOG_EFFECT_SIZE="-0.12703628162591804" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="366" O_E="-15.43" SE="0.13768567816430285" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="52.75" WEIGHT="7.8515718028101915"/>
<IPD_DATA CI_END="1.1725782106316176" CI_START="0.43968483355502375" EFFECT_SIZE="0.7180284502523632" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="40" LOG_CI_END="0.06914181967107516" LOG_CI_START="-0.35685851463265333" LOG_EFFECT_SIZE="-0.1438583474807891" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="368" O_E="-5.29" SE="0.2502347051056742" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="15.97" WEIGHT="2.3770540604905928"/>
<IPD_DATA CI_END="2.1088845598547143" CI_START="1.1394046157741393" EFFECT_SIZE="1.5501202539265384" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="83" LOG_CI_END="0.3240528071504604" LOG_CI_START="0.05667797446871984" LOG_EFFECT_SIZE="0.19036539080959014" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="17.77" SE="0.15705730024402176" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.54" WEIGHT="6.034174803524647"/>
<IPD_DATA CI_END="1.242237609675948" CI_START="0.9216603130561425" EFFECT_SIZE="1.0700098617414928" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="342" LOG_CI_END="0.09420467369996081" LOG_CI_START="-0.03542911294603589" LOG_EFFECT_SIZE="0.0293877803769625" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="370" O_E="11.67" SE="0.07614752797345155" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="172.46" WEIGHT="25.669802333889017"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="19.28948946909591" CI_END="0.8636686838795349" CI_START="0.7367975184185525" DF="10" EFFECT_SIZE="0.7977148256227025" ESTIMABLE="YES" EVENTS_1="1174" EVENTS_2="1174" I2="48.1582961746022" ID="CMP-002.06.02" LOG_CI_END="-0.06365282738023545" LOG_CI_START="-0.13265184554050174" LOG_EFFECT_SIZE="-0.09815233646036858" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03673614258842439" P_Z="2.458750629010642E-8" STUDIES="11" TAU2="0.0" TOTAL_1="1455" TOTAL_2="1425" WEIGHT="99.99999999999997" Z="5.576167591658893">
<NAME>Docetaxel containing</NAME>
<IPD_DATA CI_END="1.1593563745095063" CI_START="0.7168939139296295" EFFECT_SIZE="0.9116663473888819" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="134" LOG_CI_END="0.06421695424912825" LOG_CI_START="-0.1445451065410079" LOG_EFFECT_SIZE="-0.04016407614593982" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="88242" O_E="-6.15" SE="0.12262786789699316" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="66.5" WEIGHT="10.924024640657082"/>
<IPD_DATA CI_END="0.8606019036744375" CI_START="0.5529144933305723" EFFECT_SIZE="0.6898110361029879" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="153" LOG_CI_END="-0.0651976975813867" LOG_CI_START="-0.2573420259212832" LOG_EFFECT_SIZE="-0.1612698617513349" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="88243" O_E="-29.15" SE="0.11286652959662007" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="78.5" WEIGHT="12.895277207392194"/>
<IPD_DATA CI_END="0.9480785668560276" CI_START="0.6053951307104737" EFFECT_SIZE="0.7576028959194938" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="165" LOG_CI_END="-0.02315567137692133" LOG_CI_START="-0.2179610764651355" LOG_EFFECT_SIZE="-0.12055837392102842" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="88244" O_E="-21.2" SE="0.11442965925112424" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="76.37" WEIGHT="12.545379876796712"/>
<IPD_DATA CI_END="1.3236716880191266" CI_START="0.725510274191262" EFFECT_SIZE="0.9799680654562001" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="79" LOG_CI_END="0.12178027984474586" LOG_CI_START="-0.1393564329947128" LOG_EFFECT_SIZE="-0.008788076574983443" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="361" O_E="-0.86" SE="0.1533929977694741" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="42.5" WEIGHT="6.9815195071868565"/>
<IPD_DATA CI_END="1.3092933958457849" CI_START="0.6166154300557208" EFFECT_SIZE="0.8985157262666935" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="56" LOG_CI_END="0.11703697727585574" LOG_CI_START="-0.2099856117791347" LOG_EFFECT_SIZE="-0.046474317251639495" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="362" O_E="-2.9" SE="0.19209468759882464" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="27.1" WEIGHT="4.451745379876796"/>
<IPD_DATA CI_END="0.8816359665874274" CI_START="0.5031422888900299" EFFECT_SIZE="0.6660242774828647" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="105" LOG_CI_END="-0.05471070096525379" LOG_CI_START="-0.29830917887829855" LOG_EFFECT_SIZE="-0.17650993992177622" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="363" O_E="-19.85" SE="0.1430909517580356" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="48.84" WEIGHT="8.022997946611909"/>
<IPD_DATA CI_END="1.4111895869133404" CI_START="0.8018057285579703" EFFECT_SIZE="1.0637198385235052" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="95" LOG_CI_END="0.1495853631656067" LOG_CI_START="-0.0959308452266442" LOG_EFFECT_SIZE="0.026827258969481224" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="365" O_E="2.97" SE="0.14421743613444024" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="48.08" WEIGHT="7.898151950718684"/>
<IPD_DATA CI_END="1.091154611787768" CI_START="0.7291510882488825" EFFECT_SIZE="0.8919734147567617" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="145" LOG_CI_END="0.03788629255792961" LOG_CI_START="-0.1371824716902087" LOG_EFFECT_SIZE="-0.04964808956613951" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="371" O_E="-10.81" SE="0.10283625872371589" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="94.56" WEIGHT="15.533470225872687"/>
<IPD_DATA CI_END="0.7330919635853363" CI_START="0.45974830958841484" EFFECT_SIZE="0.5805495594961814" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="132" LOG_CI_END="-0.13484154135828819" LOG_CI_START="-0.3374798589094025" LOG_EFFECT_SIZE="-0.2361607001338453" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="88245" O_E="-38.38" SE="0.1190307508053739" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="70.58" WEIGHT="11.59425051334702"/>
<IPD_DATA CI_END="1.0946881874122818" CI_START="0.5629872265202923" EFFECT_SIZE="0.7850448818607547" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="68" LOG_CI_END="0.0392904317142165" LOG_CI_START="-0.2495014586383228" LOG_EFFECT_SIZE="-0.10510551346205321" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="375" O_E="-8.41" SE="0.16963778593599418" STUDY_ID="STD-TXT" TOTAL_1="88" TOTAL_2="90" VAR="34.75" WEIGHT="5.70841889117043"/>
<IPD_DATA CI_END="1.3398711650835016" CI_START="0.5692494150059186" EFFECT_SIZE="0.8733389244199996" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.12706304091461088" LOG_CI_START="-0.24469740701906822" LOG_EFFECT_SIZE="-0.0588171830522287" MODIFIED="2014-09-30 15:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="376" O_E="-2.84" SE="0.21837392736013947" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="20.97" WEIGHT="3.444763860369609"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="77.98212684649558" CI_END="0.9679295800001945" CI_START="0.867503253095707" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_SIZE="0.91634167176754" ESTIMABLE="YES" EVENTS_1="2590" EVENTS_2="2437" I2="73.0707524285179" I2_Q="90.73197862772686" ID="CMP-002.07" LOG_CI_END="-0.014156237867030696" LOG_CI_START="-0.0617288879505" LOG_EFFECT_SIZE="-0.03794256290876536" MODIFIED="2014-10-07 17:40:43 +1100" MODIFIED_BY="Melina L Willson" NO="7" P_CHI2="1.750459954763528E-8" P_Q="0.0010206221848700903" P_Z="0.001769482749607607" Q="10.789789533628719" SCALE="5.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3105" TOTAL_2="2855" WEIGHT="200.0" Z="3.1264206072962226">
<NAME>Prior anthracyclines</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="27.5079130527492" CI_END="0.8593160414630693" CI_START="0.6677782703885263" DF="4" EFFECT_SIZE="0.7575173792628943" ESTIMABLE="YES" EVENTS_1="474" EVENTS_2="466" I2="85.4587296668795" ID="CMP-002.07.01" LOG_CI_END="-0.06584708084820041" LOG_CI_START="-0.17536771706346418" LOG_EFFECT_SIZE="-0.12060739895583227" MODIFIED="2014-10-07 14:52:24 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="1.5690725814865303E-5" P_Z="1.5834914965326585E-5" STUDIES="5" TAU2="0.0" TOTAL_1="571" TOTAL_2="554" WEIGHT="100.0" Z="4.316741874250365">
<NAME>Prior anthracyclines</NAME>
<IPD_DATA CI_END="0.8606019036744375" CI_START="0.5529144933305723" EFFECT_SIZE="0.6898110361029879" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="153" LOG_CI_END="-0.0651976975813867" LOG_CI_START="-0.2573420259212832" LOG_EFFECT_SIZE="-0.1612698617513349" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88274" O_E="-29.15" SE="0.11286652959662007" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="78.5" WEIGHT="32.48903236487046"/>
<IPD_DATA CI_END="0.9552546863030363" CI_START="0.3717309154505096" EFFECT_SIZE="0.5959007459533988" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="-0.019880823065822117" LOG_CI_START="-0.4297713187771968" LOG_EFFECT_SIZE="-0.22482607092150944" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88275" O_E="-8.93" SE="0.2407717061715384" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="17.25" WEIGHT="7.139309659796375"/>
<IPD_DATA CI_END="0.7330919635853363" CI_START="0.45974830958841484" EFFECT_SIZE="0.5805495594961814" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="132" LOG_CI_END="-0.13484154135828819" LOG_CI_START="-0.3374798589094025" LOG_EFFECT_SIZE="-0.2361607001338453" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88276" O_E="-38.38" SE="0.1190307508053739" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="70.58" WEIGHT="29.21115801672047"/>
<IPD_DATA CI_END="2.1088845598547143" CI_START="1.1394046157741393" EFFECT_SIZE="1.5501202539265384" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="83" LOG_CI_END="0.3240528071504604" LOG_CI_START="0.05667797446871984" LOG_EFFECT_SIZE="0.19036539080959014" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="17.77" SE="0.15705730024402176" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.54" WEIGHT="16.77841238308087"/>
<IPD_DATA CI_END="1.0946881874122818" CI_START="0.5629872265202923" EFFECT_SIZE="0.7850448818607547" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="68" LOG_CI_END="0.0392904317142165" LOG_CI_START="-0.2495014586383228" LOG_EFFECT_SIZE="-0.10510551346205321" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="375" O_E="-8.41" SE="0.16963778593599418" STUDY_ID="STD-TXT" TOTAL_1="88" TOTAL_2="90" VAR="34.75" WEIGHT="14.382087575531827"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="39.68442426011766" CI_END="1.0178633171271216" CI_START="0.9013096564635188" DF="16" EFFECT_SIZE="0.9578152414148898" ESTIMABLE="YES" EVENTS_1="2116" EVENTS_2="1971" I2="59.68191476049761" ID="CMP-002.07.02" LOG_CI_END="0.007689463066675791" LOG_CI_START="-0.04512597595853528" LOG_EFFECT_SIZE="-0.018718256445929744" MODIFIED="2014-10-07 14:52:35 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="8.655660810868993E-4" P_Z="0.164754622507891" STUDIES="17" TAU2="0.0" TOTAL_1="2534" TOTAL_2="2301" WEIGHT="100.00000000000001" Z="1.3892569735108966">
<NAME>Anthracycline naive</NAME>
<IPD_DATA CI_END="1.1593563745095063" CI_START="0.7168939139296295" EFFECT_SIZE="0.9116663473888819" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="134" LOG_CI_END="0.06421695424912825" LOG_CI_START="-0.1445451065410079" LOG_EFFECT_SIZE="-0.04016407614593982" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88278" O_E="-6.15" SE="0.12262786789699316" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="66.5" WEIGHT="6.400569795085517"/>
<IPD_DATA CI_END="0.9480785668560276" CI_START="0.6053951307104737" EFFECT_SIZE="0.7576028959194938" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="165" LOG_CI_END="-0.02315567137692133" LOG_CI_START="-0.2179610764651355" LOG_EFFECT_SIZE="-0.12055837392102842" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88279" O_E="-21.2" SE="0.11442965925112424" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="76.37" WEIGHT="7.350549101514"/>
<IPD_DATA CI_END="1.5489655912672018" CI_START="0.8922374420026595" EFFECT_SIZE="1.1756041412407432" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" LOG_CI_END="0.19004177044561008" LOG_CI_START="-0.04951955590503314" LOG_EFFECT_SIZE="0.07026110727028849" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88280" O_E="8.17" SE="0.14071950894605836" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="50.5" WEIGHT="4.860583077470957"/>
<IPD_DATA CI_END="1.3236716880191266" CI_START="0.725510274191262" EFFECT_SIZE="0.9799680654562001" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="79" LOG_CI_END="0.12178027984474586" LOG_CI_START="-0.1393564329947128" LOG_EFFECT_SIZE="-0.008788076574983443" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="361" O_E="-0.86" SE="0.1533929977694741" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="42.5" WEIGHT="4.090589718663677"/>
<IPD_DATA CI_END="1.3092933958457849" CI_START="0.6166154300557208" EFFECT_SIZE="0.8985157262666935" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="56" LOG_CI_END="0.11703697727585574" LOG_CI_START="-0.2099856117791347" LOG_EFFECT_SIZE="-0.046474317251639495" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="362" O_E="-2.9" SE="0.19209468759882464" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="27.1" WEIGHT="2.608352502959662"/>
<IPD_DATA CI_END="0.8816359665874274" CI_START="0.5031422888900299" EFFECT_SIZE="0.6660242774828647" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="105" LOG_CI_END="-0.05471070096525379" LOG_CI_START="-0.29830917887829855" LOG_EFFECT_SIZE="-0.17650993992177622" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="363" O_E="-19.85" SE="0.1430909517580356" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="48.84" WEIGHT="4.7008094555184465"/>
<IPD_DATA CI_END="1.153991159066027" CI_START="0.6796321910775032" EFFECT_SIZE="0.8856012307580152" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="107" LOG_CI_END="0.06220248162426451" LOG_CI_START="-0.16772605876675473" LOG_EFFECT_SIZE="-0.05276178857124513" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="364" O_E="-6.66" SE="0.13506116279031571" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="54.82" WEIGHT="5.276379491226888"/>
<IPD_DATA CI_END="1.2481431775239" CI_START="0.7611578256089859" EFFECT_SIZE="0.974696848795964" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="83" LOG_CI_END="0.09626440717488878" LOG_CI_START="-0.11852528319730952" LOG_EFFECT_SIZE="-0.01113043801121038" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88282" O_E="-1.61" SE="0.1261685273507441" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="62.82" WEIGHT="6.046372850034168"/>
<IPD_DATA CI_END="1.188372704901193" CI_START="0.7187967787097458" EFFECT_SIZE="0.9242285822184708" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="83" LOG_CI_END="0.0749526681678691" LOG_CI_START="-0.143393877850928" LOG_EFFECT_SIZE="-0.034220604841529494" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88283" O_E="-4.79" SE="0.12825784196427567" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="60.79" WEIGHT="5.8509870352368205"/>
<IPD_DATA CI_END="1.9313798497361756" CI_START="1.2426029621310652" EFFECT_SIZE="1.5491734319573207" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" LOG_CI_END="0.28586769605857143" LOG_CI_START="0.09433238455445257" LOG_EFFECT_SIZE="0.19010004030651198" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88284" O_E="34.58" SE="0.1125087900926024" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="79.0" WEIGHT="7.603684418221892"/>
<IPD_DATA CI_END="1.2032284459026727" CI_START="0.7397644396507601" EFFECT_SIZE="0.943454088472272" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="125" LOG_CI_END="0.08034809066157232" LOG_CI_START="-0.13090654897984424" LOG_EFFECT_SIZE="-0.02527922915913598" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="88285" O_E="-3.78" SE="0.1240920210526996" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="64.94" WEIGHT="6.250421090118097"/>
<IPD_DATA CI_END="1.4111895869133404" CI_START="0.8018057285579703" EFFECT_SIZE="1.0637198385235052" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="95" LOG_CI_END="0.1495853631656067" LOG_CI_START="-0.0959308452266442" LOG_EFFECT_SIZE="0.026827258969481224" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="365" O_E="2.97" SE="0.14421743613444024" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="48.08" WEIGHT="4.627660086431754"/>
<IPD_DATA CI_END="0.9776017720116648" CI_START="0.5698564347541257" EFFECT_SIZE="0.7463864015427149" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="115" LOG_CI_END="-0.009838019893879411" LOG_CI_START="-0.24423454335795655" LOG_EFFECT_SIZE="-0.12703628162591804" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="366" O_E="-15.43" SE="0.13768567816430285" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="52.75" WEIGHT="5.0771437096355045"/>
<IPD_DATA CI_END="1.091154611787768" CI_START="0.7291510882488825" EFFECT_SIZE="0.8919734147567617" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="145" LOG_CI_END="0.03788629255792961" LOG_CI_START="-0.1371824716902087" LOG_EFFECT_SIZE="-0.04964808956613951" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="371" O_E="-10.81" SE="0.10283625872371589" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="94.56" WEIGHT="9.101321501102053"/>
<IPD_DATA CI_END="1.1725782106316176" CI_START="0.43968483355502375" EFFECT_SIZE="0.7180284502523632" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="40" LOG_CI_END="0.06914181967107516" LOG_CI_START="-0.35685851463265333" LOG_EFFECT_SIZE="-0.1438583474807891" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="368" O_E="-5.29" SE="0.2502347051056742" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="15.97" WEIGHT="1.5370992425190333"/>
<IPD_DATA CI_END="1.242237609675948" CI_START="0.9216603130561425" EFFECT_SIZE="1.0700098617414928" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="342" LOG_CI_END="0.09420467369996081" LOG_CI_START="-0.03542911294603589" LOG_EFFECT_SIZE="0.0293877803769625" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="370" O_E="11.67" SE="0.07614752797345155" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="172.46" WEIGHT="16.599131832487945"/>
<IPD_DATA CI_END="1.3398711650835016" CI_START="0.5692494150059186" EFFECT_SIZE="0.8733389244199996" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.12706304091461088" LOG_CI_START="-0.24469740701906822" LOG_EFFECT_SIZE="-0.0588171830522287" MODIFIED="2014-09-30 15:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="376" O_E="-2.84" SE="0.21837392736013947" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="20.97" WEIGHT="2.0183450917735835"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-10-08 11:37:56 +1100" MODIFIED_BY="Melina L Willson" NO="3">
<NAME>Time to Treatment Failure</NAME>
<IPD_OUTCOME CHI2="44.22872432523079" CI_END="0.9849842644933583" CI_START="0.8182887645039697" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.8977758945572784" ESTIMABLE="YES" EVENTS_1="820" EVENTS_2="816" I2="90.95610361586179" I2_Q="91.06881801597942" ID="CMP-003.01" LOG_CI_END="-0.006570707470196195" LOG_CI_START="-0.0870934118538753" LOG_EFFECT_SIZE="-0.04683205966203577" MODIFIED="2014-10-07 17:39:18 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="5.750945941684904E-9" P_Q="8.194209579650558E-4" P_Z="0.022617608392884115" Q="11.196726276423114" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="868" TOTAL_2="856" WEIGHT="100.0" Z="2.2798327741715934">
<NAME>Subquestions A, B &amp; C</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="30.796733143917546" CI_END="1.2293944914736041" CI_START="0.9318441206229541" DF="1" EFFECT_SIZE="1.0703289348634486" ESTIMABLE="YES" EVENTS_1="320" EVENTS_2="326" I2="96.75290234413222" ID="CMP-003.01.01" LOG_CI_END="0.08969126285350891" LOG_CI_START="-0.03065673058080309" LOG_EFFECT_SIZE="0.0295172661363529" MODIFIED="2014-09-30 14:51:49 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.8653231232134146E-8" P_Z="0.3363385833254867" STUDIES="2" TAU2="0.0" TOTAL_1="357" TOTAL_2="356" WEIGHT="44.76710367354244" Z="0.961424896226667">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<IPD_DATA CI_END="0.9854279379723963" CI_START="0.7104536650544782" EFFECT_SIZE="0.8367203177762363" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="206" LOG_CI_END="-0.006375129157467225" LOG_CI_START="-0.14846424098400562" LOG_EFFECT_SIZE="-0.07741968507073642" MODIFIED="2014-09-30 14:51:49 +1000" MODIFIED_BY="[Empty name]" ORDER="88115" O_E="-25.59" SE="0.08346384763935573" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="143.55" WEIGHT="32.11553089623697"/>
<IPD_DATA CI_END="2.5951633466108595" CI_START="1.5409214791844283" EFFECT_SIZE="1.9997357182349915" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="120" LOG_CI_END="0.4141646987159188" LOG_CI_START="0.1877805089158562" LOG_EFFECT_SIZE="0.30097260381588753" MODIFIED="2014-09-30 14:51:49 +1000" MODIFIED_BY="[Empty name]" ORDER="437" O_E="39.19" SE="0.1329791937083694" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="56.55" WEIGHT="12.651572777305471"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.235264904890124" CI_END="0.8819814832160084" CI_START="0.6872453824368339" DF="2" EFFECT_SIZE="0.7785484581803446" ESTIMABLE="YES" EVENTS_1="500" EVENTS_2="490" I2="10.525146454696774" ID="CMP-003.01.02" LOG_CI_END="-0.05454053257966073" LOG_CI_START="-0.1628881694749485" LOG_EFFECT_SIZE="-0.10871435102730459" MODIFIED="2014-10-07 16:57:36 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.32705349746086265" P_Z="8.382404767301964E-5" STUDIES="3" TAU2="0.0" TOTAL_1="511" TOTAL_2="500" WEIGHT="55.23289632645756" Z="3.9331953833398106">
<NAME>Single agent taxane v Regimen C</NAME>
<IPD_DATA CI_END="1.0369840090873261" CI_START="0.6676349948682423" EFFECT_SIZE="0.8320617847164153" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="161" LOG_CI_END="0.01577205936041917" LOG_CI_START="-0.17546090734352024" LOG_EFFECT_SIZE="-0.07984442399155053" MODIFIED="2014-10-07 16:57:36 +1100" MODIFIED_BY="Melina L Willson" ORDER="88116" O_E="-14.57" SE="0.11233119126034609" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="79.25" WEIGHT="17.730099780750816"/>
<IPD_DATA CI_END="0.8443358356640933" CI_START="0.5656369266718339" EFFECT_SIZE="0.6910770775853676" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="184" LOG_CI_END="-0.07348477782272216" LOG_CI_START="-0.24746224608823453" LOG_EFFECT_SIZE="-0.16047351195547838" MODIFIED="2014-10-07 16:57:36 +1100" MODIFIED_BY="Melina L Willson" ORDER="88117" O_E="-35.38" SE="0.1021952260615192" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="95.75" WEIGHT="21.421540113651616"/>
<IPD_DATA CI_END="1.0685671100032954" CI_START="0.67298327898377" EFFECT_SIZE="0.848014031431219" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="145" LOG_CI_END="0.028801802671234045" LOG_CI_START="-0.17199572617021938" LOG_EFFECT_SIZE="-0.07159696174949269" MODIFIED="2014-09-30 14:51:49 +1000" MODIFIED_BY="[Empty name]" ORDER="438" O_E="-11.85" SE="0.11794946240526792" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="71.88" WEIGHT="16.081256432055124"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-04-17 13:53:01 +1000" MODIFIED_BY="Melina L Willson" NO="4">
<NAME>Overall Response Rate</NAME>
<DICH_OUTCOME CHI2="89.28835993858289" CI_END="1.2672322308247201" CI_START="1.1428633747004555" CI_STUDY="95" CI_TOTAL="95" DF="28" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2034422727532577" ESTIMABLE="YES" EVENTS_1="1740" EVENTS_2="1372" I2="68.64092921041463" I2_Q="52.30502931505152" ID="CMP-004.01" LOG_CI_END="0.10285621024550749" LOG_CI_START="0.05799431511949761" LOG_EFFECT_SIZE="0.08042526268250254" METHOD="MH" MODIFIED="2014-10-29 10:03:05 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="2.5600195852071295E-8" P_Q="0.12286652194734582" P_Z="2.1045935591674097E-12" Q="4.193314245250511" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3613" TOTAL_2="3386" WEIGHT="100.0" Z="7.02737224373241">
<NAME>Overall effect: assessable patients</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours taxane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.002113740700571" CI_END="1.922725773653832" CI_START="1.2034045384350431" DF="1" EFFECT_SIZE="1.5211235722915646" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="61" I2="75.0132039019723" ID="CMP-004.01.01" LOG_CI_END="0.28391734795069196" LOG_CI_START="0.08041164502631927" LOG_EFFECT_SIZE="0.1821644964885056" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0454433192394037" P_Z="4.5004266920855375E-4" STUDIES="2" TAU2="0.0" TOTAL_1="317" TOTAL_2="198" WEIGHT="5.39203841078851" Z="3.5088535333285145">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="1.6967810964648395" CI_START="0.9696932079989449" EFFECT_SIZE="1.2827147401908803" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="41" LOG_CI_END="0.2296258171381967" LOG_CI_START="-0.01336564629859075" LOG_EFFECT_SIZE="0.10813008541980297" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88049" O_E="0.0" SE="0.14273438844991188" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="0.020373105646170335" WEIGHT="3.950880785717422"/>
<DICH_DATA CI_END="3.3649857904453544" CI_START="1.4054665835446887" EFFECT_SIZE="2.174712643678161" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.5269832346389846" LOG_CI_START="0.14782052425532638" LOG_EFFECT_SIZE="0.33740187944715544" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22272205296504727" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="87" TOTAL_2="86" VAR="0.04960511287696532" WEIGHT="1.4411576250710887"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.341517384181408" CI_END="1.2646826536743934" CI_START="1.1240080592027173" DF="13" EFFECT_SIZE="1.1922724080779095" ESTIMABLE="YES" EVENTS_1="1097" EVENTS_2="929" I2="48.700782976339006" ID="CMP-004.01.02" LOG_CI_END="0.1019815618372145" LOG_CI_START="0.05076942516072982" LOG_EFFECT_SIZE="0.07637549349897214" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.020809605919556717" P_Z="5.035173772805357E-9" STUDIES="14" TAU2="0.0" TOTAL_1="1863" TOTAL_2="1877" WEIGHT="66.21483302207476" Z="5.846005508619748">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.536157456099993" CI_START="1.0865433434376244" EFFECT_SIZE="1.2919371727748692" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="100" LOG_CI_END="0.18643573315034767" LOG_CI_START="0.036047055498080745" LOG_EFFECT_SIZE="0.1112413943242142" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88050" O_E="0.0" SE="0.08833905368890205" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="191" TOTAL_2="199" VAR="0.007803788406650718" WEIGHT="7.017414000180369"/>
<DICH_DATA CI_END="1.408793430863048" CI_START="0.9005511750714384" EFFECT_SIZE="1.1263616557734204" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" LOG_CI_END="0.14884731786937053" LOG_CI_START="-0.04549160275600805" LOG_EFFECT_SIZE="0.051677857556681236" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.11415564396851927" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.013031511049867328" WEIGHT="5.889758287906328"/>
<DICH_DATA CI_END="1.4830399658986637" CI_START="0.837879151315788" EFFECT_SIZE="1.1147234042553191" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" LOG_CI_END="0.17115285482836756" LOG_CI_START="-0.07681861585831211" LOG_EFFECT_SIZE="0.04716711948502774" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.14565966935993205" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.021216739278044724" WEIGHT="3.567009013202873"/>
<DICH_DATA CI_END="2.6864607098855635" CI_START="1.256766049918451" EFFECT_SIZE="1.837458193979933" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" LOG_CI_END="0.4291804932930726" LOG_CI_START="0.0992544402271543" LOG_EFFECT_SIZE="0.2642174667601135" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.19380019673122237" STUDY_ID="STD-Bonneterre" TOTAL_1="65" TOTAL_2="67" VAR="0.03755851625306049" WEIGHT="1.622839613202112"/>
<DICH_DATA CI_END="2.1064383759537617" CI_START="1.1776394829859727" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" LOG_CI_END="0.32354875832414987" LOG_CI_START="0.07101235792708874" LOG_EFFECT_SIZE="0.19728055812561932" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14834113166857663" STUDY_ID="STD-Bontenbal" TOTAL_1="106" TOTAL_2="106" VAR="0.02200509134471399" WEIGHT="2.8657502199689464"/>
<DICH_DATA CI_END="1.5183458459349983" CI_START="0.9759506073659042" EFFECT_SIZE="1.217304625199362" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.1813707056001994" LOG_CI_START="-0.010572161320233463" LOG_EFFECT_SIZE="0.08539927213998297" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.11274819016157708" STUDY_ID="STD-CECOG-BM1" TOTAL_1="114" TOTAL_2="129" VAR="0.012712154384711148" WEIGHT="4.4366058961000725"/>
<DICH_DATA CI_END="1.3493656075155886" CI_START="0.9082111117569299" EFFECT_SIZE="1.107027027027027" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="74" LOG_CI_END="0.13012963670963695" LOG_CI_START="-0.041813188908078294" LOG_EFFECT_SIZE="0.04415822390077935" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88052" O_E="0.0" SE="0.1010000668985596" STUDY_ID="STD-EORTC-10961" TOTAL_1="125" TOTAL_2="128" VAR="0.010201013513513515" WEIGHT="5.238772635318727"/>
<DICH_DATA CI_END="1.2331166566609042" CI_START="0.8117069561690625" EFFECT_SIZE="1.0004645760743323" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.0910041641444564" LOG_CI_START="-0.09060073219860322" LOG_EFFECT_SIZE="2.0171597292656092E-4" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.10667561507064832" STUDY_ID="STD-HERNATA" TOTAL_1="123" TOTAL_2="118" VAR="0.011379686850701133" WEIGHT="5.119109832766106"/>
<DICH_DATA CI_END="1.5229728419683077" CI_START="1.0116713625725295" EFFECT_SIZE="1.2412687099073414" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.18269215895753657" LOG_CI_START="0.005039456574253741" LOG_EFFECT_SIZE="0.09386580776589516" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.10435407677499979" STUDY_ID="STD-Jassem" TOTAL_1="122" TOTAL_2="129" VAR="0.01088977333956255" WEIGHT="4.805554850935974"/>
<DICH_DATA CI_END="1.2730541423427089" CI_START="0.44915400232278513" EFFECT_SIZE="0.7561728395061729" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.10484687436901707" LOG_CI_START="-0.3476047260531764" LOG_EFFECT_SIZE="-0.12137892584207965" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.2657723097595395" STUDY_ID="STD-Lyman" TOTAL_1="36" TOTAL_2="35" VAR="0.07063492063492063" WEIGHT="1.3077508046055475"/>
<DICH_DATA CI_END="1.4974079276713104" CI_START="1.042543539216611" EFFECT_SIZE="1.2494450610432852" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" LOG_CI_END="0.17534012806729096" LOG_CI_START="0.01809420124452399" LOG_EFFECT_SIZE="0.09671716465590746" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.09236703579558464" STUDY_ID="STD-Nabholtz" TOTAL_1="238" TOTAL_2="237" VAR="0.008531669301662815" WEIGHT="7.610225952565957"/>
<DICH_DATA CI_END="1.9101942914513945" CI_START="0.8555830215978812" EFFECT_SIZE="1.2784090909090908" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.2810775428570588" LOG_CI_START="-0.06773784226263357" LOG_EFFECT_SIZE="0.10666985029721264" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.20489588388331093" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.04198232323232323" WEIGHT="1.3100572434143756"/>
<DICH_DATA CI_END="1.032510424235336" CI_START="0.5874860608585397" EFFECT_SIZE="0.7788359788359789" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.013894444991907054" LOG_CI_START="-0.23100243333543524" LOG_EFFECT_SIZE="-0.10855399417176406" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.14385363858857964" STUDY_ID="STD-TRAVIOTA" TOTAL_1="35" TOTAL_2="32" VAR="0.020693869335173684" WEIGHT="2.0209954909482497"/>
<DICH_DATA CI_END="1.3315994703099245" CI_START="1.0358916579633837" EFFECT_SIZE="1.1744755353103407" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="186" LOG_CI_END="0.12437361372890535" LOG_CI_START="0.015314335709277042" LOG_EFFECT_SIZE="0.06984397471909119" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06406195976086253" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="347" TOTAL_2="343" VAR="0.00410393468840237" WEIGHT="13.402989180959112"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="55.69458783056224" CI_END="1.3057310667796398" CI_START="1.0468760327101323" DF="12" EFFECT_SIZE="1.1691614768613607" ESTIMABLE="YES" EVENTS_1="491" EVENTS_2="382" I2="78.45392080733734" ID="CMP-004.01.03" LOG_CI_END="0.11585373724482219" LOG_CI_START="0.019895257134936298" LOG_EFFECT_SIZE="0.06787449718987924" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.3582915614485103E-7" P_Z="0.005559501532349532" STUDIES="13" TAU2="0.0" TOTAL_1="1433" TOTAL_2="1311" WEIGHT="28.39312856713674" Z="2.772690226201763">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="1.8035920109003933" CI_START="1.0720844754249497" EFFECT_SIZE="1.3905405405405404" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="55" LOG_CI_END="0.25613830291000483" LOG_CI_START="0.030229007152908556" LOG_EFFECT_SIZE="0.1431836550314567" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88055" O_E="0.0" SE="0.13270023859676755" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="148" TOTAL_2="147" VAR="0.017609353323639037" WEIGHT="3.953763862804615"/>
<DICH_DATA CI_END="4.050499724291161" CI_START="1.6758482530661707" EFFECT_SIZE="2.6053834433722702" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="22" LOG_CI_END="0.6075086069464841" LOG_CI_START="0.22423469100091198" LOG_EFFECT_SIZE="0.41587164897369805" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88056" O_E="0.0" SE="0.22513699546291122" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="179" TOTAL_2="171" VAR="0.0506866667260669" WEIGHT="1.612189195176816"/>
<DICH_DATA CI_END="1.2039759718054135" CI_START="0.54751038047308" EFFECT_SIZE="0.8119047619047619" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.08061781963239625" LOG_CI_START="-0.2616076424432017" LOG_EFFECT_SIZE="-0.09049491140540274" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88057" O_E="0.0" SE="0.20102493046656472" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="0.04041102266908718" WEIGHT="2.655033292030054"/>
<DICH_DATA CI_END="13.884687519807166" CI_START="0.6481960783893099" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1425361102331597" LOG_CI_START="-0.18829360079383486" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88058" O_E="0.0" SE="0.7817359599705715" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="0.611111111111111" WEIGHT="0.14328751099844733"/>
<DICH_DATA CI_END="1.2598770545645035" CI_START="0.6871608467301118" EFFECT_SIZE="0.9304505272126957" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="41" LOG_CI_END="0.10032816644344705" LOG_CI_START="-0.16294159384136997" LOG_EFFECT_SIZE="-0.03130671369896147" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88059" O_E="0.0" SE="0.15464596039763273" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="0.02391537306730619" WEIGHT="3.945238829221179"/>
<DICH_DATA CI_END="0.8572154767817504" CI_START="0.4528417756009675" EFFECT_SIZE="0.6230433199854387" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="67" LOG_CI_END="-0.06690999649601129" LOG_CI_START="-0.34405351539732076" LOG_EFFECT_SIZE="-0.205481755946666" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88060" O_E="0.0" SE="0.16279547488517315" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="0.02650236664308904" WEIGHT="4.8148109200334535"/>
<DICH_DATA CI_END="2.0841246357233123" CI_START="0.9004743400491385" EFFECT_SIZE="1.3699272812573304" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.3189236872706438" LOG_CI_START="-0.045528658340109295" LOG_EFFECT_SIZE="0.13669751446526726" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.21408111187996276" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.04583072246376113" WEIGHT="2.0847599296463515"/>
<DICH_DATA CI_END="3.394214123737704" CI_START="0.9058797929897697" EFFECT_SIZE="1.7534965034965035" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.530739236279962" LOG_CI_START="-0.04292942782517406" LOG_EFFECT_SIZE="0.24390490422739394" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="0.3369758130010424" STUDY_ID="STD-Meier" TOTAL_1="52" TOTAL_2="59" VAR="0.11355269854771351" WEIGHT="0.738382489109116"/>
<DICH_DATA CI_END="2.9698931881319073" CI_START="1.4218166028685626" EFFECT_SIZE="2.0549071618037136" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="29" LOG_CI_END="0.47274083024681823" LOG_CI_START="0.15284358127504383" LOG_EFFECT_SIZE="0.31279220576093103" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88061" O_E="0.0" SE="0.18790922756294137" STUDY_ID="STD-Sjostrom" TOTAL_1="130" TOTAL_2="127" VAR="0.03530987780330129" WEIGHT="2.101921853946095"/>
<DICH_DATA CI_END="1.840869576489006" CI_START="0.28449535113941016" EFFECT_SIZE="0.7236842105263158" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2650230203249784" LOG_CI_START="-0.5459248258980733" LOG_EFFECT_SIZE="-0.14045090278654748" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="0.4763547791280005" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="0.22691387559808612" WEIGHT="0.5312122358966829"/>
<DICH_DATA CI_END="0.9807975833277779" CI_START="0.3869531621904246" EFFECT_SIZE="0.6160541586073501" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="33" LOG_CI_END="-0.008420612920178601" LOG_CI_START="-0.4123415999249679" LOG_EFFECT_SIZE="-0.21038110642257324" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.23726518720774548" STUDY_ID="STD-TOG" TOTAL_1="94" TOTAL_2="91" VAR="0.0562947690607265" WEIGHT="2.4025830222550466"/>
<DICH_DATA CI_END="1.578252580752933" CI_START="0.7754949386113446" EFFECT_SIZE="1.106312292358804" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="35" LOG_CI_END="0.19817650815674395" LOG_CI_START="-0.11042103233179087" LOG_EFFECT_SIZE="0.043877737912476525" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="0.18127172286542734" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="0.032859437510600296" WEIGHT="2.4505420915075367"/>
<DICH_DATA CI_END="2.2473072843259305" CI_START="0.6916693899098874" EFFECT_SIZE="1.2467532467532467" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.3516624594965548" LOG_CI_START="-0.1601014437623817" LOG_EFFECT_SIZE="0.09578050786708653" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.3006126500464765" STUDY_ID="STD-Yardley" TOTAL_1="44" TOTAL_2="48" VAR="0.09036796536796536" WEIGHT="0.9594033345113431"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="77.40130788333634" CI_END="1.2687251518540736" CI_START="1.1412298081256262" CI_STUDY="95" CI_TOTAL="95" DF="28" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2032900571410787" ESTIMABLE="YES" EVENTS_1="1743" EVENTS_2="1372" I2="63.82490068229442" I2_Q="57.406322657052186" ID="CMP-004.02" LOG_CI_END="0.10336754962707237" LOG_CI_START="0.057373106601766866" LOG_EFFECT_SIZE="0.08037032811441962" METHOD="MH" MODIFIED="2014-10-29 10:03:05 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="1.6169893030104632E-6" P_Q="0.09558262751492475" P_Z="7.403020860780403E-12" Q="4.695532587845782" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3834" TOTAL_2="3582" WEIGHT="100.0" Z="6.849651313018946">
<NAME>Overall effect: randomised patients</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours taxane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2622841071187647" CI_END="1.9686081459729348" CI_START="1.22119863346791" DF="1" EFFECT_SIZE="1.5505036529128022" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="61" I2="69.34663054582344" ID="CMP-004.02.01" LOG_CI_END="0.2941592778558316" LOG_CI_START="0.08678630964752322" LOG_EFFECT_SIZE="0.19047279375167742" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07089037691651534" P_Z="3.1764553814720255E-4" STUDIES="2" TAU2="0.0" TOTAL_1="333" TOTAL_2="210" WEIGHT="5.350044389757203" Z="3.6004674959661065">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="1.7690352789198354" CI_START="0.9967216088575962" EFFECT_SIZE="1.3278688524590163" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="41" LOG_CI_END="0.24773649389753397" LOG_CI_START="-0.001426126161768602" LOG_EFFECT_SIZE="0.12315518386788268" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88033" O_E="0.0" SE="0.14635935639769523" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="244" TOTAL_2="123" VAR="0.02142106120514757" WEIGHT="3.9022307529122497"/>
<DICH_DATA CI_END="3.3333490373857972" CI_START="1.3874682771237532" EFFECT_SIZE="2.150561797752809" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.5228807913305165" LOG_CI_START="0.14222306226130746" LOG_EFFECT_SIZE="0.33255192679591195" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22360023434140164" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="89" TOTAL_2="87" VAR="0.04999706479752973" WEIGHT="1.447813636844953"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.761036207951054" CI_END="1.2637745237436198" CI_START="1.118852968868007" DF="13" EFFECT_SIZE="1.1891080177470423" ESTIMABLE="YES" EVENTS_1="1100" EVENTS_2="929" I2="22.439162837479607" ID="CMP-004.02.02" LOG_CI_END="0.10166959623363032" LOG_CI_START="0.048773018606307984" LOG_EFFECT_SIZE="0.07522130741996914" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21045981166001093" P_Z="2.4850786675075786E-8" STUDIES="14" TAU2="0.0" TOTAL_1="1974" TOTAL_2="1979" WEIGHT="66.30732743240752" Z="5.57431350103086">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.5294510592071564" CI_START="1.0644401082390673" EFFECT_SIZE="1.2759345794392523" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="100" LOG_CI_END="0.1845355845855995" LOG_CI_START="0.02712123045914323" LOG_EFFECT_SIZE="0.10582840752237133" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88034" O_E="0.0" SE="0.09246597082750033" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="0.00854995576107214" WEIGHT="7.141045653352232"/>
<DICH_DATA CI_END="1.408793430863048" CI_START="0.9005511750714384" EFFECT_SIZE="1.1263616557734204" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" LOG_CI_END="0.14884731786937053" LOG_CI_START="-0.04549160275600805" LOG_EFFECT_SIZE="0.051677857556681236" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.11415564396851927" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.013031511049867328" WEIGHT="5.884295329811303"/>
<DICH_DATA CI_END="1.5140818076277711" CI_START="0.8519764269979575" EFFECT_SIZE="1.1357649442755826" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" LOG_CI_END="0.18014934124164653" LOG_CI_START="-0.06957242139097367" LOG_EFFECT_SIZE="0.05528845992533643" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.1466877995130624" STUDY_ID="STD-Blohmer" TOTAL_1="126" TOTAL_2="114" VAR="0.021517310525984393" WEIGHT="3.532339922522619"/>
<DICH_DATA CI_END="2.7094313789547018" CI_START="1.2408028947796468" EFFECT_SIZE="1.8335403726708075" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" LOG_CI_END="0.4328781562272794" LOG_CI_START="0.0937027980110292" LOG_EFFECT_SIZE="0.26329047711915426" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.1992332843613262" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="0.03969390159740106" WEIGHT="1.6230909642996751"/>
<DICH_DATA CI_END="2.0725262487886322" CI_START="1.153388550942963" EFFECT_SIZE="1.5461009174311926" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" LOG_CI_END="0.3165000396478214" LOG_CI_START="0.06197563609258921" LOG_EFFECT_SIZE="0.18923783787020532" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14950889456446062" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="0.022352909553887003" WEIGHT="2.889602248151642"/>
<DICH_DATA CI_END="1.4739742050057214" CI_START="0.9306001318197358" EFFECT_SIZE="1.1711876832844574" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.168489883304783" LOG_CI_START="-0.03123689028482772" LOG_EFFECT_SIZE="0.06862649650997764" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.11732049547001158" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="0.01376409865732901" WEIGHT="4.523464486341766"/>
<DICH_DATA CI_END="1.3238943408484354" CI_START="0.8700539245050954" EFFECT_SIZE="1.073247160203682" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="74" LOG_CI_END="0.12185332572486562" LOG_CI_START="-0.06045382969259034" LOG_EFFECT_SIZE="0.03069974801613765" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88036" O_E="0.0" SE="0.10708812552718723" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="0.01146786662892661" WEIGHT="5.315981252839787"/>
<DICH_DATA CI_END="1.2955672718134004" CI_START="0.8161233848420456" EFFECT_SIZE="1.0282717282717282" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.1124599684749316" LOG_CI_START="-0.08824417788189734" LOG_EFFECT_SIZE="0.012107895296517129" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.11789460907154876" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="0.013899138848133308" WEIGHT="5.045695823801164"/>
<DICH_DATA CI_END="1.4423470887170105" CI_START="0.9412299959528678" EFFECT_SIZE="1.1651524983776769" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.15906978228082388" LOG_CI_START="-0.026304240793478612" LOG_EFFECT_SIZE="0.0663827707436726" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.10888961877005862" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="0.011856949075888704" WEIGHT="4.957331439597787"/>
<DICH_DATA CI_END="1.3985025946633711" CI_START="0.4519999851059977" EFFECT_SIZE="0.7950617283950617" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.1456632764615247" LOG_CI_START="-0.3448615794992" LOG_EFFECT_SIZE="-0.09959915151883765" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.2881367285285271" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="0.08302277432712214" WEIGHT="1.2742333131782722"/>
<DICH_DATA CI_END="1.506215629448624" CI_START="1.0452120346922" EFFECT_SIZE="1.2547169811320755" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" LOG_CI_END="0.177887149803683" LOG_CI_START="0.019204401600948117" LOG_EFFECT_SIZE="0.09854577570231557" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.09321103178655833" STUDY_ID="STD-Nabholtz" TOTAL_1="242" TOTAL_2="242" VAR="0.008688296446714788" WEIGHT="7.587194159825686"/>
<DICH_DATA CI_END="1.9571470055864042" CI_START="0.8725832834508476" EFFECT_SIZE="1.3068181818181819" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.29162344769029747" LOG_CI_START="-0.05919311128341124" LOG_EFFECT_SIZE="0.11621516820344308" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.20607138331113045" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="0.04246541501976285" WEIGHT="1.2920620920457868"/>
<DICH_DATA CI_END="1.233841622370692" CI_START="0.6178975281687252" EFFECT_SIZE="0.8731481481481481" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.09125941663013439" LOG_CI_START="-0.20908354212937713" LOG_EFFECT_SIZE="-0.058912062749621345" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.17642294069696046" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="0.031125054004163225" WEIGHT="1.9087280905221853"/>
<DICH_DATA CI_END="1.3458340049478892" CI_START="1.0430450773554127" EFFECT_SIZE="1.1848061165433001" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="186" LOG_CI_END="0.1289914973464983" LOG_CI_START="0.018303077768507325" LOG_EFFECT_SIZE="0.07364728755750284" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06501892557662553" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="0.004227460683138769" WEIGHT="13.33226265611762"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="52.59602398448587" CI_END="1.3098354962310585" CI_START="1.0467509999295075" DF="12" EFFECT_SIZE="1.170927673011029" ESTIMABLE="YES" EVENTS_1="491" EVENTS_2="382" I2="77.18458717803533" ID="CMP-004.02.03" LOG_CI_END="0.11721675552963784" LOG_CI_START="0.01984338443182311" LOG_EFFECT_SIZE="0.06853006998073047" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="4.860039740650635E-7" P_Z="0.005801533758069026" STUDIES="13" TAU2="0.0" TOTAL_1="1527" TOTAL_2="1393" WEIGHT="28.342628177835277" Z="2.758792624840234">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="1.8784421317045794" CI_START="1.0959087317464697" EFFECT_SIZE="1.434782608695652" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="55" LOG_CI_END="0.27379782049682827" LOG_CI_START="0.03977438722376088" LOG_EFFECT_SIZE="0.15678610386029457" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88039" O_E="0.0" SE="0.13746652313927746" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="0.018897044984001504" WEIGHT="3.888447985024682"/>
<DICH_DATA CI_END="3.968433256696449" CI_START="1.6246865723520847" EFFECT_SIZE="2.5391849529780566" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="22" LOG_CI_END="0.5986190804984799" LOG_CI_START="0.21076959114445737" LOG_EFFECT_SIZE="0.40469433582146863" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88040" O_E="0.0" SE="0.22782470993248866" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="0.05190409845582259" WEIGHT="1.6309399844908314"/>
<DICH_DATA CI_END="1.2200882556352586" CI_START="0.5522807775133903" EFFECT_SIZE="0.8208722741433022" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.08639124669858905" LOG_CI_START="-0.2578400724112023" LOG_EFFECT_SIZE="-0.08572441285630665" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88041" O_E="0.0" SE="0.20220318081760236" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="0.04088612633275599" WEIGHT="2.638428446659614"/>
<DICH_DATA CI_END="13.650872303713893" CI_START="0.6275298292405901" EFFECT_SIZE="2.926829268292683" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1351604040936405" LOG_CI_START="-0.20236562543786202" LOG_EFFECT_SIZE="0.4663973893278893" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88042" O_E="0.0" SE="0.7856694106074307" STUDY_ID="STD-Dieras" TOTAL_1="41" TOTAL_2="40" VAR="0.6172764227642276" WEIGHT="0.14492194761372149"/>
<DICH_DATA CI_END="1.3177967312308463" CI_START="0.7095002566715729" EFFECT_SIZE="0.9669421487603306" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="41" LOG_CI_END="0.11984842595384064" LOG_CI_START="-0.14904744309441753" LOG_EFFECT_SIZE="-0.014599508570288439" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88043" O_E="0.0" SE="0.15795076453496565" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="242" TOTAL_2="123" VAR="0.02494844401718016" WEIGHT="3.8914520782522852"/>
<DICH_DATA CI_END="0.858040992185618" CI_START="0.45247298153859394" EFFECT_SIZE="0.6230893724150333" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="67" LOG_CI_END="-0.0664919636026299" LOG_CI_START="-0.3444073486555197" LOG_EFFECT_SIZE="-0.2054496561290748" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88044" O_E="0.0" SE="0.16324887288341056" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="0.02665019449770394" WEIGHT="4.81016778461958"/>
<DICH_DATA CI_END="2.0841246357233123" CI_START="0.9004743400491385" EFFECT_SIZE="1.3699272812573304" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.3189236872706438" LOG_CI_START="-0.045528658340109295" LOG_EFFECT_SIZE="0.13669751446526726" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.21408111187996276" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.04583072246376113" WEIGHT="2.082826241440975"/>
<DICH_DATA CI_END="3.223895804183195" CI_START="0.8465621892230513" EFFECT_SIZE="1.652037617554859" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.50838099702898" LOG_CI_START="-0.07234113271824896" LOG_EFFECT_SIZE="0.2180199321553655" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="0.3411190536344258" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="0.11636220875244625" WEIGHT="0.7611053260957213"/>
<DICH_DATA CI_END="2.9761362210660627" CI_START="1.4046508758725644" EFFECT_SIZE="2.044610561851941" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="29" LOG_CI_END="0.47365280547040645" LOG_CI_START="0.14756839433128183" LOG_EFFECT_SIZE="0.31061059990084416" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88045" O_E="0.0" SE="0.19154359724698955" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="0.03668894964631694" WEIGHT="2.1051849445200803"/>
<DICH_DATA CI_END="1.7582921656073456" CI_START="0.26881553546405984" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24509104102701695" LOG_CI_START="-0.5705456360224165" LOG_EFFECT_SIZE="-0.16272729749769974" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="0.479109021565504" STUDY_ID="STD-Talbot" TOTAL_1="20" TOTAL_2="22" VAR="0.22954545454545455" WEIGHT="0.5453508830063386"/>
<DICH_DATA CI_END="1.0102240935220186" CI_START="0.3929617145880666" EFFECT_SIZE="0.6300630063006301" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="33" LOG_CI_END="0.0044177220845504385" LOG_CI_START="-0.405649759937772" LOG_EFFECT_SIZE="-0.2006160189266108" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.24087566880668546" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="0.05802108782306802" WEIGHT="2.3738025095934487"/>
<DICH_DATA CI_END="1.578252580752933" CI_START="0.7754949386113446" EFFECT_SIZE="1.106312292358804" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="35" LOG_CI_END="0.19817650815674395" LOG_CI_START="-0.11042103233179087" LOG_EFFECT_SIZE="0.043877737912476525" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="0.18127172286542734" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="0.032859437510600296" WEIGHT="2.4482691274737687"/>
<DICH_DATA CI_END="2.0086252913417075" CI_START="0.6011990540851" EFFECT_SIZE="1.098901098901099" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.30289892675289676" LOG_CI_START="-0.22098171139508388" LOG_EFFECT_SIZE="0.04095860767890644" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.307730080099106" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="0.09469780219780219" WEIGHT="1.0217309190442285"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="54.31918806194155" CI_END="1.2275191176566587" CI_START="1.1003668130582875" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.162205360280178" ESTIMABLE="YES" EVENTS_1="1456" EVENTS_2="1177" I2="63.18059839702779" I2_Q="87.15934265005382" ID="CMP-004.03" LOG_CI_END="0.08902826464685085" LOG_CI_START="0.04153748364149124" LOG_EFFECT_SIZE="0.06528287414417103" METHOD="MH" MODIFIED="2014-10-29 10:03:03 +1100" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="5.186837165660485E-5" P_Q="4.1478073665557336E-4" P_Z="7.104740714572807E-8" Q="15.575526590999509" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2869" TOTAL_2="2643" WEIGHT="100.0" Z="5.388501912208867">
<NAME>First-line trials only: assessable patients</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours taxane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.002113740700571" CI_END="1.922725773653832" CI_START="1.2034045384350431" DF="1" EFFECT_SIZE="1.5211235722915646" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="61" I2="75.0132039019723" ID="CMP-004.03.01" LOG_CI_END="0.28391734795069196" LOG_CI_START="0.08041164502631927" LOG_EFFECT_SIZE="0.1821644964885056" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0454433192394037" P_Z="4.5004266920855375E-4" STUDIES="2" TAU2="0.0" TOTAL_1="317" TOTAL_2="198" WEIGHT="6.264995508666546" Z="3.5088535333285145">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="1.6967810964648395" CI_START="0.9696932079989449" EFFECT_SIZE="1.2827147401908803" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="41" LOG_CI_END="0.2296258171381967" LOG_CI_START="-0.01336564629859075" LOG_EFFECT_SIZE="0.10813008541980297" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88080" O_E="0.0" SE="0.14273438844991188" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="0.020373105646170335" WEIGHT="4.590518184787362"/>
<DICH_DATA CI_END="3.3649857904453544" CI_START="1.4054665835446887" EFFECT_SIZE="2.174712643678161" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.5269832346389846" LOG_CI_START="0.14782052425532638" LOG_EFFECT_SIZE="0.33740187944715544" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22272205296504727" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="87" TOTAL_2="86" VAR="0.04960511287696532" WEIGHT="1.6744773238791848"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.341517384181408" CI_END="1.2646826536743934" CI_START="1.1240080592027173" DF="13" EFFECT_SIZE="1.1922724080779095" ESTIMABLE="YES" EVENTS_1="1097" EVENTS_2="929" I2="48.700782976339006" ID="CMP-004.03.02" LOG_CI_END="0.1019815618372145" LOG_CI_START="0.05076942516072982" LOG_EFFECT_SIZE="0.07637549349897214" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.020809605919556717" P_Z="5.035173772805357E-9" STUDIES="14" TAU2="0.0" TOTAL_1="1863" TOTAL_2="1877" WEIGHT="76.93484353902066" Z="5.846005508619748">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.536157456099993" CI_START="1.0865433434376244" EFFECT_SIZE="1.2919371727748692" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="100" LOG_CI_END="0.18643573315034767" LOG_CI_START="0.036047055498080745" LOG_EFFECT_SIZE="0.1112413943242142" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88081" O_E="0.0" SE="0.08833905368890205" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="191" TOTAL_2="199" VAR="0.007803788406650718" WEIGHT="8.153515209687578"/>
<DICH_DATA CI_END="1.408793430863048" CI_START="0.9005511750714384" EFFECT_SIZE="1.1263616557734204" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" LOG_CI_END="0.14884731786937053" LOG_CI_START="-0.04549160275600805" LOG_EFFECT_SIZE="0.051677857556681236" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.11415564396851927" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.013031511049867328" WEIGHT="6.843294948907587"/>
<DICH_DATA CI_END="1.4830399658986637" CI_START="0.837879151315788" EFFECT_SIZE="1.1147234042553191" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" LOG_CI_END="0.17115285482836756" LOG_CI_START="-0.07681861585831211" LOG_EFFECT_SIZE="0.04716711948502774" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.14565966935993205" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.021216739278044724" WEIGHT="4.144498563358919"/>
<DICH_DATA CI_END="2.6864607098855635" CI_START="1.256766049918451" EFFECT_SIZE="1.837458193979933" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" LOG_CI_END="0.4291804932930726" LOG_CI_START="0.0992544402271543" LOG_EFFECT_SIZE="0.2642174667601135" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.19380019673122237" STUDY_ID="STD-Bonneterre" TOTAL_1="65" TOTAL_2="67" VAR="0.03755851625306049" WEIGHT="1.8855731568333898"/>
<DICH_DATA CI_END="2.1064383759537617" CI_START="1.1776394829859727" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" LOG_CI_END="0.32354875832414987" LOG_CI_START="0.07101235792708874" LOG_EFFECT_SIZE="0.19728055812561932" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14834113166857663" STUDY_ID="STD-Bontenbal" TOTAL_1="106" TOTAL_2="106" VAR="0.02200509134471399" WEIGHT="3.329707781966655"/>
<DICH_DATA CI_END="1.5183458459349983" CI_START="0.9759506073659042" EFFECT_SIZE="1.217304625199362" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.1813707056001994" LOG_CI_START="-0.010572161320233463" LOG_EFFECT_SIZE="0.08539927213998297" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.11274819016157708" STUDY_ID="STD-CECOG-BM1" TOTAL_1="114" TOTAL_2="129" VAR="0.012712154384711148" WEIGHT="5.154880936526155"/>
<DICH_DATA CI_END="1.3493656075155886" CI_START="0.9082111117569299" EFFECT_SIZE="1.107027027027027" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="74" LOG_CI_END="0.13012963670963695" LOG_CI_START="-0.041813188908078294" LOG_EFFECT_SIZE="0.04415822390077935" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88083" O_E="0.0" SE="0.1010000668985596" STUDY_ID="STD-EORTC-10961" TOTAL_1="125" TOTAL_2="128" VAR="0.010201013513513515" WEIGHT="6.086916399840229"/>
<DICH_DATA CI_END="1.2331166566609042" CI_START="0.8117069561690625" EFFECT_SIZE="1.0004645760743323" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.0910041641444564" LOG_CI_START="-0.09060073219860322" LOG_EFFECT_SIZE="2.0171597292656092E-4" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.10667561507064832" STUDY_ID="STD-HERNATA" TOTAL_1="123" TOTAL_2="118" VAR="0.011379686850701133" WEIGHT="5.947880498492303"/>
<DICH_DATA CI_END="1.5229728419683077" CI_START="1.0116713625725295" EFFECT_SIZE="1.2412687099073414" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.18269215895753657" LOG_CI_START="0.005039456574253741" LOG_EFFECT_SIZE="0.09386580776589516" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.10435407677499979" STUDY_ID="STD-Jassem" TOTAL_1="122" TOTAL_2="129" VAR="0.01088977333956255" WEIGHT="5.583561774620577"/>
<DICH_DATA CI_END="1.2730541423427089" CI_START="0.44915400232278513" EFFECT_SIZE="0.7561728395061729" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.10484687436901707" LOG_CI_START="-0.3476047260531764" LOG_EFFECT_SIZE="-0.12137892584207965" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.2657723097595395" STUDY_ID="STD-Lyman" TOTAL_1="36" TOTAL_2="35" VAR="0.07063492063492063" WEIGHT="1.5194722836016847"/>
<DICH_DATA CI_END="1.4974079276713104" CI_START="1.042543539216611" EFFECT_SIZE="1.2494450610432852" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" LOG_CI_END="0.17534012806729096" LOG_CI_START="0.01809420124452399" LOG_EFFECT_SIZE="0.09671716465590746" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.09236703579558464" STUDY_ID="STD-Nabholtz" TOTAL_1="238" TOTAL_2="237" VAR="0.008531669301662815" WEIGHT="8.842301886679449"/>
<DICH_DATA CI_END="1.9101942914513945" CI_START="0.8555830215978812" EFFECT_SIZE="1.2784090909090908" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.2810775428570588" LOG_CI_START="-0.06773784226263357" LOG_EFFECT_SIZE="0.10666985029721264" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.20489588388331093" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.04198232323232323" WEIGHT="1.522152128899042"/>
<DICH_DATA CI_END="1.032510424235336" CI_START="0.5874860608585397" EFFECT_SIZE="0.7788359788359789" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.013894444991907054" LOG_CI_START="-0.23100243333543524" LOG_EFFECT_SIZE="-0.10855399417176406" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.14385363858857964" STUDY_ID="STD-TRAVIOTA" TOTAL_1="35" TOTAL_2="32" VAR="0.020693869335173684" WEIGHT="2.3481894432526036"/>
<DICH_DATA CI_END="1.3315994703099245" CI_START="1.0358916579633837" EFFECT_SIZE="1.1744755353103407" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="186" LOG_CI_END="0.12437361372890535" LOG_CI_START="0.015314335709277042" LOG_EFFECT_SIZE="0.06984397471909119" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06406195976086253" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="347" TOTAL_2="343" VAR="0.00410393468840237" WEIGHT="15.57289852635448"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.406831220148671" CI_END="1.0515834044528622" CI_START="0.7543809080092527" DF="4" EFFECT_SIZE="0.890670782892653" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="187" I2="61.563708343269774" ID="CMP-004.03.03" LOG_CI_END="0.021843723676796427" LOG_CI_START="-0.12240931132474592" LOG_EFFECT_SIZE="-0.050282793823974756" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.034104889907633607" P_Z="0.17181870534406463" STUDIES="5" TAU2="0.0" TOTAL_1="689" TOTAL_2="568" WEIGHT="16.800160952312794" Z="1.3663832436661028">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="1.2039759718054135" CI_START="0.54751038047308" EFFECT_SIZE="0.8119047619047619" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.08061781963239625" LOG_CI_START="-0.2616076424432017" LOG_EFFECT_SIZE="-0.09049491140540274" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88086" O_E="0.0" SE="0.20102493046656472" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="0.04041102266908718" WEIGHT="3.0848763274102833"/>
<DICH_DATA CI_END="1.2598770545645035" CI_START="0.6871608467301118" EFFECT_SIZE="0.9304505272126957" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="41" LOG_CI_END="0.10032816644344705" LOG_CI_START="-0.16294159384136997" LOG_EFFECT_SIZE="-0.03130671369896147" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88087" O_E="0.0" SE="0.15464596039763273" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="0.02391537306730619" WEIGHT="4.583962810100429"/>
<DICH_DATA CI_END="0.8572154767817504" CI_START="0.4528417756009675" EFFECT_SIZE="0.6230433199854387" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="67" LOG_CI_END="-0.06690999649601129" LOG_CI_START="-0.34405351539732076" LOG_EFFECT_SIZE="-0.205481755946666" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88088" O_E="0.0" SE="0.16279547488517315" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="0.02650236664308904" WEIGHT="5.594316377408196"/>
<DICH_DATA CI_END="2.0841246357233123" CI_START="0.9004743400491385" EFFECT_SIZE="1.3699272812573304" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.3189236872706438" LOG_CI_START="-0.045528658340109295" LOG_EFFECT_SIZE="0.13669751446526726" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.21408111187996276" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.04583072246376113" WEIGHT="2.422277179952875"/>
<DICH_DATA CI_END="2.2473072843259305" CI_START="0.6916693899098874" EFFECT_SIZE="1.2467532467532467" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.3516624594965548" LOG_CI_START="-0.1601014437623817" LOG_EFFECT_SIZE="0.09578050786708653" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.3006126500464765" STUDY_ID="STD-Yardley" TOTAL_1="44" TOTAL_2="48" VAR="0.09036796536796536" WEIGHT="1.1147282574410107"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="45.01007967083128" CI_END="1.2290315365266329" CI_START="1.0984756628273695" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1619213535011024" ESTIMABLE="YES" EVENTS_1="1459" EVENTS_2="1177" I2="55.56550855660678" I2_Q="87.15443599133859" ID="CMP-004.04" LOG_CI_END="0.08956302687650652" LOG_CI_START="0.04079043939320326" LOG_EFFECT_SIZE="0.06517673313485492" METHOD="MH" MODIFIED="2014-10-29 10:03:22 +1100" MODIFIED_BY="Melina L Willson" NO="4" P_CHI2="0.0011000038409770818" P_Q="4.160164150032175E-4" P_Z="1.6201470333125015E-7" Q="15.569577160266803" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3021" TOTAL_2="2775" WEIGHT="100.00000000000001" Z="5.238354418576863">
<NAME>Overall effect: randomised patients - firstline only</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours taxane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2622841071187647" CI_END="1.9686081459729348" CI_START="1.22119863346791" DF="1" EFFECT_SIZE="1.5505036529128022" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="61" I2="69.34663054582344" ID="CMP-004.04.01" LOG_CI_END="0.2941592778558316" LOG_CI_START="0.08678630964752322" LOG_EFFECT_SIZE="0.19047279375167742" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07089037691651534" P_Z="3.1764553814720255E-4" STUDIES="2" TAU2="0.0" TOTAL_1="333" TOTAL_2="210" WEIGHT="6.21361385418848" Z="3.6004674959661065">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="1.7690352789198354" CI_START="0.9967216088575962" EFFECT_SIZE="1.3278688524590163" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="41" LOG_CI_END="0.24773649389753397" LOG_CI_START="-0.001426126161768602" LOG_EFFECT_SIZE="0.12315518386788268" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88188" O_E="0.0" SE="0.14635935639769523" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="244" TOTAL_2="123" VAR="0.02142106120514757" WEIGHT="4.532103530758981"/>
<DICH_DATA CI_END="3.3333490373857972" CI_START="1.3874682771237532" EFFECT_SIZE="2.150561797752809" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.5228807913305165" LOG_CI_START="0.14222306226130746" LOG_EFFECT_SIZE="0.33255192679591195" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22360023434140164" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="89" TOTAL_2="87" VAR="0.04999706479752973" WEIGHT="1.6815103234294986"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.761036207951058" CI_END="1.26377452374362" CI_START="1.1188529688680071" DF="13" EFFECT_SIZE="1.1891080177470426" ESTIMABLE="YES" EVENTS_1="1100" EVENTS_2="929" I2="22.43916283747963" ID="CMP-004.04.02" LOG_CI_END="0.1016695962336304" LOG_CI_START="0.04877301860630807" LOG_EFFECT_SIZE="0.07522130741996921" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21045981166001093" P_Z="2.4850786675074876E-8" STUDIES="14" TAU2="0.0" TOTAL_1="1974" TOTAL_2="1979" WEIGHT="77.01022615008941" Z="5.574313501030867">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.5294510592071564" CI_START="1.0644401082390673" EFFECT_SIZE="1.2759345794392523" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="100" LOG_CI_END="0.1845355845855995" LOG_CI_START="0.02712123045914323" LOG_EFFECT_SIZE="0.10582840752237133" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88189" O_E="0.0" SE="0.09246597082750033" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="0.00854995576107214" WEIGHT="8.293706925126193"/>
<DICH_DATA CI_END="1.408793430863048" CI_START="0.9005511750714384" EFFECT_SIZE="1.1263616557734204" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" LOG_CI_END="0.14884731786937053" LOG_CI_START="-0.04549160275600805" LOG_EFFECT_SIZE="0.051677857556681236" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.11415564396851927" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.013031511049867328" WEIGHT="6.834100115777055"/>
<DICH_DATA CI_END="1.5140818076277711" CI_START="0.8519764269979575" EFFECT_SIZE="1.1357649442755826" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" LOG_CI_END="0.18014934124164653" LOG_CI_START="-0.06957242139097367" LOG_EFFECT_SIZE="0.05528845992533643" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.1466877995130624" STUDY_ID="STD-Blohmer" TOTAL_1="126" TOTAL_2="114" VAR="0.021517310525984393" WEIGHT="4.102507321679566"/>
<DICH_DATA CI_END="2.7094313789547018" CI_START="1.2408028947796468" EFFECT_SIZE="1.8335403726708075" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" LOG_CI_END="0.4328781562272794" LOG_CI_START="0.0937027980110292" LOG_EFFECT_SIZE="0.26329047711915426" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.1992332843613262" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="0.03969390159740106" WEIGHT="1.8850797802143642"/>
<DICH_DATA CI_END="2.0725262487886322" CI_START="1.153388550942963" EFFECT_SIZE="1.5461009174311926" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" LOG_CI_END="0.3165000396478214" LOG_CI_START="0.06197563609258921" LOG_EFFECT_SIZE="0.18923783787020532" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14950889456446062" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="0.022352909553887003" WEIGHT="3.35602310077731"/>
<DICH_DATA CI_END="1.4739742050057214" CI_START="0.9306001318197358" EFFECT_SIZE="1.1711876832844574" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.168489883304783" LOG_CI_START="-0.03123689028482772" LOG_EFFECT_SIZE="0.06862649650997764" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.11732049547001158" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="0.01376409865732901" WEIGHT="5.253612784049878"/>
<DICH_DATA CI_END="1.3238943408484354" CI_START="0.8700539245050954" EFFECT_SIZE="1.073247160203682" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="74" LOG_CI_END="0.12185332572486562" LOG_CI_START="-0.06045382969259034" LOG_EFFECT_SIZE="0.03069974801613765" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88191" O_E="0.0" SE="0.10708812552718723" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="0.01146786662892661" WEIGHT="6.174052466647025"/>
<DICH_DATA CI_END="1.2955672718134004" CI_START="0.8161233848420456" EFFECT_SIZE="1.0282717282717282" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.1124599684749316" LOG_CI_START="-0.08824417788189734" LOG_EFFECT_SIZE="0.012107895296517129" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.11789460907154876" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="0.013899138848133308" WEIGHT="5.86013931675335"/>
<DICH_DATA CI_END="1.4423470887170105" CI_START="0.9412299959528678" EFFECT_SIZE="1.1651524983776769" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.15906978228082388" LOG_CI_START="-0.026304240793478612" LOG_EFFECT_SIZE="0.0663827707436726" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.10888961877005862" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="0.011856949075888704" WEIGHT="5.757511726792765"/>
<DICH_DATA CI_END="1.3985025946633711" CI_START="0.4519999851059977" EFFECT_SIZE="0.7950617283950617" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.1456632764615247" LOG_CI_START="-0.3448615794992" LOG_EFFECT_SIZE="-0.09959915151883765" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.2881367285285271" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="0.08302277432712214" WEIGHT="1.4799117897771905"/>
<DICH_DATA CI_END="1.506215629448624" CI_START="1.0452120346922" EFFECT_SIZE="1.2547169811320755" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" LOG_CI_END="0.177887149803683" LOG_CI_START="0.019204401600948117" LOG_EFFECT_SIZE="0.09854577570231557" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.09321103178655833" STUDY_ID="STD-Nabholtz" TOTAL_1="242" TOTAL_2="242" VAR="0.008688296446714788" WEIGHT="8.811869829747394"/>
<DICH_DATA CI_END="1.9571470055864042" CI_START="0.8725832834508476" EFFECT_SIZE="1.3068181818181819" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.29162344769029747" LOG_CI_START="-0.05919311128341124" LOG_EFFECT_SIZE="0.11621516820344308" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.20607138331113045" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="0.04246541501976285" WEIGHT="1.5006183744901223"/>
<DICH_DATA CI_END="1.233841622370692" CI_START="0.6178975281687252" EFFECT_SIZE="0.8731481481481481" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.09125941663013439" LOG_CI_START="-0.20908354212937713" LOG_EFFECT_SIZE="-0.058912062749621345" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.17642294069696046" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="0.031125054004163225" WEIGHT="2.21682259867859"/>
<DICH_DATA CI_END="1.3458340049478892" CI_START="1.0430450773554127" EFFECT_SIZE="1.1848061165433001" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="186" LOG_CI_END="0.1289914973464983" LOG_CI_START="0.018303077768507325" LOG_EFFECT_SIZE="0.07364728755750284" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06501892557662553" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="0.004227460683138769" WEIGHT="15.4842700195786"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.73790947701502" CI_END="1.0562670065332316" CI_START="0.7553034142794646" DF="4" EFFECT_SIZE="0.8931976692901182" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="187" I2="58.923421814081934" ID="CMP-004.04.03" LOG_CI_END="0.02377371441604954" LOG_CI_START="-0.1218785521102207" LOG_EFFECT_SIZE="-0.04905241884708555" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.045081783679032594" P_Z="0.1867869840013311" STUDIES="5" TAU2="0.0" TOTAL_1="714" TOTAL_2="586" WEIGHT="16.77615999572212" Z="1.32014388224465">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="1.2200882556352586" CI_START="0.5522807775133903" EFFECT_SIZE="0.8208722741433022" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.08639124669858905" LOG_CI_START="-0.2578400724112023" LOG_EFFECT_SIZE="-0.08572441285630665" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88194" O_E="0.0" SE="0.20220318081760236" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="0.04088612633275599" WEIGHT="3.0643064533887303"/>
<DICH_DATA CI_END="1.3177967312308463" CI_START="0.7095002566715729" EFFECT_SIZE="0.9669421487603306" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="41" LOG_CI_END="0.11984842595384064" LOG_CI_START="-0.14904744309441753" LOG_EFFECT_SIZE="-0.014599508570288439" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88195" O_E="0.0" SE="0.15795076453496565" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="242" TOTAL_2="123" VAR="0.02494844401718016" WEIGHT="4.519585032347048"/>
<DICH_DATA CI_END="0.858040992185618" CI_START="0.45247298153859394" EFFECT_SIZE="0.6230893724150333" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="67" LOG_CI_END="-0.0664919636026299" LOG_CI_START="-0.3444073486555197" LOG_EFFECT_SIZE="-0.2054496561290748" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88196" O_E="0.0" SE="0.16324887288341056" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="0.02665019449770394" WEIGHT="5.5865938691472685"/>
<DICH_DATA CI_END="2.0841246357233123" CI_START="0.9004743400491385" EFFECT_SIZE="1.3699272812573304" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.3189236872706438" LOG_CI_START="-0.045528658340109295" LOG_EFFECT_SIZE="0.13669751446526726" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.21408111187996276" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.04583072246376113" WEIGHT="2.419022543899359"/>
<DICH_DATA CI_END="2.0086252913417075" CI_START="0.6011990540851" EFFECT_SIZE="1.098901098901099" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.30289892675289676" LOG_CI_START="-0.22098171139508388" LOG_EFFECT_SIZE="0.04095860767890644" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.307730080099106" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="0.09469780219780219" WEIGHT="1.1866520969397159"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="89.27819289567181" CI_END="1.2596326032041598" CI_START="1.1380104935191064" CI_STUDY="95" CI_TOTAL="95" DF="28" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1972782134596465" ESTIMABLE="YES" EVENTS_1="1740" EVENTS_2="1457" I2="68.63735802457373" I2_Q="59.49477986593963" ID="CMP-004.05" LOG_CI_END="0.10024389300008335" LOG_CI_START="0.05614626667806153" LOG_EFFECT_SIZE="0.07819507983907246" METHOD="MH" MODIFIED="2015-04-17 13:53:01 +1000" MODIFIED_BY="Melina L Willson" NO="5" P_CHI2="2.569371260197073E-8" P_Q="0.0846849910074563" P_Z="3.6291118718335114E-12" Q="4.937635182281661" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3613" TOTAL_2="3610" WEIGHT="300.0" Z="6.950920175777348">
<NAME>Subquestions A, B &amp; C: assessable patients</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours taxane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.296709530422575" CI_END="1.7917435591181625" CI_START="1.2077153406042835" DF="1" EFFECT_SIZE="1.4710255547664435" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="101" I2="76.72637647670702" ID="CMP-004.05.01" LOG_CI_END="0.25327585196146446" LOG_CI_START="0.08196458281739179" LOG_EFFECT_SIZE="0.16762021738942812" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03818636764177785" P_Z="1.2532456797662958E-4" STUDIES="2" TAU2="0.0" TOTAL_1="317" TOTAL_2="310" WEIGHT="100.0" Z="3.8354696781536353">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="1.6208185220742695" CI_START="1.0403595229767368" EFFECT_SIZE="1.298550724637681" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="81" LOG_CI_END="0.2097343909904688" LOG_CI_START="0.017183446859270896" LOG_EFFECT_SIZE="0.11345891892486985" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88118" O_E="0.0" SE="0.1131053777252112" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="224" VAR="0.012792826470362702" WEIGHT="80.31473105819909"/>
<DICH_DATA CI_END="3.3649857904453544" CI_START="1.4054665835446887" EFFECT_SIZE="2.174712643678161" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.5269832346389846" LOG_CI_START="0.14782052425532638" LOG_EFFECT_SIZE="0.33740187944715544" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22272205296504727" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="87" TOTAL_2="86" VAR="0.04960511287696532" WEIGHT="19.68526894180092"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.341517384181405" CI_END="1.2646826536743934" CI_START="1.1240080592027173" DF="13" EFFECT_SIZE="1.1922724080779095" ESTIMABLE="YES" EVENTS_1="1097" EVENTS_2="929" I2="48.70078297633899" ID="CMP-004.05.02" LOG_CI_END="0.1019815618372145" LOG_CI_START="0.05076942516072982" LOG_EFFECT_SIZE="0.07637549349897214" MODIFIED="2015-04-17 13:53:01 +1000" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.020809605919556717" P_Z="5.0351737728053745E-9" STUDIES="14" TAU2="0.0" TOTAL_1="1863" TOTAL_2="1877" WEIGHT="100.00000000000003" Z="5.846005508619747">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.536157456099993" CI_START="1.0865433434376244" EFFECT_SIZE="1.2919371727748692" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="100" LOG_CI_END="0.18643573315034767" LOG_CI_START="0.036047055498080745" LOG_EFFECT_SIZE="0.1112413943242142" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88119" O_E="0.0" SE="0.08833905368890205" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="191" TOTAL_2="199" VAR="0.007803788406650718" WEIGHT="10.597948646704129"/>
<DICH_DATA CI_END="1.408793430863048" CI_START="0.9005511750714384" EFFECT_SIZE="1.1263616557734204" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" LOG_CI_END="0.14884731786937053" LOG_CI_START="-0.04549160275600805" LOG_EFFECT_SIZE="0.051677857556681236" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.11415564396851927" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.013031511049867328" WEIGHT="8.894922812752236"/>
<DICH_DATA CI_END="1.4830399658986637" CI_START="0.837879151315788" EFFECT_SIZE="1.1147234042553191" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" LOG_CI_END="0.17115285482836756" LOG_CI_START="-0.07681861585831211" LOG_EFFECT_SIZE="0.04716711948502774" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.14565966935993205" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.021216739278044724" WEIGHT="5.387024100798837"/>
<DICH_DATA CI_END="2.6864607098855635" CI_START="1.256766049918451" EFFECT_SIZE="1.837458193979933" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" LOG_CI_END="0.4291804932930726" LOG_CI_START="0.0992544402271543" LOG_EFFECT_SIZE="0.2642174667601135" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.19380019673122237" STUDY_ID="STD-Bonneterre" TOTAL_1="65" TOTAL_2="67" VAR="0.03755851625306049" WEIGHT="2.4508702040539596"/>
<DICH_DATA CI_END="2.1064383759537617" CI_START="1.1776394829859727" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" LOG_CI_END="0.32354875832414987" LOG_CI_START="0.07101235792708874" LOG_EFFECT_SIZE="0.19728055812561932" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14834113166857663" STUDY_ID="STD-Bontenbal" TOTAL_1="106" TOTAL_2="106" VAR="0.02200509134471399" WEIGHT="4.327958086088597"/>
<DICH_DATA CI_END="1.5183458459349983" CI_START="0.9759506073659042" EFFECT_SIZE="1.217304625199362" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.1813707056001994" LOG_CI_START="-0.010572161320233463" LOG_EFFECT_SIZE="0.08539927213998297" MODIFIED="2015-04-17 13:53:01 +1000" MODIFIED_BY="Melina L Willson" ORDER="444" O_E="0.0" SE="0.11274819016157708" STUDY_ID="STD-CECOG-BM1" TOTAL_1="114" TOTAL_2="129" VAR="0.012712154384711148" WEIGHT="6.700320296240865"/>
<DICH_DATA CI_END="1.3493656075155886" CI_START="0.9082111117569299" EFFECT_SIZE="1.107027027027027" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="74" LOG_CI_END="0.13012963670963695" LOG_CI_START="-0.041813188908078294" LOG_EFFECT_SIZE="0.04415822390077935" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88121" O_E="0.0" SE="0.1010000668985596" STUDY_ID="STD-EORTC-10961" TOTAL_1="125" TOTAL_2="128" VAR="0.010201013513513515" WEIGHT="7.911781086229156"/>
<DICH_DATA CI_END="1.2331166566609042" CI_START="0.8117069561690625" EFFECT_SIZE="1.0004645760743323" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.0910041641444564" LOG_CI_START="-0.09060073219860322" LOG_EFFECT_SIZE="2.0171597292656092E-4" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.10667561507064832" STUDY_ID="STD-HERNATA" TOTAL_1="123" TOTAL_2="118" VAR="0.011379686850701133" WEIGHT="7.7310620583449845"/>
<DICH_DATA CI_END="1.5229728419683077" CI_START="1.0116713625725295" EFFECT_SIZE="1.2412687099073414" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.18269215895753657" LOG_CI_START="0.005039456574253741" LOG_EFFECT_SIZE="0.09386580776589516" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.10435407677499979" STUDY_ID="STD-Jassem" TOTAL_1="122" TOTAL_2="129" VAR="0.01088977333956255" WEIGHT="7.257520153126257"/>
<DICH_DATA CI_END="1.2730541423427089" CI_START="0.44915400232278513" EFFECT_SIZE="0.7561728395061729" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.10484687436901707" LOG_CI_START="-0.3476047260531764" LOG_EFFECT_SIZE="-0.12137892584207965" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.2657723097595395" STUDY_ID="STD-Lyman" TOTAL_1="36" TOTAL_2="35" VAR="0.07063492063492063" WEIGHT="1.9750118590038108"/>
<DICH_DATA CI_END="1.4974079276713104" CI_START="1.042543539216611" EFFECT_SIZE="1.2494450610432852" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" LOG_CI_END="0.17534012806729096" LOG_CI_START="0.01809420124452399" LOG_EFFECT_SIZE="0.09671716465590746" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.09236703579558464" STUDY_ID="STD-Nabholtz" TOTAL_1="238" TOTAL_2="237" VAR="0.008531669301662815" WEIGHT="11.493234378509804"/>
<DICH_DATA CI_END="1.9101942914513945" CI_START="0.8555830215978812" EFFECT_SIZE="1.2784090909090908" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.2810775428570588" LOG_CI_START="-0.06773784226263357" LOG_EFFECT_SIZE="0.10666985029721264" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.20489588388331093" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.04198232323232323" WEIGHT="1.978495125069073"/>
<DICH_DATA CI_END="1.032510424235336" CI_START="0.5874860608585397" EFFECT_SIZE="0.7788359788359789" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.013894444991907054" LOG_CI_START="-0.23100243333543524" LOG_EFFECT_SIZE="-0.10855399417176406" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.14385363858857964" STUDY_ID="STD-TRAVIOTA" TOTAL_1="35" TOTAL_2="32" VAR="0.020693869335173684" WEIGHT="3.0521793965326305"/>
<DICH_DATA CI_END="1.3315994703099245" CI_START="1.0358916579633837" EFFECT_SIZE="1.1744755353103407" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="186" LOG_CI_END="0.12437361372890535" LOG_CI_START="0.015314335709277042" LOG_EFFECT_SIZE="0.06984397471909119" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06406195976086253" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="347" TOTAL_2="343" VAR="0.00410393468840237" WEIGHT="20.24167179654567"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="54.873950693276136" CI_END="1.271604660022692" CI_START="1.0269475652073028" DF="12" EFFECT_SIZE="1.1427472640599774" ESTIMABLE="YES" EVENTS_1="491" EVENTS_2="427" I2="78.13170029058908" ID="CMP-004.05.03" LOG_CI_END="0.10435211079545026" LOG_CI_START="0.011548269573443478" LOG_EFFECT_SIZE="0.05795019018444689" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.9065613865443254E-7" P_Z="0.014375149327651942" STUDIES="13" TAU2="0.0" TOTAL_1="1433" TOTAL_2="1423" WEIGHT="99.99999999999999" Z="2.447749665599593">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="1.8035920109003933" CI_START="1.0720844754249497" EFFECT_SIZE="1.3905405405405404" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="55" LOG_CI_END="0.25613830291000483" LOG_CI_START="0.030229007152908556" LOG_EFFECT_SIZE="0.1431836550314567" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88124" O_E="0.0" SE="0.13270023859676755" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="148" TOTAL_2="147" VAR="0.017609353323639037" WEIGHT="12.889917969819122"/>
<DICH_DATA CI_END="4.050499724291161" CI_START="1.6758482530661707" EFFECT_SIZE="2.6053834433722702" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="22" LOG_CI_END="0.6075086069464841" LOG_CI_START="0.22423469100091198" LOG_EFFECT_SIZE="0.41587164897369805" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88125" O_E="0.0" SE="0.22513699546291122" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="179" TOTAL_2="171" VAR="0.0506866667260669" WEIGHT="5.2560009142571325"/>
<DICH_DATA CI_END="1.2039759718054135" CI_START="0.54751038047308" EFFECT_SIZE="0.8119047619047619" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.08061781963239625" LOG_CI_START="-0.2616076424432017" LOG_EFFECT_SIZE="-0.09049491140540274" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88126" O_E="0.0" SE="0.20102493046656472" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="0.04041102266908718" WEIGHT="8.655843527572207"/>
<DICH_DATA CI_END="2.301539682672946" CI_START="0.3192184271607981" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36201846731051207" LOG_CI_START="-0.49591204657173854" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88127" O_E="0.0" SE="0.5039526306789697" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="0.25396825396825395" WEIGHT="1.6349926663191945"/>
<DICH_DATA CI_END="1.2100774913431935" CI_START="0.7332145201888141" EFFECT_SIZE="0.9419375707585315" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="81" LOG_CI_END="0.08281318270086843" LOG_CI_START="-0.13476894308865753" LOG_EFFECT_SIZE="-0.025977880193894534" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88128" O_E="0.0" SE="0.12780881773766062" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="224" VAR="0.01633509389149855" WEIGHT="19.128022054591447"/>
<DICH_DATA CI_END="0.8572154767817504" CI_START="0.4528417756009675" EFFECT_SIZE="0.6230433199854387" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="67" LOG_CI_END="-0.06690999649601129" LOG_CI_START="-0.34405351539732076" LOG_EFFECT_SIZE="-0.205481755946666" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88129" O_E="0.0" SE="0.16279547488517315" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="0.02650236664308904" WEIGHT="15.697072448680917"/>
<DICH_DATA CI_END="2.0841246357233123" CI_START="0.9004743400491385" EFFECT_SIZE="1.3699272812573304" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.3189236872706438" LOG_CI_START="-0.045528658340109295" LOG_EFFECT_SIZE="0.13669751446526726" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.21408111187996276" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.04583072246376113" WEIGHT="6.796658933709143"/>
<DICH_DATA CI_END="3.394214123737704" CI_START="0.9058797929897697" EFFECT_SIZE="1.7534965034965035" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.530739236279962" LOG_CI_START="-0.04292942782517406" LOG_EFFECT_SIZE="0.24390490422739394" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="0.3369758130010424" STUDY_ID="STD-Meier" TOTAL_1="52" TOTAL_2="59" VAR="0.11355269854771351" WEIGHT="2.4072478896642964"/>
<DICH_DATA CI_END="2.9698931881319073" CI_START="1.4218166028685626" EFFECT_SIZE="2.0549071618037136" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="29" LOG_CI_END="0.47274083024681823" LOG_CI_START="0.15284358127504383" LOG_EFFECT_SIZE="0.31279220576093103" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88130" O_E="0.0" SE="0.18790922756294137" STUDY_ID="STD-Sjostrom" TOTAL_1="130" TOTAL_2="127" VAR="0.03530987780330129" WEIGHT="6.852609618703016"/>
<DICH_DATA CI_END="1.840869576489006" CI_START="0.28449535113941016" EFFECT_SIZE="0.7236842105263158" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2650230203249784" LOG_CI_START="-0.5459248258980733" LOG_EFFECT_SIZE="-0.14045090278654748" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="0.4763547791280005" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="0.22691387559808612" WEIGHT="1.7318389218154535"/>
<DICH_DATA CI_END="0.9807975833277779" CI_START="0.3869531621904246" EFFECT_SIZE="0.6160541586073501" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="33" LOG_CI_END="-0.008420612920178601" LOG_CI_START="-0.4123415999249679" LOG_EFFECT_SIZE="-0.21038110642257324" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.23726518720774548" STUDY_ID="STD-TOG" TOTAL_1="94" TOTAL_2="91" VAR="0.0562947690607265" WEIGHT="7.832814287138442"/>
<DICH_DATA CI_END="1.578252580752933" CI_START="0.7754949386113446" EFFECT_SIZE="1.106312292358804" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="35" LOG_CI_END="0.19817650815674395" LOG_CI_START="-0.11042103233179087" LOG_EFFECT_SIZE="0.043877737912476525" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="0.18127172286542734" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="0.032859437510600296" WEIGHT="7.989168710423336"/>
<DICH_DATA CI_END="2.2473072843259305" CI_START="0.6916693899098874" EFFECT_SIZE="1.2467532467532467" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.3516624594965548" LOG_CI_START="-0.1601014437623817" LOG_EFFECT_SIZE="0.09578050786708653" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.3006126500464765" STUDY_ID="STD-Yardley" TOTAL_1="44" TOTAL_2="48" VAR="0.09036796536796536" WEIGHT="3.127812057306285"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="78.46858414804075" CI_END="1.2666066580397475" CI_START="1.1413381679915138" CI_STUDY="95" CI_TOTAL="95" DF="28" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2023420988441431" ESTIMABLE="YES" EVENTS_1="1743" EVENTS_2="1452" I2="64.31692975729686" I2_Q="61.74280712510233" ID="CMP-004.06" LOG_CI_END="0.10264176660802413" LOG_CI_START="0.05741434094163537" LOG_EFFECT_SIZE="0.08002805377482976" METHOD="MH" MODIFIED="2014-10-29 10:03:41 +1100" MODIFIED_BY="Melina L Willson" NO="6" P_CHI2="1.1261049258637357E-6" P_Q="0.07324935116636233" P_Z="4.0292991517007485E-12" Q="5.227775091967851" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3834" TOTAL_2="3826" WEIGHT="300.0" Z="6.936149950629062">
<NAME>Subquestions A, B &amp; C: randomised patients</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours taxane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5610048642535763" CI_END="1.83568781337182" CI_START="1.2277761014960493" DF="1" EFFECT_SIZE="1.5012706708203756" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="101" I2="71.9180389210277" ID="CMP-004.06.01" LOG_CI_END="0.26379882476386823" LOG_CI_START="0.08911917564030093" LOG_EFFECT_SIZE="0.17645900020208458" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05915207380393783" P_Z="7.499440703121234E-5" STUDIES="2" TAU2="0.0" TOTAL_1="333" TOTAL_2="332" WEIGHT="100.0" Z="3.9598577954479124">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="1.6801202557583361" CI_START="1.0668162479346912" EFFECT_SIZE="1.3387978142076502" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="81" LOG_CI_END="0.2253403677634505" LOG_CI_START="0.028089621504755448" LOG_EFFECT_SIZE="0.12671499463410296" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88134" O_E="0.0" SE="0.11586606475929873" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="244" TOTAL_2="245" VAR="0.013424944962806006" WEIGHT="79.98520999870311"/>
<DICH_DATA CI_END="3.3333490373857972" CI_START="1.3874682771237532" EFFECT_SIZE="2.150561797752809" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.5228807913305165" LOG_CI_START="0.14222306226130746" LOG_EFFECT_SIZE="0.33255192679591195" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22360023434140164" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="89" TOTAL_2="87" VAR="0.04999706479752973" WEIGHT="20.01479000129688"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.76103620795106" CI_END="1.26377452374362" CI_START="1.1188529688680071" DF="13" EFFECT_SIZE="1.1891080177470426" ESTIMABLE="YES" EVENTS_1="1100" EVENTS_2="929" I2="22.439162837479643" ID="CMP-004.06.02" LOG_CI_END="0.1016695962336304" LOG_CI_START="0.04877301860630807" LOG_EFFECT_SIZE="0.07522130741996921" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2104598116600105" P_Z="2.4850786675074876E-8" STUDIES="14" TAU2="0.0" TOTAL_1="1974" TOTAL_2="1979" WEIGHT="100.0" Z="5.574313501030867">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.5294510592071564" CI_START="1.0644401082390673" EFFECT_SIZE="1.2759345794392523" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="100" LOG_CI_END="0.1845355845855995" LOG_CI_START="0.02712123045914323" LOG_EFFECT_SIZE="0.10582840752237133" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88135" O_E="0.0" SE="0.09246597082750033" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="0.00854995576107214" WEIGHT="10.769617672544083"/>
<DICH_DATA CI_END="1.408793430863048" CI_START="0.9005511750714384" EFFECT_SIZE="1.1263616557734204" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" LOG_CI_END="0.14884731786937053" LOG_CI_START="-0.04549160275600805" LOG_EFFECT_SIZE="0.051677857556681236" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.11415564396851927" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.013031511049867328" WEIGHT="8.874276128546496"/>
<DICH_DATA CI_END="1.5140818076277711" CI_START="0.8519764269979575" EFFECT_SIZE="1.1357649442755826" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" LOG_CI_END="0.18014934124164653" LOG_CI_START="-0.06957242139097367" LOG_EFFECT_SIZE="0.05528845992533643" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.1466877995130624" STUDY_ID="STD-Blohmer" TOTAL_1="126" TOTAL_2="114" VAR="0.021517310525984393" WEIGHT="5.3272240931794785"/>
<DICH_DATA CI_END="2.7094313789547018" CI_START="1.2408028947796468" EFFECT_SIZE="1.8335403726708075" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" LOG_CI_END="0.4328781562272794" LOG_CI_START="0.0937027980110292" LOG_EFFECT_SIZE="0.26329047711915426" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.1992332843613262" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="0.03969390159740106" WEIGHT="2.447830469346279"/>
<DICH_DATA CI_END="2.0725262487886322" CI_START="1.153388550942963" EFFECT_SIZE="1.5461009174311926" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" LOG_CI_END="0.3165000396478214" LOG_CI_START="0.06197563609258921" LOG_EFFECT_SIZE="0.18923783787020532" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14950889456446062" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="0.022352909553887003" WEIGHT="4.357892800154326"/>
<DICH_DATA CI_END="1.4739742050057214" CI_START="0.9306001318197358" EFFECT_SIZE="1.1711876832844574" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.168489883304783" LOG_CI_START="-0.03123689028482772" LOG_EFFECT_SIZE="0.06862649650997764" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.11732049547001158" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="0.01376409865732901" WEIGHT="6.82196773946726"/>
<DICH_DATA CI_END="1.3238943408484354" CI_START="0.8700539245050954" EFFECT_SIZE="1.073247160203682" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="74" LOG_CI_END="0.12185332572486562" LOG_CI_START="-0.06045382969259034" LOG_EFFECT_SIZE="0.03069974801613765" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88137" O_E="0.0" SE="0.10708812552718723" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="0.01146786662892661" WEIGHT="8.017185217212685"/>
<DICH_DATA CI_END="1.2955672718134004" CI_START="0.8161233848420456" EFFECT_SIZE="1.0282717282717282" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.1124599684749316" LOG_CI_START="-0.08824417788189734" LOG_EFFECT_SIZE="0.012107895296517129" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.11789460907154876" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="0.013899138848133308" WEIGHT="7.609559937315607"/>
<DICH_DATA CI_END="1.4423470887170105" CI_START="0.9412299959528678" EFFECT_SIZE="1.1651524983776769" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.15906978228082388" LOG_CI_START="-0.026304240793478612" LOG_EFFECT_SIZE="0.0663827707436726" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.10888961877005862" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="0.011856949075888704" WEIGHT="7.476295051480096"/>
<DICH_DATA CI_END="1.3985025946633711" CI_START="0.4519999851059977" EFFECT_SIZE="0.7950617283950617" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.1456632764615247" LOG_CI_START="-0.3448615794992" LOG_EFFECT_SIZE="-0.09959915151883765" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.2881367285285271" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="0.08302277432712214" WEIGHT="1.9217081467763908"/>
<DICH_DATA CI_END="1.506215629448624" CI_START="1.0452120346922" EFFECT_SIZE="1.2547169811320755" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" LOG_CI_END="0.177887149803683" LOG_CI_START="0.019204401600948117" LOG_EFFECT_SIZE="0.09854577570231557" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.09321103178655833" STUDY_ID="STD-Nabholtz" TOTAL_1="242" TOTAL_2="242" VAR="0.008688296446714788" WEIGHT="11.442467150496954"/>
<DICH_DATA CI_END="1.9571470055864042" CI_START="0.8725832834508476" EFFECT_SIZE="1.3068181818181819" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.29162344769029747" LOG_CI_START="-0.05919311128341124" LOG_EFFECT_SIZE="0.11621516820344308" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.20607138331113045" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="0.04246541501976285" WEIGHT="1.9485962443033031"/>
<DICH_DATA CI_END="1.233841622370692" CI_START="0.6178975281687252" EFFECT_SIZE="0.8731481481481481" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.09125941663013439" LOG_CI_START="-0.20908354212937713" LOG_EFFECT_SIZE="-0.058912062749621345" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.17642294069696046" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="0.031125054004163225" WEIGHT="2.8786080881753344"/>
<DICH_DATA CI_END="1.3458340049478892" CI_START="1.0430450773554127" EFFECT_SIZE="1.1848061165433001" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="186" LOG_CI_END="0.1289914973464983" LOG_CI_START="0.018303077768507325" LOG_EFFECT_SIZE="0.07364728755750284" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06501892557662553" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="0.004227460683138769" WEIGHT="20.106771261001715"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="52.948607628576866" CI_END="1.2930859625575444" CI_START="1.0402814122428705" DF="12" EFFECT_SIZE="1.1598160592442208" ESTIMABLE="YES" EVENTS_1="491" EVENTS_2="422" I2="77.33651452333284" ID="CMP-004.06.03" LOG_CI_END="0.11162739713363394" LOG_CI_START="0.017150838579641992" LOG_EFFECT_SIZE="0.06438911785663798" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="4.207012298529378E-7" P_Z="0.007549740871655903" STUDIES="13" TAU2="0.0" TOTAL_1="1527" TOTAL_2="1515" WEIGHT="100.0" Z="2.6715696237642614">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="1.8784421317045794" CI_START="1.0959087317464697" EFFECT_SIZE="1.434782608695652" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="55" LOG_CI_END="0.27379782049682827" LOG_CI_START="0.03977438722376088" LOG_EFFECT_SIZE="0.15678610386029457" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88140" O_E="0.0" SE="0.13746652313927746" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="0.018897044984001504" WEIGHT="12.87002067928977"/>
<DICH_DATA CI_END="3.968433256696449" CI_START="1.6246865723520847" EFFECT_SIZE="2.5391849529780566" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="22" LOG_CI_END="0.5986190804984799" LOG_CI_START="0.21076959114445737" LOG_EFFECT_SIZE="0.40469433582146863" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88141" O_E="0.0" SE="0.22782470993248866" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="0.05190409845582259" WEIGHT="5.398100066637332"/>
<DICH_DATA CI_END="1.2200882556352586" CI_START="0.5522807775133903" EFFECT_SIZE="0.8208722741433022" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.08639124669858905" LOG_CI_START="-0.2578400724112023" LOG_EFFECT_SIZE="-0.08572441285630665" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88142" O_E="0.0" SE="0.20220318081760236" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="0.04088612633275599" WEIGHT="8.73269458666041"/>
<DICH_DATA CI_END="13.650872303713893" CI_START="0.6275298292405901" EFFECT_SIZE="2.926829268292683" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1351604040936405" LOG_CI_START="-0.20236562543786202" LOG_EFFECT_SIZE="0.4663973893278893" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88143" O_E="0.0" SE="0.7856694106074307" STUDY_ID="STD-Dieras" TOTAL_1="41" TOTAL_2="40" VAR="0.6172764227642276" WEIGHT="0.479663986725466"/>
<DICH_DATA CI_END="1.258310103654411" CI_START="0.7553233672910327" EFFECT_SIZE="0.9749005203550658" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="81" LOG_CI_END="0.0997876838035627" LOG_CI_START="-0.121867079411699" LOG_EFFECT_SIZE="-0.01103969780406816" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88144" O_E="0.0" SE="0.13020110512141822" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="242" TOTAL_2="245" VAR="0.016952327774838596" WEIGHT="19.07127387417237"/>
<DICH_DATA CI_END="0.858040992185618" CI_START="0.45247298153859394" EFFECT_SIZE="0.6230893724150333" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="67" LOG_CI_END="-0.0664919636026299" LOG_CI_START="-0.3444073486555197" LOG_EFFECT_SIZE="-0.2054496561290748" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88145" O_E="0.0" SE="0.16324887288341056" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="0.02665019449770394" WEIGHT="15.920737296043448"/>
<DICH_DATA CI_END="2.0841246357233123" CI_START="0.9004743400491385" EFFECT_SIZE="1.3699272812573304" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.3189236872706438" LOG_CI_START="-0.045528658340109295" LOG_EFFECT_SIZE="0.13669751446526726" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.21408111187996276" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.04583072246376113" WEIGHT="6.893757329903586"/>
<DICH_DATA CI_END="3.223895804183195" CI_START="0.8465621892230513" EFFECT_SIZE="1.652037617554859" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.50838099702898" LOG_CI_START="-0.07234113271824896" LOG_EFFECT_SIZE="0.2180199321553655" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="0.3411190536344258" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="0.11636220875244625" WEIGHT="2.519113364430755"/>
<DICH_DATA CI_END="2.9761362210660627" CI_START="1.4046508758725644" EFFECT_SIZE="2.044610561851941" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="29" LOG_CI_END="0.47365280547040645" LOG_CI_START="0.14756839433128183" LOG_EFFECT_SIZE="0.31061059990084416" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88146" O_E="0.0" SE="0.19154359724698955" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="0.03668894964631694" WEIGHT="6.967760369702089"/>
<DICH_DATA CI_END="1.7582921656073456" CI_START="0.26881553546405984" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24509104102701695" LOG_CI_START="-0.5705456360224165" LOG_EFFECT_SIZE="-0.16272729749769974" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="0.479109021565504" STUDY_ID="STD-Talbot" TOTAL_1="20" TOTAL_2="22" VAR="0.22954545454545455" WEIGHT="1.8050073368066315"/>
<DICH_DATA CI_END="1.0102240935220186" CI_START="0.3929617145880666" EFFECT_SIZE="0.6300630063006301" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="33" LOG_CI_END="0.0044177220845504385" LOG_CI_START="-0.405649759937772" LOG_EFFECT_SIZE="-0.2006160189266108" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.24087566880668546" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="0.05802108782306802" WEIGHT="7.856833241611104"/>
<DICH_DATA CI_END="1.578252580752933" CI_START="0.7754949386113446" EFFECT_SIZE="1.106312292358804" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="35" LOG_CI_END="0.19817650815674395" LOG_CI_START="-0.11042103233179087" LOG_EFFECT_SIZE="0.043877737912476525" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="0.18127172286542734" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="0.032859437510600296" WEIGHT="8.103303534058748"/>
<DICH_DATA CI_END="2.0086252913417075" CI_START="0.6011990540851" EFFECT_SIZE="1.098901098901099" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.30289892675289676" LOG_CI_START="-0.22098171139508388" LOG_EFFECT_SIZE="0.04095860767890644" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.307730080099106" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="0.09469780219780219" WEIGHT="3.381734333958307"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="55.43376900463008" CI_END="1.2257017068102924" CI_START="1.1008923434215911" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1616219799686243" ESTIMABLE="YES" EVENTS_1="1456" EVENTS_2="1257" I2="63.92090893489579" I2_Q="87.9127810238256" ID="CMP-004.07" LOG_CI_END="0.08838479086051243" LOG_CI_START="0.04174485126607989" LOG_EFFECT_SIZE="0.06506482106329615" METHOD="MH" MODIFIED="2014-10-29 10:03:42 +1100" MODIFIED_BY="Melina L Willson" NO="7" P_CHI2="3.535953962852112E-5" P_Q="2.5526787656360295E-4" P_Z="4.5392032862429886E-8" Q="16.546403303706853" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2869" TOTAL_2="2867" WEIGHT="300.0" Z="5.468476462599296">
<NAME>Subquestions A, B &amp; C: assessable patients - first-line only</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours taxane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.296709530422575" CI_END="1.7917435591181625" CI_START="1.2077153406042835" DF="1" EFFECT_SIZE="1.4710255547664435" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="101" I2="76.72637647670702" ID="CMP-004.07.01" LOG_CI_END="0.25327585196146446" LOG_CI_START="0.08196458281739179" LOG_EFFECT_SIZE="0.16762021738942812" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03818636764177785" P_Z="1.2532456797662958E-4" STUDIES="2" TAU2="0.0" TOTAL_1="317" TOTAL_2="310" WEIGHT="100.0" Z="3.8354696781536353">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="1.6208185220742695" CI_START="1.0403595229767368" EFFECT_SIZE="1.298550724637681" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="81" LOG_CI_END="0.2097343909904688" LOG_CI_START="0.017183446859270896" LOG_EFFECT_SIZE="0.11345891892486985" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88179" O_E="0.0" SE="0.1131053777252112" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="224" VAR="0.012792826470362702" WEIGHT="80.31473105819909"/>
<DICH_DATA CI_END="3.3649857904453544" CI_START="1.4054665835446887" EFFECT_SIZE="2.174712643678161" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.5269832346389846" LOG_CI_START="0.14782052425532638" LOG_EFFECT_SIZE="0.33740187944715544" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22272205296504727" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="87" TOTAL_2="86" VAR="0.04960511287696532" WEIGHT="19.68526894180092"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.341517384181408" CI_END="1.2646826536743934" CI_START="1.1240080592027173" DF="13" EFFECT_SIZE="1.1922724080779095" ESTIMABLE="YES" EVENTS_1="1097" EVENTS_2="929" I2="48.700782976339006" ID="CMP-004.07.02" LOG_CI_END="0.1019815618372145" LOG_CI_START="0.05076942516072982" LOG_EFFECT_SIZE="0.07637549349897214" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.020809605919556717" P_Z="5.035173772805357E-9" STUDIES="14" TAU2="0.0" TOTAL_1="1863" TOTAL_2="1877" WEIGHT="100.00000000000001" Z="5.846005508619748">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.536157456099993" CI_START="1.0865433434376244" EFFECT_SIZE="1.2919371727748692" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="100" LOG_CI_END="0.18643573315034767" LOG_CI_START="0.036047055498080745" LOG_EFFECT_SIZE="0.1112413943242142" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88180" O_E="0.0" SE="0.08833905368890205" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="191" TOTAL_2="199" VAR="0.007803788406650718" WEIGHT="10.597948646704129"/>
<DICH_DATA CI_END="1.408793430863048" CI_START="0.9005511750714384" EFFECT_SIZE="1.1263616557734204" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" LOG_CI_END="0.14884731786937053" LOG_CI_START="-0.04549160275600805" LOG_EFFECT_SIZE="0.051677857556681236" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.11415564396851927" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.013031511049867328" WEIGHT="8.894922812752236"/>
<DICH_DATA CI_END="1.4830399658986637" CI_START="0.837879151315788" EFFECT_SIZE="1.1147234042553191" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" LOG_CI_END="0.17115285482836756" LOG_CI_START="-0.07681861585831211" LOG_EFFECT_SIZE="0.04716711948502774" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.14565966935993205" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.021216739278044724" WEIGHT="5.387024100798837"/>
<DICH_DATA CI_END="2.6864607098855635" CI_START="1.256766049918451" EFFECT_SIZE="1.837458193979933" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" LOG_CI_END="0.4291804932930726" LOG_CI_START="0.0992544402271543" LOG_EFFECT_SIZE="0.2642174667601135" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.19380019673122237" STUDY_ID="STD-Bonneterre" TOTAL_1="65" TOTAL_2="67" VAR="0.03755851625306049" WEIGHT="2.4508702040539596"/>
<DICH_DATA CI_END="2.1064383759537617" CI_START="1.1776394829859727" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" LOG_CI_END="0.32354875832414987" LOG_CI_START="0.07101235792708874" LOG_EFFECT_SIZE="0.19728055812561932" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14834113166857663" STUDY_ID="STD-Bontenbal" TOTAL_1="106" TOTAL_2="106" VAR="0.02200509134471399" WEIGHT="4.327958086088597"/>
<DICH_DATA CI_END="1.5183458459349983" CI_START="0.9759506073659042" EFFECT_SIZE="1.217304625199362" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.1813707056001994" LOG_CI_START="-0.010572161320233463" LOG_EFFECT_SIZE="0.08539927213998297" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.11274819016157708" STUDY_ID="STD-CECOG-BM1" TOTAL_1="114" TOTAL_2="129" VAR="0.012712154384711148" WEIGHT="6.700320296240865"/>
<DICH_DATA CI_END="1.3493656075155886" CI_START="0.9082111117569299" EFFECT_SIZE="1.107027027027027" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="74" LOG_CI_END="0.13012963670963695" LOG_CI_START="-0.041813188908078294" LOG_EFFECT_SIZE="0.04415822390077935" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88182" O_E="0.0" SE="0.1010000668985596" STUDY_ID="STD-EORTC-10961" TOTAL_1="125" TOTAL_2="128" VAR="0.010201013513513515" WEIGHT="7.911781086229156"/>
<DICH_DATA CI_END="1.2331166566609042" CI_START="0.8117069561690625" EFFECT_SIZE="1.0004645760743323" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.0910041641444564" LOG_CI_START="-0.09060073219860322" LOG_EFFECT_SIZE="2.0171597292656092E-4" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.10667561507064832" STUDY_ID="STD-HERNATA" TOTAL_1="123" TOTAL_2="118" VAR="0.011379686850701133" WEIGHT="7.7310620583449845"/>
<DICH_DATA CI_END="1.5229728419683077" CI_START="1.0116713625725295" EFFECT_SIZE="1.2412687099073414" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.18269215895753657" LOG_CI_START="0.005039456574253741" LOG_EFFECT_SIZE="0.09386580776589516" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.10435407677499979" STUDY_ID="STD-Jassem" TOTAL_1="122" TOTAL_2="129" VAR="0.01088977333956255" WEIGHT="7.257520153126257"/>
<DICH_DATA CI_END="1.2730541423427089" CI_START="0.44915400232278513" EFFECT_SIZE="0.7561728395061729" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.10484687436901707" LOG_CI_START="-0.3476047260531764" LOG_EFFECT_SIZE="-0.12137892584207965" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.2657723097595395" STUDY_ID="STD-Lyman" TOTAL_1="36" TOTAL_2="35" VAR="0.07063492063492063" WEIGHT="1.9750118590038108"/>
<DICH_DATA CI_END="1.4974079276713104" CI_START="1.042543539216611" EFFECT_SIZE="1.2494450610432852" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" LOG_CI_END="0.17534012806729096" LOG_CI_START="0.01809420124452399" LOG_EFFECT_SIZE="0.09671716465590746" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.09236703579558464" STUDY_ID="STD-Nabholtz" TOTAL_1="238" TOTAL_2="237" VAR="0.008531669301662815" WEIGHT="11.493234378509804"/>
<DICH_DATA CI_END="1.9101942914513945" CI_START="0.8555830215978812" EFFECT_SIZE="1.2784090909090908" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.2810775428570588" LOG_CI_START="-0.06773784226263357" LOG_EFFECT_SIZE="0.10666985029721264" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.20489588388331093" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.04198232323232323" WEIGHT="1.978495125069073"/>
<DICH_DATA CI_END="1.032510424235336" CI_START="0.5874860608585397" EFFECT_SIZE="0.7788359788359789" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.013894444991907054" LOG_CI_START="-0.23100243333543524" LOG_EFFECT_SIZE="-0.10855399417176406" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.14385363858857964" STUDY_ID="STD-TRAVIOTA" TOTAL_1="35" TOTAL_2="32" VAR="0.020693869335173684" WEIGHT="3.0521793965326305"/>
<DICH_DATA CI_END="1.3315994703099245" CI_START="1.0358916579633837" EFFECT_SIZE="1.1744755353103407" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="186" LOG_CI_END="0.12437361372890535" LOG_CI_START="0.015314335709277042" LOG_EFFECT_SIZE="0.06984397471909119" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06406195976086253" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="347" TOTAL_2="343" VAR="0.00410393468840237" WEIGHT="20.24167179654567"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.518765877345928" CI_END="1.0508347221210463" CI_START="0.7698779005131701" DF="4" EFFECT_SIZE="0.8994522942618423" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="227" I2="61.972725254635364" ID="CMP-004.07.03" LOG_CI_END="0.021534414491301425" LOG_CI_START="-0.11357814669517324" LOG_EFFECT_SIZE="-0.0460218661019359" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.03253951771899255" P_Z="0.18181063430446553" STUDIES="5" TAU2="0.0" TOTAL_1="689" TOTAL_2="680" WEIGHT="100.0" Z="1.3352008024868767">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="1.2039759718054135" CI_START="0.54751038047308" EFFECT_SIZE="0.8119047619047619" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.08061781963239625" LOG_CI_START="-0.2616076424432017" LOG_EFFECT_SIZE="-0.09049491140540274" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88185" O_E="0.0" SE="0.20102493046656472" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="0.04041102266908718" WEIGHT="16.207803078578017"/>
<DICH_DATA CI_END="1.2100774913431935" CI_START="0.7332145201888141" EFFECT_SIZE="0.9419375707585315" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="81" LOG_CI_END="0.08281318270086843" LOG_CI_START="-0.13476894308865753" LOG_EFFECT_SIZE="-0.025977880193894534" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88186" O_E="0.0" SE="0.12780881773766062" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="224" VAR="0.01633509389149855" WEIGHT="35.81663806144042"/>
<DICH_DATA CI_END="0.8572154767817504" CI_START="0.4528417756009675" EFFECT_SIZE="0.6230433199854387" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="67" LOG_CI_END="-0.06690999649601129" LOG_CI_START="-0.34405351539732076" LOG_EFFECT_SIZE="-0.205481755946666" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="88187" O_E="0.0" SE="0.16279547488517315" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="0.02650236664308904" WEIGHT="29.392289538042412"/>
<DICH_DATA CI_END="2.0841246357233123" CI_START="0.9004743400491385" EFFECT_SIZE="1.3699272812573304" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.3189236872706438" LOG_CI_START="-0.045528658340109295" LOG_EFFECT_SIZE="0.13669751446526726" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.21408111187996276" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.04583072246376113" WEIGHT="12.726536615283896"/>
<DICH_DATA CI_END="2.2473072843259305" CI_START="0.6916693899098874" EFFECT_SIZE="1.2467532467532467" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.3516624594965548" LOG_CI_START="-0.1601014437623817" LOG_EFFECT_SIZE="0.09578050786708653" MODIFIED="2014-09-30 14:57:45 +1000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.3006126500464765" STUDY_ID="STD-Yardley" TOTAL_1="44" TOTAL_2="48" VAR="0.09036796536796536" WEIGHT="5.856732706655244"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="46.1350568087321" CI_END="1.2284260306267512" CI_START="1.100216492502246" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1625551938358112" ESTIMABLE="YES" EVENTS_1="1459" EVENTS_2="1257" I2="56.64901837464618" I2_Q="87.86693757990408" ID="CMP-004.08" LOG_CI_END="0.08934901066730315" LOG_CI_START="0.04147815083828214" LOG_EFFECT_SIZE="0.06541358075279262" METHOD="MH" MODIFIED="2014-10-29 10:03:48 +1100" MODIFIED_BY="Melina L Willson" NO="8" P_CHI2="7.723233345161562E-4" P_Q="2.63373285190327E-4" P_Z="8.48861396686722E-8" Q="16.483884535922364" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3021" TOTAL_2="3019" WEIGHT="300.0" Z="5.356421958293369">
<NAME>Subquestions A, B &amp; C: randomised patients - firstline only</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours taxane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5610048642535763" CI_END="1.83568781337182" CI_START="1.2277761014960493" DF="1" EFFECT_SIZE="1.5012706708203756" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="101" I2="71.9180389210277" ID="CMP-004.08.01" LOG_CI_END="0.26379882476386823" LOG_CI_START="0.08911917564030093" LOG_EFFECT_SIZE="0.17645900020208458" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05915207380393783" P_Z="7.499440703121234E-5" STUDIES="2" TAU2="0.0" TOTAL_1="333" TOTAL_2="332" WEIGHT="100.0" Z="3.9598577954479124">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="1.6801202557583361" CI_START="1.0668162479346912" EFFECT_SIZE="1.3387978142076502" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="81" LOG_CI_END="0.2253403677634505" LOG_CI_START="0.028089621504755448" LOG_EFFECT_SIZE="0.12671499463410296" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88188" O_E="0.0" SE="0.11586606475929873" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="244" TOTAL_2="245" VAR="0.013424944962806006" WEIGHT="79.98520999870311"/>
<DICH_DATA CI_END="3.3333490373857972" CI_START="1.3874682771237532" EFFECT_SIZE="2.150561797752809" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.5228807913305165" LOG_CI_START="0.14222306226130746" LOG_EFFECT_SIZE="0.33255192679591195" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22360023434140164" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="89" TOTAL_2="87" VAR="0.04999706479752973" WEIGHT="20.01479000129688"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.761036207951058" CI_END="1.2637745237436202" CI_START="1.1188529688680071" DF="13" EFFECT_SIZE="1.1891080177470426" ESTIMABLE="YES" EVENTS_1="1100" EVENTS_2="929" I2="22.43916283747963" ID="CMP-004.08.02" LOG_CI_END="0.10166959623363048" LOG_CI_START="0.04877301860630807" LOG_EFFECT_SIZE="0.07522130741996921" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21045981166001093" P_Z="2.4850786675075015E-8" STUDIES="14" TAU2="0.0" TOTAL_1="1974" TOTAL_2="1979" WEIGHT="100.00000000000003" Z="5.574313501030866">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.5294510592071564" CI_START="1.0644401082390673" EFFECT_SIZE="1.2759345794392523" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="100" LOG_CI_END="0.1845355845855995" LOG_CI_START="0.02712123045914323" LOG_EFFECT_SIZE="0.10582840752237133" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88189" O_E="0.0" SE="0.09246597082750033" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="0.00854995576107214" WEIGHT="10.769617672544085"/>
<DICH_DATA CI_END="1.408793430863048" CI_START="0.9005511750714384" EFFECT_SIZE="1.1263616557734204" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" LOG_CI_END="0.14884731786937053" LOG_CI_START="-0.04549160275600805" LOG_EFFECT_SIZE="0.051677857556681236" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.11415564396851927" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.013031511049867328" WEIGHT="8.874276128546498"/>
<DICH_DATA CI_END="1.5140818076277711" CI_START="0.8519764269979575" EFFECT_SIZE="1.1357649442755826" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" LOG_CI_END="0.18014934124164653" LOG_CI_START="-0.06957242139097367" LOG_EFFECT_SIZE="0.05528845992533643" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.1466877995130624" STUDY_ID="STD-Blohmer" TOTAL_1="126" TOTAL_2="114" VAR="0.021517310525984393" WEIGHT="5.3272240931794785"/>
<DICH_DATA CI_END="2.7094313789547018" CI_START="1.2408028947796468" EFFECT_SIZE="1.8335403726708075" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" LOG_CI_END="0.4328781562272794" LOG_CI_START="0.0937027980110292" LOG_EFFECT_SIZE="0.26329047711915426" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.1992332843613262" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="0.03969390159740106" WEIGHT="2.4478304693462793"/>
<DICH_DATA CI_END="2.0725262487886322" CI_START="1.153388550942963" EFFECT_SIZE="1.5461009174311926" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" LOG_CI_END="0.3165000396478214" LOG_CI_START="0.06197563609258921" LOG_EFFECT_SIZE="0.18923783787020532" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14950889456446062" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="0.022352909553887003" WEIGHT="4.3578928001543265"/>
<DICH_DATA CI_END="1.4739742050057214" CI_START="0.9306001318197358" EFFECT_SIZE="1.1711876832844574" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.168489883304783" LOG_CI_START="-0.03123689028482772" LOG_EFFECT_SIZE="0.06862649650997764" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.11732049547001158" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="0.01376409865732901" WEIGHT="6.821967739467261"/>
<DICH_DATA CI_END="1.3238943408484354" CI_START="0.8700539245050954" EFFECT_SIZE="1.073247160203682" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="74" LOG_CI_END="0.12185332572486562" LOG_CI_START="-0.06045382969259034" LOG_EFFECT_SIZE="0.03069974801613765" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88191" O_E="0.0" SE="0.10708812552718723" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="0.01146786662892661" WEIGHT="8.017185217212687"/>
<DICH_DATA CI_END="1.2955672718134004" CI_START="0.8161233848420456" EFFECT_SIZE="1.0282717282717282" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.1124599684749316" LOG_CI_START="-0.08824417788189734" LOG_EFFECT_SIZE="0.012107895296517129" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.11789460907154876" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="0.013899138848133308" WEIGHT="7.609559937315608"/>
<DICH_DATA CI_END="1.4423470887170105" CI_START="0.9412299959528678" EFFECT_SIZE="1.1651524983776769" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.15906978228082388" LOG_CI_START="-0.026304240793478612" LOG_EFFECT_SIZE="0.0663827707436726" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.10888961877005862" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="0.011856949075888704" WEIGHT="7.476295051480097"/>
<DICH_DATA CI_END="1.3985025946633711" CI_START="0.4519999851059977" EFFECT_SIZE="0.7950617283950617" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.1456632764615247" LOG_CI_START="-0.3448615794992" LOG_EFFECT_SIZE="-0.09959915151883765" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.2881367285285271" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="0.08302277432712214" WEIGHT="1.921708146776391"/>
<DICH_DATA CI_END="1.506215629448624" CI_START="1.0452120346922" EFFECT_SIZE="1.2547169811320755" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" LOG_CI_END="0.177887149803683" LOG_CI_START="0.019204401600948117" LOG_EFFECT_SIZE="0.09854577570231557" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.09321103178655833" STUDY_ID="STD-Nabholtz" TOTAL_1="242" TOTAL_2="242" VAR="0.008688296446714788" WEIGHT="11.442467150496956"/>
<DICH_DATA CI_END="1.9571470055864042" CI_START="0.8725832834508476" EFFECT_SIZE="1.3068181818181819" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.29162344769029747" LOG_CI_START="-0.05919311128341124" LOG_EFFECT_SIZE="0.11621516820344308" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.20607138331113045" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="0.04246541501976285" WEIGHT="1.9485962443033036"/>
<DICH_DATA CI_END="1.233841622370692" CI_START="0.6178975281687252" EFFECT_SIZE="0.8731481481481481" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.09125941663013439" LOG_CI_START="-0.20908354212937713" LOG_EFFECT_SIZE="-0.058912062749621345" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.17642294069696046" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="0.031125054004163225" WEIGHT="2.878608088175335"/>
<DICH_DATA CI_END="1.3458340049478892" CI_START="1.0430450773554127" EFFECT_SIZE="1.1848061165433001" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="186" LOG_CI_END="0.1289914973464983" LOG_CI_START="0.018303077768507325" LOG_EFFECT_SIZE="0.07364728755750284" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06501892557662553" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="0.004227460683138769" WEIGHT="20.106771261001715"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.933938081116654" CI_END="1.058365609632485" CI_START="0.7729408622705106" DF="4" EFFECT_SIZE="0.9044633916896734" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="227" I2="59.733995044688584" ID="CMP-004.08.03" LOG_CI_END="0.024635719511364007" LOG_CI_START="-0.11185373269496783" LOG_EFFECT_SIZE="-0.04360900659180192" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04155538393214231" P_Z="0.21041143038306975" STUDIES="5" TAU2="0.0" TOTAL_1="714" TOTAL_2="708" WEIGHT="100.0" Z="1.25243498218885">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="1.2200882556352586" CI_START="0.5522807775133903" EFFECT_SIZE="0.8208722741433022" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.08639124669858905" LOG_CI_START="-0.2578400724112023" LOG_EFFECT_SIZE="-0.08572441285630665" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88194" O_E="0.0" SE="0.20220318081760236" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="0.04088612633275599" WEIGHT="16.171597519580036"/>
<DICH_DATA CI_END="1.258310103654411" CI_START="0.7553233672910327" EFFECT_SIZE="0.9749005203550658" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="81" LOG_CI_END="0.0997876838035627" LOG_CI_START="-0.121867079411699" LOG_EFFECT_SIZE="-0.01103969780406816" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88195" O_E="0.0" SE="0.13020110512141822" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="242" TOTAL_2="245" VAR="0.016952327774838596" WEIGHT="35.31704472407776"/>
<DICH_DATA CI_END="0.858040992185618" CI_START="0.45247298153859394" EFFECT_SIZE="0.6230893724150333" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="67" LOG_CI_END="-0.0664919636026299" LOG_CI_START="-0.3444073486555197" LOG_EFFECT_SIZE="-0.2054496561290748" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="88196" O_E="0.0" SE="0.16324887288341056" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="0.02665019449770394" WEIGHT="29.48273905741182"/>
<DICH_DATA CI_END="2.0841246357233123" CI_START="0.9004743400491385" EFFECT_SIZE="1.3699272812573304" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.3189236872706438" LOG_CI_START="-0.045528658340109295" LOG_EFFECT_SIZE="0.13669751446526726" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.21408111187996276" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.04583072246376113" WEIGHT="12.766170605250643"/>
<DICH_DATA CI_END="2.0086252913417075" CI_START="0.6011990540851" EFFECT_SIZE="1.098901098901099" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.30289892675289676" LOG_CI_START="-0.22098171139508388" LOG_EFFECT_SIZE="0.04095860767890644" MODIFIED="2014-09-30 15:00:44 +1000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.307730080099106" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="0.09469780219780219" WEIGHT="6.262448093679733"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="79.29321757875822" CI_END="1.272601057457321" CI_START="1.1462697658019274" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2077847970937905" ESTIMABLE="YES" EVENTS_1="1717" EVENTS_2="1350" I2="65.94916838482159" I2_Q="96.31387950787754" ID="CMP-004.09" LOG_CI_END="0.1046922797737624" LOG_CI_START="0.0592868375371362" LOG_EFFECT_SIZE="0.08198955865544932" METHOD="MH" MODIFIED="2015-04-17 12:19:12 +1000" MODIFIED_BY="Melina L Willson" NO="9" P_CHI2="4.830420413659553E-7" P_Q="1.9034923737226705E-7" P_Z="1.4593766088941534E-12" Q="27.12879305321362" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3578" TOTAL_2="3354" WEIGHT="100.00000000000003" Z="7.078296087749116">
<NAME>Type of taxane: assessable patients</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours taxane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="30.33257458884955" CI_END="1.1351159417855738" CI_START="0.986087806531009" DF="13" EFFECT_SIZE="1.0579810911324063" ESTIMABLE="YES" EVENTS_1="872" EVENTS_2="749" I2="57.14178510656697" ID="CMP-004.09.01" LOG_CI_END="0.055040223032282114" LOG_CI_START="-0.006084411434022998" LOG_EFFECT_SIZE="0.02447790579912957" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.004216527717095464" P_Z="0.11646859076422268" STUDIES="14" TAU2="0.0" TOTAL_1="1857" TOTAL_2="1642" WEIGHT="56.126004404314614" Z="1.5697701655689966">
<NAME>Paclitaxel</NAME>
<DICH_DATA CI_END="1.408793430863048" CI_START="0.9005511750714384" EFFECT_SIZE="1.1263616557734204" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" LOG_CI_END="0.14884731786937053" LOG_CI_START="-0.04549160275600805" LOG_EFFECT_SIZE="0.051677857556681236" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.11415564396851927" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.013031511049867328" WEIGHT="5.989347767878274"/>
<DICH_DATA CI_END="1.2039759718054135" CI_START="0.54751038047308" EFFECT_SIZE="0.8119047619047619" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.08061781963239625" LOG_CI_START="-0.2616076424432017" LOG_EFFECT_SIZE="-0.09049491140540274" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88246" O_E="0.0" SE="0.20102493046656472" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="0.04041102266908718" WEIGHT="2.6999270503026827"/>
<DICH_DATA CI_END="1.5183458459349983" CI_START="0.9759506073659042" EFFECT_SIZE="1.217304625199362" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.1813707056001994" LOG_CI_START="-0.010572161320233463" LOG_EFFECT_SIZE="0.08539927213998297" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.11274819016157708" STUDY_ID="STD-CECOG-BM1" TOTAL_1="114" TOTAL_2="129" VAR="0.012712154384711148" WEIGHT="4.51162413155811"/>
<DICH_DATA CI_END="2.301539682672946" CI_START="0.3192184271607981" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36201846731051207" LOG_CI_START="-0.49591204657173854" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88247" O_E="0.0" SE="0.5039526306789697" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="0.25396825396825395" WEIGHT="0.5099862206127289"/>
<DICH_DATA CI_END="1.6967810964648395" CI_START="0.9696932079989449" EFFECT_SIZE="1.2827147401908803" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="41" LOG_CI_END="0.2296258171381967" LOG_CI_START="-0.01336564629859075" LOG_EFFECT_SIZE="0.10813008541980297" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88248" O_E="0.0" SE="0.14273438844991188" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="0.020373105646170335" WEIGHT="4.017685931811222"/>
<DICH_DATA CI_END="1.2598770545645035" CI_START="0.6871608467301118" EFFECT_SIZE="0.9304505272126957" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="41" LOG_CI_END="0.10032816644344705" LOG_CI_START="-0.16294159384136997" LOG_EFFECT_SIZE="-0.03130671369896147" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88249" O_E="0.0" SE="0.15464596039763273" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="0.02391537306730619" WEIGHT="4.011948575896867"/>
<DICH_DATA CI_END="0.8572154767817504" CI_START="0.4528417756009675" EFFECT_SIZE="0.6230433199854387" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="67" LOG_CI_END="-0.06690999649601129" LOG_CI_START="-0.34405351539732076" LOG_EFFECT_SIZE="-0.205481755946666" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88250" O_E="0.0" SE="0.16279547488517315" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="0.02650236664308904" WEIGHT="4.89622419579962"/>
<DICH_DATA CI_END="1.3493656075155886" CI_START="0.9082111117569299" EFFECT_SIZE="1.107027027027027" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="74" LOG_CI_END="0.13012963670963695" LOG_CI_START="-0.041813188908078294" LOG_EFFECT_SIZE="0.04415822390077935" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88251" O_E="0.0" SE="0.1010000668985596" STUDY_ID="STD-EORTC-10961" TOTAL_1="125" TOTAL_2="128" VAR="0.010201013513513515" WEIGHT="5.327354647846124"/>
<DICH_DATA CI_END="1.5229728419683077" CI_START="1.0116713625725295" EFFECT_SIZE="1.2412687099073414" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.18269215895753657" LOG_CI_START="0.005039456574253741" LOG_EFFECT_SIZE="0.09386580776589516" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.10435407677499979" STUDY_ID="STD-Jassem" TOTAL_1="122" TOTAL_2="129" VAR="0.01088977333956255" WEIGHT="4.886811616525841"/>
<DICH_DATA CI_END="1.2730541423427089" CI_START="0.44915400232278513" EFFECT_SIZE="0.7561728395061729" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.10484687436901707" LOG_CI_START="-0.3476047260531764" LOG_EFFECT_SIZE="-0.12137892584207965" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.2657723097595395" STUDY_ID="STD-Lyman" TOTAL_1="36" TOTAL_2="35" VAR="0.07063492063492063" WEIGHT="1.3298634646158887"/>
<DICH_DATA CI_END="1.9101942914513945" CI_START="0.8555830215978812" EFFECT_SIZE="1.2784090909090908" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.2810775428570588" LOG_CI_START="-0.06773784226263357" LOG_EFFECT_SIZE="0.10666985029721264" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.20489588388331093" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.04198232323232323" WEIGHT="1.3322089028250876"/>
<DICH_DATA CI_END="1.840869576489006" CI_START="0.28449535113941016" EFFECT_SIZE="0.7236842105263158" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2650230203249784" LOG_CI_START="-0.5459248258980733" LOG_EFFECT_SIZE="-0.14045090278654748" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="0.4763547791280005" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="0.22691387559808612" WEIGHT="0.5401944636455387"/>
<DICH_DATA CI_END="0.9807975833277779" CI_START="0.3869531621904246" EFFECT_SIZE="0.6160541586073501" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="33" LOG_CI_END="-0.008420612920178601" LOG_CI_START="-0.4123415999249679" LOG_EFFECT_SIZE="-0.21038110642257324" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.23726518720774548" STUDY_ID="STD-TOG" TOTAL_1="94" TOTAL_2="91" VAR="0.0562947690607265" WEIGHT="2.4432081179006717"/>
<DICH_DATA CI_END="1.3315994703099245" CI_START="1.0358916579633837" EFFECT_SIZE="1.1744755353103407" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="186" LOG_CI_END="0.12437361372890535" LOG_CI_START="0.015314335709277042" LOG_EFFECT_SIZE="0.06984397471909119" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06406195976086253" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="347" TOTAL_2="343" VAR="0.00410393468840237" WEIGHT="13.629619317095962"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="35.27680297152475" CI_END="1.5133456469020523" CI_START="1.294074181876935" DF="13" EFFECT_SIZE="1.3994218555931568" ESTIMABLE="YES" EVENTS_1="845" EVENTS_2="601" I2="63.148588009821836" ID="CMP-004.09.02" LOG_CI_END="0.17993813185540902" LOG_CI_START="0.1119591726668319" LOG_EFFECT_SIZE="0.14594865226112044" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="7.676083684636792E-4" P_Z="3.896901438176047E-17" STUDIES="14" TAU2="0.0" TOTAL_1="1721" TOTAL_2="1712" WEIGHT="43.87399559568541" Z="8.41596003935358">
<NAME>Docetaxel</NAME>
<DICH_DATA CI_END="1.8035920109003933" CI_START="1.0720844754249497" EFFECT_SIZE="1.3905405405405404" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="55" LOG_CI_END="0.25613830291000483" LOG_CI_START="0.030229007152908556" LOG_EFFECT_SIZE="0.1431836550314567" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88254" O_E="0.0" SE="0.13270023859676755" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="148" TOTAL_2="147" VAR="0.017609353323639037" WEIGHT="4.020617758632071"/>
<DICH_DATA CI_END="4.050499724291161" CI_START="1.6758482530661707" EFFECT_SIZE="2.6053834433722702" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="22" LOG_CI_END="0.6075086069464841" LOG_CI_START="0.22423469100091198" LOG_EFFECT_SIZE="0.41587164897369805" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88255" O_E="0.0" SE="0.22513699546291122" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="179" TOTAL_2="171" VAR="0.0506866667260669" WEIGHT="1.6394495810391234"/>
<DICH_DATA CI_END="1.536157456099993" CI_START="1.0865433434376244" EFFECT_SIZE="1.2919371727748692" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="100" LOG_CI_END="0.18643573315034767" LOG_CI_START="0.036047055498080745" LOG_EFFECT_SIZE="0.1112413943242142" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88256" O_E="0.0" SE="0.08833905368890205" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="191" TOTAL_2="199" VAR="0.007803788406650718" WEIGHT="7.1360709257898325"/>
<DICH_DATA CI_END="1.4830399658986637" CI_START="0.837879151315788" EFFECT_SIZE="1.1147234042553191" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" LOG_CI_END="0.17115285482836756" LOG_CI_START="-0.07681861585831211" LOG_EFFECT_SIZE="0.04716711948502774" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.14565966935993205" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.021216739278044724" WEIGHT="3.6273233003629324"/>
<DICH_DATA CI_END="2.6864607098855635" CI_START="1.256766049918451" EFFECT_SIZE="1.837458193979933" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" LOG_CI_END="0.4291804932930726" LOG_CI_START="0.0992544402271543" LOG_EFFECT_SIZE="0.2642174667601135" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.19380019673122237" STUDY_ID="STD-Bonneterre" TOTAL_1="65" TOTAL_2="67" VAR="0.03755851625306049" WEIGHT="1.6502800861818825"/>
<DICH_DATA CI_END="2.1064383759537617" CI_START="1.1776394829859727" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" LOG_CI_END="0.32354875832414987" LOG_CI_START="0.07101235792708874" LOG_EFFECT_SIZE="0.19728055812561932" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14834113166857663" STUDY_ID="STD-Bontenbal" TOTAL_1="106" TOTAL_2="106" VAR="0.02200509134471399" WEIGHT="2.914206974929879"/>
<DICH_DATA CI_END="3.3649857904453544" CI_START="1.4054665835446887" EFFECT_SIZE="2.174712643678161" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.5269832346389846" LOG_CI_START="0.14782052425532638" LOG_EFFECT_SIZE="0.33740187944715544" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22272205296504727" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="87" TOTAL_2="86" VAR="0.04960511287696532" WEIGHT="1.4655260509762977"/>
<DICH_DATA CI_END="1.2331166566609042" CI_START="0.8117069561690625" EFFECT_SIZE="1.0004645760743323" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.0910041641444564" LOG_CI_START="-0.09060073219860322" LOG_EFFECT_SIZE="2.0171597292656092E-4" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.10667561507064832" STUDY_ID="STD-HERNATA" TOTAL_1="123" TOTAL_2="118" VAR="0.011379686850701133" WEIGHT="5.205668475963955"/>
<DICH_DATA CI_END="2.0841246357233123" CI_START="0.9004743400491385" EFFECT_SIZE="1.3699272812573304" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.3189236872706438" LOG_CI_START="-0.045528658340109295" LOG_EFFECT_SIZE="0.13669751446526726" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.21408111187996276" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.04583072246376113" WEIGHT="2.120010978519808"/>
<DICH_DATA CI_END="3.394214123737704" CI_START="0.9058797929897697" EFFECT_SIZE="1.7534965034965035" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.530739236279962" LOG_CI_START="-0.04292942782517406" LOG_EFFECT_SIZE="0.24390490422739394" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="0.3369758130010424" STUDY_ID="STD-Meier" TOTAL_1="52" TOTAL_2="59" VAR="0.11355269854771351" WEIGHT="0.7508677430900409"/>
<DICH_DATA CI_END="1.4974079276713104" CI_START="1.042543539216611" EFFECT_SIZE="1.2494450610432852" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" LOG_CI_END="0.17534012806729096" LOG_CI_START="0.01809420124452399" LOG_EFFECT_SIZE="0.09671716465590746" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.09236703579558464" STUDY_ID="STD-Nabholtz" TOTAL_1="238" TOTAL_2="237" VAR="0.008531669301662815" WEIGHT="7.738906690897999"/>
<DICH_DATA CI_END="2.9698931881319073" CI_START="1.4218166028685626" EFFECT_SIZE="2.0549071618037136" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="29" LOG_CI_END="0.47274083024681823" LOG_CI_START="0.15284358127504383" LOG_EFFECT_SIZE="0.31279220576093103" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="88259" O_E="0.0" SE="0.18790922756294137" STUDY_ID="STD-Sjostrom" TOTAL_1="130" TOTAL_2="127" VAR="0.03530987780330129" WEIGHT="2.137463092506935"/>
<DICH_DATA CI_END="1.578252580752933" CI_START="0.7754949386113446" EFFECT_SIZE="1.106312292358804" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="35" LOG_CI_END="0.19817650815674395" LOG_CI_START="-0.11042103233179087" LOG_EFFECT_SIZE="0.043877737912476525" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="0.18127172286542734" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="0.032859437510600296" WEIGHT="2.4919781234485616"/>
<DICH_DATA CI_END="2.2473072843259305" CI_START="0.6916693899098874" EFFECT_SIZE="1.2467532467532467" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.3516624594965548" LOG_CI_START="-0.1601014437623817" LOG_EFFECT_SIZE="0.09578050786708653" MODIFIED="2014-09-30 15:02:23 +1000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.3006126500464765" STUDY_ID="STD-Yardley" TOTAL_1="44" TOTAL_2="48" VAR="0.09036796536796536" WEIGHT="0.9756258133460901"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="88.19786807627561" CI_END="1.2626590794226338" CI_START="1.1388290326048995" CI_STUDY="95" CI_TOTAL="95" DF="28" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1991467040894834" ESTIMABLE="YES" EVENTS_1="1740" EVENTS_2="1377" I2="68.25320088714057" I2_Q="77.32738612400802" ID="CMP-004.10" LOG_CI_END="0.10128610596945378" LOG_CI_START="0.05645853025168477" LOG_EFFECT_SIZE="0.07887231811056929" METHOD="MH" MODIFIED="2014-10-29 10:03:35 +1100" MODIFIED_BY="Melina L Willson" NO="10" P_CHI2="3.781821666937191E-8" P_Q="0.035716157029608064" P_Z="5.312872484239127E-12" Q="4.410607464448106" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3613" TOTAL_2="3386" WEIGHT="100.00000000000004" Z="6.896955742026718">
<NAME>Prior anthracyclines: assessable patients</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours taxane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="28.885532001525576" CI_END="1.716158965063287" CI_START="1.1973717538797217" DF="6" EFFECT_SIZE="1.4334853574188458" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="145" I2="79.22835556678301" ID="CMP-004.10.01" LOG_CI_END="0.23455751337998185" LOG_CI_START="0.07822900887993299" LOG_EFFECT_SIZE="0.1563932611299574" MODIFIED="2014-10-07 18:27:18 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="6.394786049923606E-5" P_Z="8.798055216283278E-5" STUDIES="7" TAU2="0.0" TOTAL_1="596" TOTAL_2="596" WEIGHT="10.30143550007295" Z="3.9215517377304514">
<NAME>Prior anthracyclines</NAME>
<DICH_DATA CI_END="4.050499724291161" CI_START="1.6758482530661707" EFFECT_SIZE="2.6053834433722702" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="22" LOG_CI_END="0.6075086069464841" LOG_CI_START="0.22423469100091198" LOG_EFFECT_SIZE="0.41587164897369805" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88287" O_E="0.0" SE="0.22513699546291122" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="179" TOTAL_2="171" VAR="0.0506866667260669" WEIGHT="1.6064346446315432"/>
<DICH_DATA CI_END="2.301539682672946" CI_START="0.3192184271607981" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36201846731051207" LOG_CI_START="-0.49591204657173854" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88289" O_E="0.0" SE="0.5039526306789697" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="0.25396825396825395" WEIGHT="0.49971621119188436"/>
<DICH_DATA CI_END="3.394214123737704" CI_START="0.9058797929897697" EFFECT_SIZE="1.7534965034965035" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.530739236279962" LOG_CI_START="-0.04292942782517406" LOG_EFFECT_SIZE="0.24390490422739394" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="0.3369758130010424" STUDY_ID="STD-Meier" TOTAL_1="52" TOTAL_2="59" VAR="0.11355269854771351" WEIGHT="0.7357469055386302"/>
<DICH_DATA CI_END="2.9698931881319073" CI_START="1.4218166028685626" EFFECT_SIZE="2.0549071618037136" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="29" LOG_CI_END="0.47274083024681823" LOG_CI_START="0.15284358127504383" LOG_EFFECT_SIZE="0.31279220576093103" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88290" O_E="0.0" SE="0.18790922756294137" STUDY_ID="STD-Sjostrom" TOTAL_1="130" TOTAL_2="127" VAR="0.03530987780330129" WEIGHT="2.0944192509098434"/>
<DICH_DATA CI_END="1.840869576489006" CI_START="0.28449535113941016" EFFECT_SIZE="0.7236842105263158" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2650230203249784" LOG_CI_START="-0.5459248258980733" LOG_EFFECT_SIZE="-0.14045090278654748" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="0.4763547791280005" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="0.22691387559808612" WEIGHT="0.5293161261405326"/>
<DICH_DATA CI_END="0.9807975833277779" CI_START="0.3869531621904246" EFFECT_SIZE="0.6160541586073501" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="33" LOG_CI_END="-0.008420612920178601" LOG_CI_START="-0.4123415999249679" LOG_EFFECT_SIZE="-0.21038110642257324" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.23726518720774548" STUDY_ID="STD-TOG" TOTAL_1="94" TOTAL_2="91" VAR="0.0562947690607265" WEIGHT="2.3940072387910813"/>
<DICH_DATA CI_END="1.578252580752933" CI_START="0.7754949386113446" EFFECT_SIZE="1.106312292358804" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="35" LOG_CI_END="0.19817650815674395" LOG_CI_START="-0.11042103233179087" LOG_EFFECT_SIZE="0.043877737912476525" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="0.18127172286542734" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="0.032859437510600296" WEIGHT="2.441795122869435"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="56.16035003485853" CI_END="1.2366770428284761" CI_START="1.1111492091114403" DF="21" EFFECT_SIZE="1.1722340713633672" ESTIMABLE="YES" EVENTS_1="1533" EVENTS_2="1232" I2="62.607070670027205" ID="CMP-004.10.02" LOG_CI_END="0.09225629879639073" LOG_CI_START="0.04577238148156822" LOG_EFFECT_SIZE="0.06901434013897945" MODIFIED="2014-10-07 19:21:04 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="4.780217814503995E-5" P_Z="5.888669731718507E-9" STUDIES="22" TAU2="0.0" TOTAL_1="3017" TOTAL_2="2790" WEIGHT="89.69856449992709" Z="5.819889067140391">
<NAME>Anthracyclines naive</NAME>
<DICH_DATA CI_END="1.8035920109003933" CI_START="1.0720844754249497" EFFECT_SIZE="1.3905405405405404" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="55" LOG_CI_END="0.25613830291000483" LOG_CI_START="0.030229007152908556" LOG_EFFECT_SIZE="0.1431836550314567" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88293" O_E="0.0" SE="0.13270023859676755" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="148" TOTAL_2="147" VAR="0.017609353323639037" WEIGHT="3.9396512921084152"/>
<DICH_DATA CI_END="1.536157456099993" CI_START="1.0865433434376244" EFFECT_SIZE="1.2919371727748692" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="100" LOG_CI_END="0.18643573315034767" LOG_CI_START="0.036047055498080745" LOG_EFFECT_SIZE="0.1112413943242142" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88294" O_E="0.0" SE="0.08833905368890205" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="191" TOTAL_2="199" VAR="0.007803788406650718" WEIGHT="6.992366032062264"/>
<DICH_DATA CI_END="1.408793430863048" CI_START="0.9005511750714384" EFFECT_SIZE="1.1263616557734204" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="81" LOG_CI_END="0.14884731786937053" LOG_CI_START="-0.04549160275600805" LOG_EFFECT_SIZE="0.051677857556681236" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.11415564396851927" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.013031511049867328" WEIGHT="5.868735375788697"/>
<DICH_DATA CI_END="1.2039759718054135" CI_START="0.54751038047308" EFFECT_SIZE="0.8119047619047619" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.08061781963239625" LOG_CI_START="-0.2616076424432017" LOG_EFFECT_SIZE="-0.09049491140540274" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88295" O_E="0.0" SE="0.20102493046656472" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="0.04041102266908718" WEIGHT="2.645556412192329"/>
<DICH_DATA CI_END="1.4830399658986637" CI_START="0.837879151315788" EFFECT_SIZE="1.1147234042553191" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" LOG_CI_END="0.17115285482836756" LOG_CI_START="-0.07681861585831211" LOG_EFFECT_SIZE="0.04716711948502774" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.14565966935993205" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.021216739278044724" WEIGHT="3.554276925850267"/>
<DICH_DATA CI_END="2.6864607098855635" CI_START="1.256766049918451" EFFECT_SIZE="1.837458193979933" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" LOG_CI_END="0.4291804932930726" LOG_CI_START="0.0992544402271543" LOG_EFFECT_SIZE="0.2642174667601135" MODIFIED="2014-10-07 19:21:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="2918" O_E="0.0" SE="0.19380019673122237" STUDY_ID="STD-Bonneterre" TOTAL_1="65" TOTAL_2="67" VAR="0.03755851625306049" WEIGHT="1.6170470470386735"/>
<DICH_DATA CI_END="2.1064383759537617" CI_START="1.1776394829859727" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" LOG_CI_END="0.32354875832414987" LOG_CI_START="0.07101235792708874" LOG_EFFECT_SIZE="0.19728055812561932" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14834113166857663" STUDY_ID="STD-Bontenbal" TOTAL_1="106" TOTAL_2="106" VAR="0.02200509134471399" WEIGHT="2.8555212068107676"/>
<DICH_DATA CI_END="1.5183458459349983" CI_START="0.9759506073659042" EFFECT_SIZE="1.217304625199362" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.1813707056001994" LOG_CI_START="-0.010572161320233463" LOG_EFFECT_SIZE="0.08539927213998297" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.11274819016157708" STUDY_ID="STD-CECOG-BM1" TOTAL_1="114" TOTAL_2="129" VAR="0.012712154384711148" WEIGHT="4.420769868321855"/>
<DICH_DATA CI_END="1.6967810964648395" CI_START="0.9696932079989449" EFFECT_SIZE="1.2827147401908803" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="41" LOG_CI_END="0.2296258171381967" LOG_CI_START="-0.01336564629859075" LOG_EFFECT_SIZE="0.10813008541980297" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88296" O_E="0.0" SE="0.14273438844991188" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="0.020373105646170335" WEIGHT="3.936778505880927"/>
<DICH_DATA CI_END="1.2598770545645035" CI_START="0.6871608467301118" EFFECT_SIZE="0.9304505272126957" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="41" LOG_CI_END="0.10032816644344705" LOG_CI_START="-0.16294159384136997" LOG_EFFECT_SIZE="-0.03130671369896147" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88297" O_E="0.0" SE="0.15464596039763273" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="0.02391537306730619" WEIGHT="3.9311566877927127"/>
<DICH_DATA CI_END="0.8572154767817504" CI_START="0.4528417756009675" EFFECT_SIZE="0.6230433199854387" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="67" LOG_CI_END="-0.06690999649601129" LOG_CI_START="-0.34405351539732076" LOG_EFFECT_SIZE="-0.205481755946666" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88298" O_E="0.0" SE="0.16279547488517315" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="0.02650236664308904" WEIGHT="4.797624926672281"/>
<DICH_DATA CI_END="1.3493656075155886" CI_START="0.9082111117569299" EFFECT_SIZE="1.107027027027027" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="74" LOG_CI_END="0.13012963670963695" LOG_CI_START="-0.041813188908078294" LOG_EFFECT_SIZE="0.04415822390077935" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="88299" O_E="0.0" SE="0.1010000668985596" STUDY_ID="STD-EORTC-10961" TOTAL_1="125" TOTAL_2="128" VAR="0.010201013513513515" WEIGHT="5.220073352371463"/>
<DICH_DATA CI_END="3.3649857904453544" CI_START="1.4054665835446887" EFFECT_SIZE="2.174712643678161" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.5269832346389846" LOG_CI_START="0.14782052425532638" LOG_EFFECT_SIZE="0.33740187944715544" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22272205296504727" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="87" TOTAL_2="86" VAR="0.04960511287696532" WEIGHT="1.436013554870155"/>
<DICH_DATA CI_END="1.2331166566609042" CI_START="0.8117069561690625" EFFECT_SIZE="1.0004645760743323" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.0910041641444564" LOG_CI_START="-0.09060073219860322" LOG_EFFECT_SIZE="2.0171597292656092E-4" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.10667561507064832" STUDY_ID="STD-HERNATA" TOTAL_1="123" TOTAL_2="118" VAR="0.011379686850701133" WEIGHT="5.100837674406787"/>
<DICH_DATA CI_END="1.5229728419683077" CI_START="1.0116713625725295" EFFECT_SIZE="1.2412687099073414" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.18269215895753657" LOG_CI_START="0.005039456574253741" LOG_EFFECT_SIZE="0.09386580776589516" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.10435407677499979" STUDY_ID="STD-Jassem" TOTAL_1="122" TOTAL_2="129" VAR="0.01088977333956255" WEIGHT="4.788401896201801"/>
<DICH_DATA CI_END="2.0841246357233123" CI_START="0.9004743400491385" EFFECT_SIZE="1.3699272812573304" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.3189236872706438" LOG_CI_START="-0.045528658340109295" LOG_EFFECT_SIZE="0.13669751446526726" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.21408111187996276" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.04583072246376113" WEIGHT="2.077318584408584"/>
<DICH_DATA CI_END="1.2730541423427089" CI_START="0.44915400232278513" EFFECT_SIZE="0.7561728395061729" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.10484687436901707" LOG_CI_START="-0.3476047260531764" LOG_EFFECT_SIZE="-0.12137892584207965" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.2657723097595395" STUDY_ID="STD-Lyman" TOTAL_1="36" TOTAL_2="35" VAR="0.07063492063492063" WEIGHT="1.3030829169108293"/>
<DICH_DATA CI_END="1.4974079276713104" CI_START="1.042543539216611" EFFECT_SIZE="1.2494450610432852" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" LOG_CI_END="0.17534012806729096" LOG_CI_START="0.01809420124452399" LOG_EFFECT_SIZE="0.09671716465590746" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.09236703579558464" STUDY_ID="STD-Nabholtz" TOTAL_1="238" TOTAL_2="237" VAR="0.008531669301662815" WEIGHT="7.583062000570742"/>
<DICH_DATA CI_END="1.9101942914513945" CI_START="0.8555830215978812" EFFECT_SIZE="1.2784090909090908" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.2810775428570588" LOG_CI_START="-0.06773784226263357" LOG_EFFECT_SIZE="0.10666985029721264" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.20489588388331093" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.04198232323232323" WEIGHT="1.3053811231134937"/>
<DICH_DATA CI_END="1.032510424235336" CI_START="0.5874860608585397" EFFECT_SIZE="0.7788359788359789" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.013894444991907054" LOG_CI_START="-0.23100243333543524" LOG_EFFECT_SIZE="-0.10855399417176406" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.14385363858857964" STUDY_ID="STD-TRAVIOTA" TOTAL_1="35" TOTAL_2="32" VAR="0.020693869335173684" WEIGHT="2.013781746594161"/>
<DICH_DATA CI_END="1.3315994703099245" CI_START="1.0358916579633837" EFFECT_SIZE="1.1744755353103407" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="186" LOG_CI_END="0.12437361372890535" LOG_CI_START="0.015314335709277042" LOG_EFFECT_SIZE="0.06984397471909119" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06406195976086253" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="347" TOTAL_2="343" VAR="0.00410393468840237" WEIGHT="13.355148531158012"/>
<DICH_DATA CI_END="2.2473072843259305" CI_START="0.6916693899098874" EFFECT_SIZE="1.2467532467532467" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.3516624594965548" LOG_CI_START="-0.1601014437623817" LOG_EFFECT_SIZE="0.09578050786708653" MODIFIED="2014-09-30 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.3006126500464765" STUDY_ID="STD-Yardley" TOTAL_1="44" TOTAL_2="48" VAR="0.09036796536796536" WEIGHT="0.9559788388018657"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2015-05-26 13:24:39 +1000" MODIFIED_BY="Melina L Willson" NO="5">
<NAME>Toxicity</NAME>
<DICH_OUTCOME CHI2="12.739439921021951" CI_END="1.568978902176549" CI_START="0.6341515225808123" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9974820097186866" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.19561710373358476" LOG_CI_START="-0.19780696048039212" LOG_EFFECT_SIZE="-0.0010949283734036654" METHOD="MH" MODIFIED="2014-10-08 13:30:03 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="0.7534466638524954" P_Q="0.48026869361105673" P_Z="0.9912956905354711" Q="0.4982532360649255" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2753" TOTAL_2="2764" WEIGHT="100.00000000000003" Z="0.01090945050252454">
<NAME>Treatment-related death: overall effect</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Regimen A plus taxane v Regimen A</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.132022139695531" CI_END="2.32789511158719" CI_START="0.6091703704758547" DF="8" EFFECT_SIZE="1.1908336271513749" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.36696340832960495" LOG_CI_START="-0.21526122853326263" LOG_EFFECT_SIZE="0.07585108989817119" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7433768479488536" P_Z="0.6095747510381286" STUDIES="11" TAU2="0.0" TOTAL_1="1590" TOTAL_2="1605" WEIGHT="41.99870166118901" Z="0.5106805688936893">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="2.186982133201492" CI_START="0.02777884374594708" EFFECT_SIZE="0.24647887323943662" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3398452350341176" LOG_CI_START="-1.5562858350996793" LOG_EFFECT_SIZE="-0.6082203000327808" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88150" O_E="0.0" SE="1.113796776596765" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="213" TOTAL_2="210" VAR="1.240543259557344" WEIGHT="10.88618439345398"/>
<DICH_DATA CI_END="105.20959770351858" CI_START="0.25119655064705015" EFFECT_SIZE="5.140845070422535" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0220553599655218" LOG_CI_START="-0.5999863284907232" LOG_EFFECT_SIZE="0.7110345157373994" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="1791" O_E="0.0" SE="1.540200267114884" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="2.37221686282076" WEIGHT="1.3324236106571279"/>
<DICH_DATA CI_END="101.99270598178947" CI_START="0.2406386649652676" EFFECT_SIZE="4.954128440366972" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.008569114260662" LOG_CI_START="-0.6186345904959724" LOG_EFFECT_SIZE="0.6949672618823448" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88151" O_E="0.0" SE="1.5432324610421255" STUDY_ID="STD-Bontenbal" TOTAL_1="108" TOTAL_2="107" VAR="2.381566428814135" WEIGHT="1.3574168230592771"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="1792" O_E="0.0" SE="0.0" STUDY_ID="STD-CECOG-BM1" TOTAL_1="122" TOTAL_2="130" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.051547807858793" CI_START="0.013599244969406173" EFFECT_SIZE="0.3309002433090024" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.905879375994775" LOG_CI_START="-1.8664852030064785" LOG_EFFECT_SIZE="-0.4803029135058517" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88152" O_E="0.0" SE="1.6285006771313308" STUDY_ID="STD-EORTC-10961" TOTAL_1="136" TOTAL_2="135" VAR="2.6520144554172034" WEIGHT="4.0684186644550095"/>
<DICH_DATA CI_END="72.48909181469382" CI_START="0.12238928000065902" EFFECT_SIZE="2.9785714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.860272658693637" LOG_CI_START="-0.9122566201025979" LOG_EFFECT_SIZE="0.4740080192955195" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="1790" O_E="0.0" SE="1.6285974226061801" STUDY_ID="STD-HERNATA" TOTAL_1="139" TOTAL_2="138" VAR="2.652329564919493" WEIGHT="1.3560331157982581"/>
<DICH_DATA CI_END="15.704008762411263" CI_START="0.06273113658179152" EFFECT_SIZE="0.9925373134328358" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1960105289165677" LOG_CI_START="-1.202516843712011" LOG_EFFECT_SIZE="-0.0032531573977218464" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88153" O_E="0.0" SE="1.4089068515840053" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="1.9850185164403547" WEIGHT="2.7125015552291964"/>
<DICH_DATA CI_END="73.31806196496962" CI_START="0.1281479270475493" EFFECT_SIZE="3.0652173913043477" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8652109766251017" LOG_CI_START="-0.8922884146774903" LOG_EFFECT_SIZE="0.4864612809738058" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="1794" O_E="0.0" SE="1.6197687922932713" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="2.623650940487203" WEIGHT="1.3366612141439975"/>
<DICH_DATA CI_END="5.868355253283708" CI_START="0.30040271553727893" EFFECT_SIZE="1.3277310924369747" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7685163969010896" LOG_CI_START="-0.522296145777306" LOG_EFFECT_SIZE="0.12311012556189184" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88154" O_E="0.0" SE="0.7582296771944264" STUDY_ID="STD-Nabholtz" TOTAL_1="238" TOTAL_2="237" VAR="0.574912243378364" WEIGHT="8.124208507239333"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="1796" O_E="0.0" SE="0.0" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.9557934807237825" CI_START="0.25136355261422405" EFFECT_SIZE="0.9971671388101983" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5972336103965156" LOG_CI_START="-0.5996976942158988" LOG_EFFECT_SIZE="-0.0012320419096915705" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="652" O_E="0.0" SE="0.7030833732348456" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="0.4943262297192892" WEIGHT="10.82485377715283"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.282892471802983" CI_END="1.5912115654253964" CI_START="0.46207902457326705" DF="8" EFFECT_SIZE="0.8574762317647461" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="0.20172792671654058" LOG_CI_START="-0.3352837452203976" LOG_EFFECT_SIZE="-0.06677790925192849" MODIFIED="2014-10-08 10:25:33 +1100" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="0.5064410453134623" P_Z="0.62594177215004" STUDIES="11" TAU2="0.0" TOTAL_1="1163" TOTAL_2="1159" WEIGHT="58.00129833881101" Z="0.48744674999180854">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="2.0828997755987926" CI_START="0.08072955705909736" EFFECT_SIZE="0.410062893081761" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31866837318750224" LOG_CI_START="-1.0929674303645647" LOG_EFFECT_SIZE="-0.38714952858853124" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88155" O_E="0.0" SE="0.8292018587164081" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="159" TOTAL_2="163" VAR="0.687575722498746" WEIGHT="13.344051696966845"/>
<DICH_DATA CI_END="5.496349598928588" CI_START="0.2827654518338382" EFFECT_SIZE="1.2466666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7400743485159909" LOG_CI_START="-0.5485736535543554" LOG_EFFECT_SIZE="0.0957503474808177" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88156" O_E="0.0" SE="0.7569582153266093" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="200" TOTAL_2="187" VAR="0.5729857397504455" WEIGHT="8.379473738819803"/>
<DICH_DATA CI_END="98.5987780410607" CI_START="0.24162263081195104" EFFECT_SIZE="4.880952380952381" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9938715326560903" LOG_CI_START="-0.6168623913403827" LOG_EFFECT_SIZE="0.6885045706578539" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88158" O_E="0.0" SE="1.533558030296877" STUDY_ID="STD-Dieras" TOTAL_1="41" TOTAL_2="40" VAR="2.351800232288037" WEIGHT="1.3674695396664363"/>
<DICH_DATA CI_END="3.1520007620168267" CI_START="0.034822399163893986" EFFECT_SIZE="0.3313008130081301" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4985863138110656" LOG_CI_START="-1.4581413105378707" LOG_EFFECT_SIZE="-0.4797774983634025" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88159" O_E="0.0" SE="1.1493914925005189" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="1.3211008030325702" WEIGHT="8.131933321948246"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="1793" O_E="0.0" SE="0.0" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="77.09661138611179" CI_START="0.13310191228526108" EFFECT_SIZE="3.2033898305084745" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8870352900009673" LOG_CI_START="-0.8758157049387675" LOG_EFFECT_SIZE="0.5056097925310999" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="1795" O_E="0.0" SE="1.6229123507605943" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="2.633844498251278" WEIGHT="1.3068888243065064"/>
<DICH_DATA CI_END="28.492103350199578" CI_START="0.31587699543905234" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4547245110038518" LOG_CI_START="-0.5004820015645269" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88160" O_E="0.0" SE="1.1484979839109946" STUDY_ID="STD-Sjostrom" TOTAL_1="140" TOTAL_2="140" VAR="1.319047619047619" WEIGHT="2.702380280769386"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88161" O_E="0.0" SE="0.0" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.687686949770939" CI_START="0.25367481504683265" EFFECT_SIZE="1.4845360824742269" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9389041632534602" LOG_CI_START="-0.5957226475954506" LOG_EFFECT_SIZE="0.17159075782900482" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88162" O_E="0.0" SE="0.901447385217879" STUDY_ID="STD-TOG" TOTAL_1="97" TOTAL_2="96" VAR="0.8126073883161512" WEIGHT="5.432764502272134"/>
<DICH_DATA CI_END="1.7552615616934024" CI_START="0.02495779799992704" EFFECT_SIZE="0.20930232558139536" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.24434184236081263" LOG_CI_START="-1.6027937346413361" LOG_EFFECT_SIZE="-0.6792259461402617" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="88163" O_E="0.0" SE="1.0850165813996322" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="1.1772609819121447" WEIGHT="13.204812735577683"/>
<DICH_DATA CI_END="7.693343509366659" CI_START="0.013373065734083651" EFFECT_SIZE="0.32075471698113206" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8861151242084245" LOG_CI_START="-1.8737690206534547" LOG_EFFECT_SIZE="-0.49382694822251516" MODIFIED="2014-09-30 15:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="653" O_E="0.0" SE="1.6211696083387173" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="2.6281908990011096" WEIGHT="4.131523698483965"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="261.411127992128" CI_END="1.1687543943803647" CI_START="0.9746761550332252" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0673129996832418" ESTIMABLE="YES" EVENTS_1="2207" EVENTS_2="1932" I2="89.67144198971779" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.06772325678030122" LOG_CI_START="-0.011139658603626429" LOG_EFFECT_SIZE="0.028291799088337413" METHOD="MH" MODIFIED="2015-05-26 13:24:16 +1000" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="-8.881784197001252E-16" P_Q="0.3765678797427813" P_Z="0.15964674072175605" Q="1.9533143902608723" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.036502869028830105" TOTALS="YES" TOTAL_1="3404" TOTAL_2="3160" WEIGHT="100.0" Z="1.4062606486466613">
<NAME>Leukopaenia: overall effect</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7661220617399573" CI_END="1.6620674861184714" CI_START="0.9582951804112058" DF="1" EFFECT_SIZE="1.2620424959031689" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="109" I2="73.44748832867096" ID="CMP-005.02.01" LOG_CI_END="0.22064865377650678" LOG_CI_START="-0.01850069605928931" LOG_EFFECT_SIZE="0.10107397885860876" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.052300795067838246" P_Z="0.09757676926661492" STUDIES="2" TAU2="0.029063175338748547" TOTAL_1="315" TOTAL_2="197" WEIGHT="9.14657306188575" Z="1.6567166791216923">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="1.3642865124188617" CI_START="0.8799131819253931" EFFECT_SIZE="1.0956521739130434" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="56" LOG_CI_END="0.13490558563996516" LOG_CI_START="-0.055560176112062765" LOG_EFFECT_SIZE="0.039672704763951176" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="0.1118805312738675" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="0.012517253278122843" WEIGHT="4.377704767331343"/>
<DICH_DATA CI_END="1.7179006405112571" CI_START="1.1969538438480054" EFFECT_SIZE="1.4339622641509433" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="53" LOG_CI_END="0.23499804161073695" LOG_CI_START="0.0780774037492676" LOG_EFFECT_SIZE="0.15653772268000227" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.09217595944951214" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="85" TOTAL_2="85" VAR="0.008496407500438105" WEIGHT="4.768868294554406"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="45.338648180427725" CI_END="1.19573243426101" CI_START="1.0214864778470796" DF="12" EFFECT_SIZE="1.1051807602020558" ESTIMABLE="YES" EVENTS_1="1170" EVENTS_2="1055" I2="73.53251479345984" ID="CMP-005.02.02" LOG_CI_END="0.07763400964891683" LOG_CI_START="0.009232621937368488" LOG_EFFECT_SIZE="0.04343331579314269" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="9.015233207398943E-6" P_Z="0.012807970882077007" STUDIES="13" TAU2="0.011153354728336097" TOTAL_1="1606" TOTAL_2="1603" WEIGHT="52.77047305937751" Z="2.4890645506404576">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.1489760428969233" CI_START="1.0196133240422218" EFFECT_SIZE="1.082363747703613" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="184" LOG_CI_END="0.060310973382681696" LOG_CI_START="0.008435502081856037" LOG_EFFECT_SIZE="0.03437323773226885" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="530" O_E="0.0" SE="0.03047190862982933" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="213" TOTAL_2="210" VAR="9.285372155446673E-4" WEIGHT="5.733036630184395"/>
<DICH_DATA CI_END="0.9625161212474107" CI_START="0.5882747413847057" EFFECT_SIZE="0.7524785194976867" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="89" LOG_CI_END="-0.016591987730985518" LOG_CI_START="-0.23041979841306465" LOG_EFFECT_SIZE="-0.1235058930720251" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="655" O_E="0.0" SE="0.12560351445938686" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.015776242844549405" WEIGHT="4.104806210902472"/>
<DICH_DATA CI_END="1.2578577408739422" CI_START="0.951063353253795" EFFECT_SIZE="1.0937560975609757" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="82" LOG_CI_END="0.09963152676346707" LOG_CI_START="-0.021790552408413183" LOG_EFFECT_SIZE="0.038920487177526934" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="560" O_E="0.0" SE="0.07132393035454793" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.005087103041220403" WEIGHT="5.15979243161951"/>
<DICH_DATA CI_END="2.0204624624686773" CI_START="0.8736128849727098" EFFECT_SIZE="1.3285714285714285" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.30545078623417055" LOG_CI_START="-0.05868096915481394" LOG_EFFECT_SIZE="0.12338490853967826" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="532" O_E="0.0" SE="0.2138927955967487" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="0.04575012800819252" WEIGHT="2.6089702606425695"/>
<DICH_DATA CI_END="1.1749153959610277" CI_START="0.9505410933204439" EFFECT_SIZE="1.05679012345679" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="90" LOG_CI_END="0.07000659478635125" LOG_CI_START="-0.022029103189344385" LOG_EFFECT_SIZE="0.023988745798503436" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="533" O_E="0.0" SE="0.05406222457497615" STUDY_ID="STD-Bontenbal" TOTAL_1="108" TOTAL_2="107" VAR="0.002922724125995155" WEIGHT="5.4430537614384455"/>
<DICH_DATA CI_END="1.2093852492396324" CI_START="1.00903508456511" EFFECT_SIZE="1.104677395097007" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="109" LOG_CI_END="0.08256466725247698" LOG_CI_START="0.003906267097292279" LOG_EFFECT_SIZE="0.043235467174884606" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="657" O_E="0.0" SE="0.04620433361651584" STUDY_ID="STD-CECOG-BM1" TOTAL_1="122" TOTAL_2="130" VAR="0.0021348404449462958" WEIGHT="5.554046190651144"/>
<DICH_DATA CI_END="1.206559988224829" CI_START="0.9881575002808293" EFFECT_SIZE="1.0919117647058822" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="110" LOG_CI_END="0.08154891920573798" LOG_CI_START="-0.005173828639710817" LOG_EFFECT_SIZE="0.0381875452830136" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="534" O_E="0.0" SE="0.05094137136894187" STUDY_ID="STD-EORTC-10961" TOTAL_1="136" TOTAL_2="135" VAR="0.0025950233169484502" WEIGHT="5.488674970518803"/>
<DICH_DATA CI_END="2.807785951039697" CI_START="1.309015032153775" EFFECT_SIZE="1.9171421483502853" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="29" LOG_CI_END="0.4483639966822701" LOG_CI_START="0.11694463382650136" LOG_EFFECT_SIZE="0.2826543152543858" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.1946773742937832" STUDY_ID="STD-HERNATA" TOTAL_1="139" TOTAL_2="138" VAR="0.03789928006192176" WEIGHT="2.8842664592465046"/>
<DICH_DATA CI_END="1.5576025639539735" CI_START="1.1832934195450158" EFFECT_SIZE="1.3576085091782466" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="87" LOG_CI_END="0.1924566534003587" LOG_CI_START="0.07309244935202205" LOG_EFFECT_SIZE="0.13277455137619038" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="536" O_E="0.0" SE="0.07011512432033226" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="0.004916130658455649" WEIGHT="5.1810914010119635"/>
<DICH_DATA CI_END="1.3024562466129908" CI_START="0.7529236238918989" EFFECT_SIZE="0.9902777777777778" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" LOG_CI_END="0.11476314297063803" LOG_CI_START="-0.12324907612944384" LOG_EFFECT_SIZE="-0.004242966579402887" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="537" O_E="0.0" SE="0.1398095556788741" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="0.019546711859124197" WEIGHT="3.828674893168247"/>
<DICH_DATA CI_END="1.2451770256199128" CI_START="1.0839400374914256" EFFECT_SIZE="1.161764705882353" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="192" LOG_CI_END="0.095231099049874" LOG_CI_START="0.03500525811853627" LOG_EFFECT_SIZE="0.06511817858420514" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="0.03537695708578847" STUDY_ID="STD-Nabholtz" TOTAL_1="238" TOTAL_2="237" VAR="0.001251529092649719" WEIGHT="5.683990046082137"/>
<DICH_DATA CI_END="6.525452847107317" CI_START="0.30305008845119896" EFFECT_SIZE="1.40625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8146106558073412" LOG_CI_START="-0.5184855848964657" LOG_EFFECT_SIZE="0.1480625354554377" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="658" O_E="0.0" SE="0.7830673307222339" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.6131944444444444" WEIGHT="0.3303009242428411"/>
<DICH_DATA CI_END="0.44827806500770756" CI_START="0.06510251126669783" EFFECT_SIZE="0.17083333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" LOG_CI_END="-0.34845251136659033" LOG_CI_START="-1.1864022586171505" LOG_EFFECT_SIZE="-0.7674273849918705" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="656" O_E="0.0" SE="0.4922158294531248" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="0.24227642276422764" WEIGHT="0.7697688796684766"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="188.4251268663895" CI_END="1.2135790287234995" CI_START="0.8153999094811947" DF="12" EFFECT_SIZE="0.9947623988518152" ESTIMABLE="YES" EVENTS_1="835" EVENTS_2="768" I2="93.63142262416567" ID="CMP-005.02.03" LOG_CI_END="0.08406806300909997" LOG_CI_START="-0.08862934109556164" LOG_EFFECT_SIZE="-0.0022806390432308123" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="9.992007221626409E-16" P_Z="0.958714746086792" STUDIES="13" TAU2="0.08125143836386378" TOTAL_1="1483" TOTAL_2="1360" WEIGHT="38.08295387873674" Z="0.051766503493698615">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="1.0828283484250505" CI_START="0.9832861526083501" EFFECT_SIZE="1.0318576067743659" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="153" LOG_CI_END="0.03455961706837129" LOG_CI_START="-0.00732007686363017" LOG_EFFECT_SIZE="0.01361977010237057" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="0.02460033952348606" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="159" TOTAL_2="163" VAR="6.051767046707903E-4" WEIGHT="5.7829944659300105"/>
<DICH_DATA CI_END="1.0500609345910399" CI_START="0.9499463599114752" EFFECT_SIZE="0.99875" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="176" LOG_CI_END="0.02121450172593456" LOG_CI_START="-0.022300917081838928" LOG_EFFECT_SIZE="-5.432076779521811E-4" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="540" O_E="0.0" SE="0.025561172412483225" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="200" TOTAL_2="187" VAR="6.533735351006934E-4" WEIGHT="5.775493115297693"/>
<DICH_DATA CI_END="0.6040028042064538" CI_START="0.31508419456876224" EFFECT_SIZE="0.43624733475479743" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="67" LOG_CI_END="-0.21896104507330205" LOG_CI_START="-0.5015733816045818" LOG_EFFECT_SIZE="-0.3602672133389419" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="541" O_E="0.0" SE="0.16600788543210157" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="0.027558618025637763" WEIGHT="3.3498383035638066"/>
<DICH_DATA CI_END="18.10078044382217" CI_START="0.9310750797665134" EFFECT_SIZE="4.105263157894737" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.257697300567432" LOG_CI_START="-0.031015297092128934" LOG_EFFECT_SIZE="0.6133410017376515" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="542" O_E="0.0" SE="0.7569961590954674" STUDY_ID="STD-Dieras" TOTAL_1="38" TOTAL_2="39" VAR="0.5730431848852902" WEIGHT="0.35205809592288506"/>
<DICH_DATA CI_END="1.51252862354524" CI_START="0.9812444963379822" EFFECT_SIZE="1.218261214767765" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="55" LOG_CI_END="0.1797036021212834" LOG_CI_START="-0.0082227661363703" LOG_EFFECT_SIZE="0.08574041799245652" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="543" O_E="0.0" SE="0.11038887896507155" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="0.012185704599165216" WEIGHT="4.407515092923643"/>
<DICH_DATA CI_END="0.574742873451016" CI_START="0.3875004296409879" EFFECT_SIZE="0.47192489910510615" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="139" LOG_CI_END="-0.2405264050784086" LOG_CI_START="-0.4117278116335243" LOG_EFFECT_SIZE="-0.3261271083559665" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="544" O_E="0.0" SE="0.10056455367110505" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="0.010113229455068568" WEIGHT="4.6034659720061155"/>
<DICH_DATA CI_END="2.354460770601708" CI_START="1.089923971224988" EFFECT_SIZE="1.6019310950186527" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="31" LOG_CI_END="0.3718914587400326" LOG_CI_START="0.03739620433598161" LOG_EFFECT_SIZE="0.20464383153800714" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="545" O_E="0.0" SE="0.1964841682151529" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.03860602835920051" WEIGHT="2.8571265266971086"/>
<DICH_DATA CI_END="0.4632641298703861" CI_START="0.1313573934968411" EFFECT_SIZE="0.246684350132626" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="39" LOG_CI_END="-0.3341713255305896" LOG_CI_START="-0.8815454777731259" LOG_EFFECT_SIZE="-0.6078584016518578" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="546" O_E="0.0" SE="0.32153028657301846" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="0.10338172518372739" WEIGHT="1.5340904716943382"/>
<DICH_DATA CI_END="7.202298983015497" CI_START="3.2205766312322837" EFFECT_SIZE="4.8161764705882355" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="21" LOG_CI_END="0.857471145913171" LOG_CI_START="0.5079336373299602" LOG_EFFECT_SIZE="0.6827023916215655" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="547" O_E="0.0" SE="0.20532006278035037" STUDY_ID="STD-Sjostrom" TOTAL_1="136" TOTAL_2="131" VAR="0.04215632818012701" WEIGHT="2.728169505064271"/>
<DICH_DATA CI_END="23.21027631249378" CI_START="1.444101961083674" EFFECT_SIZE="5.7894736842105265" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3656803106531188" LOG_CI_START="0.15959785775767354" LOG_EFFECT_SIZE="0.7626390842053961" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="659" O_E="0.0" SE="0.7084588030352126" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="0.5019138755980861" WEIGHT="0.39856788493272555"/>
<DICH_DATA CI_END="1.211860960770467" CI_START="0.3018467905193187" EFFECT_SIZE="0.6048109965635738" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.08345279521474874" LOG_CI_START="-0.5202134375582637" LOG_EFFECT_SIZE="-0.21838032117175749" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="548" O_E="0.0" SE="0.35459653332691277" STUDY_ID="STD-TOG" TOTAL_1="97" TOTAL_2="96" VAR="0.12573870144746435" WEIGHT="1.3226919740010072"/>
<DICH_DATA CI_END="1.4751672954884603" CI_START="1.0325563772680224" EFFECT_SIZE="1.2341772151898733" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="60" LOG_CI_END="0.16884127549213362" LOG_CI_START="0.013913773324057072" LOG_EFFECT_SIZE="0.09137752440809536" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="549" O_E="0.0" SE="0.09100518167703239" STUDY_ID="STD-TXT" TOTAL_1="79" TOTAL_2="90" VAR="0.008281943092069673" WEIGHT="4.791705333919841"/>
<DICH_DATA CI_END="1.5888126697594127" CI_START="0.023276657610182657" EFFECT_SIZE="0.19230769230769232" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2010726943843503" LOG_CI_START="-1.6330793816539486" LOG_EFFECT_SIZE="-0.7160033436347991" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="550" O_E="0.0" SE="1.0773900086641006" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="1.1607692307692308" WEIGHT="0.17923713678328296"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="351.173194651709" CI_END="1.1990915062262095" CI_START="1.0355142154822985" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1143052994405622" ESTIMABLE="YES" EVENTS_1="2207" EVENTS_2="1932" I2="92.31148606693105" I2_Q="48.31982478215288" ID="CMP-005.03" LOG_CI_END="0.07885232666240219" LOG_CI_START="0.015156065241198577" LOG_EFFECT_SIZE="0.047004195951800394" METHOD="MH" MODIFIED="2015-05-26 13:24:39 +1000" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="-1.1102230246251565E-15" P_Q="0.14442759524591864" P_Z="0.0038196717075778016" Q="3.869955919401226" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.050861417712270006" TOTALS="SUB" TOTAL_1="3404" TOTAL_2="3384" WEIGHT="300.0" Z="2.892682525857774">
<NAME>Leukopaenia: subquestions A, B &amp; C</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.824518528774268" CI_END="2.797727467026186" CI_START="1.105311300999199" DF="1" EFFECT_SIZE="1.758510672819448" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="109" I2="88.66793699011134" ID="CMP-005.03.01" LOG_CI_END="0.4468054066063757" LOG_CI_START="0.043484610388516774" LOG_EFFECT_SIZE="0.24514500849744628" MODIFIED="2014-10-08 10:26:56 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="0.0029721205572166287" P_Z="0.01719101895319883" STUDIES="2" TAU2="0.09967633220419905" TOTAL_1="315" TOTAL_2="309" WEIGHT="100.0" Z="2.3825966434184322">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="2.8289516597480686" CI_START="1.6973831024136823" EFFECT_SIZE="2.1913043478260867" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="56" LOG_CI_END="0.4516255264304672" LOG_CI_START="0.22977987442539763" LOG_EFFECT_SIZE="0.3407027004279324" MODIFIED="2014-10-08 10:26:56 +1100" MODIFIED_BY="Melina L Willson" ORDER="528" O_E="0.0" SE="0.13031323414146606" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="224" VAR="0.016981538992408556" WEIGHT="48.11299461004056"/>
<DICH_DATA CI_END="1.7179006405112571" CI_START="1.1969538438480054" EFFECT_SIZE="1.4339622641509433" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="53" LOG_CI_END="0.23499804161073695" LOG_CI_START="0.0780774037492676" LOG_EFFECT_SIZE="0.15653772268000227" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="529" O_E="0.0" SE="0.09217595944951214" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="85" TOTAL_2="85" VAR="0.008496407500438105" WEIGHT="51.887005389959434"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="45.33864818042769" CI_END="1.19573243426101" CI_START="1.0214864778470798" DF="12" EFFECT_SIZE="1.1051807602020558" ESTIMABLE="YES" EVENTS_1="1170" EVENTS_2="1055" I2="73.53251479345981" ID="CMP-005.03.02" LOG_CI_END="0.07763400964891683" LOG_CI_START="0.009232621937368582" LOG_EFFECT_SIZE="0.04343331579314269" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="9.015233206732809E-6" P_Z="0.012807970882076943" STUDIES="13" TAU2="0.011153354728336088" TOTAL_1="1606" TOTAL_2="1603" WEIGHT="100.0" Z="2.4890645506404594">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.1489760428969233" CI_START="1.0196133240422218" EFFECT_SIZE="1.082363747703613" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="184" LOG_CI_END="0.060310973382681696" LOG_CI_START="0.008435502081856037" LOG_EFFECT_SIZE="0.03437323773226885" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="530" O_E="0.0" SE="0.03047190862982933" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="213" TOTAL_2="210" VAR="9.285372155446673E-4" WEIGHT="13.361957379202995"/>
<DICH_DATA CI_END="0.9625161212474107" CI_START="0.5882747413847057" EFFECT_SIZE="0.7524785194976867" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="89" LOG_CI_END="-0.016591987730985518" LOG_CI_START="-0.23041979841306465" LOG_EFFECT_SIZE="-0.1235058930720251" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="655" O_E="0.0" SE="0.12560351445938686" STUDY_ID="STD-AGO" TOTAL_1="204" TOTAL_2="198" VAR="0.015776242844549405" WEIGHT="5.994806449570448"/>
<DICH_DATA CI_END="1.2578577408739422" CI_START="0.951063353253795" EFFECT_SIZE="1.0937560975609757" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="82" LOG_CI_END="0.09963152676346707" LOG_CI_START="-0.021790552408413183" LOG_EFFECT_SIZE="0.038920487177526934" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="560" O_E="0.0" SE="0.07132393035454793" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.005087103041220403" WEIGHT="9.940466426808076"/>
<DICH_DATA CI_END="2.0204624624686773" CI_START="0.8736128849727098" EFFECT_SIZE="1.3285714285714285" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.30545078623417055" LOG_CI_START="-0.05868096915481394" LOG_EFFECT_SIZE="0.12338490853967826" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="532" O_E="0.0" SE="0.2138927955967487" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="0.04575012800819252" WEIGHT="2.8370447194199127"/>
<DICH_DATA CI_END="1.1749153959610277" CI_START="0.9505410933204439" EFFECT_SIZE="1.05679012345679" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="90" LOG_CI_END="0.07000659478635125" LOG_CI_START="-0.022029103189344385" LOG_EFFECT_SIZE="0.023988745798503436" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="533" O_E="0.0" SE="0.05406222457497615" STUDY_ID="STD-Bontenbal" TOTAL_1="108" TOTAL_2="107" VAR="0.002922724125995155" WEIGHT="11.46894152021576"/>
<DICH_DATA CI_END="1.2093852492396324" CI_START="1.00903508456511" EFFECT_SIZE="1.104677395097007" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="109" LOG_CI_END="0.08256466725247698" LOG_CI_START="0.003906267097292279" LOG_EFFECT_SIZE="0.043235467174884606" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="657" O_E="0.0" SE="0.04620433361651584" STUDY_ID="STD-CECOG-BM1" TOTAL_1="122" TOTAL_2="130" VAR="0.0021348404449462958" WEIGHT="12.148958011909837"/>
<DICH_DATA CI_END="1.206559988224829" CI_START="0.9881575002808293" EFFECT_SIZE="1.0919117647058822" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="110" LOG_CI_END="0.08154891920573798" LOG_CI_START="-0.005173828639710817" LOG_EFFECT_SIZE="0.0381875452830136" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="534" O_E="0.0" SE="0.05094137136894187" STUDY_ID="STD-EORTC-10961" TOTAL_1="136" TOTAL_2="135" VAR="0.0025950233169484502" WEIGHT="11.74231059711375"/>
<DICH_DATA CI_END="2.807785951039697" CI_START="1.309015032153775" EFFECT_SIZE="1.9171421483502853" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="29" LOG_CI_END="0.4483639966822701" LOG_CI_START="0.11694463382650136" LOG_EFFECT_SIZE="0.2826543152543858" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="535" O_E="0.0" SE="0.1946773742937832" STUDY_ID="STD-HERNATA" TOTAL_1="139" TOTAL_2="138" VAR="0.03789928006192176" WEIGHT="3.291112208438051"/>
<DICH_DATA CI_END="1.5576025639539735" CI_START="1.1832934195450158" EFFECT_SIZE="1.3576085091782466" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="87" LOG_CI_END="0.1924566534003587" LOG_CI_START="0.07309244935202205" LOG_EFFECT_SIZE="0.13277455137619038" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="536" O_E="0.0" SE="0.07011512432033226" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="0.004916130658455649" WEIGHT="10.046228695472966"/>
<DICH_DATA CI_END="1.3024562466129908" CI_START="0.7529236238918989" EFFECT_SIZE="0.9902777777777778" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" LOG_CI_END="0.11476314297063803" LOG_CI_START="-0.12324907612944384" LOG_EFFECT_SIZE="-0.004242966579402887" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="537" O_E="0.0" SE="0.1398095556788741" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="0.019546711859124197" WEIGHT="5.258546418925728"/>
<DICH_DATA CI_END="1.2451770256199128" CI_START="1.0839400374914256" EFFECT_SIZE="1.161764705882353" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="192" LOG_CI_END="0.095231099049874" LOG_CI_START="0.03500525811853627" LOG_EFFECT_SIZE="0.06511817858420514" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="654" O_E="0.0" SE="0.03537695708578847" STUDY_ID="STD-Nabholtz" TOTAL_1="238" TOTAL_2="237" VAR="0.001251529092649719" WEIGHT="13.014045721344072"/>
<DICH_DATA CI_END="6.525452847107317" CI_START="0.30305008845119896" EFFECT_SIZE="1.40625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8146106558073412" LOG_CI_START="-0.5184855848964657" LOG_EFFECT_SIZE="0.1480625354554377" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="658" O_E="0.0" SE="0.7830673307222339" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.6131944444444444" WEIGHT="0.2585701838433081"/>
<DICH_DATA CI_END="0.44827806500770756" CI_START="0.06510251126669783" EFFECT_SIZE="0.17083333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" LOG_CI_END="-0.34845251136659033" LOG_CI_START="-1.1864022586171505" LOG_EFFECT_SIZE="-0.7674273849918705" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="656" O_E="0.0" SE="0.4922158294531248" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="0.24227642276422764" WEIGHT="0.6370116677350894"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="243.97879844632456" CI_END="1.3392333799721439" CI_START="0.8569302468713627" DF="12" EFFECT_SIZE="1.0712747504342193" ESTIMABLE="YES" EVENTS_1="835" EVENTS_2="768" I2="95.08153984017589" ID="CMP-005.03.03" LOG_CI_END="0.12685626543789694" LOG_CI_START="-0.06705452770545178" LOG_EFFECT_SIZE="0.0299008688662226" MODIFIED="2014-10-08 10:26:59 +1100" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="0.0" P_Z="0.545544939671087" STUDIES="13" TAU2="0.10832733024955574" TOTAL_1="1483" TOTAL_2="1472" WEIGHT="100.0" Z="0.6044493463644156">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="1.0828283484250505" CI_START="0.9832861526083501" EFFECT_SIZE="1.0318576067743659" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="153" LOG_CI_END="0.03455961706837129" LOG_CI_START="-0.00732007686363017" LOG_EFFECT_SIZE="0.01361977010237057" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="539" O_E="0.0" SE="0.02460033952348606" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="159" TOTAL_2="163" VAR="6.051767046707903E-4" WEIGHT="11.910271758934883"/>
<DICH_DATA CI_END="1.0500609345910399" CI_START="0.9499463599114752" EFFECT_SIZE="0.99875" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="176" LOG_CI_END="0.02121450172593456" LOG_CI_START="-0.022300917081838928" LOG_EFFECT_SIZE="-5.432076779521811E-4" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="540" O_E="0.0" SE="0.025561172412483225" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="200" TOTAL_2="187" VAR="6.533735351006934E-4" WEIGHT="11.905004428770877"/>
<DICH_DATA CI_END="0.6040028042064538" CI_START="0.31508419456876224" EFFECT_SIZE="0.43624733475479743" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="67" LOG_CI_END="-0.21896104507330205" LOG_CI_START="-0.5015733816045818" LOG_EFFECT_SIZE="-0.3602672133389419" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="541" O_E="0.0" SE="0.16600788543210157" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="0.027558618025637763" WEIGHT="9.547828731925993"/>
<DICH_DATA CI_END="18.10078044382217" CI_START="0.9310750797665134" EFFECT_SIZE="4.105263157894737" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.257697300567432" LOG_CI_START="-0.031015297092128934" LOG_EFFECT_SIZE="0.6133410017376515" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="542" O_E="0.0" SE="0.7569961590954674" STUDY_ID="STD-Dieras" TOTAL_1="38" TOTAL_2="39" VAR="0.5730431848852902" WEIGHT="1.9041266570657789"/>
<DICH_DATA CI_END="3.1376541380938314" CI_START="1.8920637165051957" EFFECT_SIZE="2.43652242953553" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="55" LOG_CI_END="0.4966050698450531" LOG_CI_START="0.27693575746782234" LOG_EFFECT_SIZE="0.3867704136564377" MODIFIED="2014-10-08 10:26:59 +1100" MODIFIED_BY="Melina L Willson" ORDER="543" O_E="0.0" SE="0.1290348414710187" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="224" VAR="0.01664999031345093" WEIGHT="10.381209609569254"/>
<DICH_DATA CI_END="0.574742873451016" CI_START="0.3875004296409879" EFFECT_SIZE="0.47192489910510615" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="139" LOG_CI_END="-0.2405264050784086" LOG_CI_START="-0.4117278116335243" LOG_EFFECT_SIZE="-0.3261271083559665" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="544" O_E="0.0" SE="0.10056455367110505" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="0.010113229455068568" WEIGHT="10.95415087907801"/>
<DICH_DATA CI_END="2.354460770601708" CI_START="1.089923971224988" EFFECT_SIZE="1.6019310950186527" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="31" LOG_CI_END="0.3718914587400326" LOG_CI_START="0.03739620433598161" LOG_EFFECT_SIZE="0.20464383153800714" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="545" O_E="0.0" SE="0.1964841682151529" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="0.03860602835920051" WEIGHT="8.829960558252594"/>
<DICH_DATA CI_END="0.4632641298703861" CI_START="0.1313573934968411" EFFECT_SIZE="0.246684350132626" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="39" LOG_CI_END="-0.3341713255305896" LOG_CI_START="-0.8815454777731259" LOG_EFFECT_SIZE="-0.6078584016518578" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="546" O_E="0.0" SE="0.32153028657301846" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="0.10338172518372739" WEIGHT="6.128296017152477"/>
<DICH_DATA CI_END="7.202298983015497" CI_START="3.2205766312322837" EFFECT_SIZE="4.8161764705882355" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="21" LOG_CI_END="0.857471145913171" LOG_CI_START="0.5079336373299602" LOG_EFFECT_SIZE="0.6827023916215655" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="547" O_E="0.0" SE="0.20532006278035037" STUDY_ID="STD-Sjostrom" TOTAL_1="136" TOTAL_2="131" VAR="0.04215632818012701" WEIGHT="8.621638885880435"/>
<DICH_DATA CI_END="23.21027631249378" CI_START="1.444101961083674" EFFECT_SIZE="5.7894736842105265" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3656803106531188" LOG_CI_START="0.15959785775767354" LOG_EFFECT_SIZE="0.7626390842053961" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="659" O_E="0.0" SE="0.7084588030352126" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="0.5019138755980861" WEIGHT="2.1260703944184756"/>
<DICH_DATA CI_END="1.211860960770467" CI_START="0.3018467905193187" EFFECT_SIZE="0.6048109965635738" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.08345279521474874" LOG_CI_START="-0.5202134375582637" LOG_EFFECT_SIZE="-0.21838032117175749" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="548" O_E="0.0" SE="0.35459653332691277" STUDY_ID="STD-TOG" TOTAL_1="97" TOTAL_2="96" VAR="0.12573870144746435" WEIGHT="5.54294765370442"/>
<DICH_DATA CI_END="1.4751672954884603" CI_START="1.0325563772680224" EFFECT_SIZE="1.2341772151898733" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="60" LOG_CI_END="0.16884127549213362" LOG_CI_START="0.013913773324057072" LOG_EFFECT_SIZE="0.09137752440809536" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="549" O_E="0.0" SE="0.09100518167703239" STUDY_ID="STD-TXT" TOTAL_1="79" TOTAL_2="90" VAR="0.008281943092069673" WEIGHT="11.126179968602635"/>
<DICH_DATA CI_END="1.5888126697594127" CI_START="0.023276657610182657" EFFECT_SIZE="0.19230769230769232" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2010726943843503" LOG_CI_START="-1.6330793816539486" LOG_EFFECT_SIZE="-0.7160033436347991" MODIFIED="2014-10-08 09:31:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="550" O_E="0.0" SE="1.0773900086641006" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="1.1607692307692308" WEIGHT="1.022314456644167"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="46.593265830849575" CI_END="0.8285608784645104" CI_START="0.46438934539379206" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6203022198646715" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="278" I2="46.34417752393865" I2_Q="49.60786415200086" ID="CMP-005.04" LOG_CI_END="-0.08167557630937451" LOG_CI_START="-0.3331177529510445" LOG_EFFECT_SIZE="-0.20739666463020956" METHOD="MH" MODIFIED="2014-10-08 13:30:50 +1100" MODIFIED_BY="Melina L Willson" NO="4" P_CHI2="0.005473446441846774" P_Q="0.13745822271651364" P_Z="0.0012238262127285359" Q="3.9688732504466993" RANDOM="YES" SCALE="134.41" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.22243897982128946" TOTALS="YES" TOTAL_1="3244" TOTAL_2="3001" WEIGHT="100.0" Z="3.233268170186351">
<NAME>Nausea or vomiting: overall effect</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4193461232340589" CI_END="1.497445672919933" CI_START="0.35372185634501707" DF="1" EFFECT_SIZE="0.7277906726532375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.1753510752155539" LOG_CI_START="-0.451338104457872" LOG_EFFECT_SIZE="-0.13799351462115908" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5172635138234338" P_Z="0.38805687581737525" STUDIES="2" TAU2="0.0" TOTAL_1="315" TOTAL_2="197" WEIGHT="8.666993484630094" Z="0.8631466045050077">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="1.4999170856175712" CI_START="0.24702058568982338" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.17606725221966496" LOG_CI_START="-0.6072668528983746" LOG_EFFECT_SIZE="-0.21559980033935483" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="0.4601343309126934" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="0.21172360248447206" WEIGHT="5.024571925986393"/>
<DICH_DATA CI_END="3.328690569990711" CI_START="0.300418431504371" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5222734256789172" LOG_CI_START="-0.5222734256789172" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="552" O_E="0.0" SE="0.6135719910778964" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="85" TOTAL_2="85" VAR="0.3764705882352941" WEIGHT="3.6424215586437"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.807308171598812" CI_END="1.1071453825454833" CI_START="0.5650108728179404" DF="11" EFFECT_SIZE="0.7909166700281237" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="153" I2="38.227609170351236" ID="CMP-005.04.02" LOG_CI_END="0.04420465312046893" LOG_CI_START="-0.24794319473029622" LOG_EFFECT_SIZE="-0.10186927080491368" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.08616083000776853" P_Z="0.17167456112809495" STUDIES="12" TAU2="0.11761568110571084" TOTAL_1="1493" TOTAL_2="1497" WEIGHT="53.6641061631573" Z="1.366842873413729">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.9481577092046212" CI_START="0.4251391096354379" EFFECT_SIZE="0.9100758396533044" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.28962411140548766" LOG_CI_START="-0.3714689413335486" LOG_EFFECT_SIZE="-0.040922414964030415" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="553" O_E="0.0" SE="0.38832933164229855" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="213" TOTAL_2="210" VAR="0.15079966981375428" WEIGHT="5.844735330867688"/>
<DICH_DATA CI_END="2.616380661998738" CI_START="0.7133428091977874" EFFECT_SIZE="1.366153846153846" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.41770093054620056" LOG_CI_START="-0.14670171227470974" LOG_EFFECT_SIZE="0.1354996091357454" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="660" O_E="0.0" SE="0.33153290623114307" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.1099140679140679" WEIGHT="6.56374640531154"/>
<DICH_DATA CI_END="3.0370237049490267" CI_START="0.3483539433523209" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4824481817399242" LOG_CI_START="-0.4579792689059011" LOG_EFFECT_SIZE="0.012234456417011586" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="554" O_E="0.0" SE="0.5524117397003164" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="0.30515873015873013" WEIGHT="4.1347433491511945"/>
<DICH_DATA CI_END="1.194164990116905" CI_START="0.23380466147447637" EFFECT_SIZE="0.528395061728395" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.07706433462174649" LOG_CI_START="-0.631146834352702" LOG_EFFECT_SIZE="-0.27704124986547773" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="0.4160067463574167" STUDY_ID="STD-Bontenbal" TOTAL_1="108" TOTAL_2="107" VAR="0.17306161301488404" WEIGHT="5.5157467823844994"/>
<DICH_DATA CI_END="1.334942901581641" CI_START="0.41161258630363207" EFFECT_SIZE="0.7412687099073414" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="23" LOG_CI_END="0.12546269037599977" LOG_CI_START="-0.38551135383515894" LOG_EFFECT_SIZE="-0.13002433172957956" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="662" O_E="0.0" SE="0.30014868293194646" STUDY_ID="STD-CECOG-BM1" TOTAL_1="122" TOTAL_2="130" VAR="0.09008923186578212" WEIGHT="6.980109445452435"/>
<DICH_DATA CI_END="0.4640469678469493" CI_START="0.058982785727412966" EFFECT_SIZE="0.16544117647058823" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" LOG_CI_END="-0.33343806072862936" LOG_CI_START="-1.229274719789081" LOG_EFFECT_SIZE="-0.7813563902588551" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="0.5262188879950896" STUDY_ID="STD-EORTC-10961" TOTAL_1="136" TOTAL_2="135" VAR="0.2769063180827887" WEIGHT="4.368682616064883"/>
<DICH_DATA CI_END="6.7899929870245295" CI_START="0.4032336303301893" EFFECT_SIZE="1.6546762589928057" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8318693257240773" LOG_CI_START="-0.3944432541970817" LOG_EFFECT_SIZE="0.2187130357634978" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="557" O_E="0.0" SE="0.7203420797908606" STUDY_ID="STD-HERNATA" TOTAL_1="139" TOTAL_2="138" VAR="0.5188927119174226" WEIGHT="2.942651915029913"/>
<DICH_DATA CI_END="4.777909233052034" CI_START="0.693008656733627" EFFECT_SIZE="1.8196517412935322" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6792378951084866" LOG_CI_START="-0.15926134035476752" LOG_EFFECT_SIZE="0.25998827737685953" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="0.49253860154927165" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="0.24259427401611217" WEIGHT="4.691021780412371"/>
<DICH_DATA CI_END="2.0442816265243753" CI_START="0.08554400273859042" EFFECT_SIZE="0.41818181818181815" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3105407253277854" LOG_CI_START="-1.0678104322810873" LOG_EFFECT_SIZE="-0.378634853476651" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.8096502929277212" STUDY_ID="STD-Lyman" TOTAL_1="44" TOTAL_2="46" VAR="0.6555335968379447" WEIGHT="2.484680251253429"/>
<DICH_DATA CI_END="11.053467973901965" CI_START="0.01953200005809987" EFFECT_SIZE="0.46464646464646464" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.0434985572641102" LOG_CI_START="-1.709253283096062" LOG_EFFECT_SIZE="-0.33287736291597586" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="663" O_E="0.0" SE="1.616980057368938" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="2.6146245059288535" WEIGHT="0.7689222089404477"/>
<DICH_DATA CI_END="5.431149398907067" CI_START="0.04836107989459014" EFFECT_SIZE="0.5125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7348917494375433" LOG_CI_START="-1.3155040099819597" LOG_EFFECT_SIZE="-0.29030613027220814" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="661" O_E="0.0" SE="1.2044126187057163" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="1.450609756097561" WEIGHT="1.303895741667801"/>
<DICH_DATA CI_END="1.2037007328471339" CI_START="0.5097704889318513" EFFECT_SIZE="0.7833333333333333" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="42" LOG_CI_END="0.08051852493799201" LOG_CI_START="-0.2926253098338443" LOG_EFFECT_SIZE="-0.10605339244792618" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="665" O_E="0.0" SE="0.2191865356367483" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="330" TOTAL_2="329" VAR="0.04804273740443953" WEIGHT="8.065170336621101"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="19.36361428565721" CI_END="0.7117446250162649" CI_START="0.25620104211147354" DF="11" EFFECT_SIZE="0.42702425533733684" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="112" I2="43.19242349220005" ID="CMP-005.04.03" LOG_CI_END="-0.14767580389240972" LOG_CI_START="-0.5914191080716524" LOG_EFFECT_SIZE="-0.36954745598203104" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.05487079645908821" P_Z="0.0010965799331591332" STUDIES="12" TAU2="0.32407736215894944" TOTAL_1="1436" TOTAL_2="1307" WEIGHT="37.668900352212596" Z="3.264498630093641">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="0.6662250106077457" CI_START="0.09859162961394326" EFFECT_SIZE="0.2562893081761006" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="20" LOG_CI_END="-0.17637906758442912" LOG_CI_START="-1.006159954904483" LOG_EFFECT_SIZE="-0.591269511244456" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="0.4874174006934365" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="159" TOTAL_2="163" VAR="0.237575722498746" WEIGHT="4.742198697922516"/>
<DICH_DATA CI_END="3.177970519039005" CI_START="0.27508908429533185" EFFECT_SIZE="0.935" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5021498640865691" LOG_CI_START="-0.5605266423415334" LOG_EFFECT_SIZE="-0.0291883891274822" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.6242214402094118" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="200" TOTAL_2="187" VAR="0.3896524064171123" WEIGHT="3.5639794504764155"/>
<DICH_DATA CI_END="0.9252991828832365" CI_START="0.015011691763486393" EFFECT_SIZE="0.11785714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.03371782135080984" LOG_CI_START="-1.8235703615778538" LOG_EFFECT_SIZE="-0.9286440914643318" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="1.0513682420423305" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="1.1053751803751803" WEIGHT="1.6429114764407269"/>
<DICH_DATA CI_END="73.25905270934848" CI_START="0.12923256950732645" EFFECT_SIZE="3.076923076923077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8648612986342514" LOG_CI_START="-0.8886280205920004" LOG_EFFECT_SIZE="0.4881166390211256" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="1.6174132561054522" STUDY_ID="STD-Dieras" TOTAL_1="38" TOTAL_2="39" VAR="2.616025641025641" WEIGHT="0.7685426502573015"/>
<DICH_DATA CI_END="1.2181986513722876" CI_START="0.14426247774161072" EFFECT_SIZE="0.4192139737991266" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.08571811437251307" LOG_CI_START="-0.8408466129731522" LOG_EFFECT_SIZE="-0.3775642493003196" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="0.5442687074122154" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="0.29622842586816384" WEIGHT="4.205934474458619"/>
<DICH_DATA CI_END="0.512836198892118" CI_START="0.06367712708672232" EFFECT_SIZE="0.18070953436807094" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="22" LOG_CI_END="-0.2900213274357156" LOG_CI_START="-1.1960165388402524" LOG_EFFECT_SIZE="-0.743018933137984" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="0.5321860719276504" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="0.2832220151537823" WEIGHT="4.314117845840235"/>
<DICH_DATA CI_END="2.195010555209821" CI_START="0.028087588021388877" EFFECT_SIZE="0.24829931972789115" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3414366129874153" LOG_CI_START="-1.551485553570818" LOG_EFFECT_SIZE="-0.6050244702917014" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="1.11191185075215" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="1.2363479638430714" WEIGHT="1.495407627441176"/>
<DICH_DATA CI_END="1.2175758668749004" CI_START="0.2336153764073164" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.08549603152001763" LOG_CI_START="-0.631498575647493" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.42116618143074164" STUDY_ID="STD-Sjostrom" TOTAL_1="140" TOTAL_2="140" VAR="0.17738095238095236" WEIGHT="5.456159002257603"/>
<DICH_DATA CI_END="1.2232037018163102" CI_START="0.1217858589625333" EFFECT_SIZE="0.38596491228070173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.08749878672405104" LOG_CI_START="-0.9144031364246213" LOG_EFFECT_SIZE="-0.4134521748502852" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="664" O_E="0.0" SE="0.5885221491520354" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="0.34635832004253053" WEIGHT="3.8352522469596306"/>
<DICH_DATA CI_END="0.4897141370354578" CI_START="0.008889428436747672" EFFECT_SIZE="0.06597938144329897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.310057358616314" LOG_CI_START="-2.0511261619484014" LOG_EFFECT_SIZE="-1.1805917602823577" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="1.022712433506841" STUDY_ID="STD-TOG" TOTAL_1="97" TOTAL_2="96" VAR="1.0459407216494845" WEIGHT="1.719895958471827"/>
<DICH_DATA CI_END="3.014558148505397" CI_START="0.2325114930186366" EFFECT_SIZE="0.8372093023255814" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4792236654883053" LOG_CI_START="-0.6335555751129038" LOG_EFFECT_SIZE="-0.07716595481229924" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.6536520342752287" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="0.4272609819121447" WEIGHT="3.3576746973279454"/>
<DICH_DATA CI_END="13.624855488776609" CI_START="0.6107225081406655" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1343319046543885" LOG_CI_START="-0.21415607381262425" LOG_EFFECT_SIZE="0.46008791542088207" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.7921085136746716" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="0.6274358974358973" WEIGHT="2.566826224358592"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="47.440007722879265" CI_END="0.9452100229521425" CI_START="0.5567120617176443" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7254032124507508" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="278" I2="47.30186355356967" I2_Q="55.69797281440528" ID="CMP-005.05" LOG_CI_END="-0.024471681781809126" LOG_CI_START="-0.2543693691714738" LOG_EFFECT_SIZE="-0.1394205254766415" METHOD="MH" MODIFIED="2014-10-08 13:31:16 +1100" MODIFIED_BY="Melina L Willson" NO="5" P_CHI2="0.004349382232281096" P_Q="0.10463974273241328" P_Z="0.017443467499845742" Q="4.51446610246838" RANDOM="YES" SCALE="134.41" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.23151368275500198" TOTALS="SUB" TOTAL_1="3244" TOTAL_2="3225" WEIGHT="300.0" Z="2.3772245101074563">
<NAME>Nausea or vomiting: subquestions A, B &amp; C</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.06530087313781484" CI_END="2.3426280586458943" CI_START="0.548063896018589" DF="1" EFFECT_SIZE="1.1330974630383444" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.36970334070950894" LOG_CI_START="-0.26116880635025225" LOG_EFFECT_SIZE="0.05426726717962832" MODIFIED="2014-10-08 10:30:45 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="0.7983057828010368" P_Z="0.7359736767858256" STUDIES="2" TAU2="0.0" TOTAL_1="315" TOTAL_2="309" WEIGHT="100.0" Z="0.3371899986619909">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="3.0283421695362738" CI_START="0.48939040073158063" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.48120494412590287" LOG_CI_START="-0.3103445534766502" LOG_EFFECT_SIZE="0.08543019532462637" MODIFIED="2014-10-08 10:30:45 +1100" MODIFIED_BY="Melina L Willson" ORDER="551" O_E="0.0" SE="0.46496009312494524" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="224" VAR="0.21618788819875775" WEIGHT="63.52234941453435"/>
<DICH_DATA CI_END="3.328690569990711" CI_START="0.300418431504371" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5222734256789172" LOG_CI_START="-0.5222734256789172" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="552" O_E="0.0" SE="0.6135719910778964" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="85" TOTAL_2="85" VAR="0.3764705882352941" WEIGHT="36.47765058546565"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.807308171598816" CI_END="1.1071453825454833" CI_START="0.5650108728179403" DF="11" EFFECT_SIZE="0.7909166700281237" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="153" I2="38.22760917035124" ID="CMP-005.05.02" LOG_CI_END="0.04420465312046893" LOG_CI_START="-0.2479431947302963" LOG_EFFECT_SIZE="-0.10186927080491368" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.08616083000776853" P_Z="0.17167456112809504" STUDIES="12" TAU2="0.11761568110571093" TOTAL_1="1493" TOTAL_2="1497" WEIGHT="100.0" Z="1.3668428734137288">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="1.9481577092046212" CI_START="0.4251391096354379" EFFECT_SIZE="0.9100758396533044" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.28962411140548766" LOG_CI_START="-0.3714689413335486" LOG_EFFECT_SIZE="-0.040922414964030415" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="553" O_E="0.0" SE="0.38832933164229855" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="213" TOTAL_2="210" VAR="0.15079966981375428" WEIGHT="10.97168263672301"/>
<DICH_DATA CI_END="2.616380661998738" CI_START="0.7133428091977874" EFFECT_SIZE="1.366153846153846" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.41770093054620056" LOG_CI_START="-0.14670171227470974" LOG_EFFECT_SIZE="0.1354996091357454" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="660" O_E="0.0" SE="0.33153290623114307" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.1099140679140679" WEIGHT="12.943221964601246"/>
<DICH_DATA CI_END="3.0370237049490267" CI_START="0.3483539433523209" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4824481817399242" LOG_CI_START="-0.4579792689059011" LOG_EFFECT_SIZE="0.012234456417011586" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="554" O_E="0.0" SE="0.5524117397003164" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="0.30515873015873013" WEIGHT="6.965814312898334"/>
<DICH_DATA CI_END="1.194164990116905" CI_START="0.23380466147447637" EFFECT_SIZE="0.528395061728395" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.07706433462174649" LOG_CI_START="-0.631146834352702" LOG_EFFECT_SIZE="-0.27704124986547773" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="555" O_E="0.0" SE="0.4160067463574167" STUDY_ID="STD-Bontenbal" TOTAL_1="108" TOTAL_2="107" VAR="0.17306161301488404" WEIGHT="10.131400369686991"/>
<DICH_DATA CI_END="1.334942901581641" CI_START="0.41161258630363207" EFFECT_SIZE="0.7412687099073414" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="23" LOG_CI_END="0.12546269037599977" LOG_CI_START="-0.38551135383515894" LOG_EFFECT_SIZE="-0.13002433172957956" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="662" O_E="0.0" SE="0.30014868293194646" STUDY_ID="STD-CECOG-BM1" TOTAL_1="122" TOTAL_2="130" VAR="0.09008923186578212" WEIGHT="14.178615243045305"/>
<DICH_DATA CI_END="0.4640469678469493" CI_START="0.058982785727412966" EFFECT_SIZE="0.16544117647058823" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" LOG_CI_END="-0.33343806072862936" LOG_CI_START="-1.229274719789081" LOG_EFFECT_SIZE="-0.7813563902588551" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="556" O_E="0.0" SE="0.5262188879950896" STUDY_ID="STD-EORTC-10961" TOTAL_1="136" TOTAL_2="135" VAR="0.2769063180827887" WEIGHT="7.464648488983061"/>
<DICH_DATA CI_END="6.7899929870245295" CI_START="0.4032336303301893" EFFECT_SIZE="1.6546762589928057" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8318693257240773" LOG_CI_START="-0.3944432541970817" LOG_EFFECT_SIZE="0.2187130357634978" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="557" O_E="0.0" SE="0.7203420797908606" STUDY_ID="STD-HERNATA" TOTAL_1="139" TOTAL_2="138" VAR="0.5188927119174226" WEIGHT="4.626754458218081"/>
<DICH_DATA CI_END="4.777909233052034" CI_START="0.693008656733627" EFFECT_SIZE="1.8196517412935322" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6792378951084866" LOG_CI_START="-0.15926134035476752" LOG_EFFECT_SIZE="0.25998827737685953" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="558" O_E="0.0" SE="0.49253860154927165" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="0.24259427401611217" WEIGHT="8.175698653628329"/>
<DICH_DATA CI_END="2.0442816265243753" CI_START="0.08554400273859042" EFFECT_SIZE="0.41818181818181815" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3105407253277854" LOG_CI_START="-1.0678104322810873" LOG_EFFECT_SIZE="-0.378634853476651" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="559" O_E="0.0" SE="0.8096502929277212" STUDY_ID="STD-Lyman" TOTAL_1="44" TOTAL_2="46" VAR="0.6555335968379447" WEIGHT="3.809054899392442"/>
<DICH_DATA CI_END="11.053467973901965" CI_START="0.01953200005809987" EFFECT_SIZE="0.46464646464646464" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.0434985572641102" LOG_CI_START="-1.709253283096062" LOG_EFFECT_SIZE="-0.33287736291597586" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="663" O_E="0.0" SE="1.616980057368938" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="2.6146245059288535" WEIGHT="1.0778584031842857"/>
<DICH_DATA CI_END="5.431149398907067" CI_START="0.04836107989459014" EFFECT_SIZE="0.5125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7348917494375433" LOG_CI_START="-1.3155040099819597" LOG_EFFECT_SIZE="-0.29030613027220814" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="661" O_E="0.0" SE="1.2044126187057163" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="1.450609756097561" WEIGHT="1.8778984036663637"/>
<DICH_DATA CI_END="1.2037007328471339" CI_START="0.5097704889318513" EFFECT_SIZE="0.7833333333333333" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="42" LOG_CI_END="0.08051852493799201" LOG_CI_START="-0.2926253098338443" LOG_EFFECT_SIZE="-0.10605339244792618" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="665" O_E="0.0" SE="0.2191865356367483" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="330" TOTAL_2="329" VAR="0.04804273740443953" WEIGHT="17.777352165972548"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.830481240893103" CI_END="0.7832671976919967" CI_START="0.2705352974043352" DF="11" EFFECT_SIZE="0.4603275184851157" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="112" I2="47.192770667220664" ID="CMP-005.05.03" LOG_CI_END="-0.10609006081811738" LOG_CI_START="-0.5677760633934631" LOG_EFFECT_SIZE="-0.3369330621057902" MODIFIED="2014-10-08 10:30:47 +1100" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="0.035170493623888355" P_Z="0.004226831996122987" STUDIES="12" TAU2="0.38157294520095736" TOTAL_1="1436" TOTAL_2="1419" WEIGHT="100.0" Z="2.8607177312913006">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="0.6662250106077457" CI_START="0.09859162961394326" EFFECT_SIZE="0.2562893081761006" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="20" LOG_CI_END="-0.17637906758442912" LOG_CI_START="-1.006159954904483" LOG_EFFECT_SIZE="-0.591269511244456" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="561" O_E="0.0" SE="0.4874174006934365" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="159" TOTAL_2="163" VAR="0.237575722498746" WEIGHT="11.878830266711587"/>
<DICH_DATA CI_END="3.177970519039005" CI_START="0.27508908429533185" EFFECT_SIZE="0.935" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5021498640865691" LOG_CI_START="-0.5605266423415334" LOG_EFFECT_SIZE="-0.0291883891274822" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="562" O_E="0.0" SE="0.6242214402094118" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="200" TOTAL_2="187" VAR="0.3896524064171123" WEIGHT="9.53646287435278"/>
<DICH_DATA CI_END="0.9252991828832365" CI_START="0.015011691763486393" EFFECT_SIZE="0.11785714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.03371782135080984" LOG_CI_START="-1.8235703615778538" LOG_EFFECT_SIZE="-0.9286440914643318" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="563" O_E="0.0" SE="1.0513682420423305" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="1.1053751803751803" WEIGHT="4.946212855015161"/>
<DICH_DATA CI_END="73.25905270934848" CI_START="0.12923256950732645" EFFECT_SIZE="3.076923076923077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8648612986342514" LOG_CI_START="-0.8886280205920004" LOG_EFFECT_SIZE="0.4881166390211256" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="564" O_E="0.0" SE="1.6174132561054522" STUDY_ID="STD-Dieras" TOTAL_1="38" TOTAL_2="39" VAR="2.616025641025641" WEIGHT="2.453551308457089"/>
<DICH_DATA CI_END="2.4559865541670716" CI_START="0.286223644881567" EFFECT_SIZE="0.8384279475982532" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.39022598483597454" LOG_CI_START="-0.5432944921086513" LOG_EFFECT_SIZE="-0.07653425363633841" MODIFIED="2014-10-08 10:30:47 +1100" MODIFIED_BY="Melina L Willson" ORDER="565" O_E="0.0" SE="0.5483545491581606" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="224" VAR="0.3006927115824496" WEIGHT="10.779909351058313"/>
<DICH_DATA CI_END="0.512836198892118" CI_START="0.06367712708672232" EFFECT_SIZE="0.18070953436807094" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="22" LOG_CI_END="-0.2900213274357156" LOG_CI_START="-1.1960165388402524" LOG_EFFECT_SIZE="-0.743018933137984" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="566" O_E="0.0" SE="0.5321860719276504" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="0.2832220151537823" WEIGHT="11.063203501935144"/>
<DICH_DATA CI_END="2.195010555209821" CI_START="0.028087588021388877" EFFECT_SIZE="0.24829931972789115" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3414366129874153" LOG_CI_START="-1.551485553570818" LOG_EFFECT_SIZE="-0.6050244702917014" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="567" O_E="0.0" SE="1.11191185075215" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="1.2363479638430714" WEIGHT="4.545810547569383"/>
<DICH_DATA CI_END="1.2175758668749004" CI_START="0.2336153764073164" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.08549603152001763" LOG_CI_START="-0.631498575647493" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="569" O_E="0.0" SE="0.42116618143074164" STUDY_ID="STD-Sjostrom" TOTAL_1="140" TOTAL_2="140" VAR="0.17738095238095236" WEIGHT="13.158083278930201"/>
<DICH_DATA CI_END="1.2232037018163102" CI_START="0.1217858589625333" EFFECT_SIZE="0.38596491228070173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.08749878672405104" LOG_CI_START="-0.9144031364246213" LOG_EFFECT_SIZE="-0.4134521748502852" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="664" O_E="0.0" SE="0.5885221491520354" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="0.34635832004253053" WEIGHT="10.103648908396968"/>
<DICH_DATA CI_END="0.4897141370354578" CI_START="0.008889428436747672" EFFECT_SIZE="0.06597938144329897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.310057358616314" LOG_CI_START="-2.0511261619484014" LOG_EFFECT_SIZE="-1.1805917602823577" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="570" O_E="0.0" SE="1.022712433506841" STUDY_ID="STD-TOG" TOTAL_1="97" TOTAL_2="96" VAR="1.0459407216494845" WEIGHT="5.152148175010037"/>
<DICH_DATA CI_END="3.014558148505397" CI_START="0.2325114930186366" EFFECT_SIZE="0.8372093023255814" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4792236654883053" LOG_CI_START="-0.6335555751129038" LOG_EFFECT_SIZE="-0.07716595481229924" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="571" O_E="0.0" SE="0.6536520342752287" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="0.4272609819121447" WEIGHT="9.093043314486176"/>
<DICH_DATA CI_END="13.624855488776609" CI_START="0.6107225081406655" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1343319046543885" LOG_CI_START="-0.21415607381262425" LOG_EFFECT_SIZE="0.46008791542088207" MODIFIED="2014-10-08 10:29:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="572" O_E="0.0" SE="0.7921085136746716" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="0.6274358974358973" WEIGHT="7.2890956180771465"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.731119612569497" CI_END="7.353081123698319" CI_START="3.180791438774303" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="4.836177983374117" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="27" I2="7.615637250055426" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.8664693574011137" LOG_CI_START="0.5025351937980536" LOG_EFFECT_SIZE="0.6845022755995837" METHOD="MH" MODIFIED="2014-10-08 13:31:41 +1100" MODIFIED_BY="Melina L Willson" NO="6" P_CHI2="0.35848047282544804" P_Q="0.9628734691805884" P_Z="1.6712993198503643E-13" Q="0.07566653760521456" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07440847928088899" TOTALS="YES" TOTAL_1="3013" TOTAL_2="2770" WEIGHT="100.0" Z="7.372761019348356">
<NAME>Neurotoxicity: overall effect</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.244449267265296" CI_START="1.467690552694566" DF="0" EFFECT_SIZE="6.086956521739131" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="2" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="1.4021659005693683" LOG_CI_START="0.16663449875192202" LOG_EFFECT_SIZE="0.7844001996606452" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.01282329096677706" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="112" WEIGHT="7.602404086433073" Z="2.48863952553437">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="25.244449267265296" CI_START="1.467690552694566" EFFECT_SIZE="6.086956521739131" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="2" LOG_CI_END="1.4021659005693683" LOG_CI_START="0.16663449875192202" LOG_EFFECT_SIZE="0.7844001996606452" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.7257572614066442" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="0.5267236024844721" WEIGHT="7.602404086433073"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.441461746337955" CI_END="9.384696918968771" CI_START="2.5493728341027526" DF="9" EFFECT_SIZE="4.891328181742336" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="18" I2="27.66123319352665" ID="CMP-005.06.02" LOG_CI_END="0.9724202515396919" LOG_CI_START="0.40643335369323746" LOG_EFFECT_SIZE="0.6894268026164647" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.18955007123363243" P_Z="1.798398820301109E-6" STUDIES="12" TAU2="0.26602711180928185" TOTAL_1="1494" TOTAL_2="1497" WEIGHT="60.55973878402206" Z="4.774851531886359">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.0" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="213" TOTAL_2="210" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="666" O_E="0.0" SE="0.0" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="105.20959770351858" CI_START="0.25119655064705015" EFFECT_SIZE="5.140845070422535" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0220553599655218" LOG_CI_START="-0.5999863284907232" LOG_EFFECT_SIZE="0.7110345157373994" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="1.540200267114884" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="2.37221686282076" WEIGHT="1.8678989856997616"/>
<DICH_DATA CI_END="194.70421790715125" CI_START="0.6101049176979181" EFFECT_SIZE="10.899082568807339" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2893753598094997" LOG_CI_START="-0.21459547440039722" LOG_EFFECT_SIZE="1.037389942704551" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="1.4708448628704243" STUDY_ID="STD-Bontenbal" TOTAL_1="108" TOTAL_2="107" VAR="2.163384610632317" WEIGHT="2.042212488499665"/>
<DICH_DATA CI_END="243.1935471275427" CI_START="0.7882555292701005" EFFECT_SIZE="13.845528455284553" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.385952047228657" LOG_CI_START="-0.10333297418225068" LOG_EFFECT_SIZE="1.141309536523203" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="668" O_E="0.0" SE="1.4622183437363523" STUDY_ID="STD-CECOG-BM1" TOTAL_1="122" TOTAL_2="130" VAR="2.138082484759081" WEIGHT="2.0655673036305524"/>
<DICH_DATA CI_END="164.34899153222312" CI_START="0.48568496302185316" EFFECT_SIZE="8.934306569343066" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.215767043535779" LOG_CI_START="-0.3136453422295077" LOG_EFFECT_SIZE="0.9510608506531356" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="1.4857893561917717" STUDY_ID="STD-EORTC-10961" TOTAL_1="136" TOTAL_2="135" VAR="2.207570010972759" WEIGHT="2.0026696195506335"/>
<DICH_DATA CI_END="16.17165774256843" CI_START="3.1304620360531925" EFFECT_SIZE="7.115107913669065" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="6" LOG_CI_END="1.20875454133794" LOG_CI_START="0.4956084413482288" LOG_EFFECT_SIZE="0.8521814913430843" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="0.41890554926408446" STUDY_ID="STD-HERNATA" TOTAL_1="139" TOTAL_2="138" VAR="0.17548185920424428" WEIGHT="18.288218034371457"/>
<DICH_DATA CI_END="540.4455608444457" CI_START="1.9852627118939417" EFFECT_SIZE="32.75555555555555" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="2.7327519539496823" LOG_CI_START="0.2978179855456958" LOG_EFFECT_SIZE="1.515284969747689" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="1.4302922661580355" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="2.0457359666314887" WEIGHT="2.155536620964681"/>
<DICH_DATA CI_END="73.31806196496962" CI_START="0.1281479270475493" EFFECT_SIZE="3.0652173913043477" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8652109766251017" LOG_CI_START="-0.8922884146774903" LOG_EFFECT_SIZE="0.4864612809738058" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="1.6197687922932713" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="2.623650940487203" WEIGHT="1.6938281497491317"/>
<DICH_DATA CI_END="3.3528378654359794" CI_START="0.5898105252527189" EFFECT_SIZE="1.40625" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5254125525791405" LOG_CI_START="-0.22928748166826513" LOG_EFFECT_SIZE="0.1480625354554377" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="670" O_E="0.0" SE="0.4433145359423462" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.19652777777777777" WEIGHT="16.867616924040675"/>
<DICH_DATA CI_END="41.95152918959903" CI_START="0.626094578848201" EFFECT_SIZE="5.125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.622747796070571" LOG_CI_START="-0.20336005661498693" LOG_EFFECT_SIZE="0.7096938697277919" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="667" O_E="0.0" SE="1.0726647920471526" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="1.150609756097561" WEIGHT="3.7305967069846577"/>
<DICH_DATA CI_END="18.07568190099063" CI_START="1.5641078010086784" EFFECT_SIZE="5.317171717171717" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.2570946899362143" LOG_CI_START="0.19426668208048403" LOG_EFFECT_SIZE="0.7256806860083491" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="672" O_E="0.0" SE="0.6243104328979444" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="330" TOTAL_2="329" VAR="0.38976351662521874" WEIGHT="9.845593950530844"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.036314591629798" CI_END="10.583368878284013" CI_START="2.497437835428474" DF="10" EFFECT_SIZE="5.141138576514225" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="7" I2="0.36183193838985983" ID="CMP-005.06.03" LOG_CI_END="1.0246239335177825" LOG_CI_START="0.3974946868614291" LOG_EFFECT_SIZE="0.7110593101896058" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.43731316397256437" P_Z="8.807995303404172E-6" STUDIES="11" TAU2="0.005547326167042299" TOTAL_1="1289" TOTAL_2="1161" WEIGHT="31.837857129544872" Z="4.444540407815481">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="299.38942312924155" CI_START="1.0141661713577887" EFFECT_SIZE="17.425" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.476236453462796" LOG_CI_START="0.006109120077297962" LOG_EFFECT_SIZE="1.241172786770047" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="582" O_E="0.0" SE="1.4509650229581414" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="159" TOTAL_2="163" VAR="2.10529949784792" WEIGHT="2.0966336054423396"/>
<DICH_DATA CI_END="72.33531944049352" CI_START="1.2085728061506371" EFFECT_SIZE="9.35" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8593504036939148" LOG_CI_START="0.08227281805112058" LOG_EFFECT_SIZE="0.9708116108725178" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="583" O_E="0.0" SE="1.0438641704824974" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="200" TOTAL_2="187" VAR="1.0896524064171125" WEIGHT="3.9259535742915035"/>
<DICH_DATA CI_END="333.65291510215513" CI_START="1.1763374820990566" EFFECT_SIZE="19.81132075471698" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.5232949236038427" LOG_CI_START="0.07053193533445498" LOG_EFFECT_SIZE="1.2969134294691491" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="1.440765120682044" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="2.0758041329739445" WEIGHT="2.1253940046917466"/>
<DICH_DATA CI_END="165.80316501833371" CI_START="0.513905151221294" EFFECT_SIZE="9.23076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.219592816545244" LOG_CI_START="-0.28911702906366776" LOG_EFFECT_SIZE="0.965237893740788" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="585" O_E="0.0" SE="1.4736285816246903" STUDY_ID="STD-Dieras" TOTAL_1="38" TOTAL_2="39" VAR="2.171581196581197" WEIGHT="2.034759573480615"/>
<DICH_DATA CI_END="9.061089727086788" CI_START="0.42238125116217873" EFFECT_SIZE="1.9563318777292575" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.9571804310102683" LOG_CI_START="-0.3742953676937563" LOG_EFFECT_SIZE="0.291442531658256" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="669" O_E="0.0" SE="0.7821154750702446" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="0.6117046163443544" WEIGHT="6.660780888804335"/>
<DICH_DATA CI_END="479.1978543690609" CI_START="1.733807745081462" EFFECT_SIZE="28.824242424242424" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.680514864811632" LOG_CI_START="0.23900093865386288" LOG_EFFECT_SIZE="1.4597579017327478" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="587" O_E="0.0" SE="1.4341573659139237" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="2.056807350205164" WEIGHT="2.1443388941049104"/>
<DICH_DATA CI_END="56.15204168978069" CI_START="0.8726307810979861" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7493655518438738" LOG_CI_START="-0.059169471815359996" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.0" SE="1.0623424252901832" STUDY_ID="STD-Sjostrom" TOTAL_1="140" TOTAL_2="140" VAR="1.1285714285714286" WEIGHT="3.798940418762205"/>
<DICH_DATA CI_END="146.58922064703708" CI_START="0.4420686576677686" EFFECT_SIZE="8.05" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1661020358874516" LOG_CI_START="-0.3545102751517145" LOG_EFFECT_SIZE="0.9057958803678685" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="671" O_E="0.0" SE="1.480620148736576" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="2.1922360248447204" WEIGHT="2.016217799739163"/>
<DICH_DATA CI_END="28.04364899899084" CI_START="0.3143453093778532" EFFECT_SIZE="2.9690721649484537" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4478345227404013" LOG_CI_START="-0.502593015754429" LOG_EFFECT_SIZE="0.472620753492986" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="591" O_E="0.0" SE="1.145690790883889" STUDY_ID="STD-TOG" TOTAL_1="97" TOTAL_2="96" VAR="1.312607388316151" WEIGHT="3.2948786684152815"/>
<DICH_DATA CI_END="4.295726935753989" CI_START="0.010187499577483432" EFFECT_SIZE="0.20919540229885059" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6330366669968177" LOG_CI_START="-1.9919323962639048" LOG_EFFECT_SIZE="-0.6794478646335437" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="592" O_E="0.0" SE="1.5419198215657732" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="2.3775167361374256" WEIGHT="1.8638614938830105"/>
<DICH_DATA CI_END="97.79736254956951" CI_START="0.23670175556152834" EFFECT_SIZE="4.811320754716981" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.990327142664765" LOG_CI_START="-0.625798520998433" LOG_EFFECT_SIZE="0.6822643108331661" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="1.5367251648666533" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="2.361524232334443" WEIGHT="1.8760982079297588"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.94318068613396" CI_END="9.213875388643826" CI_START="3.687423307510688" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="5.82884712962901" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="27" I2="8.46953485969079" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="0.9644423344208586" LOG_CI_START="0.5667229964516359" LOG_EFFECT_SIZE="0.7655826654362473" METHOD="MH" MODIFIED="2014-10-08 13:32:02 +1100" MODIFIED_BY="Melina L Willson" NO="7" P_CHI2="0.3470154850620728" P_Q="0.5208181902449907" P_Z="4.502284338554539E-14" Q="1.304708648487961" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08362100889210904" TOTALS="SUB" TOTAL_1="3013" TOTAL_2="2994" WEIGHT="300.00000000000006" Z="7.545594635176321">
<NAME>Neurotoxicity: subquestions A, B &amp; C</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="50.793522553461145" CI_START="2.917776742776256" DF="0" EFFECT_SIZE="12.173913043478262" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="2" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="1.7058083323891828" LOG_CI_START="0.46505205826007" LOG_EFFECT_SIZE="1.0854301953246264" MODIFIED="2014-10-08 10:32:01 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="1.0" P_Z="6.053510971024475E-4" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="224" WEIGHT="100.0" Z="3.429205453039953">
<NAME>Regimen A plus taxane v Regimen A</NAME>
<DICH_DATA CI_END="50.793522553461145" CI_START="2.917776742776256" EFFECT_SIZE="12.173913043478262" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="2" LOG_CI_END="1.7058083323891828" LOG_CI_START="0.46505205826007" LOG_EFFECT_SIZE="1.0854301953246264" MODIFIED="2014-10-08 10:32:01 +1100" MODIFIED_BY="Melina L Willson" ORDER="573" O_E="0.0" SE="0.7288263772660522" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="224" VAR="0.5311878881987578" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.441461746337957" CI_END="9.384696918968778" CI_START="2.549372834102753" DF="9" EFFECT_SIZE="4.891328181742338" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="18" I2="27.661233193526662" ID="CMP-005.07.02" LOG_CI_END="0.9724202515396922" LOG_CI_START="0.4064333536932376" LOG_EFFECT_SIZE="0.6894268026164649" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.18955007123363277" P_Z="1.798398820301109E-6" STUDIES="12" TAU2="0.266027111809282" TOTAL_1="1494" TOTAL_2="1497" WEIGHT="100.00000000000001" Z="4.774851531886359">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="575" O_E="0.0" SE="0.0" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="213" TOTAL_2="210" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="666" O_E="0.0" SE="0.0" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="105.20959770351858" CI_START="0.25119655064705015" EFFECT_SIZE="5.140845070422535" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0220553599655218" LOG_CI_START="-0.5999863284907232" LOG_EFFECT_SIZE="0.7110345157373994" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="576" O_E="0.0" SE="1.540200267114884" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="2.37221686282076" WEIGHT="4.18960427981074"/>
<DICH_DATA CI_END="194.70421790715125" CI_START="0.6101049176979181" EFFECT_SIZE="10.899082568807339" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2893753598094997" LOG_CI_START="-0.21459547440039722" LOG_EFFECT_SIZE="1.037389942704551" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="577" O_E="0.0" SE="1.4708448628704243" STUDY_ID="STD-Bontenbal" TOTAL_1="108" TOTAL_2="107" VAR="2.163384610632317" WEIGHT="4.549742699103417"/>
<DICH_DATA CI_END="243.1935471275427" CI_START="0.7882555292701005" EFFECT_SIZE="13.845528455284553" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.385952047228657" LOG_CI_START="-0.10333297418225068" LOG_EFFECT_SIZE="1.141309536523203" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="668" O_E="0.0" SE="1.4622183437363523" STUDY_ID="STD-CECOG-BM1" TOTAL_1="122" TOTAL_2="130" VAR="2.138082484759081" WEIGHT="4.597626606986765"/>
<DICH_DATA CI_END="164.34899153222312" CI_START="0.48568496302185316" EFFECT_SIZE="8.934306569343066" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.215767043535779" LOG_CI_START="-0.3136453422295077" LOG_EFFECT_SIZE="0.9510608506531356" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="578" O_E="0.0" SE="1.4857893561917717" STUDY_ID="STD-EORTC-10961" TOTAL_1="136" TOTAL_2="135" VAR="2.207570010972759" WEIGHT="4.468471500671642"/>
<DICH_DATA CI_END="16.17165774256843" CI_START="3.1304620360531925" EFFECT_SIZE="7.115107913669065" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="6" LOG_CI_END="1.20875454133794" LOG_CI_START="0.4956084413482288" LOG_EFFECT_SIZE="0.8521814913430843" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="579" O_E="0.0" SE="0.41890554926408446" STUDY_ID="STD-HERNATA" TOTAL_1="139" TOTAL_2="138" VAR="0.17548185920424428" WEIGHT="25.03504792195104"/>
<DICH_DATA CI_END="540.4455608444457" CI_START="1.9852627118939417" EFFECT_SIZE="32.75555555555555" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="2.7327519539496823" LOG_CI_START="0.2978179855456958" LOG_EFFECT_SIZE="1.515284969747689" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="580" O_E="0.0" SE="1.4302922661580355" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="2.0457359666314887" WEIGHT="4.781285050520853"/>
<DICH_DATA CI_END="73.31806196496962" CI_START="0.1281479270475493" EFFECT_SIZE="3.0652173913043477" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8652109766251017" LOG_CI_START="-0.8922884146774903" LOG_EFFECT_SIZE="0.4864612809738058" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="581" O_E="0.0" SE="1.6197687922932713" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="2.623650940487203" WEIGHT="3.8250621859105465"/>
<DICH_DATA CI_END="3.3528378654359794" CI_START="0.5898105252527189" EFFECT_SIZE="1.40625" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5254125525791405" LOG_CI_START="-0.22928748166826513" LOG_EFFECT_SIZE="0.1480625354554377" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="670" O_E="0.0" SE="0.4433145359423462" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.19652777777777777" WEIGHT="23.89597104283673"/>
<DICH_DATA CI_END="41.95152918959903" CI_START="0.626094578848201" EFFECT_SIZE="5.125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.622747796070571" LOG_CI_START="-0.20336005661498693" LOG_EFFECT_SIZE="0.7096938697277919" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="667" O_E="0.0" SE="1.0726647920471526" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="1.150609756097561" WEIGHT="7.802421705730852"/>
<DICH_DATA CI_END="18.07568190099063" CI_START="1.5641078010086784" EFFECT_SIZE="5.317171717171717" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.2570946899362143" LOG_CI_START="0.19426668208048403" LOG_EFFECT_SIZE="0.7256806860083491" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="672" O_E="0.0" SE="0.6243104328979444" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="330" TOTAL_2="329" VAR="0.38976351662521874" WEIGHT="16.854767006477427"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.324645475292503" CI_END="12.314174902499229" CI_START="2.9124586997438624" DF="10" EFFECT_SIZE="5.98869984428602" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="7" I2="0.0" ID="CMP-005.07.03" LOG_CI_END="1.0904053177344986" LOG_CI_START="0.46425977554462794" LOG_EFFECT_SIZE="0.7773325466395633" MODIFIED="2014-10-08 10:32:04 +1100" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="0.5971586466130314" P_Z="1.1363752306541663E-6" STUDIES="11" TAU2="0.0" TOTAL_1="1289" TOTAL_2="1273" WEIGHT="100.00000000000003" Z="4.866420641105038">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="299.38942312924155" CI_START="1.0141661713577887" EFFECT_SIZE="17.425" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.476236453462796" LOG_CI_START="0.006109120077297962" LOG_EFFECT_SIZE="1.241172786770047" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="582" O_E="0.0" SE="1.4509650229581414" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="159" TOTAL_2="163" VAR="2.10529949784792" WEIGHT="6.4255736100307566"/>
<DICH_DATA CI_END="72.33531944049352" CI_START="1.2085728061506371" EFFECT_SIZE="9.35" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8593504036939148" LOG_CI_START="0.08227281805112058" LOG_EFFECT_SIZE="0.9708116108725178" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="583" O_E="0.0" SE="1.0438641704824974" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="200" TOTAL_2="187" VAR="1.0896524064171125" WEIGHT="12.414745119559026"/>
<DICH_DATA CI_END="333.65291510215513" CI_START="1.1763374820990566" EFFECT_SIZE="19.81132075471698" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.5232949236038427" LOG_CI_START="0.07053193533445498" LOG_EFFECT_SIZE="1.2969134294691491" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="584" O_E="0.0" SE="1.440765120682044" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="2.0758041329739445" WEIGHT="6.516875402498487"/>
<DICH_DATA CI_END="165.80316501833371" CI_START="0.513905151221294" EFFECT_SIZE="9.23076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.219592816545244" LOG_CI_START="-0.28911702906366776" LOG_EFFECT_SIZE="0.965237893740788" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="585" O_E="0.0" SE="1.4736285816246903" STUDY_ID="STD-Dieras" TOTAL_1="38" TOTAL_2="39" VAR="2.171581196581197" WEIGHT="6.2294501885906275"/>
<DICH_DATA CI_END="18.223648228694216" CI_START="0.8400588878342097" EFFECT_SIZE="3.912663755458515" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2606353236242116" LOG_CI_START="-0.07569026897973723" LOG_EFFECT_SIZE="0.5924725273222372" MODIFIED="2014-10-08 10:32:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="669" O_E="0.0" SE="0.7849642680139269" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="224" VAR="0.6161689020586401" WEIGHT="21.954624534581228"/>
<DICH_DATA CI_END="479.1978543690609" CI_START="1.733807745081462" EFFECT_SIZE="28.824242424242424" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.680514864811632" LOG_CI_START="0.23900093865386288" LOG_EFFECT_SIZE="1.4597579017327478" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="587" O_E="0.0" SE="1.4341573659139237" STUDY_ID="STD-EORTC-10923" TOTAL_1="164" TOTAL_2="163" VAR="2.056807350205164" WEIGHT="6.577065612505332"/>
<DICH_DATA CI_END="56.15204168978069" CI_START="0.8726307810979861" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7493655518438738" LOG_CI_START="-0.059169471815359996" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="590" O_E="0.0" SE="1.0623424252901832" STUDY_ID="STD-Sjostrom" TOTAL_1="140" TOTAL_2="140" VAR="1.1285714285714286" WEIGHT="11.986620033174454"/>
<DICH_DATA CI_END="146.58922064703708" CI_START="0.4420686576677686" EFFECT_SIZE="8.05" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1661020358874516" LOG_CI_START="-0.3545102751517145" LOG_EFFECT_SIZE="0.9057958803678685" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="671" O_E="0.0" SE="1.480620148736576" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="2.1922360248447204" WEIGHT="6.170757501141233"/>
<DICH_DATA CI_END="28.04364899899084" CI_START="0.3143453093778532" EFFECT_SIZE="2.9690721649484537" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4478345227404013" LOG_CI_START="-0.502593015754429" LOG_EFFECT_SIZE="0.472620753492986" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="591" O_E="0.0" SE="1.145690790883889" STUDY_ID="STD-TOG" TOTAL_1="97" TOTAL_2="96" VAR="1.312607388316151" WEIGHT="10.30601916079139"/>
<DICH_DATA CI_END="4.295726935753989" CI_START="0.010187499577483432" EFFECT_SIZE="0.20919540229885059" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6330366669968177" LOG_CI_START="-1.9919323962639048" LOG_EFFECT_SIZE="-0.6794478646335437" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="592" O_E="0.0" SE="1.5419198215657732" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="2.3775167361374256" WEIGHT="5.689868209533674"/>
<DICH_DATA CI_END="97.79736254956951" CI_START="0.23670175556152834" EFFECT_SIZE="4.811320754716981" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.990327142664765" LOG_CI_START="-0.625798520998433" LOG_EFFECT_SIZE="0.6822643108331661" MODIFIED="2014-10-08 10:31:39 +1100" MODIFIED_BY="Melina L Willson" ORDER="593" O_E="0.0" SE="1.5367251648666533" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="2.361524232334443" WEIGHT="5.728400627593803"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="112.19405467938851" CI_END="3.8682961728120797" CI_START="1.4518820006047508" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3698754368772432" ESTIMABLE="YES" EVENTS_1="589" EVENTS_2="363" I2="93.76081021404961" I2_Q="97.82176316709572" ID="CMP-005.08" LOG_CI_END="0.5875197180722287" LOG_CI_START="0.161931321206598" LOG_EFFECT_SIZE="0.3747255196394134" METHOD="MH" MODIFIED="2014-10-08 13:32:18 +1100" MODIFIED_BY="Melina L Willson" NO="8" P_CHI2="0.0" P_Q="1.2390422021724135E-11" P_Z="5.575831897568998E-4" Q="45.908690225694485" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3533101237406611" TOTALS="YES" TOTAL_1="1209" TOTAL_2="1228" WEIGHT="100.0" Z="3.451449936090205">
<NAME>Alopecia: overall effect</NAME>
<GROUP_LABEL_1>Taxane containing</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Regimen A plus taxane v Regimen A</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.172669750942039" CI_END="1.3439448596204966" CI_START="1.0234124990850106" DF="3" EFFECT_SIZE="1.172778737621324" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="309" I2="28.10358405855849" ID="CMP-005.08.02" LOG_CI_END="0.12838145052301272" LOG_CI_START="0.010050716769868873" LOG_EFFECT_SIZE="0.06921608364644077" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.24341257381280934" P_Z="0.021853021787304968" STUDIES="6" TAU2="0.005636447564898114" TOTAL_1="807" TOTAL_2="827" WEIGHT="52.7976495791246" Z="2.2929128687893656">
<NAME>Regimen A plus taxane v Regimen B</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="608" O_E="0.0" SE="0.0" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="213" TOTAL_2="210" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.407896071148468" CI_START="1.1014781450655267" EFFECT_SIZE="1.6285714285714286" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="24" LOG_CI_END="0.3816377381087172" LOG_CI_START="0.041975884535714346" LOG_EFFECT_SIZE="0.21180681132221577" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="673" O_E="0.0" SE="0.1995190541420736" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="0.039807852965747695" WEIGHT="15.897610708150928"/>
<DICH_DATA CI_END="1.2806895627839396" CI_START="0.8865907034425293" EFFECT_SIZE="1.0655737704918034" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="81" LOG_CI_END="0.10744387017496242" LOG_CI_START="-0.052276826910785286" LOG_EFFECT_SIZE="0.02758352163208857" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="675" O_E="0.0" SE="0.09382072809836989" STUDY_ID="STD-CECOG-BM1" TOTAL_1="122" TOTAL_2="130" VAR="0.008802329020908252" WEIGHT="17.25882804745592"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="0.0" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.48758668839782743" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="674" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-TRAVIOTA" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="2.1029964591307353"/>
<DICH_DATA CI_END="1.29572569295298" CI_START="1.0441055996222088" EFFECT_SIZE="1.1631313131313132" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="204" LOG_CI_END="0.11251307048057699" LOG_CI_START="0.018744424924823148" LOG_EFFECT_SIZE="0.06562874770270005" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="678" O_E="0.0" SE="0.055080166561731196" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="330" TOTAL_2="329" VAR="0.003033824748468051" WEIGHT="17.538214364387017"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.308260307742733" CI_END="5.7705841601866315" CI_START="2.9413553245796455" DF="3" EFFECT_SIZE="4.119871168556113" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="54" I2="30.366324555448745" ID="CMP-005.08.03" LOG_CI_END="0.7612197793089689" LOG_CI_START="0.4685474917573109" LOG_EFFECT_SIZE="0.61488363553314" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.23004420491109656" P_Z="1.788248834037827E-16" STUDIES="5" TAU2="0.03525943761565618" TOTAL_1="402" TOTAL_2="401" WEIGHT="47.202350420875405" Z="8.235489532744317">
<NAME>Single agent taxane v Regimen C</NAME>
<DICH_DATA CI_END="4.576836664008196" CI_START="2.2124523784943992" EFFECT_SIZE="3.182142857142857" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="24" LOG_CI_END="0.6605654138068745" LOG_CI_START="0.3448739315824366" LOG_EFFECT_SIZE="0.5027196726946556" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="598" O_E="0.0" SE="0.18543873935667465" STUDY_ID="STD-ANZ-TITG" TOTAL_1="105" TOTAL_2="99" VAR="0.034387526054192714" WEIGHT="16.119872171939555"/>
<DICH_DATA CI_END="6.591668322784956" CI_START="3.0424498675937524" EFFECT_SIZE="4.478260869565218" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="23" LOG_CI_END="0.8189953465640256" LOG_CI_START="0.48322343081113317" LOG_EFFECT_SIZE="0.6511093886875794" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="0.1972340854110379" STUDY_ID="STD-Sjostrom" TOTAL_1="140" TOTAL_2="140" VAR="0.03890128444792859" WEIGHT="15.934356894201752"/>
<DICH_DATA CI_END="352.18723172975456" CI_START="1.3555928693245267" EFFECT_SIZE="21.85" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.5467736069128364" LOG_CI_START="0.13212927570004468" LOG_EFFECT_SIZE="1.3394514413064407" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="677" O_E="0.0" SE="1.418374032836604" STUDY_ID="STD-Talbot" TOTAL_1="19" TOTAL_2="22" VAR="2.0117848970251715" WEIGHT="2.6424462870125023"/>
<DICH_DATA CI_END="12.02696989221766" CI_START="2.6835086888781747" EFFECT_SIZE="5.681063122923588" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="7" LOG_CI_END="1.080156223778025" LOG_CI_START="0.42870300581859594" LOG_EFFECT_SIZE="0.7544296147983105" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="606" O_E="0.0" SE="0.38266684497480546" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="0.14643391424297178" WEIGHT="12.505675067721596"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-30 15:05:21 +1000" MODIFIED_BY="[Empty name]" ORDER="607" O_E="0.0" SE="0.0" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2015-04-17 11:55:31 +1000" MODIFIED_BY="Melina L Willson" NO="6">
<NAME>Risk of bias</NAME>
<IPD_OUTCOME CHI2="45.79248793190623" CI_END="0.9911193812882022" CI_START="0.881890616047913" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_SIZE="0.93491116248619" ESTIMABLE="YES" EVENTS_1="2314" EVENTS_2="2163" I2="51.95718557001278" I2_Q="71.03909660406703" ID="CMP-006.01" LOG_CI_END="-0.003874031173559493" LOG_CI_START="-0.0545852785788082" LOG_EFFECT_SIZE="-0.029229654876183807" MODIFIED="2015-04-17 11:54:17 +1000" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="0.0021027045772009645" P_Q="0.06313982169359122" P_Z="0.023857105963129004" Q="3.452930961195195" SCALE="2.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3139" TOTAL_2="2869" WEIGHT="99.99999999999999" Z="2.259422663380447">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>Taxane</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="32.54222827987453" CI_END="0.9710291676803422" CI_START="0.8526470685667087" DF="17" EFFECT_SIZE="0.9099149264164287" ESTIMABLE="YES" EVENTS_1="1771" EVENTS_2="1811" I2="47.760184539933576" ID="CMP-006.01.01" LOG_CI_END="-0.012767724600367823" LOG_CI_START="-0.06923069672458416" LOG_EFFECT_SIZE="-0.04099921066247599" MODIFIED="2014-10-08 15:17:41 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="0.012874798342539684" P_Z="0.004422215181173592" STUDIES="18" TAU2="0.0" TOTAL_1="2440" TOTAL_2="2410" WEIGHT="80.66425313670162" Z="2.8463601284126985">
<NAME>Low risk of bias</NAME>
<IPD_DATA CI_END="1.1651388929210809" CI_START="0.6756586038191097" EFFECT_SIZE="0.8872632741449409" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.06637769946825568" LOG_CI_START="-0.17027268856897562" LOG_EFFECT_SIZE="-0.05194749455036" MODIFIED="2014-10-08 15:12:11 +1100" MODIFIED_BY="Melina L Willson" ORDER="3035" O_E="-6.19" SE="0.13900960937138318" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="51.75" WEIGHT="4.59191822392589"/>
<IPD_DATA CI_END="0.9273038448186192" CI_START="0.5779689705180647" EFFECT_SIZE="0.7320880060124333" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="138" LOG_CI_END="-0.03277793952680448" LOG_CI_START="-0.23809547696790737" LOG_EFFECT_SIZE="-0.13543670824735593" MODIFIED="2014-10-08 15:12:20 +1100" MODIFIED_BY="Melina L Willson" ORDER="3036" O_E="-21.44" SE="0.12060453783110545" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="68.75" WEIGHT="6.1003744520754575"/>
<IPD_DATA CI_END="1.094482737649094" CI_START="0.7158603766291184" EFFECT_SIZE="0.8851535600038837" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="176" LOG_CI_END="0.03920891619827272" LOG_CI_START="-0.14517167541924206" LOG_EFFECT_SIZE="-0.05298137961048469" MODIFIED="2014-10-08 15:14:20 +1100" MODIFIED_BY="Melina L Willson" ORDER="3037" O_E="-10.4" SE="0.10830607221477646" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="85.25" WEIGHT="7.564464320573568"/>
<IPD_DATA CI_END="1.0218698332411622" CI_START="0.5465909835724658" EFFECT_SIZE="0.7473585733998898" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="82" LOG_CI_END="0.00939557847442258" LOG_CI_START="-0.262337536596928" LOG_EFFECT_SIZE="-0.12647097906125274" MODIFIED="2014-10-08 15:14:30 +1100" MODIFIED_BY="Melina L Willson" ORDER="3038" O_E="-11.43" SE="0.15961737689352443" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="39.25" WEIGHT="3.482759232639443"/>
<IPD_DATA CI_END="0.9470766982483457" CI_START="0.46425324017403724" EFFECT_SIZE="0.6630862883932402" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="62" LOG_CI_END="-0.02361484858150474" LOG_CI_START="-0.3332450564954644" LOG_EFFECT_SIZE="-0.1784299525384846" MODIFIED="2014-10-08 15:14:56 +1100" MODIFIED_BY="Melina L Willson" ORDER="3039" O_E="-12.42" SE="0.181878316822908" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="30.23" WEIGHT="2.682390104527143"/>
<IPD_DATA CI_END="1.2990436194752013" CI_START="0.5221833933701784" EFFECT_SIZE="0.8236133834229744" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="41" LOG_CI_END="0.11362373412101308" LOG_CI_START="-0.28217694385427516" LOG_EFFECT_SIZE="-0.08427660486663102" MODIFIED="2014-10-08 15:15:06 +1100" MODIFIED_BY="Melina L Willson" ORDER="3040" O_E="-3.59" SE="0.23249527748763857" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="18.5" WEIGHT="1.6415553071039413"/>
<IPD_DATA CI_END="0.9411828890058769" CI_START="0.5195714670653201" EFFECT_SIZE="0.6992937683245575" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="93" LOG_CI_END="-0.026325977031373307" LOG_CI_START="-0.2843547067836339" LOG_EFFECT_SIZE="-0.15534034190750357" MODIFIED="2014-10-08 15:15:13 +1100" MODIFIED_BY="Melina L Willson" ORDER="3041" O_E="-15.57" SE="0.15156735311928954" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="43.53" WEIGHT="3.862535271255923"/>
<IPD_DATA CI_END="3.4568880967894726" CI_START="0.7340935615929518" EFFECT_SIZE="1.593009508760216" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.5386853211873501" LOG_CI_START="-0.13424858491494696" LOG_EFFECT_SIZE="0.2022183681362016" MODIFIED="2014-10-08 15:15:46 +1100" MODIFIED_BY="Melina L Willson" ORDER="3043" O_E="2.98" SE="0.39528470752104744" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="6.4" WEIGHT="0.5678894035386608"/>
<IPD_DATA CI_END="1.4272106364991446" CI_START="0.8726729889114566" EFFECT_SIZE="1.1160144138674604" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="124" LOG_CI_END="0.1544880736882081" LOG_CI_START="-0.059148466164880106" LOG_EFFECT_SIZE="0.047669803761664034" MODIFIED="2014-10-08 15:15:57 +1100" MODIFIED_BY="Melina L Willson" ORDER="3044" O_E="6.97" SE="0.12549116102763172" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="63.5" WEIGHT="5.63452767573515"/>
<IPD_DATA CI_END="1.4930454940731153" CI_START="0.8267377539045406" EFFECT_SIZE="1.1110162367163237" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="74" LOG_CI_END="0.17407304116366792" LOG_CI_START="-0.0826322293759436" LOG_EFFECT_SIZE="0.04572040589386211" MODIFIED="2014-10-08 15:16:11 +1100" MODIFIED_BY="Melina L Willson" ORDER="3045" O_E="4.63" SE="0.15078994662655074" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="43.98" WEIGHT="3.9024649949422345"/>
<IPD_DATA CI_END="1.3709306552239469" CI_START="0.7004846843394492" EFFECT_SIZE="0.9799571048141957" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" LOG_CI_END="0.13701548774702912" LOG_CI_START="-0.15460135585226642" LOG_EFFECT_SIZE="-0.00879293405261867" MODIFIED="2014-10-08 15:11:50 +1100" MODIFIED_BY="Melina L Willson" ORDER="3046" O_E="-0.69" SE="0.17129717745688292" STUDY_ID="STD-EU_x002d_93011" TOTAL_1="89" TOTAL_2="87" VAR="34.08" WEIGHT="3.0240110738433685"/>
<IPD_DATA CI_END="1.4284508487654215" CI_START="0.7142101539442994" EFFECT_SIZE="1.0100564838654404" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="65" LOG_CI_END="0.1548653014375587" LOG_CI_START="-0.14617397972342236" LOG_EFFECT_SIZE="0.004345660857068142" MODIFIED="2014-10-08 15:16:53 +1100" MODIFIED_BY="Melina L Willson" ORDER="3047" O_E="0.32" SE="0.17683196392243516" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="31.98" WEIGHT="2.8376723633072456"/>
<IPD_DATA CI_END="0.8883608577417056" CI_START="0.5209462145046005" EFFECT_SIZE="0.6802854003685522" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="120" LOG_CI_END="-0.05141058524432588" LOG_CI_START="-0.28320711345606614" LOG_EFFECT_SIZE="-0.16730884935019605" MODIFIED="2014-10-08 15:17:01 +1100" MODIFIED_BY="Melina L Willson" ORDER="3048" O_E="-20.78" SE="0.1361584280828961" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="53.94" WEIGHT="4.786242879199276"/>
<IPD_DATA CI_END="1.045016871455751" CI_START="0.6720002152530321" EFFECT_SIZE="0.8380045122559394" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="125" LOG_CI_END="0.019123302046103026" LOG_CI_START="-0.17263058783428623" LOG_EFFECT_SIZE="-0.0767536428940916" MODIFIED="2014-10-08 15:17:11 +1100" MODIFIED_BY="Melina L Willson" ORDER="3049" O_E="-13.93" SE="0.11263718411280402" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="78.82" WEIGHT="6.9939129354558185"/>
<IPD_DATA CI_END="1.4768182261764857" CI_START="0.6818850378674761" EFFECT_SIZE="1.0035039870771474" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="53" LOG_CI_END="0.16932704356741982" LOG_CI_START="-0.16628883887474255" LOG_EFFECT_SIZE="0.0015191023463385711" MODIFIED="2014-10-08 15:17:20 +1100" MODIFIED_BY="Melina L Willson" ORDER="3050" O_E="0.09" SE="0.1971424306719378" STUDY_ID="STD-Meier" TOTAL_1="58" TOTAL_2="62" VAR="25.73" WEIGHT="2.2830928676640223"/>
<IPD_DATA CI_END="1.8703500986063712" CI_START="1.0088337927458086" EFFECT_SIZE="1.3736347344689426" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="77" LOG_CI_END="0.27192290689037213" LOG_CI_START="0.003819621302168777" LOG_EFFECT_SIZE="0.1378712640962704" MODIFIED="2014-10-08 15:17:27 +1100" MODIFIED_BY="Melina L Willson" ORDER="3051" O_E="12.8" SE="0.157485197087178" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.32" WEIGHT="3.577703242293563"/>
<IPD_DATA CI_END="1.3734359661262925" CI_START="0.7173879199803462" EFFECT_SIZE="0.9926159231875833" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" LOG_CI_END="0.137808416063621" LOG_CI_START="-0.14424594063753687" LOG_EFFECT_SIZE="-0.0032187622869579344" MODIFIED="2014-10-08 15:17:35 +1100" MODIFIED_BY="Melina L Willson" ORDER="3052" O_E="-0.27" SE="0.1656801253178433" STUDY_ID="STD-TXT" TOTAL_1="86" TOTAL_2="90" VAR="36.43" WEIGHT="3.2325329642052205"/>
<IPD_DATA CI_END="1.1929135387911767" CI_START="0.8721316127970808" EFFECT_SIZE="1.019989023722031" ESTIMABLE="YES" EVENTS_1="321" EVENTS_2="320" LOG_CI_END="0.07660896757089686" LOG_CI_START="-0.059417971032557006" LOG_EFFECT_SIZE="0.008595498269169935" MODIFIED="2014-10-08 15:17:41 +1100" MODIFIED_BY="Melina L Willson" ORDER="3053" O_E="3.1" SE="0.07990289707987444" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="156.63" WEIGHT="13.898205824415694"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="9.797328690836501" CI_END="1.1954536717832855" CI_START="0.9166586820485408" DF="4" EFFECT_SIZE="1.0468156414703382" ESTIMABLE="YES" EVENTS_1="543" EVENTS_2="352" I2="59.17254461676658" ID="CMP-006.01.02" LOG_CI_END="0.0775327502730114" LOG_CI_START="-0.03779234382470323" LOG_EFFECT_SIZE="0.01987020322415414" MODIFIED="2014-10-08 15:26:08 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.043983659782235174" P_Z="0.4994260935730358" STUDIES="5" TAU2="0.0" TOTAL_1="699" TOTAL_2="459" WEIGHT="19.335746863298372" Z="0.6753930354799594">
<NAME>Unclear or high risk of bias</NAME>
<IPD_DATA CI_END="1.2553793807837803" CI_START="0.771132304878123" EFFECT_SIZE="0.9839022285777522" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="86" LOG_CI_END="0.09877499122136313" LOG_CI_START="-0.11287110268962938" LOG_EFFECT_SIZE="-0.007048055734133123" MODIFIED="2014-10-08 15:23:46 +1100" MODIFIED_BY="Melina L Willson" ORDER="3027" O_E="-1.05" SE="0.1243219632283784" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="64.7" WEIGHT="5.741006938898649"/>
<IPD_DATA CI_END="1.1842933690356112" CI_START="0.7208776733635518" EFFECT_SIZE="0.9239754587922093" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="86" LOG_CI_END="0.07345929763303452" LOG_CI_START="-0.14213842500378135" LOG_EFFECT_SIZE="-0.0343395636853734" MODIFIED="2014-10-08 15:23:57 +1100" MODIFIED_BY="Melina L Willson" ORDER="3054" O_E="-4.93" SE="0.1266431695028047" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="62.35" WEIGHT="5.532485048536797"/>
<IPD_DATA CI_END="3.3335070603080483" CI_START="1.2853844047239367" EFFECT_SIZE="2.069985021288101" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="33" LOG_CI_END="0.5229013792904649" LOG_CI_START="0.10903302641036595" LOG_EFFECT_SIZE="0.3159672028504154" MODIFIED="2014-10-08 15:24:06 +1100" MODIFIED_BY="Melina L Willson" ORDER="3028" O_E="12.31" SE="0.2431083191631576" STUDY_ID="STD-Lyman" TOTAL_1="45" TOTAL_2="46" VAR="16.92" WEIGHT="1.5013576106053346"/>
<IPD_DATA CI_END="1.2936595494582188" CI_START="0.7500290738179914" EFFECT_SIZE="0.9850290725232165" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="105" LOG_CI_END="0.11181999870868686" LOG_CI_START="-0.12492190146964363" LOG_EFFECT_SIZE="-0.0065509513804783565" MODIFIED="2014-10-08 15:25:03 +1100" MODIFIED_BY="Melina L Willson" ORDER="3031" O_E="-0.78" SE="0.1390633640560572" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="51.71" WEIGHT="4.588368915153773"/>
<IPD_DATA CI_END="1.8487852758950991" CI_START="0.8050362294154025" EFFECT_SIZE="1.2199750520011896" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="0.2668864736745507" LOG_CI_START="-0.0941845744381699" LOG_EFFECT_SIZE="0.0863509496181904" MODIFIED="2014-10-08 15:25:32 +1100" MODIFIED_BY="Melina L Willson" ORDER="3034" O_E="4.42" SE="0.21209492099192592" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="22.23" WEIGHT="1.972528350103817"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="77.98212684649559" CI_END="0.9679295800001945" CI_START="0.867503253095707" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_SIZE="0.91634167176754" ESTIMABLE="YES" EVENTS_1="2641" EVENTS_2="2481" I2="73.0707524285179" I2_Q="82.3045149635496" ID="CMP-006.02" LOG_CI_END="-0.014156237867030696" LOG_CI_START="-0.0617288879505" LOG_EFFECT_SIZE="-0.03794256290876536" MODIFIED="2015-04-17 11:55:31 +1000" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="1.7504599436612978E-8" P_Q="0.01744397400550035" P_Z="0.001769482749607607" Q="5.6511590269502605" SCALE="5.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3105" TOTAL_2="2855" WEIGHT="100.0" Z="3.1264206072962226">
<NAME>Time to progression</NAME>
<GROUP_LABEL_1>Taxane</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours taxane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="61.01716854802447" CI_END="1.0043198621484268" CI_START="0.8898590815702211" DF="16" EFFECT_SIZE="0.9453587415019392" ESTIMABLE="YES" EVENTS_1="2103" EVENTS_2="2101" I2="73.77787206332434" ID="CMP-006.02.01" LOG_CI_END="0.001872051695971927" LOG_CI_START="-0.05067876295287508" LOG_EFFECT_SIZE="-0.024403355628451532" MODIFIED="2014-10-08 15:39:08 +1100" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="3.524145074651486E-7" P_Z="0.06871000545403771" STUDIES="17" TAU2="0.0" TOTAL_1="2419" TOTAL_2="2396" WEIGHT="81.95128807815148" Z="1.8203218524125109">
<NAME>Low risk of bias</NAME>
<IPD_DATA CI_END="1.1593563745095063" CI_START="0.7168939139296295" EFFECT_SIZE="0.9116663473888819" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="134" LOG_CI_END="0.06421695424912825" LOG_CI_START="-0.1445451065410079" LOG_EFFECT_SIZE="-0.04016407614593982" MODIFIED="2014-10-08 15:35:05 +1100" MODIFIED_BY="Melina L Willson" ORDER="3066" O_E="-6.15" SE="0.12262786789699316" STUDY_ID="STD-_x0033_03-Study-Group" TOTAL_1="161" TOTAL_2="165" VAR="66.5" WEIGHT="5.192918888949625"/>
<IPD_DATA CI_END="0.8606019036744375" CI_START="0.5529144933305723" EFFECT_SIZE="0.6898110361029879" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="153" LOG_CI_END="-0.0651976975813867" LOG_CI_START="-0.2573420259212832" LOG_EFFECT_SIZE="-0.1612698617513349" MODIFIED="2014-10-08 15:35:12 +1100" MODIFIED_BY="Melina L Willson" ORDER="3067" O_E="-29.15" SE="0.11286652959662007" STUDY_ID="STD-_x0033_04-Study-Group" TOTAL_1="203" TOTAL_2="189" VAR="78.5" WEIGHT="6.129986959136023"/>
<IPD_DATA CI_END="0.9480785668560276" CI_START="0.6053951307104737" EFFECT_SIZE="0.7576028959194938" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="209" LOG_CI_END="-0.02315567137692133" LOG_CI_START="-0.2179610764651355" LOG_EFFECT_SIZE="-0.12055837392102842" MODIFIED="2014-10-08 15:35:19 +1100" MODIFIED_BY="Melina L Willson" ORDER="3068" O_E="-21.2" SE="0.11442965925112424" STUDY_ID="STD-_x0033_06-Study-Group" TOTAL_1="214" TOTAL_2="215" VAR="76.37" WEIGHT="5.963657376677937"/>
<IPD_DATA CI_END="1.5489655912672018" CI_START="0.8922374420026595" EFFECT_SIZE="1.1756041412407432" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" LOG_CI_END="0.19004177044561008" LOG_CI_START="-0.04951955590503314" LOG_EFFECT_SIZE="0.07026110727028849" MODIFIED="2014-10-08 15:35:26 +1100" MODIFIED_BY="Melina L Willson" ORDER="3069" O_E="8.17" SE="0.14071950894605836" STUDY_ID="STD-ANZ-TITG" TOTAL_1="107" TOTAL_2="102" VAR="50.5" WEIGHT="3.94349479536776"/>
<IPD_DATA CI_END="1.3236716880191266" CI_START="0.725510274191262" EFFECT_SIZE="0.9799680654562001" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="79" LOG_CI_END="0.12178027984474586" LOG_CI_START="-0.1393564329947128" LOG_EFFECT_SIZE="-0.008788076574983443" MODIFIED="2014-10-08 15:36:05 +1100" MODIFIED_BY="Melina L Willson" ORDER="3070" O_E="-0.86" SE="0.1533929977694741" STUDY_ID="STD-Blohmer" TOTAL_1="125" TOTAL_2="111" VAR="42.5" WEIGHT="3.3187827485768278"/>
<IPD_DATA CI_END="1.3092933958457849" CI_START="0.6166154300557208" EFFECT_SIZE="0.8985157262666935" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="56" LOG_CI_END="0.11703697727585574" LOG_CI_START="-0.2099856117791347" LOG_EFFECT_SIZE="-0.046474317251639495" MODIFIED="2014-10-08 15:36:13 +1100" MODIFIED_BY="Melina L Willson" ORDER="3071" O_E="-2.9" SE="0.19209468759882464" STUDY_ID="STD-Bonneterre" TOTAL_1="70" TOTAL_2="72" VAR="27.1" WEIGHT="2.116212058504283"/>
<IPD_DATA CI_END="0.8816359665874274" CI_START="0.5031422888900299" EFFECT_SIZE="0.6660242774828647" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="105" LOG_CI_END="-0.05471070096525379" LOG_CI_START="-0.29830917887829855" LOG_EFFECT_SIZE="-0.17650993992177622" MODIFIED="2014-10-08 15:36:19 +1100" MODIFIED_BY="Melina L Willson" ORDER="3072" O_E="-19.85" SE="0.1430909517580356" STUDY_ID="STD-Bontenbal" TOTAL_1="109" TOTAL_2="107" VAR="48.84" WEIGHT="3.813867045658642"/>
<IPD_DATA CI_END="1.153991159066027" CI_START="0.6796321910775032" EFFECT_SIZE="0.8856012307580152" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="107" LOG_CI_END="0.06220248162426451" LOG_CI_START="-0.16772605876675473" LOG_EFFECT_SIZE="-0.05276178857124513" MODIFIED="2014-10-08 15:36:36 +1100" MODIFIED_BY="Melina L Willson" ORDER="3073" O_E="-6.66" SE="0.13506116279031571" STUDY_ID="STD-CECOG-BM1" TOTAL_1="124" TOTAL_2="135" VAR="54.82" WEIGHT="4.280839300634863"/>
<IPD_DATA CI_END="0.9552546863030363" CI_START="0.3717309154505096" EFFECT_SIZE="0.5959007459533988" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="-0.019880823065822117" LOG_CI_START="-0.4297713187771968" LOG_EFFECT_SIZE="-0.22482607092150944" MODIFIED="2014-10-08 15:37:04 +1100" MODIFIED_BY="Melina L Willson" ORDER="3074" O_E="-8.93" SE="0.2407717061715384" STUDY_ID="STD-Dieras" TOTAL_1="36" TOTAL_2="36" VAR="17.25" WEIGHT="1.3470353508929478"/>
<IPD_DATA CI_END="1.9313798497361756" CI_START="1.2426029621310652" EFFECT_SIZE="1.5491734319573207" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" LOG_CI_END="0.28586769605857143" LOG_CI_START="0.09433238455445257" LOG_EFFECT_SIZE="0.19010004030651198" MODIFIED="2014-10-08 15:37:20 +1100" MODIFIED_BY="Melina L Willson" ORDER="3075" O_E="34.58" SE="0.1125087900926024" STUDY_ID="STD-EORTC-10923" TOTAL_1="166" TOTAL_2="165" VAR="79.0" WEIGHT="6.169031462060456"/>
<IPD_DATA CI_END="1.2032284459026727" CI_START="0.7397644396507601" EFFECT_SIZE="0.943454088472272" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="125" LOG_CI_END="0.08034809066157232" LOG_CI_START="-0.13090654897984424" LOG_EFFECT_SIZE="-0.02527922915913598" MODIFIED="2014-10-08 15:36:51 +1100" MODIFIED_BY="Melina L Willson" ORDER="3076" O_E="-3.78" SE="0.1240920210526996" STUDY_ID="STD-EORTC-10961" TOTAL_1="138" TOTAL_2="137" VAR="64.94" WEIGHT="5.071100039825392"/>
<IPD_DATA CI_END="1.4111895869133404" CI_START="0.8018057285579703" EFFECT_SIZE="1.0637198385235052" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="95" LOG_CI_END="0.1495853631656067" LOG_CI_START="-0.0959308452266442" LOG_EFFECT_SIZE="0.026827258969481224" MODIFIED="2014-10-08 15:38:03 +1100" MODIFIED_BY="Melina L Willson" ORDER="3078" O_E="2.97" SE="0.14421743613444024" STUDY_ID="STD-HERNATA" TOTAL_1="143" TOTAL_2="141" VAR="48.08" WEIGHT="3.754519401213503"/>
<IPD_DATA CI_END="0.9776017720116648" CI_START="0.5698564347541257" EFFECT_SIZE="0.7463864015427149" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="115" LOG_CI_END="-0.009838019893879411" LOG_CI_START="-0.24423454335795655" LOG_EFFECT_SIZE="-0.12703628162591804" MODIFIED="2014-10-08 15:38:12 +1100" MODIFIED_BY="Melina L Willson" ORDER="3079" O_E="-15.43" SE="0.13768567816430285" STUDY_ID="STD-Jassem" TOTAL_1="134" TOTAL_2="133" VAR="52.75" WEIGHT="4.11919505852771"/>
<IPD_DATA CI_END="1.091154611787768" CI_START="0.7291510882488825" EFFECT_SIZE="0.8919734147567617" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="145" LOG_CI_END="0.03788629255792961" LOG_CI_START="-0.1371824716902087" LOG_EFFECT_SIZE="-0.04964808956613951" MODIFIED="2014-10-08 15:38:21 +1100" MODIFIED_BY="Melina L Willson" ORDER="3080" O_E="-10.81" SE="0.10283625872371589" STUDY_ID="STD-JCOG9802" TOTAL_1="147" TOTAL_2="146" VAR="94.56" WEIGHT="7.38409639306882"/>
<IPD_DATA CI_END="2.1088845598547143" CI_START="1.1394046157741393" EFFECT_SIZE="1.5501202539265384" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="83" LOG_CI_END="0.3240528071504604" LOG_CI_START="0.05667797446871984" LOG_EFFECT_SIZE="0.19036539080959014" MODIFIED="2014-10-08 15:38:49 +1100" MODIFIED_BY="Melina L Willson" ORDER="3082" O_E="17.77" SE="0.15705730024402176" STUDY_ID="STD-TOG" TOTAL_1="101" TOTAL_2="100" VAR="40.54" WEIGHT="3.1657282971130494"/>
<IPD_DATA CI_END="1.0946881874122818" CI_START="0.5629872265202923" EFFECT_SIZE="0.7850448818607547" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="68" LOG_CI_END="0.0392904317142165" LOG_CI_START="-0.2495014586383228" LOG_EFFECT_SIZE="-0.10510551346205321" MODIFIED="2014-10-08 15:38:59 +1100" MODIFIED_BY="Melina L Willson" ORDER="3083" O_E="-8.41" SE="0.16963778593599418" STUDY_ID="STD-TXT" TOTAL_1="88" TOTAL_2="90" VAR="34.75" WEIGHT="2.7135929532481122"/>
<IPD_DATA CI_END="1.242237609675948" CI_START="0.9216603130561425" EFFECT_SIZE="1.0700098617414928" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="342" LOG_CI_END="0.09420467369996081" LOG_CI_START="-0.03542911294603589" LOG_EFFECT_SIZE="0.0293877803769625" MODIFIED="2014-10-08 15:39:08 +1100" MODIFIED_BY="Melina L Willson" ORDER="3084" O_E="11.67" SE="0.07614752797345155" STUDY_ID="STD-UKCCCR-AB01" TOTAL_1="353" TOTAL_2="352" VAR="172.46" WEIGHT="13.467229948695524"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="11.313799271520853" CI_END="0.9048384144616142" CI_START="0.6991858573116472" DF="4" EFFECT_SIZE="0.7953931245263912" ESTIMABLE="YES" EVENTS_1="538" EVENTS_2="380" I2="64.64494460257202" ID="CMP-006.02.02" LOG_CI_END="-0.04342896993653448" LOG_CI_START="-0.15540736491831822" LOG_EFFECT_SIZE="-0.09941816742742633" MODIFIED="2014-10-08 15:33:35 +1100" MODIFIED_BY="Melina L Willson" NO="2" P_CHI2="0.02325478793342972" P_Z="5.009586911317369E-4" STUDIES="5" TAU2="0.0" TOTAL_1="686" TOTAL_2="459" WEIGHT="18.048711921848522" Z="3.4802432665413248">
<NAME>Unclear or high risk of bias</NAME>
<IPD_DATA CI_END="1.2481431775239" CI_START="0.7611578256089859" EFFECT_SIZE="0.974696848795964" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="83" LOG_CI_END="0.09626440717488878" LOG_CI_START="-0.11852528319730952" LOG_EFFECT_SIZE="-0.01113043801121038" MODIFIED="2014-10-08 15:29:38 +1100" MODIFIED_BY="Melina L Willson" ORDER="3057" O_E="-1.61" SE="0.1261685273507441" STUDY_ID="STD-ECOG-E1193-_x0028_A_x0029_" TOTAL_1="230" TOTAL_2="112" VAR="62.82" WEIGHT="4.905551347425796"/>
<IPD_DATA CI_END="1.188372704901193" CI_START="0.7187967787097458" EFFECT_SIZE="0.9242285822184708" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="83" LOG_CI_END="0.0749526681678691" LOG_CI_START="-0.143393877850928" LOG_EFFECT_SIZE="-0.034220604841529494" MODIFIED="2014-10-08 15:29:51 +1100" MODIFIED_BY="Melina L Willson" ORDER="3058" O_E="-4.79" SE="0.12825784196427567" STUDY_ID="STD-ECOG-E1193-_x0028_B_x0029_" TOTAL_1="229" TOTAL_2="112" VAR="60.79" WEIGHT="4.747030665552597"/>
<IPD_DATA CI_END="1.1725782106316176" CI_START="0.43968483355502375" EFFECT_SIZE="0.7180284502523632" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="40" LOG_CI_END="0.06914181967107516" LOG_CI_START="-0.35685851463265333" LOG_EFFECT_SIZE="-0.1438583474807891" MODIFIED="2014-10-08 15:32:34 +1100" MODIFIED_BY="Melina L Willson" ORDER="3061" O_E="-5.29" SE="0.2502347051056742" STUDY_ID="STD-Rugo" TOTAL_1="32" TOTAL_2="46" VAR="15.97" WEIGHT="1.2470814234063987"/>
<IPD_DATA CI_END="0.7330919635853363" CI_START="0.45974830958841484" EFFECT_SIZE="0.5805495594961814" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="132" LOG_CI_END="-0.13484154135828819" LOG_CI_START="-0.3374798589094025" LOG_EFFECT_SIZE="-0.2361607001338453" MODIFIED="2014-10-08 15:32:52 +1100" MODIFIED_BY="Melina L Willson" ORDER="3062" O_E="-38.38" SE="0.1190307508053739" STUDY_ID="STD-Sjostrom" TOTAL_1="143" TOTAL_2="139" VAR="70.58" WEIGHT="5.511522032813"/>
<IPD_DATA CI_END="1.3398711650835016" CI_START="0.5692494150059186" EFFECT_SIZE="0.8733389244199996" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.12706304091461088" LOG_CI_START="-0.24469740701906822" LOG_EFFECT_SIZE="-0.0588171830522287" MODIFIED="2014-10-08 15:33:26 +1100" MODIFIED_BY="Melina L Willson" ORDER="3065" O_E="-2.84" SE="0.21837392736013947" STUDY_ID="STD-Yardley" TOTAL_1="52" TOTAL_2="50" VAR="20.97" WEIGHT="1.6375264526507312"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-05-25 17:10:02 +1000" MODIFIED_BY="Melina L Willson">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-05-25 16:41:38 +1000" MODIFIED_BY="Melina L Willson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Review update: study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAATuCAYAAABZFkIOAACAAElEQVR42uydD2Qd2dvHX9aqqFWl
oqpqhYiIiCgRFVVRoqp+VpWKVfWzyqqoqCgVEVERKiIiokRURVSoWrUqQkRV1AoVEbWqREVVVYmq
iqrz+p73Pde5k/l7702a3Pv5cCX3zsyZM3Oe5znfOX/m/I/x+J//+R8+fPik/Ow1KBPsD/vjU6n2
B0X4ru/EAJCt4iMvQJljf9gf7HshSIEC7N9giP9if9gfUPZQRDlSkAD7NRjiv4D9AWIQEIIAVMSA
/WF/gA0AQhCAihiwP+wPsAFACAJQEQP2h/0BNgAIQQAqYsD+sD/ABgAhCEBFDNgf9gfYACAEAaiI
AfvD/n4Uq6ur2B/sbSH4+fNnc+vWLXP06FHz888/m+PHj9vvm5ubJTWOUhpSUlofP3403d3dprq6
2l5TQ0ODmZmZwSm45rKsiL9+/Wpqa2u3/f7p0ydz4cIFU1VVZQ4ePGguX75sPnz4kJdu8PPTTz+l
3k7ZVbb9vX//3vz222/mwIED1sYuXbqUZ1/cw/9D96eUef8R14EQLGMhuLW1Zdra2szg4KAVT+L7
9+/mxYsX5uzZs6nE4F5zaAnbkydPmqmpKXt94p9//jG//vqruX//Pk4BZSUEv337Zi5evBi6z8DA
gOnv77c+rc+DBw9Mb29vZFp//fVXUdspu8qyv/b2dvPw4cOcfel/1RtQ+rL70TZMnVfGQlACcHh4
OHSbRFNfX1+eIUggqpVNQivMOFTx/PLLL+bw4cNmbGws8ilG/0uonThxwrYwqNXu6dOnue1v3rzJ
tWRoW11dnXn8+HEqo1Sew65JYtDl26GWT7WU6DxnzpwxGxsbeSL5ypUrdpvOv7S0lHf+0dHRyPyH
3as01xR3T9z9PXTokM2zWjyTHDeYh6g0JJ7VEqyWpeCDQmNjY2RZh+VFgts9VKyvr9vjdO9dC4K2
78fAsleFoOz27du3ofuoUl5bW8sTjefOnQtNRxV5U1OTtYVCtme1uTR+luSjYedTPq9fv27j0LFj
x2xPgH9v/v77b+tb8jHZ9uLiIvZX4Ll1H9P8lqU808TAqDomTfqlPJdPlF2Frd0blo7/W5INp43F
pbR3hGAZC0EF9qhWPzXxq0vVN4Suri5rpO/evdtmHHKqnp4eu13Hnjp1KlYIShQ5J5UD+gFE+Zqe
ns49acoJFezTGGV9fb2tGJOQWFS67hwTExO2QvIF5ezsrP3/yZMnNl3//OfPn4/Mf9i9SnNNcfdE
+dM91rGq0BUchoaGYh03mIe4NP78889tAnpkZMQGmeA9j0vn999/N48ePbL/q4VA3SLa33337zFC
sPhzz8/PR+6jikRlFPwtDJVRXGtf0vZCbC7Jz5J8NOx8slk94Lo4pB4P/974Ff7c3JypqanB/ops
EXSoHE+fPl1wzE2KgUl1TJr0S3WuMAEcZVfB45KEYJINp43FpbR3hGAZC8GksQv+dqXhP10FjaO1
tdW2+DiWl5djhWBcWmEExy7FOWQaJHJd17FrmThy5EieoAxWomnzH7Y9zTXFpdnc3LwtP3FOHZZe
XBqvXr2yrYJuu/6q9c6lkTYvakmWqBR//PGH6ezstB9x9erVko7VRAjG75OlxUYPKmrBjSJpeyE2
l+RnST4adj61DPrHBOOQHr6c8MT+iju3YoZay1xrl/7Xb4XG3GLrmDTpl+pcQeLsKqsQTLLhLPVC
qewdIYgQTGW8wbRknHFCMMnQ1OWj1gKJCDl42sGy6hJIQ9igd7+SjBOUSfmPyl/Wawq2ZGQZuB8l
DOLS0NO8ni6FWi/1xJw1L6oIJBqEuiJWVlaswBTq+ksSE1TEpROCSTbuV+gtLS2RaSdtL8bm4vws
Kf9pxG8wDqlVRN9VgWr8JPZX+LkVH9QK51rg7t69a8erlrI8s9QxWdIv9lxB4uwqqxBMsuEs9UKp
7B0hWMZCUMYRNebny5cvufFhpTbepLTUqqSWgsnJSdv1pW6ftEJQIiRs5pqazf0xeWEVUNz1FCsE
C7mmpCBXCmHgo645iTUn4ly3Y9a8qGVAZeAEoMbhaKya+44Q3B0hGNYNHPabxrtqbFUUSduLsbk4
P0vy0bStoGEPmbL1jo4O2/2H/RV2boklvzVK/8c9iBdSnlnqmCzpF3uuqAf9MLsqVgjG5T1NvVAK
e0cIlrEQ1NOcgnwYEk3+mKAk41WLgS/AXr58WbATqrLyxy66SQdpjFJPPa5Vy0czJjXOwyGhE+xG
8J8C9TqOuK7hrAGtkGvyf1N+s8ziDksvTRoSbRqj4iZ1FJIXtQr897//zXUJu+5h9x0huDtCUIFf
D3QOTQbSAPqw8lJFEVeecduLsbk4P0vy0bDzqUvPP0YPIFH3T63V+6WC24v2FxR9KkdNWIiikPLM
UsdkSb/Yc8URtKskIRisC5JsuNB6oRh7RwiWsRBUK5kG/EoMOmOSMy8sLNjZhXoPWVrHCQ6uVYVT
qBCUGHGtd3ICOWVaIag8q9t1fHzcVoLKjyYvqJXq2bNn20Sw69bQ/v672NSFq2Z1ofsRnCySVQgW
ck3BgdBuALE++h5WqcellyYNDTTWTLXgRJQsedF91dgc3VNx7949W2mECXSE4M4JQU308ctJrdFh
3UMaU+QmW4SRtL0Ym4vzsyQfDTufhjTcuXMnF4cU3/z9lL5mUorgBAHsL9u5NVFHNqV6RPdbD5Ca
7RpFIeWZpY7Jkn6x5woSZ1eKfRqP6MSdP4FDExvVxe6nnWTDWWJxqewdIVjGQtC1EqjlT0LFvVBa
DuCLwDSOI2S8msYuIaHZTIU+jUmwqfJRfmTIGuya5YWaci7NXtXTqZrONfhWlUwQ96oBfTS77PXr
13n3RS9IdS+k1oDdYoRgIdcU/E3lpJZF3VcFj7jKOeoeJaWhV79oW7B7PUtenj9/nvfaGDfY+d9/
/923gWU/CkGViSoRlZE+muke9GtXMUW1yqXZXozNxflZko9GnU9j1fQgolikOOTvp24ynce9MsRV
kthf9nOr7CQGnX1JBAZfQZUl5hZbx2RJvxTn8omzKz1Uu3vkCzLtK6GqfYPnjrPhLLG4VPaOECxz
IbhTKCDs5zFhAPtJCAL2V2n2t5t1TKXXZ8QghGAq9PSicUTufUZ6MtsvA7EBqIgB+9vb9rebdQz1
GTEIIVgAmmGqLlg1T2s83s2bN60DARAICcKA/e2nOob6jBiEEAQAKmLA/rA/wAYQggBARQzYH2B/
gBAEIBAShAH7A+wPEIIABEKCMGB/gP0BQhCAQEgQBuwPsD9ACMJ2VldXuQkEwn0fhPeKHVeqP2F/
2B9CEHZdCOoFmv7yPI7379+b3377zU6r19I5WhUguArFThhQsen8qOPj3kZfyLn3kkPqLfV6W31z
c3PZB529WBEn5amUeQ7asZ920A520tfi8lHOtoL9YX+Van/wg4Sg3pekhebDjtOSVQ8fPsytbaj/
z549u+eN+0cdXwoH2qtO6K+ZyRPx3jt3KfMcl1ap7SDuXMFtVMTYH/aHEIQdEIJatFrr9YYdF7Zo
ddxC1sHWLC3mrXWN3dqHvgNrUW6tD6mWxrq6OrO0tBSZTtx5JFC17qXWX9Q6kTMzM9uOGRgYsOs4
ak3K7u7uvG1pjvdxT6S6psbGRrO4uJjLk/8pRd6zXEdUvqLKSetSVldX2xepJqUfdm1J+Qk7R9Rv
aW3GnVP3Sy9+HRsbq8gWmWJtPu4+x9lxGhsvla9FnWt0dDTSPqLs2q1Jq1ijeLexsZE6viTZXFKe
sD/sD/uDPS8E9Vb1qMJ3LYKO2dlZc/r06dRCUItiO6N3i287+vr6bHpCy/vU19cXJARHRkbM4OCg
dXJ1W7e1teVt1yLeCjpu+SA5vxYGT3t83BPp3NycqampyfQEmSXvWa4jLl9hedAC8krLLVqelH7w
WtLsHzxH1G9pbUbn09JP7n6dOnWqIoVgsTafdJ/j7DhuW6l9Lexc58+fj8130L6Gh4dt5el6NZRH
PYCm9dEkm0vKE/aH/WF/sOeFYFzhv3r1yj6FuKci/a/f0gpB/8knuF3CT8adJp247XryUuuiY3l5
OW+7xpIEz+OLpKTjg+hpzwnYQroSsuQ9y3XE5SssD8GySUo/eC1p9g8r/zibSNre2tpqx62mLaty
rYiLtfk05VDItlL7Wti5stpPQ0ND3jn1v9aWTeujSTaXlCfsD/vD/mBfC0E9temJxj3N3L17144n
TCsE47Zn6WLOko7yGdwebOZXE3ra44OotU3bFXT6+/uLEoJJ585yHXH5SlPWSekHj8m6f5rfkrYH
B28nlVW5VsTF2nzWcki7rdS+ltWfwrb75w/LR7E2l9bOsT/sD/uDHyoEo8Z4JRW+jNB/wtL/Guew
l4VgcHuYI0Y5ZVpH0DgQdWd3dHTYZvtSCcG4a0+6jrh8pbm+pPSDx2TdvxRCMGsgr5SKOKut7FRF
XGpfK0VFnMXHin1Yq1QhiP1hf1DGLYJB0Scj1KDXUgg4va6mkK7h9fX1bU3nftP72tpa3nZNnNjc
3IzMc9LxcaysrKQOUoXkPct1xOUrTVknpR88Juv+pRCCLS0tea8vevnyZUUKwWJtfqcq4lL7Wikq
YuUp2DXnt7Ik+WiSzVWiEMT+sD+oICGoga+Tk5N24K1EmwbbatZVKYSgJouoO1MsLCxEThbxJ0Fo
drO6q/3t09PT5s6dO7nBtJrg4m9X17YbIKyPvmvmVtrjgyifmqErggNzJZw1XsM5frF5z3IdcflK
U9ZJ6QePybp/KYRgcOC0zleJQrBYm0+6z0E7TlsRl9rX4vKR1n6UB82qdHkaHx/Pe2dqko8m2Vwl
CkHsD/uDChKCetG0xKCeYPSRCNRvpRCCSkcvqJYjaECtBsGG7edEjZr95UASO8G0NXZRA3D12gDN
ygpu7+3ttdPvdQ1yNDejK+3xPup+VX7dVH0nvoRmqLl7VYq8Z7mOuHyldfS49MOOybp/sUJQKJDr
Xun1D7pfpXiJ936riIu1+aT7HLTjLK3epfS1uHyktR/hXt+hj2Zsvn79OlN8ibO5ShSC2B/2B2Uq
BAH2G3qYOH78eEUIQShvm8P+APsDhCBAAnqS12QY954wPWnHTYqhIob9YnPYH2B/gBAESEAvP9e7
wNQ1onda3rx50wZHKmLY7zaH/QH2BwhBgL3jRFTEgP0B9gcIQQACIUEYsD/A/gAhCEAgJAgD9gfY
HyAEAQiEBGHA/gD7A4QgAIGQIAzYH2B/sPeF4Orq6p7K6G7k50de816731DZFTH2iP0Vc+5KsZ+9
dJ0/Ki8IwTIWgqVagUEvtPSXyHF8/vzZvjVd59G7j7q7u82nT58i09mJFSF+xDn24rkJFJUhBLPs
m9UeqQywv6z2s1O2u5v3tNTXWco6ZLfOi++XsRAsReHq/UUXL14MTevatWt2SR63pqLWV9S+P9LY
6GIBhGBh14T9Yn87mae9al97KV9Jy+lRd0EmIajf/I/DrYGoxbW1mLUW2I5D+2hh7LBz6OlFAtCh
/7XmY5ShBfOjv1ovt7q62r5A0zEwMGDXWVQ+1cro8+bNG7uepPKv9Rrr6urM48ePY88xOTlpWyz1
cs6HDx/aRcGVT3/x7zTnVlpaEPzEiRO59X3d8VH320cLmasFVXlXvpeWlvK2x5VNluvQvvfv37f7
Kj2tHe2vFx13D6PKxb8mrY3p1spsbGw0i4uLma4j6h6mSbuSKmL5k9b6VhlrzdGZmZm8fbP6Qppy
V1k5Gz137lzeeuBJxyeVXZxvEcT3lv2ljddp7THpGgupC9x2+Ydi4tjYWOQ6wFG2Wch1JuUrzg+S
7kFYXtTAEhUvS+VXCMEKahGUcJCzuBY8LWatoB+H3nIeZShBISihE9fMHva0I5GiNNxC4cqThIJb
XkeVn1odHU1NTWZ6ejp3DboeOWzcOa5evWrT+uuvv2zQUEumvrvFvx1J51ZaCnRO2ASPT3Kmvr4+
Mzs7a//XEkL19fWpyybLdWjf5uZmm0+lpUBx48aNTPcwWC7+tfnBaG5uztTU1GS6jrh7GJd2pQnB
kZERMzg4aO/jhw8fTFtbW96+WX0hzf6tra3m/fv3dvujR4+szaU9Pq7sknyLIL73WwST4kJWeyy2
LtA2Lb3m/OPUqVORQjDONrNeZ1K+iolhYXk5f/58ZLwslV8hBCtICDY0NFix5gs3tRoVaiiq4PW0
IiNUi5PEhp5ashh5sEVSAsYXlyLJkfxzJp1D3zc3N0P3Tzp3WH6jAk8YEn7B9NOWTZbr0P9+a+OX
L18SFy0P3sO461Rwd4K22OvIknalVcRqjfDvpVrnkvIZ5wtp9vdbAGWr8om0x8eVXSF+jRDce0Iw
zneLscdC6gL30BLlH2njStbrTMpXMTGs1HlBCCIEtxVumEjzny6yGoomhly+fNmmockkevrJ2iIY
lp9gE3kw32q2V+taZ2enFR5xYizL96RzR3WhpHWmuHudVDZZrkP/B4ND8NxZ7mHwN5Wza3Xs7+8v
6jqypF1pFXGwzFSmwX2zlmPW/bPYTVzZpfFrhODeF4JJ+2S1r2LqgmBdE/SPtLaZ9TqT8lVMDCt1
XhCCCMFthRsmRNIaQJr91tbW7FimYow8yYg19k0taxovp25rNd2XSggmnXsnhWBS2WQVgnHpZ72H
UQFf3dsdHR22e6bQ68iSdqULweC+WcuxkHL3K9uk4+PKDtFX/kKwEPsqpi5IelBKa5tZrzONLRca
w3YiLwhBhGDedw1cDXbbpX3FRBpD0ZgiPQkWY+TKo9/lGURj4/zt6+vrJROCSecuVgiq1TSqazip
bLIKwZWVldx3tdz6k3iy3sO4a9N5gvcwy3VkSbvSKmJ1ffn3Ug9a/r5ZyzHN/q9evcorO39IQdLx
SXYR51sE8f0vBAuJK8XUBS0tLXZsoOPly5epzhe0zazXmcWWs8awncwLQrBChaBmb2l8gatMNJDf
jenTZ3x8PPT9gGkNRU9/En9CM8b09OOPMUrKT1iayqMbIK+PvmvmqUOzp9xMNFWMCgZ+OknniPue
dO4kpwyeO4i6TNRtIBYWFrZNFokrm6xCUPlWkFRat2/fznutT9I9TLpO5Vsz40Rw8HLW68iSdqVV
xBp4f+fOndxg+Pb29rx9s/pCmnI/e/as+fjxoz2nfMGfLJJ0fJJdxPkWQXzv2V+aeJ3FHrMKwSSb
CU4W0bao88XZZtbrTMpXMTGs1HlBCCIE7ewhtcb4LTLu1R76aLLH69evCzYUiT4NaHdjBJMGyAbz
E5Xv3t5e+3Sp/TTD1M3cEs+ePbODYXVOOZzO6aeTdI6k73HnTnLKsPvtowk1ly5dsnnX+JmgaI4r
m6xCUAH56NGjduDyzZs38170nXQPk65T3R7Kv3udgQt6hVxH1rQrqSIWd+/etZNt9HoIzRD0983q
C2nKXefQuXSMRKE/UD3p+KSyi/Mtgvjes7808TqLPWYVgmlsRg9KslcNSZLtRvU+xNlm1utMylfc
uZLKudR5QQgiBIFKBfa5EATsD/tLhx60k96OAMQghCDg1EBFDNhfGdifWso1IcO9Q089Ebs1uQz7
A4Qg7GnKec1jKmLA/rA/oZnJGpqkeKeVRTQERoIQiEEIQQCgIgbsD/sDbAAhCABUxID9YX+ADSAE
AYCKGLA/7A+wAYQgAFARA/aH/QE2gBAEACpiwP4A+wOEIKRjdXWVm0AgJAgD9gfYH+xfIaj3LelN
5FrORitdvH//fl8YSCnzUmhapXg1S5b1iYGKeD/cH+y4vOxPK2P4q8oIrVakffXuPh/tp/3jriP4
++fPn209pNWPtPqGXgSt70nr5gbT0XKI3d3ddgUlt2LTzMzMtmOiPlH7KC3VkX/++afNa9h+WjnE
1aH+msfYH+x5Iaglq8bGxnJrE2qJnri1CcvVQAq9rlLcD5yOQFhuQhDKy/60bNm9e/fyfuvq6jJt
bW3mxo0beb9rP61nnlYIah1dpaM1ciXkhOoiLc2mZQ3jxKCfjgSa3iOoNYfd2rz//POP+fXXX839
+/cz3eew35W+XlB9/fr1yP2U70ePHpnLly9jf7B/hKDWgvzy5Uveb3GLYutJy8etI6snIQlI/6lR
+ZBTavFxt86iFt32GRgYsE9aegGoBGkw70npl+pcwevy0dqQSk/pNjY2msXFxdCnxigH8n9ToFAg
UT60HqaeVuNaBJVnrZ2pe6An3TT5gvIUgknlHWcrb968seuOyo+URl1dnW3R8c+pild+oMrUVdBa
G1rHaP+lpaW8/UdHRyP9rZS+if39+HOr7P/zn//k/abWtufPn+da/xzaz9lKGqElATg8PBy6nwRc
X19fqrxqv7B0JAadTRcjBF38ln8l7bffX+KPEKwwIeijJy8F5M7Ozsh9/vvf/+b+l9P5rYla5FsV
h29MqnyceFPw90WmKgc9YelYNaWfOnUqzwDTpF+qc/nXFcSvuObm5qx4jnKYJCE4MjJiA5/Lh56E
o4Sgrlf5dksmSTRqEfI0+YLyE4Jx5Z1kK01NTWZ6ejrnS/Ir/+FH51QLj7a5RepVsc7Oztr/1f1X
X1+ft//58+cj/a2Uvon97Y1z68FVZSQ0fMjZgx4SnM3I9tS9m0VoyTajWv1kD0GhGZWO8vP27duS
XGvc/U8SgkGxiP3BvhGCasqW8erz8uXLVMfIQV0TvGtB0HqPvjEFx5X4eWttbc0bj7i8vJy3PU36
pTpXHKowXYWY5DBJQlBPpv41BfPh/9/c3JwLvA6/8o/LF5RfRRxX3km2EoZa5+L8RxVrMM20/rZb
von97d659bCsVmmhBw3XJay/eshwDwxXr17NSytpPF5S61ncdj+duJ6sUghBiUw9yOuBKWo/95Dl
dx9jf7BvhKBDXbHqdkqDX5GEOWOSKAo6uJzI354l/WLPFYdaX7SvKtv+/v6ihGAwWAXzEdw3GDz9
exKXLyi/ijiuvJNsRajrV618avHXQ1aS/8RVrEl2vlu+if3t3rk1lMCJIDUcyB6dXboxcRJAwSEH
SecolRDUEIZSCsHgRy2iqh/99YuD+2hoQ3BCCfYHe0YIRj2NBZGRp32yCtsvSwWQJIqypF/suZJQ
Jaqn3Y6ODtuNVSohGHcdYUI4bb6g/CriuPJOshWNtVIL3+TkpJmfn7ddeXtFCBbrm9jf7pxbdUNt
ba393+8m1l+NTXXb/R6PNEJQDzZRwknj1+MaJoJdzGGzdZUvX5ymFYIOtVafO3fOrKysVIxgQgiW
qRCMQt1NvvMEu1/jkIMGu279p7ekCqClpSXv3OqS9rdnSb/Yc6VFwSDuvMHv6+vr27rB/GtaW1uL
TE/Xn/T6hKh8QXkKwajyTrIVTcTwtwftMuycqtTjuoZLJQRL5ZvY386fW2M9f//9d/Pbb7/l/a4J
IvpN40azCi2NBdfEozAk4DRjOU1e1Uqu8aZBHjx4YMedFioEnZjUtf/1118IQSg/IaimbjmQG0Su
af9u6n8SzoHdsePj47knxjQVQHCQuGYFhwWINOkXe6441JLixsYEB7qrO0Ljn5y48wf0a0yJgod/
Ho2l0St6XD7a29sjr0PX7yaW6KPv/qt94vIF5VcRx5V3kq1oxq5rFdHDh8RXkv+oG9l1/y0sLGyb
LFIqIViMb2J/u3tuvRpG2zU5Kc3vaYSWRJbioGK9e1iRLcjm1BL36dOnVHnVfhryoHpCLYnuVS7q
rn327FlRQlCoZVDjbvUQhRCEshKCckKN+1BLmyaKSBhmwb3eRR/N6H39+nXqCkBIFKlbQV0NCiLB
8SBp0y/FuaJQd5wCjHv1hauMhWZmKh2Xlqugta9Eq/YN5kPvblSrq/KifMRdh56G1Zqj9CUq3ey8
pHxB+VXESeUdZyuqCFWJ6TgJOk06SfKfr1+/2pfjuhfzahLHTgjBYnwT+9vdc7shBcHZufqeNCko
7nfZmuxXDyzuhdJ6OIgTgWHpKB9qsVR9IT/R5DwJyqzXGvW70jp9+jRCEMpLCO4lFAwUAMrtXEAg
JAjjm9gfYH+AEAygVjENfHfvPlPr305NeNjNcwGBkCCMb2J/gP0BQjABzV5U0726gTSO4+bNm3lT
8/fruYBASBDGN7E/wP4AIQhAICQIA/YH2B8gBAEIhARhwP4A+wOEIACBkCAM2B9gf4AQBCAQEoQB
+wPsDxCCAARCgjBgf4AQBIQgABUxYH/Y315mdXUV+wOEIACBcHfPrSXf/PVctVScWzouiJbX0nY/
3ahP3D7+solp708wzZmZmcR9kvJWLFq+LCl9vcNQq7No6UitqqJlxRxatuzPP/+0q1boVTfanrTy
BUKwfPOYdfWb3c5zMedDQyAEAXCiPVoRNzc3m1evXuXtK7Gn1Th8tPZ1U1NT4lJvac4tEShh5IvB
rEJQ7wkM5jFr3opFL62WeItCSz+OjY3l1mvWsnf+es03btyw69i67RKNcekhBMs7j1nzgBAEhCAA
QrCocz9//tycPXt2274SMPfu3cv7/cGDB6a/v78kQtCJQbUMFioElT/l50cKQQm70dHRyO1ai1mt
fj7+Netl1xKADr302m8VKuU17EX709rWbh31xsZGs7i4mLd9YGDArhetFtPu7u68bW/evLHrX+uB
QmnU1dXltWTrnFpLu7q62j40uIcZrS+vY7T/0tJS3v4qS61N7NbeDrZaB6/p/v37dhUb5a+rq2vb
g4lb117n0wOAv25yMH9hrcpprjGKNMdOTU1FXq/s8vr167Y1W+t1qwUeIYgQ5C4AlFlFrBYpVWbB
fdfX182pU6fyfu/o6DD//vtvyYRgVuEWtq9aLoOVazH3O2tX8sWLF62QllhRhamKPwp1I0vYdHZ2
Ru4joSJhUCn254sPDVGQcHZMTExYoeKWCZQQGRoaym1X6/T09HSuNVUtr/690zklzrTt3bt39re+
vj4zOztr/1drbn19fd7+GiLh7Cn4oBJ2TWpN1/46h8pW/uQYHh7Oaw3W9UiExuUveJ/SXGMUaY6V
UIy63pGRETM4OGiP/fDhg2lra0MIUodRiADlVhFLSK2trYXuKyEo4Sc0rk0VS5jYSjNGcKeE4LNn
z8zly5cj99npMYJHjx61LaWuBUWtlBIbQZRHtQzp8/Lly8j0lFbY8eVqfxImTpgFkcjyW0uFLxTD
UMuWf07/IUFI+AXTjNs/yXb9FkW1/B4/fjz3vaGhwQp7X+Sr9bDQ80VdYxaS7o+fnlop/fwvLy8j
BKnDKESAcquI1W0UrBjdvuomu337dq51wLXG7KUWQSeyJAgLyVup0b2UOIxCLYbqAg3j48eP9lp2
ak3kvWh/agV0LWvBbn61TgUFvC9khLpWJZzVyirhlVT+SS18WW036Dt++sG8BrenPV/WayzmWP+3
4L3StSIEEYLcBYAyq4jDKiu3r7qrNDZIFYAqanUX70Uh+Pbt29xM5t3uGk57Tx0SeWFiRL///vvv
tguukuzPiRV102roQU9PT6r7KDSkQS18k5OTZn5+3trrbgvBuPTDzpVFiBV6jcUcGycEi7UhNEQZ
1GEUJMD+rITjzh/XIig0wF2tgq2trQWJt7h9ip0s4qPWJHXL7naLoLr6Pn/+nPuurjQNyneo69MX
d8HuQaGWQL1CxgntShOCjpWVlbz91HKqcZVRaEymv133L6n8a2trY7uGswpB5dmh1/4oT37+g13D
SROBgr8Vco3FHOv/Jp/3868hJAhBhCCFCbBPA2DcGEGN/YnaVwPc1TKjruFSCkHNFpUI1d9SCEHN
1lSr5W4LwZs3b9pJAm5AvrrP9ToYh7qCJVLddolq190uNGv79OnTee8WrCQhqBYrZwPBBwNNtnCT
FfTRd//VO5rt6mbBSqTIlpPKX92k6o4WCwsL2yaLZBWCyo+EvitbTR7y86/hFS7/sgsJ0bi05RMa
t+cEWCHXWMz98X/TRBPNineTRdrb2xGCCMH8AuXDh0+6z14Wo5rlKLEXta9aOSQE3azGMEFWyhdK
x6WVVIkFX2+xG2UiAXrt2jXb0qNXwUi4+KjLVzNDtV0TRYKzijW5oNCJNuUgBNUtrLFr7vUl/oOB
6O3ttS1bun+a4erbocaFavKIjpOg06STpHun8tJ7GnWMzus/BBUiBCW0NCZULb96KAi+DNy9PkYf
zRh+/fp1bNp6kNC1upbDQq6xmPsT/E2vkVILtmbFK04gBBGCQMsTlJltaNaj38oCe4s//vijrIUg
8ZYYBAhBwNHgB9uGulTLeY3T/UwpXyWDEOSauF+AEMTRANvYhrpo//Of/3CTiA/EpgxkXRcY+6N+
QggCjgbYBiAEAfsDhCDgaIBtAEIQsD9ACAKOBtgGIAQB+wOEIOBogG0AQhCwP0AIAo4G2AYgBAH7
A4Qg4GiAbQBCELA/QAgCjgYlto00q29oaSq3VFWQR48e2e1R6WnJrI6OjrwVFRxa4kv7zM/Pb9um
9Xu16olWNdDKCFohQUu5Zc17KQmuzCC+fPli1wnWyhF6nYhWrfBXl9Bar3tltZm9KgS11nJ3d7dd
ncOt+KFVYqKOz3IdpbrmUqxY8yPyTf0ECEEqe4BEIZjmWIk9Lc/lo/VQm5qaYitp7aP1SlW5B/nt
t99MT09P6DsMOzs7zYMHD+w6py4dLdflL9G2m/b+9u1buwJL8JwSq1pD1q0nq/xJDDqePHmS971S
40PUuSX4T548aaampnLr6/7zzz/m119/Nffv398zsa0Y/yGWUz8hBAFHg30vBLXm6L179/J+l1Dr
7+9P1VqjlkEfrRmrdXaFKv3379/nbVfLUJho0Hq+P8Le1ar577//bjun8uPEqtDawv6LhiWCR0dH
94TP7kUhqJVThoeHt/0uMSiBGHZ88H+JyBMnTuTWK/bXsPb3ldDUer+yxbq6Oru8ouPNmzd2LWNt
Uxra7reCZ/Uf/a51lNXK6a7D3zfL+bT+svbR9TU2NprFxcXYe62Wc63PLNscGxvblke3/rHOrYeb
jY0N61vyx7CHPZ2T+gkQgghBqHAhuL6+bk6dOpUojoLpSSQNDg5uq+wlkG7fvm3/7+3t3dbtW19f
b4aGhnKtRKWy90K69JRXVahpzqn8qvJ3XLx40Zw9e9YcOnTIVs5+i2YlxYeoc6uc1dqa5fjg/xJU
EjNCItB/iPD3lehU975QS63O7VDL9vT0dK5lV+Xtl2MhQrCrq8umpYee4L5ZzueL27m5OTtMIgqJ
YrWyK80PHz5Yn/XTkh/qXO68ExMTVhwLDXEI+unIyMg236R+QggCQhDKTAgmiSP3vyoVCT+hFjxV
ZmEVc9hHrYc+asFRq4iQyFSroM/y8rKt8FQJnj9/3rZGPnv2LHPei0UtUxJyaX1M1+mvD3z06NHc
tavi1XWUcv3g/S4Ew1p+swpBJwKT9pXw81tvk1ALXDFCMC5fWc4ngegEbBKtra15revyIz8tDdHw
H670v8bhilevXtlWQXeP9Fd+GbwO6ieEICAEocyEYNpj1cXpWvHUUqAWu7iK11UmavlQ15dDrRrq
kvJpb28PnTSi7jWdS60+Eg3qot4te3fj1/yKNWnSw+XLl233cBS6HxKHCMH/IzhkoBAhmHbfJNEp
W5NI1/hUCaY0Qx6y/B78Le355C/63tzcbIdixBFc/1j25qfli82w+3L69Gnbqijkt/I76idACCIE
ASFo/6qL69ixY7ZyUaWklrw0FXOwglLlEtaKl1TprK6u5nWL7XTX8NWrV+2s6DT3S+Lv999/t91x
SYRVxpUqBNWqHHbPdD+jxszthBDUxBS1GE5OTtoHEtn6TgrBrOeTaFR3toZjqOs3iuA1BoVg2D3w
t+sc7qFNYwPDHs6onxCCgBCEChWCQi15ahVUF1TailmVuut+UjeTuoWDXXT6rt9d61twEoZDg9x3
y97Tdj2rJVDjq5ww9tF1q2XRoa44v3W00oWgWrhcC5SPutP9MamlEIK1tbWRXcMav6lX/ThUljsp
BAs938rKSmw5ana/L6xfvnyZt7/EXbBrONiKKD9UK3xwuAb1E1CCCEFACNrB5WrRUkWRpmLWLEQJ
R9eKoYo/bJaoULevG5iuSRXaz00kUDrqmtYA/B9p78FzPn/+3HanBWc9O27evGmvyQ3OV3e6XjeD
EPw/9M5FdYvqnuidjLpHaoXVg4A/JrQUQlDdsOpmFXqHpT9ZROLHtUCura1ZQbWTQjDL+ZRPzRwW
wckwQYKTRYKvPJJPyY+cPeq+SyD7yEbV8u+GflA/AUIQIQhlLgTTThZxFbeEoJsJGVbx+h9V6BJv
7rUU6goMvqLCISHgv6pCAkqVlM6nljWJQ781Y7dfKB12HzW4Pu78utZr167ZVhfdC82g/lE+u1df
KC2xr251tfaqrDUuU0ItjbjLIgRVFnqno3tptSZSOCQ63eQkCa/gy8NLLQSznE/dwsqvez2OE4VR
59Isd81Sl5jTg1uwxc+9PkYfzRgOvuxdLdw6Js0wB+onhCAgBAHbgCL4448/Kl4Iws4h8eve10kM
AoQglT1gG7DH2M1XySAEyx+1nGvCh7p9NTZXrX9xk0uwAUAIUtkDtgHYAPZXJmiWr7rW3VAEjVGN
e50RNgAIQQI9YBuADWB/gA0AQhBHA2wDsAHsD7ABQAjiaIBtADaA/QE2AAhBHA2wDcAGsD/ABoAS
xNEA2wBsAPsDbAAhCDgaYBuADWB/gA0gBAFHg31tG1oH98aNG/b9Y1q1QKsduGXe9prNplnpAT9C
CAL2BwhBHA0gpW10dnaaBw8e2BfQCi3hppfQ6lOp9o0Q5J4CNgAIQRwNKsI2whawVyuhXkbrH3v/
/n3baqj1Sf21gx1qRdT6ptre3d2dt03iUmuaVlVVmbq6OrO0tBSarzdv3pgLFy7Y/ZQv7fv48ePQ
ff3/tfaq9tdarFqreHFxMXXeJICvX79ufvnlF7s268zMDEKQ2ATYACAEcTSoDNvQgvdDQ0NWrMUd
29zcbDY2NqxwkrBSd7JDC9tPTU3llrWSmFKaDi2jNjs7a//X8lc6Z1i+mpqazPT0tE1Hn7GxMVNd
XZ0oBCUCnz59av+fm5uz3dtp8zYyMmIGBwft9g8fPpi2tjaEILEJsAFACOJoUBm2sby8bIWTxNT5
8+fNvXv3zLNnz7Yd67fiffnyJW8he4lE17Xs8MWYhF9we1qbVStfkhCUWHRCM0hS3rQcly+CdT8Q
gsQmwAYAIYijQUXZxosXL2zrmLpmJQrv3r2bd2xQTPldyvpf+/gfX8CFdT9H5Uv5UAuixi42NDRE
ij//f7UCulbL/v7+bfnMkjddJ0KQ2ATYACAEcTSoWNtYXV3NazULO9YXUL6wCiOtENQ4RLUeTk5O
mvn5efPu3btUQtAJSHU7d3R0mJ6enqLyhhAkNgE2AAhBHA0qwjY0KSSs21YTK/xjV1ZWct8/ffpk
J1c4NEFjc3Mz8ty1tbWpuoaVpp/O+vp6aiHoUD79bUl5a21tzesaXltbQwgSn4CyB4QgzgaVYRt6
Tczw8LB5+/at/a7ZwKOjo3ZmsH/smTNn7GQKCbrbt2+bixcv5rbreDfhQh991/4OdfWq+1YsLCxE
ThY5ceJEbpawBFlLS0sqIaj0NHNYaNKI38qXlDdNTrlz505uskh7eztCkBgFlDkgBHE4qBzb0Cxg
tdqpG1WviJE49FvJdKwE2tGjR+3EjJs3b9pWQZ/e3l7bonfgwAE7zlDdug6Jy0uXLlmBpnF/mpAR
li9NUnETVyTuNAEkjRBUt7DSVf51rBOFafImNB5S161XzGiWMUJw5/PBp3I+gBAEhCDsc9vArrAB
4P4DYMEEGkAIAvEBuP+AEAQCDVSSbahLFYgPwP0HhCAQaADbAGwAuP+AEAQCDWAbgA0A9x8QgkCg
AWwDsAHg/gNCEAg0gG0ANgDcf0AIAoEGsA3ABoD7DwhBINAAtpEOrXMMxAfuPwBCEAg0sAu2EVwF
QCtzaBWOP//803z+/HnXbXMvvapGK6JoxZUgX758sfdH6zErv1o1xV9pRf9rBZOqqiq7z+XLl+3y
dcQHfBAAIQgEGthzQjCIBGBPT4+5fv16xdrwt2/f7HrKYfm5ceOGGR8fz61frCX5JAYdWrKvv78/
t/3Bgwd2mTviAz4IgBAEAg3seSEoJGDUmuUjgaP1ePV7d3f3tmO0Xa2Jhw8fNmNjY5FrA2stYLU8
am3gxsZGs7i4mNsnbI3SuPNqP601rDWQT548WbL7debMGfP27dvQ+6Pr0/3xRaPfknn27FmztraW
t/3cuXPEB3yQmwAIQSDQwP4QgsIXghMTE2ZqasoKIAmbmZkZMzQ0lNuubWpF1HZ1g546dSpSCEoE
Pn361P4/NzdnampqIvOTdF7t39XVZbe/e/cu8hrDPnHMz8+n9qmtrS0rRB0Sw75QdL8RH/BBAIQg
EGhgzwtBtYSNjIxYgeVobm7eJm58Adfa2mrev3+f+768vBwpBCWaZmdnU+Un6bzaf2Nj44f6lLp+
+/r68oRukLDfiA/4IABCEAg08MOFYPBz7NgxO+5NLXC+kAnup65dR3CSh8RblBBUK6C+S+RpLF1c
PpPOu9M2n5T+x48f7WQQ/175+UMIAvcfEIJAoIE9LQQdatHTWLaVlZVt+4WJmzihEycEhcb1PXny
xHR0dNgu5aj9ks6bxuYL6RpOk77E3++//75tRnBYNzBdw8D9B4QgEGhgTwtBJ2706pO//vor73dN
6tjc3IxMv6WlJU8QvXz5MlYIOiQ64/ZLOu+PahFUS6BeIbO+vr5tm8StXjHj0GtoNPmE+IAPAiAE
gUADe1oICrUMahyeL3KGh4fN4OBg7pUo+u6Lm+BkEW2LEnj19fV25rDQpBG/NVHv3tOYP03ASHPe
HyEEnz9/bk6fPp03JtJHs5z9PE9OTm7rAic+4IMACEEg0MCeFIJiYWHBih0fvQtPXZwaD6hWw+As
3Tt37tjXvGiMoWb7+uMG/fOoW7ihocF2+0oEOlEoNCNYx/nHxp33RwjB48ePx3Y1K3/t7e256zh/
/nzeC6eJD/ggAEIQCDRQ1rah7lAJJiA+APcfEIJAoIEyt40jR47YyR/ufX+adexPAgHiA/ef+w8I
QSDQQJnahl7ArJU91BWqlTdu3ryZ90oVID5w/7n/gBAEAg1gG4ANcP8BEIJAoAFsA7AB7j8AQhAI
NIBtADbA/QdACAKBBrANwAa4/wAIQSDQALYB2AD3HwAhCAQawDYAG+D+AyAEgUADFWEbafOrlUa0
CgoQH7j/AAhBColAAxUmBF+9emXfXwjEB+4/AEKQQiLQQEbb0O9a+7e6ujpPUA0MDNh1gw8ePGi6
u7vzjtna2jJXrlwxVVVVpq6uziwtLeVt16oiOk7bz5w5YzY2NmLPp9VIrl+/btcT1jrFMzMzefnV
WsRak1hrEzc2NprFxcW88509e9Y8f/6cQiY+cP8BEIIEGoCsQrCrq8uKsXfv3tnfJiYmzNTUVG65
OAmzoaGh3DF9fX1mdnbW/q9l5err63PbhoeHzdjYmD1WH6Ul0Rh3vpGRETM4OGh/+/Dhg2lra8vL
r0Tg06dP7f9zc3OmpqYm7xomJyfNjRs3KGTiA/cfACFIoAHIKgT9FjvR3NxsRZmPL74k/ILbHQ0N
DbbF0KH/tQ5x3PnUMugfs7y8nJdftR464RnG2tqaaWlpoZCJD9x/AIQggQYgqxAMohY4/e5/1C3r
b4/C3y9s/6jz+Uhk+vupFVDfJVD7+/u3Ha/91RUNxAfuPwBCkEADUKQQDBNzccItaZt/jjRCMGw/
jStUN3RHR4fp6enJlCcgPnD/ARCCBBrANlL+rgkZm5ubkWnV1tZGdg3r2GDX8IEDB2LP19ramneM
unqj8ruysrJtm8Yx0iJIfOD+AyAEKSQCDZRACGrCh5u8oY++a/avQ5NF1F0r9A6/4GSR0dHR3LHj
4+NWOMadb3p62ty5cyc3WaS9vT1vP6WvmcNCk0aCrX8vX75kjCDxgfsPgBAEAg2UQgiK3t5e+zoX
tebppc1uhq/4+vWruXTpkhVkmhyiyR0+7vUx+mjG8OvXrxPPd/fuXTupRK+s0Uxjfz91C+s86rLW
OZ0odNy7d49Zw8QH7j8AQhAINFCJtqHXzUgsAvGB+w+AECTQAFSQbWg8oWYTA/GB+w+AEKSQCDRQ
Ybbxn//8h7WGiQ/cfwCEIBBoANsAbID7D4AQJNAAYBuADXD/ARCCBBoAbAOwAe4/AEKQQAPYBmAD
wP0HQAgSaADbAGwAuP8ACEECDWAbgA0A9x8AIUigAWwDsAHg/gMgBAk0gG0ANgDcfwCEIIEGsA3A
BoD7D4AFE2gA2wBsALj/gBAEAg1gG4ANAPcfEIJAoAFsA7AB4P4DQhAINIBtADYA3H9ACAKBBrAP
oOyBMgCEIBBoABsByhwoB0AIAoEG9oyd8KmcDxCfARCCBBoA/AP/AOwPACFIoAHAPwCwPwCEIIEG
AP8AwP4AEIIEGgD8AwD7A0AIEmgA8A8A7A8AIUigAcA/ALA/AIQggQYA/wDA/gAhCAQaAPwDAPsD
hCAQaADwDwDsDxCCQKABwD8AsD9ACAKBBgD/AMD+ACEIBBoA/AMA+wOEIBBoAPAPwP4AEIJAoAHA
PwD7A0AIAoEGAP8A7A8AIQgEGgD8A7A/AIQgEGgA8A/A/gAQgkCgAcA/APsDQAgCgQYA/wDsDwAh
CAQaAPwDsD8AhCAQaABS+wcfPj/yA4AQBIQgABBfAAAhCARqACC+AABCEAjUAEB8AQCEIBCoAYD4
AgAIQSBQAwDxBQAQgkCgBgDiCwAgBIFADQDEFwBACAKBGgCILwCAEAQCNQAQXwAAIUigBgAgvgAA
QpBADQBAfAEAhCCBGgCg0LjCmrkAgOcjBAEAIUicAUAIAkIQACpVDAIAQhAQggCAEAQAhCAgBAEA
IQgACEFACAIAQhAAEIKAEAQA4gsAIASBQA0AxBcAQAgCgRognR3z4cMn3QcAIQgIQcCGAfAZAIQg
AYFiAuwXAN8BQAgSDACwXQB8CAAhSCAAwHYB8CEAhCCBAADbBcCHABCCBAIAbBcAHwJACBIIALBd
AHwIACFIIADAdgHwIQCEIIEAANutMFZXV7kJ+/Q+4EOAEAQCAZSd7X7+/NlcuXLFHDhwwBw5csR0
d3ebT58+5bbr/wsXLpiqqipz8OBBc/nyZfPhw4e8NG7dumV++eUXu8+lS5fM+/fv8e3/5++//zY/
//yzaW5utt91n/fb9fhplSrd3boPxH9ACAKBACDGdq9du2aGhobM9+/f7Wd0dNRcvHgxt31gYMD0
9/fntj948MD09vbmtt+9e9eMjY3ltt+5c8ecOXMG3/5/JAKfPn266zFkp4RgJcdS4j8gBIFAAGVn
u2qZkYBz6H+17jnOnj1r1tbWct+/fftmzp07l/teU1Njvnz5sk38xOXjxYsXprq62pw8eTJPcB46
dMi2OqpV0mdra8u2WqrFsa6uziwtLeVtV4ukjtN2idCNjY3Y8+kar1+/bq/z2LFjZmZmJu/+uFa8
n376yTQ2NprFxcXI63nz5k2uxVTHKH+PHz/OnTvNGrZx1x51v3ySries7IPb79+/b1uElYeuri7z
9evXyH3TlEuW+5LmPmQpE+I/IASBQABQoBBU5e5320lc+Nvdb2Fsbm7ayryzszM2HxIaSvPdu3f2
t4mJCTM1NWV/k9CUkFErpaOvr8/Mzs7a/588eWLq6+tz24aHh/NaJJWWxEnc+UZGRszg4KD9Td3c
bW1teffHb8Wbm5uzYjeKpqYmMz09nTu/8iLRFnXfg9+Trj0s/0GSrieNEFTXtQS00lAZ3rhxI1EI
xpVL1vuSdB+ylAnxHxCCQCAASGm7Ek3qDlYFrFYgCQC1uvgVcJCw3zR2UC05+rx8+TI2H36LnZAI
CYpNv6KXwAhudzQ0NFjx6gtZtWzFnU8ta/4xy8vLefdHgsUJnELw71+SEEy69rD8B0m6njRC0G/N
Uwvv8ePHE4VgXLlkvS9J96HYMiH+A0IQCASA7YagySAScRJ3tbW1trXFbxH0K+84IehQN6267rLk
Q+kFuwuTxGja/EWdz0cCxN9P98C1kml8ZBLqulXrmFpCJUzjRFjwe9K1p4k5SdeTRggGRVjUPQy2
nJbqviTdh6xlQvwHhCAQCAAKsF2NB9Q4M0dYN3BU17BQt17SGME0Yi6t8AzbliSCko5xIkbdnR0d
Haanpyfy/Bpbp5axyclJMz8/b7tvswjBpGsvRAimuQdZ7lEhQjDrfUm6D1nKhPgPCEEgEAAUaLuP
Hj3KG+OnStefDKLuY39WsLrs/NfJBLtm0+RDLYgaXxiFWiqjuiB1bLBr2G/RDDtfa2tr3jESv1H3
Z2VlJfbeSRT7eV9fX88kBJOuPU25JV1PMI2wPOo6HWol9sV+VFpx5ZL1viTdhyxlQvwHhCAQCABS
2q5abST+hGZ6SvhpjJlDEwfcRAR91MLjd82pK9h/vczt27ftJ0s+NOHDP4e++2JT3YvqGhQLCwvb
Jou4MY76jI+PW4ESdz5NYtBrbtzkivb29m1j3zRLVWiCQlzL14kTJ3KzYSXAWlpaYgWPZtFqzJ8T
bknXnibmJF2PP9Hi7du3djZvMI86p451Zei/QihuskhUuSTdl6z3IUuZEP8BIQgEAoCUtivRp8kG
boxgcEC+uvQkLNTKps/58+fzXjitrmDNatU2TRSRMCwkH3o3oVqRlI6Eij9DVq2QelG18qixZr5Q
dWLUTVTR5JfXr18nnk/vP1TLpV5Xohmr/n7qgtR51F2pczoBEsazZ8/spAbtJ7Gi+xcnBDUT1t3L
NNeeNubEXY8TTroelbGuJ5hHibajR4/aFt6bN2/mlXHU9cSVS9J9yXofspQJ8R8QgkAgAMB2Advg
PgFCEAgEANguYBvcJ0AIAoEAsF2AbezHdX/xIUAIAoEAANsFwIcAIQgEAgBsFwAfAoQgEAgAsF0A
fAgQgkAgAMB2AfAhQAgCgQCwXWwXAB8ChCAQCADbBQB8CBCCQCAAbJfrBMC2ACEIBALAdrlOAGwL
EIJAIICKsl39rnVctcas1hx2DAwM2HVrtX5vd3f3tmMmJyft2raHDx82Dx8+NMPDw3adWK0Dq7Vt
fdxawFVVVebMmTNmY2PDfP782Rw/ftyuV+uztbVlGhsbU+Xj+/fv5vr16/a8x44dMzMzM/goEP8B
IQgEAoAsQrCrq8uKqnfv3tnfJiYmzNTUlP3t27dvVmANDQ3lHXP16lW77a+//rJC7Nq1a/a7RKDE
oEMCcWxszKalj9K+cuWK3fbnn3/a7T4jIyNW/KXJh/YdHBy02z98+GDa2trwUSD+A0IQCAQAWYSg
Wuh8mpubrbjyqampiTxG3zc3N0PP1dDQYFv5HPpfLYni1atXtlXQnUt/f/3111zaSflQC6af9vLy
Mj4KxH9ACAKBACCLEAyiFj397n9++umnyGPivvvH+ek7Tp8+bVv9xPT0tLlw4ULqfPjpOCGJjwLx
HxCCQCAAKEIIhom3tMIv+D0o1oLbnzx5Yurq6uz/Ghs4Pz+fOh9JaQMQ/wEhCAQCgIxCUILM7+ot
RggqrWDX8IEDB/L2P3HihB3vp27hLPlobW3NS3ttbQ0fBeI/IASBQABQjBDUBA43CUMffdds30KE
oI4dHR3NpTU+Pm5qa2vz9tcEEM369SeCpMmHupLv3LmTmyzS3t6OjwLxHxCCQCAAKEYIit7eXjsb
WK13GrfnZhRnFYLCvT5GH80Yfv36dd72jx8/2vNIzGXJh7h7966dfKJXzGiWMT4KxH9ACAKBAADb
BcCHACEIBAIAbBcAHwKEIBAIANsFAHwIEIJAIABsFwDwIUAIAoEAsF0AwIcAIQgEAsB2AQAfAoQg
EAgA2wUAfAgQgkAgAGwXAPAhQAgCgQCwXQB8CAAhSCAAwHYB8CEAhCCBAADbBcCHABCCBAIAbBcA
HwJACBIIALBdAHwIACFIIADAdgHwIQCEIIEAANsFwIcAEIIEAgBsFwAfAkAIEggAsF8AfAcQgkAw
AMCGAfAZQAgCAQFgB+2YDx8+6T4ACEFACAIA8QUAEIIEaooJAIgvAIAQJFADABBfAAAhSKAGACC+
AABCkEANAEB8AQCEIIEaAID4AgAIQQI1AADxBQAQggRqAADiCwAgBAnUAADEFwBACBKoAYD4QnwB
QAgCgRoAiC8AgBAEAjUAEF8AACEIBGoAIL4AAEIQCNQAQHwBAIQgEKgBgPgCAAhBIFADAPEFABCC
QKAGAOILACAEgUANAMQXAEAIAoEaAIgvAIAQBAI1ABBfAAAhCARqACC+AABCEAjUAEB8AQCEIBCo
AYD4AgAIQSBQAwDxBQAQgkCgBgDiCwAgBAnUAADEFwBACBKoAQCILwCAECRQAwAQXwAAIUigBgAg
vgAAQpBADQBAfAEAhCCBGgCA+AIACEECNQAA8QUAEIIEagAA4gsAMYBbQKAGAOILACAEgUANAMQX
AEAIAoEaAIgvAIAQBAI1ABBfAAAhCARqACC+AABCEAjUAEB8AQCEIBCoAYD4AgAIQSBQAwDxBfZV
+fOpnA9CkEANAEB8AcqeMkcI4qwAAMQXyh0qveyxBBwWAIgvQJlDhdoA1oDTAgDxBShzQAgCTgsA
xBegzAEhCDgtABBfgDIHhCDgtABAfAHKHBCCgNMCAPEFKHNACAJOCwDEF6DMASEIOC0AEF9g35f5
+/fvzW+//WYOHDhgqqqqzKVLl8yHDx9y2zc3N2NXq0jajk8gBAGjBADiC+zRMm9vbzcPHz40379/
tx/9f/bs2dz2J0+eWHEYRdJ2fAIhCBglABBfYI+W+c8//xz72507d8zo6Ghkuknbw/Lx4sULU11d
bU6ePJn7fWBgwBw6dMgcPHjQdHd35x2ztbVlrly5Ylss6+rqzNLSUt72W7du2eO0/cyZM2ZjYyP2
fBK8169fN7/88os5duyYmZmZybs/f//9t70HP/30k2lsbDSLi4sIQSBQAwDxBcqvzF2LoGN2dtac
Pn069/3ixYu2hVAiTcJJossnaXtYPrq6uqwYe/funf1tYmLCTE1N2d++fftmhdnQ0FDumL6+Ppsv
oRbI+vr63Lbh4WEzNjaWa9FUWhKNcecbGRkxg4OD9jd1g7e1teXdH4nAp0+f2v/n5uZMTU0NQhAI
1ABAfIHyK/NXr16Zw4cP58b26X/95jh69Kh58OCB/V/C6d69e1aYpd0elg+/xU40NzfbY3188SXh
F9zuaGhosC2GDv1/5MiR2POpZdA/Znl5Oe/+qPXQCc9ytQEiAIEaAIgvQJmbCxcu2FY116J29+5d
28oXhfaR+Ct0e1g+1AIXnGyibll/exT+fmH7R50vmGd/P7UC6rsEan9/P0IQCNQAQHyB8ixzzRb2
W9v0v8baxREmvtJuD8tHUnpxQjBsW57gSSEEw/bTuEJ1Q3d0dJienh6EIBCoAYD4AuVX5kHRJyGo
iRcOdbN+/vw5911dqpqwkXZ7mnxoQoZeQxNFbW1tZNewjg12DUvcxp2vtbU175i1tbXI+7OyslI2
/oIQJFADABBfKPM8NJFicnLSTtKQ2NJECs2oddy8edPO6HVdx5rEMT4+nnp7mnyoa9pN3tBH3zX7
16Exh+quFQsLC9smi2jWsjtW55ZwjDvf9PS0ne3sJotowoy/n9LXzGGhSSNxLZIIQSBQAwDxBfZt
mX/9+tWKQbWi6SMRqN/87deuXbPbNJFEgi14fNz2tPno7e21s46VjsYtuhm+7hx6V6EEmSaHaHKH
j3t9jD6aMfz69evE82kspFozNdtZM439/dQtrPOoy1rndKIQIQgEagAgvgBlDghBwGkBgPgClDkg
BAGnBQDiC1DmgBAEnBYAiC9AmQNCEHBaACC+AGUOCEHAaQGA+AKUOSAEAacFAOILUOaAEAScFgCI
L0CZA0IQcFoAIL4AZQ4IQcBpAYD4Avu7zIs9104ev9ds/0eVCxEApwWACo0rwQ9QpyAEEYKAEAQA
hCBUaJ0yMDBg19zVWr3d3d253y9fvmwWFhZy37Xm7rlz5+z/W1tbdl3fqqoqU1dXZ5aWlsIFR8h5
/d++f/9u1zfWOsPHjh0zMzMz246Jyl/a44Pn3tjYyOVd1+OvXfzmzRu71rG2aZ1hXdvjx4/z7oF+
1zrEjY2NZnFxccfyihDEabkJALCjYhCoUyYmJszU1JQVKd++fbPiZGhoyG579+6daWlpsdu+fv1q
ampqzKtXr+y2vr4+Mzs7a/9/8uSJqa+vL0gIjoyMmMHBQXuODx8+mLa2trztcflLc3zYuVtbW837
9+/tMY8ePTJXr17NbW9qajLT09N2mz5jY2Omuro6t10i8OnTp/b/ubk5e092Kq8IQZyWmwAACEHY
0TqlubnZChOfoLiRgJGguXHjRu53Cb/gcYUIwZMnT9rWRYda5/ztSflLOj7s3H4LoNLWOeJQ659D
otAJ4Kz3MmteEYI4LTcBABCCsKN1ilq4gsMFfOHjBM6RI0fMx48f845LJTgShGAwHQmp4Pa4/CUd
n+Y+BNN48eKFbfHs7Ow0DQ0NeceoFVDfdU/6+/sz3cuseUUI4rTcBABACMKO1ilB0RfG+fPnbQvg
bgjB4Pak/CUdn2bbgQMHcv/fv3/fXuvk5KSZn5+33ePBYyQU1R3e0dFhenp6diyvCEGclpsAAMQX
2NEy14SHzc3NyOPGx8ftuDcJI79ruLa2tqCu4fX19bzfNF7P7y5dW1vL256Uv6Tjw/LmxjkKHXv8
+PHcd03k8M8XzK/PysrKjuYVIYjTchMAgPgCO1rmw8PDuQkM+uj7mTNn7Da1hp06dSpP6Pz777/2
f3WdqptUaGZx1GQRf3LF27dv7Yxcf7smZty5cyc3gaK9vT1ve1z+0hwfdh/Onj1rWzd1jNL2J4uc
OHEiN0tYQk2TZfz0dJ2aOSx0XX4rX6nzihDEabkJALvgZ3wq50OdEk5vb69tCVMXqYSaBKC4dOlS
3utj9L+2C80i1nYJIY2j8ydg+OdyYkndpmpFlIgK5uXu3bt2DKJeu6LJKcHtUflLe3zwPmgf7av0
JAr1OhnHs2fP7AQP5VmiTxND/PTULazr1fVoHycKdyKvCEEqKG4CAD4GlDnXDghBnBYA8C+g7Llu
QAjitACAbwE2wDUDQhCnBQB8C7ABrhkQgjgtAOBbgA1wzYAQxGkBAN8CbIBrBoQgTgsA+BZgA9g9
IARxWgDAtwAhCNg9QhCnBcC3ABvgmneE1dXVgrYBQhAIVAA/1Lc+f/5srly5YlcE0Jv/u7u7zadP
n3Lb9b9WCqiqqjIHDx40ly9ftstE+dy6dcuuKqB9tOrC+/fviT1cY0Vds/wn6rxx27ALhCAQqAB+
qG9du3bNDA0N5dYJHR0dNRcvXsxtHxgYMP39/bntDx48sMtJObR01NjYWG671hT11xkl9nCNlXDN
Scu7IQQRgoBBAuxJ31JrhQScQ/+rdc+hNUm1CL3j27dv5ty5c7nvWp/0y5cveWn6C9KH5UPrllZX
V5uTJ0/mCU6tQ6pWR7VK+mxtbdlWS7U41tXVmaWlpbztapHUcdouEeqvoRp2Pl3j9evX7XUeO3bM
zMzM5N0fraPq1oltbGw0i4uLxNcyvOYku5mamjInTpzIra+r9YOjzhFc29n/G7Utje0HefPmTa6F
XnmSPzx+/Dh1vpNsHyEIBCqACheCEl1+V5YqDH+7+y2Mzc1NW6l1dnbG5qOrq8um6Ram1yL0qrz0
m4SmKie1Ujr6+vrM7Oys/f/Jkyemvr4+t214eDivRVJpSTTGnW9kZMQMDg7a39TN3dbWlnd//Mpz
bm7Oil3ia3ldcxq7keBy4lD2kPSAEyk+YrYl2X6QpqYmMz09ncu3rkEPOWnznWT7CEEgUAFUmG+p
8lN3sCqGr1+/mhs3btiWBF8UBQn7TWMH1aKhz8uXL2Pz4be8iObm5m1i0xdfEn7B7Y6GhgYrXn0h
q7GOcedTy6B/zPLyct79UcXqhCfxtTyvuRC7KbT7N25bku2nwffXpHwn2T5CEAhUABXmW5oMIhEn
cVdbW2tbwPwWQb+SiROCDnW3qTs1Sz6UXrALLUmMps1f1Pl8VBH7++ke6LsqaY2PJL6W3zUXYjc7
IQSTbD8MDXVQK7la3iVo484Vdr4420cIAoEKoMJ9S+MBNXbIEdYNHNU1LNS9laULLapSTis8w7Yl
VYxJx7jKVt3QHR0dpqenh/haZtdciN3shBBMsv0g9+/fty3kk5OTZn5+3g53KEYIVoJdIAQJVACQ
wbcePXqUN8ZPQsifDKLuY39WsLpR/dfJBLvY0uRDLYgaXxiFWiqjuoZ1bLCLz2/RDDtfa2tr3jES
v1H3Z2VlpWziEkKwOLvZCSGYZPthD2H+/uvr65mEYBbbRwgCgQqgAnxLrQsSf0IzEiX8NG7Iockf
bnC5PmqJ8LtL1RXsv17m9u3b9pMlHxq4759D332xqW4wddeKhYWFbZNF3BhHfcbHx61wjDufBtvr
NTduwHx7e3vefkpfM4dF0iQB4uv+vOZC7Cbu/mkWr8bmOZHl7xu3Lcn2g2g2sJslLBHX0tKSSQgm
2T5CEAhUABXmWxJ9GkDuxggGJ0mo60mVhVpL9Dl//nzeC6fVFaxZudqmiSIShoXkQ+8mVGuH0tGs
RzfDV6gVUi+qVh41JsoXqk6Muokqmvzy+vXrxPPp/YdqudRrOzRz099P3cI6j3v9hhOFxNfyuuas
dhOXlmb6Oh8J7hu3Lcn2gzx79sxOJpFd6oFF/pq1SzvO9hGCQKACwLcAG+CaASEIOC0AvgXYANcM
CEHAaQHwLcAGuGZACAJOC4BvATbANQNCEHBaAHwLsAGuGRCCgNMC4FuADXDNgBAEnBYA3wJsgGsG
hCDgtAD4FmADO31NWVb8AIQgEKgA8C3ABspMCAY/P/KaV1dX93X6CEEgUAHgW1x3Gd+LKPFUrp/d
tht/zeKdYKfTLzf/RAhiFACAEARDi+Bu3audvs/YNEKQQAUAJfMtraOrdUu1rm5jY6NZXFzMbdva
2rJrsFZVVZm6ujqztLSUl57W5K2urrZrFTsGBgbsGqZav7W7u3vb+eK2K82pqSlz4sSJ3Dq/T58+
TX389+/fzfXr1+26rceOHTMzMzPElAoRglmv+c2bN3ZdX9m27Ez2/fjx47zjNjY2cvZ/7ty5vDWu
o/wmTJCG+UrS+aN8L01r537y6aBoT+P/8u/Dhw+bsbGxVDaNECRQAUCMb/nBdm5uzi5o7+jr67OL
2osnT57YRe799Lq6uqz4evfunf1NC9grkOu3b9++WSE2NDSUOyZpu9JU5agKWChfyl/a40dGRszg
4KDd/uHDB9PW1kZMqfD4GnXNTU1NZnp62tqKPhIVEkD+ca2treb9+/d2+6NHj8zVq1dT+U3wnGG+
knT+JN+LYz/5dFAIxu2r8/T09OT8+9SpUwhBAhUAFOtbqnxcxRBElYSCblR6LmA7mpubt+3vV0JJ
28PS9POddLxaMdTi4VALDjEFIZgWtUL5x/ktgLI72V8avwkTgkG7Tjp/ku/FsZ98Ovh/3L5OmGf1
b4QggQoAYnxLLQbapoDe39+/rWUhS3raP9h15VduSdvD0vR/S5O+jyooYgpCMAp1g6qFrLOz0zQ0
NCSOLfTtK85vwoRg1vNn9b396tNJ99z/LThJJq1/IwQJVACQokJUN1FHR4fteim00vArgKQWj7Rp
+r8lHR+WX2IKQjCM+/fv29axyclJMz8/b7tCk0RJUIhE+U0aIZh0/mKE4H7y6SxCsNAHPYQggQoA
UvrWyspK3n61tbWZuqc0MH1zczMy/aTtSRVB0vHqOvK7htfW1ogpCMHQ3zXhwLel9fX1baLk1atX
ue+yq+PHj6fymzRCMOn8WX1vv/p0FiHY0tJixwY6Xr58iRAkUAFAsb6lVgnNMhTBwdnqtlI3k1hY
WEgcsD48PJybrKGPvp85cyb19qSKIOl4Db6/c+dObjB5e3s7MQUhGPq7Zqa6Wbp6YJDICIqSs2fP
mo8fP1p7kt35k0Xi/EYzcjXWzT2UhOUh6fxxvhdMfz/7dBYhGJwsovMgBAlUAFCkb6kLSeOT3Osa
XAUivn79ai5dumR/1z7+4Pmo9Hp7e21rh7rRNAPQzT5Msz2pIkiT/t27d82RI0fs6yw0o5GYghAM
49mzZ3ZSg2xbYkiTK4KiRPYjO5KtSRT6Exni/EazZnWM60oOy0PS+eN8L5j+fvbpLEJQ6EFPZaLX
Q6l80rxcGyFIoAIAfAsQglBmSNRGddcjBHFaAMC3ABvA7ssItfRrAox7Z+GtW7fyJsIgBHFaAMC3
ABvA7ssUza7Wu0LVHayVRW7evGkFIUIQpwUAfAuwAa4ZEII4LQDgW4ANYPeAEMRpAQDfAoQgdo/d
IwRxWgDAtwAhCNg91oDTAuBbgA1wzYAQBJwWAN8CbIBrBoQg4LQA+BZgA1wzIAQBpwXAtwAb4JoB
IQg4LQC+BdgA1wwIQcBpAfAtwAa4ZkAIAk4LgG8BNsA1A0IQcFoAfAuwAa4ZEIKA0wLgW4ANcM2A
EAScFgD/Asqea4e9WPZYAg4LgI/hY5Q59wAqtMyxApwVAP7fz/hUzgewe+weIYgQBADiC/EFoLJj
ALeAQA0AxBcAQAgCgRoAiC8AgBAEAjUAEF8AACEIBGoAIL4AAEIQCNQAQHwBAIQgEKgBgPgCAAhB
IFADAPEFABCCQKAGAOILACAEgUANAMQXAEAIAoEaAIgvAIAQBAI1ABBfAAAhCARqACC+AABCEAjU
AEB8AQCEIBCoAYD4AgAIQSBQAwDxBQAQggRqbgIAEF8AACFIoAYAIL4AAEKQQA0AQHwBAIQggRoA
gPgCAAhBAjUAAPEFABCCBGoAAOILACAECdQAAMQXAEAIEqgBAIgvAIAQJFADAPGFmwCAEAQCNQAQ
XwAAIQgEagAgvgAAQhAI1ABAfAEAhCAQqAGA+AIACEEgUAMA8QUAEIJAoAYA4gsAIASBQA0AxBcA
QAgCgRoAiC8AgBAEAjUAEF8AACEIBGoAIL4AAEIQCNQAQHwBAIQgEKgBgPgCAAhBIFADAPEFABCC
QKAGAOILACAEgUANAMQXAEAIEqgBAIgvUOLy51M5H4QggRoAgPgClD1ljhDEWQEAiC+UO1R62WMJ
OCwAEF+AMocKtQGsAacFAOILUOaAEAScFgCIL0CZA0IQcFoAIL4AZQ4IQcBpAYD4ApQ5IAQBpwUA
4gtQ5oAQBJwWAIgvQJnvDKurq3sqnZ1OEyEIBGoAIL7ADy3zz58/mytXrpgDBw6YI0eOmO7ubvPp
06fIdP7++2/z888/m+bm5uziI8HulIdSUKp04tJM60N7ydcQggRqAADiC2Wex7Vr18zQ0JD5/v27
/YyOjpqLFy9GpiMR+PTp08LER4Ldlcoud8K+C00TIQgEagAgvsCeLXO1dEkAOvT/L7/8EplGcA3b
0OXLIsRfnN1FrY87MDBgDh06ZA4ePGhbKx2XL182CwsLue9qqTx37lyqdXbfvHljLly4YKqqqqyw
raurM48fP87Ly4sXL0x1dbU5efJk4nVvbW3ZVlWlp7SWlpYirznqetw1KD8//fSTaWxsNIuLiwhB
nBYAgPgCuycEJWriula3LVVWIiEYtn1iYsJMTU3Z/H379s3MzMzY1kvx7t0709LSYrd9/frV1NTU
mFevXqU6T1NTk5mens61go6NjVnR5+ejq6vLbtN5kq67r6/PzM7O2v+fPHli6uvrQ/eLux7ht7bO
zc3Za0II4rQAAMQX2LEyV0uWuoOdoLpx44ZtkdoLQlDjEH2RKnxxJGE1MjJixZTyXYx9+9es4zc2
NlJft4RfMJ9h+yVdj8SoE5Q7bQNEAAI1ABBfgDK3E0PUzarWqNraWtsStVdaBJWnYLdsUKRKXGmS
y8ePHzPZt7p+1ZLX2dlpGhoaEvMZd93KZ5prSroe3Xv9pmvq7+9HCOK0FBMAEF9gd8t8bW3NHDt2
bEeFYNQ4vmBacS2TjvPnz9sWuSxC8P79+/aYyclJMz8/b7t/d0MIprkeCVR1L3d0dJienh6EIE4L
AEB8gd0r80ePHtlWskKF4Pr6eslaBDVhYnNzM3L/8fFxO+ZOgi5L17Amw/jpxuU5zXWrJTVN13DS
9fisrKyU3E8RggRqAADiC2Weh1rGJP6EZtOqJWp5eTl1Ov4Eh7dv39rZuIUKQc261dg8TVgRw8PD
ZnBwMDepQ9/PnDljt6kV79SpU3ki699//w1NJ8iJEydys4TVAqpJJ0n5DKYZnCyibl2hmcxRk0Xi
rseVhWYOC93TuJZGhCCBGgCA+AJFl7lEn16R4sYIJk1WCKbjBIu6PXW8hEyhQlCTPjQ+0R+j2Nvb
a1vw9JtEppvFe+nSpbzXx+h/bY9Kx+fZs2d2kobyLfGla07KZzBNfx9NslF+lJ7GG/pCOphW1PUI
dQvreN1LpeVEIUIQpwUAIL4AZQ4IQZwWAID4ApQ5IARxWgAA4gtQ5oAQxGkBAIgvQJkDQhCnBQAg
vgBlDghBnBYAgPgClDkgBHFaAADiC2UO2ABCEKcFACC+UOaAEAScFgCIL0CZQwZWV1cRgoDTAgDx
BSjznTrXjz4+Lr3gaiX7yZcQgjgtAADxhTJHCJYwbYQgEKgBgPgC+7rMBwYGzKFDh8zBgwdNd3d3
7vfLly/nreertW/PnTtn/9/a2jJXrlwxVVVVpq6uziwtLYULjpDz+r99//7dXL9+3a6/e+zYMTMz
M7PtmKj8pT0+il9//dV8/PjR/r++vm6P++eff+z39+/f2+1+fvXX/7jfRkdHzYkTJ3JrBGv9ZYQg
EKgBgPgCe77MJyYmzNTUlBVU3759s0JqaGjIbnv37p1paWmx275+/WpqamrMq1ev7La+vj4zOztr
/3/y5Impr68vSAiOjIyYwcFBe44PHz6Ytra2vO1x+UtzfBy///67efTokf3/4cOHtttX53PfJXST
rkffz58/bzY2Nux3iUCJQYQgEKgBgPgCe77Mm5ubrYjykeDzhZjElsTXjRs3cr9L+AWPK0QInjx5
0rYuOpaXl/O2J+Uv6fg47t+/b/7880/7/x9//GE6OzvtR1y9etWKzjRC0InAve5fCEECNQAA8YUy
z0OtV8EuT3VxBsXikSNHct2o7rhUgiNBCAbTkegLbo/LX9Lxcah1s6mpyf7f2NhoVlZWzPHjx+13
dXeruziNENwv/oUQJFADABBfKPM8gqIvDHV9qgVwN4RgcHtS/pKOT+Lw4cO2S9kJQI31W1tby31H
CAKBGgCIL1C2Za6WsM3NzcjjxsfH7Ri9ycnJvK7h2tragrqG3aQMR2tra17XrkSYvz0pf0nHJ3Hx
4kXz3//+N9cl7LqH3XeEIBCoAYD4AmVb5sPDw7nJFvro+5kzZ+w2TRY5depUnij7999/7f+aLDI3
N2f/18ziqMki/izat2/fmgsXLuRtn56eNnfu3MlN9mhvb8/bHpe/NMcnoRm/6vaW4BX37t2zM6El
fsOuR9s0JtCJT4QgEKgBgPgC+7rMe3t77etXNGtWQk0CUFy6dCnv9TH6X9uFZhFru4ReQ0ODnaQR
di43i1ZdvGpF1Ctognm5e/euFWN6RYwmpwS3R+Uv7fFx1/78+fO818a4ySZO8AaP16QZ5cO9WBoh
CARqACC+AGW+h9GMYEAI4rQAAMQXyrwCUTc2IARxWgAA4gtlDtgAQhCnBQDiC1DmgBAEnBYAiC9A
mQNCEHBaACC+AGUOCEHAaQGA+AKUOSAEAacFAOILUOaAEAScFgCIL0CZA0IQcFoAIL4AZQ4IQcBp
AYD4ApQ5IAQBpwUA4gvsrzLX7y9evDDV1dXm5MmTud8HBgbs2r0HDx403d3dece8efPGrvlbVVVl
1xGuq6szjx8/zm3XesJufeHGxkazuLiYd/ytW7dsujr+zJkzZmNjIy8/U1NT5sSJE/Z4paP1itOk
jV0jBAnUAADEF8goBLu6usz379/Nu3fv7G8TExNWjOm3b9++mZmZGTM0NJQ7pqmpyUxPT9vt+oyN
jVkh6fDF29zcnKmpqcltGx4etvu7Y3WuK1eu5OVHItOJQ6Wj9NKkDQhBAjUAAPEFMgpBv0VONDc3
W5HmkyS41ELnkCicnZ0N3a+hocFsbW3lvuv/I0eOxObHz3tc2oAQJFADABBfIKMQDKJWN/3uf3yh
J9Sd3NfXZzo7O62489NRS52+S1D29/dHCkb/fHH5SZs2IAQJ1AAAxBcoUgiGiTWf+/fvm/r6ejM5
OWnm5+dtl3IwHQnFJ0+emI6ODtPT0xMq+kIFSoIQjEsbEIIEagAA4gsUKQQ1CWNzczMyrV9++SVv
+/r6emT6KysreduUdrBr+MCBA5mEYFTagBAkUAMAEF+gSCGoCR2Dg4O5CR36rtm9Ds3odbOE19bW
TEtLS146ai3U7F4RnOyhtEZHR3Npj4+Pm9ra2tRCMC5tQAgSqAEAiC9QpBAUvb29tuVPrXWaxetm
FItnz57ZySMSYRJmmrzhp6OuW40bdK9/ccLN4V4fo49mDL9+/Tq1EIxLG7tGCBKoAQCIL0CZA0IQ
pwUAIL4AZQ4IQZwWAID4QplzE7ABhCBOCwBAfKHMASEIOC0AEF+AMgeEIOC0AEB8AcocEIKA0wIA
8QUoc0AIAk4LAMQXoMwBIQg4LQAQX4AyB4Qg4LQAQHwByhwQgoDTAgDxBShzQAgCTgsAxBegzAEh
CDgtABBfgDIHhCDgtABAfAHKHBCCgNMCAPEFKHNACAJOCwDEF6DMASEIOC0AEF+AMgeEIOC0AEB8
AcocEIKA0wIA8QUo87JldXUVIQg4LQAQX2DvlvmtW7fML7/8YqqqqsylS5fM+/fvsfMSnevAgQM/
5NoQghgwAADxhTJP5O7du2ZsbMx8//7dfu7cuWPOnDmDnZfoXKXIF0IQpwUAIL7AjpR5TU2N+fLl
S95vP//8c2zaL168MNXV1ebkyZO53wcGBsyhQ4fMwYMHTXd3d94xW1tb5sqVK7bFsa6uziwtLeVt
V4ukjtN2idCNjY3Y80mwXr9+3bZiHjt2zMzMzORd899//22v4aeffjKNjY1mcXGxpNfjn+vNmzfm
woULNu86p67v8ePHuf38T5q0k64NIYjTAgAQX2BHynxzc9OKlM7Ozti0u7q6rGB59+6d/W1iYsJM
TU3Z3759+2bFy9DQUO6Yvr4+Mzs7a/9/8uSJqa+vz20bHh7Oa5FUWhKNcecbGRkxg4OD9rcPHz6Y
tra2vGuWIHv69Kn9f25uzordUl6Pf66mpiYzPT2dy7+uRaIyqiyS0k66NoQgTgsAQHyBkpf55cuX
bQuVPi9fvoxN22+xE83NzVa4+PjiS8IvuN3R0NBgWwwd+v/IkSOx51PLnX/M8vJy3jVLiDnhmeZe
Zb2epPurlsiofZPSTro2hCBOCwBAfIEdK3N106o7NUvaaoELdoP6Yiiuq9nfL2z/qPP5SFj5+6kV
UN8luvr7+zPfq6TrCR6jrmW1eqolVcI2T4QF9s16r4LXhhDEaQEAiC+QucyjxqsFUXdl0hjBNGIu
TrglbYsTUmmOceJM3dAdHR2mp6enpNfjH3P//n3b4jk5OWnm5+dt93Jc/gu5VwhBAjUAAPEFdqTM
1Y2qsWiOYNdsmrTVgqjxhVHU1tZGdg3r2GDXsP/KlbDztba25h2ztrYWec0rKyux96OQ6/GP0aQO
f9/19fVYIZiUdpZrQwgSqAEAiC9QVJmrK1jdp26yw+3bt+0nS9qa8OEmOOij7/4raNRtqu5asbCw
sG2yyOjoaO7Y8fFxKxzjzqfJGXrNjZtQ0d7enref0tfMYaFJI1lbOJOuxz/mxIkTuVnCEm0tLS15
2zWbWGMQnbhLSjvp2hCCOC0AAPEFSlbm6grWrFm1wmmiiIRhIWn39vba1jGlo9epuBm44uvXr/ZF
1RJkGkOnCRBBMeomqmjG8OvXrxPPp/cfquVSr2HRTFx/P3UL6zzqhtU5nSgs1fX4xzx79sxO9tB5
JEA1ScXfrhnBSsNv5YxLO+naEII4LQAA8QUoc0AI4rQAAMQXoMwBIYjTAgAQX4AyB4QgTgsAQHyh
zAEbQAjitAAAxBfKHBCCgNMCAPEFKHNACAJOCwDEF6DMASEIOC0AEF+AMgeEIOC0AEB8gTIv89XV
1T2X1x+Zp714PxCCOC0AAPEFdqTM/dUt9go/Mk/Bc5eTryAECdQAAMQXynzP28KPzFM5+wZCkEAN
AEB8oczzfvM/DrfOb1VVlTlz5ozZ2NiITFdr9mpNXa3h29jYaBYXF+26wE1NTdv21RrGx48fN58/
fw49Li5PAwMDdp1d5au7u3vbdUxOTtq1eA8fPmwePnxohoeH7dq9OsfTp09z+75588au5atr07a6
ujrz+PHjyHP7edja2rLrHutYHbe0tIQQBAI1ABBfYP+WefB3CaixsTHz/ft3+5mYmLDiJwpfaM3N
zZmamhr7f3t7e07cOaampsy1a9dijwvLk/KgY5UficmZmRkzNDSUt//Vq1fttr/++ssKQJ1H33UO
ncshgTo9PZ27Pl1rdXV15Ln97319fWZ2dtb+/+TJE1NfX48QBAI1ABBfoHyEYENDg235+l/23j+y
zqT////jtlattUrVqqgKEZF3RISKiqoosVatW5WKqqq1VFVFxbKiIiJCRURElIpYERWqbrVWhIqq
qhUqKqqqREVFVImqilrX13N853zmTM41c13nnKRJ+nhw9ORc1zU/X6+ZZ+fHNRZ910hbGhJRVhy5
SCh1dnYW/dba2po8e/Ys+FypNLW0tBjR5uILR3fUUn9vbGxktneNSmYRghJ+fjoQgkBDDQC0L7Bv
hKAriizuiJqPRvMUhsRaX19f0bWjR48mL168MN8XFxeNEMzynJ8mxe9P22YVb6X+fvr0qRnd6+rq
MsK3SCAFng2VA0IQaKgBgPYF9rwQLCV2YvYiYWVHAHt6egq/DwwMJFeuXDHfNb18+/btTM9lEad5
hJ/799TUlBnZ05rC+fn55O3btwhBoKEGANoXQAgKbdzwp4azvs5laWmpKLz19XWzsWJtbc1s9Pj0
6VOm50qlyZ3qrUQIav2gG9bKykpmIVhXV8fUMNBQAwDtC+yfOpdQ0/o6K/60WWR0dLSwmWJ8fNwI
oDQ0uqYdwMLfmCE0EvjLL78k165dy/xcqTQNDg4W0qS/tZu5HCGo6Wq7S3h5eTk5fvx40XU/bn+z
iKa0xcOHD9ksAjTUAED7Anu7zrX7ViN+7qiffX2MPhJyeh1MGpre1To7Td9KzFlxZ9ErVhS3f2JH
6LlSaert7TWjefpNr3/RlG45QvDRo0dmo4nilJDThhX3uh+3e00jmufOnTPPKu1a94gQBBpqAKB9
Aeo8BQk2jcIBQhBoqAGA9gW+ojrXNK5G8vxdwYAQBBpqAKB9gX1e51pvd/r06dRNIoAQBBpqAKB9
AeocEIKA0wIA7QtQ54AQBJwWAGhfgDoHhCAVBgBA+wLUOSAEcVoAANoXoM4BIYjTAgDQvgB1DghB
nBYAgPYFdk2dY1sIQcCZAGAXtyv+B+hTACEIOC0AIAThK+xT9LvO/T18+HDS2tpa+L2/vz/54Ycf
zHnD3d3d5rcPHz4kNTU1W14Qvbm5mTQ1NZWMp1Q44tixY8m7d+/M95WVFfPcP//8Y/5eW1sz14XO
INbZvjqTWHEsLCxQmQhBhCAAQDXEINCn6Pdr166Z4+B0LrCYmJhIJicnzW+fP39OZmZmkqGhIXPt
ypUryfDwcFEYIyMjRvD58YTCuXDhQnLv3j3z/e7du8m3335r7rd/X7x40XyXCPz777/N97m5uaS2
tpbKRAgiBAEAEIJQLSG4urpa9FtLS4sRby5WgL148cKMCtrr+lejdzYMN55QOFNTU0ZUil9//TXp
6uoyH3Hp0iUjGoVGKmdnZ6lAhCBOCwCAEITtEII+GoXzlxBoatZy8uRJM9InpqenkzNnzpQMLxSO
BGVzc7P5rinfpaUlIzBFfX29mS4WGgXUcxKVfX19VCRCEKcFAEAIwnYKQVf0leLBgwdGrFkRNz8/
XzK8WDgHDx5M1tfXCwLw6NGjyfLycuFvi9YwKs7Ozs6kp6eHykQIIgQBAGhfYLuEoMTdxsZGMDyJ
Nq0NtJs6SoUXC+fs2bPJ5cuXC1PCdnrY/u2jUUNsFyFIQw0AQPsC2ygEtRlkcHDQrO/TR3+fOnWq
6B5t+jhy5Ehh80ep8GLhjI6OJocOHUrGx8fN37dv304OHDhQmHYWDQ0NZuew0KYRTTcDQpCGGgCq
5md8vp4PfUr233t7e5Pvv//e7ObVGkC7o9iiV7/omqZ2Q+GFwnn8+HHRa2MWFxfN3y9fvizco2nh
xsZGM80sEWhFISAEEYIAgI8BdU7eASGI0wIA/gXUPfkGhCBOCwD4FmAD5BkQgjgtAOBbgA1g94AQ
xGkBAN8ChCBg9whBnBYA38K3sAGEICAEAacFwLcAGyDPgBAEnBYA3wJsgDwDQhBwWgB8a9fz/Pnz
XRXOdoeJDZBnQAjitACwY741Ozu75b61tbXkv//9rzkhQcdgnTt3bsupCi46AUEnIbS0tORvpCNp
VBqqQbXCCYWZtS3byTYPIRhnZmbGnCOs+jx+/Lg55/dr6Ufz+i5CEGioAPaRb71588ach+rf19HR
kdy9e7dwbqq+nz59OjUcdSQ6G7WsRjqSxmq1D9vRzpQbJkJw9+RZR761tbUlKysrxtanp6fNmb9f
Sz+a13cRgkBDBbCPfKuzs9OcderfV+qw+1K/2Tj8M25LxZsm/kJpTDs/t7+/P/nhhx+S7777Lunu
7i78fv78+eThw4dFox0//fRTpnN4X79+bc6H1Qio8lpfX5/cv3+/KC06C/bw4cNJa2trNN+bm5vJ
xYsXTXgK68mTJ6l5TsuPzYPSo/Nnm5qakoWFBdrXKua5q6sruXXrVq6wXTvIUochWxC///67eU7X
9R+z1dXVYHwSrFevXjXnGh85csSMaLp5zmozaX6RNz0IQUAIAuxB3xoYGEjGxsZK3mdHBC2aPj55
8mTmeKolBEtdn5iYSCYnJ01n+PnzZ9MJDg0NmWtv3741U3u69unTp6S2tjZ58eJFpniam5vNaJAd
BVXZqLNz03Ht2jVzTfHE8n3z5k1TbuLBgwdFo0zufaH8+CM2c3NzJk+0r9XL89GjR3Ot9SxlB7E6
DNnC8PCwsTVrdwpLojEU38jISDI4OGh+05KN9vb2ojznsRm/rMpJD0IQEIIAe8y3NB3mTvX690k8
HTx4sDBSoO9WUH1pIai1TOqEXNyOTh2XOkp1xNevX6+ondGIivu8OzISy7c6ez+dpe6L5Udi1IoI
2tfq51miSWJJI3V2Pez79++DYft2EKvDkC00NjaaEUOLvh86dCgYn0bi3GcWFxeL8pzHZvyyKic9
CEFACALsId/68OGD6Ui0ISTtPk2RamTAjgpo6uzs2bO7Qgiq4/antFzBZjtmdV7v3r3L1c5oykuj
N5ouVIcYS2co32lT6aXuC+VHIkW/KU99fX20r1XOs+69cuVKsrGxURgBU/3nCTtWhyFb8G3Xvz8t
Phel270vj8344ZeTHoQgIAQB9pBvXbp0Kbl3717wPu2edEcw9F2jJdspBNPWK2XpqHx+/vlnMwqT
RwhOTU2ZZ+7cuZPMz8+baa+dEIJZ8iOBqilFrens6emhfS0jz2n2pXV27giYbD20w7xU2LE6DNlC
qWsxu4s9k8dmsqwPzvMfN4QgIAQB9liHWKpz9EWfOkctHi9XCGpHZrVGBLX4XaM3aYyPj5v1WhJ0
eaaGJQjccENpzpLvurq6TFPDsfy46LUmedtLhGAYbSbybT3Pf3qy1GHIFvSsPxXrCtFS8WmXs/vM
8vJyap5jNlPKv/KmByEICEGAPe5b/n1aDC4hpYXv6sC05k67FPOMKtjF6npFjaaayxWC6pS1Jsl2
Tpqytgvl9dHf2tkoNIp34sSJok5Nu6JLheOjTQN2l7A6Vm06iaXTD9PfLKIpOqGdzGmbRUL5EXpO
u0CFyjQ0ukT7mj/PWkunjy3/0dFRU/d5wo7VYcgWdK/itM/qPzISjqH4tKlJm73sZhFt7vLXp2a1
mVKbRfKmByEICEGAfSYEteNWYlAjAfpIBOq3rM/bzkdTZupE1CmVKwS16cOmw9Lb22tG8PSbRKbd
vaiF/u7rY/Rd19PCcXn06JFZ4K90qyP1X7RdKp1+mO49Ki+lR+FpvaEW9KeFlZYfoSk+Pa+yVFi2
g6d9rV6eJXy0wcKWv/3PQ56wQ3UYsgVhX9eij3bovnr1Khqf1u1qHaxeWaN1je59eWymVPjlpAch
CAhBAHwLsAHyDAhBwGkB8C3ABsgzIAQBpwXAtwAbIM+AEAScFgDfAmyAPANCEHBaAHwLsAHyDAhB
wGkB8C3ABsgzIASpMADAtwAbIM+AEKShAgB8C7AB8gwIQZwWAPCtHef58+fYAHnG5hGCgNMC4Ftf
Y97STh8pN/4vWQ8IQSjH5vOc/rMb6wshiNMCAL61a8oNIUie91qZ7WQZIgQBpwX4Ar5lzxM9cOBA
curUqWR1dbXoOZ1XqvNXW1tbyw5jcnIyOXr0aOHMU51B7NLf32/OZz148GAyNja2Jb2x8KsZlxuW
+0krD/f5169fm/NllU7FXV9fn9y/fx8huMvynGbXsg2d2Stb6+7uLnomVrc6x9eeq93U1JQsLCxU
zUdiYef1x7RySrP5SnwtrTz//fdfc3a5fPHIkSPJzMwMQhAQggA77VvDw8NGDKlR1keH1utwefe5
a9eumWtv374tOwx1oLYzUmehTsOizqSnp8c8u76+npw4caIovVnCr1ZcWUZH/PJw72lubk6mp6cL
aVW6JTYQgrtPCPr1KLuSfei3z58/G2EyNDSUuW5dITQ3N5fU1tZWzUdCYZfjj0GxFBgRzONrsfIc
GRlJBgcHC77Y3t6OEASEIMBO+1ZjY2OyublZ+FvfDx06VPScO5pQrTDc9LS1tSVra2uFvxcXF4uu
Zwm/WnFlEYKh8Euh0RKE4O4Tgn49trS0GFHiEhJcft1KFM7Ozm6Lj4TCLieuagnBUJpj5amRWDed
MV9ECCIEAWAbfMvtyNzRhzw+WU4Y7m/+4nR1Hu71POFXGlcWIRi7R1OON2/eTLq6ukynvJOL7Wlf
swvBUjblT436theqW43U6W8JoL6+vqr6SCjsavtjHiEYCidWnm6asvgiQhAhCADb4Ft+Y5ylsa9G
GH6HEeoQ8oRfaVyVCsGpqamkoaEhuXPnTjI/P2+mHRGCe0MIlhJQLrG6tULxwYMHSWdnp1mCUC0f
CYVdbX+slhCMlWcsnQhBOisA2AHf0sJzfxrJHTXL4pPlhOH+dvz4cbNGyPLs2bOi63nCrzSuSoWg
Fr5vbGwU/l5ZWUEI7hEhKDtz684nVrcuS0tLZdtwLO1+2JX6Y8xGyxWCsfLUMg03ncvLywhBQAgC
7LRvaWH56OhoYWH5+Ph4UldXl8snywnD/c3fwKFdjv5mkazhVxqXj3Zdah2U7bBi4WsHpd1Jqo5N
whMhuDeEoOzMbl7QR3/LPrLWrUYLtbtX+BsnKvWRUNh5/dHdePLmzRuz4cONK2TzeXwtVp7aeDMw
MFDwxY6ODoQgIAQBvoRv2VdN6KPdha9evcrtk3nD8H9Th6DXTOg1Etpt6K/lyxp+NeJy0S5HXbf3
xMJ/9OiRWRCvzladtxb4IwT3hhAUvb29ZuRP9S2B5O6Uj9Wtpm61btC+SsUKt2r4SCzsPP5ohaTC
kkBUWG5cIZvP62uh8hS3bt0yG1nkj/JFhCAgBAHwreTTp09JTU3NvosLGyDP8GVtAGvAaQHwrV2I
RgS0CN6+b0yjGaHF8HslLmyAPANCEHBaAHwrgnZg6p1imj7SaR83btwwIm2vx4UNkGdACAJOC4Bv
ATZAngEhCDgtAL4F2AB5BoQg4LQA+BZgA+QZEIKA0wLgW4ANkGdACAJOC4BvATaQM095ToYBhCDQ
UAHgW4AN7DMh6H+we0AI0lABwB72LdqC6peNfS5NPO3XT7Xta7tts9Lwv/TzCEHAAAHwLdqCXSwE
91tZ7PSIIEIQIQg0/gD7xrf0u84xPXz4sHnRsqW/v9+c/6mzSru7u4ue0WH0Or9Uh9PX19cnT548
KbpuzznVdR0yrwPsQ/HplI+rV6+aM0l1/u/MzExRenUWqj0btampKVlYWEjN5+vXr82Zpopbzyh9
9+/fzxRWLJ5QmWxXuLGyQQiWt0bQF4uTk5PJ0aNHC2f56jzeNGS7Werv/PnzycOHD4vs4Keffor6
UJ7zfLPYx07ZF0IQEIIAe1QIXrt2zXQI9kB4Hf6ujtEew6bOQQfRW27evJnMzs6a7zquraGhoXBt
eHg4GRsbM8/qo7DU4YXiGxkZSQYHB81v6+vrSXt7e1F63Y55bm4uqa2tTc1nc3NzMj09XYhfaXE7
7lBYoWuxMtmucGNlQ/tavt273/WfB/sfFtWV6iyNy5cvZ6o/2ffx48fNNZ1prXp/8eJF1IfyCMGY
feykfSEEASEIsEc7RHfETrS0tJiOwcUVL+q0/OuWxsZGM9ph0Xed7xuKTyOD7jOLi4tF6ZWQs51m
OWiUJ0tYoWuxMtmucGNlQ/taHSHo22TWsorVn4SYxJbE1/Xr1zP5UB4hGLOPnbQvhCAgBAH2eIdo
0WiIv+bKFVOh0RL3vlL3p8Xnoo7LvU+jaPpbnVpfX180r5p61ohLV1eXEaZZwwpdi5XJdoUbKxva
1+oIwXLLKlZ/VozpP0Pv3r3L5EN50hazj520L4QgIAQB9okQLCXmQsItdi3WscWeseJOU2idnZ1J
T09PavxTU1NmtOXOnTvJ/Py8mZ7LE1batViZbFe4WcqG9vXLCcEsdvHzzz8bm9wJIehf30n7QggC
QhBgnwhBbWjY2NhIDauuri51WkvP+lPD3377bTC+tra2omeWl5dT07u0tBRsJ7To3U37yspKWWH5
12Jlsl3h5ikb2tedF4Kx+hsfHzdr9PQfE3dqOORDobT59hyzj520L4QgIAQB9okQ1IYPu4BcH/2t
3b8WTbtqulNoV6S/WWR0dLTwrDpCdXqh+LS5Y2BgoLBgvaOjo+g+ha8dlyK2kF87P+0uYXVqWqyf
NazQtViZbFe4sbKhff2yQjBUfxqNPnHiRJEoe/nyZdSH0jZKvXnzxmxqca/H7GMn7QshCAhBgH0i
BEVvb68ZXdNonjofu8NXaAfkuXPnTCelNXhaYO5iXx+jj3YMv3r1KhrfrVu3zDoqveZCC+zd+zSt
qnjsqz2sqCrFo0ePzGJ43afOVZs0soYViydUJtsVbqxsaF+/rBAM1Z98xH19jL7resyH3Ljtfxxk
O/oPlWzHT1vMPnbKvhCCgBAEwLcAGyDPgBAEnBYA3wJsgDwDQhBwWgB8C7AB8gwIQcBpAfAtwAbI
MyAEAacFwLcAGyDPgBAEnBYA3wJsgDwDQhBwWgB8C7AB8gwIQSoMAPAtwAbIMyAEcVoAwLe2hefP
n2MD5Pmrt4v9XhYIQRoqAAj4lk4q0MkFLS0tX6ZhzuHzeZ5Lu9f97p6BTPtKnqtpF+Xa+G6rP78s
9qINIQRpqAAg4FvuWaZ7yc/LFZBfc3uDENyd9rmb628/2AxCkIYKAJL081Tdj8WeFXzgwAFzQP3q
6mrRMzo79/Dhw0lra2tqfP39/ebsUoXT3d2d3jB76dJzOhf14MGDydjYWHBkT+nSWcZK508//ZR6
Xmup737em5ubt+Th8+fPSU1NTfLhwwfa132WZzsSrjN8m5qakoWFhVSfiJ1F/O+//yZXr141dnvk
yJFkZmYmauNpvpGWLiGfSyP0XCzOzc3Ngh/V19cnT548yVwWsbZicnIyOXr0aOGc7Z3+TydCkIYK
ACK+5f8+PDxsBJg6N310CL06Cff+a9eumWv+4fUWPaMOQPdITKljHBoaioo0PdPT02OeW19fT06c
OBEUdG1tbcna2pq5/969e8mlS5cyC0H/e0dHx5bOU+n57bffaF/3YZ5dUTI3N5fU1tamPhMTgiMj
I8ng4GDBbtvb21PtLOYboXRdvnw5NZ+h52Jx3rx5M5mdnTXfHzx4kDQ0NGQqiyxtxZkzZwriUOlT
OhGCQEMFsIuFYGNjoxkhcEcLDh06VHS/+7/+Umi9oToGl7SO1v1uhZ1FI3whEeeOACo+d51jXiGo
DrCzs7MozRrxfPbsGe3rPsyzRtes+Ik9ExOCshPXZ0J2G/ONULpChJ6LxSnh51/PUhbltBVfenob
hUFDBYBvRX7XFE6p0YY8Pqr7/WklN9ysmzfUOWURcbF0Zg1DU1gvXrwodOahqW/a172dZ42a6ZpE
Ul9fX0VC0B/lCtltzDdC6QoRei4WZ2iULlQW5bQVCEGgoQLY5UKwVKeQdwdkqQ4iS3h5OtRS6XCF
ZDlCcGBgILly5Yr5rimu27dv077u4zxrrasdCdaShGoJwZCdxXwjlK5yn4vFWa4QLKetQAgCDRXA
LheCWmjuT/ekCaw0FMbGxkZuIXj8+HGzxsqiadmQiLOjdzad2thRiRBU3Fr0rulpLaz/9OkT7etX
kOelpaWgXfh/r6ysbFnS4PrM8vJyangx3wilKyv+c7E46+rqypoaLqetQAgCDRXALheCWgA+Ojpa
WAA+Pj5uOoo8Pqow7OJ5ffS3dhTGxJi/WUTPhETc6dOnk3fv3pn7FV/ezSISfVrD5HZmGgn85Zdf
zIYY2tf9m2eti9NOW+FvYvDtwt2I8ebNG7MBwg13enrajCZbu9XGozSbi/lGKF0hQs/F4tRmEU0t
i4cPHxZtFvHLws9L3rYCIQg0VAC7XAgK+0oIfSSMXr16ldtHe3t7zes0NEKgjtPdYRybntVonF7D
oV2IoeleXde9ukei0H91Rey7dk7qWTcOvTpD9+zH0yUQgv8PTaNqs4N9rYkVUaXswgor3Suho3v9
cG/dumU2SsgeZZchGw/5RihdIWLPheLUyPe5c+fMcwrD3YTll0Xa62OythUIQaChAsC3MqMOyp3u
3QnUQWrTCDZAnmH/2QDWgNMC4Fu7GI2oaLG7fd+ZRhvyLJavFMWrkZM8uzWxAfIMCEHAaQHwrSow
Pz9vXtmiaSidLHLjxg0jCHcKrYfSFPN+2ySCEATaPoQgTguAb1EI2AB5BoQg4LQA+BZgA+QZEIKA
0wLgW4ANkGdACAJOC4BvATZAngEhCDgtAL4F2AB5BoQg4LQA+BZgA+QZEIKA0wLgW4ANkGdACAJO
C4BvATZAngEhCDgtAL4F2AB5BoQg4LQA+BZgA+QZEIKA0wLgW4ANkGdACAJOC4BvATZAngEhCDgt
AL4F2AB5BoQg4LQA+BdQ9+QddrbusQQcFgAfw8eoc8oAvtI6xwpwVgD4//2Mz9fzAeweu0cIIgQB
gPaF9gXg624DKAIaagCgfQEAhCDQUAMA7QsAIASBhhoAaF8AACEINNQAQPsCAAhBoKEGANoXAEAI
Ag01ANC+AABCEGioAYD2BQAQgkBDDQC0LwCAEAQaagCgfQEAhCDQUAMA7QsAIASBhhoAaF8AACEI
NNQAQPsCAAhBoKEGANoXAEAIAg01ANC+AABCEGioAYD2BQAQgjTUFAIA0L4AAEKQhhoAgPYFABCC
NNQAALQvAIAQpKEGAKB9AQCEIA01AADtCwAgBGmoAQBoXys0w2UAAIAASURBVAAAIUhDDQBA+wIA
CEEaagAA2hcAQAjSUAMA7QuFAIAQBBpqAKB9AQCEINBQAwDtCwAgBIGGGgBoXwAAIQg01ABA+wIA
CEGgoQYA2hcAQAgCDTUA0L4AAEIQaKgBgPYFABCCQEMNAHugXfE/AIAQBIQgACAEAQAhCAhBAPha
xCAAIAQBIQgACEEAQAgCQhAAEIIAgBAEhCAAIAQBACEICEEAoH0BAIQg0FADAO0LACAEgYYadpOt
8OHDh892fwAhCAhBwE4AgPYGEIKAwwE2AgC0O4AQBJwNsA8AoP0BhCDgaIB9AADtDyAEAUcD7AMA
aH8AIQg4GmAfAED7AwhBwNEA+wAA2h9ACAKOBtgHAND+AEIQcDTAPgCA9gcQgoCjQaX28fvvvyff
f/99cuDAgeTcuXPJ2tpa4dqHDx+SixcvJt9++21y6NChpLu7O3n//v1X4x/V8qtKw/nSzwNgfwhB
wNFgH9rHrVu3krGxseTff/81n4GBgeTUqVOF67/99lsyNDRUuD46OpqcPXsW/0AIAmB/CEHA0WCv
20dtbW3y8ePHot+++eabwneNBEoAWvRdo4eheJ4+fZocPnw4aW1tLfze39+f/PDDD8l3331nRhVd
Njc3zaijRiTr6+uTJ0+eFF3XiKWe03WJ1NXV1WB8SuPVq1dNOo8cOZLMzMwU5f+vv/4yefzPf/6T
NDU1JQsLC5nKTd8nJyeTo0ePmmcVxt9//50pH344oXhi6Y+VZ+x52gqgfwKEII4G2McWNjY2jMDo
6upKFYISO/otFM+1a9fMM2/fvjW/TUxMGAGl3z5//myEiUYZLTdv3kxmZ2fN9wcPHiQNDQ2Fa8PD
w0UjlgpLYisU38jISDI4OGh+W19fT9rb24vy7wq4ubk5I4azCsEzZ84UhKjCcEVzKB95hGAs/bHy
jD0PQP8ECEEcDbCPIs6fP29Gl/R59uxZ4XeJLk0HS1R8+vQpuX79uhkNC8XjjtiJlpaWIjEpXPEl
weRftzQ2Nhrx6QpRrVUMxaeRQfeZxcXFovxr9NAKtjzlViou93ooH3mEYCz9sfKMPQ9A/wQIQRwN
sI+SaBpW06UWbQyRSNTIV11dnRlBi40I+uhZ/e5+XDHpjqr5lBKd7v1p8blINLn3KQ/6W4Kqr68v
lxAMXQ/lo5Jw/PTnLU//eQD6J0AI4miAfZREU40hQbO8vGzWneWJJzSCGBNQpa7FRFXsGaF1hZq+
7ezsTHp6ena1EPSvl1OetA9A/wQIQRwNsI8taJpU68gs/tSrz71794rWEGaJRyOMWn+YhkYa06ZU
9aw/NeyOSJaKr62tregZide0/C8tLQV9J4+AC+UjFM7KykrRb7H0x8ozT/4B6J8AIYijwVdsH5oK
1vSo3Yzxxx9/mI9F694k/sTr16/NCJrWnOWJRxs+7OYFffS3+4oabbLQdK14+PDhls0ido2iPuPj
40ZwheKbnp42r8GxmyU6Ojq2rOXTzmHhb/ioRAiG8pG2WeXNmzdmA4p7PZb+WHnGngegfwKEII4G
2IdBU8HadatRNm0UkTB0kejT5gO7RjC2ySItnt7eXvM6E8Uj4WN3+AptQtGLrBWHNof4QtO+PkYf
bV559epVND69H1Ejm3rFinbZuvdpWljx2FfAWFFYqRAM5cO9z4pPxa8yVfx+2KH0x8oz9jxtBdA/
AUIQRwPsAwCA9gcQgjgaYB8AALQ/gBDE0QD7AACg/QGEII4G2AcAAO0PIARxNMA+AABofxCCgKMB
9gEAQPuDEAQcDbAPAADaH4Qg4GiAfQAA0P4gBAFHA+wDAID2ByEIOBpgHwAAtD8IQcDRAPsAANof
QAgCjgbYBwDQ/gBCEHA0wD4AgPYHEIKAowH2AQC0P4AQBBwNsA8AoP0BhCDgaIB9AADtDyAEAUcD
7AMAaH8AIQg4GmAfAED7AwhBwNEA+9iHPH/+fE+HT/kD7Q9CEHA02Af28enTp6Surm7L72tra8l/
//vf5Ntvv00OHDiQnDt3LllfX8dnqhSXynU746tG+CH7+PjxY3LlypXku+++M3HJPt6/f79n7KLa
5b+ddjY3N5f8/PPPmetG9XDmzBnjt6qf8+fP74jv0j8hBAEhCHvMPj5//pycPXu25HMdHR3J3bt3
k3///dd89P306dP4TJXiqka6QmFUI/yQfVy/fj0ZHx8v2Mfvv/9uxODXZBc7ZVstLS3JixcvMtdN
f39/0tfXV6ibP//8M+nt7aV/AoQgQhCwj2JOnTqVvHnzpuRz33zzTabf3LifPn2aHD58OGltbS3q
lH744QczMtHd3V30zObmZnLx4kUzclFfX588efKk6LrEhZ7TdaV1dXU1GJ86vatXrybff/99cuTI
kWRmZqYob3/99ZfJw3/+85+kqakpWVhYqGp+3Lhev35dGJVRnMrf/fv3C/e5nyxhx/Lmp6NU+KHy
zGsfBw8eNGlyhUlolE1hTE5OJkePHjXlrzL5+++/twiYUvk/duxY8u7dO/N9ZWXFhPXPP/+YvzVy
reulSKvvUuVTKo/ub7Hy958P1WUeO3z8+HHJ/4CF6kb3Ly8vF9XNTz/9RP8ECEGEIGAfxczPz6c+
Z0cELbOzs8nJkyeDcV+7ds10mG/fvjW/TUxMmM5fv6kzUuc5NDRUeObmzZsmXPHgwYOkoaGhcG14
eDgZGxsrjGooLInGUHwjIyPJ4OCg+U1TYe3t7UV5c8WHpttqa2urmh83rubm5mR6erqQfuVFojKt
rmJhx/IWs4VYeea1Dx+Jejd/pdIjYWzFp+rB/Y9FKP8XLlxI7t27Z77LJiU4db/9Oy0fofr28xQT
grHyd7/H6jKPHWrkdWpqKlfdSKy6It3+Rv8ECEGEIGAfmZ/TVJRGfeyoib7701N+GP4Ik6a0/A7J
7fQk/PzrlsbGRiMuXKFx6NChYHwauXOfWVxcLMqbhIoVnlnKJG9+YuWvEaC0e2Nhx/IWq9NYeVZq
V5p+lLDPU55uuKH8SwhpPaL49ddfk66uLvMRly5dMkKrFKH6zisEY+WfNS957fD48eNFo3tZ6ibv
aD79EyAEEYKAENzym0ZvNIpkR5Bu3bpl1iTl7ZD8aThXDIU6J/e+Uvdn6QCVbvc+jb7ob3XUWkOV
t0xi+fGf0dSyxJFEi4RYaCoxb1n5eYulP1aeldiVpm21IUGjX3nC8Edr0/Kv/4BohFVoKnVpaSmp
qakxf2vKXdPFpQjVd14hGCv/rHnJa4eaxk/7z1Jauiupa/onhCAgBGGf2UfaerHYc5p+czsgfVen
VGmHlLVzKnUttksz9owVZ5qG7uzsTHp6eqqaH/cZjWJpxPPOnTtmGk/Ty6H0l1NWeYRg3uez3ifx
p6nb2K7UmNCK5V8j0orDCkCtNdRImf07jbT6rlQIhuwxlpc8dpjH5iylpoGZGgaEIEIQsI9cz/mi
T0JQC9/zhKHRm42NjdRn9OqLtNEOPetPZbqbEUrF19bWVvSMhEJamWhUKe+u21h+3GfU8br32k0O
aeHHws6Tt7TwQ+VZjl1pJFBTtmkjcnmEViz/Go2+fPlyYUrYTg/bv2P49R0Tgn59xco/T17y2GE5
I4ISl3q9j0WvmdHmEvonQAgiBAH7yPycNkpoNEsjPuqItFheuybzhKGpZbvAXh/97XZImjbVNJl4
+PDhls0io6OjhWf1qhL3nWml4tPmjIGBgcKCfm14ce9T+NqxKfzNCtXIj/uMRqzsLmGJBq31cq+r
g9eaOSsuYmHH8lZKQPjhh8ozr31oN6s2D2nXbrlhuL/F8q+0a02j0i1u375t8qhNGWmE6tsvH3cD
h3bjammEm75Y+efJSx47lN1oPWKectWOZTd++XFsCpr+CRCCCEFACBahUQSJQY0a6SMRqN/yxq33
l2l0TGGoc7U7cG0cevecOkKtofM7PPu6E320M/TVq1fR+LSWUYJBr+7Q7k33Pk3HKR77+hLbGVcr
P+4zjx49MhsEFI86fm0OcK9rF6kt2yxhx/LmUyr8UHnmtQ9NyfrLDvKOsPq/hfIv4em+NsZu1nj5
8mVqnKH69svHCjLdK4Gse/30hco/T17y2KF2Ddsd0lnLVXFJqNr86WXUO/Gyb/onhCAgBAH7AIAq
ondr7sS0Lu0PIATp6AH7AIBdiHYX74WzkWl/EIKAowH2AQBVRtPWv/zyC+0PIAQBRwPsAwBofwAh
iKMBYB8AQPsDCEEcDQD7AADaH0AI4miAfVAIAED7AwhBHA2wDwAA2h9ACOJogH0AVJG98CoToP0B
hCCOBtjHLrEpNw6doqDTFPRutGrEv1M+ETpF4kul/Us9n/WM4r1WntWMT2f96hxmneKi8tIJOjtx
ugf9EyAE6egB+9jVNuWe6bqXfGI74tmrQrAaZbEby7Oa8eloOJ2LbM/71fF+EoO0P4AQBBwNdtw+
Njc3zdmyBw4cSOrr682xVaWeef36tTkXVfdJsOne+/fvF67b0TydkdrU1JQsLCxkumbjKHUurZ/m
/v5+c5arRlK6u7uLrqlD1ZnHOsP1yJEjyczMTNAnKsmPz+HDh0uWmb5PTk4mR48eLZwd6wrdrGUf
O4s3S96rWXZpZZOlDvOmPU8+QnXm1lFeW4jVY97yO3jwoHnG8vnz56qMpNI/AUKQjp5CgNz2cfPm
zWR2dtZ8f/DgQdLQ0FDymebm5mR6erowijE2NlbUubqd49zcXFJbW5vpWqjTd/+emJgwnbHiVsep
znZoaKhwfWRkJBkcHDTX19fXk/b29qBPVJIfn8uXL6fmRwJjdXXV/K3wFG7eso+JqVjeq112Weuz
GmnPk49Qutw6ymsLsXrMW36l/jMWEqr0T4AQBBwNts0+JD7c0Yk8NqXREXfExYqaUiNmadeyCkGt
G/TT6Xb0ra2tpkO1LC4u5vaJrPnJWs76bsVDqetZyz4mpmJ5r3bZZa3PaqQ9Tz7KrbOYLcTqsVLb
+/PPP81/CuifACEIOBrsuH24IxuxZ54+fWo6rK6urqSxsbHoukZg9Lc6676+vqLnQteyCkGl0596
dDtrPx8SDDGfKDc/eYRg6HrWss8bjp/3apdd1vqsRtrz5KPcOovZQqV5CPHu3bvk/PnzZoST/gkQ
goCjwa4VglNTU2YE686dO8n8/Hzy9u3bkkJRU5ydnZ1JT09PpmtZhaDb4WfNR8gnKs3PbhaC2112
WeuzGmnPk49y6yxmC5XmIQ2JvwsXLpjpZPonQAgCjgZfxD7q6uoyTU9qIfzGxkbh75WVldQwl5aW
Ml/LKgS1+N+N36etra1oem55eTnoE9XKTyUCLmvZ++H4aY3lvdpll7U+q5H2PPkot85ithCrx3LK
TyOBeoWM4qJ/AoQg4GjwxexD02GaUhMPHz5M3bCgHZN2J6U6uuPHj29Z76Zdm8JfTB+6llVEDA8P
Fxbk66O/T506Vbiuxf4DAwOFBfsdHR1Bn6gkP9USglnL3t0E8ebNG7Nxwb0ey3u1yy5UNtp5q/V0
VhhVmvY8+Si3zmK2EKvHvOX3+PHj5OTJk8na2hr9EyAEAUeDL2sfnz59Mu8wU6eptVFa6F7qmUeP
HpmF+bpPHa4W5bvXNSWn5+3rNWyHHLuWZzSpt7fXjN7oVRsSFJrCc7l161Zy6NAh83oR7TAN+UQl
+amWEMxa9lbUKC0aRVRa/LBjea9m2YXKRrt4FYd9HUqlac+Tj3LrLGYLsXrMW341NTVb1jru9/ab
/gkhCDgaYB8AQPsDCEHA0QD7AADaH0AIAo4G2AcA0P4AQhBwNMA+AID2BxCCgKMB9gEAtD+AEAQc
DbAPAKD9AYQg4GiAfQAA7Q8gBAFHA+wDAGh/ACEIOBpgH181z58/pxAoT9ofQAgCjgbVt4+dsCk3
Dp0EodMdWlpaqhL/TvnETvueG589weNLtwN73VZ2ojzdsHQqio4VpP0BhCDgaPBVC0EX91zaveQT
X9L3dovf73Vb2Yl8uGG/ePEiaW1tpf0BhCDgaPBl7WNzczO5ePFicuDAgaS+vj558uRJyWdev35t
RjF0nzph3Xv//v3CdTtCo3Nem5qakoWFhUzXbBylzl3109zf32/Ocv3uu++S7u7uomv//vtvcvXq
VXMO7ZEjR5KZmZmgT1SSH5/Dhw9nCvfYsWPJu3fvzPeVlRWTvn/++cf8vba2Zq5nSVvWMtP3ycnJ
5OjRo4Xzd33xpDJVmR08eDAZGxsLltlesZVQOkNpy2KDv//+u7E/PX/q1KlkdXU1c3m7diJOnz6d
PH78mP4JEIKAo8GXs4+bN28ms7Oz5vuDBw+ShoaGks80Nzcn09PTRnDpI9Hgdmxupzc3N5fU1tZm
uuYLl7Q0T0xMmE5WcX/+/NkIvaGhocL1kZGRZHBw0FxfX19P2tvbgz5RSX58Ll++nCncCxcuJPfu
3TPf7969a6YhlS/7t8RLlrRlLTN9l+ixYkX5Ub4sKs+enp5CmZ04cSJYZnvFVkLpzFO2/t/Dw8Pm
fvus6s7WWZbydu1E3LlzJ7l+/Tr9EyAEAUeDL2cf6iTVqZVjUxr1cEc7bOdbasQs7VrWzl1rwfx0
uiJB02waCbIsLi7m9oms+cmLDXdqaiq5cuWK+f7rr78mXV1d5iMuXbpkxG2WtOURgu6IlX+9ra3N
jERmLbO9YiuhdOYpW//vxsbGIhvT90OHDmUub5/l5eXk+PHj9E+AEAQcDb6cfbgjFrFnnj59akZb
JF7UKbrXNXqjvyXY+vr6ip4LXcvauSud/tSd24H7+ZAQiPlEufmJkRau1oVpREpo2nNpaSmpqakx
f2uKUtPFWdKWRwiG6tTfGBErs71kK+XWeyhc195KxRUrbx+Vt6aZ6Z8AIQg4Gux6IajRLI20aDpr
fn4+efv2bcnOX1NxnZ2dZsoxy7VKOuFYPkI+UWl+yg1Xa/E0DWsFoNaTaWTI/p0ljGoJwbziea/Y
Siideco2S7h5yjtvmdI/AUIQcDTYdvuoq6vLNN2nDQUbGxuFv+1mh1JopCvrtaydsEbQ3Ph9NM3p
TttJXIV8olr5yRvu2bNnzVoxOyVsp4ft31nCqJYQ1LSkRKnl2bNnwXzuFVsJpTNP2ZayQX9q2B1V
zSsEtdaVEUFACAKOBl/UPjRFpuk4ofeapW0A0MiV3V1p1zb567K041P4i+RD17J2wlqobzeD6KO/
tWvTog0AAwMDhY0PHR0dQZ+oJD8hYuGOjo6adWXj4+Pm79u3b5sdqNq4kTUM97ue1bo0K1DyCEF/
s4jKM7ZZZC/YSiidsbSFylM2p/qzNqg6lOgsVwhKeLNGEBCCgKPBF7WPT58+JefOnTMdrtZLacNA
qWcePXpkNmfoPnWsWtDvXtd0np63r82wnXnsWtbOXfT29poRHY3CaHempvVcbt26ZUSWXjGjHZ0h
n6gkPyFi4ep1Ie5rY+wGjZcvX2YOw/2undMqDzsylXeqUuJZ5aVX7qjM/HWDe9FWQumMpS1UnsK+
PkYf7Rh+9epV2UJQ/wlg1zAgBAFHA+wDdgUSUO5aRdhe9IojCV/aH0AIAo4G2AfsOBo91aYM+25G
jXZl3RQDlaFpaXs8Hu0PIAQBRwPsA3Yc7ZrV+xc1DardzDdu3DCCELafX375hbOGASEIOBpgHwBA
+wMIQcDRAPsAANofQAgCjgbYBwDQ/gBCEHA0wD4AgPYHEIKAowH2AQC0P4AQBBwNsI9dxfPnz0k/
5Qu0PwhBwNFg/9jHzMxMcuzYMfNqER2DpXNf8YnSYfuncewGX8yThtBpIttV1juZPp1OopNEqv3e
vv3gI/RPgBDE0QD72IKOP2tra0tWVlbMy4Z1jq97Xis+EY5nrwnBaqR3O4VgpemTCNS5xdVkv/gI
/RMgBHE0wD620NXVZc7tzRO2jso6fPiweUGxpb+/35xjq3NZu7u7i57Z3Nw0Z7UeOHAgqa+vT548
eVJ03Z7pquunTp1KVldXg/GpM7569ao5i1jn5mq0xs2zHRXSGbZNTU3JwsJCybxohOfdu3fmuzp5
91zgtbU1c90tT/3rfuxvo6OjydGjRwtn5oaESOyMWn2fmpoyJ4GoTK5du2aOg7PE8v769WtzNrPK
UmlRed+/fz81/bG6i8XnU+30he4vVY6l8pfXvir1Edof+ieEIOBosGfsQwImz7oshS1xog7/7du3
5reJiYlkcnKycHyZOv+hoaHCMzdv3kxmZ2fNdx1z5o6mDA8PJ2NjY+ZZfRSWRGMovpGRkWRwcND8
tr6+bs5xdfPsirG5ubmktra2ZF4uXLiQ3Lt3z3y/e/eumfZT/PZvmw5fqPnl8fPPPxfEheJV/JUI
QU1rKjzlTyLt+vXrheuxvDc3N5sRK1ueKluJnLT4Y3UXi8+n2umL3R8r33Lsq1Ifof2hf0IIAo4G
e8Y+JFokljTSohGTc+fOJe/fvw+G7Y6oCAkXdaQurviS8POvWxobG82IoUXfNRoWik8jN+4zi4uL
RXmWULDCM4RG3q5cuWK+//rrr2bkRx9x6dIlI4qyCEE/faHyzyIE3RHTjx8/JjU1NZnzXgqNVKbF
H6u7vPFVO32x+2PlW459VeojtD/0TwhBwNFgz9iH7pUY2tjYKIyYWDGUNWx1lP60nNtZh0bISnXq
7v1p8bko3e596rTtyFpfX19q3C9evDAjTkJTyNoAYEWXOn1NF2cRgnnKP4sQ9IWZm99Y3oWmOjUK
q3qUEAqlP2/dlYovT93kTV/s/lj5lmNflfoI7Q/9E0IQcDTYdfaRtn5Ka7ncERN1dKGdm6XCDo3Q
xIRgqWsxYRB7xooHTUN3dnYmPT09qfEfPHjQTGFaAahpwOXl5aJRuJ0WgqH8xvKuUU6NwN65cyeZ
n583052h8MupuzxCsNL0xe6Ppa0c+/LJ6yO0P/RPCEHA0WDP2MdPP/20ZQRH0195wtZomkZL0qir
q0udGtaz/tSd28mWik87ON1nJNzS8qxRvlB5nD17Nrl8+XJhhMdOD7sjPtspBO0mFfe6+2oSTUFK
iGTNu+5166JU+HnqLk9Zb0f6YvfHyrcc+6rUR2h/6J8QgoCjwZ6xD62l08cuptcOWL0nLU/YWpBv
Nwjoo7+1O9OiaT1N14qHDx9u2SyiOO2z4+PjRjiG4tPmgYGBgcKGhI6OjqL7FL52DovY5g3FrTVj
ilfcvn3bdPLaQFEqDbqmNWVWXOQVgu5Gljdv3pgdsb4QUtkpX8rfH3/8YcRq1rxrRNPuqpUIU12G
0h+ru1h8eesmb/pi98fKvhz7qtRHaH/onxCCgKPBnrIPdWzaYKGREgmTly9f5g67t7fXjN7YMNwd
mHr9iRbYSwRpjZc2ELjY13voox2dr169isan13lIwOm1J1qz5d6naWHFY1/nYkVhKR4/flz02hi7
ucEtAzds7ahVHu2oUl4haIWp0iZBorT5QlDC58cffzR1cuPGjS0bE0J5f/TokdnsoTgkiCVgQumP
1V0svrx1kzd9sfuzlH059lWJj9D+0D8hBAFHA+wDqDvAhgEhCDgaYB9A3QE2DAhBwNEA+4AI7EYF
2h9ACAKOBtgHAND+AEIQcDTAPgCA9gcQgoCjAfYBALQ/gBAEHA2wDwCg/QGEII4GgH0AAO0PIARx
NADsA7Lz/PlzCgFofwAhiKMB9rG301FuPNVKX6XhfKnnq/GqmtA5wUD7AwhBwNEA+9j3+d2rQrAa
5UZbBNgEQhBwNNgj9qHfp6amzDmwOnf12rVr5hxg97rO6dWZqq2trYXf+/v7zbmxeqa7u9v89uHD
h6SmpqboebG5uZk0NTWVTIc98/XAgQPJqVOnktXV1WCa3d90Jq89o1fhLywsFN2n82Obm5u3hPH5
82eTTqU3FL6+T05OJkePHi2cUaxzgd186Zxapb2+vj558uRJajiheP7999/k6tWr5mzfI0eOJDMz
M1ueKVXeeZ53SSs3PeN+qpH2PPkI1SfQPwFCEHA02CYh2NLSYgSYOnV11NevXy+6LnGoa2/fvjW/
TUxMGIGk3ySq1PkPDQ2Za1euXEmGh4eL4hgZGTHh+unQfWNjYyYcfRSuhFVWAeUKs7m5uaS2tnbL
fR0dHVsEhdL+22+/RctJ38+cOVMQp4pLcVpu3ryZzM7Omu8PHjxIGhoayhKCKp/BwUFTBuvr60l7
e3vR9VB5Z3neJ0u5VSvtefIRShfQPwFCEHA02CYh6I5kffz40YyWudfdUToh4ajO3MV22i9evDDP
2+v699ixY4Uw3HQ0NjaaUTWLvmtkMqsI0SilFWJp90mgdXZ2Fl3TyOazZ88yCUE/7+51CT+/HMoR
gkqPWw6Li4tF10PlneV5nyzlVq2058lHKF1A/wQIQcDRYJuEoN85u6NepZ7TdX8aUdN5lpMnT5qR
HzE9PW1G1UqF5z6TNW73N40a2RHNvr6+1Ps0tSuBaoWKO8VdiYBz01rNcFQf/vVQecee98labtVI
e558hNIF9E+AEAQcDbZJCOYVY6UEnItG4bRmTmit1/z8fGYhlUdACa1ftKN+PT09Je8bGBgwU9ZC
U8+3b9/e1UIwi2BOq6+s7UGWcqtG2vPkI5QuoH8ChCDgaLBNQnBpaanw9/v3783C/9BzEncbGxvB
+DQKp/VjmhZOS4fC8aeG3deX+HGvrKyk5kN5SBMgWrumDR1ra2tmo4K/maVcAVdXV1fW1LCfj7a2
tqJyWF5e3lJOofKOPR8iVG7VSHuefITSBfRPgBAEHA22SQhqt67EkkTNH3/8kZw9ezb4nDZ52A0C
+uhvheGiTQDaRepuBvDD03Ojo6OFcMbHx424sribB968eWOmmP01etppKvyNHH66NRL4yy+/mI0v
WcspJgS1WUTTmeLhw4epm0Vi+dD0uUYt7YYLbXDxyylU3rHnfULlJsGsdZFW3FWa9jz5CKUL6J8A
IQg4GmyTELx//37y448/msX6N27cMKOCsed6e3vNyKFG8CQO7I5iy7t378w1iYNQOuzrY/SRWNMr
XyxWDGhKUQJRIsF9XtOI2nBiX+1iRUSpeLQhRr/FTs7IIwQ1snju3DkTt9Kh9Yel7ovlQ9y6dcts
lNGIpXbX+tdj5R173iVUbhLuisOOzFaa9jz5CKUL6J8AIQg4GmyTEPwakODQdDUA0D8BQhBHA+zj
K7IbTUNqJIqdqAD0T4AQxNEA+3Coxtmyux2tezt9+nRwkwgA0D8BQhBHA+wDAID2BxCCOBpgHwAA
tD+AEMTRAPsAAKD9QQgCjgbYBwAA7Q9CEHA0wD4AAGh/EIKAowH2AcXEXlwN+7t+qH/aH4Qg4Giw
L+xjdnZ2V9vWbk3b1/Bant1WP3niqkb9hOKrRvg6dUensOj1RzrBRmdlYweAEAQcDXbMPnS2rM6C
RQjij/tNCFYjXaEwKg1fx/aNjY0VzmXWec7+ed7YASAEAUeDbbWPzs7O5OXLl9FndSasPY+2qakp
WVhYCMbrn0U7NTVlzqrVecPXrl0revFzlusu/f395sxb3dvd3b0l3jt37piwDh48mNy9ezcZHh42
oy5Kv87VzRPW5OSkObbOno1rn9c19yNev35tztbV6I7ura+vN2c8u+HprF2d9/x///d/SXNz85Zy
+/z5c1JTU5N8+PChZJna51tbWzPlYXNz05zvrDQpPTqP2cWeA63rEiGrq6vB+CRYrl69asrzyJEj
yczMTFH9hOykGvlx4wqVd6n6iYUdy5ufjlLhh8rTp7a2Nvn48WPRb8oH/RMgBAFHgx2xD41AaEQi
y7OuCJqbmzOdWB4h2NLSYjpFdbbqjK9fv57rumViYsKIM90n0aTOemhoqOjeS5cumWv/+9//TKf+
22+/mb+VfrejzRKWhIbtzP3n/XxL2E1PTxdGeFS2Ejnu/RK5uqZzkTs6OrYIJaVH6U2rX/f5LHm4
efOmmfoXDx48SBoaGgrXJJDdESmFJdEYim9kZCQZHBw0v62vryft7e1F5RCyk2rkx40rS3m7xMKO
5S3mb7HyDLGxsWHsvquri/4JEIKAo8H228c///xjjmTL+qw6WCsossTrC0F3JEqjIBr1ynPdIsGo
TtYfWXHv9Ue11MlWI6xS+YqhkbG08CTMNCLropGxZ8+epZazn55YHiT8/OuWxsZGM2Lojh5qJDUU
n9LnPrO4uFhUDiE7qUZ+YmXul3eesGN5i9l9rDzTOH/+vBlF1Cet7umfACEIOBpUzT407ahOz12Y
HntWozt25K6vry+3EPQ7YH9kLXbd/d2flgt1/qG/84aVRQhqqlOjcBrZkTCI3a9p5xcvXhSEhztF
mqV+Y3kITTW698XKPS081Zt7X8hOqpEf/5k85Z23rPy8xdIfK88YmlbWdDr9EyAEAUeDqtlHqbVM
mjq9d+9ebttSp2tHsXp6eioSTHkEh3u9VGebVfhVGlYsX1rnqBE4rVGcn583052xctD0/JUrV8x3
TSPevn07V3pieQgJkVLX8tRbSJyVspNq5Md9Jm95l1NWeYRg3ud9NF3NGkFACAKOBttuH744LLXo
PcTS0lKww11ZWdlyXc9Y3r9/b9bu5blu0YiJO9VbiRDMG1ZMKCnNbnilysFHa9G0sUCjs9rE4G6S
yZKeWB7q6upSp4b1rD+V6b4SpVR8bW1tRc8sLy+n2o1vJ9XIj/tM3vKOhZ0nb2nhh8rTR9Poqn/3
/ixTyfRPgBCkoweoun3EntXIi3aECn/ThLtBQK+j0QYLv0PWDkp1ehIlf/zxR3L27Nlc1y1akG8X
9Oujv91XbuQRgnnD8n+TgNMaN9v5a5rX7lqViDh+/HimNYUaCfzll1/Mxom8dRTLg6ZNNV0rHj58
uGWzyOjoaOHZ8fFxIxxD8WlzhkYx7YYKbXhx7wvZSTXy4z4TK2+/fmJhx/LmUyr8UHn6aCpY0+f2
ftm9PvRPgBAEHA12nRDUdJ/WYNnXqNjO3u3wdU0dn675Akgd9o8//mhGQW7cuGFG/fJcd+nt7TWj
QRptkei0O07zCsG8Yfm/acepnrOjPo8ePTKbD1QWEkT+i7rTylgbZXQtdlJF2vOhPGiEUS8qVppU
f1qH6IsRu1FBgvTVq1fR+PT+O41caQRTO2Pd+0J2Uo38uM/Eytuvn1jYsbz5lAo/VJ4+mgqW+Nfz
ul/P0j8BQhBwNNh39hFL19du1xIjGt0CoP0BhCDgaIAQ/IrQlKBGqWI7bAFofwAhCDga7En7iJ3J
+jWf2at1ZnqfY2iTCADtDyAEAUcD7AMAaH8AIYijAWAfAED7AwhBHA0A+wAA2h9ACOJoANgHAND+
AEIQRwPsAwCA9gcQgjgaYB8AxcReXA1A+4MQBBwNsI9dn45y46lW+ioN50s9X43X9WQ5MQVofwAh
CDgaYB/7Nr97VQhWo9xoiwCbQAgCjgZ7xD70+9TUlDlDVWea6nxT9wXGuq4zYnXOb2tra+H3/v5+
c+aqnunu7ja/ffjwIampqdnyAuTNzc2kqampZDrs+at6efKpU6eS1dXVYJrd33RWrT3HWOEvLCwU
3aezXJubm7eEoXNclU6lNxS+vk9OTpoj3uz5uDo72c2XzoxV2uvr6825wGnhhOLRCSJXr14159we
OXIkmZmZ2fJMqfLO87xLWrnpGfdTjbTnyUeoPoH+CRCCgKPBNgnBlpYWI8DUqaujvn79etF1iUNd
07m3YmJiwggk/SZRpc5/aGjIXLty5UoyPDxcFMfIyIgJ10+H7hsbGzPh6KNwJayyCihXmM3NzSW1
tbVb7uvo6NgiKJT23377LVpO+n7mzJmCOFVcitNy8+bNZHZ21nx/8OBB0tDQUJYQVPkMDg6aMlhf
X0/a29uLrofKO8vzPlnKrVppz5OPULqA/gkQgoCjwTYJQXck6+PHj2a0zL3ujtIJCUd15i62037x
4oV53l7Xv8eOHSuE4aajsbHRjKpZ9F0jk1lFiEYprRBLu08CrbOzs+iaRjafPXuWSQj6eXevS/j5
5VCOEFR63HJYXFwsuh4q7yzP+2Qpt2qlPU8+QukC+idACAKOBtskBP3O2R31KvWcrvvTiJrOs5w8
edKM/Ijp6WkzqlYqPPeZrHG7v2nUyI5o9vX1pd6nqV0JVCtU3CnuSgScm9ZqhqP68K+Hyjv2vE/W
cqtG2vPkI5QuoH8ChCDgaLBNQjCvGCsl4Fw0Cqc1c0Jrvebn5zMLqTwCSmj9oh316+npKXnfwMCA
mbIWmnq+ffv2rhaCWQRzWn1lbQ+ylFs10p4nH6F0Af0TIAQBR4NtEoJLS0uFv9+/f28W/oeek7jb
2NgIxqdROK0f07RwWjoUjj817L6+xI97ZWUlNR/KQ5oA0do1behYW1szGxX8zSzlCri6urqypob9
fLS1tRWVw/Ly8pZyCpV37PkQoXKrRtrz5COULqB/AoQg4GiwTUJQu3UlliRq/vjjj+Ts2bPB57TJ
w24Q0Ed/KwwXbQLQLlJ3M4Afnp4bHR0thDM+Pm7ElcXdPPDmzRszxeyv0dNOU+Fv5PDTrZHAX375
xWx8yVpOMSGozSKazhQPHz5M3SwSy4emzzVqaTdcaIOLX06h8o497xMqNwlmrYu04q7StOfJRyhd
QP8ECEHA0WCbhOD9+/eTH3/80SzWv3HjhhkVjD3X29trRg41gidxYHcUW969e2euSRyE0mFfH6OP
xJpe+WKxYkBTihKIEgnu85pG1IYT+2oXKyJKxaMNMfotdnJGHiGokcVz586ZuJUOrT8sdV8sH+LW
rVtmo4xGLLW71r8eK+/Y8y6hcpNwVxx2ZLbStOfJRyhdQP8ECEHA0WCbhODXgASHpqsBgP4JEII4
GmAfX5HdaBpSI1HsRAWgfwKEII4G2IdDNc6W3e1o3dvp06eDm0QAgP4JEII4GmAfAAC0P4AQxNEA
+wAAoP0BhCCOBtgHAADtD0IQcDTAPgAAaH8QgoCjAfYBAED7gxAEHA2wD6gesZde7/bwqSOg/UEI
Ao4G+8A+9LoV98i3vNfxmfLiqsYrfULxVRr+bmprvlRaql1H1crHbu0H6J8QgoCjwR6zj8+fP5sz
h9Oei13HZ8qPqxrpCoVRafi0NdtfRwhBQAgCjgZf1D5OnTqVvHnzJvW52HU/bp0jq7OMW1tbC7/3
9/eb82l1znB3d3fRM5ubm+bsYb0Mur6+3pwV7GLPKNZ1pWV1dTUYn04XuXr1qjnn9siRI8nMzExR
2nWurT1Tt6mpKVlYWKhqfty4Xr9+bc7ZVdoVp/Kn857tfe4nS9ixvPnpKBV+qDx9lO88dTE5OWmO
97NnCOv8YhflTWk/ePBgMjY2lnoedVr41YzLJc0mSpVh7FzqWB35z4fqO2Srft3QPwFCkI4eoCz7
mJ+fDz4Xu+7Hfe3aNdMZ6sxfMTExYTpt/abRRXWMQ0NDhWdu3ryZzM7Omu8PHjxIGhoaCteGh4dN
J65n9VFYEo2h+EZGRpLBwUHz2/r6etLe3l6Udlc0zM3NJbW1tVXNjxtXc3NzMj09XUi/8uJ24H6Z
xsKO5S1mC7Hy9Ll8+XKuupDoteJNZayytihfPT09hbSfOHGiKH1Zwq9WXD4hm/CfiwnBWB2532P1
HUqXWzf0T4AQpKMHqNg+Ys9lFYL+CFNLS4vp6FzcDk3Cz79uaWxsNCOG7ujhoUOHgvFp5M59ZnFx
sSjtEmJWeG5HfmLlpNGdtHtjYcfyFquzWHmGKKcu3Pjb2tqStbW11LRnCb9acfmEbCKvEIzVkfs9
Vt95bJX+CRCCdPQAu0IIlhpt8afYXDHkjuSERFOp+9Pic1FH696nkRX9rU64r6+v6vnxn9HUskY9
u7q6jNgJTRPmLSs/b7H0x8ozq4DNWhfub/6mCz/tecKvNC6fkE3kFYKxOvLvDdV3HlulfwKEIB09
QLCjKrVebCeEYKkOPqsQKXUtJghiz1hxpmnozs5OM4VYzfy4z0xNTZkRzzt37pgpdk0vh9JfTlnl
EYJ5n6+0LvIIpDzhVxpXKdJsolIhGEp7rL7z2Cr9EyAEEYIAFdnHdglBLXLf2NhIfUavpUmbGtaz
/nShO9pTKj5NC7rPLC8vp6Z9aWkp967bWH7cZ7RhwL13ZWUlKGhiYefJW1r4ofIMUU5duL8dP37c
rJmzPHv2rOh6nvArjSuEbxMxIejXaayO/DyH6juPrdI/AUKQjh5gVwpBbQKwi+f10d/aEWrRtKmm
wMTDhw+3bBYZHR0tPDs+Pl70PsNS8WlzxsDAQGGxfkdHR9F9Cl+7MYW/yaAa+XGf0a5Wu0tYgkAC
xb2u3bFa62aFQyzsWN58SoUfKs8Q5dSF+5u/gUP58jeLZA2/0rh8Qjbhl6G7gUO76bVpxQ07Vkd+
nkP1ncdW6Z8AIUhHD7ArhaDo7e01o2Ma4VHHaXfgCr2s+ty5c6aT0xo6La53sa8U0Ue7SF+9ehWN
79atW2ajgV7LoZ2Z7n2aalM89rUjtqOtVn7cZx49emQW/ysedepa+O9e1w5RheGOfIXCjuXNp1T4
ofKMkbcu/N8kkJRuvVZFafdHI7OGX424XEI24ZehFWS6V0JV9/pxh+rIvzdU33lslf4JEIJ09ADY
B+wZ9B+AmpqafRcX7Q/tD0IQcDTAPgA8NEKmTQ/2nXka/duuzQ87GRfQ/iAEAUcD7AMggnZN6x17
mgLVaR83btwwIm2vxwW0PwhBwNEA+wAAoP1BCAKOBtgHAND+AEIQcDTAPgCA9gcQgoCjAfYBALQ/
gBAEHA2wDwCg/QGEIOBogH0AAO0PIAQBRwPsAwBofwAhCDgaYB8AQPsDCEHA0QD7AADaH0AIAo4G
2AcA0P4AQhBwNMA+AID2BxCCOBoA9gEAtD+AEMTRALAPAKD9AYQgjgaAjQAA7Q4gBHE2wE4AAGhv
ACGIw8HXayt8+PDhs90fQAgCQhAAaF8AACEINNQAQPsCAAhBoKEGANoXAEAIAg01ANC+AABCEGio
AYD2BQAQgkBDDQC0LwCAEAQaagCgfQEAhCDQUAMA7QsAIASBhhoAaF8AACEINNQAQPsCAAhBGmoK
AQBoXwAAIUhDDQBA+wIACEEaagAA2hcAQAjSUAMA0L4AAEKQhhoAgPYFABCCNNQAALQvAIAQpKEG
AKB9AQCEIA01AADtCwAgBGmoAYD2hUIAQAgCDTUA0L4AAEIQdmVDzYcPHz7b9QEAhCAAMMIDAAAI
QQBACAIAAEIQABCCAACAEAQAhCAAACAEAQAhCAAACEEAQAgCAABCEAAQggAAgBAEAIQgAAAgBAEA
IQgAAAhBAEAIAgAAQhAAEIIAAIAQBIDqCUDOkAUAAIQgAEIQIQgAAAhBgK9VDAIAACAEARCCAAAA
CEEAhCAAAABCEAAhCAAA9BsUAcD+E4MAAAAIQQCEIAAAQOVCsNSrKfjw4cOHDx8+5X0A9owQxGAB
AACq3AHTt8JeEIIYKgAAAGIQvkIhiIECAAAgBgEhCAAAAAhBQAgCAAAAQhAQggAAAIAQBIQgAAAA
IAQBIQgAAAAIQUAIAmwPz58/pxAAACEI8CWE4H4w2o8fPyZXrlxJvvvuu+Tbb79Nzp07l7x//75w
Xd/PnDmTHDhwwNxz/vz5ZH19fUs4nz59Surq6krG8fvvvyfff/+9CUPhr62t0bBUKc2qMwAAhCAA
QrAsrl+/noyPjyf//vuv+Ui0SaxZ+vv7k76+vsL1P//8M+nt7S0K4/Pnz8nZs2dLlsetW7eSsbGx
wvMDAwPJqVOnsLgqNYY0nACAEATYBUJQ3ycnJ5OjR48m//nPf5Jvvvkm+fvvv1PD/Ouvv8w9urep
qSlZWFgIxufHdefOneTQoUPJwYMHk7t37ybDw8Nm1C0Wr4+el0BzRZ07ynT69OlkeXm56PpPP/1U
FIaE3Zs3b0qmu7a21ow6uiiNobJ++vRpcvjw4aS1tbVIkP7www9mVLK7u9v89uHDh6SmpsaMRrps
bm6aMi1VlqXCEceOHUvevXtnvq+srJjn/vnnH/O3RjB1Patt+HU1NTVl6kpxXrt2rSi9KvurV6+a
ujty5EgyMzNT9Pzr168LI7Iqt/r6+uT+/fuFsEud15mWRxpaAEAIAmyjEFSHvbq6av6WGAsJHlew
zc3NGcGUR1xcunTJiLL//e9/RkT89ttv5u9YvDEkoiTCLArbFYr2N5f5+flMTryxsWFESldXV7Cs
JZYU59u3b81vExMTRmTrN+VRYmloaMhc07S2RLDLyMiIicdPUyicCxcuJPfu3TPfJawlhnW//fvi
xYtlC8GWlhZjF4pX6dIorJvWwcFBc01T7u3t7UXPNzc3J9PT04URVY2uuvXjxx/KIwAAQhBgG4Wg
FYFZjFqd+ezsbNniwo1Lf0tkVcOZNPV78+bNIsFaSsTmdWKtLdQIlT7Pnj0LlrVfjhJSvhi1wvnF
ixdmVNBe178avbNhuGkKhaNRO4lK8euvvxqxagWrRLcEVbl19eTJk8LfGh1Vei0a9ZT4tiwuLkbr
T6PIafGH8ggAgBAE2EYhmMeoNQpoR4u0Bi+vuAjdX64zaWpUgk0jSaVERyVC0KI1iHbaNmsYis+f
BnXTdfLkSTMKJjR6ppHZUuGFwpGg1OibUPqWlpYKgk3TsZouLlcI+sLMLT+/LHWvH6amyiXOJUwb
GxuDthArKwAAhCDALhCCtoN/8OBB0tnZmfT09HxRISjxp+lRf0ewPw2c9lvWeBVPbI2gT0zIqAwl
1qyIs1PVfnixcLReUvm3AlDrPbU+0h3BK0cIhoR0qbJwn9FIZUNDg1kTqnxpujwUPqIPABCCAHtE
CFo0+hQKy25e2C4hqJFATYuWGvWSSHU3e2ijQ9qu31LxagrcFZeaBtXGiTxlLXHnTn2XQqJN6+38
TR1ueLFwtPP58uXLhSlhOz0cW9MYqyvVr0Wv43GFdFtbW9HUsISn+7zuddMcs4UsZQUAgBAE+MJC
UKM82jks/A0e7kYS7cbVVOd2CcHHjx+bqdW0d/tpc4PdzKCPRqb8qexQvJoKdl8/88cff5hPnrLW
ZhA3DfrbF6PaEKFdt/7GCDe8WDijo6NGpOp1OuL27dtmt66ddi5FlrpSHBLDNv8SnBZNZeuVOnaz
SEdHR9HzErh2l7BE4vHjx4uuK31aD2nFZJayAgBACAJ8YSGoaWGt97KvmrGi0BWGuqaXNOtaJUIw
lA5Ne/prytz7NRUpcaJdtPr8/PPPRS+cjsWjqWDtAtaz2igiYVhOWevdhRodUzgSW3ZHsUWjmrrm
T2374YXCkSh2XxtjN268fPkyNb1Z6kpC7scffzSjozdu3NhSfnrXogSoXvmiXb/u848ePTKbPRSH
/vOgDUbudQlfWzdZ8khDCwAIQYAqCcG9gnbBAg0bAADtJcBXKATd18EADRsAAO0lwFckBOHLwVnA
AAAIQUAIAgAAAH0tIAQBAACAvhYQggAAAEBfCwhBAAAAhCAAQhAAAAAhCIAQDPP8+XNqjvr4oun5
knnG/gEQggC7TgjqXF6d26tTNPTqkHPnzhWdJKGj3P773/+aazoeTNf90zCyUo1Xk8ROR/lS6IQO
nabR0tKyZxqaSusjZjsfPnxILl68aK7pJJLu7u7UU16qZR87YYN7MW46RADsHhCCJbl+/bo5q9ae
9aoj1dShW3Rc2927dwvX9f306dNfzGl2q+O5Z/h+LY1YzHZ+++03c6Scva6zkd1zi79E3X5J+6HT
AEAIAuw6IXjw4EHTSVt01q47ciGBU0r0pGFHxnSWbVNTU7KwsFBIk382cOy8Y6Xr6tWr5hzaI0eO
JDMzM8ERwf7+fnP+rUaoNPqUJV1p5aezlXXWbmtrazT8tHOPQ+kpFUfab+4zk5OTydGjRwtnPvvi
U3GqvFSvY2NjwXOnS6VZYk7p1ejvqVOnktXV1bJtR9/d6/qutGVNT956EK9fvzbnFSv9Kp/6+npz
dnIojjt37pgRS+VH/9EZHh426Uwr31CdptVPWnm7bG5umhFUpV3pfvLkSdH1UN3kyYfunZqaMvcq
PJ2t/enTp0xlmMVOY74Wy0fIxvP4MQBCEBCCZaDOSA28xY4IWmZnZ5OTJ09mGhmbm5tLamtrU9MV
E4IjIyPJ4OCgERCajm5vb08VghMTE6YD0b0SJBKNGo3Kkq5SaVDnqLDevn2bKXw/L1nu9+NI+819
Rh207TiVH1eUK76enp5CeZ04cSJoC/41CQeJRzuCpzxImJRrO74Q1PXQ9Ggp+8hbD83Nzcn09HQh
D8qPm6ZScVy6dMmE9b///c8IJ41k6m+/fLPUaah+Yn6poxXlX+LBgwdJQ0ND5rrJkw/dqyUMSqfC
krjV6G6eMgzZacjXsuQjVIZ5/BgAIQgIwTL4888/i876ffHihRlhsCMZ+q7f0lCHYTuzLB196B6N
Nkg8WBYXF1OFoDo2V3QIt5MIpatUGvyRsFj4fl6y3O/HkfZb1uttbW1mTWdaecXqo7Gxsai89V2j
RuXajjp4TQerHDTiJLGhkZw8QjBvPZTCjTMWh/7e2Ngoy8ay1F8ICT8//Kx1kycf+u6ONmqtZ01N
Ta4yDOUz5Gt585EnbACEICAEKzTOd+/eJefPnzejCBb971z/i7f/g79161ZwnZf+l25HHPr6+ioS
gv4UtOJP61h1rz/95nZeoXRlKb9Y+P4zee/P8lvsuj/a5pdXLL5SIi20DCBmO9oYot8URl1dnamD
vCOCeetBaNpSgrSrq8sIj1AZ5vm70jqN+WWorGN1kycf+u4LTj/uPGXo/xbytbz5yBM2AEIQEIKR
xjS0Rkkd+IULF7bsCC61zktre0KoE9HUVmdnp5mqrJYQDHWsoZGmWLqylF8s/CyiKk/eyxGCMeEc
iy9W3mmk2Y7P8vKyWetZiRCMlavWvmlkTevl5ufnzdRltYRgpXVaiRDM4wtZhGAo/LxlWOq3NF/L
m488YQMgBAEhWKZxajRHrwFZWVnZcs0XfRIXWuidhaWlpVydleL3pzrdaSQJibTwtHDcnQrLk64s
5RcL338m7/3VEILHjx8vEmPPnj3LlU+l2Z+2i73yJGQ7Pvfu3TMjTJUIwVi5am2ce923qUqEYKV1
GvNLjZqmTQ3H6iavEJQPWDRy627iyVuGobz5vpY3H3nCBkAIAkKwDON8/Pix2fzhri1z0aJwjQxo
1EedlDZwaCdvGhpJ0M4+4S/0lqjU+h/bEbgLv9+8eWOmod20a8H6wMBAYfODNq6kdUiavrYbS/TR
39qRmCVdWcovFn6pjRd57q+GEPQ3iyi+kC349aE02jV9+ujVMBIn5dqOylziT2gnqkZwtG4xa3rK
qQftNrU7XPUfB4ljN5xYHKG/K61TP24fTcVq6lM8fPhwy2aRUN3kFYJKt2xEYf3xxx9Fyz1iZRjL
Z8jX8uYjT9gACEFACJZhnFok7k8bu89rkb/EoP7Xro9EoPuqCR9N22hNkX31g220hXZY2nDchlz3
qjPQvX7atSZRi8n1yg7tMAx1SL29vWY0Q+FLVNodjbF0ZS2/UPilnsl7f6VCUEg4q6w0BavyCo3o
+fUh7Ks99NFmj1evXpVtOxJ92vBj1wjGFvn76SmnHh49emQ2cChOiQbF6YYTiyP2dyV1Wqq8XeRX
eg+j0i5b9UVzqG7yCkEJvR9//NFsvrhx40bRi75jZRjLZ8zX8uQjb9gACEFACGKc4AiL2G5QoPMC
AHwJEIKwD9DIqRbR2/fcaeSFxfRA+wCALwFCEL4CtMNTU7GaetT7HjXl577OBUDs5zOPARCCgBDE
OAEAABCCgBAEAAAAhCAgBAEAAAAhCAhBAAAAQAgCQhAAAAAQgoAQrAbPnz/f9wX/NeSROgTKEwAh
CF+JEPz48aM5K1Zv+ddrJXSygXvKQB6q8VqKPGezfgl2w6s3trNcdqrMd7pu3fj8OvxSdrYT8bpx
6BQOncbR0tJS1fi3szzpaAEhCLDNQvD69evmvE979qdeQiwx+KWcYrc71n53/P0qBHdjHe50Otyz
vfmPCQD2CQhBg148LAFo0QuIQ6NedlRBZ302NTUlCwsLhTj982Zj54YqXp1drLNbdTbuzMxMcESw
v7/fnKOr0cvu7u5M6SrF5uamOeP0wIEDSX19ffLkyZPCtdevX5szZHVN4em6zmVNy2MsXfa68qiy
Hhsb25Ive/aq4jx16lSyurpaVAY6X1Vnwupl0X65xPIdSlus/H1CZZO3DpSfLOEeO3Yseffunfm+
srJi0vfPP/+Yv9fW1sz1LGlzbTJkp/o+OTmZHD16tHCerS+eYvWZ1dbc5yop29C1rPmupk/kte9Q
ebt2AoAQBNgGIViq4wo1vm5DPTc3Zw6nT4s3JgRHRkaSwcFBI0jW19eT9vb2VCE4MTFhOgx7fJpE
y9DQUKZ0+dy8eTOZnZ0133UkW0NDQ+Fac3NzMj09XRghVUfvloefp1i6dE3HvNk8njhxoiiM4eFh
E4eNT+GpQ3bju3btmrn29u3bLWkI5TuWtlj5+8TKJk8dXL58OVO4Fy5cSO7du2e+37171/wnRfmy
f9uyylNvITvVd4keK1aUH+Ura33msTX3uUrKNqtPhvJdTZ/Ia9+h8nbtBAAhCLADQvDPP/80nUJo
JMd2GLF4Y0JQI1wSnpbFxcXUjkvrmtyRS+F2eKF0+aiT88MKoZGKtDzF0tXW1mZGrtLy2NjYWFQG
+q4zg9343BEUPw2hfMfSFiv/vGWTpw6yhjs1NWXWsIpff/016erqMh9x6dIlI27z1ltMCIbKO1af
eWwtVtZZyzarT4byXU2fqKZ9AyAEAXZQCGoK7vz588HzaTXioPAlMvr6+ioSgu7//IU6orSOS/f6
01BuZxRKV6lRzRCaipUYluBQRxbqTGPp8qfZ/Ty695ZKX6wMQ/mOpS1W/nnLJk8dZA33xYsXZkRK
aNpzaWkpqampMX9rilLTxXnrLSYEQ+Udq888tuY/V27ZZvXJUL6r6RPVtG8AhCBAlYRg2vo2i8Sf
puE03ZWl09b0UWdnp5kmq5YQDHVcpTqUrOnK0zlrBEqjI3fu3Enm5+fNdGyo04ulKya28pRBSECU
ynfetMUatljZ5KmDPOFqLZ7s0gpArSdbXl4u/J233ioRgnnFc1YhWGnZZvHJcoVgXp+otn0DIAQB
tnlEUCOBmn5zR1eyoNGZrB2CsIv9LZpmc6eN1LmnhafRoI2NjbLS5VNXV5c6DaZNAG48fpr9cGPp
On78eJG4fvbs2ZZ8+VNn7qhTno7Sz3csbbHyz1s2eeogT7hnz541a8XslLCdHrZ/5623SoRgrD7z
2Jr7XLXKNuSToXxX0ye2y74BEIIA2yAEHz9+nJw8ebJo3VMIjQxol6LwF3ZrV6DW+9iG313E/ubN
G7Mo3E2bFqAPDAwUFt53dHSkdjBadG43Nuijv7UDMUu6fDTFpek08fDhw6KF8RptsjsiJYzU8bvp
8PMYS5e/uUDX/HyNjo4WnterfNQpZ+0oQ/mOpS1W/j6xsslTB3nCVfloXZnKRty+fdvUg8o2axih
OswjBGP1mcfW3OcqKdvQtTybRarlE9W0bwCEIMA2C0FNr/nTxqHnNQWlNUL2VQ+2AxLakar/7dv/
8dtOSfeq8de9fti3bt0ynbxecaIdhaGOq7e314xOKHyJSruLNpYun0+fPpl3Jeo+PaMF/5ZHjx6Z
DRW6ps5Qi/DddPh5jKVLSGwpf3pFi/LorzOzr9fQRzsqX716lbmjjOU7lrZQ+fvEyiZPHeQJV/9Z
cV8bYzdovHz5MnMYoTrMO1UZq8+stuaGW0nZhq5lFYLV9Im018eUY98ACEGAbRaCsLOow3XXtgH1
CQAIQQCE4D5Fo21axG/f5afRkaybKID6BACEIABCcA+jXZZ6X5+mzbT79caNG8HX8wD1CQAIQQCE
IAAAAEIQACEIAACAEARACAIAACAEAfvDOAEAABCCgBDEOAEAABCCgBDEOHcbz58/pxAAABCCALtb
COrFuO7RT3mv70bHqGZayg0rdOpEOXHT8AAAIAQBqioE9R60s2fPpj4Xu/41OEa5+apGedDYAAAg
BAG2TQieOnUqefPmTepzsesuhw8fLvrbnjOqg+kVjg6nd9M5OTlpDrW356TqfGKX/v5+c1auXt47
NjaWeo5pWvjVisvPl4vOdrVnKjc1NSULCwuFOP3zm2Nnq+rEiqtXr5p06CzbmZmZ4Iig0qxzb1UG
3d3dmdIFAAAIQUAIFtBpCaHnYtddLl++XPg+PDxsBJXEjT4TExPm0Hk3nWfOnCmINwkzCReLhJuO
79Kz6+vryYkTJ4rSkCX8asXl5svHFZVzc3NJbW1tal3EhODIyEgyODhYSEd7e3uqEFR+lW573JlE
49DQUKZ0AQAAQhAQgrmeyxtuY2Njsrm5Wfhb33VWqxueO4Lnx9HW1pasra0V/l5cXCy6niX8asUV
QqOFs7OzmcosJgR1fJmbJz8d7veWlhYjAl1csRdKFwAAIAQBIbitQlBTkj7uKFxMFPkbLSR63Ot5
wq80rhAabdO9EmZ9fX0VCUE3/aXS4d/rTz+7ZRJKFwAAIAThKxKCpdarbbcQ9EVNXnEWE0V5wq80
rhhPnz5NHjx4kHR2dpop5moJwVA+SgnhrOkCAACEIHxFQrAaRp03XG1Q8Kdu3ZG3mCg6fvy4WSdn
efbsWdH1POFXGldWlpaWgvH6f6+srGyZonbztLy8nBqe8r+xsVFWugAAACEICMFtFYLazDE6OlrY
zDE+Pl70LsKYOPM3cGhXsL9ZJGv4lcYVoqGhwezQFf4mFO1m1tpEK+7cDRzaia0NLG4809PTycDA
QCEdHR0dqflQ/u3GEn30t9KdJV0AAIAQBITgtgpBYV/voo929L569SqzOBMSRXo9il6lol2y/lq+
rOFXI640NP2qjSv2tTRWfAnt4lU4NiwryHSvRKvu9dNx69Yts+lFaVE6Qvno7e01r5pR+BKVb9++
zZQuAABACAJCcE+h001qamr2XVwAAIAQBEAIemhUTBsd7HvyNPq3XRsedjIuAABACAIgBCPoRdZ6
r56mPXXax40bN4xI2+txAQAAQhAAIQgAAIAQBEAIAgAAIAQBEIIAAAAIQQCEIAAAAEIQACEIAACA
EARACAIAACAEASGIcQIAACAEASGIcQIAACAEASGIcQIAACAEASEIAAAACEFACAIAAABCEBCCAAAA
gBAEhCAAAAAgBAEhCAAAAAhBQAgCAAAAQhC+PiH4/PnzfVlg+zVfXzPUKeUMgBAEhGAO4/zw4UNy
/fr15NChQ8k333yT1NbWJv39/UX3fPvtt1V1ji/pKG7cfr72kgPH0lpJXvI8+9dffxm7aWlp2RXl
spfrNJbe3ZSXarQJAAhBgF0gBLu6upI///wz+ffff83fm5ubye+//24+1TTs3egcfpoQgvmRCPz7
779phL8yIUhnB4BvwD4RgurIfTRKePDgwcJz7ictLPc3icqrV68m33//fXLkyJFkZmYmOCKoEcgf
fvgh+e6775Lu7u6ia3bE6T//+U/S1NSULCwslMzHsWPHknfv3pnvKysrJo5//vnH/L22tmauu3Gn
5Wt0dDQ5evSoiS8mcmLlEEt7KN+vX79Ozpw5kxw4cMCEUV9fn9y/f78ontXV1eTixYvmnp9++ilZ
XFwsq4xDedD3ycnJkmVSqgyF/hOheJSuU6dOmXS64T19+jQ5fPhw0traWvjtzp07ZlRadnf37t1k
eHjY2I9fB6FyyWKrsbSl5bUUWeooFF7MT0rVS6k6f/XqVdLc3Lzl/s+fPyc1NTXGn0sRK4s0uyhV
zvoPpE2XyuHJkye54spa/zFbphMGhCAgBHMaZ0NDQzI0NGQa8kpGztzfRkZGksHBQdPRra+vJ+3t
7alCcGJiwnSWulcdlzpDpafUiNPc3JyZui7FhQsXknv37pnv6kj+v/bON0LL7P/jD3++j1asNbJW
loyMJJEk+UqMrK+sLBk9GCtDkozRk5GMJJGVjJXIGBkZkTV6lEhGslaMkZE1YiRZyZJkZR/cP6/D
uZ37zHWdP9d13ff8e7+5zdz3dV3nz+d8zue8r8/582HqirTtdwapIpLj1+GHH35oD1LkW0SUU+UQ
Knus3gzsMzMz5jqfyclJQ57cfA4cOGBILtep+/DwcCUZx4ggZKdMJr4MGMApqy03eVvZ2/vPnTtn
rr179679G2WnbHNzc4YAjIyMmO9+filyKatLStlCdfWRUpZQerF+UtQuZW1+5MiRVS8atDlyLEKK
LGJ64eLSpUut+/fvm/8fPnxo7EpOXqntn6vLgiAiKIgIRpQTjwIEBWMLCbp9+3Zrfn6+FhHE0+MS
S/IoG0RYW2anpS1cwsTAageYEKanp1tnzpwx/58+fdpMefMBDDIMGClE0PVUxDp1TA6hssfqXQS8
Sm4+rgeQtNx1ejkyjg34IZn4MhgYGOhoe/7H0xNLz/cQffz4Mdmw+nIpK2vVsuXAL0sovVg/KWqX
sjaHfA0ODnbcT/oLCwuFaaXIIocIQvx8Hasq91D7V+k3giAiKIgIJign03V4KPBgQAqvX79emQj6
XhQMd9kgwr3+VJM7mOJJ4zcGgImJidLyv3r1qj09xjTs4uKimRYDTFUxXZxCBHPkFrs/VPZYvW2b
4GmB0DKYxjbclHnqUvJKHfBj14vSDXkQU9rB/54jF/d7E2Ur6jc5bZTTT1LK4qbBFDT9wJJKO/Ue
I6xVZOFfD3lOc/MKfc/VZUEQERREBCsoJ0dDuG/ZdYlgaBBJMeIMttbjceHChdL7WF/EFJslgAyM
S0tL7e+9JoKhssfqjYcTLwtrpx4/fmymUWMkw93JmSvjpohgTttXIQK5cqmqlyntX6WNcsqTcs1t
8ytXrrS94ky94t0vQ11Z5BDB3LxyybwgiAgKQg0iCHkqmtJhIXaqobabMyxYx+ROBUHGygw/3jt3
GigEvHyhTnbixInWzz//3J4SttPD9nu3iaAvh1DZY/VmnZR73U+b/633ByDvMsKbI+O6hIC8/GnA
MoJahQikyKXs2SbKlttGofRi/aTo2VCb8xLEZgzWELKZ4p9//ilNK1cWsbrt3LmzdGo4N69YG+bo
siCICAoighHlZDcfi7nfvHljvjN4sHOWBf0WDC6s4bHG3N0EwXNMJ7vps4Ae74RdBM9C9rJBhLzt
gnk+fGdXoQUeF3bfgtjifcrN2qNff/3VfMcjQtlZXF6Ut1+vXCIQk0Oo7LF64820O1AhCPv3718l
w6NHj5qd0jxPWmWbRWJ5NUkESZt2sHnRFpCEpohgTC6hNm2ibC5S2iiUXqyfFD0banPrCTx+/HhH
/y1CTBYx3fblzPQ4SyHAkydPVm0WyZF7bMNPji4LgoigICKYoJwcx4BhZtoFIgU5dN/g2ZXHG7x9
i7ekhvt5DrLjp88aQ9LCM8FOv9AAefHiReNdIX0GHLubFDC1ytore/yGJVZFePbsWcexMXbx/Z9/
/lmYt1+vXCIQk0Os7KF6s2HHbuJhUGXTiS9D5Ip8eR6CEDr+I5RXk0TQvlzgUeYDMeF4k6aIYEwu
sTatWzYXKW0USy/UT4qeDbU54NgW7kuJ/BGSRUy3fTnzAvnTTz+ZZ9B5d1NLrtxj30O6rEFYEBEU
RASlnIKwZQEpwlMpCIKIoCAiKOUUhC0EpkrxloV21wuCICIoiAgKgrAJwbo9potDm0QEQRARFEQE
BUEQBEEQERREBAVBEARBEBEURAQFQRAEQRARFEQEBUEQBEEQERREBAVBEARBEBEURAQFQegFUg6D
3gh5rMe8BUFEUBARLMCnT5/Myf99fX0mMgDxS/m+1jE9Y1EaNnInX0/G4vPnz60zZ86YqA9EayBC
xN9//518fb3KqFf6kyIf+hPRMDjihevEAy6DG4e3W+hFHusxb5EAQTogiAh6IJTcoUOHTPxOYpgC
DqYlPBpnkq0lGVyPRHAzGovz58+b+K82fiukBbKSen29yqhXMo7JhzByk5OT7evEF06N9bwZ9U8D
pSAiKAjriAhCAAncXoTp6WkTTB6PIV5C/6BaSOTu3bvb34lZTBxUPCOjo6Or8odcfvPNN619+/aZ
316/fm1iheIlwRPZ39/f+u2337KJIHFQbVxUyvP06dPgc366tlx79+6N1pP7U+TRVN3s9ampKRM6
zMYtJhZsU9i2bZshKBb//vtvh9cmdj0m31DZkRmxZ5ETMiJWbqqM3N8o39mzZ43Xbfv27a179+6V
Pp8iT3SZtKg7JC7URjH5EI8Yr6EL8iyTnfsp6zux/hbSv7I87ty5Y+IeU5/Z2VljF5BBmXxCfb1M
vkV5F72clukEsHGLuQ6h9mNsp9aDe7Fx3Et6586d6+jTKX3Ybxe3TiG7lFKPkI7G0hZEBAURwWTl
3LNnT6nX7/379yaAPGDqyyeMN27cMAMCuHXrljFcDIgMhAzEBKZ388fQct0GiSfvmZmZtqeEARej
mkuWXCP56NEjM/DmEEG3XLF62mdj9+XULcWwMCDZgYK6lhGJosE2NOiWDcRuWXOv+/INlZ0Xjfv3
75v/Hz582Nq1a1clIojsealB1ugtXu4QEQyVCT2+cOFCO62DBw82Jj/6GjoyNDSU3FeL+k6sv+Xq
H9+Hh4dNWnNzc4Y4jYyMmO++fFL6eki+MVmGdII+53pXKQuksUo9uJeXP8pJWrQL3t0cGfrt4tYt
ZJdS6hGSYShtQURQEBHMUs7Yeh17/dWrV8YLZj0f/N2xY0fbUGFQXa+I9YS4+btvvGXgDTeXCGKc
7cCRUm8/XbdcsXraZ2P35dQtxbD46XbT2Ny9e9cMxlWvh+TrX2eQ9/WmChHEIwMBs3jx4kWQCIbK
dODAgY41fH5aVeV38uRJ4wHis7CwkEUE/fLG+luu/vl58N19QXTvr9LXczzgIZ3gxdRtZ/7Ho1el
Hvzvehvx2tKnc2QYqmfILuXWIydtQURQEBHsChEEhw8fNp4AwJsyb6zuG6rvgUohPkytMGjiIcE4
hgbvMvBGbN/uJyYmsomgj1A93ftD9+XUrYph6ZaxYZ0ohAUPSpXruQQu5tmsmg5EIkeX3N/8PuGn
VUd+gClBd0lFChH0EetvufqX871KX8/R/ZBO+HX078+pB//7hNPPO7cPu7+F7FJuPXLSFkQEBRHB
LOXEkLDmrQi8IbsDFtM0rJMB/P748eOgYYvlz/oc3v5Z00NaTK9UIYLWYFO+wcFBM61XZ1AK1dO9
P3RfTt2aJoJVp4YhL6dOnTLToVWuryciGHq+LqmsKj/3vtR6l5U31t9y9S/ne5W+3hQRzGnnFCIY
Sr9KH/Z/K7NLufXISVsQERREBLOUk7UqN2/eLLzGwuiLFy92/MbiZdZjMQ3qAiIU2mFclD/rd9xn
VlZWKhNBi8XFxeBzoTxS6unfX3ZfTt3Wg0cQTxbrHilnletVB7SdO3dWmhr25cl0rjvVtrS0VJkI
7t+/v4PMMY0bk3dIPkzjuen504BViGCsv+XqX873Kn09R/dDOkHe/pSq68HNJYLYCwuO/EFudfpw
Wd18u5Rbj5y0BRFBQUQwSznxThw5csSQQWv0MMJPnjxpHTt2bNV5aCwKZ1emuzjcEkq7WJ8P390j
Moryh0TZXXgM3AzAVYggb+3sogOhRdVv3rwx07cp6ZbV07+/7L6cuq01EXz27JmZ5i472y52vQ4R
ZNqNaS6AzpVtFom1I1PzHMtiN3ig01WJoL9ZBD0OyTsmH6aCmb6zfWN8fNx8ysAuUtaHWaJQlHes
v8X0L5ZH6HuVvh7K20dIJ+yLq82bY3sgjlWJIOWmjW27nDhxolYf9te/ltml3HrkpC2ICAoigtnK
yZEJeP4wfPZAaQbCokOD8Xzw5lo0/UUavEVznYHa7qQry39+ft4sMidPDBuLn6sQQaZIWL9jj1mw
BtI1klzD0HItJd2yevr3l93XVN16QQRp79BUcux6HSKI7nHmHnKiDdmYUXRfrB0B5/XhaeNYE3Zh
ViWCAFJJOpB80gqtpY3Jh5ctdpeSBhtFIIYh8FLBvTbPMlmH+ltM/2J5xL7n9vVQ3kX2qEwnLLG2
m27Yabu8vFyZCEL0OEgfr+3Y2FiHzcvpw0W/hexSbj1y0xZEBAURQSmnIDQEiElsN6mgAVsQpFeC
iKAgbALgVWQRvj0nD8+NFuNrwBYE6ZUgIigIWwDsEOVcQqYuiU7BlGHoOBhhY2IzxzwWRAQFEUEp
pyAIgiCICAoiglJOQRAEQRARFEQEBUEQBEEQERREBAVBEARBEBEURAQFQRAEQRARFEQE1xYvX75U
KwrCJu17a9m/ZVsEEUFBRLBEOYsiIviREXql2DrOYesYmM+fP5vYvERVoN2JJFEUyYbDnN3QW92W
Td10etVvYvJLlW8v+95a9u/NbFtEPNQeglCLCK4nBVYH2jo4f/68ia9qY61yaDNkxQVn9xH7tZd6
0SQRXEv5pci31+Vey/4t2yJI1wQRwRpE0Pdy3Llzx0Rf4LDd2dlZE0CduKPEvCQmrIvLly+bmK14
JkZHR4N5F3kjbTxOAtUTIJ5g9aE0pqenTdl4hviueJTc68ToJK4oBwan5kEdqB/1nZycXCWPojRD
9SYuqI2bu3v37tbTp0+TrvntEyo3905NTZn40TYeqds2KfGNQ8/XBbKEoLikz/faUKc3b95k626s
7F++fDGxXZFbf39/6/nz56XphPKh/GfPnjW6QUzie/fuBeMbx+QZ0rNc+aXIN9T3quj169evTdxh
5Er9kC2xfEN5NGVLQvJNiZEd0omUvpZaj5iNCsmwrF3cOoXsR12bEUtbEBEUthARHB4eNgPL3Nyc
MXYjIyPmO0YDQ2Fx69YtY1hsqC4GSgLOp+aPMWVAtF4N0sNYh57fu3evMW7cz8CBZ8S9juHl2rt3
75LyoPyEF+Pa+/fvWwcPHlwlDz/NWL1dA/vo0SMT2D7lmptvrNzcy4BiDb3fNim6kPN8bHlBDAzE
DG4uiPBRRXdjZb906VLr/v375n9Cye3atasSEbxx40br6tWrbd04dOhQkAiGyhTTsyryy7nu51VF
r/fs2dOamZlp6yT66eZZlEdTtiQm35gsQzqR0tdS6xGzUSky9NvFrVvIftS1GaG0BRFBYYsRQf8t
8uPHj4X3YvBcrwQIGQ8//4GBATOAuYMZb9Kh5903edZJffvtt6VlT8njwIEDrb/++qv9/cWLF0F5
pNQbw24HHR+ha26+sXIXlSvHQNV9Phd37941g3ETuhsrO4O83z5ViCAeGbcNinQjtUwxPasjv5Tr
RSQtV6+LgPcoNY86tiQm35gsQzqR29dC9YjZqBQZhuoZsh91bUYobUFEUNhiRDA2gLhvkL6HyDVq
sfyL7o15pXxjHvMKxPLwp9NIPzbAxOrN27T1DExMTHQ8G7rm5hUrd4zEVNGFbhm4Dx8+tE6ePFka
z7cKEQxdj+lQ1XRCuhFLK6ZndeQXu57Sr1P7M9OWEM6hoSFDPKrajlxbEpNvTJYhncjta6HvMRuV
K0P/t5D9qGszQmkLIoKCiGAyWcnJv8g4h+pRNnilXq872OfUG2PPFNTg4KCZEky5FiMzOQNG00Sw
6tQw5OTUqVNmOrQp3V0rIhh6vi6prCq/FPmmEsGYXrP2Dc8a6+WY1mfqsikiGMu7m0Qwt6/FiGAo
/VwZFv1WZj+asBkhuyWICAoigqu+s6DYnSLJzZ/n/amM0DEQPL+4uNj+znEZrNcJ1S+Wx/79+zsG
0YWFhajxzKk35S2Tu3/Nl22o3BvBI4iniiNOVlZWWk3qbqzsHEdTZWqYcvrTuW4bLC0tVSaCMT2r
Ir9U+aYSwZhe09fc67686hDBWN51iWBIJ3L7WowIhmxUrgxDdfPtR5M2I2S3RAQlF0FEsP0/i5Pt
Yno+fGenWhnYycYaFWusuP/mzZvt5zkOI3SmHHmTPgMq94+Pj5vjR0L1i+XhL+In/ZhhjtWbN352
4AF/QXbomi/bULnXOxF89uxZ6/Dhwx3r4npFBJl2Y5oLPHnypHSziLs4nt3LLKR3r7Oo/8qVK23d
OHLkSGUiGNOzXPnlyLeo71XRa3ab2h2ukGLIrZtOLI86tiQmXz9vHyGdyO1rMSIYslExGcbqGbIf
dW1GKG1BRFAQESz9fvHiRfOWy5snA6nd6VYEdgFyn/uWao874MMOt+Xl5WD5MaJ9fX1mYfPY2FjH
Ibpl9YvlwWDPsRUcEcJOu9hbdKzeTK+w9sce0WCNa+xa2fExReWu6yHpNhFkgXzqVHLTRJDjOjhT
D/kiazZmFN1nBzvaggGTtvDTvn79ullwj36gG1WJYEzPcuWXI9+ivldFr+fn580GDmQGaWBjgZtO
LI86tiQm3yLb4iKkE7l9LUYEQzYqJsNYPUP2o67NiKUtiAgKm4AIqgPGwYAR2+UnCNIzQSRBbSwI
IoKboAPi7WFxtD2/jDdqLZIWpGeCSIKgNhZEBNcZuhFPlJ17nBdH2kQNYCondAyHIEjPhF7aKEFE
UBBEBAVBEARBRFAQEZRyCoIgCIKIoCAiKOUUBEEQBBFBQURQyikIgiAIIoKCiKAgCIIgCCKCgojg
+sPLly/X9Pn1ksd6zFsQBEEQERQ2IREsij7gRyHolWLXPVqhF0czrOXxD7G8OemfE//37t2bbbA2
u/EifmtOpA1BEAQRQWFLEMH1pMB18+9F+ddSRrG83di4Ml6d4LBmQogJgiCICAoigpn3+J6jO3fu
mEgIHHw7OztrgpkTA7SIiFy+fNnETyW25ejoaDDvIk+NjY1J0HiCtRM4PvV5/hIfk5ieHNabUqbX
r1+bOKbkR336+/vbQeDL8mhKHqQ1NTVlAs/beJ72+Zgnq+h6qC5F7RrSA/96rlxTYhuX1b0JEMf3
5s2bshKCIIgICiKCdYng8PCwiXowNzdnCM/IyIj5zsDNAG5x69YtM7jbsFn37t0zwd9T84dQTU5O
muf5kB6B0lOf5/u5c+fMszZAfaxMe/bsac3MzLTzJH8ITyiPpuRBWhA3S3b951PIlIucuuQSwVy5
puheqO4x4hub6j1x4kTr6NGjhqjSRrxgCIIgiAgKIoIViKDrleM766+K7mWtGsTAxffff5+c/8DA
QOvLly/t7/yP5y2HCPoexNwyATxUqXnUkUdReXPW8aW0cVldcolgE3KNtVWTBrWvr6919+5d8z/l
vH37duvSpUuyGoIgiAgKIoK5RDBGvizw6PgeG5eIxPIvujfmJYrVJ6VMTHtCEoaGhgwZrVr/XHmk
ELDc9kutSy4RrCLX3LJ306BCBiGHgiAIIoKCiGCXiGAOEShKq4j0heqRQgRjZZqenm7t2rXLrPt7
/PixmfpsigjG8m6aCObUpS4RzG3rukQwd2q4CHXLLAiCICIoiAgGvu/evbtjmjQ3f573p4ZDR6ik
EMFYmVg/5l5fWVlpjAjG8m6aCObUJZRPTAZV2rouEcwFSwo+ffrUoUtsnhEEQRARFEQEu0QE2exx
9erV9mYFvrPztwzsbmWdmCV/3M9OT/v8r7/+2tq5c2fy80X1iZWJXat2Z+3S0lJr//79HenE8qgj
jxgZ8vOOtV+sLmX/uzt237x5YzZxxIhgblv3mgiOjY2ZXc22fGxkQZ8EQRBEBAURwS4RQXDx4kXj
mcKTB6Gwu0yLwODMfa7Xzx4fw4cdw8vLy8nPl9UnVKb5+XmzyQEyxLTq/fv3O9KJ5VFHHjEyVCSf
UF6xupT9b3fsMnUK8eag6hTPZG7dekkE//nnH7Obm7JxzA+kVRAEQURQEBEUBEEQBEFEUBARFARB
EARBRFAQERQEQRAEQURQEBEUBEEQBEFEUBARFARBEARBY60gIigIgiAIgsZaQURQEARBEASNtYKI
oCAIgiCICAqCiGANvHz5clPlI2wtvRKkPxtRR9U/RASFLUwEicFKBI++vj4TUeLbb7813/3YsVWi
Q1SBHzmjWx0rFLdY2HzYaO39+fPn1pkzZ0xUHcr+008/tf7+++/29b/++qv1448/mmuEH+T6+/fv
u94/66aTEz+7m/LD7hGtiGvEoh4dHe24vhb6s5Y6KnsoIihsUSJI3NpDhw6ZkFsfPnwwvxGL9fff
f28dPXq0gwz2SsE3Wz6CDHQVnD9/3sRDtvGReTmDzFgcOXKkNTs7277O//TZ9S7HXrVDTH6EHCRs
o71OXPMTJ06sabnXUkdlDyVHYYsSQQjgL7/8Unhtenq6denSpY403r59a96i8UAcO3as9eLFi9I8
Ll++3Prqq6/MGzlv2z4Bten09/e3nj9/3k7D/djfeHvHU0nMWD+d3bt3J+Xpy6Mon5j34s6dO8Z7
QLxaBl5kR3xdPKnE6HVh4yRTx//+979GdqH28POCjH/zzTetffv2ldah6J6QDIgbbOMII7enT592
pEebUz+ePXfu3Cp5x+o0NTXV+u6770z6vkxCeee0XVndX79+bWIcUzbyQa9+++230vaO5ZniAQ/V
ty7QMQiKxb///tvhtSE/H0W/lelXqOxl/bMonVA+lP/s2bOmj2zfvr117969YLzrmDxpL9JCNpOT
k8E2ismP/93r/E/aOfYit//l6miuzYnpc5l8y/qHICIobAEiuGfPnlVTwBZMMw0MDHSkceDAATMl
hdF88OBBa3h4uDCPW7duGaPDfRhgBgDevi0gmPfv3zf/P3z4sLVr167SstrvTPP4pPXGjRvG+KXk
GZNJCjmjvqQ9NzdnjDFeBb5jUN1BmHIyUFlvA2VjYM3JCyLGs+/evSstv39PTAau8X/06FHr+++/
70hv7969htzxPHLFq5JTJwY5Sw59mYTyrtJ2ft3R5ZmZmXb5KCuDdJnMc/MsKkOovjEykTvoQs7c
+liPoAX96fDhw8lEMFT21P4Z02P6Jy+byBh7wuxDiAiGykRbXbhwoZ3WwYMHa8nPJ4JcD02PFtmL
3P6Xq6M5NieWd0y+IjAigsIWJYKxdSHuddJwPYAYHIhDUR787hpZ4A78DCz+9RhBe/XqlfEK2uf4
u2PHjrZhi+XZBBH0PWBlU+cQaAYWd5Dhrb5qXmXl9++JyYBBxw7wRem5nh/WWCHvnDr55XHrFMq7
StvF5APwfJTJPDfPlDJ0cxC4e/duh4ee/oCXyBJK/ue3VCIYKntq/4zpMZ4yV2ewHyEiGCqTfQkt
SytXfrzEMB1MPfF889Lj6kuKvcjtf7k6mmNzYnnH5CsCIyIoiAgmEUEfZW+U/O57PlyDlzqF5X/H
48FbL+DNmjfc1DybIIKpzxflG3v7zjXKZe0RkgGeOOv5m5iYWJWeP5C4Za5bp1DeddvOgqk6Bvuh
oSFDXEMyzc0zpQzdGgRYv3vy5Enj6bFA9/HSWu/S9evXk9e4xcqeM8Wckw7lDBHBUFq+rfLTypUf
G0P4jTLu3LnT6GeuRzC3/+XqaM73WN5N2BxBRFDYhESQQZn1d0XAI+SuvytKo4woxgbUqkSQaSrW
1QDK9vjx4+Q8e0kEi+qXM+hVJYIpMmAgQo6Dg4Nmqi2V6NetUyjvum0HWN+IJ4s1VegF03Wh8uXm
WZcIVp0ahrycOnVq1Y7gojVurD1bz0Qw9HxdUpkrPx9LS0tmHWMdexHTqVwdrfvyWce+CSKCwhYh
gngUmB4pAouYL1682JGGO/XElI87dejmAUkrW3sIeAPPnRq2YLEza4+YFnYRyzM3n5WVlcpGmrL4
06gh72osr9Q2zZHB4uLiqjz5zfWYuIvnc+sUqoefd922A5TVTSMm09w818IjiCeLtbHUxYdP+uhP
bBJogsCl9s+YHjOd6+oMZKsqEdy/f38HmVtYWIjKOyQ/H6x5xktXhwjGdCpXR3NtTihvEUERQUFE
sPRtmUXnkEFrRBgAnjx5YnYFu+dqkQbHU2BcuYdF4GWbRSCYdpE4H76zy9SCqRGmYgB5uYvRGeBY
y2IHEL/sLIDmzd1f2B/Ls2ggdfNxNzO8efPGTL1VNdKWYNuycIwFg6vr3cjJK7VNYzJAzuzeBUWL
xbmXwZZnx8fHO6YaY3WKDTShvHPbrigvXhDsDkwIB8TBvc9v79w8e00Enz17ZpZCuOviXLBRAc8S
fZjy83LEDt0miGCof/peupAes3zjypUr7Q0e2JqqRNDfLEJbheQdkx91gvwBdvPipXbXQMfsRZX+
l6ujuTYnlHdMvn7egoigsEWIIGChNJ4/jJQ9UBqD6x+uShrsTON4AjxBkMLQkSikyRsw9zJAuLtf
yZMzvciPdTKuAYbg8Yz1NvnpQkS5VjTVE8rTh5+PJSdMsUBwIC113tbtUSt8WJi+vLzcvpabV06b
hmTA1CzytsdHWGJm02OQ4mBxNnaMjY2t0oFQnWIDTSjv3LYrymt+ft4sjidtBnk2prj3+e0dy7PK
AepNDgL0w9BUMn0IMmjrBAn0j/upSgRD/dO9L6bHgLWLbCrCbmA/qhJBAKkkHV4ESSu0pi8mP+rE
Zha7RrBsI1OqXUrRqVwdzbU5ufoc6x+CiKCwRYigOoCg9hM2GiCr7tIUQZAdFUQE10g5mYawhwUL
MmCC0A3gVWSjkT0nD++0u+FIEGRHBRHBNVJO1pKxvqTJqApC76EpIWE9g122TOWip5yZyNIF9zgY
QRARFEQEpZyCIAiCICIoiAhKOQVBEARBRFAQEZRyCoIgCIKIoCAiKAiCIAiCiKAgIigIgiAIgoig
ICIoCIIgCIKIoCAiqA4nCIIgCBqXBBFBQRAEQRBEBIVNTQQJME7MWA6E7u/vbz1//rzjuo0ty3UC
mPuxhQl6z4n/HPA6OztrAp0T69INRm/vnZ6eNveSHjFS3bioBH0nNib58CxlscHZ7fPEqiUGLofK
+nWykU2Iebp79+7W06dPs+pBQHtiLds4uG7ZY2kLgiAIgoigsCGJ4KVLl9rB1gnfRCB0C0jd5OSk
CenEhyDvkEY3zeHhYXO6/9zcnCGAIyMj5rsNRu/eu3fvXkPASOvy5cut8+fPt6/v2bOnNTMz086L
fCF97vOQR67ZQOpunVzy9ujRIxPYPacekFBLDv2yh9IWBEEQBBFBYcMSQYgf5KgIAwMDxmNowf94
9Nw0fc/ax48fC/Pkf9fb+Pnz52jAeDxwZXn56UMaLaGtW4+ctAVBEARBRFDYsETQ9XyFiFjR/X6a
oe/87xNOP2+mfvFQDg0NGfLmPx+qE54663WcmJioVY+ctAVBEARBRFDYlESw6FqInMWIYCh91g/i
nWTNIcHlmf7NIYKWSDK9PTg42Lpw4ULleuSkLQiCIAgigsKGJYI7d+4snRpmY4Q/pfp///d/lYng
4uJi+/vff/9t1hRa8L87rbyyspJN1izIx72WW4+ctAVBEARBRFDYsESQqVimPsGTJ09WbRa5efNm
e5PFr7/+aohjVSLIbt3379+btMbHx1snTpxoX2fHrt0lvLS01Nq/f38WEaTc7O4F/maP3HrkpC0I
giAIIoLChiWCHOHy008/GXLDurwXL150XLfHrvBhp+3y8nJlIgjR6+vrM5svxsbGjFfQYn5+3uzG
pRwQLzZn5BBBpm4pvz3+xRK3KvXITVsQBEEQRASFDUkE1TkEQRAEQWOdICKoziEIgiAIGusEEcHm
4W7OEARBEAQRQUHYQkRQEARBEEQEBUFEUBAEQRBEBAVBRFAQBEEQRAQFQURQEARBEEQEBUFEUBAE
QRBEBAVhCxLBly9frsu01jKP9Zh3r8qw1eUrCIKIoCB0lQjye9mnVx3Cva/JY2Z6cWTNWh6L0628
c9q+iTKE8muqjmuti03j8+fPrTNnzphIOZST6EBupJ7Y9RQQQYdIOq5N+M9//tN6+vTpqnuJ3EO8
cK6T119//dVx/fXr1x3hKy38CELdHlg38iC9nsse07ei8YVITSEQ+vSHH35IzgOd+/HHH801q4eE
NFU7CSKCGcq5HhR4oxn9tZRZt/LOSbfbLwybUb5N4Pz58yZmto2fDRFj4Eu9HgMxtRlM+euCMJEQ
vufPn7d/u379emtycrKd15UrV0xccRfE+qYMLt68eWPuExHc+MjVt7m5udbFixeDae7du7f16tWr
5DyOHDnSmp2dbV/n/6NHj8puCCKCTRFBG6uXwQHj/fbtW/P7yZMnW0+ePOnwIhw7dmxVel++fDEx
fnm+v7+/YyCx9/lvjHv27FlVjn///bf17bfftj59+hQlEL53k7/EDSbW8b59+9r3Xr58ufXVV1+Z
+o2Ojq7yZPzvf/8z5cY7QtkZDEN53Llzp/X111+3tm3bZozRL7/8YgZPnvcH1lDepDU1NdX67rvv
2nGO7fOp3tsqdXbTy61/LG0M9NmzZ408tm/f3rp3716yt3o962JR2cvargmgW8jSLYvrwYxdjyEU
U5v2Jy64Bf/jrfGfd8Eg/ezZs47fBgcHW3/++Wc2EUzV3aLf/OvoC8Q1plv22enpadO3uefcuXMm
VntKX6nb33P6ZZkM11IffRtAfyrqNxboik/iYnn4Olf2m4igICJY4R6IjPvGf+vWLTOQgnfv3rX2
799vfscoMijYtzg3vUuXLplpIPDw4cOOaaIyQ83g4U9DYcxGRkYqdUi+Y7wpK+UG1IU0+Q3DAjG5
du1a+xkM1szMTLvuyAFSFcpjeHjYpMVbL4SH8vIdw+sapljepIWxt4OR/3xqm+bW2U03t/6xtG/c
uNG6evWquc60zaFDh7I8ghtFF2NtFyO9ucszILduu+Rez7UXtG0RPn78aMjO0NBQ+zfagkHcBeSL
dkzJy72eo7uxNuUFwCVjId2yz+Klok25Tj3xUqX2lSb7eyyv9ayPyCHmDUSukO6cPKxH0II+fvjw
YRFBQUSwCSI4MDBgOp3bAXkrdjs2AzxGzTWMbnoMtu7bXIqhZpDGa+ACr9bCwkJlIui+4QMMu18u
19tRBHdtSywPvjM4Ft0fy7uovCHvRpkMcuscSzdU/1jatJ+rSy9evMgightFF2Nt1zTu3r1rCG7V
600MZnhk8XTxceXC4Hzq1Kn29z/++KPD25NDBKvoblGb4iX/+eefs3SLZ13vMV5QPMKpfaXb/T20
5m496SMkdmVlJfg8L3RLS0tZefDSxwuHJa38704tiwgKIoI1iGCRgfHfJjFyGM0PHz4Uphd7+ywr
A1MZtjNDGtzpzSpEsKgesUXMDBoYHLwcDBah8uZ8j+WdO82V2qa5+ebUP5a2rwcMjDlEcKPoYqzt
mgT1hISVeeli13PKn+IdYnp19+7d7e+QQOuBZToQubmbSXKIYBN9BpKKjrC2MUe3eNYncr4uhfpK
0/09lNd61Uf6DyQvBqa8y17WyvLA44lX13pJad8TJ06ICAoigk0QwaKB07+X3V14WpoefJlCYqcY
YJrm9u3bjRLB2M41pieoF+v+Hj9+bKYfmyKCsbxzBoayQbpKnd1ncusfSztFl0LXNoou5g68Vafi
GAghWmW7I2PXq9qL0HXydGWMZ8aupWPZxIMHDyrn1USfYXoWbx464hLSmG6VvVSl9pUm+3ssr/Wq
j0WbhnK9m2V5sF7QJY/8D6EUERREBBsggrzd+1Mm7iJddnJhXDFKZdNxO3fuzJ6OA3R2OjMGm0XW
7uLsJoggdXOnbn2wxs+9zpRGU0Qwlne3PII5+ebWP5b2gQMHOnSJ6Z+cAWyj6GIvPDAQXYhp2TRb
7HqMsJdtJvDXl7FOyx2U3SlV1lW6U+pVjquq02dC+oqOuNPDMd3i2cXFxfZ3ji6hf6T2lSb7eyyv
9aiPAA8dyyyqegRDefikj+dZpiAiKIgINkAEcbfzJmdd7gy2DKaAN9GDBw92GDt2AvrpMYXBuVCA
nXplC/TpzKxlcQ0y3pfjx4+bTQ858NMqqh91s5sX+PDdPfqC6UC7Gw/SwrRGqLw5RDCWd8x4F8kq
pU1z8s2tfyxtFrjjWbObRVjgHdLNovQ3gi52e+BlVyUL4f3z+lKvx1B2fAw7ifnd3VGMh2diYqLd
JuPj4+Zjr9FeTXkfY/rlEliOp2G6MPbiwprFmG7ZZ8kLvbX1dKceY32lbn/P6ZfrTR8tWBNpN62F
QH1YfpGTB30Sco/HEPmyVpgTCkQEBRHBBoigNeh2ITiD4fLysvmdc5zcIzv4H+Prp4f3hHsx1Kxn
cTu5ex+L/HkLd9/EWaDNPX6kh1id/LTK7mcHG2/Y3EfZXUM1Pz9vjBflhjD4B+DG8oh9D+UdM95F
skpt09R8c+sfSxuwdgePEV41NneE2rEo/fWoi70eeNmkEPKqxa6nlMd6/tznizyFDLwMwsiJNnGn
/tAZjjppigjG9MuWmalFSByENXZ8jHs0UJlu2WchX319fcYLOjY21nGgcayv1O3vOf1yvemjS9RD
a/8s8OZjG3LyoF9bPeQDCcyZQRIRFEQE1zEwlrwBC4J0sTmcPn1aDaoBfl2CFy7/UHLpiSBsUSLI
2yNv0Uw9CYJ0sTnkHCcjaIDvNdjZvRHjfUtPBBHBhsF6JM4cWwsXvyBIFwWL9Rx7ejOCaX7W44oI
CsIWJ4KCIAiCICIoCCKCgiAIgiAiKAgigoIgCIIgIigIIoKCIAiCICIoCCKCgiAIgiAiKIgISjkF
oSfYiMdbCIIgIiiICKrDNQSiA7jRLFJBxAM/agPHkxCb1QfRDohGwHUiYvghlojc4IZJs4hFG9gM
KKt7r/TOP1JkI8v78+fPJo4rUTWoF7rmRs4gtm1OjGBAKL8ffvghOQ9w79691o4dO8x1Qo258X1l
v2S/1K6CICK4rvDq1avWvn37sp4pi+NK+CoMJqfqWxCObXJysh2flDi9/on7xEd1w3oB4qxy32Zv
96K6y+hXA2G9iK9rdQ25MnBbPHz4sON7CjgUmD6Smgdxfw8cONBaWVkx14lN3WuiL/sl+yWbIGwp
IvjlyxcTU5OO3d/f39GJ7dscb+9cp2O+ffu2I02CfBM3dtu2ba3Z2VkTSB1j4Mck5d7p6WlzL+kR
E9I9mJe3Qt5OyYdnKYsNqm6f//33302MT2u43DrZN1RijBJI3n8zjdVjamrKhA7jeb/ssbQ5ZJiA
6KkgLdIsAnUmhqgF/+NF8Z93ceTIkVX5Dw4Otv7888+kOK6huqe0S0jXYrK7fPmyiTlM24yOjq7y
FITytnV//PixiUPqH/SMbpNnN3TZ/vU9Y35s2JBsbf3JgzwZMGPxYmPp1QFlcOPAEkPY9XgyiDNo
pwKdpG/k5DE0NGTIQypkv7a2/RIRFIQGiCBhpnDB2zd+9+0bo+i+zREEHKPrpjk8PGyM+dzcnDGg
IyMj5rsN/u7ei3cAA0ZaDIB4BywI/M7bv82LfDGa7vMYX67ZQO1unVzjx3SUa4xS6oERt8bVL3so
bcBg4talrqFAfkVgag65MVhaMBgxiLlgwKa+KXnF6p7SLqH6hWRHOzCAkS51Zkrw2rVryXm7dWe6
kXZ2cePGDSOvbuhyWf39ayHZUvcLFy6Y8rx//7518ODBKBEMpVd0f+5Urk+yXHmfOHHCkAaIO/KJ
eWLpE5CnnDwgMznrLmW/trb9EhEUhAaIIIbTfUN3MTAwYAy1a7R5I3bT9N9M6exlg6L7ts5bIl6c
EHiDLcvLTx+jaweEuvXISRssLS2ZtUzdNBQnT540HgE+CwsL7d/xYpw6dar9nak11wuTQgRDdU9p
l1D9QrJjYPV1zx+kQnm7dWeKC32y6fGXdWa2bk3rcioRDMmWKVB3vdSLFy+iRDC3rerg7t27HfGI
+/r6zG9Wvrdv3w7GK6ZP0Ddy8oC0QFbwqNk1Zf4aQtkv2S8RQUFokAiGPAquISu6PzQIFhlS32D7
eTN1wqDAGyPGLzTg+r8xeNi39omJiVr1yEnbDooYuDqGItVrgxfGne7EiFoj/+nTJzPt5JKLFCIY
+61b7eIvNufjt1Uob7fu4PDhw8bLBvDO4CXpli7n3lf0m7/RBD2KEcFeDTofPnwwg3eZd8eWF3JY
BohcGUkry4P64N2FkFnvl+tBkv2S/RIRFIQeEsGia6mDYMqg6KbPFBJv90xTsOaL6ZMcQ2oNMdND
rC9hyq1qPXLSTpFjrqEIXWfQdPNiWsWuVWKa68GDB7Xzcn/rZrsUDXAuYnm7dQfkgScJMNjwTLd1
uQ4R9MvUNBGsOjWMjjFAM10dQ6gNQ9fK8mB61vV+IROfMMt+yX6JCApCg0Rw586dpW/tDKb+lIRr
lHMNqXsMBNM9GH13AHCnZdg1mGvsLMjHvZZbj5y0rXHLeaMOLfL31/cwreMOlu60EIu+Meyxgb8O
uchtF/96rF3ctH2E8vbrbsEaM9YGMi3cTV1ugggyHee2LVNma+0RxEuHRw5Z+0Dv8Nq4MrTEO8cj
GMrj2LFjq8gx6ZRB9mtr2y8RQUFogAgylcHUAeA8KX+xNbsE7SJljn3A8FY1pOx2wyiQ1vj4uFl8
7g7gdpedXbOSY0gpt93J5huj3HrkpG0H8Jw1NmXHL5AHv7s78phKYTrHlh258bHXYrs463oEY+3i
Dgoc+cB0bE67XL16tV03vrtHS4TyLqs7m022b9/esemkG7rskh3WZ9mBOkdn/c0iseMyuk0E2bnJ
9Lp/zpvF2NiYWexvZYiMkWMZaC/WPebkwTQhH5sHbRbqW7JfW9t+iQgKQgNEELc8C7IxDqxr8Q23
PbaADzvVlpeXKxtSDCVrinhLZFBxF4HPz8+bjQKUA8PlHyYaM3ZMfVB+e3yCf7xBTj1y02bRvL/r
LmYMrEF233qL3rR5W2e3IR4Ayu7u1EROHFvRTSIYaxdbD2TD4IRscmR38eJF402hfpBIu6MylndZ
3fE2kVbRtGaTuuwST/KzHppcLxA7JNmFC3llPVxoGrTbRJDNDyFvDLaCXbWUkSk9SHwI9AnqlJMH
gBxgI6xOcIxIGWS/trb9EhEUhAaIoDpHfRw6dMgYWxenT5+WRgpZgNTEdqJuJLDL1j88eMMaV9kv
QboiiAiqcxSBaSB24/kIHashCIC1Uizgt+co4i0pWsi/kUHf2AzxmGW/BBFBQUSwJkJTXhsZx48f
rxSrUxDYXcpxGXaqlenG0HEtGxFMFdJHNjpkvwQRQUFEUBAEQRAEEUFBRFAQBEEQBI21goigIAiC
IAgaawURQUEQBEEQERQEEUFBEARBEBEUBBHBKljL4yY2w1EXgiAIgoigICK4YZWzqaMaUuvs3ree
j4n4/PmzidHKCf2Uk4gKbnQDwFl0ROog1BPXy0J5WRCe64cffsjKw8KPniCD3jyIrFHleA+iR/iR
H9AJ4rv6iOkM0R/c0G1Ntv960Z+NoMccOO6Glsu9LkiXBBFBdaQN3okJA0WcURu3kwGcgdvi+vXr
rcnJyfZ1wpfFIjtwmOyrV6+S87AgrnAsNq5QH7QNZw3moCwWLCHSIHxE/MjRGUK+uaHBmmx/6U8a
OF+S2MZl8opdFzSGCCKCpcrJ71NTUyZouo1F6Q8gBJonHipeotHR0Wi6foxNwhcRn9Md0GzsTAYs
BpS3b9+27y+KQVp2/8mTJzs8JnhCjh07tqocX758MTE6eb6/v79jMLT3+Xnv2bOn0OASBuzTp0+V
ZFkHHDrMYO2WxfVgEusUj54LP8C8i2fPnrWOHj2alYfF4OCgiQEbM3ohuYfa1crzzp07JgIH5Zqd
nW398ssvhsz4suXe6elpcy/pEd8UD4kFXi28a+TDs5QFYhTSU7du1sNGu+7evXuVZy1Wj5BexNKm
jWirVBTFk3XJIHqSozNHjhxZlX9q+6fIPUeOoTaO2aoUG5BS5l73e4AsIN9l8o5dF0QEBRHBIBHE
6FmDa4OJWxA0HiNnw2Ddu3evde3atSwiiMHm+Xfv3pnfGMxdLwR5ZNZxYAAADVJJREFUYKDL0gzd
T5r79+83vzMoMLBZD5ebDiGTmMoChPVyp7rKgsMzAPqDMrIYGRmpJMui+4s+qWBgg7gU4ePHj2ZQ
HBoaCnoYGVhz88BrRHukGL2Q3FP0YHh42Ojd3NycIYDInu++bLkX7yayJy3qTv0sIPUzMzPtvMjX
rVeRnrp1cwd3ptNdMpVSj5BehNIGkGG3LnUHorLoJUU6Q5+ChFdt/xS558gx1MYxW5VqA2JlXot+
TxSakLxj1wURQUFEMEgE3bdu/14Mr+shsl6EHCLopz8wMGAIhks2eMsvSzN2PwPAjRs3jNF3BwY3
HYy+X48YEWSwwPPhAm/RwsJCJVk2jbt37xbGBMVLikeET1lZAQSaWKM5efzxxx8dXsRY/UJyT9ED
3yMEWSlrN9fDg5cLz20IeG9S2w4iYElE3XrkpA1oI9qqmwNRmc7ghT116lTl9k+Re44cQ20cs1Wp
NiBW5rXs97F0RUJEBAURwUpEMPSbv+CcT5khjxGrkFH1vTs599tBgEHjw4cPpfVIkY2fN9M91sP4
4sWL4HqtmCyaBPVk8A7FpmWajanGMjD1VTYwFuXBdDj1dzcTxOoXknuuHoS+879fFz9vpn4htXi8
IB0xPXV/w1NnPVITExO16pGTNqBeELQ6A1Gq98nXGUigJalV2j9H7ilyDLVxzFal2oBYmdey34sI
iggKQs+JYOhNuCoRLDLIoWdi9wN2vvLG3zQRZBqMXbSAaarbt283NiBUnRqGmDFAv3//PnpfLhEL
5cE07YMHD7KMXij/XD2IEcFQ+kyBox9MszKNxvRvDhG05MB6iS9cuFC5Hjlpp8ixSbLg6wzTwnYd
XpX2z5F7FTm6z8RsVaoNiJV5rfq9iKCIoCCsCRHEO+BOx8WeX1lZiRpv0vSngNwNCf4zsfvZ5cra
IH8tlZsOxyrkTg0DiBCeM7wgLEL3F6f32jMA0YWYImcfTDG6xM2fWkv1CJblUTaAheoYknuuHsSI
4OLiYvs7R96wptCC/109TtHTsnqRj99HcuqRk7YlZzkewdBmBX/9WkhnWB/rLo2o0v45ck+RY6iN
Y7Yq1QbEyiyPoKA2ELYUEWQB99WrV9sLp/nuHi/hDjrsWmPRdGyAJQ2OpLBpQuTc868gKKy5sYNC
6H7e1g8ePNgxGLCb0c+baR6m4AC7jMsWivt5W0/g8ePHzWaCXBk3aRTYuXn48OHSswGZ1mNq0cpp
fHzcfMrAujOmu3PyyK1fSO4xPcglguglpMbWneM0LJjitzs/7Zq7HCJIue1OXJ9M5dYjJ23Amr2c
NYJlx8eQB7+7O4pDOsM16lWn/XPkniLHUBvHbFWqDYiVWURQUBsIW4oIgosXL5q3ZN7OIXp2V6U7
cDEtg9FmkIkNsHaQsYvTIVrLy8vta2z6IC/XG1B2P2fcucfH8D9l9PPGk8e9lJU1Py4Bcu8rypsF
6twTizrS7QGBhfEhbwyeI8gqZUdO/tlvPvCestEmJ4/c+oXkHtODXCLI4N3X12e8XGNjYx0HYc/P
z5uNA5QDAuAfhhxrO6ZuKb89HsQ/niWnHrlpsxzB3zUck7vtl24bFnkKQzqDnDhKpc6glyv3mBxD
bRyzVak2IFZmEUFBbSBsKiIoxMFggpdgswGCGztwWsZ37XHo0CFDFl2cPn1aA6wgSE8FQUSw22CK
CS9D0W7OzQB2qm6G+MqbVb+ZmqSNfBQdG6QBVhCkp4KIoJSzYbCminPTQptENjKYKmT940bHeo4R
XQe0TZVYw5sRm7WNBRFBQRARFARBEAQRQUEQERQEQRAEEUFBEBEUBEEQBBFBQRARFARBEAQRQUEQ
ERQEQRAEEUFB2DxEcDMcXyIIvdbptew36rOCICIobCIi+OnTJ3NWHlElOE2fv5zwH4rbWbeDuP93
81gIojRQp6Kz2EJlij23XsExN25YLovPnz+b+MFEbEDeRFjwozJ0w5jVTSclSk0v5AfoE0St4Egh
5BcKw9eLo07W8jiVzXyUiwZyQfojbCkiSExdYvUSo/PDhw/twZCwVsTYhCR2u4N0s+MUhdVKyTv2
3HoE4cKIvVpUJ0KUEbvVxmGF1EBm1rtR7KVRDcnv+vXrrcnJybb8rly5EozK0otyr+WAo8FOENQ3
hE1CBBngCM5eBMigG8EgFlOTuKTE98RjApHq7+9vB2/377X/+zFt9+zZUzhA46UsI6U2Pin5Mji/
ffu2MO2YXMrKZHH58uXWV199ZfIaHR3N6vxcn5qaMqHqbEzZpokmdX/z5k1hWbZt22YIjCvTkFfH
l0uo7LxMEBcW+dPmhK4LybcsH8p39uxZ43Xbvn176969e6XPp8iT9iIt6g6Ji7VRSH7EnsWr6r8s
lMnO1x/+EiaOGLn79u1L0qlQfyrL486dO62vv/7a1Hl2dtb0bWRQJp+QPpfJN6VfhXQi1Gdz68G9
09PT5l7SI26ye/h7ik3y26VoZgAZ7N69u/X06dOseoR0NJa2ICIoCD0hgkx9lk0Bv3//voOYxQZy
7p2ZmWl7TRh8MbAxUuD+f+TIkVUGEWM6MjJSWEYGCNdTc+vWLTMA5RC0FNJCupSDPCBRkJRr165l
GQcGJDtQMCCUEYmiwTY06Fo8fvw42RAxULttE5NLqOy8LNy/f9/8//Dhw9auXbsqEcEbN24YzzQy
RveIsRtqn1CZaKsLFy6008Lr3ZT86C+QqKGhoeT+xndICuUhdnWKTuX0J/t9eHjYpDU3N2eIE/2G
7758YnnH5BuTUUgnUvpsaj24FxtGOUmLdsH7nSNDv13curnk7dGjR+aFIKceIRmG0hZEBAWhZ0Qw
ttaHN93UgbwIvO3mkC4GjcHBwY40eFNfWFgoTH9gYMCQGpfg4B1omggy2LgeNeslyjEOrregmwYj
Jd27d+8G49X6sgiVnUHel00VIkg7u2354sWLYPuEynTgwIGONXx+WlXld/LkSeMB4lOmk2UkzS9v
FZ0q609FefDdfclz74/lHZNvTJYhnUjps6n14H/X24jXltmDHBmG6glptIS2bj1y0hZEBAWhZ0Qw
5JXCkOcSQaZZIBh4SzCUKUTLT4OplFevXrUHcHcqLWTUi+rUFBEkTd87V5R3jvzXigiyFhRCg4cl
Vy5Fv8U8m1XTQf9S28f/zX/B8dOqa8iZEmQ6L4cIFulpTKdS+1Pu91jeMfnGZBTSidw+G/rO/z7h
9PPOkaH/G54663WcmJiobXtS0xZEBAWhZ0SQDSFMnRVhaWnJTKmlGjbW6uAJYH0P02xMtVQhgizE
Z4crYKqFtYo5A07OgJVaphzS1wQRrDI1nJIu5O/UqVOlbb6eiGBO++SSyrqGHDmm1rsszZhO5fSn
3O+xvLtJBHP7bIwIhtLPlWHZy62dqWC5QR3bk5q2ICIoCD0jgqxzYV2WBdNdLNhnSgMSxjqisjRW
VlY6fmMtjzuF419PHdQhKXgimdpjMbu7+NsHXhl/esb1BjVFBMmnznE668EjiCcQgk275KQRKzvH
rVSZGvb1g+lcty15EalKBP0XHPS6DhFkGs9Nz58GrEIEYzqV059yv8fyrksEQzqR22djRHBxcbH9
nSORkFtVGYbqRj6+DHNtT2ragoigIPSMCGKs2aDx4MED851dkxBADBpkzJ0+dBc3cx8Lod10mdK1
O/IYxBmMUwZy8oF4ukaVMhw/ftws5A4BInvz5s32gm2OSHHPgWuKCFrCbPPhe+j4kPVGBJ89e9Y6
fPhw8Oy7qkSQaTemucCTJ09KN4vE9IdF/XiD7QYP9LIqEfQ3i9BWdYggU8FM39n2Hx8fN58y+Dpd
lGZMp2L9KZZH6Hss75h8i/qsi5BO5PbZGBGk3LSxbReOAKpik4p+o9zs7gX+Zo8qtic1bUFEUBB6
RgQBx7IwaO7YscMQQAwUholDpt2dkdZYMa2EwcOIuenOz8+bBefcQxoshE4ZyNmtSL7u2zQLwLkn
JYKBPcKBDwRyeXm5cSIIkAceBsoJibG7DHPzWQsiyAL6nKnmnMESjy1nEtLurMFiXWfRfTH9ARxn
hKcNTzC7MKsSQQCpJB2OoiGt1EOQi9LmhYiXEtJAz9C5EHydLpN1SKdi/SmWR+x7rj7H+qyLkE7k
9tkYEYTo9fX1Ga/t2NhYx0HpOTap6Dembim/Pf7FEreqticnbUFEUBB6RgRDYHfpWoBBibd5QWgC
EJPYblJBg64gSCcFEcF1AKZZ8FZoJ51QFXgVWYRvz8nDc6PF+Bp0BUE6KYgIbgCw/ujo0aPBTSKC
EAI7RDl2iKlLolMwZRg6LkfYmNjMMY8FEUFB2LJEUBAEQRBEBAVBRFAQBEEQRAQFQURQEARBEEQE
BUFEUBAEQRBEBAVBRFAQBEEQRAQFQURQEARBEEQEBRFBKacgCIIgiAgKIoJSTkEQBEEQERREBKWc
giAIgiAiKIgICoIgCIIgIiiICAqCIAiCICIoiAgKgiAIgiAiKIgICoIgCIIgIihsGiIoBRUEQRAE
kUBhCxNBKaogCIIgiAQKW5gIWoXVRx999NFHH32a+QjCesD/A68GxsSE8naDAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-05-25 17:10:02 +1000" MODIFIED_BY="Melina L Willson" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAYQAAAVRCAIAAAAPY2kLAABaW0lEQVR42u2dsU4jyfaHW0JCBAQE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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Figure 3b.fw.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-11-11 12:36:31 +1100" MODIFIED_BY="Melina L Willson" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Summary of chemotherapy regimens used in the included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyAAAAMsCAYAAACsssYTAACAAElEQVR42uydB1hUR9fH10RjorH3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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-05-25 17:10:02 +1000" MODIFIED_BY="Melina L Willson" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Overall Survival, outcome: 1.1 Overall effect: Taxane-containing regimens vs. not.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA60AAAMACAMAAAD4+XHdAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-05-25 17:10:02 +1000" MODIFIED_BY="Melina L Willson" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Time to Progression, outcome: 2.1 Overall effect: Taxane-containing regimens vs not.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA60AAALwCAMAAABLHGNwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-05-25 17:10:02 +1000" MODIFIED_BY="Melina L Willson" NO="6" REF_ID="CMP-004.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Overall Response Rate, outcome: 4.1 Overall effect: assessable patients.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAw8AAANgCAMAAABdoKRrAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-05-20 07:56:50 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-11-03 11:00:45 +1100" MODIFIED_BY="Melina L Willson" NO="1">
<TITLE MODIFIED="2014-11-03 11:00:34 +1100" MODIFIED_BY="Melina L Willson">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-03 11:00:45 +1100" MODIFIED_BY="Melina L Willson">
<TABLE COLS="2" ROWS="36">
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>randomized controlled trial.pt.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>controlled clinical trial.pt.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>randomized.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>randomised.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>placebo.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>randomly.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>trial.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>groups.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>advanced breast cancer$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>advanced breast carcinoma$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>advanced breast tumour$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>advanced breast tumor$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>advanced breast neoplasm$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>metastatic breast cancer$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>metastatic breast carcinoma$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>metastatic breast tumour$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>metastatic breast tumor$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>metastatic breast neoplasm$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>taxane containing regimen$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>taxane containing chemotherapy regimen$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>exp Taxoids/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>exp Paclitaxel/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>docetaxel.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>taxane$.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>taxol.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>taxotere.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>29</P>
</TD>
<TD VALIGN="TOP">
<P>paxene.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>nsc-125973.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>anzatax.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P>4alpha.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>7-epi-taxol.tw,sh.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>9 and 20 and 34</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>limit 35 to (humans and yr="2010 -Current")</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-11-03 11:00:56 +1100" MODIFIED_BY="Melina L Willson" NO="2">
<TITLE MODIFIED="2014-11-03 11:00:47 +1100" MODIFIED_BY="Melina L Willson">EMBASE (via EMBASE.com) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-03 11:00:56 +1100" MODIFIED_BY="Melina L Willson">
<P>
<B>#41</B>
<BR/>
<B>#40</B> AND [humans]/lim AND [embase]/lim AND [2010-2011]/py<BR/>
<B>#40</B>
<BR/>
<B>#8</B> AND <B>#19</B> AND <B>#39</B>
<BR/>
<B>#39</B>
<BR/>
<B>#37</B> AND <B>#38</B>
<BR/>
<B>#38</B>
<BR/>
<B>#26</B> OR <B>#27</B> OR <B>#28</B> OR <B>#29</B> OR <B>#30</B> OR <B>#31</B> OR <B>#32</B> OR <B>#33</B> OR <B>#35</B>
<BR/>
<B>#37</B>
<BR/>
<B>#20</B> OR <B>#21</B> OR <B>#22</B> OR <B>#23</B> OR <B>#24</B> OR <B>#25</B>
<BR/>
<B>#36</B>
<BR/>
<B>'7 epi taxol'</B>
<BR/>
<B>#35</B>
<BR/>
<B>4alpha</B>
<BR/>
<B>#34</B>
<BR/>
<B>'anzatax'</B>/exp OR <B>'anzatax'</B>
<BR/>
<B>#33</B>
<BR/>
<B>'nsc 125973'</B>/exp OR <B>'nsc 125973'</B>
<BR/>
<B>#32</B>
<BR/>
<B>'paxene'</B>/exp OR <B>'paxene'</B>
<BR/>
<B>#31</B>
<BR/>
<B>'taxotere'</B>/exp OR <B>'taxotere'</B>
<BR/>
<B>#30</B>
<BR/>
<B>taxol*</B>
<BR/>
<B>#29</B>
<BR/>
<B>taxane*</B>
<BR/>
<B>#28</B>
<BR/>
<B>'docetaxel'</B>/exp OR <B>'docetaxel'</B>
<BR/>
<B>#27</B>
<BR/>
<B>'paclitaxel'</B>/exp OR <B>'paclitaxel'</B>
<BR/>
<B>#26</B>
<BR/>
<B>'taxoids'</B>/exp OR <B>taxoids</B>
<BR/>
<B>#25</B>
<BR/>
<B>taxane*</B> AND <B>contain*</B> AND <B>chemotherap*</B> AND <B>regimen*</B>
<BR/>
<B>#24</B>
<BR/>
<B>'taxane containing chemotherapy regimens'</B>
<BR/>
<B>#23</B>
<BR/>
<B>'taxane containing chemotherapy regimen'</B>
<BR/>
<B>#22</B>
<BR/>
<B>'taxane containing regimens'</B>
<BR/>
<B>#21</B>
<BR/>
<B>'taxane containing regimen'</B>
<BR/>
<B>#20</B>
<BR/>
<B>taxane</B> AND <B>containing</B> AND <B>regimens</B>
<BR/>
<B>#19</B>
<BR/>
<B>#9</B> OR <B>#10</B> OR <B>#11</B> OR <B>#12</B> OR <B>#13</B> OR <B>#14</B> OR <B>#15</B> OR <B>#16</B> OR <B>#17</B> OR <B>#18</B>
<BR/>
<B>#18</B>
<BR/>
<B>metastatic</B> NEAR/6 <B>breast</B> AND <B>tumor*</B>
<BR/>
<B>#17</B>
<BR/>
<B>metastatic</B> NEAR/6 <B>breast</B> AND <B>tumour*</B>
<BR/>
<B>#16</B>
<BR/>
<B>metastatic</B> NEAR/6 <B>breast</B> AND <B>carcinoma*</B>
<BR/>
<B>#15</B>
<BR/>
<B>metastatic</B> NEAR/6 <B>breast</B> AND <B>neoplasm*</B>
<BR/>
<B>#14</B>
<BR/>
<B>metastatic</B> NEAR/6 <B>breast</B> AND <B>cancer*</B>
<BR/>
<B>#13</B>
<BR/>
<B>advance*</B> NEAR/6 <B>breast</B> AND <B>tumor*</B>
<BR/>
<B>#12</B>
<BR/>
<B>advance*</B> NEAR/6 <B>breast</B> AND <B>tumour*</B>
<BR/>
<B>#11</B>
<BR/>
<B>advance*</B> NEAR/6 <B>breast</B> AND <B>carcinoma*</B>
<BR/>
<B>#10</B>
<BR/>
<B>advance*</B> NEAR/6 <B>breast</B> AND <B>neoplasm</B>
<BR/>
<B>#9</B>
<BR/>
<B>advance*</B> NEAR/6 <B>breast</B> AND <B>cancer*</B>
<BR/>
<B>#8</B>
<BR/>
<B>#1</B> OR <B>#2</B> OR <B>#3</B> OR <B>#4</B> OR <B>#5</B> OR <B>#6</B> OR <B>#7</B>
<BR/>
<B>#7</B>
<BR/>
<B>groups</B>:ab<BR/>
<B>#6</B>
<BR/>
<B>trial</B>:ab<BR/>
<B>#5</B>
<BR/>
<B>randomly</B>:ab<BR/>
<B>#4</B>
<BR/>
<B>placebo</B>:ab<BR/>
<B>#3</B>
<BR/>
<B>randomi*ed</B>:ab<BR/>
<B>#2</B>
<BR/>
<B>controlled</B> AND <B>clinical</B> AND <B>trial</B>
<BR/>
<B>#1</B>
<BR/>
<B>randomised</B> AND <B>controlled</B> AND <B>trial</B>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-11-03 11:01:13 +1100" MODIFIED_BY="Melina L Willson" NO="3">
<TITLE MODIFIED="2014-11-03 11:01:08 +1100" MODIFIED_BY="Melina L Willson">WHO ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-03 11:01:13 +1100" MODIFIED_BY="Melina L Willson">
<P>
<B>Basic Search:</B>
</P>
<P>1. Taxane containing regimens for metastatic breast cancer<BR/>2. Metatstatic breast cancer AND taxane<BR/>3. Advanced breast cancer AND taxane<BR/>4. (chemotherapy AND taxane) AND metastatic breast cancer<BR/>5. (chemotherapy AND taxane) AND advanced breast cancer</P>
<P>
<B>Advanced Search:</B>
</P>
<P>1. <U>Title:</U> Taxane containing regimens for metastatic breast cancer<BR/>
<U>Recruitment Status:</U> ALL</P>
<P>2. <U>Condition:</U> advance breast cancer OR advanced breast cancer OR advance breast cancers OR advanced breast cancers OR metastatic breast cancer OR metastatic breast cancers<BR/>
<U>Intervention:</U> chemotherapy AND taxane containing regimen<BR/>
<U>Recruitment Status:</U> ALL</P>
<P>3. <U>Condition:</U> advance breast cancer OR advanced breast cancer OR advance breast cancers OR advanced breast cancers OR metastatic breast cancer OR metastatic breast cancers<BR/>
<U>Intervention:</U> chemotherapy AND taxane containing regimens<BR/>
<U>Recruitment Status:</U> ALL</P>
<P>4. <U>Title:</U> chemotherapy AND taxane containing regimen<BR/>
<U>Condition:</U> advance breast cancer OR advanced breast cancer OR advance breast cancers OR advanced breast cancers OR metastatic breast cancer OR metastatic breast cancers<BR/>
<U>Recruitment Status:</U> ALL</P>
<P>5. <U>Title:</U> chemotherapy AND taxane containing regimens<BR/>
<U>Condition:</U> advance breast cancer OR advanced breast cancer OR advance breast cancers OR advanced breast cancers OR metastatic breast cancer OR metastatic breast cancers<BR/>
<U>Recruitment Status:</U> ALL</P>
<P>6. <U>Condition:</U> advance breast cancer OR advanced breast cancer OR advance breast cancers OR advanced breast cancers OR metastatic breast cancer OR metastatic breast cancers<BR/>
<U>Intervention:</U> taxane OR taxol OR taxotere OR paclitaxel OR paxene OR nsc-125973 OR docetaxel OR anzatax OR taxanes OR taxane containing regimen OR taxane containing regimens<BR/>
<U>Recruitment Status:</U> ALL</P>
<P>7. <U>Condition:</U> metastatic breast cancer<BR/>
<U>Intervention:</U> taxane OR taxol OR taxotere OR paclitaxel OR paxene OR nsc-125973 OR docetaxel OR anzatax OR taxanes<BR/>
<U>Recruitment Status:</U> ALL</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2015-05-20 07:56:50 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-11-03 11:01:21 +1100" MODIFIED_BY="Melina L Willson">ClinicalTrials.gov</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-20 07:56:50 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Basic Search:</B>
</P>
<P>1. Taxane containing regimens for metastatic breast cancer<BR/>2. Metastatic breast cancer AND taxane<BR/>3. Advanced breast cancer AND taxane<BR/>4. (chemotherapy AND taxane) AND metastatic breast cancer<BR/>5. (chemotherapy AND taxane) AND advanced breast cancer</P>
<P>
<B>Advanced Search:</B>
</P>
<P>1. <U>Title Acronym/Titles:</U> Taxane containing regimens for metastatic breast cancer<BR/>
<U>Recruitment:</U> All Studies<BR/>
<U>Study Results:</U> All Studies<BR/>
<U>Study Type:</U> All Studies<BR/>
<U>Gender:</U> All Studies</P>
<P>2. <U>Condition:</U> (advanced OR metastatic) AND breast cancer<BR/>
<U>Intervention:</U> chemotherapy AND taxane<BR/>
<U>Recruitment:</U> All Studies<BR/>
<U>Study Results:</U> All Studies<BR/>
<U>Study Type:</U> All Studies<BR/>
<U>Gender:</U> All Studies </P>
<P>3. <U>Condition:</U> (advanced OR metastatic) AND breast cancer<BR/>
<U>Intervention:</U> chemotherapy AND taxane containing regimen<BR/>
<U>Recruitment:</U> All Studies<BR/>
<U>Study Results:</U> All Studies<BR/>
<U>Study Type:</U> All Studies<BR/>
<U>Gender:</U> All Studies </P>
<P>4. <U>Condition:</U> (advanced OR metastatic) AND breast cancer<BR/>
<U>Intervention:</U> taxane OR taxol OR taxotere OR paclitaxel OR paxene OR nsc-125973 OR docetaxel OR anzatax OR taxanes<BR/>
<U>Recruitment:</U> All Studies<BR/>
<U>Study Results:</U> All Studies<BR/>
<U>Study Type:</U> All Studies<BR/>
<U>Gender:</U> All Studies</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_26EFB0D882E26AA200DE99847B111CF7_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="26EFB0D882E26AA200DE99847B111CF7">
<ADDRESS>
<DEPARTMENT>Medical Oncology</DEPARTMENT>
<ORGANISATION>Central Coast Cancer Centre, Gosford Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Gosford</CITY>
<ZIP>2250</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_5088_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="5088">
<ADDRESS>
<DEPARTMENT>Sydney Medical School</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;In sum, 2013 review update:&lt;br&gt;-28 studies referring to 29 treatment comparisons&lt;br&gt;-2 studies categorised as 'awaiting classification'&lt;br&gt;-11 'ongoing' studies&lt;/p&gt;&lt;p&gt;Studies with useable information and by outcome:&lt;br&gt;Overall survival: n = 22 including 23 treatment comparisons&lt;br&gt;Time to progression: n = 21 including 22 treatment comparisons&lt;br&gt;Time to treatment failure: n = 5&lt;br&gt;Objective tumour response rate: n = 28 including 29 treatment comparisons&lt;br&gt;Toxicity: treatment-related toxicity n = 22, G3/4 leukopaenia n = 27 (28 comparisons), G3/4 nausea/vomiting n = 25 (26 comparisons), G3/4 neurotoxicity n = 23 (24 comparisons), G3/4 alopecia n = 11&lt;br&gt;Quality of life: n = 12 including 13 treatment comparisons&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="466">
<FLOWCHARTBOX TEXT="&lt;p&gt;Original Cochrane review:&lt;br&gt;-18 included studies referring to 19 treatment comparisons&lt;br&gt;-3 'ongoing' studies&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;39 records included:&lt;/p&gt;&lt;p&gt;-18 records related to 12 new studies (10 classified as 'included studies' and 2 classified as 'awaiting classification')&lt;br&gt;-6 records with updated data for 6 previously included studies&lt;br&gt;-4 supplementary records related to 3 previously included studies&lt;br&gt;-11 records related to 'ongoing studies'&lt;/p&gt;" WIDTH="279">
<FLOWCHARTBOX TEXT="&lt;p&gt;48 full-text articles or ongoing trial records assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;903 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;903 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1077 records identified through database searching (MEDLINE = 532; EMBASE = 425; Specialised Register = 120 records)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;8 ongoing studies identified through trial registries: the WHO ICTRP search portal and ClinicalTrials.gov&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;855 records excluded based on title and abstract screening&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;9 full-text articles excluded, with reasons:&lt;/p&gt;&lt;p&gt;-3 records related to systematic reviews&lt;br&gt;-6 records for reasons outlined in 'excluded studies' section&lt;br&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>